Microsatellite scanning of the immunogenome for associations with graft-versus-host disease following haematopoietic stem cell transplantation by Harkensee, Christian
 1
 
Microsatellite scanning of the Immunogenome 
for Associations with  
Graft-versus-Host Disease following  
Haematopoietic Stem Cell Transplantation 
 
 
A thesis submitted to the University of Newcastle in accordance 
with the requirements for the degree of Doctor of Philosophy 
(PhD)  
 
 
 
Christian Harkensee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Institute for Cellular Medicine, University of Newcastle 
 
 
July 2012 
 
 2
 
 
 
 
Candidate’s Declaration 
 
I, Christian Harkensee, hereby certify that this thesis has been written by 
me, that it is the record of work carried out by me (unless stated otherwise) 
and that it has not been submitted in any previous application for a higher 
degree. 
 
 
 
Newcastle, July 2012    Christian Harkensee   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dedicated to the memory of 
 
Akira Sasaki 
 
Without whom this work would never have been undertaken. 
 
 
 
 
 
 4
Acknowledgements 
 
I am greatly indebted to the patients and donors who volunteered for this 
work, and the staff members of the transplantation centers, donor centers, 
and the Japan Marrow Donor Program (JMDP) Office for their generous 
cooperation, in particular Dr Yasuo Morishima.  
I am thankful for the generous aid this project has received from a range of 
donors. This work was supported by the Research on Allergic Disease and 
Immunology (Health and Labor Science Research Grant H20-014, H23-
010), the Ministry of Health, Labor, and Welfare of Japan, through JMDP. I 
was supported during this research by a Short-term Post-doctoral 
Fellowship from the Japan Society for Promotion of Science (JSPS) – 
thanks to Polly Watson from the London Office for helping to make this 
happen. This was followed by an International Fellowship from the Kay 
Kendall Leukaemia Fund UK (KKLF) (grants No 291,297), which has been 
exceedingly supportive of helping to steer this work through very difficult 
economical times (special thanks to Liz Storer). The Great Britain 
Sasakawa Foundation (GBSF) contributed to the laboratory costs of the 
exploratory study with a Butterfield Award, and the Daiwa Anglo-Japanese 
Foundation funded the custom design of microsatellite markers with a 
Small Grant. 
My special thanks go to my colleagues and the laboratory staff at the 
Division of Molecular Life Sciences at Tokai University for their kind 
support: Professor Hidetoshi Inoko, Dr Akira Oka and Dr Makoto Onizuka 
for their contributions to the design of the study and the laboratory 
procedures, and Dr Hirofumi Nakaoka for advice on statistics. Mr Hideki 
 5
Hayashi, my teacher in the laboratory and companion during endless 
weeks of pipetting, for all his technical advice; Ms Yamaguchi, Ms 
Matsushita and Ms Higuchi for assisting in the genotyping work, and Ms 
Oda and Ms Takahashi for helping with the local administrative work. 
I am most grateful to my supervisors in Newcastle, Dr Pete Middleton and 
Dr Andy Gennery, for all their constructive feedback and discussions; and 
Heather McGrath, who fought through my funding administration.   
The work described in this thesis is exclusively my own, unless stated 
otherwise. 
 
Finally, this work could not have been done without the support of my 
family, my wife Ena and my children Aila and Kai. The time should have 
been yours… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6
Publications 
 
The work described in this thesis has been published in part. 
 
 
 
Peer-reviewed journal publications 
 
HARKENSEE, C., OKA, A., ONIZUKA, M., MIDDLETON, P. G., INOKO, H., 
HIRAYASU, K., KASHIWASE, K., YABE, T., NAKAOKA, H., GENNERY, A. 
R., ANDO, K. & MORISHIMA, Y. (2012) Single nucleotide polymorphisms 
and outcome risk in unrelated mismatched Haematopoietic Stem Cell 
Transplantation: An exploration study. Blood 2012 Jun 28;119(26):6365-
6372. Epub 2012 May 14 . 
 
 
Conference abstracts 
 
HARKENSEE, C., OKA, A., MIDDLETON, P. G., ONIZUKA, M., 
GENNERY, A. R., INOKO, H. & MORISHIMA, Y. (2010) A systematic 
scanning of the immunogenome with microsatellite markers in a Japanese 
HSCT population reveals multiple genetic risk loci for graft-versus-host 
disease. European Bone Marrow Transplantation (EBMT). Vienna, Austria. 
(oral presentation). 
 
HARKENSEE, C., OKA, A., MIDDLETON, P. G., ONIZUKA, M., 
GENNERY, A. R., INOKO, H., ANDO, O., MORISHIMA, Y. (2012) 
Microsatellite scanning of the Immunogenome for associations with 
Haematopoietic Stem Cell Transplantation outcomes. 26th European 
Immunogenetics and Histocompatibility Conference (EFI) / 23rd British 
Society of Histocompatibility and Immunogenetics Conference, Liverpool, 
UK (poster).  
 
HARKENSEE, C., OKA, A., INOKO, H., MORISHIMA, Y. (2012) TNF-1031 
single nucleotide polymorphism: An independent predictor of severe graft-
versus-host disease? 26th European Immunogenetics and 
Histocompatibility Conference (EFI) / 23rd British Society of 
Histocompatibility and Immunogenetics Conference, Liverpool, UK (poster). 
 
 
 
 
 
 
 
 
 
 7
Abstract 
 
Non-HLA gene polymorphisms contribute to the immune response, 
leading to complications of haematopoietic stem cell transplantation 
(HSCT). A systematic approach using 4,321 microsatellite (MS) markers 
typing for 2,909 immune response genes (‘immunogenome’) on pooled 
DNA of 922 Japanese donors and recipients of HSCT was used to identify 
recipient and donor risk loci for graft-versus-host disease (GVHD).  
 
Splitting the population into discovery and confirmation cohorts (460/462 
pairs), DNA pools were created for a 2-step pooled DNA screening. 
Fisher’s exact test for 2x2 (each MS allele) and 2xm Chi Square tests 
were performed, comparing allele frequencies of recipient/donor pools 
with GVHD grade 0-1 with those of GVHD grade 2-4.  
The independent, 2-step pooled DNA screening process has effectively 
reduced false-positive associations. In the final pooled DNA analysis, 17 
(recipient) and 31 (donor) MS loci remained associated with risk or 
protection from GVHD and were further investigated by individual 
genotyping in the combined cohorts.  
Ten of these loci were confirmed to have consistent associations with 
GVHD; of these, two associations remained when applying multiple 
testing correction and multivariate statistics: D6S0035i (MAPK14, 
p=0.00035, OR=0.68) and D1S0818i (ELTD1, p=0.000078, OR=1.52). 
 
These findings implicate important new immunoregulatory genes with the 
process of moderate to severe acute GVHD. These data show that 
genetic susceptibility to GVHD following HSCT is complex and depends 
on multiple recipient and donor risk loci. Large-scale genomic screening 
with microsatellites on pooled DNA, here described for the first time in a 
HSCT population, is a useful method for the systematic evaluation of 
multigeneic traits.  
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1.1. Haematopoietic Stem Cell Transplantation  
and Graft versus Host Disease 
 
 
Graft versus Host Disease (GVHD) and its consequences remain the 
single most important contributor to morbidity and mortality in patients 
following haematopoietic stem cell transplantation (HSCT). Despite 
progress made in Human Leukocyte Antigen (HLA) matching, and  the use 
of pharmacologic immunosuppression as GVHD prophylaxis after 
myeloablative transplantation, moderate to severe acute GVHD (grades II-
IV) occured in 25% to 60% of matched related donor transplant recipients, 
and up to 45% to 70% in unrelated donor recipients (Horowitz, 2004, 
Andre-Schmutz et al., 2002, Grewal et al., 2003, Laughlin et al., 2001, 
Morishima et al., 2002). The unpredictability of occurrence and severity of 
GVHD is the main obstacle today that prevents the wider application of 
HSCT. 
 
The first successful human bone marrow transplant (BMT) was performed 
1959 by Thomas in the US on a patient with leukaemia, using syngeneic 
bone marrow from his identical twin (Thomas et al., 1959) . 
 
The history of BMT began with the work of Jacobson and Lorenz in the 
early 1950’s, demonstrating that infusion of marrow or spleen cells could 
‘rescue’ mice after a lethal radiation dose (Jacobson et al., 1949, Lorenz et 
al., 1951).  
 
Later in the 1950’s, van Bekkum and De Vries established murine models 
that provided fundamental knowledge of the biology of marrow 
transplantation (van Bekkum and De Vries, 1967). Billingham was the first 
to describe a condition that was initially termed ‘Secondary Disease’ 
(because it occurred after successful engraftment), ‘runt disease’ or 
‘wasting disease’, and later re-named ‘Graft-versus-Host Disease’, after it 
became clear that this was an immunological reaction of donor T-cells 
against host tissues (Billingham and Brent, 1959). In 1957, Uphoff (Uphoff, 
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1957) was the first to suggest a genetic cause for the graft-versus-host 
reaction in allogeneic transplants.  
In 1958, a first classification of HLA groups as the most important marker 
of an individuals biological identity was established (van Rood et al., 1958, 
Dausset, 1958). The capability of the immune system to generate 
antibodies against antigens on the leukocyte surface was already 
described in 1954 (Miescher and Fauconnet, 1954). Dausset 
demonstrated that MHC (Major Histocompatibility Complex) genes (which 
encode for HLA) were required for the presentation of peptide antigens to 
T-cell receptors, playing an important role in transplant immunology. In 
humans, the MHC cluster on chromosome 6 was identified as the coding 
region for HLA. Further research lead to the detection of the different gene 
loci (HLA A,B,C,DR, DP, DQ) and a large number of HLA alleles (Shiina et 
al., 2004). Two main pathways of antigen recognition were detected: A 
direct response, in which CD8+ cytotoxic T-cells interact with HLA, and an 
indirect response in which CD4+ T-cells are activated to induce a delayed-
type hypersensitivity reaction, cell-mediated toxicity and alloantibody 
production. Major events were the discovery of the role of lymphocytes and 
the thymus in the ontogeny of the immune system (1961), the delineation 
of the human MHC (1963), distinction of B/T-cell subsets (1968) and 
demonstration of the MHC restricted nature of the adaptive immune 
response (reviewed in: (Thomas, 1994). 
 
In the 1960’s, studies in canine models laid the foundations for 
conditioning regimens, GVHD prophylaxis and genetic matching. 
Observations included that total body irradiation (TBI) did not cure 
leukaemia nor did it prevent GVHD or bone marrow recovery. HLA 
mismatch was likely to result in rejection or GVHD, and methotrexate was 
introduced as an immunosuppressive agent (Thomas et al., 1962). By the 
end of the 1960’s, the supportive care had also seen significant 
improvement.  
 
The increasing knowledge of histocompatibility lead to a renewed interest 
in allogeneic transplantation, using fully or partially matched siblings as 
donors. While some success was achieved in the transplantation of 
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patients with immunodeficiency (Gatti et al., 1968), the initial results of 
BMT for leukaemic patients were not encouraging (Thomas et al., 1975a, 
Thomas et al., 1975b). The reason for this was thought to be patient 
selection: BMT was seen as a ‘last resort’ for patients with advanced 
disease, or after multiple chemotherapy failures. A small percentage of 
patients, however, achieved long-term cure, indicating that BMT had the 
potential to cure even very advanced disease. Outcome for leukaemic 
patients improved greatly from the late 1970’s onwards after the 
introduction of transplantation after first remission, or in early first relapse 
(Thomas et al., 1979a, Beutler et al., 1979). The increased use of 
allogeneic bone marrow lead to the first bone marrow donor registries (UK 
1975, US 1984). 
 
Transplant conditioning regimens, given as an immunosuppression and for 
tumour eradication, had come a long way from the early, simple TBI 
regimen to the reduced intensity conditioning (RIC) regimens of today. 
Observations with TBI, as well as cyclophosphamide (CY) as single 
therapies in the 1950’s and 1960’s were such that leukaemia relapsed 
rapidly after transplantation. The combination of TBI and CY lead to the 
first observed long term remissions in the mid 1970’s (Thomas et al., 
1975a, Thomas et al., 1975b). Introduction of newer chemotherapeutic 
agents such as busulphan, and fractioned irradiation have reduced toxicity 
and improved survival. Nevertheless, these myeloablative regimens 
proved still far too toxic for elderly patients or those with co-morbidities, in 
which transplant-related mortality (TRM) would reach unacceptable high 
levels. The last two decades have opened up transplant opportunities for 
this age and risk group by the development of RIC regimens (Koh and 
Chao, 2008). 
 
Whilst immunosuppressive regimens achieved far-reaching control of 
transplant rejection, GVHD and its consequences remained the single 
most important complication of stem cell transplantation. Studies in animal 
models and observations in human patients clarified important checkpoints 
in the pathophysiology of GVHD (Korngold and Sprent, 1978, Shlomchik, 
2007). In the 1980’s, even with HLA matched sibling donors up to 50% of 
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recipients developed GVHD. In the 1960’s and 1970’s, methotrexate and 
steroids were first used for treatment, later for prevention with only limited 
effect (Thomas et al., 1979b). The introduction of cyclosporin A, an 
inhibitor of T-cell activation and proliferation, in 1980, used in combination 
with a short course of methotrexate, resulted in improved prevention of 
GVHD (Deeg et al., 1982). T-cell depletion, first described in the early 
1980’s (Martin et al., 1985), was found to prevent GVHD, however, at the 
expense of the loss of the GVL (Graft versus Leukaemia) effect, risk of 
graft failure and delayed immunologic recovery. Newer agents used in 
prophylaxis include Tacrolimus and Sirolimus, believed to be more potent 
in blocking T-cell proliferation, and Mycophenolate Mofetil, active against 
both T-cells and B-cells. 
 
Over the last two decades, improved techniques of molecular genetics 
replaced the HLA serum typing with genotyping, allowing for matching at 
individual allele level, further reducing the incidence of GVHD (Little, 2007). 
Advanced molecular techniques also permitted the identification of minor 
histocompatibility antigens (mHags), which play an important role in 
otherwise fully HLA-matched transplants (Goulmy, 2006). The process of 
GVHD also seemed to be modified by polymorphisms in immunoregulatory 
genes (Mullighan and Bardy, 2007). Presence of active infection 
represented a risk factor for GVHD, while in turn GVHD (and its treatment) 
produced profound immune suppression, increasing the risk of infection. 
 
The concept of the GVL effect was first pointed out in the 1950’s (Barnes 
et al., 1956), and observed in mouse experiments during the 1960’s. It was 
first described in human patients in the mid-1970’s when it became 
apparent that patients with GVHD had a reduced risk of leukaemia relapse 
(Weiden et al., 1979). Around the same time, animal experiments 
demonstrated that the GVL effect could be separated from GVHD (Bortin 
et al., 1979). The introduction of post-transplant donor lymphocyte 
infusions (DLI) in the second half of the 1980’s was the first established 
method with the aim to enhance the GVL in patients with haematological 
and other malignancies. The potential of DLI to induce long-lasting 
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remission was demonstrated, however, at the expense of increased GVHD 
and prolonged bone marrow suppression (Kolb et al., 1990). 
 
Current directions in progress in BMT can be described as four big areas. 
Firstly, there is continuing improvement in supportive care, anti-infectious 
therapy, and reduction of toxicity of induction regimens. Secondly, the 
study of clinical and genetic (HLA and non-HLA) risk factors may lead to a 
more reliable prediction of transplant complications. Thirdly, separation of 
GVL from GVHD and fourthly, enhancement of immune reconstitution, 
could be summarized under the term ‘Adoptive Immunotherapy’. Some 
methods applied, amongst others, include in vivo and in vitro tumor-
specific alloimmunization, the use of immunomodulatory cells (T-regulatory 
cells, dendritic cells, Mesenchymal stem cells), cytokines, growth 
hormones, non-specific immune regulators and monoclonal antibodies to 
suppress GVHD, enhance GVL and stimulate the reconstitution of a 
healthy immune function. With GVHD being the major hurdle of the 
application of HSCT for other indications, advances in its control are likely 
to expand the future role of HSCT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
• The history of HSCT spans five decades, during which the 
procedure has become more effective and safe. 
• Progress in timing, genetic matching, conditioning 
regimen, GVHD prophylaxis and clinical care has widened 
the applicability and indications of HSCT 
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1.2  Pathophysiology and pathobiology of GVHD 
 
1.2.1. Overview 
 
Pathophysiologically, GVHD involves the recognition of target tissues as 
being foreign by immunocompetent donor cells, resulting in the induction of 
an inflammatory response. Acute GVHD has been described in three 
different phases: (I) presence of a profoundly damaged host milieu prior to 
contact with donor tissue, characterized by excessive endo- and epithelial 
damage due to preparing chemotherapy regimes, irradiation, damaged 
and dying malignant cells and infections, (II) donor T cell activation by host 
antigen-presenting cells (APC), and (III) the inflammatory response 
consisting of activation of donor cytotoxic T cells, natural killer cells (NKC) 
and monocytes. Cytokine toxicity and viral and bacterial infections also 
contribute to the inflammatory response (Ferrara and Levine, 2006, 
Ferrara et al., 1999).  
 
 
1.2.2. GVHD phase 1: Preceding tissue damage, pre-transplant 
conditioning, and activation of antigen-presenting cells 
 
Preceding local tissue damage 
 
The damage to recipient tissues caused by conditioning regimens and 
previous chemotherapy or radiation, the underlying malignancy, and 
concurrent infections had a major impact on the incidence and severity of 
acute GVHD (Xun et al., 1994, Perez-Simon et al., 2005, Couriel et al., 
2004, Gratama et al., 1987). The local micro-environment of inflammatory 
mediators determined the degree and specificity of APC activation, and 
subsequently, induction of naïve T-cells. An important mechanism 
appeared to be the increased cytokine secretion in the local environment, 
leading to increased expression of adhesion molecules and MHC, 
increased antigen presentation by APC, increased antigen recognition by T 
cells, and subsequently increased T cell activation and proliferation. TNF, 
IL1 and IL6 were the most important cytokines involved in stimulating local 
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tissue inflammation in GVHD (Nestel et al., 1992, Imamura et al., 1994, 
Remberger et al., 1995, Cooke et al., 1998) 
Tissue insults by toxic effects of chemotherapeutics, irradiation, dying 
diseased cells, or infection with bacterial, viral, fungal or protozoal 
pathogens, were causing a mixed pattern of cells either weakened by 
stress, or cell apoptosis and cell necrosis with disruption of tissue 
architecture. Those tissues which were environmentally exposed, or 
rapidly dividing and renewing, such as the epithelia of the liver, intestinal 
tract and skin, were the most vulnerable. 
There is evidence that the initial immune response to the tissue damage 
were triggered by endogenous stress or danger signals, powerful enough 
to induce activation of local APC in a paracrine fashion (Lotze et al., 2007, 
Skoberne et al., 2004, Gallucci et al., 1999, Gallucci and Matzinger, 2001). 
In contrast to pathogen-associated proteins, which induce a specific 
immune response, endogenous proteins from injured tissue represented a 
potentially unlimited source of self-antigen. While apoptotic cells were 
engulfed in quiescence and their antigens presented to T-cells without co-
stimulation, hence inducing tolerance; proteins from necrotic cells 
presented as antigens lead to T-cell activation (Shlomchik, 2007). 
Nevertheless, a mouse model (Teshima et al., 2002) demonstrated that 
alloantigen presentation on host epithelium was not a requirement for 
acute GVHD, but that GVHD could be abrogated by TNFα blockade, 
supporting the notion of the importance of the cytokine micro-environment. 
 
Activation of host APC 
 
The first circle of augmentation of the pro-inflammatory response occurred 
still in the injured tissue itself. When local APC became activated, they 
secreted further pro-inflammatory cytokines like tumour necrosis factor 
alpha (TNFα), interleukin 1 (IL-1), granulocyte-macrophage stimulating 
factor (GM-CSF) and Interferon gamma (IFNγ) (Ferrara et al., 1999), which 
in turn recruited more epithelial cell and APC for cytokine secretion. 
Increased cytokine concentrations eventually reached systemic circulation, 
providing a powerful chemoattractant stimulus. Increased cytokine 
expression stimulates the excretion of chemokines and their receptors, 
 23
which had an important role in dendrictic cell (DC) activation and 
maturation, as well as CD8+ T-cell homing to GVHD target tissues (New et 
al., 2002, Mapara et al., 2006). This micro-climate, in turn, attracted and 
activated DC and other antigen-presenting cells and broke the ground for 
mature donor  T-cells, which after transplantation recognised increasingly 
expressed MHC molecules and/or mHags (Matzinger, 2002). 
 
The consequences of tissue damage and subsequent immune system 
activation were even more imminent in the intestinal mucosal surface. 
Here, local TNFα secretion negatively affected the surface integrity (Laster 
et al., 1988), enhancing the potential injuries caused by intramucosal 
displacement of bacterial endotoxins and lipopolysaccharides (LPS), which 
could potentiate even further the pro-inflammatory cytokine production by 
gut-associated macrophages and lymphocytes (Nestel et al., 1992). The 
intestinal Peyer’s Patches (PP) had been identified as a key lymphoid 
compartment for the development of acute GVHD (Murai et al., 2003) by 
demonstrating that acute GVHD was abrogated in mice which were PP-
deficient or whose T-cell homing had been interrupted by C-chemokine 
receptor 5 (CCR5) -blockade; suggesting that GVHD induction was 
determined by the local inflammatory environment, rather than tissue-
specific mHags. On the other hand, PP were redundant, hence T-cells 
primed elsewhere in the body were capable of inducing intestinal GVHD 
(Welniak et al., 2006).  
APC were either tissue-specific and residing (e.g. Langerhans’ cell in skin, 
Kupfer cell in liver) or circulated through the body’s blood and lymphoid 
system in their naïve and immature form. Their key function for the 
adaptive immune system was their capability of inducing a specific, 
adaptive immune response by presenting a specific antigen to naïve or 
memory T-cells through their MHC receptor. DC, the most important APC 
in GVHD induction, could be activated in a specific (antigen, foreign-
recognition) or non-specific (micro-environmental stimuli, danger 
recognition) manner. The antigen was internalised and processed in 
endolysosomes to peptide which was loaded onto MHC molecules. 
Physiologically, immature DC relentlessly sampled endogenous antigen, 
which was presented to T-cells rendering those tolerant to self-antigen. 
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Antigen recognised as ‘non-self’, however, lead to DC maturation and 
antigen presentation to T-cells accompanied by appropriate co-stimulatory 
signals. DC were able to suppress the response of T-regulatory cells, and 
control the blood flow to the lymph node into which they home. In the 
lymph node, the matured DC interacted with naïve or memory CD4 T-cells 
through the MHC/T-cell receptor (TCR) ‘immunological synapse’, resulting 
in effective activation and proliferation of an antigen-specific T-cell clone 
(Lee and Iwasaki, 2007).  
It was thought that in early GVHD, tissue antigen was presented to the 
infused donor T cells by host DC which were critical, and sufficient, to 
induce a GVHD response (Shlomchik et al., 1999, Duffner et al., 2004). 
Host Langerhans cells in the skin had been shown to be critical mediators 
of skin GVHD (Merad et al., 2004). Antigen presentation by host APC to 
donor T-cells, also called direct recognition, was the predominant mode of 
allorecognition in the MHC mismatched transplant setting (Ruggeri et al., 
2002).  
Removal of APC from their specific organ could potentially abrogate GVHD 
in the same organ (Zhang et al., 2002b). The same authors suggested that 
host APC localised in specific target organs recruited mature donor T-cells, 
while DC and macrophages homed to lymph nodes and other secondary 
lymphoid organs were critical for the activation of  a cytotoxic CD8+T-cell 
response.  
Of the different subsets of APC, DC probably was the most critical one in 
the development of GVHD, supported by its role as the most important 
‘professional’ APC, and also by observation in experimental GVHD 
settings (Duffner et al., 2004, Zhang et al., 2002a).  
APC regulation in the context of GVHD is not fully understood. TBI as part 
of an HSCT conditioning regimen, in combination with G-CSF exacerbated 
APC activation (Morris et al., 2009), while γδ T-cells, host Natural Killer T-
cells (NKT), natural killer (NK) cells and B cells reduced activation 
(Paczesny et al., 2009a).  
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1.2.3.  GVHD phase 2: Activation of donor T-cells 
 
Activated host APC relocated into secondary lymphoid organs, where 
following HSCT they met donor T cells. Donor T-cells recognized antigen 
presented by host APC (foreign antigen or the host MHC receptor itself - 
direct presentation) or donor APC (recognition of the foreign antigen - 
indirect presentation) (Shlomchik, 2003, Sayegh and Carpenter, 1996). 
Donor T-cells required co-stimulation of their T-cell receptor in the binding 
to the MHC receptor of the APC in order to become activated (Appleman 
and Boussiotis, 2003), with CD28, ICOS, CD40, OX40 (activation) and 
CTLA4 (inhibition) being the most important co-stimulatory molecules 
(Paczesny et al., 2009a). 
 
Different subsets of T-cells had varying roles in induction of GVHD. The 
two main subsets, CD4+ and CD8+ T cells were both capable of inducing 
GVHD. In the absence of HLA mismatch, this potency was determined by 
host mHags which could lead to specific T-cell clones in either CD4+ or 
CD8+ subset (Goulmy, 2006, Wu and Ritz, 2006). Selective elimination of 
either subset from grafts did not lead to a reduction in GVHD, and research 
on selecting specific antigeneic clones for elimination is ongoing 
(Bondanza et al., 2006).  
Naïve donor T-cells (CD62L+ CD44+) also had the potential of inducing 
GVHD (Anderson et al., 2003). Non-alloreactive donor memory T-cells 
(CD62L-) did not induce GVHD, but were able to mediate GVL effects 
through memory transfer (Zheng et al., 2008). Alloreactive donor T-cells, 
however, were a main cause of GVHD (Zhang et al., 2005). 
Regulatory T-cells (Treg) had been the focus of more recent research. 
Several studies had demonstrated that Treg are capable of suppressing 
the expansion of activated donor T-cells, and therefore reduce the risk of 
GVHD, whilst preserving GVL reactions (Yan and Da, 2006, Salomon et al., 
2006, Ruggeri et al., 2002). Host and donor NKT also had GVHD-reducing 
properties (Pillai et al., 2007), by shifting cytokine responses to a T-helper 
type 2 (Th2) profile (Lowsky et al., 2005), or eliminating host APC (Morris 
et al., 2005). 
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In the late 1980’s it was discovered that following activation subsets of 
mainly CD4+ T-cells had antagonistic cytokine excretion profiles, 
described as Th1 (T-helper type 1) and Th2 (T-helper type 2) cells 
(Mosmann et al., 1986). Th1 cells secreted pro-inflammatory cytokines like 
IL2 (interleukin 2), TNF, IFNγ (interferon gamma), while the Th2 (T-helper 
2 cell) had anti-inflammatory properties, secreting cytokines like IL4 
(interleukin 4) and IL10 (interleukin 10). These phenotypes followed each 
other over time (in the initial phase of an inflammatory reaction, the 
response was predominantly pro-inflammatory, followed by an anti-
inflammatory response to counteract and prevent excessive inflammation). 
There is good evidence that genetic polymorphisms resulting in over- or 
under-expression of certain cytokines could tilt this balance to either a 
more pro-inflammatory or an anti-inflammatory response (see below). In 
Phase 2, donor T cells stimulated by APC secrete IL2 and IFNγ (Mosmann 
et al., 1986), which was central in the control and amplification of the 
immune reaction against the foreign antigen. IFNγ primed macrophages to 
produce and secrete IL1 (interleukin 1) and TNF (Nestel et al., 1992), 
induced the skin and gut pathology of GVHD (Dickinson et al., 1991), and 
impaired T-lymphocyte function (Huchet et al., 1993). The levels of IFNγ 
were predictive of GVHD severity (Tanaka et al., 1994). This could be 
described as a Th1-type response, promoting GVHD. On the other side, 
Th2-type cytokines like IL4 and IL10 had antagonistic effects on IL2 and 
IFNγ secretion (Seder and Le Gros, 1995), dampening down reactions 
leading to acute GVHD and ‘shifting’ the immune response towards 
chronic GVHD (Krenger and Ferrara, 1996). Nevertheless, the biology of 
cytokines in GVHD is likely to be more complex, as opposing effects of the 
same cytokine (e.g. IL2 or IFNγ) had been observed, depending on factors 
like timing, concentration and tissue location (Wang et al., 1995, Krenger 
et al., 1996, Baker et al., 1995, Yang et al., 1998, Brok et al., 1997). Sun et. 
al. (Sun et al., 2007) postulated that “early Th1 polarization of donor T-cells 
and Th1 cytokines are critical for GVHD induction, whereas inadequate 
production could modulate acute GVHD through a breakdown of negative 
feedback mechanisms for activated T-cells”. 
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IL17 (interleukin 17) Th-cells were a more recently described subset of 
CD4+ T-cells, characterized by the production of IL17. Their role in GVHD 
remained controversial (Sun et al., 2007, Paczesny et al., 2009a), as 
studies had shown that IL17 deficient T- cells enhanced Th1 skewing 
augmenting acute GVHD, whereas Th17 cells caused severe GVHD in 
vitro. 
 
1.2.4.  GVHD Phase 3: Effector phase 
 
Once activated donor T-cells migrate from secondary lymphoid tissue into 
target organs, where they cause tissue damage. Potentially any organ is 
capable of expressing alloantigen and therefore to become a target organ 
for GVHD, however, skin, gut, liver and thymus are the most commonly 
affected target tissues.  
 
Recent studies have shed some light onto mechanisms that control the 
‘homing’ of alloreactive T-cells into their target tissues. Chemokines 
appeared to be one of the key players. Inflammatory chemokines were 
expressed by a wide variety of tissues and cells (endothelial cells, 
fibroblasts, DC, monocytes, NK cells and T-lymphocytes) and regulated 
trafficking of donor T-cells towards the lymphoid organs where they 
interacted with APC, as well as target tissues (reviewed in: (Wysocki et al., 
2005). Activated T-lymphocytes expressed chemokine receptors which, at 
least in part, determined their destination by homing to tissues where the 
according ligands were expressed (e.g.: liver: receptors CXCR3, CCR2, 
CCR5, ligands: CXCL9/10/11, CCL2/3; gut: receptors CXCR3, CCR9, 
ligands CXCL9/10/11, CCL25; skin: receptors CXCR3, ligands 
CXCL9/10/11, CCL2/5/17).  
 
Other mechanisms of T-cell trafficking included selectins and integrins 
(also reviewed in (Wysocki et al., 2005). E, P and L-selectin were 
expressed in various tissues including on cells of the myeloid and lymphoid 
system, and found their ligands, the peripheral node addressins (PNAds) 
expressed in chronically inflamed tissue. Integrins were transmembrane 
proteins expressed on immune cells which interacted with molecular 
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structures in tissues that lay exposed due to tissue damage (e.g. collagen, 
laminin, fibronectin) or specific expressed ligands like adhesion molecules 
(MADCAM1, VCAM1, ICAM). Expression of MADCAM1 and ICAM1, for 
example, was critical for induction of acute GVHD in the PP of the intestine 
and in the liver. 
 
Donor T-cells exerted their deleterious effect on target tissues by direct 
cytotoxicity (van den Brink and Burakoff, 2002) using different pathways of 
apoptosis. CD4+ cytotoxic T-lymphocytes (CTL) applied mainly the Fas-
FasL (TNF-receptor superfamily member 6) pathway (Via et al., 1996). Fas 
is widely expressed, its expression is inducible by TNF and IFNγ and 
therefore enhanced in inflamed tissues. The same cytokines enhanced 
FasL expression on CTL, hence this mechanism appeared to be a self-
augmenting cycle of tissue damage, inflammation, CTL recruitment and 
apoptosis. CD8+ CTL worked preferentially through the perforine-
granzyme pathway. Perforin is secreted by the CTL causing pores in the 
target cell membrane. This allows granzyme to enter and induce a cell-
death sequence. In experimental GVHD, survival was better in 
peforin/granzyme deficient mice, but the cytotoxic effect was less 
pronounced than for Fas/FasL (Graubert et al., 1997). Experimental 
studies for both pathways, by inactivating important components, had 
shown that GVHD can be abrogated or delayed in onset (reviewed in: (Sun 
et al., 2007)). 
Other apoptosis mechanisms include TRAIL (TNF-related apoptosis-
inducing ligand) (Pan et al., 1997), TWEAK (TNF-like weak inducers of 
apoptosis) and LTβ/LIGHT pathways (Brown et al., 2005). 
 
Much of the tissue damage of the effector phase of GVHD could be 
attributed to an excessive release of pro-inflammatory cytokines, the so-
called ‘cytokine storm’. Local tissue damage, due to conditioning or 
infection, induced APC activation through TLR and non-TLR pathways, 
and caused chemoattraction to macrophages, which in response secreted 
TNF and IL1 (Antin and Ferrara, 1992). These cytokines could significantly 
augment T-cell activation, which in turn stimulated TNF, IL1 and IFNγ 
secretion from an array of immune cells. In that sense, the degree of 
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priming of immune cells determined the severity of GVHD. In contrast, 
tissue damage in itself without the interaction of CTL was capable of 
inducing GVHD damage (Teshima et al., 2002).  
TNF was the most important cytokine in the effector phase (Reddy and 
Ferrara, 2003). It had synergistic and pleiotrophic effects, causing 
cachexia, induce APC maturation, recruited T-effector cells, neutrophils 
and monocytes, and primed homing by chemokine induction. TNF could 
also cause direct tissue damage by inducing apoptosis and necrosis, and 
could activate T-cells directly through the receptors TNFR1 (TNF receptor 
1) and TNFR2 (TNF receptor 2). 
Other effector molecules that had been studied include IL1 and nitric oxide 
(NO). IL1 had effects very similar to TNF, but might be more organ specific 
to spleen and skin (Abhyankar et al., 1993). NO is a product of activated 
macrophages that caused direct tissue insult, and inhibited repair 
mechanisms. Development of GVHD correlated with levels of oxidation 
products of NO (Nestel et al., 2000, Weiss et al., 1995). 
More recently, larger studies of protein components, genetic expression 
and genetic polymorphism were aiming to dissect the pathobiology of 
GVHD further and identifying molecules (biomarkers) that could predict 
GVHD (Hansen, 2008, Kaiser et al., 2004, Mohty et al., 2007, Paczesny et 
al., 2008, Srinivasan et al., 2006, Weissinger and Dickinson, 2009). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 
 
• GVHD is the most important cause of adverse outcome of HSCT 
and remains largely unpredictable. 
• Host antigen recognition by donor T-cells is the key step in the 
induction of GVHD. 
• However, modulation of this process is very complex and 
involves pathophysiological events before, during and after T-
cell activation. 
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1.3. The Genetics of HSCT 
 
1.3.1. Self/non-self genetics 
 
Human Leukocyte Antigens (HLA) 
 
The HLA complex is the strongest known determinant of self/non-self 
recognition. Six HLA loci are now commonly used for donor/recipient 
matching: HLA-A, B, C (HLA class I) and HLA-DRB1, DQB1 and DPB1 
(HLA class II). Disparity between donor and recipient HLA antigens results 
in either rejection of the graft (host-versus-graft reaction), or cellular toxicity 
of the graft against the host (GVHD and GVL).  
Well into the 1980’s, HLA matching was based on serologic typing at 
antigen level. Observations from this time (Kernan et al., 1993) showed 
that unrelated HSCT had a higher prevalence of GVHD and worse survival, 
compared to related HSCT.  
The introduction of DNA-based high resolution typing since the 1990’s did 
contribute a great deal to the understanding of HLA matching. More than 
2,000 different alleles had been identified within HLA class I and II (Shiina 
et al., 2009), and large scale registry studies, primarily in the US and 
Japan, had analysed the effects of different mismatch combinations in 
unrelated HSCT. For the US registry (Petersdorf et al., 1998), the first 
high-resolution data showed that in fact 47% of serologically matched 
HSCT (HLA-A, B, C, DRB1, DQB1) had one allele level mismatch, and 
25% had 2 mismatches. Combined mismatches in HLA class I and class II 
significantly increased the risk of severe GVHD and death. Single class II, 
but not class I mismatches increased the risk of GVHD. HLA-DRB1 
mismatch was the strongest predictor of GVHD. The first data of high-
resolution typing from Japan were published in the same year (Sasazuki et 
al., 1998), coinciding with the US data that combined HLA class I and II 
mismatches carry the highest risk for GVHD and death. However, single 
class II mismatches did not increase the GVHD risk, whereas HLA-A 
mismatch had the strongest association with GVHD and death. HLA-C 
mismatch was also associated strongly with GVHD, but not with survival 
risk. These data were expanded in 2002 (Morishima et al., 2002), showing 
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that single mismatches in any of HLA-A, B, C, DRB1 implicated a higher 
risk of GVHD, with multiple class I mismatches, in particular involving HLA-
C, resulting in the highest risk. HLA-A and/or B mismatches increased the 
risk of death, with combined mismatches of HLA-A or B + HLA-C + HLA-
DRB1 or DQB1 showing the poorest survival. 
Updates on the US registry confirmed a high GVHD risk for a single or 
combined HLA-A mismatch, and worse survival with single or combined 
HLA-A, B, C and DRB1 mismatches (Flomenberg et al., 2004). Conversely, 
allele-level HLA-A, B, C and DRB1 matching had the best survival, while 
even a single mismatch of any of those had a measurable effect on 
survival (Lee et al., 2007). As in previous studies, no effect of HLA-DQB1 
and DPB1 was found. 
The Japanese registry has recently advanced into identifying individual 
GVHD high-risk allele mismatch pairs (Kawase et al., 2007), assuming that 
not all mismatches would actually induce alloreactivity. This study found 29 
high-risk allele mismatch combinations in HLA-A, B, C, DRB1 and DPB1. 
Following on from this work, high risk and low risk mismatch combinations 
for relapse of haematological malignancies were identified and correlated 
with high-risk GVHD allele mismatches. Eight mismatch combinations in 
HLA-DPB1 and HLA-Cw were found that have a very low relapse risk and 
no increased GVHD risk, elucidating the HLA-basis of the GVL effect 
(Kawase et al., 2009). The Japanese registry was also the first to describe 
highly conserved HLA haplotypes and their association with risk or 
protection from GVHD (Morishima et al., 2010) 
 
 
Other self/non-self genetics: KIR, LILR, mHags 
 
Killer immunoglobulin-like receptors (KIR) are cell surface receptors on NK 
cells. Their function is to recognize normal MHC class I receptor 
expression on cells, hence normal MHC expression leads to inhibition of 
NK cell activity whereas an abnormal expression (‘missing self’) releases 
the inhibition and results in killing of the target cell by an apoptotic signal. 
KIR are highly polymorphic. In mismatched related HSCT for leukaemia, 
this effect (termed the KIR ligand mismatch) could be exploited for a graft-
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versus-tumour effect without a higher risk of GVHD (Ruggeri et al., 2007, 
Leung et al., 2004). However, for the unrelated HSCT setting the data 
were more controversial. Yabe et. al. (Yabe et al., 2008) and Morishima 
et.al. (Morishima et al., 2007) had described the effects of HLA and KIR 
matching for the Japanese registry. These data show that KIR2DL ligand 
mismatch in the GVHD direction increased the risk for GVHD and mortality, 
but dependent on HLA matching, underlying malignancy and 
administration of ATG. 
 
Leukocyte immunoglobulin-like receptors (LILR) have a wider distribution 
as compared to KIR, but also recognize MHC class I molecules (Sloane et 
al., 2004). As KIR, LILR are predominantly inhibitory and also highly 
polymorphic. They had a role in controlling the maturation of DC (Young et 
al., 2008), and so far unpublished data from the Japanese registry showed 
associations of LILR with GVHD and survival (verbal communication 
Toshio Yabe, Kouyuki Hirayasu). 
 
Non-HLA recipient proteins that resulted from gene polymorphisms that 
were disparate between donor and recipient represented Minor 
Histocompatibility Antigens (mHags) (Spencer et al., 2010). Donor T-cells 
recognized such antigens and responded with clonal expansion. If a mHag 
happened to derive from a malignant protein or cell, the donor T-cell 
response could exert a strong and specific graft-versus tumour effect, 
which could be beneficial (Goulmy, 2006). However, if the mHag derived 
from otherwise healthy tissue, severe GVHD could be the result. In theory, 
the potential number of mHags could be as vast as the polymorphic 
disparity between donor and recipient (Brickner, 2006), however, only few 
mHags induced donor T-cell responses (immunodominance) for reasons 
that are not fully understood. Experimental matching for known mHags did 
not result in reduction of GVHD (Warren, 2009). Gene polymorphisms on 
the Y-chromosome of male recipients of female grafts were potentially a 
source of many mHags, and several have been identified; female into male 
HSCT had been recognized as having a higher risk of GVHD and mortality 
(Randolph et al., 2004). 
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More recent efforts had attempted to capture mHags with genome-wide 
approaches (Hansen et al., 2010, Ogawa et al., 2008, Kawase et al., 2008). 
 
1.3.2. Non-HLA genetics 
 
Non-HLA genetics in HSCT is defined as the effect of functional gene 
polymorphisms that impact on outcome by modulating existing immune or 
metabolic responses, rather than having direct involvement in self/non-self 
recognition. HSCT outcomes like acute and chronic GVHD, relapse and 
survival are not rare events and vary between individuals who may 
otherwise be genetically similar; possibly comparable to how phenotypes 
of inflammation, infection and immunity vary in a normal population. It was 
therefore assumed that the non-HLA genetic effects on HSCT outcome 
were determined by common genetic variants.  
Studies that were aiming at understanding the pathophysiology of GVHD 
(see above) had identified several immunoregulatory key players, like e.g. 
cytokines, adhesion molecules, regulators of innate immunity and 
chemokines. The first such study was published in 1998, implicating TNF 
and IL10 with GVHD (Middleton et al., 1998).  
 
For this study, a systematic literature search was undertaken that identified 
248 gene association studies with outcome of HSCT (list: supplementary 
file 1.1). At least 105 genes, including cytokines, regulators of innate and 
adaptive immunity, drug metabolism genes, DNA repair and metabolic 
genes were found to associate with any HSCT outcome (which included 
acute and chronic GVHD, relapse, rejection, survival, VOD, infection, drug 
toxicity). These findings are summarized in table 1.1. Of these, markers for 
49 genes associated with acute or chronic GVHD, described in 141 studies. 
 
Analyzing the methodology of these studies, the vast majority (n=238, 
96%) were single cohort candidate gene association studies. Only seven 
studies sought independent confirmation of findings within the same 
study’s setup (Xiao et al., 2010, Chien et al., 2006, Lin et al., 2003, Bochud 
et al., 2008, Elmaagacli et al., 2009, Mullighan et al., 2004, Espinoza et al., 
2011), and only three studies used larger scale approaches. Mullally et. al. 
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reported a study of 1143 SNP for 220 candidate genes, identifying several 
chemokines associating with HSCT outcome (Mullally et al., 2008). JMDP 
had conducted a genome-wide association study with SNP markers, which 
failed to identify any non-HLA gene association but detected a possible 
mHag locus (Ogawa et al., 2008). Finally, the NMDP carried out a 
genome-wide association study (Hansen et al., 2010) the results of which 
have not been finally reported. Imputation of SNP previously associated, 
however, confirmed association of IL10 and IL6 with GVHD (Chien et al., 
2012). 
Given the rapid evolution of HSCT, it had been difficult in the past to build 
large-scale HSCT study cohorts. Limited availability of study subjects 
made consideration of demographic or clinical risk factors in study cohort 
selection difficult, despite the existence of these risks being well 
established in the literature (e.g. patient and donor age (Kollman et al., 
2001, Loren et al., 2006, Wojnar et al., 2006), female donor to male 
recipient (Randolph et al., 2004, Gahrton, 2007), diagnosis and staging 
(Chaidos et al., 2007, Wojnar et al., 2006), prior chemotherapy (Hahn et al., 
2008), conditioning regimen (Perez-Simon et al., 2005, Hahn et al., 2008), 
concurrent infections (Hahn et al., 2008, Ljungman, 2007, Young, 2008)). 
Previous studies often relied on study populations displaying different 
underlying ethnicities, underlying diagnosis, stem cell sources 
(related/unrelated), conditioning regimens and GVHD prophylaxis, 
weakening study power and leading to disparate results. HLA matching 
and HSCT from sibling donors  were the most common measures applied 
in the study of non-HLA gene polymorphisms, presuming that reducing the 
‘noise’ from genetic mismatching would make small effect-size non-HLA 
association more readily identifiable. Very few studies deliberately chose 
unrelated or HLA mismatched HSCT, therefore there is a paucity of data 
on these settings, although these represent the majority of HSCT. Also, 
earlier serotypical HLA matches may have actually represented 
mismatches at allele level (Weisdorf et al., 2008), hampering the 
comparison of results from different studies. Many of the early studies in 
particular lacked statistical power for the allele/genotype frequency 
reported; sample sizes <100 were not uncommon.  
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More recently, the collection of large HSCT cohorts has become reality. 
Both NMDP and JMDP have now conducted >10,000 unrelated donor 
HSCT, allowing for future studies with better stratification of genetic, 
demographic and clinical risk factors. Eventually, the availability of such 
study populations would allow for study designs that comply with 
recommendations for the design of genetic association studies (Colhoun et 
al., 2003, Gambaro et al., 2000, Hirschhorn et al., 2002, McCarthy et al., 
2008, Lander and Schork, 1994, Schork, 1997). 
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Gene function gene function gene function gene function 
ABO haematopoietic system ESR innate immunity IL15RA cytokine NOS2A innate immunity 
ACE other effector Factor V haematopoietic system IL17A cytokine OGGI DNA repair 
BAFF haematopoietic system Fas adaptive immunity IL18 cytokine P2X7 Drug metabolism 
BP1 other effector FCGR2A adaptive immunity IL1RA cytokine PAI1 haematopoietic system 
CASP8 adaptive immunity FCGR3B adaptive immunity IL2 cytokine PARP1 DNA repair 
CCL27 chemokines FCRL3 adaptive immunity IL23R cytokine PCAM1 adhesion 
CCL3 chemokines FOXP3 adaptive immunity IL4  cytokine PGP Drug metabolism 
CCL4 chemokines GRZB adaptive immunity IL4R cytokine PIR innate immunity 
CCL5 chemokines GSTA1 Drug metabolism IL6 cytokine Prothrombin haematopoietic system 
CCR5 chemokines GSTM1 Drug metabolism IL7R cytokine PTPN22 haematopoietic system 
CCR6 chemokines GSTP1 Drug metabolism IMPDH1 Drug metabolism PTPRC haematopoietic system 
CCR9 chemokines GSTT1 Drug metabolism LCT metabolic RFC1 DNA repair 
CD14 adaptive immunity HFE haematopoietic system LIG3 DNA repair TGFB1 cytokine 
CD3EAP DNA repair HLA-E adaptive immunity MADCAM1 adhesion TGFB1R cytokine 
CD86 adaptive immunity HLA-G adaptive immunity Mal adaptive immunity TLR1 innate immunity 
CPS1 metabolic HMGB1 adaptive immunity MASP2 innate immunity TLR4 innate immunity 
CTLA4 adaptive immunity HO1 haematopoietic system MBL innate immunity TLR9 innate immunity 
CXCL12 chemokines HP  haematopoietic system MBL2 innate immunity TNF cytokine 
CYP2B6 Drug metabolism HPA5 haematopoietic system MCP1 innate immunity TNFRSF1 cytokine 
CYP2C19 Drug metabolism HPSE haematopoietic system MDR1 Drug metabolism TNFRSF2 cytokine 
CYP3A4 Drug metabolism HSP70 innate immunity MIF innate immunity VDR innate immunity 
CYP3A5 Drug metabolism ICOS adaptive immunity MPO innate immunity VEGF adhesion 
DAAM2 metabolic IFNg cytokine MTHFR Drug metabolism VLA4 adhesion 
DARC chemokines IL1 cytokine MUTYH DNA repair XRCC3 DNA repair 
DECTIN1 innate immunity IL10 cytokine NKG2D adaptive immunity     
DNAM1 adaptive immunity IL12 cytokine NLRP2 innate immunity     
ERC2 DNA repair IL13 cytokine NOD2 innate immunity     
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Table 1.1 (previous page): Genes associated with HSCT outcomes from 
248 previous gene association studies. Forty-nine genes (in bold) have 
been implicated with acute or chronic GVHD. 
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SUMMARY 
 
• The genetics of HSCT outcome, including GVHD, involves 
multiple genetic mechanisms. 
• Self/non-self recognition strongly predicts GVHD. 
• Matching of the Human Leukocyte Antigen (HLA) complex 
reduces the risk of GVHD and is widely applied in clinical 
practice. 
• Other self/non-self recognition mechanisms (e.g. KIR, LILR, 
mHag) also influence the risk of GVHD but are less well 
understood and not commonly used in clinical practice. 
• Non-HLA gene polymorphisms modulate innate and 
adaptive immune responses, >100 genes have been 
reported to associate with HSCT outcomes. 
• Results for non-HLA gene polymorphisms are often 
inconclusive due to limited study quality, therefore findings 
have been applied little in clinical practice. 
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1.4. Summary and conclusion; aim of this study 
 
HSCT has become an ever more important treatment option for an ever 
wider variety of indications, now moving well beyond malignant and non-
malignant conditions of the haematopoietic system. The procedure itself and 
surrounding medical and nursing care has evolved dramatically, improving 
cure of the underlying disease and survival, whilst reducing transplant-related 
mortality and morbidity. 
GVHD remains the single major hurdle in wider application of HSCT. Even 
full HLA matching from sibling donors cannot guarantee its prevention, 
indicating that other genetic and non-genetic factors are at play which we are 
just beginning to understand. The research into the KIR and LILR systems 
are likely to provide a better understanding of self/non-self recognition in the 
future. A small number of immunodominant minor histocompatibility antigens 
will probably give explanation for some strong GVHD and GVl effects. Non-
HLA gene polymorphisms determine the ‘milieu’ in which self/non-self 
recognition occurs and may therefore be of important influence on the 
strength of the immune responses leading to GVHD or GVT. 
Despite an abundance of data from >200 previous studies, effects of many 
non-HLA gene polymorphisms remain inconclusive, which is founded in the 
generally small effect size of associations of common alleles and genotypes, 
and issues with study design (heterogeneous study populations, lack of 
statistical power, lack of validation by confirmatory study on a similar 
population). 
The aim of this study is to elucidate the role of non-HLA gene polymorphisms 
for the risk of GVHD in a more robust fashion, by applying recommendations 
for high-quality gene association study design. Key elements of the study 
include: 
 
• Study population: genetically homogeneous background, control of 
clinical confounders, clinically relevant population, adequate sample 
size 
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• Gene targets: More indiscriminate approach (genome-wide/targeted), 
rather than a candidate gene approach 
• More stringent study design: screening and independent confirmation 
cohorts 
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1.5 Outline of study plan/brief history of the project 
 
The idea of this study was conceived in 2004. The author’s plan was to 
conduct a high-quality association study in the field of immunogenetics; the 
search for an adequate study population led to co-operation with institutions 
in Japan. 
In 2005, the author spent six months at the Division of Molecular Life 
Sciences at Tokai University, Kanagawa, Japan, at the invitation of Professor 
Hidetoshi Inoko, a renowned expert in the field of HLA genetics. Tokai 
University hosts the DNA sample collection of JMDP and is involved in many 
of the registry research projects. During these six months, the author 
finalised a proposal for a genome-wide association study into the non-HLA 
genetics of GVHD using microsatellite markers, a methodology also 
pioneered at Tokai University. Dr Peter Middleton and Dr Andrew Gennery 
would act as supervisors for a PhD thesis with Newcastle University, whilst 
Professor Inoko would provide local supervision. 
After funding for this work was obtained (JSPS post-doctoral fellowship, Kay-
Kendall Leukaemia Fund international fellowship), the work started in Japan 
in March 2007. An initial assessment of the availability of DNA samples 
(March-June 2007), however, showed that a genome-wide association study 
would be unfeasible due to the lack of samples with a sufficient amounts of 
DNA. The study plan was adjusted to a targeted genomic screening focusing 
on the immune system. 
The selection of an appropriate study population received particular attention 
in order to control confounding variables (see chapter 2), and a small-scale 
pilot study (October-December 2007) using 41 candidate SNP markers was 
conducted to ensure that a study based on the selected study population 
would be capable of demonstrating small effect-size non-HLA gene 
polymorphisms. After this was achieved, the large-scale approach was 
carried out. Main steps included the identification of the genes of the 
immunogenome and allocation of microsatellite markers (July-December 
2007), pooling of DNA samples (January-March 2008 and December-
February 2009), and genotyping of pooled DNA in a screening (April-
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December 2008) and confirmatory cohort (March-August 2009), followed by 
data analysis and evaluation (until February 2010). 
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2. METHODOLOGY 
 
2.1 Aim and purpose 
2.2 Objectives 
2.3 Study question and hypothesis 
2.4 Overview of Study design 
2.5 Selection of the study population 
2.6 Selection of genes and markers 
2.7 Preparation of DNA 
2.8 Construction of DNA pools 
2.9 Procedure of individual sample DNA PCR 
2.10 Procedure of pooled DNA PCR 
2.11 DNA genotyping 
2.12 Data retrieval and processing 
2.13 Data analysis 
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2.1 Aim and purpose of the study 
 
The aim of this study was to improve health, survival and quality of life of 
recipients of matched unrelated donor HSCT for acute leukaemia by 
identifying genetic risk factors that increase or decrease risk of GVHD. 
This study aimed to identify ‘risk’ and ‘protection’ recipient and donor 
non-HLA genetic polymorphisms that contribute to the severity of acute 
GVHD, enabling clinicians to stratify the risk of GVHD prospectively. 
 
Findings were expected to be applicable to future patient care: 
 
• identified “risk” alleles in donors/recipients that predict the occurrence 
and severity of acute GVHD 
• identification of ‘risk’ donors or recipients as a guide for planning 
conditioning and GVHD prophylaxis regimens 
• identified “risk” genes in donors aid donor selection for reducing acute 
GVHD 
 
Potential broader future scope of results: 
 
• contribution to the understanding of genetic pathology of acute GVHD 
• facilitating the development of new, specific prophylaxis and treatment 
options for GVHD (monoclonal antibodies, gene therapy) 
• impact on research and management of similar or related 
 inflammatory disorders 
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2.2 Objectives 
 
2.2.1. Objective 
 
The objective of this study was to investigate allele frequency 
differences of microsatellite markers between cases of absent or mild 
acute GVHD (grade 0-1, controls) and moderate to severe acute GVHD 
(grade 2-4, cases). As cases we considered HSCT recipients (‚intrinsic’ 
risk of GVHD) as well as donors (‚graft’ risk of GVHD).  
 
 
2.2.2 Key objective elements 
 
Variables 
 
Genetic polymorphisms presenting in the form of microsatellite allele 
frequency differences between the study groups of different severity of 
acute GVHD (grade 0-1 versus 2-4) separately for donors and 
recipients. 
 
Outcome parameters 
  
Pooled DNA genotyping outcomes: 
Moderate to severe acute GVHD (grade 2-4) was the single outcome of 
the two-step pooled DNA screening (discovery and confirmatory 
cohorts). 
Standard definitions and classifications were used to clinically define 
acute GVHD - the modified Glucksberg criteria according to international 
consensus (Glucksberg et al., 1974, Rowlings et al., 1997, Przepiorka et 
al., 1995). 
From a clinician’s perspective, acute GVHD grade 2 was seen as a cut-
off point for starting active and aggressive intervention to stop progress 
of acute GVHD (Hara et al., 2007). Acute GVHD grade 2 or more severe 
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was associated with increased morbidity and mortality, and reduced 
quality of life (Pasquini, 2008, Kanda et al., 2012, Kodera et al., 1999, 
Morishima et al., 2007, Sasazuki et al., 1998, Yano et al., 2000). 
 
 
Individual genotyping: outcomes  
 
• Degree of severity of acute GVHD (grade 0 versus 1-4, grade 0-1 
versus 2-4, grade 0-2 versus grade 3-4, grade 0-3 versus 4) 
• Degree of severity of chronic GVHD (absent chronic GVHD versus 
limited and extensive disease, absent and limited disease versus 
extensive disease) 
• 100 day/one year/three years/five years survival rate, log rank test for 
survival 
• Relapse rate 
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2.3 Study Question and Hypothesis 
 
2.3.1. Study Question 
 
“Are non-HLA microsatellite polymorphisms in unrelated HSCT donor 
and/or recipient immune system genes associated with graft versus host 
disease?” 
 
2.3.2. Hypothesis 
 
The hypothesis was based on the concept that genetic susceptibility to 
GVHD is the result of a complex genetic trait, involving multiple loci:   
 
• GVHD has in part a complex genetic trait, and that common allele 
    polymorphism of non-HLA genes in the patient and donor genomes 
    contribute to the development of GVHD; these risk alleles may 
    be detectable with a systematic genome scanning approach. 
 
• Such non-HLA risk alleles can have an effect size that reaches that 
    of certain HLA mismatches, hence can be consistent despite variation 
    in clinical and genetic risk factors over time. Such risk alleles can be 
    useful for prediction of acute GVHD risk in clinical practice.  
 
Hypothesis: 
“Allele frequency differences of microsatellite markers are associated 
with moderate-severe acute GVHD.” 
 
Null hypothesis: 
“Allele frequency differences of microsatellite markers are not 
associated with moderate-severe acute GVHD.” 
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2.4. Overview of study design 
 
2.4.1. Key features of a robust genetic association study design 
 
Considering the above methodological issues about genetic association 
studies, as discussed in the introduction part of this thesis, a more 
robust design should entail: 
 
•  Study and control cohorts should stem from a genetically 
homogenous population 
• Confounding variables needed to be well controlled 
• Cases and controls needed to be well defined, phenotypes well 
established and graded 
• Environmental factors that influence gene function well established 
• Genes and markers selected that are biologically meaningful 
• Outcomes well defined, consistently reported 
• Study design addressing error by chance, multiple testing issues: 
Design with at least a discovery and independent confirmation cohort, 
appropriate rigorous statistics 
• Sufficiently powered cohorts – adequate sample size 
• Systematic rather than random/candidate marker approach 
 
 
2.4.2. Measures to achieve a more robust study design 
 
This study has taken measures to address the above issues by: 
 
• Identifying of a study population from a more homogeneous 
background 
• Control of confounding parameters: All known genetic, demographic 
and clinical risk factors were carefully analyzed. 
• ‘Modelling’ of hypothetic cohorts were used to design a study cohort 
with ideally minimal confounders and maximum statistical power. 
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• Definition of phenotypes: Ensuring that GVHD in all subjects of this 
study was defined using the modified Glucksberg criteria (Przepiorka 
et al., 1995)  
• Estimating impact of environmental factors  
• Defining the scope of approach: Weighing the advantages and 
disadvantages of different options: candidate gene approach, targeted 
screening, whole genome screening.  
• Addressing type I (incorrectly rejecting the null hypothesis) and type II 
(false acceptance of the null hypothesis) errors by considering issues 
of statistical power, reproducibility, multiple testing. 
 
2.4.3. Outline of the study design 
 
• Modification of a whole-genome scanning approach with microsatellite 
markers (Tamiya et al., 2005). 
• Descriptive, retrospective case-control study with two nested cohorts 
(discovery/confirmatory) of pooled DNA screening, followed by 
individual genotyping of the combined cohorts for confirmation. 
• Selection of a genetically and clinically homogenous cohort of 
approximately n=1000 donor-recipient pairs (see power calculation) 
from the JMDP registry 
• Microsatellite markers as screening tool – indiscriminate approach (i.e. 
large scale rather than candidate gene approach) 
• Focus on immune system genes would be expected to yield targets 
with a higher positive predictive value than a more indiscriminate 
approach. A review of genome-wide association studies on immune 
system disorders had shown that genetic associations are more likely 
to be located in immunoregulatory genes (Zhernakova et al., 2009) 
• Estimating impact of environmental factors by dividing the cohort into 
two subsequent time frames (1993-2000, 2001-2005). HSCT practice 
was likely to have changed during these time periods, not all of these 
changes may have been recorded in the dataset. 
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• Introduction of a two-step independent screening, estimate of 
statistical power, use of statistical correction for multiple testing. 
• A phased, 2-step pooled DNA screening: Splitting of cohort of n=1000 
pairs into two groups of approximately n=500 pairs each. Within each 
group, construction of four DNA pools (Donors GVHD 0-1, Donors 
GVHD 2-4, Recipients GVHD 0-1 and Recipients GVHD 2-4) using an 
established, highly accurate DNA pooling method. Pooled typing of the 
full MS marker set in the 1st screening step, followed by retyping of 
positively associated MS markers only in the confirmatory step, to 
eliminate pseudo-positive markers. 
• Individual genotyping of remaining associated MS markers on the 
combined cohort of approximately n=1000 pairs, to eliminate artefacts 
introduced by DNA pooling. 
• Analyses planned for pooled genotyping: two directions of analysis: 
o Donors GVHD 0-1 with Donors GVHD 2-4 (‘intrinsic risk of 
donor to induce severe GVHD in recipient’) 
o Recipients GVHD 0-1 with Recipients GVHD 2-4 (‘intrinsic risk 
of recipient to develop severe GVHD’) 
• Significance of allele frequency differences would be determined by 
Fisher’s Exact Test for each individual marker allele (2x2 test) and for 
alleles of a marker (2xm test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 51
 
 
 
 
Donors GVHD 0‐1
n=276
Donors GVHD 2‐4
n=184
Recipients GVHD 0‐1
n=276
Recipients GVHD 2‐4
n=184
Discovery cohort – pooled DNA
n=460 donor/recipient HSCT pairs ‐ 4 DNA pools
4321 microsatellite markers (20,194 alleles)
Confirmation cohort – pooled DNA
n=462 donor/recipient HSCT pairs – 4 DNA pools
Positive markers
2x2, 2xm
Donors GVHD 0‐1
n=225
Donors GVHD 2‐4
n=237
Recipients GVHD 0‐1
n=225
Recipients GVHD 2‐4
n=237
Positive markers
2x2, 2xm
Same OR direction
Positive markers
2x2, 2xm
Same OR direction
Individual genotyping
n=922 donor/recipient pairs (combined discovery/confirmatory cohorts)
Positive markers
2x2, 2xm
 
 
Figure 2.1: Overview of the design of this study. In a first screening 
step (Discovery Cohort), microsatellite markers representing the 
entire immunogenome are typed on pooled DNA of 460 HSCT 
recipients and their donors; aiming to detect allele frequency 
differences between those recipients and donors of no or low 
grade GVHD (grade 0-1) and those of moderate to severe grade 
GVHD (grade 2-4). Positive markers only will be taken over to a 
second screening step (Confirmation Cohort) with an identical 
setup. Markers still remaining associated with GVHD will then be 
typed on all individuals of the combined discovery and 
confirmation cohorts. 
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2.4.4. Ethical approval 
 
Ethical approval to this study was granted by the Ethics Committee of 
the School of Medicine of Tokai University, approval number No 02-4-1, 
9 June 2006. 
This study was also approved by a meeting of the Research Committee 
of the Japan Marrow Donor Programme (JMDP). Use of DNA samples 
and clinical data was explicitly granted. Donors and recipients have 
given written informed consent at the time of graft harvesting or 
transplantation for DNA samples and data to be used for research 
purposes, according to the declaration of Helsinki. 
 
 
 
 
 
Summary –  study design 
 
• Study cohort from a genetically homogenous population 
with little/no admixture, controlled confounding 
parameters, well defined phenotypes and outcomes 
• Sample size with adequate statistical power 
• Confirmatory testing of identified associations in two 
independent cohorts 
• Targeted genome scanning approach, focusing on 
biologically meaningful genes 
• Using microsatellite markers in a pooled DNA typing 
approach 
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2.5. Selection of the study population 
 
2.5.1. Analysis of JMDP registry population and cohort selection 
 
The JMDP registry confirmed that all selected HSCT pairs were of 
Japanese origin – hence there was no genetic admixture other than that 
of the overall Japanese population. 
For the purpose of selection of study cohorts, an opportunity was given 
to analyze data from the JMDP registry of unrelated donor HSCT 
performed between 1993 and 2000 (n=2469 HSCT pairs) for risk factors 
of acute GVHD grade 0-1 versus grade 2-4. This was followed by 
‘modelling’ of potential study cohorts according to the identified risk 
factors, aiming for a clinically meaningful study population with an 
optimal control of confounding variables. Given here is a brief summary; 
the details of the analysis are available in supplementary file 2.1. 
Univariate and backward multivariate logistic regression analyses were 
performed on the registry population. Univariate analysis showed that T-
cell depletion, antithymoglobulin (ATG), HLA matching, GVHD 
prophylaxis with a tacrolimus-based regimen, standard dose 
cyclophosphamide/total body irradiation (Cy/TBI) conditioning regimen, 
donor age ≤30 years, and underlying diagnosis other than acute 
lymphoblastic leukaemia (ALL) or chronic myeloid leukaemia (CML) are 
all protective of acute GVHD grade 2-4. Multivariate analysis was 
performed by stepwise logistic regression, including all the variables 
showing associations in univariate analysis. ATG administration, HLA 
matching, GVHD prophylaxis with tacrolimus, donor age ≤30 years and 
Cy/TBI standard regimen were upheld in the final step of multivariate 
analysis.  
Based on these findings, four model cohorts were devised, by selecting 
out for the established risk factors in a step-wise fashion. Decision 
criteria included the results of multivariate analyses of the models, 
clinical meaningfulness of the model, and available sample size. 
Eventually, the most suitable model for the discovery cohort was a 
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selection by diagnosis (acute leukaemia: ALL and acute non-
lymphoblastic leukaemia (ANLL)), recipient age ( ≥4 years, ≤40 years) 
and no T-cell depletion; resulting in a cohort of approximately 1000 
sample pairs. This selection would include all degrees of HLA matching 
and mismatching, and therefore somehow reflect a population as 
typically seen in HSCT practice. 
 
 
2.5.2. Power estimation 
 
A statistical power estimation (conducted by Dr Hirofumi Nakaoka, 
details in supplementary file 2.2) showed that a sample size of 
approximately 500 pairs per cohort would be required to provide 
sufficient statistical power (0.8) to demonstrate effect sizes of an Odd’s 
ratio of 1.5 at allele frequencies of 0.3-0.6. Larger effect sizes would 
detect lower frequency allele associations (approximately allele 
frequency of 0.1 for OR=2.0; allele frequency of 0.05 for OR=2.5). 
Associations with an OR between 1.3-1.5 represented the lower limit of 
detection for the screening and confirmatory cohorts. 
 
 
2.5.3. Construction of the actual study cohorts 
 
The next step in constructing the actual study cohorts was an 
assessment of DNA sample availability (supplementary file 2.3). This 
assessment showed that of the initial n=1000 sample pairs, n=112 were 
depleted of DNA, and a further n=345 sample pairs were transferred for 
use for another study. The DNA content of each available sample was 
determined by DNA quantification and multiplication by volume. This 
revealed that a genome-wide study would have been unfeasible 
because the vast majority of samples would not provide sufficient DNA. 
However, for a targeted genome scanning or a candidate gene approach 
enough samples would have been available. The options were 
discussed amongst all contributors and decided to opt for a targeted 
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genomic scanning (of immune system genes) in a two-step pooled DNA 
screening design. For the first step, samples of the 1993-2000 registry 
cohort would be included, for a second step samples from a later cohort 
(2001-2005) would be made available by JMDP. 
Based on the estimates made of DNA amount required (see section 
2.7.2. below), sample pairs were selected on the basis of DNA amount 
availability for both samples per pair (supplementary file 2.3). N=460 
pairs were chosen from the 1993-2000 registry cohort for the discovery 
cohort (first screening step), following the criteria: Diagnosis (acute 
leukaemia: ALL and acute non-lymphoblastic leukaemia (ANLL)), 
recipient age ( ≥4 years, ≤40 years), full bone marrow as stem cell 
source and no T-cell depletion. 
The same criteria were used for selection of the confirmatory cohort, this 
time incorporating HSCT pairs from the time period 2001-2005. The HLA 
matching of the confirmatory cohort were to be ‘adjusted’ to that of the 
discovery cohort by pairing of each sample pair for HLA matches and 
mismatches at the same HLA locus, or combination of loci. 
The characteristics of this population are shown in supplementary file 
2.3. 
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SUMMARY - cohort construction 
 
• Careful univariate and multivariate analysis of a large stem 
population (here: JMDP HSCT registry 1993-2000, n=2469 
HSCT) can provide a good understanding of demographic, 
clinical and genetic risk factors for the intended outcome (here: 
GVHD grade 2-4). 
• Designing of hypothetical cohorts with repeat univariate and 
multivariate analysis can optimize control of confounding 
variables whilst maintaining adequate sample size for good 
statistical power. 
• The heterogeneous nature of HSCT, lack of large numbers of 
study subjects, and variability of HSCT management over time 
makes control of confounding variables difficult. 
• The cohort construction of this study faced challenges over the 
availability of DNA samples, demanding a flexible approach to 
cohort and study design. 
• The process resulted in devising of two study cohorts with well 
established confounders (i.e. diagnosis, HLA mismatch as the 
most consistent), and a strategy for a study design 
(confirmation by independent cohort).  
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2.6. Selection of genes and markers 
 
2.6.1 Systematic identification of genes 
 
As outlined above, it was decided to adopt an approach of a targeted 
genome scanning, focusing on genes that are biologically meaningful in 
the context of GVHD. The pathobiology has been studied in some detail 
(Ferrara et al., 2003, Duran-Struuck and Reddy, 2008, Sun et al., 2007). 
Key pathophysiological pathways are located within the immune system, 
or are driven by immune responses:  
 
• Development and maturation of immune cells 
• Innate immunity 
• Adaptive immunity 
• Lymphocyte receptor repertoires, MHC, tyrosine kinases, protein 
kinases 
• Pattern recognition – Toll/like Receptors 
• Effector pathways of lymphocytes – apoptosis 
• Intracellular mechanisms 
• Extracellular mechanisms (cytokines, complement, chemokines) 
• Modifiers of immune responses 
 
The approach was inclusive of genes for which some involvement with 
the immune system was described, rather than exclusive of genes 
without described immune system involvement; because such a role 
may not yet have been investigated for many genes. Exclusion on the 
basis of absent evidence would be more arbitrary then inclusion of 
genes for which such evidence exists; recognizing, however, that such 
an approach had its limitations as potentially relevant genes may not 
have been included. The minimum inclusion criteria for admission into 
the immunogenome panel were a functional role of the gene in 
immunoregulation (i.e. function of the transcribed gene product or a 
genetic variation of the gene) and belonging to the same gene family of 
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such a gene. Genes that would not fulfil these criteria would not be 
included in this study. As the search approach was inclusive and aimed 
at identifying those genes that were eligible rather than those that were 
not, there was no active process of exclusion. A literature search was 
carried out using defined search terms with the objective to compile a 
complete ‘Immunogenome’. This literature search included general 
textbooks (Janeway et al., 2005, Mak and Saunders, 2006) and used a 
wide variety of databases to broaden and deepen the search, as well as 
to include the very latest information from recently published journal 
papers. Overall information on candidate genes were extracted from 
>2000 journal papers. 
In addition, genes specifically linked to GVHD and other HSCT 
outcomes were traced and categorised: 
 
• Genes associated with GVHD and other HSCT outcomes in previous 
studies 
• Genes whose expression has been associated with GVHD and other 
HSCT outcomes 
• Genes that have been associated, by identification of polymorphism or 
gene expression, with immune processes that are highly relevant also 
in the GVHD pathophysiology 
• Genetic susceptibility loci of acute leukaemia (as potential 
confounders as these have an impact on survival) 
• Genes that may have implications for GVHD or transplant outcomes in 
a broader sense, e.g. enzymes and other metabolic genes influencing 
immune responses, drug metabolism genes, DNA repair genes, etc. 
 
Gene names were initially compiled in a list, which was standardised to 
current nomenclature by identifying the official gene symbol from the 
GeneCard and NCBI databases. Additional information, such as the 
exact genomic location, was retrieved. Literature searches were ongoing 
throughout the duration of the project until completion of genotyping 
work (February 2010) to include cutting-edge research and new 
 59
associations. The compiled ‘HSCT-specific Immunogenome’ included 
eventually n=3093 genes (see supplementary file 2.4). Finally, this 
‘immunogenome’ was compared with a similar collation reported in the 
previous literature (Ortutay and Vihinen, 2006), finding that genes from 
this previous study were included, but that this study’s gene inclusion 
was far more comprehensive than that of the previous one.  
 
2.6.2. Selection of MS markers 
 
With regards to larger scale and genome wide studies Lander et.al. 
pointed out that genetically younger, isolated populations have larger 
haplotype blocks with wider linkage desequilibrium, requiring fewer 
markers, and predicatively less disease alleles (Lander and Schork, 
1994). 
MS markers for this study were selected from the existing panel of 
approximately 30,000 markers routinely used for whole genome 
association studies. 
This marker panel was collated over several years by a research team at 
Tokai University devoloping the above mentioned genome wide 
scanning methodology (Tamiya et al., 2005) with MS markers. Almost 
70,000 markers were typed on different East-Asian populations 
(Japanese, Mongolian, Korean), and eventually 30,000 markers selected 
that were highly polymorphic, had a limited average number of alleles 
(6.4+/-3.1) and an average heterozygosity of 0.67+0.16. According to 
haplotype block structure of East-Asian populations, which was well 
preserved in Japanese in particular, an average marker linkage 
disequilibrium (LD) of 100 kB was estimated. Markers were also 
selected by position, aiming to chart the entire euchromatic genome at 
regular 100 kB intervals, thus providing overlapping/double coverage for 
each LD region. For 95% of the genome marker coverage with inter-
marker distance of <200kB was achieved. 
 
For this study, markers from this panel were selected that would flank 
the candidate gene to provide overlapping cover within the range of LD, 
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estimated to be approximately 100 kb. Hence, if the two flanking 
markers would be no more than 100 kb apart, full overlapping coverage 
for the locus would have been provided. 
 
In this study, of the n=3,093 target genes, n=184 (6%) had to be 
excluded because these were located in regions lacking appropriate 
microsatellites or their exact genomic location was unclear. For n=34  
further genes not represented by the marker panel we identified suitable 
microsatellites and designed primers accordingly (appendix 2.2). 
The final selection included n=2,909 genes. Because many of these 
genes were located in clusters at close proximity, n=2,297 target genes 
were selected as representative for the n=2,909 genes (table 2.1). 
These gene loci were tagged with n=4,321 microsatellite markers 
(supplementary file 2.5). When measuring the distance between the 
centre of the gene and the marker start point, for 88% of target genes 
full overlapping coverage within a 100 kb range was identified. A further 
8% of genes had partial coverage within estimated LD, with one or two 
flanking markers at >100 kb but <200 kb range. For 3% of target genes 
the range of one or two microsatellite markers was >200 kb (table 2.2). 
Each target gene locus was tagged with an average of 1.8 microsatellite 
markers. There was a broad variation in the number of markers covering 
a gene locus, between a single flanking marker pair covering several 
candidate genes in regions of high gene density, and up to ten markers 
covering a single, very large gene. It was estimated that the total LD 
range of the selected markers taken together may cover up to 15% of 
the genome (table 2.3), hence cover substantially more genes than the 
selected target genes. From the number of genes within the LD range of 
65 microsatellites (associated at an interim step in pooled screening) we 
extrapolated that our selection of microsatellite markers may have 
covered up to a third of all human genes. 
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  N= % 
Selected immunogenome genes 3,093     100  
Unknown gene location/no marker 184         6 
Immunogenome genes included in this 
study 2,909       94 
Target genes selected to represent 
immunogenome of 3,093 genes 2,481 100 
Included: genes covered with markers 
from MS panel 2,263 91.2 
Included: genes for which markers were 
designed 34 1.4 
excluded: unknown gene location -35 -1.4 
excluded: no MS marker available -149 -6.0 
Total target genes included in study, 
representing 2,909 immunogenome 
genes 2,297 92.6 
 
Table 2.1: Gene and marker selection. As many MS markers had 
several genes within their LD range, one ‘target gene’ was selected 
for each such MS marker. For 7.6% of gene loci appropriate marker 
cover could not be established. 
 
Markers markers % 
Total markers selected: 4,321   
Total genes selected: ,2297   
Markers per gene average: 1.88   
Markers intronic: 1,320 30.55 
Markers outside genes: 3,001 69.45 
markers/genes covered with 2 flanking 
markers within 100 kb range 3,801 87.97 
markers/genes not covered with 2 
flanking markers within 100 kb range 516 11.94 
markers exact location unknown 4 0.09 
  4,321 100 
 
Table 2.2: Specification of the degree of LD coverage of genes 
provided by the selected MS markers 
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  n= % 
Base pairs human genome 3,164,700,000 100 
LD cover 4321 MS markers 432,100,000 13.7 
Total number of genes human 
genome 30,000 100 
Estimated genes covered by 
4321 MS markers 10,301 34.3 
 
Table 2.3: Estimation of total gene coverage of the selection of MS 
markers for this study. Data on the number of base pairs and genes 
of the genome are from the Human Genome Project website. LD of 
MS markers assumes 100kb, and the estimated number of genes 
covered by this selection is an extrapolation from the number of 
genes within the 100 kb LD range of 65 MS markers from this study. 
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Summary – genes and markers 
 
• As GVHD is a disorder of immunoregulation, associated 
polymorphic genes are more likely to be located in the 
immune system. Targeting functional and structural genes 
of the immune system would be expected to yield a higher 
positive predictive value for such associations than a more 
indiscriminate approach. 
• A genomic screening of the immunogenome is feasible at 
high density with gene-flanking microsatellite markers. 
• Due to their long range linkage disequilibrium, 
microsatellite markers cover large genomic areas around 
the target genes. 
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2.7. Preparation of DNA 
 
2.7.1 Provision of DNA samples 
 
All DNA samples for this study were provided by JMDP, DNA 
preparation was not part of this study. In brief, samples were obtained 
from patients and donors at the time of HLA matching confirmation and 
stored for research purposes with appropriate consent. Tokai University 
is hosting the sample collection for JMDP. 
Fresh samples were centrifuged and the buffy coat removed, from which 
the DNA of nucleated cells was extracted using commercial DNA 
extraction sets (QIAmp DNA blood extraction kit®, QIAGEN). 
 
 
2.7.2 Estimation of DNA requirements for this study 
 
The requirement of DNA amount was determined mainly by two factors: 
The number of planned reactions (i.e. the number of microsatellite 
markers, approximately n=4,000), and the DNA concentration of the 
DNA pool aimed for. The latter one depended on the DNA samples with 
the lowest DNA concentration to be included, and had its limitation in the 
composition of the PCR mixture. The standard PCR mixture for this 
experiment had a total volume of 20 μl, of which 8 μl was dedicated for 
the DNA. Dilution of the DNA sample was limited by the need for a 
restricted use of TE buffer (as >10 μl buffer per well is known to inhibit 
the PCR reaction). In addition, if the total amount of DNA in the reaction 
was <40 ng, PCR might become more unstable and the capability to 
detect small allele frequency differences of MS markers decreases 
(observations by Dr Akira Oka of his own experiments). 
As the lowest sample concentrations was approximately 10 ng/μl, the 
estimated final DNA pool concentration would be approximately 6-8 
ng/μl, therefore total amount of DNA per reaction well is 48-64 ng. Thus, 
the amount of DNA required from each sample varied with the total 
 65
number of individual samples in the pool – the higher the number of 
individual samples, the lower the amount of DNA required from each 
individual as the total amount of DNA per marker plate well was constant.  
Based on the measurements of DNA concentrations, estimates of total 
amount per sample, and a preliminary estimate of total DNA 
requirements for the study, only samples with a total DNA amount of >4 
μg were ‘shortlisted’ for the first pooled screening, and samples with an 
amount of >2.5 µg for the second pooled screening (details of the 
estimation of DNA amounts required: appendix 2.3).  
 
 
2.7.3 Measurement of DNA concentration 
 
Amount of DNA available was likely to be limited, given the age of DNA 
samples, the large number of previous studies performed on this 
collection, and the large amount of DNA required for this study. 
In order to preserve the collection for future work, it was agreed with 
JMDP that the total DNA amount of each selected sample would be 
assessed by measurements of concentration and volume. DNA 
concentration of each selected sample would be determined by an 
established standardized method for measurement of DNA 
concentration (PICO Green®), and volume would be estimated by visual 
comparison with a standard volume set (identical sample tubes with 
volumes in steps of 50 µl, ranging from 50 - 1000 µl). 
 
For the DNA concentration measurement with PICO green® dsDNA 
quantification kit (Molecular Probes, P-7589) a DNA dilution of 1:200 
was used according to the maker’s instructions. In preparation, 5 µl of 
original DNA was diluted in 995 µl of 1/10 TE buffer pH 7.5. Of this 
solution, 100 µl was pipetted onto the measurement plate and incubated 
for 3 min with a 100 µl of a 1/200 solution of PICO green fluorescent 
reactant. For quality control, a set of different concentrations of a 
standard DNA of a known concentration was divised: 1/1000, 1/300, 
1/100, 1/30, 1/10 dilutions as well as a control well containing buffer with 
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no DNA. Three independent measurements were then obtained using a 
Flouroskan Ascent CF (Thermo Labsystems) photometer, with settings: 
Integration time 20 ms, filter pair: Excitation 485nm, Emission 527nm, 
normal beam, single measurement. A customized excel worksheet was 
used for quality control and calculation of concentrations.    
 
 
2.7.4. Estimation of total DNA amount of sample, allocation of pairs 
to screening steps 
 
Availability of DNA concentrations and sample volumes were allowing 
for a more exact estimation of total available DNA amount per sample. 
The total content of a DNA per sample in ng/μl was estimated by a 
simple formula: 
 
Total amount of DNA/sample in ng = DNA concentration in ng/μl x 
sample volume in μl 
 
Sample pairs were then ranked according to DNA amount in both 
partners in descending order, grouping them in three distinct groups: 
 
• Total amount >4,000 ng: For inclusion into 1st pooled screening 
• Total amount >2,500 ng: For inclusion into 2nd pooled screening 
• Total amount >500 ng: For inclusion into individual typing 
• Total amount <500 ng: exclusion from the study 
 
 
 
Decision on inclusion and exclusion from the study, and allocation to 
pools were based on the estimated requirements, the total amount of 
DNA available per sample, and the original sample concentration.  
Agreement with JMDP on sample handling, in- and exclusion criteria: 
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• At least a minimum of 500 ng of DNA should remain in each sample, 
hence samples with an amount of DNA of 500 ng or less were 
excluded from the study. 
• Samples with a total amount of 4,000 ng or more were included into the 
first screening, pipetting 3,500 ng 
• Samples with a total amount between 2,500 and 4,000 ng were 
included into the second screening, pipetting 2000 ng 
• From samples with a total amount between 1000 and 2500 ng, 500 ng 
were pipetted to store for inclusion into individual MS or SNP typing. 
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2.8 Construction of DNA pools 
 
2.8.1. Considerations for definition of DNA pools 
 
At the outset, decisions had to be made on defining the pools (‘which 
samples to pool together?’) and how large the intended pool was going 
to be. Key aspects here are: 
 
• Sufficient statistical power of individual pool: The power calculation 
(see above) suggested that a minimum pool size should be in the 
range n=200-250 samples (at a cohort size of 400-500). 
• The definition of pools should be clinically meaningful 
 
Although it would have been desirable to pool different degrees of 
GVHD (e.g. grades 0, 1-2 combined, 3-4 combined) separately, resulting 
pool sizes would not have provided a sufficient statistical power. From 
the sample numbers available, separating degrees of GVHD into two 
groups seemed the only feasible option. Donors and Recipients were 
pooled separately but accordingly. 
Three scenarios were considered: 
 
• Grade 0 GVHD versus Grade 1-4 GVHD. This approach would have 
separated samples at a ~50:50 proportion, in view of statistical power 
the strongest option. Drawback: Would not have distinguished 
between degrees of GVHD, but only presence of GVHD yes/no. 
• Grade 0-1 GVHD versus Grade 2-4 GVHD: Would have separated 
samples at a ~2/3: 1/3 proportion. Resulting in acceptable power, and 
would have distinguished groups with a survival advantage from 
groups with survival disadvantage, also marking the stage of clinical 
intervention. Drawback: May not have distinguished risk genes for 
severe GVHD very clearly. 
• Grade 0-2 GVHD versus Grade 3-4 GVHD: Would have separated 
samples at a ~3/4:1/4 proportion. Advantage: Clearly would have 
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distinguished severe GVHD. Disadvantages: Reduced statistical 
power for severe GVHD group, would have ignored distinction by 
survival and point of clinical intervention. 
 
The decision to choose the Grade 0-1 GVHD versus Grade 2-4 GVHD 
was based on: 
 
• The aim of the study to provide a risk predicting tool for clinical 
decision making – determining which genetic risks separated 
recipients with favourable and poor survival perspective, and which 
genetic risks separated recipients requiring treatment intervention 
from those who did not. 
• The acceptable statistical power for this option. 
 
 
2.8.2. Existing methods of DNA pooling 
 
Methods of DNA pooling and their accuracy compared to individual 
typing and family typing for the study of complex genetic diseases had 
been described previously (Shaw et al., 1998, Barcellos et al., 1997, 
Craig et al., 2005, Hoffjan et al., 2006). 
Here a high-accuracy pooling method was applied that was a standard 
procedure for genome wide association studies (GWAS) in the same 
department (Tamiya et al., 2005, Oka et al., 2003, Collins et al., 2000, 
Daniels et al., 1998), which had been  modified further to increase 
accuracy (unpublished, internal validation data available). 
 
In some aspects the application of the pooling method differed from the 
application to WGA studies: 
 
• This study cohort consisted of paired samples – therefore inclusion of 
both partners was essential to reflect allele frequency differences. 
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• Genome wide association studies (GWAS) with microsatellites rarely 
used pool sizes >200 samples – there were no data on pooling 
accuracy for such a pool size. 
• DNA amount, concentration and quality was very variable – compared 
to previous studies, samples of this study had rather low DNA 
concentrations.  
 
The initial preparation of samples consisted of measuring sample DNA 
concentration measured by the PICO green® method (described above). 
 
Key features to ensure a high accuracy of DNA pooling were: 
 
• The use of calibrated pipettes for all pipetting 
• Repeat measurements with PICO green®, acceptance of a narrow 
variation margin (<5%) only for DNA pooling 
 
 
2.8.3. Practical procedure of DNA pooling 
 
Sequential steps were involved in the pooling process. The pooling 
process was divided into four phases. 
 
Phase 1 – Individual sample measurement 
 
• Pipette testing (procedure described in appendix 2.4) 
• Dividing samples into groups of the intended pools (see above) 
• Ranking of samples by DNA concentration in decreasing order 
• Dividing of the sample group into sub-groups of 96-well plate format 
size 
• Choosing a target concentration for each group. To pool equal 
amounts of DNA at equal concentration, by definition the final pool 
concentration was determined by the lowest sample concentration, 
towards which the pooling process aimed. The limitation of this 
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approach lay within a minimum concentration of 6 ng/μl required for 
pooled DNA PCR. Thus, any samples with a lower concentration had 
to be excluded; and caution had to be applied not to dilute low 
concentration samples too much to render them unsuitable. As higher 
concentrations ranged from ~30 – 200 ng/μl, a step-wise approach in 
dilution was applied, diluting the first group of samples to a target 
concentration of ~25 ng/μl. 
• Dilution to this initial target concentration (using non-calibrated 
pipettes) and measurement of sample concentration by PICO green 
(the PICO green assay set up by using calibrated pipettes) using 1/10 
TE Buffer pH 8.0. Three measurements were performed on the same 
plate, and an average concentration calculated. 
• Ranking of tested samples in decreasing order of concentration. 
Exporting result file into excel to identify subgroups of samples that lie 
within a +/- 2.5% range of concentration – separation of these 
samples for small pool construction. 
• The remaining samples of all subgroups combined were again ranked 
in decreasing order of concentration. A new subgroup of plate format 
size is identified, a new target concentration chosen, dilution and 
concentration measurements performed. Again this subgroup was 
ranked by sample concentration, groups for intermediate pool 
construction identified and separated. 
• This procedure was repeated until all samples were allocated to 
intermediate pools. This procedure required 3-5 rounds until all or 
most samples were resolved. Concentration of the last small pools 
often approached required minimum concentration of the final DNA 
pool. Occasionally, a very few samples with borderline-low 
concentration were allocated into the final DNA pool, rather than one 
of the intermediate pools. 
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Phase 2 – Construction of intermediate pools 
 
• Using the calibrated pipettes, between 5 and 13 intermediate pools 
were created from each group of samples representing a DNA pool. 
The average concentration of samples considered for each 
intermediate was calculated as a fixed volume to be pipetted into the 
intermediate pool. The volume depended on the intended DNA 
amount for the final DNA pool. 
 
Phase 3 – Construction of final DNA pool 
 
• The concentration of intermediate pools was assessed by PICO green 
measurements (each pool in three independent wells, three 
measurements per well, calculation of average) 
• Careful, stepwise dilution of intermediate pools was applied to adjust 
these pools to an equal concentration within a range of +/- 2.5% 
• Intermediate pools were then pooled together using calibrated 
pipettes to achieve a final DNA pool 
 
 
Phase 4 – Adjusting final DNA pool concentrations 
 
• In order to ensure comparable conditions among all pools (i.e. 
measurement of true allele frequencies), final DNA pools in each 
screening step were also adjusted to an equal concentration, amount 
and volume. 
• DNA pools were assessed in the same way as intermediate pools by 
multiple, repeat concentration measurement. 
• Concentration was adjusted by a cautious stepwise dilution (2-3 
steps) towards the pool with the lowest concentration, accepting a 
range of no more than +/- 2.5%. 
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DNA pooling represented the most technically difficult step of this project. 
To keep a consistently high standard and avoid human error, these 
considerations were applied: 
 
• Use of calibrated pipettes for all pipetting actions (except the initial 
sample dilution, see appendix 2.4). All calculations of DNA amount 
and sample volumes were based on the actual volumes measured in 
pipette testing, rather than the nominal volume on the pipette. 
• Careful tracking of all pipetted volumes, correcting at each step for 
volumes abstracted for concentration measurements. 
• DNA protection by aseptic working conditions, light protection 
• Adequate mixing at spinning at each handling step 
• DNA-saving approach: Dilution to low concentration, early pooling into 
intermediate pools to avoid DNA-consuming repeat measurements 
(the Tokai standard protocol dilutes all samples to a relatively low 
concentration within a narrow margin of variation +/- 5%) before 
constructing intermediate pools of equal sample numbers). To 
compensate for the possibly induced increased variation, we 
decreased the margin of variation to +/- 2.5%. 
• The pooling strategy resulted in a number of intermediate pools with a 
wider range of concentrations – again, we compensated by applying a 
more narrow margin for concentration variation (+/-2.5% for 
intermediate and large pools)  
• Requirement for DNA top-up of low concentration samples for 
inclusion – for a small number of samples, top-up with highly 
concentrated original DNA was necessary to increase concentration to 
a level suitable for inclusion.  
 
Results of the pooling process 
 
Due to the requirement of highest attainable accuracy, pooling of DNA 
was a time consuming process. Construction of each DNA pool took 
between 3 and 6 weeks. 
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Table 2.4 summarizes the eight DNA pools constructed, and Figure 2.2 
illustrates a typical process of pool building.  
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1st Screen     
Pool 
average 
concentration 
ng/μl 
No. 
individuals 
Pool volume 
(ml) 
DNA amount 
pool (ng) 
DNA amount 
per individual 
(ng) 
D01 6.78688 276 82382.57 559120.6 2025.799 
D24 6.6247 184 90477.92 599389.1 3257.549 
P01 6.426204 276 83366.22 535728.4 1941.045 
P24 6.487866 184 83667.12 542821.1 2950.115 
      
Average all 6.581412     
      
2nd screen     
Pool 
Average 
concentration 
ng/μl 
No. 
individuals 
Pool volume 
(ml) 
DNA amount 
pool (ng) 
DNA amount 
per individual 
(ng) 
D01 20.10275 225 18115.88 364179 1618.573 
D24 19.78577 237 18992.85 375788.2 1585.604 
P01 20.40206 225 18231.22 371954.4 1653.131 
P24 20.48707 237 19979.93 409330.3 1727.132 
      
Average all 20.19441     
 
 
Table 2.4: Constructed DNA pools for 1st and 2nd screening. Concentration variation for each screening step is within a 2.5% 
margin of the average concentration. Note that samples of the first screening step were diluted previously and had therefore a 
lower initial concentration than samples of the 2nd screening, explaining the difference in concentration. 
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Fig 2.2: Example of a ‘pooling tree’, summarising the pooling 
process (here for the Donor GVHD grade 0-1 pool of the 2nd 
screening). Individual samples are concentration-adjusted and 
then pooled into small pools (here: 12 small pools). These small 
pools are then concentration-adjusted again and pooled together 
into intermediate pools. In a stepwise process one large pool 
results. Some individual samples of low initial concentration have 
to run alongside to be added to intermediate pools or even the 
final large pool. 
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2.8.4. Quality control of pooled DNA 
 
Test marker for pooled/individual PCR and genotyping 
 
Prior to embarking on pooled genotyping, individual DNA samples and 
pooled DNA were tested for accuracy with the applied methods by 
typing of a microsatellite test marker. 
 
Objectives of test marker typing: 
 
• To ensure appropriate PCR conditions 
• To investigate if the different amounts of DNA lead to appropriate 
PCR results 
• To define the optimal typing dilution 
• To investigate whether the results of pooled PCR typing reflect 
results of individual typing (= quality check of DNA pooling process) 
 
Microsatellite marker 066B03 was a standard test marker that had 
been used in most previous microsatellite genome-wide association 
studies from this laboratory to study the quality of DNA pools. It 
amplified well under standard pooled PCR conditions, and typed well 
under standard typing conditions. It had six major alleles, and reflected 
therefore an ‘average’ microsatellite. 
 
Important variables of the PCR and genotyping process (details see 
below) were the amount of DNA used in the PCR mixture, and the 
dilution of resulting DNA product used for the genotyping process. Both 
of these factors could influence the fluorescent signal in genotyping, 
which determined the allele frequency in the pool. For this experiment, 
a high, medium and low level DNA setup was chosen (appendix 2.5) 
for the PCR procedure, and the PCR product diluted for each of these 
x10, x20 and x40. This was performed separately for each of the DNA 
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pools, and then compared with results from typing all 922 HSCT pairs 
individually. 
 
The results of the test marker typing were summarized in the 
supplementary file 2.6. 
 
Comparison of allele frequencies between pooled and individual 
genotyping showed a very high concordance between pooled DNA and 
individual sample typing. Using a high amount of DNA gave results 
most accurately reflecting allele frequencies seen in the individual 
typing. Dilution of the PCR product had relatively little influence on 
results, although we saw increasing inaccuracies with using the higher 
dilution.  
Using high amount DNA and a PCR product dilution x20, the mean 
difference in allele frequency for the test marker in the discovery cohort 
was 0.45% (standard deviation (SD): -2.61 – 0.942%, range -5.42-
6.3%); for the confirmatory cohort -0.08% (SD: -0.62 – 0.26%, range -
1.16 – 0.82%). The pooled genotyping was able to pick up allele 
frequencies as low as 0.02. There were no significant differences in 
allele numbers for frequencies of 0.05 and above, which we therefore 
used as a lower cut off value for reporting allele frequency in this study.  
 
For the process of pooled DNA PCR and genotyping, a high amount of 
DNA (93 ng/reaction) for PCR and a PCR product dilution x20 was 
chosen. 
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2.9. Procedure of individual sample PCR 
 
As a first step, two sets of individual typing master plates of individual 
samples were created. Using concentration data from DNA pooling, the 
volume required was calculated to pipet an amount of 100 ng of DNA 
(an amount estimated to cover all individual genotyping needs of this 
study). Matching volumes of dH2O were added manually to achieve a 
concentration of 1ng/ μl. 
Using a Beckman MultiMek pipetting robot (Beckman Coulter Inc), 50 
μl/well of this solution was separated onto yet another set of plates. As 
a final step, again using MultiMek, both sets of plate were diluted by 
pipetting 50 μl/well of dH2O to a final concentration of 0.5 ng/ μl. 
 
Sequence of Individual PCR and genotyping: 
 
• A set of reaction plates was prepared in accordance with the 
individual typing DNA masterplates 
• Using Beckman MultiMek, 2 μl of DNA were transferred from the 
master plate onto the reaction plate 
• A PCR reaction mixture for individual typing was prepared in a tube 
at -30°C: 
 
dH2O     5.45 μl/well 
ABI 10x Buffer   1.00 μl/well 
ABI 2.0 M dNTP   1.00 μl/well 
Roche AmpliTaq Gold 5U/ μl 0.05 μl/well 
Primer Mix 10 μM each  0.5 μl/well 
 
• Using a reservoir, 8 μl/well of this solution was pipetted into each 
well using MultiMek. 
• PCR conditions on an ABI gene amplification system (Applied 
Biosystems) were used as described in the protocol (figure 5); here 
56°C were applied as annealing temperature for both markers. 
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• Individual genotyping was identical to the protocol for pooled 
genotyping (see above), a dilution of x20 was used for individual 
plates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
81
81
 
Individual DNA Typing 
(PCR)    
    
Marker:    
    
Basic Mixture    
    
Ingredient per well Total (x1030) Lot 
dH2O 5.45 5613.5   
10x Buffer 1 1030   
2.0 mM dNTP 1 1030   
Ampli Taq Gold 5U/ul 0.05 51.5   
Primer mix 10 uM each 0.5     
DNA (0.5ng/ul) 2     
sum 10 7725   
    
Main Marker Mixture    
    
Ingredient x1000 wells   
Basic mixture 7500   
dH2O 400   
primer F- 100uM 50   
primer R- 100uM 50   
sum 8000  - 8ul/well  
    
Control Marker Mixture    
    
Marker 1:    
Marker 2:    
    
Ingredient x12 wells x2  
Basic mixture 90   
dH2O 3   
Primer mix 20M each) 3   
  96  - 8ul/well  
    
PCR settings    
    
95 C 9 min   
* 1 min  hold  
72 C 1 min     
96 C 45 sec   
* 45 sec 40 cycles  
72 C 1 min   
72 C 5 min   
4 C ∞ hold  
 
 
Figure 2.3: Protocol and worksheet for individual MS PCR 
  
82
82
2.10. Procedure of pooled DNA PCR 
 
2.10.1. Primer preparation 
 
Primers for microsatellite markers (Sigma-Genosys, Japan) were 
extracted manually from master plates of the MS marker collection for 
genome-wide association studies onto plates specific for this study. 15 
μl of 10μMol primer mix were pipetted into each well. A set of 44 
marker plates was created for the first screening. On the original 
master plates, markers were located in order of chromosomes and 
known typing requirements (PCR product dilution x10, x20,x40) to 
reduce typing error. This order was disrupted when creating plates for 
this study, resulting in a higher rate of typing error as compared to the 
previous studies. 
 
2.10.2. Steps of PCR procedure 
 
• For each marker plate, a set of four reaction plates representing the 
four pools was created. 
• Onto each reaction plate, 2 μl of primer mix was pipetted into each 
well using a multi-channel pipette. 
• A PCR mix of sufficient volume for all four plates was prepared in a 
bottle kept at -20°C. Volumes per well:  
 
AB 10x PCR Buffer 15mM   2.0 μl 
AB Gene Amp dNTP mix 2mM  2.5 μl 
Roche AmpliTaq Gold 5U/ul  0.1 μl 
 
• Prepared reaction plates were set onto frozen metal block trays. 
• PCR mix and pooled DNA (13.4 μl/well) were mixed manually in a 
sample tray after appropriate mixing and spinning down of the 
ingredients. 
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• 18 μl/well of the PCR mix/DNA mixture was then pipetted onto the 
reaction plate under intense manual mixing with the primer in the 
bottom of the well. 
• Plates were sealed, spun down and immediately amplified on a ABI 
DNA amplification system using a standard amplification protocol. 
• Following amplification, PCR products were sealed and stored at 
           -30°C for further processing, usually the following day. 
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PCR Procedure for Pooled DNA 
1. Preparations 
Get reagents (dNTP, buffer) and marker plates out of freezer            AB Gene Amp dNTP mix 2mM lot: 
Switch on PCR Thermocyclers (AB GeneAmp PCR System 9700)    AB 10x PCR Buffer 15mM lot: 
PCR PE plates: Label/ clearly distinguish by colour    Roche AmpliTaq Gold 5U/ul lot: 
Get 2 large ice boxes 
25 ml tube for PCR mix – into ice box 
X1 pipetting tray on frozen block – into ice box 
Pipettes and pipette tips for corresponding volumes 
 
2. Preparation of mixture 
Mix and spin down reagents. 
Prepare PCR mixture according to number of plates: 
 
           Marker plates   1 plate 2 plates 3 plates 4 plates   
Total pool plates 1 well 4 plates 8 plates 12 plates 16 plates 1 plate 
Ingredient  vol ul/wellx410 wellsx820 wellsx1230 wellsx1640 wellsx100 wells
10x buffer 2 820 1640 2460 3280 200 
2.0 mM dNTP 2.5 1025 2050 3075 4100 250 
AmpliTaq Gold 0.1 41 82 123 164 10 
Total PCR mix all pools 4.6 1886 3772 5658 7544 460 
           
DNA/each pool 13.4 1340 2680 4020 5360 1340 
Primer Mix 2 NA NA NA NA NA 
PCR mix/each pool NA 460 920 1380 1840 460 
Total each pool mix 20 1800 3600 5400 7200 1800 
       
3. Preparation of plates 
 
Get ice trays for plates from freezer – put plates on trays. 
First step: divide marker plate into the four plates of each set of pools. Pipet marker into the bottom of each 
well. Use same pipette tips for each row for all four plates. Cover with strong sticky sheet. 
Second step: Add PCR mix by rows, mix well using one set of pipette tips per row. Cover with clear rubber  
sheets. Spin down. 
 
vol mix/DNA 
per well:   18 ul     
Vol primer per 
well:   2 ul     
Total per well:   20 ul     
 
PCR Run (Applied Biosystems GeneAmp PCR System 9700) 
 
96°C  9 min  
57°C 1 min  hold 
72°C  1 min    
96°C  45 sec  
57°C 45 sec 
30 
cycles 
72°C  1 min  
72°C  5 min  
4°C  ∞ hold 
 
 
 
Figure 2.4: Pooled DNA PCR protocol and worksheet 
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2.11. DNA Genotyping 
 
2.11.1. Protocol for individual and pooled DNA genotyping 
 
Pooled and individual DNA genotyping followed the same protocol. A 
stored PCR product was diluted, dried up and denatured before a run 
on a DNA analyzer.  
 
Sequence of pooled DNA genotyping: 
 
• Set up of ABI 3730 DNA analyzer (Applied Biosystems)– fresh 
reagents (AB 3730 Buffer (10x), Polymer, dH2O) for each typing lot 
• Preparation of a typing plate for each PCR product plate 
• Dilution of PCR product x20/x40 (reasoning see below) with dH2O 
using the Beckman MultiMek pipetting robot. Briefly, the robot 
prepared an intermediate mixing solution of a variable amount of 
dH2O and 2μl of PCR product; and pipetted an aliquot of 2μl 
(representing the desired target dilution)  of that solution onto the 
prepared typing plate 
• Dry up of diluted DNA in a SpeedVac vacuum centrifuge for 10 min 
at 45°C 
• Preparation of a mixture of 1 ml of standard Formamide with 5 μl AB 
GeneScan 500LIZ Size Standard per plate 
• Pipetting 10 μl of this solution by Eppendorf Multi-pipette into each 
well, sealing of plate 
• Denature of plate for 3 min at 95°C on a ABI DNA amplification 
system, followed by 5 min cooling on an ice tray 
• Running of plates on an ABI 3730 DNA analyzer in gene mapper 
modus (protocol: GM_in2kV10sec_RV7_RT3500). Usually, two DNA 
analyzers were run in parallel, one running donor plates and one 
running recipient plates, swapping over donors and recipients on a 
daily base to randomise technical artefacts introduced by the 
individual machine. 
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At laboratory peak times, part of the pooled DNA genotyping work 
(overall <10%) was carried out by Ms Yamaguchi and Miss Matsushita, 
two laboratory technicians at Tokai University, following the protocols 
established by the author and under his supervision, using PCR 
products created by the author. Approximately one third of the 
individual microsatellite marker genotyping was undertaken by Ms 
Higuchi, a further laboratory technician at Tokai University, mostly in 
summer 2010 (following the return of the author to the UK), using the 
established protocols, under guidance from the author and direct 
supervision by Dr Akira Oka. 
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Pooled Genotyping – Run on ABI 3730 DNA analyser 
Preparations 
• Get PCR products, Formamide, 500 LIZ out of freezer/fridge 
• Switch on RTV400 
• Switch on L,R pumps 
• Switch on Speed vac, open valve, check rubber ring, set temp 45°C, t=10min 
• Switch on multimek, set up: water, trays 
• Switch on x4 PCR Thermocyclers, set for heat 95°C 
• Prepare ABI 3730 DNA analyser: 
1.  remove and clean water/wast/buffer plates 
2. Mix new buffer: 15 ml of 3730 buffer plus 135 ml aqua dest (total 150) 
3. Replace water/waste/buffer trays – ensure buffer tray cable secured 
4. Fill glass bottle with buffer 
5. Check polymer 
6. Close, buffer tray back in to place 
7. Insert sample sheets: Run 3730 data Collection – Tree: Plate Manager – connect USB – 
Import – Mark All – open – ok.  Tree: Run Scheduler – advanced search (put in plate date) – 
search – add all – done 
 
PCR Product Dilution Dilution Factor : x10 x20 x40 
• Spin down PCR product plates 
• Prepare a set of PCR PE plates – label 
• Prepare a set of NUNC plates – no label 
• Prepare plate covers – strong for PCR prod, tissue for new plates 
• Make dilution on multimek according to plan 
• Cover new plates/PCR product plates, discard NUNC plates 
 
Dry up 
• Speed Vac temp 45°C, t=10min 
 
Add Size Standard, Formamide 
• Preparation: Get 1 bottle of Formamide (1 ml) for each plate 
• To each 1 ml of Formamide add 5 ul of 500LIZ 
• Mix well and spin down 
• Use multipipette to pipette 10 ul of Formamide/500LIZ into each well 
• Cover with strong cover 
• Spin down 
 
Denature 
• Get 2 Ice boxes 
• Switch on PCR thermocylers 
• Denature for 3 min at 95°C, Ice cooling for 5 min 
 
Prepare 3730 run:     Machine No 1: 
• Spin down    Machine No 2: 
• Remove strong plate cover  Machine No 3: 
• Put into 3730 plate tray, grey rubber cover   AB 2730 Buffer (10x) lot: 
• Slot in according to order                              AB GeneScan 500LIZ Size Standard lot: 
• Start run – green arrow                                   Formamide: 
 
Figure 2.5: Protocol/worksheet for Pooled PCR genotyping 
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2.12. Data input, retrieval and processing 
 
2.12.1. Data input to 3730 DNA analyzer (Applied Biosystems): 
 
• A Java-based application (SampleSheetMaker v1.0, Applied 
Biosystems) was used for data input for the genotyping process. This 
application produced a text file (.txt) that contained, besides the 
technical information for the run, details such as the marker name, 
amplicon size and allele size to facilitate further processing with the 
GeneMapper and MultiTyper softwares (see below). 
 
2.12.2. Raw typing data retrieval and processing 
 
• Peak signal quality was initially assessed using the ‘capillary 
viewer’ function in the Run 3730 Data Collection v2.0 software 
(Applied Biosystems®). 
• Electrophoretic runs were analysed using the GeneMapper v3.5 
software (Applied Biosystems®). In particular, peak signal and 
size standard quality were assessed. Settings for the analysis 
methods were such that the optimum analysis quality was 
achieved for peak height between 2000 and 11,000 fu 
(fluorescent units), with lowest recognition level at 200 fu and 
highest at 30,000 fu. 
• Raw data were retrieved from GeneMapper in the form of ‘fsa’ 
(per well) and ‘ser’ file (containing the data analysis per plate) 
• These data were combined using a Java-based application from 
ABI, called ‘Fsa2Fsb’. 
 
 
2.12.3. Assessing peak heights 
 
• Fsa2Fsb files were imported into the MultiPeaks software 
(Applied Biosystems®), a further Java-based application. This 
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application could visually display allele size and peak heights of 
MS markers, based on the data input information, and allowed 
selection and logging of marker peaks.  
• Within Multipeaks, peaks were selected manually in a 
simultaneous display of all four pools for each screening step. 
Information provided included the peak height (fu), the allele 
size (in base pairs), and the allele frequency (in %). As markers 
names were coded by their plate location in the institutes primer 
stock (e.g. ‘136A04’), there was a blinding to the analyzer as to 
which candidate gene he was assessing.  
• All markers were assessed by the same analyzer in at least 
triplicate at different time intervals, in order to reduce intra-
observer variability.  
• As a general rule, alleles with a frequency <5% in all pools were 
excluded as such frequencies represent the limits of technical 
resolution and statistical power of this study. Allele frequencies 
<5% were occasionally selected if the other three pools had a 
consistent frequency of this allele >5%, and if the quality of the 
allele signal was appropriate (>200fu). 
• Microsatellite allele selection involved an element of judgment, 
consisting in recognition of a particular microsatellite pattern 
(size of repeat units) and certain known microsatellite artifacts. 
The repeated microsatellite analysis lead to a ‘training effect’ in 
the observer, with the result that almost all microsatellite 
patterns were recognized and alleles determined. The strategy 
for resolving unclear typing results involved: 
o re-analysis by the same observer at a different time 
o retrieval of repeat size information of the marker and 
attempt to identify the microsatellite pattern 
o re-analysis by a different observer experienced in 
microsatellite analysis 
o re-typing/re-PCR of the same marker and re-analysis 
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o exclusion of marker if no meaningful analysis can be 
obtained 
o Using a source reference of MS graphs from previous 
studies, as archived in the laboratory. 
 
• In almost all cases it was possible to identify the MS by its 
typical peak pattern and by the base pair distance between 
peaks. If the MS identification was unclear, one or more 
independent opinions from other experienced researchers in the 
team were sought.  
• For individual genotyping, the software Multityper (Applied 
Biosystems®) presented peak height data in a similar way for 
single datasets only. 
• Results of chosen peaks were stored in a text file. Text files had 
to be manually edited (elimination of null and error well) before 
statistical analysis. 
 
 
2.12.4. Genotyping artefacts 
 
Microsatellite genotyping has a number of inherent artefacts which 
could affect the number of alleles, or allele allocation measured 
(Olejniczak and Krzyzosiak, 2006, Matsumoto et al., 2004, Miller and 
Yuan, 1997). 
 
• Stutter alleles: these are artificial peaks that derive from product 
amplification one to two repeat units shorter than the correct 
sized PCR product or allele. The reason for this effect is 
slippage of Taq polymerase on the repeated sequence. In 
pooled typing, these stutter peaks are included with the correct 
sized alleles one or two units shorter, and therefore not 
identifiable. Stutter is more prevalent in dinucleotide repeats. 
Identification of stutter alleles requires at least some individual 
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typing to identify and quantify the stutter effect. A number of 
mathematical methods have been devised to analyze stutter 
alleles. The stutter effect is usually marker specific, very 
consistent and reproducible between pools, therefore it is not 
thought to influence consistency of pooled DNA typing by e.g. 
mimicking allele frequency differences. Nevertheless, it can lead 
to a wrong estimate of allele frequencies in pooled as well as 
individual genotyping. 
• “+A peaks”: An artificial fragment created by DNA polymerase 
adding a non-templated nucleotide at the 3’ end of the DNA 
fragment. This results in artefacts one base pair longer than the 
true allele for each peak, true or stutter allele. These artefacts 
are often recognisable as a parallel pattern ‘shifted’ from the 
true microsatellite pattern by one base pair, and would become 
apparent on visual inspection of the peak graph. 
• Differential amplification: Preferential amplification of a shorter 
allele or PCR product. Reason: larger alleles reanneal at a 
faster rate because of more repeat units), resulting in reduced 
PCR efficiency. Short sized PCR products, artefacts (“starter 
peaks”) as well as short-sized alleles, can be grossly over-
estimated and lead to false-positive results. This is not a 
consistent effect and tends to vary with each genotyping – 
hence the repeated independent typing (eight pools, if a marker 
passed through both screenings) is likely to have reduced a 
large proportion of such artefacts. 
• Compound/interrupted microsatellite repeats, areas of gene 
copy number variation: As our marker panel is highly selected 
for informative markers, such microsatellites have largely been 
excluded previously. 
 
Individual genotyping of markers that would remain associated with 
GVHD outcome would reveal the majority of such artefacts. 
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2.13. Data Analysis 
 
3.13.1. Preparation of data 
 
Data from text files, specifying the marker name, the allele positions 
and peak heights, were fused together at the level of the individual 
pools. 
For the analysis a custom-made data analysis tool was used that had 
been applied in genome-wide microsatellite studies previously (Tamiya 
et al., 2005). The functions of this tool were: 
 
 
• Conversion of peak height signals into allele frequencies by a 
mathematical algorithm on the basis of numbers of pool size 
and numbers of cases and controls 
• Calculation of allele frequency differences 
• Calculation of p-values using two types of Fisher's exact test for 
the 2x2 contingency tables for each individual allele and the 
2xm contingency tables for each locus, where m referred to the 
number of marker alleles observed in a population. The Markov 
chain/Monte Carlo simulation method was employed to execute 
the Fisher's exact test for the 2xm contingency table (Tamiya et 
al., 2005). 
 
After the first screening a large number of false positive markers and 
alleles was expected (each marker has 2-20 alleles – statistically there 
is a 1:20 by-chance association of each allele). There was a deliberate 
non-application of multiple testing statistics at this point to retain a high 
sensitivity for small effect-size association. Measures for identifying 
those markers and alleles that have a consistent association with 
GVHD included: 
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• Direct comparison of associations between the first and second 
screening by p-value and direction of Odds Ratio (protective or 
risk in both screens consistent) 
• Careful inspection of peak graphs of the remaining consistently 
associated markers to identify typing errors and artifacts 
• Individual genotyping of those markers showing the highest 
technical quality and statistical consistency. Test-typing on a 
small number of samples in the first instance may identify errors 
relating to the pooled genotyping process and artifacts. 
 
Analysis of individual genotyping would be conducted in SPSS for 
Windows v 17.0 (IBM®), including: 
 
• Ensuring Hardy-Weinberg Equilibrium 
(http://genepop.curtin.edu.au/help_input.html) 
• Significance tests: 2-sided Fisher’s Exact test, Kaplan-Meyer 
Analysis for alleles and genotypes 
• Application of Bonferroni’s correction for multiple testing  
• Multivariate analysis (multiple logistic regression, Cox 
regression) in SPSS 
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3. Exploration study 
 
3.1.  Introduction 
3.2.  Aims, hypotheses, objectives and study design 
3.3.  Materials and methods 
3.4.  Results 
3.5.  Discussion 
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3.1. Introduction 
 
Evidence from a large number of previous studies showed that non-HLA gene 
polymorphisms had an impact on the risk of HSCT outcomes, such as acute 
and chronic GVHD, relapse and survival. However, the review of the literature 
also showed that very few of these associations were of larger effect size or 
consistent amongst studies in different ethnic populations or clinical settings. 
Examining quality criteria of genetic association studies it emerged that a 
more stringent design, involving a discovery or screening cohort and an 
independent confirmation cohort, was necessary. 
Having analyzed a large cohort of HSCT donor and recipient pairs, which 
encompasses almost all unrelated donor HSCT through JMDP in Japan 
between 1993 and 2000, an understanding of demographic, clinical and 
genetic risk factors within this population permitted the construction of a study 
cohort with improved control of confounding variables (supplementary file 2.2). 
Before embarking on a larger scale scanning of the extended genomic areas, 
which committed large resources, it was useful to test the study cohort with 
known determinants of HSCT outcome, such as SNP and MS markers that 
showed strong results in previous studies. 
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3.2. Aims, hypotheses, objectives and study design 
 
3.2.1. Aims 
 
This exploratory study had the aim to confirm or refute previously identified 
SNP associations with HSCT outcomes, which include acute GVHD, chronic 
GVHD, relapse and survival. 
 
3.2.2. Hypotheses 
 
A study population exists that allowed the identification of non-HLA genetic 
associations in a consistent fashion across two independent cohorts, even if 
the effect size of the association was low. 
Polymorphisms in non-HLA genes are associated with HSCT outcomes like 
acute GVHD, chronic GVHD, relapse and survival. 
 
3.2.3. Objectives 
 
The objectives of this study were: 
• Testing of a panel of SNP and MS markers previously associated with 
HSCT outcome, as a confirm/refute approach in a Japanese population 
• Variables: Genotypes of polymorphic SNP and MS markers 
• Outcomes: acute GVHD (grade 0 versus grade 1-4, grade 0-1 versus 
grade 2-4, grade 0-2 versus grade 3-4, grade 0-3 versus grade 4), 
chronic GVHD (no cGVHD versus limited and extensive disease, no 
cGVHD and limited disease versus extensive disease), relapse (yes 
versus no), survival (Kaplan-Meyer analysis) 
 
3.2.4. Study design 
 
This was a case-control study with a two-step screening/confirmation 
approach. A population was defined by modelling hypothetical cohorts with 
different risk factors and assessing them by multivariate analysis, and the 
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model with the least clinical confounding chosen (supplementary file 2.2). 
Selected markers were identified from the previous literature. Standardised 
laboratory methods were applied to PCR and genotyping. Statistical methods 
include Bonferroni’s correction for the number of included markers, and an 
additional measure of effect size (previous studies showed that associations 
with an OR<0.5 or >2.0 have a higher likelihood of being consistent, 
regardless of p-value). 
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3.3 Materials and Methods 
 
3.3.1. Population 
 
Donor and recipient HSCT pairs were selected from the JMDP registry of 
unrelated HSCT. We chose pairs with a diagnosis of acute leukaemia. These 
form the largest subgroup within HSCT. Cohorts represented 2 samplings of 
the same national pool, taken from two distinct timeframes (1993-2000, 2001-
2005). Inclusion criteria were diagnosis (acute lymphoblastic leukaemia, ALL; 
acute non-lymphoblastic leukaemia, ANLL), age (4-40 years), conditioning 
(myeloablative), and stem cell source (bone marrow). All transplants were T-
cell replete and received GVHD prophylaxis with either cyclosporin A or 
tacrolimus with methotrexate and corticosteroids. Analysis of the source as 
well as the selected HSCT population showed that HLA mismatching, donor 
age and GVHD prophylaxis regimen (cyclosporin A versus tacrolimus) were 
the only confounders remaining significant in multivariate analysis (data not 
shown here).  
All donor-recipient pairs were HLA-typed retrospectively to allele level at six 
loci (HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, and HLA-DPB1). The 
distribution of HLA matching of the confirmatory cohort was adjusted to that of 
the screening cohort by matching each sample of the screening cohort with a 
confirmatory cohort sample of the same HLA class or HLA class combination 
according to the previous literature (Sasazuki et al., 1998, Morishima et al., 
2002) and our own analyses of risk matches/mismatches within this study 
population (data not shown).  
Table 4 in supplementary file 2.3 shows the demographic and clinical 
characteristics of the selected cohorts. There was no statistically significant 
difference between the cohorts in the baseline demographic criteria. Tables 5 
and 6 in supplementary file 2.3 specify the degree of HLA matching and 
mismatching. For reasons of comparison, we have used the NMDP/CIBMTR 
classification of HLA matching (Weisdorf et al., 2008). According to this 
classification, 357 HSCT pairs have a 8/8 (HLA A, B, C, DRB1) high-
resolution allele match, 331 (35.9%) are partially matched (1 mismatch within 
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these HLA loci), and 234 (25.4%) are mismatched (two or more mismatches 
within these HLA loci). Considering the HLA DQ and DP loci also, only 78 
HSCT pairs (8.5%) had a 12/12 allele match. In Japanese, HLA A, B, and C 
mismatches are associated with risk of acute GVHD. HLA C mismatches, 
however, have a protective effect on relapse (whilst HLA A, C and B 
mismatches associate with a risk of death) (Sasazuki et al., 1998, Morishima 
et al., 2002, Morishima et al., 2007). More recent research has focused on 
specific allele mismatches, rather than mismatches in loci, aiming to identify 
non-permissive mismatches for acute GVHD (Kawase et al., 2007) or 
protective mismatches against relapse (Kawase et al., 2009), as well as risk 
HLA haplotypes for GVHD (Morishima et al., 2010). 
 
 
3.3.2. Gene and SNP marker selection 
 
Selection of candidate markers was based on a search of the published 
literature on genetic associations with HSCT outcomes. As the TaqMan® 
SNP genotyping platform was used, selection was limited to markers for which 
standard assays were available for this system. 
For some genetic loci the same markers that were associated in other 
populations were non-polymorphic in Japanese (NOD2, TGFB1). The 
HapMap data base (www.hapmap.org) was used to identify haploTag SNP for 
these loci. The SNP markers included in this study are detailed in table 3.1. 
 
 
3.3.3. Genotyping  
 
Assay information of the used genotyping assays below is supplied in 
appendix 3.1. 
 
TaqMan genotyping 
 
TaqMan® SNP genotyping assays (Applied Biosystems, Branchburg, USA) 
were applied for 38 selected SNP according to the maker’s instructions.  
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Individual genomic DNA (2.1 ng/well) was arranged onto 384-well plates 
(EDR-384 SII) and samples dried up at 45°C in vacuum over 90 minutes. A 
40x reaction mixture, consisting of 2μl/well of TaqMan Universal Master Mix, 
No Amp Erase® UNG (Applied Biosystems, Branchburg, USA), 0.05μl/well of 
40x TaqMan® SNP genotyping assay mix, and 1.95μl/well of purified water, 
was pipetted robotically directly onto the dried-up 384 well plates. Plates were 
covered with Micro Amp Optical Adhesive Film 4311971 (Applied Biosystems, 
Branchburg, USA) before running a polymerase chain reaction (PCR) on a 
Gene Amp PCR System 9700. PCR conditions consisted of an initial cycle of 
95°C (10 min), 40 cycles of 92°C (15 sec) and 60°C (1 min), and a final 
cooling to 4°C. 
Runs were analysed on a 7900HT Sequence Detection System (Applied 
Biosystems) using the SDS 2.1 (Applied Biosystems) software. Results were 
exported as txt files into Microsoft office excel for compilation and further 
processing. Genotypes were allocated considering the forward/reverse 
direction of the primer, and checked against the genotype distribution of each 
SNP for a Japanese population in HapMap (www.hapmap.org). Hardy-
Weinberg Tests were carried out using the genepop tool 
(http://genepop.curtin.edu.au/genepop_op1.html). 
 
 
Luminex genotyping of IL10 SNP 
 
The IL-10 promoter SNPs rs1800872 (-592A/C), rs1800871(-819T/C), and 
rs1800896 (-1082A/G) were genotyped by PCR-SSO using Luminex Multi-
Analyte Profiling system (xMAP) (Luminex Corp., Austin, TX).A fragment of IL-
10 promoter region, containing SNPs, -592, -819, and -1082, was amplified by 
PCR using 5’ biotinylated primers (supplementary table 1). The PCR product 
was denatured and hybridized with the mixture of the six oligonucleotide 
probes, specific for each base of the corresponding biallelic SNP, immobilized 
on fluorescent coded microsphere beads. The hybridization mixture containing 
the PCR product, hybridization buffer (Wakunaga Pharmaceuticals, Hiroshima, 
Japan), beads mixture and SAPE (Wakunaga Pharmaceuticals, Hiroshima, 
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Japan) were incubated at 55 ºC for 30 minutes. After washing, the hybridized 
product was analyzed on the Luminex 100.  
 
 
3.3.4. Statistical analysis 
 
Genotype results were imported into SPSS Statistics v 17.0 (SPSS Inc). 
Because little is known about effects of non-HLA polymorphisms in HLA-
mismatched populations, we used three analytic approaches in order to 
identify significant associations: 2-sided Fisher’s Exact Test (95% confidence 
intervals) with Bonferroni’s correction for significance testing, Odd’s Ratio 
(95% confidence intervals) as a measure of effect size, and independent 
testing in a confirmatory cohort (without application of multiple testing 
correction). Variables were the three individual genotypes, and mismatch 
between donor and recipient genotypes. Outcomes were acute GVHD (0-4), 
acute GVHD grades 2-4, acute GVHD grades 3-4, acute GVHD grade 4, 
chronic GVHD, extensive chronic GVHD, relapse, death (overall, at 100 
days/1 year/3 years) and survival (as log rank test in Kaplan Meier analysis). 
For the screening cohort we considered as significant a p-value of p=0.05 with 
Bonferroni’s correction for the number of SNP markers tested. As the p-value 
is not a good surrogate marker for effect size, and often small in HSCT-
outcome association studies, associations showing Odd’s Ratios of ≤0.5 and 
≥2.0 (this follows observations of OR’s of significant markers in previous 
studies) were included separately.  
Screening and confirmatory cohort data were analysed on the overall cohort in 
the first instance. In order to reduce confounding by HLA mismatching, we 
conducted identical analyses on a subgroup with a higher degree of HLA 
matching (8/8 allele matching at the HLA A, B, C, DRB1 loci, with additional 
exclusion of combined HLA-DQB1 and DPB1 mismatches; allowing for either 
a HLA-DQB1 or a HLA-DPB1 mismatch only), similar to previous reports from 
JMDP(Ogawa et al., 2008), resulting in cohorts of 160 (discovery) and 166 
(confirmatory) pairs. 
For the screening cohort, we would genotype all 41 chosen SNP markers 
(table 1) on both donor and recipient cohorts, and conduct overall and 
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subgroup analyses. Markers only that show a corrected p-value of <0.05 
and/or an OR of ≤0.5 and ≥2.0 in either the overall or the subgroup analyses 
would be selected for confirmatory typing. If a marker that showed an 
association that was persisting applying when Bonferroni’s correction, we 
tested other associations of the same marker in the confirmatory cohort even 
if these would not reach the multiple testing thresholds, in order to capture 
borderline significance or effect size of genotypes, building on the strength of 
testing in an independent confirmatory cohort. 
Given the high degree of linkage between the CTLA4 as well as the IL10 
SNPs in the study, unambiguous haplotypes could be determined directly 
without recourse to computational methods.  
As the distribution of acute GVHD degrees of severity was significantly 
different between the screening and confirmation cohort, all associations with 
acute GVHD as outcome were re-analysed after randomising the study 
population into two different cohorts (using an online based tool for random 
assignment: 
http://www1.assumption.edu/users/avadum/applets/RandAssign/GroupGen.ht
ml).  
Multivariate analysis was performed on the combined cohorts using STATA v 
11.0. Odds ratio (OR) of acute GVHD for the selected SNP in multivariate 
analysis was estimated by a multivariate logistic regression analysis with the 
adjustment for recipient and donor ages, underlying diagnosis, the use of TBI, 
ATG, female donor into male transplant, GVHD prophylaxis (tacrolimus versus 
cyclosporin A), relapse and HLA mismatch to address possible confounding.  
 
 
 
 
 
 
 
 
 
 
  
103
103
 
Target 
gene SNP 
Target 
gene SNP 
CCL4  rs2634508  NOD2 rs1077861 
CD86  rs1129055    rs1861757 
CTLA4 rs231777   rs1861759 
  
rs231775 (CTLA4-
49)   rs6500328 
  
rs3087243 (CTLA-
CT60)   rs2111234 
FAS 
 rs1800682 (FAS-
670)    rs2111235 
FCGR2A  rs1801274    rs7203344 
HLA-E 
rs1264457 (HLA-E 
R128G)   rs17313265 
  rs1800795 TGFB1 
rs1800469 (TGFB1-
509) 
HSP70/hom rs2075800   rs2241715 
IFNg rs2069705   rs2241716 
IL1A 
 rs1800587 (IL1A-
889)    rs4803455 
IL1B  rs16944 (IL1B-511) TLR4 rs12377632 
IL2 
 rs2069762 (IL2-
330)    rs1927907 
IL10 
rs1800896 (IL10-
1082) TNF rs361525 (TNF-238) 
  
rs1800871 (IL10-
819)   rs1799964 (TNF-1031) 
  
rs1800872 (IL10-
592)   rs1800629 (TNF-308) 
IL15RA 
 rs2228059 (IL15RA 
N182T)    rs1799724 (TNF-857) 
IL23R  rs6687620  TNFRSF1B
 rs1061622 (TNFR2 
codon 196)  
MIF  rs755622  VDR  rs731236  
MTHFR 
 rs1801133 (MTHFR 
C677T)      
 
Table 3.1: Selected candidate SNP markers of this study. 
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3.4. Results 
 
3.4.1. Screening cohort 
 
All transplants (n=460 pairs) 
 
In the screening cohort, involving 460 bone marrow transplants performed 
between 1993 and 2000, 41 single nucleotide SNP markers were typed in 
both patient and donor cohorts. Of these, six markers were excluded from 
analysis, for technical (multiple clusters: rs1927907, rs4803455) and statistical 
reasons (minor allele frequency <5%: rs1800795, rs6687620, rs361525, 
rs1800629). All 35 markers included in the analysis were in Hardy-Weinberg 
equilibrium (defined as p value >0.05, with statistical correction for the number 
of tested markers).  
Thirteen markers, plus the IL10 and CTLA4 haplotypes, showed an 
association with a HSCT outcome in the donor screening cohort (table 3.2). 
By significance testing applying Bonferroni’s correction, only the marker IL10-
1082 and the CTLA4 haplotype showed significant association, while three 
further markers were selected for confirmatory typing by their effect size 
(marker CTLA4 rs231775 also showed relevant effect size individually; marker 
CTLA4 rs231777, which showed no individual association, was included in the 
confirmatory cohort as part of the CTLA4 haplotype (not listed in table 3.2)). 
The recipient cohort (table 3.3) revealed 15 markers, plus the CTLA4 
haplotype, that were associated with a HSCT outcome. The IL2-330 SNP and 
the CTLA4 haplotype revealed significant associations above the multiple 
testing thresholds, while five SNP markers had ORs ≤0.5 and ≥2.0. 
 
HLA-matched subgroup (n=160 pairs) 
 
When analyzing the HLA-matched subgroups of these cohorts, 7 markers and 
the CTLA4 and IL10 haplotypes in the donor cohort (table 3.4) showed 
outcome associations, of which 5 markers and the CTLA4 haplotype were 
included for confirmatory typing. Only the CTLA4 haplotype had a p-value 
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significant when multiple testing correction was applied.  In the HLA matched 
recipient subgroup, three markers showed an association with HSCT outcome, 
of which one was selected for the confirmation cohort by strength of OR (table 
3.5).   
 
3.4.2. Confirmatory cohort 
 
All transplants (n=462 pairs) 
 
Seven markers for the donor cohort (CTLA4: rs231775, rs231777, 
rs3087243(included for forming the CTLA4 haplotype, only rs231775 and 
rs3087243 showed an association in the screening cohort); FAS: rs1800682; 
IL10: rs1800896; NOD2: rs2111235, rs6500328) and ten markers for the 
recipient cohort (CTLA4: rs231775, rs231777, rs3087243(part of CTLA4 
haplotype, only rs231775 and rs231777 showed were associated in the 
screening cohort) ; FAS: rs1800682; IL2: rs2069762 ; NOD2: 17313265; 
TGFB1: rs2241716; TNF: rs1799964; TNFRSF1B: rs1061622) were selected 
for typing in the confirmatory cohort. Firstly; the aim was to confirm 
associations from the screening cohorts that had significant p-values after 
multiple testing correction (high significance), then associations that had ORs  
≤0.5 or  ≥2.0 (large effect size), and thirdly associations within these selected 
markers that were consistent in both screening and confirmatory cohort 
(independent cohort confirmation), regardless of multiple testing correction or 
effect size. 
There were no consistent findings in the overall donor confirmatory cohort 
(table 3.2). In the overall recipient confirmatory cohort (table 3.3), the donor-
recipient genotype mismatch of the TNF-1031 SNP (rs1799964) was 
consistently associated in both screening and confirmatory cohorts with a 
higher risk of severe acute GVHD (grade 4). The CC genotype of the same 
marker was associated with acute GVHD grade 4 in the screening cohort, and 
just escaped significance level in the confirmatory cohort (p=0.06).   
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HLA-matched subgroups (166 pairs) 
 
In the donor HLA-matched subgroup (table 3.4), none of the markers typed in 
the confirmatory cohort showed any association. The HLA matched recipient 
cohort (table 5) revealed a consistent association between risk of chronic 
GVHD and the GT genotype of rs2069762 (IL2-330).  
Table 3.6 summarises the consistent associations of this study, comprising 
the IL2-330 and TNF-1031 SNP. 
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Donor - All   
Gene Marker Discovery cohort – genotype & association Confirmatory cohort – genotype & association 
CTLA4 rs231775 AA aGVHD (p=0.0043, OR:=0.049, CI: 0.028-0.083 
GG aGVHD (p=0.0071, OR=1.90, CI: 1.19-3.03 
n/s 
CTLA4 rs3087243 GG aGVHD (p=0.0086, OR=1.81, CI:1.18-2.78) n/s 
CTLA4 haplotype CAA aGVHD (p=0.0025, OR=0.59, CI: 0.42-0.82) 
CGG aGVHD (p=0.00057, OR=1.72, CI: 1.27-2.34) 
n/s 
FAS rs1800682 CC aGVHD4 (p=0.023, OR=0.21, CI:0.37-0.96) n/s 
IFNg rs2069705 CC ext cGVHD (p=0.035, OR=0.57, CI: 0.33-0.96) 
CC relapse (p=0.04, OR=0.60, CI:0.37-0.96) 
n/t 
IL10 rs1800896 AA survival (p=0.001) protective n/s 
IL10 haplotype CCA survival (p=0.032) protective n/t 
MTHFR rs1801133 CT cGVHD (p=0.03, OR=0.63, CI=0.42-0.96) n/t 
NOD2 rs17313265 CT survival (p=0.012) risk 
CC survival (p=0.008) protective 
n/t 
n/t 
NOD2 rs2111235 TT aGVHD4 (p=0.016, OR=0.33, CI: 0.14-0.80) n/s 
NOD2 rs6500328 GG ext cGVHD (p=0.011, OR=0.17, CI: 0.023-0.78) n/s 
TGFB1 rs1800469 CC aGVHD2-4 (p=0.035, OR=1.69, CI: 1.09-2.61) 
CT aGVHD2-4 (p=0.036, OR=0.66, CI: 0.45-0.96) 
n/t 
n/t 
TGFB1 rs2241715 GG aGVHD2-4 (p=0.047, OR=1.64, CI: 1.06-2.53 
GT survival (p=0.03) protective 
GT ext cGVHD (p=0.032, OR=0.57, CI:0.34-0.94) 
GT aGVHD2-4 (p=0.037, OR=0.67, CI: 0.46-0.98) 
n/t 
n/t 
n/t 
n/t 
TNF rs1799964 TT relapse (p=0.041, OR=1.71, CI: 1.04-2.82) n/t 
TNF rs1799724 CC survival (p=0.014) protective n/t 
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Table 3.2 (previous page): Results of SNP genotyping on all donor 
samples. Explanation of abbreviations (apply also to the the donor HLA 
matched and recipient results tables): aGVHD= acute GVHD, aGVHD4= 
acute GVHD grade 4, aGVHD 2-4= acute GVHD grade 2-4, cGVHD= 
chronic GVHD, ext cGVHD= extensive chronic GVHD, survival= p-value 
for log rank test as explored by Kaplan-Meyer analysis, mismatch= 
genotype mismatch between donor and recipient, p= p-value by 2-sided 
Fisher’s Exact Test, OR= Odds Ratio, CI= 95% confidence intervals for 
OR, n/s= non-significant, n/t= not tested. Bold: Withstanding 
Bonferroni’s multiple testing corrections or have OR ≤0.5 or ≥2, italic: 
consistent associations. Marker rs231777 had no individual association 
and is therefore not included in this table, but was included into the 
confirmatory cohort as part of the CTLA4 haplotype. 
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Recipient - All   
Gene Marker Discovery cohort – genotype & association Confirmatory cohort – genotype & association 
CTLA4 rs231775 AA cGVHD (p=0.046, OR=1.83, CI: 1.02-3.28) n/s 
CTLA4 rs231777 mismatch aGVHD (p=0.004, OR=1.91, CI: 1.24-2.96) n/s 
CTLA4 haplotype CAA  cGVHD (p=0.011, OR=1.5, CI=1.11-2.03); 
CGG cGVHD (p=0.0013, OR=0.62, CI: 0.47-0.83)  
CGG aGVHD2-4 (p=0.019, OR=0.70, CI: 0.52-0.94) 
TAG aGVHD4 (p=0.0071, OR=3.71, CI: 1.56-8.86) 
n/s 
n/s 
n/s 
n/s 
FAS rs1800682 CC relapse (p=0.017, OR=1.68, CI: 1.03-2.74) 
CT relapse (p=0.0025, OR=0.50, CI: 0.33-0.78),  
CT aGVHD (p=0.009, OR=1.79, CI: 1.15-2.77) 
TT cGVHD (p=0.024, OR=1.75, CI: 1.03-2.82) 
TT ext cGVHD (p=0.014. OR=1.74, CI: 1.03-2.94) 
n/s 
n/s 
n/s 
n/s 
n/s 
HLA-E rs1264457 mismatch survival (p=0.023) risk n/t 
IL1A rs1800578 mismatch aGVHD2-4 (p=0.026, OR=1.69, CI: 1.11-2.56) n/t 
IL1B rs16944 AA aGVHD (p=0.048, OR=0.63, CI: 0.39-0.99) 
GG aGVHD (p=0.032, OR=1.75, CI:1.08-2.82) 
n/t 
n/t 
IL15RA rs2228059 AC survival (p=0.024) risk n/t 
IL2 rs2069762 GG aGVHD4 (p=0.0014, OR=4.51, CI:1.91-10.6) 
GT survival (p=0.0021) protective,  
TT survival (p=0.0061) risk 
n/s 
n/s 
n/s 
NOD2 rs17313265 CC aGVHD2-4 (p=0.036, OR=2.15, CI: 1.06-4.37) n/s 
TGFB1 rs1800469 mismatch aGVHD2-4 (p=0.02, OR=1.63, CI:1.1-6.4) n/t 
TGFB1 rs2241715 mismatch aGVHD2-4 (p=0.015, OR=1.61, CI: 1.09-2.39) 
mismatch cGVHD (p=0.035, OR=1.58, CI: 1.04-2.41) 
n/t 
n/t 
TGFB1 rs2241716 AA ext cGVHD (p=0.0041, OR=2.58, CI:1.36-4.87) n/s 
TNF rs1799964 mismatch aGVHD4 (p=0.022, OR=2.53, CI:1.16-5.53)  
CC aGVHD4 (p=0.041, OR=4.92, CI:1.27-19.02) 
 mismatch aGVHD4 (p=0.0053, OR=3.40, CI:1.48-7.81)  
CC aGVHD4 trend (p=0.06) 
TNF rs1799724 CC survival (p=0.02) protective,  
CT survival (p=0.02) risk 
n/t 
n/t 
TNFRSF1B rs1061622 TT aGVHD4 (p=0.023, OR=4.69, CI: 1.1-20.11) n/s 
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Table 3.3 (previous page): Significant Results of SNP genotyping on all 
recipient samples. Explanations of abbreviations please see table 2. The 
marker rs3087243 was not associated individually with chronic or acute 
GVHD and is not listed here, but was included in the confirmatory cohort 
forming part of the CTLA4 haplotype. 
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Donor - 
HLA 
   
Gene Marker Discovery cohort – genotype & association Confirmatory cohort – genotype & association 
CTLA4 rs231775 GG aGVHD (p=0.026, OR=2.02, CI: 1.09-3.75) n/s 
CTLA4 rs3087243 GG aGVHD (p=0.021, OR=1.97, CI: 1.11-3.50) n/s 
CTLA4 haplotype CAA aGVHD (p=0.012, OR=0.55, CI: 0.35-0.87) 
CGG aGVHD (p=0.00097, OR=2.06, CI: 1.22-5.94) 
n/s 
n/s 
IFNg rs2069705 CC ext cGVHD (p=0.036, OR=0.42, CI:0.20-0.93) 
CT ext cGVHD (p=0.017, OR=2.69, CI: 1.22-5.94) 
n/s 
n/s 
IL10 rs1800896 AA aGVHD (p=0.038, OR=0.21, CI:0.04-0.96) n/s 
IL10 haplotype CCG aGVHD (p=0.027, OR=4.70, CI:1.08-20.54) n/s 
MTHFR rs1801133 TT aGVHD (p=0.0016, OR=12.13, CI: 2.73-53.90) n/t 
NOD2 rs17313265 CT relapse (p=0.013, OR=2.68, CI:1.02-7.09) n/s 
TNF rs1799724 CC survival (p=0.006) protective n/t 
 
Table 3.4: Results of SNP genotyping on HLA-matched donor samples. Explanations of abbreviations please see table 2. 
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Recipient - HLA   
Gene Marker Discovery cohort – genotype & association Confirmatory cohort – genotype & association 
FAS rs1800682 CT aGVHD (p=0.0024, OR=0.39, CI=0.22-0.71) n/s 
IL1B rs16944 AA aGVHD (p=0.043, OR=0.51, CI:0.27-0.97) n/t 
IL2 rs2069762 GT survival (p=0.037) protective 
GT cGVHD (p=0.039, OR=1.97, CI=1.05-3.71) 
TT survival (p=0.039) risk 
n/s 
GT cGVHD (p=0.00041, OR=3.24, CI: 1.69-6.20) 
n/s 
 
Table 3.5: Results of SNP genotyping on HLA-matched recipient samples. Explanations of abbreviations please see table 
2. 
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marker 
genotyp
e cohort outcome p= total 
cases 
all 
control
s all 
cases 
pos 
cases 
neg 
control
s pos 
control
s neg 
Odds 
ratio OR CI (95%) 
TNF-1031 mismatch Screening aGVHD 4 0.022 448 28 420 12 16 96 324 2.53 1.16-5.53 
rs1799964 
mismatch Confirmation aGVHD 4 0.0053 460 24 436 12 12 99 337 3.40 1.48-7.81 recipients (all) 
IL2-330 GT Screening cGVHD 0.039 160 72 88 39 33 33 55 1.97 1.05-3.71 
rs2069762 
GT Confirmation cGVHD 0.00041 166 75 92 40 35 23 68 3.24 1.70-6.20 
recipients 
(HLA matched)
 
CTLA4-CT60 
 GG  random 1 aGVHD  0.022 159 58 101 20 38 54 47 0.46 0.27-0.78 
rs3087243 
   
random 2 
          
donors (HLA 
matched)  GG aGVHD  0.045 166 53 11 22 31 67 46 0.49 0.29-0.83 
 
Table 3.6: SNP markers showing significant association in recipient screening and cohorts.  
 
 
 
 
 
 
  
114
114
3.4.3. Further analyses 
 
To understand the mechanism of the associated genotype, the analysis was 
extended to all IL2-330 genotypes and chronic GVHD outcomes in the 
confirmatory cohort, and it was found that GT also associated with extensive 
chronic GVHD (p=0.00022, OR: 5.18, CI: 2.37-11.39). The TT genotype 
exerts a protective effect against extensive chronic GVHD (p=0.0029, OR: 0.3, 
CI: 0.13-0.67). This finding was replicated when combining screening and 
confirmatory cohorts (GT and extensive chronic GVHD: p=0.00055, OR: 2.90, 
CI: 1.74-5.08; TT and extensive chronic GVHD: p=0.001, OR: 0.40, CI: 0.23-
0.71), suggesting that the GG genotype is likely to be the higher risk genotype. 
No significant association was found with the GG genotype, which was likely 
due to limited statistical power of this low frequency genotype. Mirroring the 
analysis by MacMillan et. al. (MacMillan et al., 2003) in the combined cohorts, 
the G allele showed a trend with risk of extensive chronic GVHD (p=0.07), but 
not with acute GVHD. 
The extended analysis of the TNF-1031 CC genotype in the confirmatory 
cohort showed that it was also associated with acute GVHD grade 2-4 
(p=0.029, OR=3.41, CI: 1.99-5.82). The TNF-1031 donor-recipient genotype 
mismatch was found to be a risk factor for acute GVHD grade 2-4 (p=0.003, 
OR=1.93, CI: 1.13-3.30) and grade 3-4 (p=0.002, OR=2.21, CI: 1.13-3.80) in 
the confirmatory cohort. 
The stratification applied in ‘matching’ the degree of HLA mismatch of the 
confirmatory cohort to that of the screening cohort may have introduced a bias 
(significantly different distribution of acute GVHD grades, see supplementary 
table 1). In order to address this, samples were randomly assigned to two 
cohorts, resolving any significant difference between time frames, and acute 
GVHD as an outcome measure. Re-analysis of the data for acute GVHD 
outcomes showed that the genotype mismatch of the TNF-1031 SNP as a risk 
factor for acute GVHD grade 4 would still hold up as significant (p=0.005, 
OR=3.26, CI: 1.91-5.58; p=0.021, OR=2.60, CI: 1.52-4.45). The CTLA4-CT60 
(rs3087243) SNP showed a consistent association of the GG genotype as 
protective against acute GVHD (p=0.022, OR=0.46, CI: 0.27-0.78; p=0.045, 
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OR=0.49, CI: 0.29-0.83) in the random cohort analysis of the HLA-matched 
subgroup.  
 
3.4.4. Multivariate analyses 
 
Multivariate analyses (tables 3.7-3.9) were performed on the combined 
(screening and confirmatory) cohorts and showed that the TNF-1031 donor-
recipient genotype mismatch (acute GVHD grade 4), the CC genotype (acute 
GVHD grade 4), and the IL2-330 GT genotype (chronic GVHD) are 
independent risk factors, while the CTLA4-CT60 GG genotype is 
independently protective against acute GVHD. 
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IL2-330: chronic GVHD Univariate   Multivariate   
Variable OR (95% CI) P-value OR (95% CI) P-value 
Recipient age 1.008 (0.99-1.03) 0.481 1.008 (0.98-1.03) 0.528 
Donor age 1.024 (0.99-1.05) 0.106 1.020 (0.99-1.05) 0.195 
Female to male transplant 0.900 (0.52-1.57) 0.71 0.876 (0.48-1.60) 0.664 
Diagnosis ANLL vs ALL 1.087 (0.70-1.69) 0.711 1.022 (0.63-1.67) 0.929 
Total body irradiation (TBI) 1.419 (0.72-2.80) 0.313 1.284 (0.62-2.67) 0.502 
Cyclosporine vs tacrolimus 1.024 (0.66-1.59) 0.916 0.996 (0.61-1.62) 0.987 
Relapse 0.526 (0.32-0.86) 0.011 0.573 (0.34-0.96) 0.033 
Genotype GT 2.507 (1.60-3.93) 0.000066 2.273 (1.42-3.63) 0.0006 
 
Table 3.7: Multivariate analysis of the IL2-330 GT genotype as risk factor for chronic GVHD in the HLA-matched subgroup. 
The genotype is an independent risk factor.  
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CTLA4-CT60: acute GVHD Univariate   Multivariate   
Variable OR (95% CI) P-value OR (95% CI) P-value 
Recipient age 1.017 (0.99-1.04) 0.146 1.020 (0.99-1.05) 0.121 
Donor age 0.995 (0.97-1.03) 0.763 0.997 (0.97-1.03) 0.854 
Female to male transplant 1.644 (0.93-2.89) 0.085 1.630 (0.89-2.97) 0.111 
Diagnosis ANLL vs ALL 1.280 (0.81-2.03) 0.296 1.129 (0.69-1.85) 0.631 
Total body irradiation (TBI) 0.847 (0.43-1.68) 0.634 0.916 (0.45-1.86) 0.809 
Relapse 1.255 (0.77-2.06) 0.369 1.330 (0.80-2.24) 0.273 
Genotype GG 0.468 (0.29-0.75) 0.002 0.497 (0.31-0.80) 0.004 
 
Table 3.8: Multivariate analysis of the CTLA4-CT60 GG genotype for acute GVHD (grade 1-4 versus no GVHD) in the HLA-
matched subgroup, confirming this genotype as an independent risk factor. 
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TNF-1031: acute grade 4 GVHD Univariate   Multivariate   
Variable OR (95% CI) P-value OR (95% CI) P-value 
Recipient age 0.978 (0.95-1.01) 0.109 0.975 (0.94-1.01) 0.112 
Donor age 1.038 (1.00-1.08) 0.044 1.033 (0.99-1.07) 0.105 
Female to male transplant 0.610 (0.27-1.38) 0.235 0.582 (0.24-1.42) 0.236 
Diagnosis ANLL vs ALL 1.001 (0.57-1.76) 0.996 1.148 (0.60-2.18) 0.673 
Total body irradiation (TBI) 0.909 (0.40-2.07) 0.819 0.992 (0.39-2.51) 0.987 
Anti-thymoglobulin (ATG) 3.562 (0.99-12.73) 0.051 2.246 (0.45-11.15) 0.322 
Cyclosporine vs tacrolimus 1.336 (0.75-2.37) 0.321 1.516 (0.80-2.86) 0.198 
Relapse 0.115 (0.03-0.48) 0.003 0.154 (0.04-0.65) 0.011 
HLA match 0.465 (0.24-0.92) 0.027 0.765 (0.35-1.67) 0.502 
Genotype CC 4.336 (1.7-11.1) 0.002 3.888 (1.39-10.90) 0.010 
Genotype mismatch 2.905 (1.65-5.1) 0.00023 2.307 (1.18-4.52) 0.015 
 
Table 3.9: Multivariate analysis of TNF-1031 genotype mismatch and CC genotype as a risk factors for acute GVHD grade 
4 in the overall (HLA matched and mismatched) cohort. Both are independent risk factors, with competing effects from 
HLA matching and relapse. 
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3.5. Discussion 
 
The exploration study has identified three non-HLA SNP associations with 
HSCT outcome: The TNF-1031 donor-recipient genotype mismatch with 
severe GVHD (grade 4, in the overall cohort), the recipient IL2-330 GT 
genotype with risk of chronic GVHD, and the CTLA4-CT60 GG genotype 
protective against acute GVHD (grade 1-4; the latter two associations were 
found in the HLA-matched subgroup only). 
TNFα is a cytokine that has been associated with severity of acute GVHD in 
several previous genetic, gene expression and animal model studies. 
Teshima et. al. (Teshima et al., 2002) have demonstrated in an animal model 
that TNF is essential in the development of acute GVHD. Previous data from a 
Japanese population have shown that the TNF haplotype including TNF-1031 
was associated with severe GVHD(Ishikawa et al., 2002), and the TNF-1031C 
allele was associated with higher TNF expression(Higuchi et al., 1998). A 
more recent study (Goyal et al., 2010) describes the C allele as a risk factor 
for grade 3-4 acute GVHD. Therefore an association of the TNF-1031 CC 
genotype with severe acute GVHD, as seen in this study, albeit showing only 
a trend in the confirmation cohort, would be biologically meaningful and 
replicate previous findings. However, the TNF-1031 CC genotype displays 
strong linkage disequilibrium with HLA, in particular with HLA-B61(Higuchi et 
al., 1998). This may explain our finding of the strong association between 
donor-recipient genotype mismatch and acute GVHD grade 4 in the overall 
cohort only, but not in the HLA matched subgroup. Our study did not have the 
power to elucidate if any particular TNF-1031 genotype mismatch 
combinations carry a higher risk. As the group affected with acute GVHD 
grade 4 is small (just above 5%), further studies should confirm this result 
independently. The finding that genotype mismatch was also associated with 
grade 2-4 as well as grade 3-4 acute GVHD (which are larger groups) in the 
confirmatory cohort gives further indication that the genotype mismatch is 
likely to be a risk factor for acute GVHD.  Nevertheless, the strength and 
consistency of this association mean that it is potentially a strong discriminator 
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for prediction of the most severe form of acute GVHD (grade 4), which could 
be exploited in clinical practice. 
The IL2-330 (rs2069762) SNP has an almost identical genotype distribution 
between Caucasian and Japanese populations (Caucasian: TT: 0.536, GT: 
0.464, GG: 0; Japanese (this study): TT: 0.450, GT: 0.440, GG: 0.110). The G 
allele is the known high-expressing allele, and high levels of IL2 have been 
described to correlate with severity of acute GVHD (Das et al., 2001, 
MacMillan et al., 2003). A previous study from North America on a cohort of 
similar time frame to our screening cohort (MacMillan et al., 2003) reported an 
association between the recipient IL2-330 G allele and acute GVHD; and a 
trend towards risk of chronic GVHD. In our study, we found an association of 
the GT genotype with risk of chronic GVHD. More detailed analysis showed 
that the low frequency GG genotype is likely to be the highest risk genotype 
for chronic GVHD, whilst GT associated with risk, and TT with protection. Our 
findings therefore confirm those of the previous study even across different 
ethnic populations, qualifying this marker as a predictor of chronic GVHD risk. 
The effect of the CTLA4-CT60 polymorphism on HSCT outcomes was studied 
previously, in settings of HLA matched sibling donors(Perez-Garcia et al., 
2007, Murase et al., 2011) and matched unrelated donors (Vannucchi et al., 
2007) in Caucasian populations. In HLA matched sibling transplants, the 
donor G allele was associated with increase of relapse and worse survival, 
while the AA genotype was linked to risk of acute GVHD. The findings in 
matched unrelated donor HSCT were similar, with the donor AA genotype 
associating with severe acute GVHD (grade 3-4), but risk of G allele or GG 
genotype with relapse or survival was not observed. Our findings are in 
accordance with these results, identifying the GG genotype as protective 
against acute GVHD (remarkably, the screening cohort result indicated a risk 
of the GG genotype with acute GVHD (see table 4) – a finding completely 
reversed by the randomisation). We could not establish any risk of the GG 
genotype with relapse or survival, or the AA genotype with acute GVHD. This 
may be explained by the fact that in the Japanese population, the GG 
genotype is more prominent than in Caucasians, while the AA genotype is 
more rare (HapMap data of genotypes: Caucasians: AA: 0.208, AG: 0.513, 
GG: 0.283; Japanese: AA: 0.047, AG: 0.389, GG: 0.542). The risk of acute 
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GVHD, relapse or survival associated with this marker may therefore be lower 
in the Japanese population, compared to Caucasians.    
The results raise also some methodological questions which are beyond the 
scope of this study: 
• By incorporating a measure of effect size into the statistical analysis, 
this study extends beyond previous approaches focussing on 
significance and correction for multiple testing. Our results suggest that 
this approach may be more sensitive, but because of limited power and 
small number of identified associations no conclusions could be made 
about the impact on sensitivity and specificity, and statistical multiple 
testing burden. 
• Despite the effort to control variability of study population 
characteristics, reproducibility of associations remains low and 
appeared to be dependent on distribution of these characteristics 
amongst the cohorts. This may be due to the overall small effect size of 
the associations, confounders in the study cohort, or both. A more 
comprehensive typing (full typing of all markers on both screening and 
confirmation cohort) and analysis would be required. 
  
Clinical and population characteristics of study cohorts may explain some of 
the contradictory results observed in previous studies, therefore careful design 
of study cohorts and control of confounders should receive more attention. 
The growing number of HSCT may facilitate in the future the availability of 
larger, genetically and clinically more homogeneous study cohorts; however, 
the changing and expanding indications of HSCT are likely to prove a 
challenge.  
In conclusion, this study demonstrates that non-HLA genetic association with 
HSCT outcomes do exist and can be detected even in the HLA-mismatched 
setting. Such associations could be useful for application in future clinical 
practice in this clinically highly relevant population. These findings should be 
verified by larger studies also on populations of different ethnicities. 
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4. RESULTS 
 
 
4.1.  Pooled DNA PCR and genotyping – 1st and 2nd 
screening steps 
4.2.  Individual Genotyping 
4.3.  Further exploration of a susceptibility region 
by SNP typing 
4.4. Genetic susceptibility regions for moderate-severe  
acute GVHD 
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4.1. Pooled DNA PCR and genotyping – 1st and 2nd 
  screening steps 
 
 
4.1.1. Technical quality aspects 
 
In the first instance, the full set of marker plates for the first screening, 
involving 4,321 MS markers, was typed in all four pools. The quality of 
peak signals was assessed within the Run 3730 Data Collection version 
2.0 software (Applied Biosystems). The Capillary Viewer would indicate 
peak signals that were excessively high, adequate or absent. 
Following import and analysis of typing data in GeneMapper version 3.5 
(Applied Biosystems), peak sizes and quality of size standardisation were 
analysed. In particular peak sizes that were off-scale, and samples with 
inadequate size standard became apparent. 
Finally, peak signal quality was evaluated in MultiPeaks version 0.21.1 (a 
Java- application also supplied by Applied Biosystems). For pooled DNA 
genotyping, consistency of peak sizes and quality amongst pools was of 
particular importance. Peak sizes >30,000 and <200 flourescence units 
(fu) were classified as typing error. For the purpose of consistency, 
however, stricter quality criteria were applied: A minimum peak height of 
1000 fu for higher frequency alleles (>15%) and 500 fu for lower 
frequency alleles (<15%), absence of noise at the baseline, and no more 
than 50% peak height variation between the four pools. The overall peak 
pattern would be consistent amongst pools. Figure 4.1 shows a typical 
four-pool graph of a marker with a significant association. 
The initial error rate was 11.36%, the majority of these were high or low 
signal errors. With re-typing applying different DNA dilutions, and re-PCR, 
the error rate was reduced to 0.8% (details see appendix 4.1). 
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First Screen 
 
 
 
Second Screen 
 
 
Figure 4.1: Example of a peak height graph of marker D6S0035i 
as displayed by the MultiTyper (Applied Biosystems®) software. 
The images show the results of the four pools (top image: first 
screening, bottom image: second screening). Allele 2 has a 
higher peak height in the donor GVHD 0-1 group, suggesting a 
protective effect. This is replicated in the 2nd screen. 
Donor aGVHD grade 0-1 
Donor aGVHD grade 0-1 
Donor aGVHD grade 2-4 
Donor aGVHD grade 2-4 
Recip. aGVHD grade 0-1 
Donor aGVHD grade 2-4 
Recip. aGVHD grade 2-4 
Recip. aGVHD grade 0-1 
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4.1.2. Results of pooled DNA screening 
 
 
First pooled DNA screening (Discovery Cohort) 
 
In the 1st pooled DNA screening, 4,321 microsatellite markers were typed 
in four DNA pools (donors of recipients with GVHD grade 0 and 1, donors 
of recipients with GVHD grade 2-4, recipients with GVHD grade 0 and 1, 
and recipients with GVHD grade 2-4). 
Allele frequency differences were analysed in two directions, separately for 
each individual allele (Fisher’s exact test for 2x2 Chi Square test) and for 
each marker as a whole (Fisher’s exact test for 2xm Chi Square test): 
 
• Between donors of recipients with GVHD grade 0 and 1 and donors 
of recipients with GVHD grade 2-4 
• Between recipients with GVHD grade 0 and 1, and recipients with 
GVHD grade 2-4. 
 
The results were collated using a custom-built analysis and database 
system. Peak height data were translated into allele frequencies, and 
significance tests performed as described in the methodology section.  
This system automatically extracted the strongest associated allele for 
each marker (2x2), and all markers associated by 2xm analysis (result 
details see table). While all markers positive by 2xm analysis also had at 
least one allele associated by 2x2 analyses; not all markers who carried an 
associated allele were also positive by 2xm analysis.  
 
In first screening analysis (tables 3.1, 3.2), 34 (0.79%, donor) and 35 
(0.81%, recipient) markers were excluded because of technical failure in 
PCR or genotyping. 
103 (2.38%, donor) and 105 (2.43%, recipient) markers were non-
polymorphic. This is an expected result as the microsatellite marker panel 
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used in this study contains microsatellites that are polymorphic for some, 
but not all populations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All markers that were positive by 2xm or 2x2 analyses were typed again in 
the 2nd screening step (tables 4.1, 4.2). Inclusion of markers positive only 
for 2x2 but not for 2xm analysis was a measure of additional sensitivity for 
the second screening step. Naturally, the first screening step contained 
many false positive associations: 
 
• Statistically false positives, estimated as 5% of 4,321 markers (that 
would equal 216 markers in the 2xm analysis) or 5% of 20,197 
(donor analysis) or 20,132 (recipient analysis) alleles (which would 
lead to 1010 (donor analysis) and 1007 (recipient analysis) false 
positives in the 2x2 analyses). 
• Errors introduced by DNA pooling process (e.g. variation in number 
of DNA copies per pool). 
• Inherent artefacts of microsatellite typing (e.g. +A alleles, 
preferential amplification). 
 
 
 
 
 
 
 
1st pooled DNA screening results: 
 
In the donor pools analysis, 1016 alleles (2x2 test) and 624 MS 
markers (2xm test) showed an association with acute GVHD 
grade 2-4, either as a risk or protective. In the recipient analysis, 
931 alleles and 543 MS markers were associated.  
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Second pooled DNA screening (Confirmation Cohort) 
 
The main purpose of the secons pooled DNA screening step was to 
eliminate false positive associations by independent confirmation. 
Following 2nd pooled screening, identification of true and false positives 
was much more specific as the independent typing, in addition to p-value, 
introduces criteria which could be used to distinguish true and false 
positive associations: 
 
• Association of the same allele within a marker 
• Consistency of the odd’s ratio (‘risk’, ‘protective’) of the same allele 
between the two screening steps 
• Consistency of the microsatellite pattern and typing quality (as 
assessed by the peak image). 
 
Tables 4.1 and 4.2 give the details of the 1st and 2nd screening steps 
separate for the donor GVHD 0-1 versus donor GVHD 2-4 analysis, and 
the recipient results accordingly. Results for 2x2 and 2xm analysis were 
also separated. 
All markers that showed a positive 2xm or 2x2 result in first screening 
(1016 (23.51%, donor analysis) and 931 (21.54%, recipient analysis) were 
typed again in second screening, but analysed separately for 2x2 and 2xm 
Chi-Square tests. 
 
In second screening, 6 (donor analysis) and 10 (recipient analysis) 
markers showed a non-polymorphic results. These markers were typed 
again in all screening pools of 1st and 2nd result, using a new primer set. 
The non-polymorphic result was confirmed (hence, the initial polymorphic 
result in 1st screening represented a false positive association). We also 
excluded 17 (donor analysis) and 13 (recipient analysis) markers for which 
we technically could not reproduce the positive association in first 
screening despite repeated attempts of PCR and typing (as described 
above). Except for those markers displaying non-polymorphism or PCR 
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failure, all markers had satisfactory allele allocations as described in 
section 2.12.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Determining consistency of associations across the two screenings 
 
In the next step, false positive markers in the 2x2 analysis were excluded 
by identifying and selecting those markers that shared the same 
associated allele, and had an Odd’s ratio that consistently pointed in the 
same direction (towards risk/protection). 
When inspecting the results of positive markers that did not share the 
same most strongly associated allele within the marker, we noticed that 
many markers had several positive alleles. On inspection of the peak 
image we found that occasionally presumed artefacts represent the 
strongest allele, with a ‘true’ allele, which showed strongest allele 
association in the other screening, ‘obscured’. Therefore we decided to 
determine all associated alleles in markers positive for 2x2 analysis and 
2xm analysis (as we assumed that if 2x2 associations of the strongest 
allele within a marker would not result in 2xm-positivity, it would be unlikely 
that an allele with an even weaker association would have had a significant 
effect on risk/protection). Markers that would have a shared associated 
allele and be 2xm positive were entered into the odd’s ratio analysis. 
 
 
 
2nd pooled DNA screening results: 
 
In the donor analysis, 335 alleles (6.44%) had a significant result 
by p-value (<0.05), while in the 2xm analysis 178 markers 
(27.73%) were significant. In recipients, 314 alleles (6.32%) and 
141 markers (25.97%) were confirmed. 
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Pooled DNA screening results –  
same allele and Odd’s ratio direction: 
 
Eventually, 97 (donor analysis) and 74 (recipient analysis) alleles 
would remain with a p-value of <0.05 for 2x2 analysis in both 
screenings, a shared allele and consistent odd’s ratio direction; with 
57 (donor) and 40 (recipient) markers by 2xm analysis, accordingly. 
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Donors   
markers 
overall % 
alleles 
2x2 % 
markers 
2x2 % 
1st 
screen tested 4321 100 20197 100 4321 100
  positive 1016 23.51 1016 5.03 642 14.86
  negative 3175 73.32 19181 94.97 3548 82.11
  non-polymorph 103 2.38 N/A   97 2.24
  failed 34 0.79 N/A   34 0.79
  expected false pos 2xm 216 5 1009 5 216 5
  
difference pos-false pos 
2xm 800 18.51 7 0.03 425 9.86
                
2nd 
screen tested 1016 100 5205 100 642 100
  positive 335 32.97 335 6.44 178 27.73
  negative 658 64.77 4870 93.56 442 68.69
  non-polymorph 6 0.59     6 0.93
  failed 17 1.67     17 2.65
  
same allele as 1st 
screen allele     125       
  not same allele     210       
  
 - 2xm pos AND 2nd 
allele     47       
  sum same allele     172       
  same OR direction     97 10.42 57 10.50
  expected false pos 2xm     51 5 32 5
  
difference pos-false pos 
2xm     46   25   
 
Table 4.1: Results of the pooled donor GVHD 0-1 v donor GVHD 2-4 analysis 
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Recipient   
markers 
overall % 
alleles 
2x2 % 
markers 
2x2 % 
1st 
screen tested 4321 100 20132 100 4321 100
  positive 931 21.54 931 4.62 543 12.57
  negative 3252 75.22 19201 95.38 3641 84.26
  non-polymorph 105 2.43 103 0.51 105 2.43
  failed 35 0.81 35 0.17 32 0.74
  expected false pos 216 5 1006 5 216 5
  
difference pos-false 
pos 715 16.55 -75 -0.38 327 7.57
                
2nd 
screen tested 931 100 4969 100 543 100
  positive 314 33.73 314 6.32 141 25.97
  negative 594 63.80 4655 93.68 386 71.09
  non-polymorph 10 1.07 N/A   10 1.84
  failed 13 1.40 N/A   6 1.10
  
same allele as 1st 
screen allele     136       
  not same allele     208       
  
 - 2xm pos AND 2nd 
allele     27       
  sum same allele     163       
  same OR direction     74 7.95 40 7.37
  
expected false pos 
2xm     46.55 5 27.15 5
  
difference pos-false 
pos 2xm     27.45   12.85   
                
 
Table 4.2: Results of the pooled recipient GVHD 0-1 v recipient GVHD 2-4 analysis 
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Further steps of selecting associated microsatellite markers 
 
The confirmation of the first screening results by independent did reduce, 
but not completely eliminate false positive associations. The number of 
associations found after analysis of the second screening step would still 
exceed the number of expected true positives (as compared to previous 
GWAS using this approach) as well as the resources allocated to individual 
genotyping. Therefore, within the 2x2 datasets we used a two-step 
selection system to identify strong association and high quality typing 
markers for preferential selection for individual genotyping, aiming to 
eliminate markers falsely positive for lower quality genotyping. 
 
1st step: 
• Selection by allele frequency (=frequency of a certain allele in the 
pool): Alleles with a consistent allele frequency of >0.10 higher were 
selected. Low frequency alleles had a lower fluorescent signal peak 
height (as peak signal height correlates with allele frequency in the 
pool; a low signal at the border of technical resolution and/or a low 
allele frequency at the border of statistical power were more likely to 
represent artefacts), and may represent new mutations within the 
microsatellite; and/or: 
• 2xm positive: An allele association also resulted in the marker being 
positive in the 2xm analysis. This was more likely to the case in 
markers with smaller number of alleles (=number o alleles of a 
marker), increasing the statistical power of each allele. 
 
2nd step: 
 
• The fluorescent signal height was determined. The signal height 
depends on the number of allele copies in the sample, hence on the 
effectiveness of PCR. The genotyping process is calibrated to give 
accurate readings of fluorescent signals between 500-30,000 fu, i.e. 
the allele frequency distribution within one marker could expected to 
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be proportionally accurate, even with a variation of amount of DNA 
in the sample. Signals below or above this range are prone to 
distort the distribution of allele frequencies (i.e. an overall low signal 
may miss or misread low frequency alleles, while a very high signal 
may exaggerate the reading for high frequency alleles). A signal of 
1000 fu or above (but <30,000 fu) of the associated allele was 
regarded as of highest quality. 
• Inspection of the microsatellite pattern: Consistency in the 
microsatellite pattern in all eight pools (allele number, sequence, 
peak height). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Associated markers remaining following  
genotyping quality assessment: 
 
This process resulted in a ‘shortlist’ of 48 ms markers (31 in the 
donor analysis, 17 in the recipient analysis) selected for individual 
genotyping (table 3.3). 
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4.2. Individual genotyping 
 
 
4.2.1. Individual genotyping of the alleles found associated with 
GVHD grade 2-4 in the pooled screenings  
 
Most artefacts introduced by pooled PCR and genotyping (as described 
above in methodology section) were readily identifiable by ‘test-typing’ on a 
small number of individual samples, therefore all remaining 48 markers 
were subjected to typing on 14 samples each that stem from a healthy 
Japanese control population, unrelated to this study. This step eliminated 9 
(donor) and 2 ms markers (recipient) from further analysis due to pooling 
artefacts, copy number variation error or discovered non-polymorphism. 
 
Eventually 19 (donor) and 11 (recipient) markers underwent individual 
genotyping on the full sample set (922 donors or recipients). Three 
(donors) and 4 (recipient) markers with weaker associations, despite 
passing the criteria for individual genotyping, were eventually not 
individually typed due to resource restrictions. The overview results of the 
individual genotyping are presented in table 4.3.  
 
After applying Hardy-Weinberg Equilibrium tests for genotyping quality 
control, 10 MS markers were confirmed to have an association with Grade 
2-4 acute GVHD that was consistent in both pooled DNA screenings and 
individual genotyping (tables 4.4-4.6) in univariate analyses. Associations 
with p-values that would withstand application of Bonferroni’s correction for 
the total number of alleles in individual genotyping (n=123, 2x2 analysis: 
corrected threshold for p=0.05 association: p=0.0004065; p=0.1 trend: 
p=0.0008131) and markers (n=30, 2xm analysis: corrected threshold for 
p=0.05 association: p=0.00166, p=0.1 trend: p=0.00333), as well as those 
showing a trend with correction, were indicated.  
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Five further markers (D16S0452i, D5S1173i, D3S1225i, D14S0499i and 
AJ133269.1_180046) showed significant associations but failed the HWE 
for both case and control cohorts. From a genotyping quality control 
perspective these markers were therefore excluded from further analysis. 
Nevertheless, from a biological perspective failed HWE does not 
necessarily imply an invalid result. Due to the underlying malignant disease 
which is in part genetically determined, both the recipient as well as the 
HLA-matched donor population cannot be expected to reflect an allele 
distribution that would be expected in a ‘healthy’ population.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Results after applying multiple testing correction statistics 
 
Four markers (recipient D5S424, donor D6S0035i, D1S0818i, 
D17S0219i), demonstrated associations by 2xm and/or 2x2 analyses 
that had p-values that held up against statistics for multiple testing 
correction, while one further marker (D6S0330i) showed a trend 
when Bonferroni’s correction was applied. 
When including markers that failed the HWE test, one further marker 
(D16S04521i) would show an association.  
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Target gene MS 
identifier 2 
Donor/ 
Recipient 
Test 
typing 
Full individual 
typing Yes/No 
outcome 
individual typing 
SNRPN D15S122 D passed Y not confirmed 
AGPAT4 D6S0330i D passed Y confirmed 
PDE4B D1S0716i D passed N Not tested 
ALKBH1 D14S594 D failed N - 
TRAF7 D16S0452i D passed Y failed HWE 
NFKBIZ DISO7_1000118
4 D failed N - 
TIAF1 D17S0406i D passed Y artefact 
ELTD1 D1S0818i D passed Y confirmed 
ITPKB D1S1143i D passed Y not confirmed 
MCM2 D3S3607 D passed Y not confirmed 
SMARCAL1 D2S0809i D passed Y artefact 
EDAR D2S1281i D failed N - 
CD86 D3S1225i D passed Y failed HWE 
FBXW7 D4S0270i D passed Y not confirmed 
C1QTNF2 D5S403 D failed N - 
MAPK14 D6S0035i D passed Y confirmed 
ETV1 D7S0119i D passed Y not confirmed 
HSPB1 D7S1218i D passed Y not confirmed 
DLG5 D10S0603i D passed N not tested 
TCF8 D10S565 D passed Y not confirmed 
CAV1 AJ133269.1_180
046 D passed Y failed HWE 
C1QBP D17S0113i D failed N - 
EIF4A3 D17S0294i D passed N Not tested 
DSCAM D21S0184i D failed N - 
ATF4 D22S428 D failed N - 
BTK DXS0923i D failed N - 
IL1RAPL2 DXS0629i D passed Y confirmed 
IL1RAPL2 DXS0151i D passed Y confirmed 
TGM3 AL031678.2_901
37 D failed N - 
SOCS3 D17S0219i D passed Y confirmed 
LTB TNF C D passed Y trend only 
F2RL1/S100Z D5S424 R passed Y confirmed 
HRK D12S0781i R passed Y multiple  alleles 
MAP3K7 D6S0738i R passed N not tested 
NFKBIZ DISO7_1000118
4 R failed N - 
C1QA D1S1655i R passed Y not confirmed 
AKT3 D1S1335i R passed Y confirmed 
NMI D2S1334i R passed Y not confirmed 
EDAR D2S1281i R failed N - 
CSF2 D5S1174i R passed Y non-polymorphic 
IL7R D5S1173i R passed Y failed HWE 
RNASE6 D14S0499i R passed Y failed HWE 
MMP25 D16S3082 R passed Y not confirmed 
DDX42 D17S0271i R passed Y confirmed 
TRIM26  R passed N not tested 
TBL1X DXS0324i R passed Y confirmed 
SSTR2 chr17.fa.O7frz.7
8835314 R passed N Not tested 
ISG20 D15S0049i R passed N Not tested 
 
Table 4.3 : overview results of individual genotyping 
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Target Gene 
Marker 
name 
(internal) 
Database name Donor/Patient allele size 
allele 
no 
1st screen 
2xm 
1st screen 
2x2 p-value 
1st 
screen 
OR 
2nd screen 
2xm 
2nd screen 
2x2 p-value 
2nd 
screen 
OR 
F2RL1/S100Z 0507E03 D5S424 P 117.7 05 0.00465911 0.00123516 1.581714 2.37636E-09 5.88101E-10 2.29902 
MAPK14 0611B04 D6S0035i D 373.2 02 0.0331471 0.0331471 0.688211 0.00163933 0.00163933 0.595028 
ELTD1 0111F11 D1S0818i D 172 01 0.000310432 3.58175E-05 1.902177 0.0167968 0.0167968 1.470116 
IL1RAPL2 2310B01 DXS0151i D 466.6 04 0.000451 0.000451 1.783574 0.000105178 0.000105 1.864524 
SOCS3 T002C05 D17S0219i D 206 03 0.000157143 4.3431E-05 0.42191 0.0111833 0.00396346 0.471879 
IL1RAPL2 2309D05 DXS0629i D 393.4 03 0.151619 0.030286 1.45962 0.0201712 0.006152 1.568938 
TBL1X 2309A04 DXS0324i P 385.1 01 0.001843 0.001843 0.604196 0.0259134 0.025913 0.693579 
DDX42 1704G02 D17S0271i P 222 01 0.0360375 0.0128895 0.676094 0.0397464 0.0397464 0.743281 
AGPAT4 0606E02 D6S0330i D 166.6 07 0.000453657 0.000453657 1.616777 0.0123369 0.0123369 1.40784 
AKT3 0109C12 D1S1335i P 90.3 03 0.00030278 0.000182015 1.637257 0.0111414 0.00302767 1.488903 
TRAF7 1601E07 D16S04521i D 271 12 0.00002303 0.00002303 0.331837 0.0008224 0.00035560 0.535539 
CD86 0310G01 D3S1225i D 97.4 03 0.000021968 0.000021968 0.370631 0.0268393 0.0268393 0.647246 
CAV1 137G11 AJ133269.1_180046 D 384.1 05 0 0.000000087 4.635323 0.002575 0.0041277 2.163354 
RNASE6 1406B07 D14S0499i P 359.9 02 0.00121386 0.000101171 1.760132 0.00000002 0.000000001 2.354878 
IL7R 0508H03 D5S1173i P 146.7 04 0.001375 0.00007793 0.634464 0.00000013 0.000000116 0.529155 
 
 
Table 4.4: Genotyping results from both pooled screening steps of 15 microsatellite markers that showed an association 
in the individual genotyping. 
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TargetGene 
Marker 
name 
(internal) 
Database name Donor/Patient allele size (bp) 
Associated 
allele no 
aGVHD 
01-24 
2xm p= 
aGVHD 
01-24 2x2 
p= 
2x2 Odds 
ratio 
95% CI 
lower 
95% CI 
higher 
HWE 
decision 
F2RL1/S100Z 0507E03 D5S424 P 117.7 05 0.0004* 0.002017 1.338207 1.113486 1.608281 ok 
MAPK14 0611B04 D6S0035i D 373.2 02 0.0004* 0.00035* 0.685984 0.558405 0.84271 ok 
ELTD1 0111F11 D1S0818i D 172 01 0.0007* 0.0000783* 1.519239 1.242103 1.858208 ok 
IL1RAPL2 2310B01 DXS0151i D 466.6 04 0.0066 0.007038 1.41669 1.125021 1.783976 ok 
SOCS3 T002C05 D17S0219i D 206 03 0.005 0.000275* 0.418673 0.259705 0.674948 ok 
IL1RAPL2 2309D05 DXS0629i D 393.4 03 0.016 0.001315 0.7778 2.698158 4.312269 ok 
TBL1X 2309A04 DXS0324i P 385.1 01 0.021 0.013253 0.753511 0.603937 0.940129 ok 
DDX42 1704G02 D17S0271i P 222 01 0.0404 0.008597 0.71826 0.563124 0.916134 ok 
AGPAT4 0606E02 D6S0330i D 166.6 07 0.071 0.00074† 1.38941 1.150105 1.678508 ok 
AKT3 0109C12 D1S1335i P 90.3 03 0.195 0.032222 1.226761 1.017861 1.478534 ok 
TRAF7 1601E07 D16S04521i D 271 12 0* 0.0002735* 0.672402 0.54339 0.83204 failed 
CD86 0310G01 D3S1225i D 97.4 03 0.029 0.0080907 0.75196 0.60978 0.92729 failed 
CAV1 137G11 AJ133269.1_180046 D 384.1 05 0.354 0.0279587 1.391733 1.04506 1.85340 failed 
RNASE6 1406B07 D14S0499i P 359.9 02 0.137 0.0076539 1.337914 1.08112 1.65570 failed 
IL7R 0508H03 D5S1173i P 146.7 04 0.0056 0.0122439 0.7072632 0.427571 0.98156 failed 
 
 
Table 4.5: individual genotyping associations of microsatellite markers (2xm) and alleles (2x2) with aGVHD grade 2-4.  
P-values shaded dark (*) are significant against multiple testing correction; p-values shaded bright (†) show a trend. 
Included in this table are the five markers failing HWE testing, one of these showing an association.  
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Target Gene Marker 
allele 
no 
aGVHD 
01-24 p= total 
cases 
all 
controls 
all 
cases 
pos 
cases 
neg 
controls 
pos 
controls 
neg 
Odds 
ratio 
lower 
CI 
(95%) 
higher 
CI 
(95%) 
F2RL1/S100Z D5S424 05 0.00202 1842 842 1000 446 396 457 543 1.338 1.1135 1.60828 
MAPK14 D6S0035i 02 0.00035 1824 832 992 207 625 323 669 0.686 0.5584 0.84271 
ELTD1 D1S0818i 01 0.000078 1832 842 990 619 223 634 347 1.519 1.2421 1.85821 
IL1RAPL2 DXS0151i 04 0.00704 1297 595 702 228 367 214 488 1.417 1.125 1.78398 
SOCS3 D17S0219i 03 0.00028 1826 838 988 24 814 65 923 0.419 0.2597 0.67495 
IL1RAPL2 DXS0629i 03 0.00132 1291 591 700 307 284 426 274 0.778 0.6234 0.97071 
TBL1X DXS0324i 01 0.01325 1271 585 686 264 321 358 328 0.754 0.6039 0.94013 
DDX42 D17S0271i 01 0.0086 1824 834 990 129 705 201 789 0.718 0.5631 0.91613 
AGPAT4 D6S0330i 07 0.00074 1828 838 990 360 478 348 642 1.389 1.1501 1.67851 
AKT3 D1S1335i 03 0.03222 1842 842 1000 364 478 383 617 1.227 1.0179 1.47853 
 
 
Table 4.6: Allele numbers and Odds Ratio calculation for associated alleles from individual genotyping, illustrating the 
effect sizes of the associations. 
 
 
 
 
 
 
 
 
 
  
140
140
4.2.2. HLA subgroup analysis of alleles 
 
Mirroring the analysis of SNP markers in the pilot study, the effects of the 
alleles were also analysed in a subgroup of higher HLA matching. HLA 
matching was defined as high-resolution (allele level) match for HLA-A, B, 
C, DRB1 (i.e. 8/8 matching), with allowing for either a HLA-DQB1 or DPB1 
only, and including 12/12 matches. Results of this subgroup analysis are 
presented in table 4.7.  While some of the associations were limited to the 
HLA mismatched group only, others showed an effect on both degrees of 
matching, and some associations appeared to have a larger effect on the 
HLA-matched subgroup than on the mismatched one. Two markers had 
other alleles than the one identified by pooled screening associated with 
acute GVHD grade 2-4. In both cases, the markers had two main alleles 
only, hence could be analysed like a single nucleotide polymorphism 
(SNP) marker. While one allele of these markers indicated a GVHD risk, 
the corresponding ‘opposite’ allele would have a protective effect, as the 
OR of the associations showed (table 4.8.) 
 
 
4.2.3. Genotype analysis with HLA subgroup analysis 
 
An analysis of genotypes was also conducted where possible. As MS have 
many alleles, and therefore a large number of possible allele combinations 
forming a genotype, such analyses would have only be useful with a 
reasonable frequency of the genotype in question. A limit of an allele 
frequency of 0.1 or above was applied. Primarily the homozygosity and 
heterozygosity of the associated allele versus the remaining genotypes 
was investigated; and then all other genotypes that had a frequency of 
10% or more were analysed. 
 
Five markers showed an association with acute GVHD grade 2-4 of the 
homozygous genotype of the same associated allele (table 4.10); while 
four further markers showed associations of other genotypes with acute 
GVHD grade 2-4 (tables 4.11, 4.12). All of the latter four markers had only 
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two or three major alleles accounting for >90% of the total allele frequency; 
the genotypic analysis showed that the genotype of the ‘oppositional’ allele 
had a stronger (and opposite) effect as compared to the allelic effect of the 
originally identified allele. One example was the above mentioned marker 
0611B04 (D6S0035i): Whilst the allelic screening suggested that the minor 
allele 02 had a protective effect, it is in fact the major homozygous allele 01 
genotype that constituted a risk of moderate-severe acute GVHD.  
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Table 4.7: Association of alleles separated by degree of HLA matching. The effect of polymorphisms is either visible 
mainly in the HLA-matched subgroup (MAPK14, AGPAT4), or mainly in the HLA-mismatched subgroup (F2RL1, ELTD1, 
SOCS3, DDX42, AKT3). 
 
 
 
 
 
 
 
 
 
 
marker info   all alleleic association     HLA mismatched   HLA matched 
TargetGene 
Marker 
name Donor/Patient 
allele 
no 
aGVHD 01-24 
2xm p= 
aGVHD 01-24 
2x2 p= 
2x2 Odds 
ratio 
aGVHD 
01-24 p= 
Odds 
ratio 95% CI 
aGVHD 
01-24 p= 
Odds 
ratio 95% CI 
F2RL1/S100Z D5S424 P 05 0.0004 0.002017 1.338207 0.0107 1.349883 1.1-1.7 0.066 1.347273 0.9-1.8 
MAPK14 D6S0035i D 02 0.0004 0.00035 0.685984 0.02457 0.74731 0.6-0.9 0.00273 0.579385 0.4-0.8 
ELTD1 D1S0818i D 01 0.0007 0.0000783 1.519239 0.0011 1.52398 1.2-2.0 0.051 1.404808 1.0-2.0 
IL1RAPL2 DXS0151i D 04 0.0066 0.007038 1.41669 0.071 1.30469 0.98-1.70 0.019 1.628809 1.1-2.4 
SOCS3 D17S0219i D 03 0.005 0.000275 0.418673 0.000872 0.384298 0.2-0.7 0.115 0.480896 0.2-1.1 
IL1RAPL2 DXS0629i D 03 0.016 0.001315 0.7778 0.06 0.768652 0.6-1.1 0.005 0.575585 0.4-0.85 
TBL1X DXS0324i P 01 0.021 0.013253 0.753511  0.298 0.85887 0.7-1.1 0.009 0.598058 0.4-0.9 
DDX42 D17S0271i P 01 0.0404 0.008597 0.71826 0.0316 0.713717 0.5-0.9 0.155 0.739331 0.5-1.1 
AGPAT4 D6S0330i D 07 0.071 0.00074 1.38941 0.027 1.304192 1.0-1.6 0.00669 1.571115 1.1-2.1 
AKT3 D1S1335i P 03 0.195 0.032222 1.226761 0.01824 1.323822 1.1-1.7 0.685 1.068627 0.8-1.5 
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marker info   all alleleic association   HLA mismatched  HLA matched 
TargetGene 
Marker 
name Donor/Patient allele no 
aGVHD 01-24 
2xm p= 
aGVHD 01-
24 2x2 p= 
2x2 
Odds 
ratio allele 
aGVHD 
01-24 p= 
Odds 
ratio 
lower CI 
(95%) 
aGVHD 01-
24 p= 
Odds 
ratio 95% CI 
F2RL1/S100Z D5S424 P 05 0.0004 0.002017 1.338207 04 0.03319 0.76 0.6-1.0 0.000696 0.54 0.4-0.8 
MAPK14 D6S0035i D 02 0.0004 0.00035 0.685984 01 0.0344 1.31 1.0-1.7 0.0066 1.64 1.2-2.3 
ELTD1 D1S0818i D 01 0.0007 0.0000783 1.519239               
IL1RAPL2 DXS0151i D 04 0.0066 0.007038 1.41669               
SOCS3 D17S0219i D 03 0.005 0.000275 0.418673               
IL1RAPL2 DXS0629i D 03 0.016 0.001315 0.7778               
TBL1X DXS0324i P 01 0.021 0.013253 0.753511               
DDX42 D17S0271i P 01 0.0404 0.008597 0.71826               
AGPAT4 D6S0330i D 07 0.071 0.00074 1.38941               
AKT3 D1S1335i P 03 0.195 0.032222 1.226761               
 
Table 4.8: Association of alleles other than those identified by pooled DNA genotyping, with HLA matching subgroup 
analysis 
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Table 4.9: Associations with moderate-to severe acute GVHD (grade 2-4) of homozygous genotypes of the same  
alleles as identified in the pooled and individual genotyping.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Target 
Gene DS name 
allele 
position 
allele 
ID 
P value 
aGVHD 01-24 
association 
p= 
total cases all 
controls 
all 
cases 
pos 
cases 
neg 
controls 
pos 
controls 
neg 
Odds 
ratio 
lower 
CI 
(95%) 
higher 
CI 
(95%) 
ELTD1 D1S0818i 172 01 0.0006 916 421 495 228 193 211 284 1.59 1.224 2.066 
IL1RAPL2 DXS0151i 466.6 04 0.0313 918 420 498 117 303 108 390 1.39 1.031 1.885 
TBL1X DXS0324i 385.1 01 0.0053 914 420 494 145 275 216 278 0.68 0.519 0.888 
AGPAT4 D6S0330i 166.6 07 0.0003 914 419 495 90 329 55 440 2.19 1.52 3.151 
AKT3 D1S1335i 90.3 03 0.0197 921 421 500 82 339 68 432 1.54 1.081 2.184 
  
145 
145
 
 
 
marker info   all homozygous genotypes 
HLA mismatched homozygous 
genotypes 
HLA matched homozygous 
genotypes 
TargetGene Marker name 
homozyg 
genotype 
aGVHD 01-
24 p= 
Odds 
ratio 95% CI 
aGVHD 01-
24 p= 
Odds 
ratio 95% CI 
aGVHD 01-
24 p= 
Odds 
ratio 95% CI 
F2RL1/S100Z D5S424 0505 0.101 1.3 0.9-1.8 0.0817 1.41 0.9-2.1 0.69 1.12 0.7-1.9 
MAPK14 D6S0035i 0202 0.099 0.64 0.3-1.1 0.0737 0.52 0.3-1.0 1 0.93 0.4-2.1 
ELTD1 D1S0818i 0101 0.0005 1.59 1.2-2.1 0.0031 1.63 1.2-2.3 0.14 1.44 0.9-2.2 
IL1RAPL2 DXS0151i 0404 0.031 1.39 1.0-1.9           
SOCS3 D17S0219i 0303 0.52 0.59 0.1-2.4 0.22 0.21 0.1-1.8 1 0.74 0.1-8.2 
IL1RAPL2 DXS0629i 0303 0.02 0.73 0.6-0.9           
TBL1X DXS0324i 0101 0.0053 0.68 0.5-0.9           
DDX42 D17S0271i 0101 0.14 0.55 0.3-1.2           
AGPAT4 D6S0330i 0707 0.00025 2.19 1.5-3.2 0.0059 1.94 1.2-3.1 0.0008 2.77 1.5-5.1 
AKT3 D1S1335i 0303 0.019 1.54 1.1-2.2 0.0233 1.7 1.1-2.6 0.56 0.83 0.5-1.5 
 
 
Table 4.10: homozygous genotype associations of the same allelic associations identified by pooled DNA genotyping, with analysis 
separate for HLA matched/mismatched subgroups. 
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marker info   all homozygous genotypes 
HLA mismatched homozygous 
genotypes 
HLA matched homozygous 
genotypes 
TargetGene Marker name 
homozyg 
genotype 
aGVHD 01-
24 p= 
Odds 
ratio 95% CI 
aGVHD 01-
24 p= 
Odds 
ratio 95% CI 
aGVHD 01-
24 p= 
Odds 
ratio 95% CI 
F2RL1/S100Z D5S424 0404 0.000059 0.36 0.2-0.6 0.0067 0.44 0.2-0.8 0.00149 0.18 0.1-0.6 
MAPK14 D6S0035i 0101 0.00053 1.6 1.2-2.1 0.069 1.36 1.0-1.9 0.00093 2.18 1.4-3.4 
ELTD1 D1S0818i                     
IL1RAPL2 DXS0151i                     
SOCS3 D17S0219i                     
IL1RAPL2 DXS0629i                     
TBL1X DXS0324i                     
DDX42 D17S0271i                     
AGPAT4 D6S0330i                     
AKT3 D1S1335i                     
 
 
Table 4.11: Genotypic associations other than those allelic associations identified by pooled DNA genotyping, with subgroup analysis for 
HLA matched/mismatched subgroup  
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Target 
Gene 
Marker 
name 
allele 
position allele ID 
P value 
aGVHD 01-24 
Association 
p= 
total cases all 
controls 
all 
cases 
pos 
cases 
neg 
controls 
pos 
controls 
neg 
Odds 
ratio 
lower 
CI 
(95%) 
higher 
CI 
(95%) 
F2RL1/ 
S100Z D5S424 116 04 6E-05 921 421 500 20 401 61 439 0.36 0.21 0.605 
MAPK14 D6S0035i 369 01 5E-04 912 416 496 229 187 215 281 1.6 1.23 2.081 
IL1RAPL2 DXS0629i 397 04 0.001 916 419 497 159 260 139 358 1.58 1.19 2.08 
LTB  TNFC 160 05 0.003 915 419 496 23 396 9 487 3.14 1.44 6.869 
 
 
Table 4.12: Associated genotypes of other alleles than those identified through pooled screening and individual genotyping. 
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4.2.4. Analysis of MS marker associations on Chromosome X 
 
Alleles from three MS markers (DXS0629i, DXS0324i, DXS0151i) were 
found to be associated with grade 2-4 acute GVHD. Analysis in the pooled 
screening was by counting overall alleles within the pool, correcting for the 
overall number of alleles (i.e. for males only one allele was counted, for 
females two). The analysis of individual genotyping was mirroring this 
approach in order to confirm the findings from pooled DNA screening. 
 
Two of the alleles had a protective effect, while one indicated a risk for 
GVHD. One allele was recipient-intrinsic with a protective effect, whereas 
the two others derived from the donor, exerting a protective or risk effect. 
Two markers of these alleles were intronic to the same, very large gene 
IL1RAPL2.  
 
An analysis separating the gender effects did show that the markers in the 
IL1RAPL2 gene had very similar effects on the recipient when coming from 
a female or male donor. The effect of the marker in TBL1X appeared to be 
mainly on the male recipient. 
  
In the context of transplantation, many polymorphisms on chromosome X 
have been described as minor histocompatibility antigens (mHag). These 
are antigens outside the major histocompatibility complex (MHC) that can 
induce strong immunological responses leading to either graft rejection, 
GVHD or graft-versus-leukaemia effects. The analysis of markers on 
chromosome X in this respect is complex and beyond the scope of this 
study. Such analysis would require careful evaluation of confounding 
variables relating to donor/recipient sex, rejection and chronic GVHD as 
outcomes, subgroup analysis of the different female/male combinations of 
donor and recipient, as well as consideration of HLA matching. 
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All 
 
Female Male 
Gene Marker 
allele 
no 
p for aGVHD 
01-24 p= 
Odds 
ratio 
lower CI 
(95%) 
higher CI 
(95%) 
p for 
aGVHD 
01-24 p= 
Odds 
ratio 
lower CI 
(95%) 
higher CI 
(95%) 
p for 
aGVHD 
01-24 p= 
Odds 
ratio 
lower CI 
(95%) 
higher CI 
(95%) 
IL1RAPL2 DXS0151i 04 D 0.00704 1.417 1.125 1.7839764 0.021 1.428118 1.05609 1.9311997 0.082 1.395542 0.9754874 1.9964762 
IL1RAPL2 DXS0629i 03 D 0.00132 0.778 0.623 0.970705 0.018 0.70393 0.5264287 0.9412825 0.036 0.683761 0.4851211 0.9637359 
TBL1X DXS0324i 01 R 0.01325 0.754 0.604 0.9401294 0.232 0.829365 0.618453 1.1122049 0.022 0.672497 0.4805425 0.9411286 
 
 
Table 4.13: X-chromosomal markers associated with acute GVHD grade 2-4
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4.2.5. Multivariate analysis 
 
In order to understand which of the identified associations would be 
consistent when compared to other major variables in the dataset which 
we identified previously, multivariate analysis was conducted in STATA v 
11 (performed by Dr Hirofumi Nakaoka). This was undertaken as backward 
multiple logistic regression, i.e. all variables showing a significant 
association in univariate analysis were include and eliminated in a 
stepwise fashion until no further improvement to the model could be 
achieved.  
Variables included were recipient age, donor age, female into male 
transplant, diagnosis, use of total body irradiation, use of antithymoglobulin, 
use of cyclosporine A versus tacrolimus for GVHD prophylaxis, relapse 
and HLA matching (HLA-DQB1 or DPB1 mismatch and fully matched pairs 
only, versus all other grades of mismatching). 
 
A single dataset containing all clinical variables and genotyping results was 
constructed. Samples for which we did not have all variable information or 
genotyping results were excluded (53 samples), therefore p-values for 
univariate analysis differ slightly from those reported in the tables above. 
Markers on the X-chromosome were not included. 
Diagnosis (ALL > ANLL), donor age (older) and HLA mismatch were the 
strongest competing variables in multivariate analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results of the multivariate analysis 
 
Five markers (D6S0035i D17S0219i D1S0818i D6S0330i D5S424) showed 
associations in multivariate analysis that had effect sizes larger than any 
of the clinical variables, and are therefore independent predictors of 
moderate-severe GVHD. 
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  Univariate     Multivariate     
  OR 95% CI P value OR 95% CI P value 
Recipient age 0.984 0.972-0.997 0.015 0.987 0.973-1.001 0.06 
Donor age 1.018 1.000-1.035 0.045 1.021 1.003-1.040 0.023 
F-M transplant 1.181 0.856-1.629 0.311 1.15 0.818-1.616 0.421 
Diagnosis (ANLL vs ALL) 0.628 0.482-0.818 5.6×10-4 0.644 0.485-0.857 2.5×10-3 
TBI 0.751 0.506-1.115 0.155 0.687 0.449-1.053 0.085 
ATG 1.186 0.467-3.016 0.72 0.788 0.292-2.126 0.638 
Cya vs tac 1.109 0.854-1.440 0.439 1.067 0.810-1.406 0.644 
Relapse 0.69 0.508-0.939 0.018 0.727 0.528-1.001 0.051 
HLA match 0.705 0.536-0.928 0.013 0.727 0.544-0.972 0.031 
D6S0035i (MAPK14) allele 2 0.67 0.541-0.829 2.3×10-4 0.672 0.538-0.839 4.5×10-4 
D17S0219i (SOCS3) allele 3 0.456 0.289-0.721 7.5×10-4 0.426 0.264-0.685 4.3×10-4 
D1S0818i (ELTD1) allele 1 1.49 1.218-1.822 1.0×10-4 1.46 1.185-1.799 3.9×10-4 
D6S0330i (AGPAT4) allele 7 1.376 1.141-1.659 8.4×10-4 1.435 1.180-1.745 2.9×10-4 
D5S424 (F2RL1) allele 5 1.495 1.212-1.838 1.4×10-4 1.497 1.206-1.859 2.5×10-4 
D17S0271i (DDX42) allele 1 0.719 0.564-0.918 8.0×10-3 0.731 0.566-0.944 0.016 
D1S1335i (AKT3) allele 3 1.229 1.018-1.483 0.032 1.221 1.005-1.484 0.045 
TNFC Allele 5 1.238 0.977-1.568 0.077 - - - 
 
 
Table 4.14: Multivariate analysis of microsatellite alleles associated with grade 2-4 acute GVHD. 
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4.3 Further exploration of a susceptibility region  
       by SNP typing 
 
 
Microsatellites as applied in this study ‘represented’ and identified a region 
of linkage disequilibrium to disease-associated genetic features like e.g. 
functional polymorphisms, assuming an average length of linkage 
disequilibrium of approximately 100 kb. Further work of investigation was 
therefore needed aiming to limit down in size the disease-associated locus, 
or even identify the underlying genetic variation that causes the disease 
association (see the more detailed discussion on this Topic in the 
discussion section). 
 
As an example, a small exploration was undertaken into the MAPK14 locus 
(marker D6S0035i) using tag SNP identified through the HapMap project. 
The region on Chr 6 was searched for 50 kb on each side of the 
microsatellite (6:36,100.000 – 6:36,200.000), identifying 159 SNP in 6 
haplotype blocks, of which 25 SNP were tag SNP. Focussing on the 
largest of the haplotype blocks, five SNP (rs6934216, rs851020, 
rs16884919, rs12530381, rs7760405) were selected and genotyped using 
TaqMan methodology. As not all of the 25 tag SNP were available for this 
platform, not all haplotypes would be captured, but haplotype analysis was 
attempted. 
 
Three of these SNP markers showed association with grade 2-4 acute 
GVHD: 
 
• rs851020 and rs12530381 (the latter is the closest to the 
microsatellite, and the coding region of MAPK14) both associated 
with allelic and genotypic risk (table 4.15). These markers had an 
almost identical allele and genotype distribution, and may have 
been linked. 
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• rs6934216 and rs851020 showed a protective allelic and genotypic 
trend towards association (table 4.15). 
 
Due to the limited capture no haplotypes were derivable from these data. 
Further work with either SNP or microsatellites would be required to 
investigate associations at this locus. 
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MAPK14
D6S0035i
rs12530381rs6934216rs851020
rs7760405rs16884919
Chromosome 6p21
36,100,000 36,200,000
 
 
 
Figure 4.2: Map of microsatellite and tagSNP positions in the intronic region of the MAPK14 gene. The shaded area of 
the gene indicates the exon. The large arrow indicates the position of the microsatellite, the small arrows show the 
position of selected SNP. Dark arrows indicate association of the marker with acute GVHD grade 2-4. 
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marker allele freq allele freq 
assoc 
allele p= OR OR 95% CI 
rs12530381 A (73%)  G (27%) A  0.0013 1.407493 1.1-1.8 
rs6934216 A (9%) G (91%) G 0.287 0.831325 0.6-1.1 
rs851020 C (72%) G (28%) C 0.0035 1.362699 1.1-1.7 
 
marker 
genotype 
freq 
genotype 
freq 
genotype 
freq 
assoc 
genotype p= OR OR 95% CI
rs12530381 GG (0.08) AA (0.53) AG (0.39) AA 0.0043 1.584844 1.2-2.1 
rs6934216 GG (0.82) AA (0.07) AG (0.16) GG 0.08 0.732426 0.5-1.1 
rs851020 GG (0.10) CC (0.53) CG (0.37) CC 0.00014 1.667178 1.3-2.2 
 
 
Table 4.15: SNP allele and genotype associations of markers close to microsatellite D6S0035i 
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4.4. Genetic susceptibility regions for moderate-severe  
 acute GVHD 
 
4.4.1. Introduction 
 
Each of the identified alleles or markers represented a region of 
approximately 100 kb of linkage disequilibrium (LD) with an associated 
genetic variation. Microsatellites in themselves are rarely directly disease 
causative, but linked to such a variation which could be a polymorphism, a 
mutation, deletion or duplication, or epigenetic trait. 
 
The specific LD for any of the associated genetic loci in this study was not 
immediately known. The HapMap database gave information about the LD 
of SNP markers but not microsatellites. Previous studies have used well 
known association loci, placing a variety of SNP and MS markers around it 
(Koch et al., 2000, Ohashi and Tokunaga, 2003) or well characterized 
populations (Varilo et al., 2003), or mathematical models (Terwilliger et al., 
2002, Shifman et al., 2003) to determine LD of MS markers. These studies 
found that the LD of MS markers extended beyond that of SNP markers 
(up to 400 kb, compared to up to 30 kb for SNP). Also, LD decreased with 
distance from the marker, even on the same haplotype block. 
 
Therefore it was reasonable to assume a LD of 100 kb as a starting point 
for locus analysis, until detailed exploration of each locus by higher density 
typing with more MS or SNP markers indicated its specific LD. 
 
Obviously, intronic MS markers with no other genes within a 100 kb range 
were prime candidates genes for further association testing. Six loci (AKT3, 
ELTD1, AGPAT4, MAPK14, IL1RAPL2 with 2 loci) fulfilled these criteria. 
All of these had been target genes, and two of these (ELTD1 and 
MAPK14) had marker as well as allele associations that were consistent 
even with application of multiple testing correction and in multivariate 
analysis. Two loci had intronic markers that were not within the target gene, 
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but coincidentally within other genes within 100 kb distance from the target 
gene (TBL1X→SHROOM2; SOCS3→DNEL2), both had further genes 
within LD range. Finally, the loci F2RL1 and DDX42 were intronic in the 
target gene but had several other, non-targeted genes at close range. The 
following sections will describe each locus in turn. Information has been 
obtained from the gene cards website (http://www.genecards.org/) and 
additional sources, as referenced. 
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4.4.2. AKT3 locus  
 
Chr 1:241718158- 242080053 
MS marker D1S1335i location: Chr1:241980312-241980412 
 
 
The AKT3 (Protein Kinase B isoform 3, PKB) gene is a large gene, more 
than 360 kb long. In the pooled screening it was covered by 5 MS markers, 
of which only this one, which was also closest to the coding region, 
showed an association (Figure 4.3). 
AKT3 has a broad effect on cell function, it is an important regulator of cell 
signalling in response to insulin and growth factors, it has a role in cell 
proliferation, differentiation, apoptosis, tumorigenesis as well as glycogen 
synthesis and glucose uptake (Somanath et al., 2006). AKT dysregulation, 
mainly studied in mice, leads to diseases like diabetes, cancer, 
cardiovascular and neurological disease (Hers et al., 2011). In T-
lymphocytes, AKT3 has in important role in cell development and 
proliferation. AKT3 regulates glucose uptake, protein synthesis, and 
stimulates the E2F and forkhead transcription factors (Matthews and 
Cantrell, 2006). In a genome-wide gene expression study of GVHD, PKB 
expression was repressed in donor CD4 T-cells in chronic GVHD (Baron et 
al., 2007). 
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Figure 4.3: Genomic map of the AKT 3 gene and position of the 
associated microsatellite 
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4.4.3. ELTD1 locus  
 
Chr 1:79128037-79279105 
MS marker D1S0818i location: Chr 1:79149764-79149943 
 
ELTD1 (EGF latrophillin and seven transmembrane containing 1) is part of 
the EGF-TM7 (Epidermal Growth Factor seven transmembrane) family. It 
has important funcions in leukocyte adhesion and neutrophil migration, and 
defects in this gene had consequences for innate and adaptive immunity 
(Yona and Stacey, 2010, Leemans et al., 2004). Genetic variation in this 
gene had been associated with parasitic susceptibility in cattle (Porto Neto 
et al., 2011) and subcutaneous fat thickness in humans (Lee et al., 2011). 
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Figure 4.4: Genomic map of the ELTD1 gene and position of the 
associated microsatellite 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
162
162
4.4.4. AGPAT4 locus  
 
Chr 6: 161332749-161458407 
MS marker D1S0818i location: Chr 6: 161511402-161511576 
 
AGPAT4 (1-acylglycerol-3-phosphate O-acyltransferase 4) is a membrane 
enzyme that is involved in de novo phospholipid biosynthesis. The wider 
function of this protein is not known. Variations in this gene, however, had 
been associated with acute as well as chronic GVHD in a population from 
Finland (Turpeinen et al., 2009). This study found the donor SNP rs749013 
associating with risk of acute as well as chronic GVHD, mirroring the 
finding of this study (donor allele of MS associated with risk of acute 
GVHD). The SNP marker is located approximately 50 kb upstream towards 
the exon, and in contrast to the Finnish population is non-polymorphic in 
Japanese.  
 
 
 
 
 
 
Figure 4.5: Genomic map of the AGPAT4 gene and position of the 
associated microsatellite 
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4.4.5. MAPK14 locus  
 
Chr 6: 36129769-36215820 
MS marker D6S0035i location: Chr 6: 36178949-36179320 
 
The gene for MAPK14 (Mitogen-activated Protein Kinase 14) is located on 
chromosome 6 close to, but outside the HLA region. The function of this 
gene has been explored extensively. MAPK14 responded to activation by 
environmental stress, pro-inflammatory cytokines, HSP70 and 
lipopolysaccharides (as part of the TLR pathway) (Kang et al., 2008, 
Lissauer et al., 2009, Mackay and Sallusto, 2006).  It was a regulator of 
chronic inflammation in rheumatoid arthritis (Korb et al., 2006) and 
inflammatory bowel disease (Waetzig et al., 2002). MAPK14 had effects on 
the recruitment of immune cells to the colonic mucosa (Kang et al., 2010) 
and epithelia of the skin (Eckert et al., 2003). MAPK14 was a key element 
in the activation of the glucocorticoid kinase, which decreased 
susceptibility to cytotoxic drugs and promotes cell survival (Meng et al., 
2005). 
On the basis of the largely pro-inflammatory effects of MAPK14, inhibitors 
have been developed for the treatment of rheumatoid arthritis and other 
inflammatory conditions. While in vitro and animal models did show very 
promising results, a recent randomized controlled clinical trial had failed to 
show any long term benefit for patients with rheumatoid arthritis (Genovese 
et al., 2011), indicating that the role of MAPK14 is complex. 
 
MAPK13, a splicing variant of MAPK14, is located close to this gene. 
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Figure 4.6: Genomic map of the MAPK14 gene and position of the 
associated microsatellite 
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4.4.6. IL1RAPL2 loci  
 
Chr X: 103697652-104898478 
MS marker DXS0629i location: Chr X: 103769044-103769435 (intronic) 
MS marker DXS0151i location: Chr X: 103689786-103690263 
 
The IL1RAPL2 (interleukin 1 receptor accessory protein-like 2) gene is 
very large, more than 1000kb, it was covered for this study by 10 MS 
markers. Only these two markers, which closely flank the coding region of 
IL1RAPL2, showed association (albeit in opposite directions). 
This gene is part of the IL1 receptor family, which was the reason for 
inclusion in this study. It has, however, so far no documented role in the 
immune system. There is extensive literature of the association of 
IL1RAPL2 with cognitive impairment and mental retardation (Valnegri et al., 
2011).  
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Figure 4.7: IL1RAPL2 gene locus on chromosome X with two MS 
markers (left: DXS0151i, right: DXS0629i), flanking the coding region 
of the gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
167
167
4.4.7. TBL1X locus  
 
Chr X: 9391369-9647778 
MS marker DXS0324i location: Chr X: 9722847-9723231 
 
The target gene TBL1X (transducin (beta)-like 1 X-linked) is a further large 
X-chromosome gene. The marker flanked the coding region at a distance 
of ~80 kb, and was co-incidentally located intronically within the gene 
SHROOM2. A further gene, GPR143, was located within a 100 kb LD 
range of the marker between SHROOM2 and TBL1X (see Figure 4.8). 
Little knowledge exists about the function of TBL1X. It had an essential 
role in transcription activation mediated by nuclear receptors (Glass and 
Ogawa, 2006). It recruited NFkB to its target for gene transcription and had 
a potential role in tumorigenesis (Ramadoss et al., 2011), and also 
regulated MYC gene expression, which is important for growth and 
expansion of somatic cells (Toropainen et al., 2010). Genetic 
polymorphisms in TBL1X had recently been linked to autism in males 
(Chung et al., 2011), but the mechanism remained unclear. 
SHROOM2 (shroom family member 2) had a broad role in the 
morphogenesis of thickened epithelial shields during embryonal 
development (Lee et al., 2009), and regulated epithelial proliferation and 
angiogenesis (Farber et al., 2011). 
GPR143 (G-protein coupled receptor 143) was involved in intracellular 
signal transduction, in particular the transfer of melanin. Mutations in 
GPR143 lead to variant forms of albinism and mental retardation. The 
protein expressed by GPR143 also represented a self or tumour antigen 
(Touloukian et al., 2003). 
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Figure 4.8: TBL1X gene locus on chromosome X. The marker is 
intronic to SHROOM2.The MS position is located outside TBL1X, but 
LD of the marker includes the coding regions of TBL1X and GPR143.  
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4.4.8. F2RL1 locus  
 
Chr 5:76150610- 76166896 
MS marker D5S424 location: Chr 5: 76193683- 76193804 
 
F2RL1 (coagulation factor II (thrombin) receptor-like 1) was implicated in 
chronic responses associated with vessel inflammation and wound 
healing; stimulated activation of T-cells and neutrophils, promoted 
leukocyte rolling, adhesion and extravasation, increased capillary 
permeability and enhances production of cytokines. High F2RL1 
expression in experimental intestinal radiation injury promoted 
inflammation and fibrosis. F2RL1 has been demonstrated on T-cells, 
where it triggered in an essential manner the IL6-secretion induced by 
thrombin, trypsin and tryptase (Li and He, 2006) 
The location of the MS marker was intronic of the S100Z gene, the 
function of which is unclear. A genome-wide association study has found 
SNP polymorphism in this gene to associate with severity of ulcerative 
colitis (Festen et al., 2010). The S100 gene family was described to have 
wide-ranging roles in tumorigenesis, autoimmunity and innate immunity. 
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Figure 4.9: F2RL1 gene locus. The MS marker is located within S100Z, 
but its LD range includes F2RL1. 
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4.4.9. DDX42 locus  
 
Chr 17: 59205299-59250409 
MS marker D17S0271i location: Chr 17: 59224879-59225107 
 
This marker was intronic of DDX42 (DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 42) in a very gene dense region. Other genes within 100 kb LD 
region included CCDC47 (coiled-coil domain containing 47) which had an 
unknown function, FTSJ3 (FtsJ homolog 3 (E.coli)), PSMC5 (proteasome 
(prosome, macropain) 26S subunit, ATPase 5) and SMARCD2 (SWI/SNF 
related, matrix associated, actin dependent regulator of chromatin, 
subfamily d, member 2). 
DDX42 was involved in the survival of cells, counteracting the apoptotic 
effect of TP53BP2 (Uhlmann-Schiffler et al., 2009), while FTSJ3 was 
involved in ribosome synthesis (Morello et al., 2011). 
PSMC5 is a functional element of the proteasome. An essential function of 
a modified proteasome, the immunoproteasome, was the processing of 
class I MHC peptides. It participated in transcriptional regulation since it 
has been shown to interact with the thyroid hormone receptor and retinoid 
X receptor-alpha. 
SMARCD2 was involved in transcriptional activation and repression of 
selected genes by chromatin remodelling. 
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Figure 4.10: DDX42 gene locus. The marker is located in DDX42, but 
the genes CCDC47 and FTSJ3 are also within in LD range. 
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4.4.9. SOCS3 locus  
 
Chr 17: 73864454- 73867753 
MS marker D17S0219i location: Chr 17: 73941484-73941691 
 
This locus has a high gene density. The target gene, SOCS3 (suppressor 
of cytokine signalling 3) was just within LD range of the marker, which was 
intronic to DNEL2, also known as DNAH17 (dynein, axonemal, heavy 
chain 17). The other gene within range was PGS1 
(phosphatidylglycerophosphate synthase 1). 
DNAH17 is the force generating protein of respiratory tract ciliae and 
sperm flagellates. The function of PGS1 is unclear. SOCS3 is an important 
negative regulator of the janus kinase pathway, which is used by most 
cytokines for transcription activation (Tamiya et al., 2011), hence it had an 
important anti-inflammatory effect (Alexander and Hilton, 2004). In the 
animal model, SOCS3 had a suppressing role on the severity of GVHD 
(Hill et al., 2010). 
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Figure 4.11: The SOCS3 gene locus. SOCS3 is just at the border of 
the LD range of the marker, which locates to DNAH17 (DNEL2). PGS 
lies between SOCS3 and DNAH17.  
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5. DISCUSSION AND CONCLUSION 
 
5.1 Strengths and limitations of the methodology 
5.2 Discussion of results 
5.3 Future 
5.4 Conclusions 
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5.1. Strengths and limitations of the methodology 
 
5.1.1. Introduction: Towards a high-quality gene association study 
 
In the introduction to this study, existing literature on non-HLA gene 
polymorphisms associating with HSCT outcome was reviewed in a 
systematic way; the finding was that the majority of these studies have 
methodological quality issues, relating to study populations (small, 
heterogeneous), target gene loci (candidate gene selection) and statistical 
analysis (statistical power, application of multiple testing correction). There 
is now quite clear guidance on the design of high-quality genetic 
association studies(Colhoun et al., 2003, Gambaro et al., 2000, Lander 
and Schork, 1994, Schork, 1997, Rannala, 2001). The question is: 
 
 
 
 
 
 
 
 
 
The main areas pointed out by these authors include: 
 
• Population: Genetic structure, confounding variables, case and 
control definitions, phenotype heterogeneity, outcome classification 
• Statistics: Requirement for a pathophysiological link between gene 
and disease, failure to attribute results to chance (type I/II error), 
sample size, statistical power, independent confirmation, multiple 
testing 
• Selection of target genes and markers 
 
More recently, a review (McCarthy et al., 2008) of the methodology of 
several very large scale genome-wide association studies with SNP 
markers for common variant genetic traits highlighted the need for careful 
definitions of cases and controls, large sample sizes and replication study 
To what extent did this study fulfil criteria of a high quality 
genetic association study? 
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in order to achieve robust results. Replication, even when using robust 
methodology, had often not being consistent; not necessarily indicating 
spurious results but the varying impact of clinical or environmental 
variables on a small effect size polymorphism. This phenomenon had been 
termed ‘informative heterogeneity’. 
 
 
5.1.2. Population 
 
Did the study population stem from a homogeneous genetic 
background? 
 
It was pointed out that the studied population should stem from a 
homogenous genetic background without genetic admixture. All HSCT 
pairs entered into this study were genetically of Japanese origin. We knew 
from data of the HapMap Consortium (Consortium, 2005, Stranger et al., 
2005) that genetic variation varies enormously between different 
populations. The Japanese population had a genetic structure of less, and 
better preserved haplotype blocks than Caucasians or Africans (Conrad et 
al., 2006, Gabriel et al., 2002). This was advantageous for the power of the 
study, as less MS markers were required for gene coverage (details of the 
genetic background were described in more detail in supplementary file 
2.1). 
As this approach was expected to yield robust results for a Japanese 
population, findings may be less applicable to other populations and would 
require confirmation. Allele frequencies and genotypes of MS as well as 
SNP markers, and associated genetic disease risks, vary amongst 
populations, some markers may be polymorphic and disease associated in 
one population and non-polymorphic in another. Nevertheless, there is 
substantial concordance of genetic variation across populations also, 
allowing for comparison of risk and large scale studies. 
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How well did this study address demographic or clinical confounders 
that affect acute GVHD severity? 
 
Clear definition of cases, controls, risk factors and outcomes were 
essential. In Japan, since 1992 the consensus on the modified Glucksberg 
criteria for the diagnosis of GVHD (Glucksberg et al., 1974, Przepiorka et 
al., 1995, Rowlings et al., 1997) was used. As these contained subjective 
elements, and as several independent centres across Japan were applying 
these criteria, there were likely elements of intra- and inter-observer 
variability, which were not quantifiable for this population.  
The criteria for selection of this study population did reduce confounding 
variables to some degree: 
 
• Selection by diagnosis: Different underlying diagnoses carried 
variable risks for GVHD. CML and ALL in particular had an intrinsic 
GVHD risk, compared to other malignancies. Focusing on ALL and 
ANLL had reduced this variability. However, ALL and ANLL in itself 
had significantly different risks for GVHD, remaining a confounder. 
• Recipient age: Recipient age >40 years per se was a risk factor for 
GVHD, and exclusion of patients above this age removed the effect 
of older age. Infants and young children with leukaemia also have a 
higher risk of GVHD, therefore exclusion of this age group reduced 
confounding. However, a minor effect towards GVHD risk remained 
in the age group below 10 years. 
• Selection of unrelated bone marrow as graft source and 
myeloablative conditioning: These measures avoided effects on 
GVHD as an outcome by donor source (reduced GVHD risk with 
related donors), other stem cell source (higher, or lower GVHD risk 
with e.g. peripheral blood stem cell transplantation (PBSCT) or cord 
blood), conditioning (lower GVHD risk with reduced-intensity 
conditioning). 
• The selection by diagnosis and age ‘streamlined’ some of the 
clinical confounders. Treatment for leukaemia was largely protocol-
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driven, compared to other indications, hence variables such as 
previous chemotherapy, conditioning regimen and GVHD 
prophylaxis were very similar. 
 
 
As previous data and sample collections were often small, there was little 
room for considering clinical risk factors for GVHD or other HSCT 
outcomes, although these were well established (Loren et al., 2006, 
Randolph et al., 2004, Perez-Simon et al., 2005, Kollman et al., 2001). In 
this situation, multivariate analysis was applied to correct for the clinical 
confounders. Despite the selection criteria applied, this study had 
remaining confounding variables that required multivariate analysis: 
 
• Donor age >30 years 
• HLA mismatching 
• GVHD prophylaxis with Cyclosporin A or tacrolimus 
• Minor effects of recipient age, conditioning regimen 
 
 
The prevention, diagnosis and management of GVHD had changed over 
this time period. Although all patients had myeloablative conditioning, this 
varied with underlying disease and staging. While the prophylactic regimen 
in Japan consisted initially of cyclosporine A, methotrexate and steroids, a 
change from cyclosporine A to tacrolimus reduced the incidence of GVHD 
(Hara et al., 2007). The JMDP database did not provide detailed 
information on dosage of methotrexate and steroids in the earlier HSCT.  
ATG and T-cell depletion, in contrast to Europe or North America, had little 
role in Japan as it was found to dramatically increase the relapse rate of 
leukaemia. A few of the more recent transplants in this study cohort used 
in addition newer agents such as mycophenolate mofetil. Similarly, the 
management of GVHD over these 12 years had evolved – improved 
diagnostics, better control of immunosuppression, better control of 
concurrent infections through improved diagnostic tests and newer 
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antibiotics, better nursing care and monitoring, and new, more powerful 
treatments of GVHD had gradually changed the characteristics of GVHD. 
Most of these characteristics were not captured in the dataset as such 
information was not prospectively collected at the time.  
 
The application of two separate time frames by this study was likely to 
provide some correction for this type of confounding, but may also have 
had effects on the sensitivity of the study: 
 
• Associations consistent across both subsequent time frames would 
indicate some degree of independence from the effects that 
changes in supportive transplant practice, factors that were not 
recorded in the dataset, over time would have had on outcome. 
• The disadvantage of this approach was that it ruled out all 
associations that did not have that degree of consistency, i.e. 
associations that evolved in the cohort of the second screening 
alone would have went undetected. This was likely to have a 
negative effect on sensitivity of the study. The findings indicate 
associations that were valid consistently over a long period of time, 
but may not necessarily represent the strongest effects on GVHD 
• Despite the effort of correcting for genetic and clinical confounders, 
significant variables affect outcome, as the multivariate analysis 
demonstrated. 
• The effects of HLA matching and mismatching could not effectively 
been adjusted between the cohorts. This study was able to adjust 
HLA match or mismatch by pairing of samples from the first 
screening cohort with those from the second cohort at the HLA 
locus or locus combination, but not by serogroups or even alleles. 
More recent research from the Japanese registry has shown that 
different allele mismatches at the same HLA locus may have risk as 
well as protection effects, depending on the specific allele (see 
below). 
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What was the effect of HLA matching and mismatching on GVHD? 
 
Because HLA matching was known as a significant risk factor for GVHD 
(Morishima et al., 2002, Morishima et al., 2007, Kawase et al., 2009, Oh et 
al., 2005, Sasazuki et al., 1998, Kawase et al., 2007), and possible to 
control in a study setting, most previous studies in the 1990’s and 2000’s 
used higher HLA-matched HSCT pairs (e.g. 8/8, or even 12/12 matched) 
or related HSCT for genetic association studies. This measure was thought 
to reduce genetic confounding caused by HLA mismatching. The 
disadvantage of this approach was that data from these studies were 
meaningful to only a small subset of the HSCT population in clinical 
practice, and that other clinical confounders could not be addressed due to 
sample size issues. 
Consequences for this study of the decision not to select samples by HLA 
matching or mismatching:  
 
• Not restricting inclusion for degree of HLA matching made this study 
population more representative of a HSCT population seen in 
clinical practice. 
• The large proportion of HLA mismatched pairs would allow for an 
analysis of the effects of non-HLA gene polymorphisms in an HLA 
mismatched population. 
• The proportion of HLA matched HSCT pairs was large enough to 
permit subgroup analysis. 
• The adjustment of the degree of HLA matching of the confirmatory 
cohort (2nd screening) to that of the discovery cohort (1st screening), 
in order to achieve a similar degree of genetic confounding, has 
introduced stratification. The JMDP registry population between 
2001 and 2005 had an overall higher degree of HLA matching than 
the population from 1993-2000. Hence, the HLA matching of the 
confirmatory cohort was not representative of the degree of HLA 
matching of the Japanese registry cohort during that time; 
mismatching was over-represented. This was reflected in the GVHD 
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prevalence, which was higher in the confirmatory cohort than in the 
discovery cohort. 
 
How could the selection study be modified to minimize confounding 
and stratification? 
 
As HSCT is rapidly expanding, larger registry cohorts may become 
available for research in the near future. Important steps to reduce clinical 
and genetic confounding would include: 
 
• Reducing the time frame of sampling (e.g. 5 years), to reduce 
confounding that stems from development in supportive therapy. 
• Use of most recent transplants – reflect more the current clinical 
practice 
• Aim for higher cohort size to increase statistical power 
• Focus on single large diagnostic groups (eg. ALL, AML separate) 
rather than combined, as these carry in themselves different risks 
for outcomes 
• Rather than by time frames, the study cohort could be divided by 
other important variables, such as degree of HLA matching. This 
requires more detailed understanding of the risk of HLA 
mismatching by e.g. high-risk allele mismatches or HLA haplotypes. 
Such analysis would be very valuable in directly comparing the 
competing risks of HLA mismatch and non-HLA gene 
polymorphisms. In addition, this analysis would give an insight into 
the non-HLA immunogenetics of HLA mismatched HSCT, an area 
that it under-researched. 
• As SNP gene-chip GWAS typing is becoming more readily 
available, it would be useful to conduct this approach in a parallel 
study mirroring the same set up. This would provide a 
complementary perspective on the genetic variation in the same 
study population, and facilitate the fine-mapping of associated 
microsatellite loci (SNP or SNP haplotype associations within LD 
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range of associated MS could limit down the area requiring 
sequencing). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY: Study population 
 
- The study population stemmed from a genetically relatively 
homogeneous background 
- Case and control definition followed standard practice of 
GVHD classification.  
- Extensive efforts were made to identify and address 
confounding variables. The effect of confounding variables 
could be reduced by careful evaluation in a larger stem 
population and selection of a study population.  
- Nevertheless, substantial clinical confounding remained and 
required multivariate analyses. 
- Selection carried a risk of stratification for new confounders, 
which needed to be identified (e.g. HLA matching, see above).  
- Limited availability of large study cohorts and rapid evolution 
of the field of HSCT made effective control of confounding 
variables difficult.  
- Careful selection of a population that would be relevant in 
clinical practice rather than just of research interest (e.g. 
understanding pathobiology) may facilitate clinical 
application of study findings (e.g. risk stratification). 
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5.1.3. Reasoning for choice of scale of approach  
 
Which genes to focus on in relation to GVHD – all, some, or few? 
 
The findings from the literature appraisal indicated that a larger scale, more 
systematic approach to candidate gene and marker selection was required 
to better understand the effect of non-HLA gene polymorphisms on GVHD. 
The initial decision was on the extent of cover of the genome - ranging 
from a selected candidate gene approach to whole genome scanning. 
Table 5.1 lays out the advantages and disadvantages of three approaches 
to gene selection, representing three degrees of indiscrimination: A 
candidate gene approach, where a small number of genes believed to 
have a high likelihood of being involved in the pathogenesis of acute 
GVHD (highly discriminate); a targeted genomic approach (e.g. focusing 
on the immune system as a whole, less discriminatory), and a genome 
wide scanning approach (indiscriminate).  
 
The decision for a targeted genome scanning approach, which includes the 
genes of the entire immune system in a broader sense (‘Immunogenome’), 
supplemented by genes relevant for GVHD (previously associated genes 
and other strong candidates) and leukaemia (e.g. susceptibility genes, 
drug metabolism genes), was based on aspects of feasibility and study 
quality: 
 
• Previous data from genome-wide association studies indicated that 
immune response associated conditions tend to have genetic 
associations within the immune system genes (Zhernakova et al., 
2009) – as GVHD is a result of immune system dysregulation, 
focusing on immune system genes should have yielded a higher 
positive predictive value for associations. 
• Reduced number of markers reduced the need for multiple testing 
statistics -  resulting in higher power 
• Feasible in the available time (3 years) and with available resources 
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• Reasonable trade-off between number of available samples, 
resulting statistical power of cohorts, multiple testing statistics 
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 Candidate 
approach 
Targeted genome 
scanning 
Whole genome 
scanning 
Advantages • Simple to 
perform 
• Simple statistics 
• Cheap 
• Powerful with 
small sample 
size 
• Systematic 
approach to 
biological 
meaningful 
selection of 
genes 
• Statistically 
robust with 
reasonable 
sample size, 
positive 
predictive value 
• Indiscriminate 
approach to 
genes 
• Reflects full 
genetic 
contribution to 
disease 
Disadvantages • Likely to miss 
important 
associations 
• May miss 
important 
associations 
outside targeted 
system 
• Requires large 
sample size 
• Issues with 
statistical power, 
multiple testing 
• Expensive 
• Time consuming 
 
 
 
Table 5.1: Advantages and disadvantages of different approaches to gene 
selection 
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SUMMARY – Scale of approach 
 
- A targeted genome scanning (indiscriminate selection of all 
immune system genes, ‘immunogenome’) provided the best 
trade-off between the competing factors of gene selection, 
statistical power and available resources. 
- Main disadvantage was that important associations outside the 
selected panel may not be detected. 
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5.1.4.  Reasoning for choice of marker type and marker number,  
and pooled/individual typing approach 
 
 
Single Nucleotide Polymorphisms or microsatellite markers? 
What were the consequences for study design by choosing 
microsatellite markers? 
 
Modern high-throughput genetic screening approaches mainly use two 
different types of genetic markers: 
 
• Single Nucleotide Polymorphisms (SNP): A SNP is a genetic 
variation where a single nucleotide within the genome sequence is 
altered. SNP in coding sequences may alter gene expression and 
cause a change in biology, or may link to a causative variant. 
• Microsatellites (MS): MS are short sequence repeats, commonly as 
a variable number of di, tri, or tetra tandem base repeats. 
Microsatellite markers often, but not always stand in linkage 
desequilibrium (LD) with SNP on the same haplotype block. 
 
SNP and MS both have their specific advantages and disadvantages (see 
table 5.2) (Bahram and Inoko, 2007, Jorgenson and Witte, 2007). 
 
At the time this study was developed (2005-2006), new miniaturized, 
standardised and automated genome-wide SNP typing platforms were 
evolving, using hundreds of thousands of SNP markers on a single sample. 
During this time there was still an ongoing debate about which markers to 
include in these assays, sample size and statistical power, typing quality, 
and processing of the vast amount of data. In addition, these systems were 
still very expensive, especially for larger scale studies (table 5.3 shows a 
cost comparison of a SNP based and MS based approach for 2007). The 
advantages of such an approach were obvious: The methodology became 
technically ever simpler, reproducible, faster and cheaper, individual 
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sample data were retained and allowed for multiple outcome measures. 
Initial studies had limited numbers of samples (in the hundreds), and 
statistical power was limited, due to the enormous multiple testing burden. 
In order to detect the small effect sizes of common variants, now sample 
sizes of tens of thousands have been used (Vercelli and Martinez, 2006, 
Anonymus, 2007). Such large numbers still remained a challenge for many 
conditions, including HSCT where the largest collections of data and 
sample have just reached (CIBMTR/NMDP) or are approaching (JMDP) 
the 10,000’ mark. Providing consistent case, control and phenotype 
definition was still a major problem. 
 
There were clearly advantages of the MS approach in this setting. The 
method of genome-wide scanning with MS markers was pioneered and 
brought to a high standard by a Japanese group (Prof Inoko, Tokai 
University), with the first study published in 2005 (Tamiya et al., 2005) 
(summarised in Figure 5.1). This approach used almost 30,000 MS 
markers spread throughout the genome at high density (charting at 100 kb 
with overlap), and sequential screening in three steps on pooled DNA. 
More than ten genome wide studies using this approach have since been 
published. 
MS markers have a larger LD range – therefore less markers were 
required to provide genome coverage, as compared to SNP, which gave 
MS an advantage with regards to power, sample size and multiple testing 
correction. The haplotype block structure of the Japanese population was 
highly preserved – allowing the full exploitation of the large LD of MS 
markers. Our selection of markers achieved a very high density of 
coverage for the target genes – 97% of target genes had either two 
flanking MS markers, or at least one, within the projected LD range of 100 
kb. (the genome-wide MS panel would provide cover to ~90% of the 
euchromatic region of the genome). On the other hand, true LD range of 
MS markers was not known, therefore the LD may have been shorter or 
longer, creating either gaps or extended coverage. In contrast to SNP 
arrays, which were so densely packed that individual markers could not 
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have been regarded as independent, MS loci could be regarded as 
independent and gave a clearer distinction of haplotype blocks.  
 
By evolution, SNP and MS were often closely linked, with a MS indicating 
mutation or causative SNP polymorphism within its LD. By mathematical 
models, SNP markers, which have only two alleles, were more resistant to 
mutations as compared to MS, which could have 2-20 or even more alleles. 
A MS marker therefore may have ‘mutated away’ and lost its linkage; while 
on the other hand it may have indicated an evolutionary more recent 
genetic risk variation that SNP may not had captured (Oka et al., 2012, 
Hiruma et al., 2011). From this model, MS and SNP approaches were 
complimentary to each other by having a large area of overlap, and each 
additional aspects of genomic variation which the other approach did not 
cover. 
 
Limitations of using a microsatellite-based approach include existing gaps 
in cover, and the fact that the pooled approach would allow for allelic, 
rather than genotypic association. 
 
• This study had a very good cover of target genes (almost 90% full 
cover, and a further 7% partial cover. However, there are gene 
regions within the genome which have no suitable natural 
microsatellites, or have genetic variation (e.g. gene duplication) that 
make microsatellite typing inherently difficult. 
• High-throughput MS typing required pooling of DNA, which lead to 
loss of individual genotypic information in the screening stages, 
relying on allele frequency differences between pools alone. Allele 
frequency differences often but not always reflect genotypic risks, 
and important associations may have been missed that way. 
Additionally, at individual level a pooled allele frequency difference 
indicating a protective effect may translate at individual genotypic 
analysis into a risk, and vice versa. Hence, at the individual 
genotyping stage the finding of an associated allele should ideally 
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backed by identifying a genotypic association. This, however, is not 
always possible given the large number of genotypes for 
microsatellites resulting from the large number of alleles. For some 
markers, nevertheless, this study was able to confirm the 
association of homozygous genotypes.  
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 SNP MS 
Advantages • Allows for individual 
genotyping and data 
analysis 
• High-throughput platforms 
available 
• Technically more simple 
• Lower mutation rate – 
more stable over time, but 
misses recently evolved 
genetic variation 
• Wider linkage desequilibrium 
• Requires less markers than 
SNP for same coverage 
(~30,000 for whole genome) 
• Statistically more powerful – 
allows for lower sample size 
with same coverage  
•  more alleles – more 
informative 
• Clear definition of haplotypes 
• Cheaper to perform than 
SNP 
Disadvantages • Short LD range – many 
gaps, may miss epigentic 
variation 
• Unclear definition of 
haplotype blocks (‘virtual’ 
haplotype definition) – 
may miss important 
associations 
• Large number of markers 
required for coverage 
(>500,000 for whole 
genome) 
• Multiple testing requires 
large sample size for 
sufficient power 
• Expensive 
• Time consuming 
• Requires high-density 
SNP typing of candidate 
regions 
• Higher mutation rate – may 
miss older SNP associations 
• No high-throughput platform 
available – requires pooled 
DNA approach 
• Technically more demanding 
• Requires high-density SNP 
typing of candidate regions 
• Artifacts introduced by DNA 
pooling 
• DNA pooling allows for single 
outcome measure only at 
screening stage 
 
 
Table 5.2: Advantages and disadvantages of large scale genomic 
approaches using SNP and MS 
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 SNP MS 
(individual) 
MS (pooled)* 
Estimated no 
of markers 
70,000 4,000 4,000 
Estimated 
assay costs 
$ 600,000 $ 8,000,000 $ 70,000 
Estimated 
time 
3 years >10 years 3 years 
 
 
Table 5.3: Estimation of assay costs and time requirements for a targeted 
immunogenome scanning study, based on n=1000 sample pairs (time 
point March 2007) in US $ 
*this includes costs for 3 pooled screening steps and individual 
genotyping of identified candidate gene regions with approximately 100 
SNP. 
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Figure 5.1: Methodological summary of a genome-wide scanning 
approach with MS markers 
 
 
 
 
 
 
 
 
 
 
Approach to genome-wide scanning (Tamiya et.al.)  
 
• A simple case-control study design of a cohort of n=375 patients and an 
equal number of controls 
• Highly accurate DNA pooling, constructing 3 pools each for cases and 
controls, each containing n=125 individuals 
• A phased three-step genomic screening on pooled DNA. A panel of 
27,039 MS markers was tested on the first set of case and control pools, 
markers found associated (n=2,748) were tested on the second pool set. 
Markers still remaining positive (n=372) were subjected to typing in the 
third screening step, which still left n=133 MS markers associated. Chi 
Square and Fisher’s exact test for 2x2 and 2xm tables, with a 
significance level of p=0,05 were used to establish the association after 
each screen 
• The remaining n=133 markers were individually genotyped on the 
combined set of n=375 cases and control pairs, to eliminate errors 
potentially caused by the pooling process. Of these, n=47 still remained 
associated. 
• Of these n=47 associated gene regions, n=7 regions were selected for 
fine mapping with SNP, based on high allele frequency and high degree 
of significance. Fine mapping was performed on a further independent 
cohort of n=565 cases and control pairs. 
• Statistical power estimation indicated that the power to detect allele 
frequencies <0.25 is limited given the sample size per pool (n=125) 
• Based on data on the pooling method, and data from test markers typed 
individually and in the created pools, difference in allele frequency was 
calculated to be <4%. 
• As the number of multiple comparisons in this screening is n+1, pseudo-
positive markers were calculated as n=1352 (first screening), n=257 
(second screening) and n=25 (third screening).  
• Pritchard’s method was used on a set of 69 randomly selected markers 
to verify the absence of stratification. 
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SUMMARY – marker choice and consequences for study design 
 
Microsatellite markers have inherent advantages over SNP markers:  
 
- They are more polymorphic and therefore more informative.  
- Because their LD range is wider, for a given genomic region 
less MS markers are required than SNP to provide the same 
cover, giving the MS approach a statistical advantage. 
 
 
Choosing a MS marker based approach has consequences for study 
design:  
 
- The variability in PCR and typing requirements means that 
there are no commercial high-throughput platforms available.  
- High throughput can be achieved by DNA pooling, which is 
technically complex.  
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5.1.5. Technical aspects 
 
What were the technical challenges of the study design, and how 
were they addressed? 
 
The microsatellite approach, however, had some drawbacks, mainly for 
technical reasons, some of which were discussed in the first reported 
genome-wide association study using this approach (Tamiya et al., 2005). 
This study was derived from this approach and shared its methodology, 
marker set and analysis tools.  
Due to their larger variability and resulting variable length of the marker 
amplicon, MS markers did require variable PCR conditions which hinder 
automatization. The genome wide study approach mentioned above 
(Tamiya et al., 2005) had therefore selected preferentially those markers 
that had similar amplicon sizes and PCR conditions. However, 3-5% of 
markers frequently failed in genome-wide scanning, requiring re-
processing in order to keep the fail rate below 2%. These circumstances 
made the development of standardized, fast and cheap assays difficult, 
and ruled out a large-scale, high throughput approach on individual 
samples. 
There was a focus on MS markers that had 3-6 major alleles, which was a 
trade-off between technical conditions, LD, statistical power and controlling 
the false-positive error rate. Smaller numbers of alleles (e.g. 2) reduced the 
informative content, while markers with larger numbers of alleles could be 
highly informative and indicate rarer variants but had a poor statistical 
power. 
Another source of technical difficulties was the requirement for a high-
throughput platform, as the individual sample PCR and typing of several 
thousand MS markers would have been prohibitive from a time and cost 
perspective. Pooling of DNA was applied, and the method for this was 
refined to a degree that the SD for allele frequency differences between 
pools and individual genotyping could be kept near +/- 1%. However, the 
pooling process required expertise and time, had size limitations (the 
volume of the PCR reaction limits the maximal pool size to ~1000 
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individuals) and produced some inherent artefacts that required individual 
inspection and allele selection of each set of pools per marker. Some 
algorithms were developed to semi-automate this inspection step and take 
the element of judgement out of this process (Schnack et al., 2004, Perlin 
et al., 1995, Miller and Yuan, 1997, Matsumoto et al., 2004, Olejniczak and 
Krzyzosiak, 2006). A further disadvantage of DNA pooling was that the 
capability to analyze individual information was lost. Samples had to be 
pooled towards a single outcome, which restricted the extent of the 
analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY – technical challenges of genomic screening with 
microsatellites 
 
- Due to their high polymorphism, MS markers have varying PCR 
and typing conditions. 
- Markers with 3-6 alleles are preferentially selected, representing 
a trade-off between marker informative content and statistical 
power. 
- DNA pooling requires time and expertise, and has drawbacks 
such as PCR and typing errors, and the loss of individual data 
and analysis. 
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What was the technical validity of this study? 
 
Typing errors 
 
It was already mentioned in the results section that the MS marker panel 
for this study was re-plated from the genome-wide marker panel plates 
which were sorted according to PCR typing conditions; therefore the higher 
number of initial PCR and typing error was expected, and corrected 
successfully (overall 1.1% (donor) and 1.0% (recipient) of the 4,321 MS 
markers eventually failed PCR and typing over the two screening steps.  
 
Was the pooled DNA representative of the true allele frequencies? 
 
The quality of the DNA pools, as assessed by a test marker, was in 
keeping with the previously reported studies, with no significant allele 
frequency differences between pools and individual typing. The mean 
allele frequency difference was below 1% in all pools (which was lower 
than the 2% reported previously (Tamiya et al., 2005)). 
This marker, however, represented only a spot measure of an ‘ideal’ 
marker under optimal PCR and typing conditions. To gain a better 
understanding of the consistency of DNA pool quality the pooled and 
individual allele frequencies for the 30 MS markers that were typed 
individually were reviewed (data not shown). Again, a very high 
concordance was found between pooled and individual typing.  
 
How were pooling/typing artefacts identified and addressed? 
 
The methodology was successful in identifying spurious associations due 
to artefacts. Of the eight MS markers that were not confirmed in individual 
typing, six had additional low frequency alleles that were not detected in 
pooled typing, and rendered the pooled allele association non-significant. 
Only two markers had an over-estimation of the associated allele in the 
pool resulting in an association that could not be confirmed in individual 
typing. This represented a known MS PCR error (preferential amplification 
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of the shorter-repeat alleles) which was exaggerated through the pooling 
process. Other artefacts that became apparent only in individual 
genotyping resulting in non-confirmation of the pooled association included 
mistaking a starter peak for an allele, non-polymorphism, and multiple 
alleles due to copy number variation. 
 
How were false positive associations addressed? 
 
The two screening steps of this study had, compared to the initial 
publication of this methodology, a higher rate of false positive association 
(table 5.4). This table shows also a projection of this study based on the 
data of Tamiya et.al.(Tamiya et al., 2005) Tamiya et.al.’s study had seen a 
reduction in marker number by approximately 90% in the first and second 
pooled screening step, and around 60% in the third pooled screening. In 
this study a reduction by approximately 75% and 65% was observed in the 
pooled screenings. Only the third screening step (which was not a pooled 
screening in this study, but a selection by allele identity and OR direction) 
reduced the number of associations close to the number projected. 
There were differences between the study by Tamiya et.al. and this study 
that could explain these findings. Tamiya et.al. had a smaller pool size 
(n=125 cases/controls), so the statistical power to detect low frequency 
alleles was much reduced, and the investigators would consequently not 
include alleles of a frequency of 20% or lower. The pool sizes of this study 
were larger, which increased statistical power and sensitivity of low 
frequency allele detection. In addition, in order to capture all potential 
associations even if of low frequency, alleles of a frequency of 5% and 
above were included. This allele frequency was within the technical 
resolution of the pooled DNA approach, but at the border or below the 
statistical power for the sample size. Analysis of the 2nd pooled screening 
showed indeed that 48% (donor) and 51% (recipient) of associations had 
allele frequencies below 15%. 
Tamiya et.al. did conduct the three pooled screening steps with selection 
of identified alleles and markers by p-value only (without correction for 
multiple testing), and selected by OR direction only after the third 
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screening. This study has shown that using a reduced number of MS 
markers for a targeted screening, a two-step pooled screening approach 
was sufficient. 
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 Tamiya 
(2005)   
This study projected 
  
This study Donors 
  
This study Recipients 
  
  
Markers 
total 
Markers 
positive % 
Markers 
total 
Markers 
positive % 
Markers 
total 
Markers 
positive % 
Markers 
total 
Markers 
positive % 
1st screen 27039 2847 10.53 4321 455 10.53 4321 1016 23.51 4321 931 21.55
2nd screen 2847 372 1.38 455 60 1.4 1016 335 7.75 931 314 7.27
3rd screen 372 133 0.49 60 22 0.5 335 31 0.72 314 17 0.39
Indiv typing 133 47 0.17 22 7 0.17 31 6 0.14 17 4 0.09
 
 
Table 5.4: Comparison of rates of positive association between the original genome-wide study (Tamiya 2005), the 
projection for and the actual results for this study. The rate of positives in the first and second screens is higher than in 
the genome-wide study and the projection, but reaches very similar rates at the entry and after individual genotyping. 
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SUMMARY - Internal quality controls point to a high degree of 
technical validity of this study: 
 
- PCR and genotyping errors were followed up and largely 
eliminated 
- Artefacts were actively sought and resolved/excluded 
- Prospective typing of a test marker showed a high degree of 
concordance between allele frequencies in the pools and by 
individual genotyping, in keeping with previous studies using 
the same approach. 
- Retrospective analysis of individually typed associated 
markers confirmed the high concordance 
- A larger number than expected of false positive associations 
was anticipated and effective measures taken to separate 
false positives from true positives  
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5.1.6. Data analysis 
 
Statistical aspects: Are the analyses valid? 
 
The targeted genomic approach had advantages over genome-wide 
approaches with regards to statistical power. Investigation of the immune 
system was achieved with around 15% of the number of markers needed 
for a genome-wide scan. The selection of disease-relevant genes 
provided a higher positive predictive value and immediately gave a 
pathophysiological link between gene and disease, thus increasing the 
likelihood that the association were true. 
 
Aspects of type I and II errors were already discussed in the previous 
section ‘technical aspects’. Knowing that non-HLA associations with 
GVHD were likely to be of small effect size, for this study a high degree 
of sensitivity was deliberately chosen for the two pooled DNA screening 
steps (by including allele frequencies at the level of technical resolution, 
rather than at the level of statistical power; and non-application of 
multiple testing correction), accepting a large number of false positive 
associations. Independent confirmation in a second screening cohort 
was sought to confirm or refute the associations of the first screening 
cohort, and provided a powerful tool for further selection (allele 
identification, OR in the same direction). This approach did indeed 
reduce the number of false positive associations efficiently to levels that 
were projected, and identified a number of consistent associations. Most 
of these associations had effect sizes close to the limit of detection given 
the statistical power of this study; hence this was a successful strategy. It 
was, nevertheless, not possible to establish which falsely negative 
associations may have been missed, as a validation study of the 
approach was beyond the remit of this project. On the other hand, 
several publications of studies having used the pooled DNA 
microsatellite based approach have been successful in identifying new 
associations, and most of these studies confirmed the findings of 
previous SNP studies, i.e. on rheumatoid arthritis (Tamiya et al., 2005), 
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hypertension (Yatsu et al., 2007), Asthma (Hui et al., 2008), adult height 
(Kimura et al., 2008), anorexia nervosa (Nakabayashi et al., 2009), 
complications after radiotherapy for cancer (Michikawa et al., 2010), 
psoriasis (Hiruma et al., 2011) and macular degeneration (Meguro et al., 
2012). The genetic risk for Behet’s disease was explored using the 
identical genome-wide marker set independently in two populations 
(Japanese, Korean), resulting in the identification of HLA-B51 as a 
genetic risk (Meguro et al., 2010, Horie et al., 2012). Multiple correction 
statistics (Bonferroni’s correction) were applied for the individual 
genotyping step only, still resulting in four MS markers being associated 
with grade 2-4 acute GVHD. 
 
Nevertheless, detection of effect sizes much below an OR=1.5 was very 
limited due to the small number of samples (for a genomic screening 
approach). Low frequency alleles caused a large number of false positive 
association, hence these were not replicated very well which may have 
statistical power as well as technical reasons.  
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SUMMARY – data analyses 
 
This study’s approach was deliberately sensitive by: 
 
- using technical resolution of the scan (rather than statistical 
power resolution)  
- non-application of multiple testing correction through a two-
step screening process.  
- Provision of specificity by independent confirmation of 
associations that were true but had a low effect size. 
 
Ten such loci were identified, while the number of false positive 
associations were effectively reduced.  
 
The statistical power given the pool and cohort sizes, allele 
frequencies and number of tests was moderate – associations of 
alleles with an OR <1.3-1.5 may not be reliably detected. 
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SUMMARY – methodological strengths and limitations I 
 
Strengths: 
 
This study fulfilled criteria for a high-quality genetic association 
study: 
- Population of genetically homogeneous background 
- Attempt to control genetic, demographic and clinical 
confounders 
- Discovery/independent confirmation study design 
- Large scale, indiscriminate gene targets 
 
Technical strengths: 
- Microsatellite markers – wide LD, informative 
- control of typing errors 
- high quality DNA pooling 
- Control of artefacts 
- Control of false positive associations 
 
Statistical strengths: 
- Sensitive and specific for small effect size associations 
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SUMMARY – methodological strengths and limitations II 
 
Limitations: 
 
The design of study cohorts for genetic association studies with 
HSCT outcomes is difficult: 
- Control of confounding variables still requires multivariate 
analyses 
- Cohort design by selection may induce stratification and new 
confounders 
- HLA matching adjusted between cohorts, but not 
representative of registry 
 
Technical limitations: 
- Targeted genomic approach may miss important associations 
- MS markers may not capture all genetic variation at a locus 
- MS requires pooled DNA approach – loss of individual 
information, potential of typing errors 
- Lack of validation study for this approach – scope of false 
negative markers unknown 
 
Statistical limitations: 
- Sample size provides limited statistical power – associations 
with Odd’s ratio <1.5 not well represented, HLA subgroup 
analysis not very powerful 
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5.2 Discussion of results 
 
5.2.1. Hypothesis and objectives 
 
The hypothesis of this study stated: “Allele frequency differences of 
microsatellite markers are associated with moderate-severe acute 
GVHD”.  
The finding of 10 microsatellite loci associated with moderate-severe 
acute GVHD through a methodology that complied with many 
requirements for a high-quality genetic association study, with valid 
technical and statistical results, confirmed this hypothesis; rejecting the 
null hypothesis: “Allele frequency differences of microsatellite markers 
are not associated with moderate-severe acute GVHD.” 
 
The assumption for this hypothesis was that GVHD is in part a complex 
genetic trait, and that common allele polymorphism of non-HLA genes in 
the patient and donor genomes contributed to the development of GVHD. 
It was also assumed that such non-HLA risk alleles had an effect size 
that reached that of certain HLA mismatches, hence could be consistent 
despite variation in clinical and genetic risk factors over time. The 
objective of this study, the demonstration of the existence of such 
polymorphisms through a targeted genome scanning with MS markers, 
was therefore achieved.  
 
 
4.2.2. Roles and functions of identified associations 
 
Exploratory study 
 
Before embarking on a large scale genomic approach, the study 
population was explored by a smaller scale pilot study in order to 
establish whether identification of small size non-HLA polymorphism 
would be feasible in this population. For this purpose 41 SNP markers, all 
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of these stemming from previous candidate gene studies, were 
genotyped using TaqMan® (Applied Biosystems) assays in a 
confirm/refute approach (Harkensee et al., 2012).  
The study was capable of confirming previously reported SNP 
associations: IL2-330 as a risk for development of chronic GVHD, TNF-
1031 as a risk for severe acute GVHD, and CTLA4-CT60 as protective 
against acute GVHD. These findings add credibility to the previous 
results, and confirmed the capability of the study population to 
demonstrate such non-HLA polymorphisms in a consistent manner. The 
associated IL2 and TNF genotypes represent high-producer variants of 
these cytokines that have been extensively studied in the context of 
GVHD. Both have essential roles in inducing and maintaining GVHD (see 
introduction section above). CTLA4 is an important second signal for T-
cell activation, and the findings of these studies are in keeping with 
previous results.   
 
Pooled DNA screening and confirmation with MS markers 
 
The identified genomic loci associated with a MS marker represented an 
area of LD within which presumably a genetic variant that had a 
causative role in grade 2-4 acute GVHD is located. Further work, using a 
variety of methods that include higher density mapping with MS or SNP, 
or sequencing, would be required to determine the true LD and detect 
such genetic variants. The following description of roles and functions of 
genes within the LD ranges of the associated markers is therefore 
assumptive; the causative genetic variants still remained to be found. 
 
The findings from this work underline the notion that modulation of the 
antigen recognition and subsequent T-cell activation by non-HLA genes 
may occur during any of the three stages in the pathophysiology of 
GVHD.  The microsatellite loci identified by this study put new pathways 
onto the map of GVHD pathobiology. Presuming that LD is strongest 
close to the MS location, genes that are in close range or are an isolated 
gene within the LD range have a higher likelihood to be a player in GVHD.  
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In this study, the MAPK14 (key player of proinflammatory response within 
the TLR pathway) and ELTD1 (a membrane protein closely involved in 
leukocyte adhesion and migration through endothelia) loci not only clearly 
have important roles in immune function, but also strong associations 
withstanding Bonferroni’ correction. AGPAT4, another isolated gene 
within the MS markers LD, has an unknown function but SNP 
polymorphisms had been associated with GVHD severity before 
(Turpeinen et al., 2009). Strikingly, that study found a donor risk 
associated with a genetic variant, as did the microsatellite in this study. 
The associated SNP in the study by Turpeinen et.al. is polymorphic in the 
Finnish as well as Caucasian population, however, not in the Japanese. 
AGPAT4 is a transcriptional variant of the AGPAT1 locus which is 
situated in the MHC Class III region on chromosome 6, and is expressed 
uniformly in most tissues. AGPAT4 is highly polymorphic, and the linkage 
it may have to other MHC genes has not been studied sufficiently. 
However, ectopic expression of AGPAT in cytokine responsive cell lines 
may lead to enhanced expression of TNF when stimulated with IL1β, 
suggesting the gene could have a role in immunoregulation (Leung, 
2001). The finding that the AGPAT4 locus shows association in a 
consistent pattern across two genetically very diverse population makes 
this gene a very strong candidate for further exploration and, hopefully, 
clinical application. 
Some loci have more than one gene within the LD range. Target gene 
F2RL1 is a clotting factor with well known immunomodulatory properties, 
like regulation of chronic inflammation in blood vessels, leukocyte rolling, 
adhesion and extravasation, and activation of T cells and neutrophils. 
The other gene at this locus, S100Z, is a known risk gene for 
inflammatory bowel disease. SOCS3 is attributed with an important 
negative feedback loop of cytokine secretion, which is a potent driver of 
GVHD. 
Other loci implicate apoptosis pathways (DDX42) or broader metabolic 
and regulatory pathways (e.g. SHROOM2 – epithelial generation and 
regeneration, TBL1X – NFkB recruitment for gene transcription, PSMC5 
– proteasome function, SMARCD2 – transcriptional activator). 
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The loci on the X-chromosome (IL1RAPL2 and TBL1X) are of particular 
interest, as they could represent potential minor histocompatibility 
antigens (mHag). In fact, the MS DXS0151i showed a protective effect for 
non-female to male HSCT (p=0.03) with regards to acute GVHD grade 2-
4. The prevalence of rejection was too small (n=20) to yield robust results, 
hence further study is required to clarify the role of this marker. 
 
 
How should the results of these studies be followed up? 
How can the findings from these studies be applied in clinical 
practice? 
 
Exploratory study (further details see supplementary file 5.1): 
 
• A confirmatory study on a larger cohort with more clearly defined 
HLA matching and clinical subgroups (this study, with participation 
of the author, of SNP markers associated with HSCT outcomes 
from previous studies in Japan, is currently under way). 
• A full typing of all SNP in both screening and confirmation cohort 
would be desirable to understand the issue of reproducibility better 
(there are no plans to conduct this at present). 
• Functional data: the possibility of correlating gene expression (e.g. 
of IL2 and TNF) with clinical phenotypes should be explored, 
prospective observation of recipients with genotype, expression 
profiles and clinical phenotype 
• If this would show a difference in GVHD outcome between cases 
and controls (i.e. confirm that these genotypes would indeed 
predict risk), an interventional clinical trial could be undertaken. 
 
MS-based pooled DNA scanning study: 
 
• Confirmation of all MS markers in a separate cohort would be 
desirable 
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• Associated MS loci should be explored further in order to identify 
underlying causative genetic variants. This requires fine mapping 
with SNP and MS markers in the first instance to limit the size of 
the susceptibility area (practically, mapping the haplotype block of 
the MS marker). Sequencing can then be applied to identify 
functional gene variations. (JMDP and Tokai University have 
agreed to perform this investigation for the MAPK14 locus lead by 
the author using newly designed MS markers, tagSNP and next 
generation sequencing). 
• All identified causative genetic variants should be confirmed 
independently, functional data gained and prospective clinical 
application sought, as described for the exploratory study. 
• The microsatellite locus in the MAPK14 gene could be a treatment 
target: This gene is known to promote inflammatory responses, 
and specific MAPK14 inhibitors have been developed and trialled 
in conditions like rheumatoid arthritis. The effects were short 
lasting with no overall benefit after a 6 month treatment period. 
The reasons for the short duration of the effect and how to 
overcome this are not currently known, nevertheless, MAPK14 
inhibitors potentially could have a future role in prevention or 
treatment of acute GVHD.   
• It would be conceivable that the information of genetic 
risk/protective loci gained by this study could be used to intensify 
or relax GVHD prophylaxis regimen, based on a predictive score. 
This information could also serve in the selection of donors, should 
there be a choice available and should GVHD be a particular risk 
to be avoided. It would be essential to test such hypotheses in a 
prospective manner on a contemporaneous HSCT population. 
• The identified MS loci suggest many pathways not implicated with 
GVHD before – there is a wide scope for further genetic and 
functional studies. 
• Further study of the X-chromosome loci – could these associations 
represent mHags? 
  
213
213
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY – Discussion of results 
 
- Demonstrating the existence of non-HLA MS susceptibility 
regions for acute GVHD risk confirms the hypothesis of this 
study 
- These susceptibility regions contain genes that implicate several 
new pathways with the pathophysiology of acute GVHD 
- All findings should be confirmed in a further independent cohort 
- Further exploration of MS loci include fine mapping or 
sequencing 
- Prospective clinical evaluation of risk genotype, gene 
expression profiling and clinical phenotype is required before 
application in clinical practice 
- The TNF-1031 and IL2-330 SNP could be applicable for 
prospective clinical observation 
- The MAPK14 locus brings potentially a clinical application. The 
pathophysiological role in inflammatory diseases is reasonably 
well understood, a treatment exists and has been used in a 
clinical trial. MAPK14/p38 inhibitors could have a future role in 
GVHD prophylaxis and treatment. 
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5.2.3. Implication of the results for study design and methodology 
 
In the SNP-based pilot study and the MS-based immunogenome 
screening alike, results pointed to themes that had so far not been well 
addressed in previous studies: 
 
• The effect size of associated markers remained small 
• Reproducibility of previous associations was low 
• Construction of appropriate study cohorts remained a challenge 
 
The objectives of the design of these two studies were to apply stringent 
methodology that would eliminate spurious results, but also allow a high 
degree of sensitivity in order to pick up low effect size associations. 
These studies were two of few who considered control of confounding 
variables by actively selecting cases to provide more homogeneity.  
The screening step of the exploration study identified several SNP 
genotypes associating with HSCT outcomes, some of these confirming 
previous reports, with appropriate significance level and effect size. It 
was surprising that only a very small number of these replicated 
independently in the confirmatory cohort. The observation was that 
associations disappeared or even reversed.  
These findings were mirrored in the MS-based study. This study included 
all genes that were reported as being associated with acute GVHD in the 
literature. Forty MS markers linking to 25 previously associated gene loci 
were positive in the first screening (table 5.5). None of these, with the 
exception of the TNF locus which showed a trend, was replicated. 
 
What could have been the reasons for this lack of replication?  
 
• Despite the effort of reducing confounders, such as demographic 
(recipient age), clinical (diagnosis, HSCT source, conditioning) and 
genetic (homogeneous ethnic background, subgroup analysis of HLA 
matching) ones, this study population had still known confounders 
  
215
215
which were significant in multivariate analysis (donor age, HLA 
matching). There were probably unknown confounders which may not 
have been captured in the dataset. 
• The adjustment of the degree of HLA matching of the confirmatory 
cohort to that of the screening cohort. As the HSCT’s of the earlier time 
frame (1993-2000) were more mismatched due to lack of better donors, 
the confirmation cohort represented the same degree of mismatching, 
although the overall HSCT population in Japan already experienced 
better HLA matching. As a result, prevalence of GVHD in the 
confirmatory cohort was slightly higher than in the overall HSCT 
population in Japan from the same time frame. 
• Allocating HSCT into two distinct time frames (1993-2000 versus 2001-
2005). This was introduced as an additional measure to make 
consistency more robust, by making associations independent of 
changes that occurred over the 13 years of development of HSCT. To 
some degree it could be expected that this measure reduced unknown 
confounding variables, but it was likely to have reduced the power of 
confirming associations from the screening cohort. This means that 
some of the positive associations in the screening step of both studies 
may well not have been spurious, but not confirmed because of 
competing confounders. 
• Statistical power of these studies was limited – if the effect size in the 
confirmatory cohort was below the level of adequate statistical power, it 
may have escaped detection. 
 
Most of the previous studies in the field of non-HLA genetics tried to 
control genetic confounding by selecting HSCT pairs that were either 
HLA matched related or unrelated HSCT. The thinking behind this 
strategy was that HLA mismatching had strong effects on HSCT outcome 
while non-HLA genetic variants had small effects. In order to show these 
small effects, HLA mismatching would have to be reduced, otherwise 
smaller effect size associations could not be detected because these 
would not be visible in the ‘noise’ of genetic confounding.  
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These studies have observed that indeed some non-HLA polymorphisms 
showed effects mainly or only in the HLA-matched subgroup (e.g. IL2-
330 and CTLA4-CT60 SNP in the exploratory study; F2RL1, AGPAT4 
loci in the MS-based study). However, it was remarkable that some 
effects were clearly stronger in the HLA mismatched subgroups, with 
weak or absent effects in the HLA matched subgroups (e.g. TNF-1031 
SNP in the exploratory study, ELTD1, SOCS3, DDX42 and AKT3 loci in 
the MS-based study). As the statistical power was only moderate, future 
confirmatory studies are certainly required to confirm this finding. 
If confirmed, the finding that different degrees of HLA matching or 
mismatching involves different genetic risk loci, could expand the current 
knowledge of the pathophysiology of GVHD. Although the T-cell 
mediated alloreaction remained in the centre of the pathophysiological 
process, modulating mechanisms that were responsible for the severity 
of GVHD could be very different depending on the degree of HLA 
matching. It could be postulated that GVHD in fact involves very diverse 
pathomechanisms according to the HSCT setting (e.g. related/unrelated 
donor, cord HSCT, presence of minor histocompatibility antigens, 
preceding tissue damage through infection or chemotherapy, etc.), and 
therefore would require diverse strategies of prevention and treatment. 
 
The literature review undertaken for these studies showed that small 
effect sizes and poor reproducibility are notorious for non-HLA 
polymorphisms associating with HSCT outcome. This study tried to 
overcome these problems by using stricter criteria for cohort inclusion 
and independent confirmation, thus improving the study quality. Despite 
this, low effect sizes and poor reproducibility persisted.  
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What are the methodological lessons learned from this study? 
What should future genetic association studies in the field of HSCT 
consider? 
 
• Studies should be adequately powered: Most associations are 
expected to be of low effect (i.e. OR <2), therefore the size of the 
cohorts should be able to provide statistical power within this range. 
• An independent confirmatory cohort from the same ethnic and clinical 
background would be essential.  
• Construction of cohorts with careful exploration and measures of 
control for demographic, clinical and confounders. Such confounders 
include: Age of donor and recipient, sex of donor and recipient 
(demographic), type and source of transplant, conditioning regimen, 
GVHD prophylaxis, etc (clinical), ethnic background, HLA matching, 
KIR, mHag (genetic). The expanding registries and application of 
HSCT may soon be able to provide adequate numbers of subjects for 
such approaches. 
• Expanding the scope of investigated populations – ‘from the bench to 
the bedside’. The research question should not just focus on 
understanding the mechanisms of GVHD, but translate into clinical 
practice (i.e. studying small subgroups like HLA-matched HSCT may 
have helped clarifying some of the non-HLA genetic risk, but was of 
little relevance in clinical practice because the results refer to a small 
and diverse population). Selecting cohorts that share clinical 
characteristics like diagnosis, type of HSCT etc. makes results more 
relevant to clinical practice and facilitates translation. 
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Genetic loci previously 
associated – positive in 1st 
screening 
Within ‘top 100’ associations by p-
value 
ABCB1 
CCL2 
CCR5 
CTLA4 
CXCR3 
ESR 
FCGR3 
GSST1 
HSPA1L 
IFNG 
IL1 
IL1RN 
IL2 
 
IL6 
IL7R 
ITGA4 
KIR 
MTHFR 
PTPN22 
TGFB 
TGFBR 
TLR3 
TLR4 
TNF 
TNFRSF1B 
 
 
IFNG 
  
Table 5.5: Gene loci associated with GVHD in previous studies 
showing an association in the 1st screening step. None of these 
were replicated in the 2nd screening step, except TNF which showed 
a trend. 
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SUMMARY – methodological implications for future studies 
 
- Although study power and cohort selection had an impact 
on results, lack of reproducibility and small effect sizes of 
associated genotypes is a common theme in non-HLA 
gene association studies 
- Associations differ between HLA-matched and HLA-
mismatched subgroups, indicating that non-HLA gene 
polymorphisms may have variable effects in different HSCT 
settings 
- Future genetic association studies need to consider 
adequate statistical power, stringent study designs and 
careful cohort construction. 
- The perspective, aim and objectives of future studies 
should also be on clinical questions 
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5.3. Future 
 
Despite the plethora of data from genome-wide association studies, very 
few of these, SNP or MS based alike, have actually been able to identify 
causative genetic variants. The epigenetic function of the genome just 
has begun of being understood, projects such as ENCODE provide a 
deeper insight on how genes are regulated (Consortium, 2007). 
According to this research, gene function could be regulated by structural 
(mutations, polymorphisms, etc) or functional (epigenetic) elements, the 
latter ones may not necessarily comply with the limitations of haplotype 
blocks or LD. For example, remote regulatory elements may cause an 
association signal, but the regulated gene could be far away outside the 
LD range (Consortium, 2007).  
The scope of genetic disease association research is rapidly expanding. 
Genome-wide, high-throughput approaches with SNP or MS markers 
have rapidly advanced knowledge about the influence of genetic 
polymorphisms on health and disease, and have enhanced 
understanding of underlying pathomechanisms. 
Despite these advances, common genetic variables only explain a very 
small fraction of the total genetic risk (2-3%), the missing proportion has 
been referred to as the ‘dark matter’ of genetic risk (Maher, 2008). SNP-
based genome-wide association studies of common genetic variants may 
not be best suited to explore missing genetic risk due to the high 
threshold of significance, which makes small effect size association 
escape detection. The MS approach using a multi-step confirmation 
design without application of multiple testing correction statistics at this 
stage, maybe somewhat more sensitive, but no direct comparison 
studies have been performed. Apart from small effect size, there are 
several reasons for this lack of detecting larger proportions of genetic risk 
(Maher, 2008):  
 
• Associated marker in LD with causative variant - loss of effect size 
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• Rare alleles that may not be captured by scanning for common 
variants 
• Copy Number Variations (CNV) – which are not picked up well by 
current genome-wide approaches (Stefansson et al., 2008, Consortium, 
2008) 
• Transcriptional control of a gene locus by several other genes which 
are not necessarily in LD (Brem et al., 2002)  
• Epigenetic effects (Waterland and Jirtle, 2003) 
 
There are several ways how more knowledge about the ‘dark matter’ 
could be established. Fine mapping of regions within LD of associated 
markers, using SNP, MS or sequencing, could reveal causative 
variations. Most recently, sequencing of selected genomic regions or the 
whole genome came within reach of broad application with the advent of 
faster and cheaper sequencing technology (next generation sequencing). 
Next generation sequencing (NGS) works by high-throughput, parallel 
sequencing of overlapping short stretches of genome (100-250 bp), 
which are annotated by computational methods (Bentley et al., 2009). 
NGS is capable of detecting rare variants that escape detection by 
genome-wide studies using SNP or MS markers; and is very effective in 
detecting new microsatellites fur further investigation (Santana et al., 
2009, Zalapa et al., 2012). 
Future efforts are aiming to integrate data from large scale genomic and 
gene transcription or expression research (Hansen, 2008). A few 
microarray studies have already been undertaken measuring protein 
signatures of GVHD in urine (Weissinger and Dickinson, 2009, Kaiser et 
al., 2004) or gene transcription in blood (Buzzeo et al., 2008, Krijanovski 
et al., 2007, Paczesny et al., 2009b). These studies, especially if capable 
of discriminating profiles in different HSCT settings, could greatly 
contribute to the understanding of GVHD pathophysiology. 
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The future of genetic research into the causes of GVHD is likely see 
new approaches: 
 
- larger scale marker-based genomic studies, using SNP or MS 
markers 
- integration of genetic and functional data, dissection of 
GVHD pathophysiology 
- Whole genome sequencing approaches is likely to identify 
further, and rarer genetic variants associating with GVHD, but 
have not yet been conducted. 
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5.4. Conclusions 
 
This study has demonstrated that a MS-based, pooled DNA scanning 
methodology, derived from a genome-wide scanning approach and for 
the first time applied in an HSCT setting, was capable of identifying non-
HLA genetic risk loci for the development of moderate-severe acute 
GVHD. 
The expected low effect size of associations suggested an approach that 
was robust, powerful and sensitive. This study did show that a 
microsatellite-based approach had some inherent advantages (i.e. more 
informative markers, a study  design of a multi-step screening) over 
similar SNP-based approaches, but also some disadvantages (e.g. the 
requirement for DNA pools, lack of high-throughput platforms). 
With regards to translating the study design, overall this study went much 
further to control confounding variables than previous studies, but some 
confounders remained. Due to the nature of rapidly evolving progress in 
this field, robust cohort design is difficult. The choice of genetic marker 
type, study design with independent confirmation, and selection of a 
population from an ethnically homogeneous background with attempt of 
controlling confounders complied with well laid out requirements for a 
high-quality genetic association study. A larger number of subjects, 
providing the study with a stronger statistical power, could potentially 
have led to a larger number of susceptibility loci identified.  From a 
technical perspective, extensive quality controls had ensured adequate 
quality of pooled DNA and interpretation of typing signals. False positive 
markers had effectively been eliminated, despite a deliberately ‘sensitive’ 
approach by using technical resolution of DNA pools as a threshold for 
inclusion, and non-application of multiple testing correction whilst building 
on confirmation in an independent cohort to rule out false positives. 
 
This approach confirmed three previous SNP associations (IL2-330, 
TNF-1031 and CTLA4-CT60) in an exploration study, and ten new target 
gene microsatellite loci (F2RL1, MAPK14, ELTD1, IL1RAPL2 (x2), 
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SOCS3, TBL1X, DDX42, AGPAT4 and AKT3) in MS-based pooled DNA 
approach. All of these loci should be confirmed in a further independent 
cohort. Some of these loci, e.g. the SNP from the exploration study which 
have known high-expression genotypes, are close to potential 
prospective observation and application in clinical practice as predictors 
of risk. The MAPK14 locus was confirmed in this study by SNP typing, 
was already one of the better understood with regards to 
pathophysiology (it was involved in pro-inflammatory responses). A 
specific treatment (p38 inhibitor) already exists that has been trialled in 
humans. Hence, the way to clinical application could be promising. An 
associated MS in the AGPAT4 locus has confirmed the finding of 
association in this locus in a genetically diverse population, rendering this 
locus a strong candidate for further exploration. 
 
Some observations in these studies raised new questions and 
hypotheses. This study demonstrated that small effect size associations 
with HSCT outcome did exist and could be consistent, but most 
associations from the screening step were not reproducible, even with 
this more stringent study design. Heterogeneity of confounders, hence 
cohort construction, was a likely cause for the lack of reproducibility. 
Future studies should consider more the issues of statistical power, study 
and cohort design. 
 
Another important observation was the discrepancy of effect markers had 
in HLA matched or mismatched subgroups. With the focus mainly on 
HLA-matched study cohorts, previous studies may have missed 
associations that are predominant in HLA-mismatched subgroups only. It 
may be possible that the pathogenesis of GVHD involves different genes 
in different degrees of HLA matching – a hypothesis that would have to 
be proven by future studies. 
The availability of ever larger HSCT registries for research is likely to 
facilitate larger scale investigations that are likely to overcome the 
methodological problems of previous studies (i.e. statistical power), 
including this one. The future will probably see larger scale genomic 
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approaches (e.g. SNP, MS or sequencing based) and integration with 
gene expression, elucidating the pathophysiology of GVHD and 
identifying new targets for clinical application.   
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Appendix 2.1 
Characteristics of the study population 
 
 
  Screening Confirmation Difference p= 
Demographic        
Recipients 460 462   
Recipient gender Male 269 (58.48%) 289 (62.55%) n/s 
Recipient gender Female 191 (41.52%) 173 (37.45%) n/s 
Donor gender Male 267 (58.04%) 278 (60.17%) n/s 
Donor gender Female 193 (41.96%) 182 (39.39%) n/s 
Female donor to Male recipient transplant 102 (22.17%) 84 (18.18%) n/s 
Recipient age range 4-40 y 4-40 y n/s 
Recipient age mean 21.7 y 24.1 y n/s 
Donor age range 20-70y 19-51 y n/s 
Donor age mean 34 y 34.3 y n/s 
Clinical       
Diagnosis Acute lymphoblastic leukaemia 260 (56.52%) 254 (54.98%) n/s 
Diagnosis Acute non-ALL 200 (43.48%) 208 (45.02%) n/s 
High risk leukaemia 279 (60.65%) 246 (53.25%) <0.1 
HLA matching – 12/12 loci 41 (8.91%) 37 (8%) n/s 
HLA matching – 12/12 and 10/10 loci 160 (34.78%) 166 (35.93%) n/s 
HLA matching - GVHD risk mismatches 220 (47.83%) 229 (49.57%) n/s 
Conditioning – Cyclophosphamide + total body 
irradiation (TBI) 334 (72.61%) 322 (69.67%) n/s 
Conditioning – Busulphan/Cyclophosphamide 
or Busulphan based 53 (11.52%) 47 (10.17%) n/s 
Conditioning - TBI based 73 (15.87%) 83 (17.97%) n/s 
Conditioning - other 0 10 (2.16%) n/s 
GVHD prophylaxis – Cyclosporin A based 279 (60.65%) 154 (33.33%) <0.05 
GVHD prophylaxis - Tacrolimus based 177 (34.48%) 305 (66.02%) <0.05 
GVHD prophylaxis - other 4 (0.87%) 3 (0.65%) n/s 
Outcome      
Acute GVHD grade 0 124 (26.96%) 124 (26.84%) n/s 
Acute GVHD grade 1 153 (33.26%) 99 (21.42%) <0.05 
Acute GVHD grade 2 105 (22.83%) 143 (30.95%) <0.05 
Acute GVHD grade 3 50 (10.87%) 72 (15.58%) <0.05 
Acute GVHD grade 4 28 (6.09%) 24 (5.19%) n/s 
Chronic GVHD - none 244 (53.04%) 242 (52.38%) n/s 
Chronic GVHD - limited disease 71 (15.43%) 63 (13.64%) n/s 
Chronic GVHD - extensive disease 95 (20.65%) 106 (22.94%) n/s 
Chronic GVHD - unknown 50 (10.86%) 49 (10.6%) n/s 
Relapse 115 (25%) 110 (23.81%) n/s 
Survival – 100 days 395 (86.9%) 403 (87.23%) n/s 
Survival – 1 year 306 (66.52%) 312 (67.53%) n/s 
Survival – 3 years 245 (53.26%) 258 (55.84%) n/s 
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Appendix 2.1: Population characteristics. p refers to statistically 
significant differences between the screening and confirmation cohorts. 
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Appendix 2.2: 
Procedure for custom-design of MS markers 
 
1. Procedure for custom-design of MS markers 
 
Some target genes were located in gene regions that did not have adequate 
cover with MS markers from the genome-wide panel. Therefore, for 59 genes 
MS markers had to be custom-designed following the procedure below: 
 
• Identification of target gene genomic location on the NCBI or GeneCard 
databases 
• Retrieving the genomic sequence, plus an additional sequence of 50 kb 
to both sides of the target gene, from the UCSC genome browser 
website (http://genome.ucsc.edu/), using the ‘Gene Sorter’ function 
• Importing the retrieved sequence into the ‘Blat’ function of the same 
website, checking for multiple sequence locations, applying settings to 
identify SNP and possible amplicons 
• Importing the same sequence into Sputnik (http://cbi.labri.u-
bordeaux.fr/outils/Pise/sputnik.html) to identify microsatellite repeats 
within the obtained ~100kb sequence.  
• Selection of an appropriate candidate microsatellite, criteria: as many 
repeats as possible, preferably 3-4 base repeats, uninterrupted repeat 
sequence. 
• Importing the same sequence into geneview, location of the identified 
microsatellite, cut and paste the microsatellite with 1000 base pairs 
flanking on each side. 
• Import of obtained sequence into primer express, primer search using 
the settings: Melting temperature (Tm) 56-58°C, amplicon length max 
400 base pairs. 
• If suitable primer pairs not found: Trying of a different microsatellite 
from the Sputnik output 
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• If suitable primer pair found: Checking of primer pair with the ‘In silico 
PCR’ function on the UCSC website to ensure uniqueness of primer 
pair for the intended target. 
• For n=8 loci it was not possible to design appropriate primers. Reasons 
were either a complete absence of suitable microsatellites within the 
target regions, or extensive duplication of highly similar sequence (e.g. 
within the FCGR gene cluster) disabling identification of a unique 
sequence.  
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Appendix 2.3: 
Estimation of DNA requirements for the pooled 
screening steps 
 
1. Estimation of DNA amounts required for single genotyping  
 
The essential DNA requirements for conducting pooled DNA genotyping are 
as outlined in table 1. 
 
Screen Cohort No. 
markers 
Amount 
for 
conc 6 
ng/μl 
Amount 
for 
conc 8 
ng/μl 
No. 
samples 
Total 
DNA at 6 
ng/μl 
Total 
DNA at 8 
ng/μl 
1 Pat 0-1 4000 48 64 281 683.27 911.03 
1 Pat 2-4 4000 48 64 195 984.61 1312.82 
1 Don 0-1 4000 48 64 281 683.27 911.03 
1 Don 2-4 4000 48 64 195 984.61 1312.82 
2 Pat 0-1 500 48 64 128 187.50 250.00 
2 Pat 2-4 500 48 64 111 216.21 288.28 
2 Don 0-1 500 48 64 128 187.50 250.00 
2 Don 2-4 500 48 64 111 216.21 288.28 
 
Table 1: Basic DNA requirement estimates 
 
2. Additional DNA amounts required for processing, further 
typing 
 
To calculate the total amount required for the first screening step, an extra 
one third for possibly necessary repeat experiments was added, and, 
depending on sample concentration, an extra 100-500 ng of DNA required for 
the pooling process (repeated concentration measurements). Therefore final 
requirements for the first and second pooled screenings were as outlined in 
table 2.  
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Screen Cohort High 
conc 
Low conc
1 Pat 0-1 1714 1314 
1 Pat 2-4 2249 1849 
1 Don 0-1 1714 1314 
1 Don 2-4 2249 1849 
2 Pat 0-1 833 433 
2 Pat 2-4 884 484 
2 Don 0-1 833 433 
2 Don 2-4 884 484 
 
Table 2: Corrected DNA requirements including allocations for 
pipetting/pooling, in ng amount. 
 
 
Following the first and second pooled screening steps, around 100 markers 
were expected to show a significant association. These markers would then 
be individually genotyped on the entire cohort. As the amount of DNA required 
for one MS marker typing was 1-2 ng/sample, this would require a further 200 
ng of DNA, plus a 15% margin for repeat experiments. 
 
Only the markers which showed a consistently significant association after the 
two pooled screenings and the individual genotyping confirmation step would 
be subjected to SNP ‘scanning’ of the 100 kb region, with approximately 50 
SNP. Using a TaqMan® assay, this required 1-2 ng of DNA per SNP studied 
(hence, 100 ng), plus a margin of 15% - approximately 120 ng of DNA. 
 
Separately, the plan was to study all SNP associated with HSCT outcomes by 
individual genotyping using a TaqMan® assay. These were approximately 
150 SNP, including a margin of 15% requiring 350 ng of DNA. 
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After summing up all these requirements, a further 15% of DNA amount was 
added for pipetting and measurement variability. 
 
In summary, maximum DNA requirements for the entire study were as in table 
3. 
 
Usage Entry 1st Screen, ng Entry 2nd Screen, ng 
First Screen 2250 N/A 
Second Screen N/A 890 
Individ MS typing 230 230 
SNP screen 120 120 
SNP previous 350 350 
Intermed sum 2950 1590 
Add for 
pipet/measure 
450 260 
Total 3400 1850 
 
Table 3: Estimated total DNA amounts required for entire study 
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Appendix 2.4: 
Calibration of pipettes for DNA pooling 
 
The process of pooling requires a very high degree of accuracy. Therefore 
for all pipetting of pools only calibrated pipettes with a fixed volume are 
used (i.e. the pipette is dedicated to this process for the duration of the 
study, the volume on the pipette is not changed). For calibration, a set of at 
least 3 pipettes is tested, and the one is chosen that has the lowest volume 
variation (which has to be <1%). Only original pipette tips of the maker are 
used. The aim was to have fixed pipette volumes for all standard procedure 
volumes. Volumes of individual samples had to be pipetted with multiple 
fixed pipettes if necessary. For all pooling into intermediate or large pools 
fixed volume pipettes with the exact volume required were ‘custom-
calibrated’.  
 
Procedure of pipette calibration 
 
Preparation 
 
• A set of five 2ml plastic flipcap tubes is prepared for each pipette 
• Each tube is weighed three times on a high sensitivity scale 
(nanograms, Mettler® Toledo) at standard conditions (stable lab 
table and temperature) 
 
Practical procedure 
 
• Each of the five tubes is pipetted with the target volume by a 
standard technique: 
• Attachment of the tip by a single, firm but gentle movement in vertical 
direction 
• Gentle, slow aspiration with 1-2 seconds wait after completion of 
aspiration 
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• Keeping pipette vertical at all times of aspiration, transfer, dispensing 
• Slow dispensing of sample into tube, wait for 1-2 seconds with tip 
inside fluid before removing 
• Each filled tube is then weighed three times 
• Calculation of mean, standard deviation, standard error and variance 
on an excel template spreadsheet. 
 
 
Pipette 
volume 
range 
Nominal 
volume 
Pipetted 
volume SD Variance 
Upper 
error % 
 Lower 
error % 
2-20 20 19.7 0.00006 0.00000003 0.4 -0.44 
10-100 100 98.9 0.0001 0.00000002 0.12 -0.24 
100-1000 380 378 0.0009 0.0000009 0.35 -0.22 
20-200 95 94.5 0.0001 0.00000003 0.24 -0.28 
20-200 87 86.8 0.00007 0.000000005 0.09 -0.06 
 
Table 1: Examples of pipette tests. The pipette that delivered the volume 
closest to the aimed volume was chosen, if the error was within a range 
of +/- 1%. 
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Appendix 2.5: 
PCR mixtures for test typing 
 
High amount DNA  Medium amount DNA       Low amount DNA 
DNA 
amt/well 
ng 93.18677  
DNA 
amt/well 
ng 62.12451  
DNA 
amt/well 
ng 46.59338
Marker 
typing 
capacity 6000  
Marker 
typing 
capacity 9000  
Marker 
typing 
capacity 12,000
        
        
ingredient 
vol 
μl/well  ingredient 
vol 
μl/well  ingredient 
vol 
μl/well 
dH2O 0  dH2O 4.2  dH2O 6.5
10xbuffer 2  10xbuffer 2  10xbuffer 2
2.0mM 
dNTP 2.5  
2.0mM 
dNTP 2.5  
2.0mM 
dNTP 2.5
Primer mix 2  Primer mix 2  Primer mix 2
AmpliTaqG 0.1  AmpliTaqG 0.1  AmpliTaqG 0.1
DNA 13.4  DNA 9.2  DNA 6.9
total vol 
(μl) 20  
total vol 
(μl) 20  
total vol 
(μl) 20
  
Table 3.11: PCR mixtures for three options of DNA amount in the PCR 
procedure, as applied for MS marker testing 
. 
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Appendix 3.1: 
Information of SNP assays used in the 
exploration study 
 
Primers for Luminex Genotyping of IL10 SNP 
 
 
 
 
PRIM ER oligonucleotide nam e sequence ( 5' --> 3' )
IL10P forw ard prim er IL10-F2 C AAATC C AAG AC AAC AC TAC TAAG G C
IL10P reverse prim er IL10-R2 G G C TAAATATC C TC AAAG TTC C C AAG
PRO B E oligonucleotide nam e sequence ( 5' --> 3' )
IL10P com m on probe IL10C R-2 TTTTTTTTTTTTTTTTTTTTC AG AC TAC TC TTAC C C A
-1082A probe 1082AS-4 TTTTTTTTTTTTTTTTTTTTC TG TTC C C C TTC C C AAAG A
-1082G  probe 1082G S-3 TTTTTTTTTTTTTTTTTTTTTTC C C C C TC C C AAAG
-819C  probe 819C R-2 TTTTTTTTTTTTTTTTTTTTAG G TG ATG TAAC ATC TC TG TG C
-819T probe 819TS-2 TTTTTTTTTTTTTTTTTTTTG C AC AG AG ATATTAC ATC AC C T
-592A probe 592AR-8 TTTTTTTTTTTTTTTTTTTTC C G C C TG TAC TG TAG G
-592C  probe 592C R-2 TTTTTTTTTTTTTTTTTTTTC G C C TG TC C TG TAG G AA
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TaqMan Assays  
 
Assay ID Context Sequence Design Strand  Category ID Group ID Gene Symbol NCBI Gene 
Reference 
Cytogenetic 
Band 
SNP Type Location on 
NCBI Assembly 
C__15944115_20 TATCTAGCTATATGATTGT
GAGTTA[A/G]CTTCTTAAAT
CTTCTATGACTCAGT 
Forward Chr12 D12S313 IFNG   12q15a INTERGENIC/UNK
NOWN 
66841278 
C__15820717_10 GTCAGCCTGTGGGGTAAC
TTGGTCC[A/G]TGGGATTT
CCCCTAAAAAGGTAGCC 
Forward Chr16 D16S3136 NOD2 NM_022162.1 16q12.1c INTRON 49291470 
C___7514871_10 GGAAGCAAAGGAGAAGCT
GAGAAGA[C/T]GAAGGAAA
AGTCAGGGTCTGGAGGG 
Reverse Chr6 D6S276 TNF;LTA;LTB   6p21.33a INTERGENIC/UNK
NOWN 
31650287 
C___9077561_20 AATGGAAAATCCCAGAAAT
TCTCCC[A/G]TTTGGATCCC
ACCTTCTCCATCCCA 
Forward Chr1 D1S484 FCGR2A NM_021642.2 1q23.3a MIS-SENSE 
MUTATION 
159746369 
C__25651063_10 CATTGCATTCTTGACAGAT
TCTCTT[A/G]TTGCCTTAAA
AAGAATCACTGGCCT 
Forward Chr16 D16S3136 NOD2 NM_022162.1 16q12.1c INTRON 49322877 
C___9546481_20 GATTTTTACATATGAGCCT
TCAATG[A/G]TGTTGCCTG
GTTACTATTATTAAAG 
Reverse Chr2 D2S160 IL1A NM_000575.3 2q13d UTR 5 113259431 
C__34029672_10 GAGCTTCTGCAAAGTGGA
AGAATAC[C/T]GCTTGGCC
CTAACTCCTCACCCCAA 
Reverse Chr16 D16S3136 NOD2 NM_022162.1 16q12.1c INTRON 49305205 
C___1384440_10 GTGCCACCCATTTATTGGG
GAAAAG[C/T]CCTAAAAGG
GGAAGTGGGGAAGGGA 
Reverse Chr16 D16S3136 NOD2 NM_022162.1 16q12.1c INTRON 49310316 
C___8861232_20 GTGGCCATCCCTGGGAAT
GCAAGCA[G/T]GGATGCAG
TCTGCACGTCCACGTCC 
Forward Chr1 D1S2667 TNFRSF1B NM_001066.2 1p36.22a MIS-SENSE 
MUTATION 
12175542 
C__16049347_10 TTGCTGTGTTTGTAATTCA
GGTAAA[C/T]CTATTTTCTG
TAAAGCAGGCATGAT 
Reverse Chr8 D8S285 CCL4   8q12.1c INTERGENIC/UNK
NOWN 
59833385 
C__15859930_10 AGTAACTCAGAAAATTTTC
TTTGTC[C/A]TAAAACTACA
CTGAACATGTGAATA 
Forward Chr4 D4S402 IL2   4q27d INTERGENIC/UNK
NOWN 
123597430 
C___1839943_10 TACCTTGGGTGCTGTTCTC
TGCCTC[G/A]GGAGCTCTC
TGTCAATTGCAGGAGC 
 
 
Forward Chr2 D2S160 IL1B   2q13d INTERGENIC/UNK
NOWN 
113311338 
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C___1202883_20 GAAAAGCTGCGTGATGAT
GAAATCG[G/A]CTCCCGCA
GACACCTTCTCCTTCAA 
Forward Chr1 D1S2667 CLCN6;MTHF
R;C1orf167 
NM_005957.3 1p36.22a MIS-SENSE 
MUTATION 
11778965 
C___8708473_10 GAGGAGGGGGCAACAGGA
CACCTGA[A/G]GGATGGAA
GGGTCAGGAGGCAGACA 
Forward Chr19 D19S220 TMEM91;TGF
B1;B9D2 
  19q13.2c INTERGENIC/UNK
NOWN 
46552136 
C___9578811_10 TCATATGGTTAACTGTCCA
TTCCAG[A/G]AACGTCTGT
GAGCCTCTCATGTTGC 
Forward Chr10 D10S1765 FAS   10q23.31b INTERGENIC/UNK
NOWN 
90739943 
C__15820716_10 TTGCTCTTGACTCTTGGCA
GGAAAC[A/G]TACAACTCTT
TCTTTCTTCTTTTCT 
Reverse Chr16 D16S3136 NOD2 NM_022162.1 16q12.1c INTRON 49291534 
C___3296043_10 TCTTCACCACTATTTGGGA
TATAAC[A/G]TGGGTTAACA
CAGACATAGCAGTCC 
Reverse Chr2 D2S117 CTLA4   2q33.2a INTERGENIC/UNK
NOWN 
204447164 
C__11722137_10 TTTTCAAACAAGAAGTAGT
TTTTCA[C/T]CAAACAATGT
CTCTTATGTAATTCA 
Reverse Chr9 D9S1776 TLR4 NM_138554.2 9q33.1c INTRON 119512585 
C__15873886_20 ATGTCAGAGACGGAGACG
AGGCAAC[A/C]GGACCGTG
GAGGAGAAAAATAGAAA 
Forward Chr19 D19S220 B9D2;TGFB1 NM_000660.3 19q13.2c INTRON 46548726 
C___1882528_10 GGAGGCGGATGCTGTGAG
TTCCCAG[G/T]TCTTGGCT
GTTGTCTGAGAGGGGGT 
Forward Chr10 D10S591 IL15RA NM_002189.2
,NM_172200.
1 
10p15.1b MIS-SENSE 
MUTATION 
6042374 
C___2213785_10 TTTCTAGCCGCCAAGTGGA
GAACAG[C/G]TTGGAGCGG
TGCGCCGGGCTTAGCG 
Forward Chr22 D22S539 SLC2A11;MIF   22q11.23a INTERGENIC/UNK
NOWN 
22566392 
C___1272348_10 CTGTTCCTATTCAGCCATC
TTGGCT[C/T]GGGACCAGA
GAACTTCGTATTTCTT 
Reverse Chr1 D1S198 IL23R   1p31.3a INTERGENIC/UNK
NOWN 
67421048 
C___7504226_10 CCATATACCTGAAAGATCT
GATGAA[A/G]CCCAGCGTG
TTTTTAAAAGTTCGAA 
Forward Chr3 D3S1558 CD86 NM_006889.3
,NM_175862.
3 
3q13.33c MIS-SENSE 
MUTATION 
123321009 
C___3052613_1_ GTGATGATAGGGTTACACA
TCTGCT[C/T]CAATTCCTTT
CTCTTATGATCAAAC 
Forward Chr6 D6S276 HSPA1A;HSP
A1L;LSM2 
NM_005527.3 6p21.33a MIS-SENSE 
MUTATION 
31885925 
C___2215707_10 GGCCCAGAAGACCCCCCT
CGGAATC[A/G]GAGCAGGG
AGGATGGGGAGTGTGAG 
Reverse Chr6 D6S276 LTB;LTA;TNF   6p21.33a INTERGENIC/UNK
NOWN 
31651080 
C___1384434_10 TGGCCTTTGGAAGGGGCA
TTTCTGA[A/T]TAAGATCTG
GGCCGCTCTCCGCTGG 
Reverse Chr16 D16S3136 NOD2 NM_022162.1 16q12.1c INTRON 49317048 
C___3017467_10 TGTTTTATTTAAGCCTCAC
AAGGGT[A/G]TAGTGTGAC
TACACTGTTTCTTAAC 
Forward Chr16 D16S3136 NOD2 NM_022162.1 16q12.1c INTRON 49294157 
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C__15873887_10 ATTGTATGGTTTGTGTTCT
TCTATC[C/T]TTCAGGGACC
ATCTAGGTGGACCTT 
Reverse Chr19 D19S220 TGFB1;B9D2 NM_000660.3 19q13.2c INTRON 46545926 
C___7514879_10 GAGGCAATAGGTTTTGAG
GGGCATG[A/G]GGACGGG
GTTCAGCCTCCAGGGTCC 
Reverse Chr6 D6S276 LTB;LTA;TNF   6p21.33a INTERGENIC/UNK
NOWN 
31651010 
C___2404008_10 TGGACAGGCGGTCCTGGA
TGGCCTC[A/G]ATCAGCGC
GGCGTCCTGCACCCCAG 
Forward Chr12 D12S85 VDR NM_000376.2
,NM_0010175
35.1 
12q13.11c SILENT 
MUTATION 
46525024 
C___2415786_20 GCACAAGGCTCAGCTGAA
CCTGGCT[A/G]CCAGGACC
TGGCCCTGCACTCTCCT 
Reverse Chr2 D2S117 CTLA4 NM_0010376
31.1,NM_005
214.3 
2q33.2a MIS-SENSE 
MUTATION 
204440959 
C__11918223_10 GTCGAGTATGGGGACCCC
CCCTTAA[C/T]GAAGACAG
GGCCATGTAGAGGGCCC 
Reverse Chr6 D6S276 LTB;LTA;TNF   6p21.33a INTERGENIC/UNK
NOWN 
31650461 
C___3017459_20 ACATTTCTCTTGGCTTCCT
GGTGCG[G/T]GCCAAAGGT
GTCGTGCCAGGGAGTA 
Forward Chr16 D16S3136 NOD2 NM_022162.1 16q12.1c SILENT 
MUTATION 
49303084 
C__31784020_10 TCTATTAAGGTAGACCACC
TCTCCC[C/T]TTTTTTTTTTT
TCAAACAAGAAGTA 
Forward Chr9 D9S1776 TLR4 NM_138554.2 9q33.1c INTRON 119512551 
C___2415784_10 CTTATCTCTCTCTAGACCT
TCTTGG[C/T]TAAGAAACCA
TGTAGTTTGTATGAA 
Forward Chr2 D2S117 CTLA4 NM_0010376
31.1,NM_005
214.3 
2q33.2a INTRON 204441833 
C__30031638_10 CCTGAATTCTCAGTAACTT
AGAAGT[A/C]ATTTCTAATG
ATTCCGGCTGGGCAC 
Forward Chr19 D19S220 TGFB1;B9D2 NM_000660.3 19q13.2c INTRON 46543349 
RS1264457-GA   Forward      HLA-E         
RS1800795-GC   Reverse      HLA-E         
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Appendix 4.1:  
Genotyping errors and their resolution 
 
1. 1st screening PCR and genotyping – technical results  
(all pools combined) 
 
The initial round of PCR and genotyping had an error rate of 11.36%. This 
was expected as there is some variation in PCR conditions of markers on the 
panel for the genome-wide association studies. In that set-up, these 
variations were addressed by grouping markers requiring the same conditions 
on the same plate. As the selection of markers for this study disrupted this 
order, markers with different typing conditions were on the same plate. The 
main causes of error were absence of peak signal (4.34%) and low peak 
signal (5.08%), indicating either PCR failure or high dilution/low concentration 
of PCR product. High peak signal, size standard errors, data collection failure 
and mechanical errors of PCR and genotyping accounted for the remaining 
2.06% of errors.  
 
 
1.1. Strategy for resolving error samples (1st step): 
 
• Samples with an absent peak signal were re-typed using a x10 
dilution. 
• Samples with a low peak signal were re-typed using a x20 dilution. 
• Samples with size standard errors, data collection failure or 
mechanical errors were re-typed using a x40 dilution. 
• Samples with high peak signals were subjected to a dilution sequence 
of x80, x200, x400 and x800 
 
Results of the 1st step of error sample resolution: 
All of the high peak/size standard/data collection/mechanical error samples 
had adequate results. Most of the low peak signal and some of the absent 
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peak signal sample errors were resolved, but 5.20% of samples remained 
with absent/low peak signal error. We presumed that the reason is primary 
PCR failure. 
 
 
1.2. Strategy for resolving error samples (2nd step): 
 
• Repeat PCR of all samples with absent/low peak signal 
• DNA purification of PCR product in persisting low peak signal samples 
 
Results of the 2nd step of error sample resolution: 
A further 2.53% of samples were resolved, remaining 2.67% with persistently 
absent/low peak signal. Possible reasons include degradation of primers 
(primers for studies in this institution stem from a master primer set on plates 
which are defrosted and re-frozen each time a primer aliquot is taken) or 
inadequate PCR conditions. 
 
1.3. Strategy for resolving error samples (3rd step): 
 
• Re-PCR with primers from a separate primer stock 
• If error persists: purchase of fresh primer, modification of PCR 
conditions (extension to 35 cycles, increasing concentration of dNTP, 
change of annealing temperature), re-typing after PCR product 
purification 
 
Results of the 3rd step of error sample resolution: 
Only 0.8% of samples remained as error. At this point, no further attempts of 
resolution were undertaken - the additional information gained would not have 
stood in relation to the time and effort to achieve it. 
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2. Error resolution for the second pooled DNA screening 
 
Error resolution of the second pooled screening followed the same principles. 
Eventually, 1.55% of markers were not reproducible and excluded (1.67% in 
the donor screen, 1.3% in the recipient screen). 
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Supplementary file 2.1: 
 
JMDP registry analysis and study cohort design 
 
 
1. Genetic background of the Japanese population 
 
It has been pointed out that the studied population should stem from a 
homogenous genetic background without genetic admixture. It was known 
from data of the HapMap Consortium (Consortium, 2005, Stranger et al., 
2005) that genetic variation varies enormously between different populations, 
more so the closer the population was to the evolutionary African population, 
and less so the further the population had moved away from Africa. The 
Japanese, as the furthest East of all Asian populations, had a genetic 
structure of less, and better preserved haplotype blocks than Caucasians or 
Africans (Conrad et al., 2006, Gabriel et al., 2002). While the European and 
North American History was characterized by large shifts and admixing of 
populations (e.g. migration within Europe, immigration and displacement of 
Caucasians, Africans and Asians to North America); due its geography Japan 
had experienced fewer admixtures. The Japanese population is genetically 
closely related to that of South East and North East Asia, areas on the Asian 
mainland from which the Japanese archipelago was initially and repeatedly 
colonised, and to which it maintained close relations through history (Omoto 
and Saitou, 1997, Nanta, 2008, Hanihara, 1991). 
According to their records, all HSCT donors and recipients in this study were 
of Japanese origin, hence genetic admixture is very low. As this population 
had larger size and a smaller number of preserved haplotype blocks, with 
fewer haplotypes per block, the linkage disequilibrium range of a selected 
marker could expected to be wider as compared to other populations, 
therefore less markers would be required to give the same LD range coverage 
as for a more genetically diverse population. This had implications for 
statistical power (potentially, the population size required could be set lower, 
and a smaller number of markers required less statistical correction for 
multiple testing). 
Difference of genetic variation between populations has been an area of 
intense research in the HSCT field. For example, the lower incidence of 
GVHD in the Japanese population could be attributed in part to differences in 
HLA alleles amongst the Japanese and other population, and subsequent 
HLA matching for HSCT (Petersdorf et al., 2007, Morishima et al., 2007a). 
With growing HSCT registries, there has been a move towards studying 
populations from a more homogenous ethnic background. Non-HLA gene 
polymorphisms previously associated with GVHD also showed considerable 
variation of allele and genotype distribution (e.g. IL10 (Middleton et al.), IL6 
(Visentainer et al., 2008), NOD2 (Tanabe et al., 2011)).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Cohort Selection 
 
 
2.1. Analysis of clinical and genetic risk factors in a large, unselected 
HSCT population 
 
Clinical risk factors for acute GVHD have been documented in studies from 
the JMDP registries or other unrelated HSCT studies in Japan. These 
included donor-recipient gender mismatch, patient age, donor age, diagnosis 
(acute lymphoblastic leukaemia(ALL) versus chronic myeloid leukaemia 
(CML)), GVHD prophylaxis (cyclosporine versus tacrolimus), relapse risk, 
antithymoglobulin (ATG), conditioning regimen (total body irradiation (TBI) 
versus non-TBI), stem cell source (bone marrow transplant (BMT) versus 
peripheral blood stem cell transplant (PBSCT)) and blood group (ABO) 
mismatch (Kawase et al., 2007, Morishima et al., 2007a, Hara et al., 2007, 
Kimura et al., 2008). Multivariate analyses in Japanese genetic association 
studies had confirmed the significance of these risk factors. Studies in other 
populations identified Donor and recipient cytomegaly virus (CMV) status, 
intensity of conditioning regimens, malignant disease stage, diagnosis, 
unrelated versus related HSCT, early transplants (before 2000), older donor 
age, older patient age, high nucleated cell count, stem cell source, ethnicity, 
gender mismatch, donor parity and ABO mismatch as further clinical risk 
factors (Hill et al., 1997, Socie et al., 2001, Aschan, 2007, Chaidos et al., 2007, 
Wojnar et al., 2006, Svennilson et al., 2003, Nash et al., 1992).  For the 
Japanese population, more recent work identified KIR and KIRL mismatches, 
HLA haplotypes and minor histocompatibility antigens (mHag) as genetic risk 
factors.(Yabe et al., 2008, Morishima et al., 2010, Kawase et al., 2008, Ogawa 
et al., 2008). Eventually, it had to be assumed that many more clinical and 
genetic risk factors exist of which we have little evidence, owed to the 
restricted nature of data collections.  
In order to identify risk factors for moderate-severe GVHD (grade 2-4), a large 
cohort (n=2469 HSCT pairs) from the JMDP registry, representing a majority 
of unrelated donor HSCT in Japan between 1993-2000, was investigated for 
significant associations by both log rank test and Fisher’s exact test, and 
binary logistic regression.  
The baseline characteristics of this population were summarised in table 1. 
Risk factors for grade 2-4 GVHD considered included recipient age, recipient 
gender, donor age, donor gender, donor-recipient gender mismatch (female 
donor to male recipient), diagnosis, AB0 mismatch, conditioning regimen, 
cyclophosphamide dose, total body irradiation dose, number of nucleated 
cells in graft, GVHD prophylaxis, antithymocyte globulin, T-cell depletion and 
HLA matching. 
Table 2 shows the associations of clinical risk factors with grade 2-4 acute 
GVHD in univariate analysis, using Fisher’s Exact Test with 95% confidence 
intervals for Odds Ratio. Donor T-cell depletion (TcD) and the use of anti-
thymocyte globulin (ATG) to eradicate recipient T-cells and 5-locus HLA 
matching confered the strongest effects on the prevention of acute GVHD. 
Certain diagnosis in itself, or by their population and treatment characteristics, 
carried a higher risk of acute GVHD. Donor age >30 years almost matched 
the effect size of HLA mismatch. A conditioning regimen consisting of 
standard dose cyclophosphamide and total body irradiation had the lowest 
risk of acute GVHD. Cyclophosphamide in itself modulated the recipient 
immune response in a GVHD protective way, even at high dose. TBI at 
standard doses has the lowest GVHD risk, but as part of conditioning (TBI 
versus no TBI) had no impact on GVHD risk. No significant effect on GVHD 
risk was found with recipient or donor gender, female into male mismatch, 
AB0 matching, graft nucleated cell count, or recipient age. Recipient age >40 
years, however, showed a tendency towards a higher risk of grade 2-4 GVHD.  
The multivariate analysis for this unselected population is shown in table 3. 
Taken all risk factors from the univariate analysis into account, seven of these 
remained significant, relating to demographics (donor age >30y, high risk 
diagnosis (ALL, CML)), conditioning (other conditioning regimen than CyTBI, 
cyclophosphamide dose none/low versus standard/high) and GVHD 
prophylaxis (cyclosporine A versus tacrolimus, no ATG versus ATG, HLA 
mismatching). 
 
 
 Category Factor Frequency Percent 
Recipient age 0-10y 406 16.4
  11-20y 542 22.0
  21-30y 600 24.3
  31-40y 453 18.3
  41-50y 421 17.1
  51-60y 47 1.9
Recipient gender Female 994 40.3
  Male 1475 59.7
Donor age 0-10y 0 .0
  11-20y 
20 .8
  21-30y 895 36.2
  31-40y 941 38.1
  41-50y 602 24.4
  51-60y 9 .4
  61-70y 1 .0
  unknown 
1 .0
Donor gender Female 974 39.4
  Male 1495 60.6
Female-male gender 
mismatch no F-M mismatch 
1950 79.0
  F-M mismatch 518 21.0
Diagnosis unknown 7 .3
  
ALL (acute lymphoblastic leukaemia) 653 26.4
  ANLL (acute non-lymphoblastic leukaemia) 617 25.0
  CML (chronic myeloid leukaemia) 643 26.0
  HD (Hodgkin’s disease) 52 2.1
  ID (primary immunodeficiency) 17 .7
  LPD (lymphoproliferative disease) 1 .0
  MDS (myelodysplastic syndrome) 201 8.1
  MF (myelofibosis) 2 .1
  MM (multiple myeloma) 2 .1
  NHL (non-Hodgkin lymphoma) 96 3.9
  SAA (severe aplastic anaemia) 178 7.2
ABO matching matched 1248 50.5
  minor mismatch 526 21.3
  major mismatch 620 25.1
  minor & major mismatch 55 2.2
  unknown 20 .8
Conditioning No of different regimens 86   
  
Busulphan+Cyclophosphamide 241 9.8
  Busulphan+Cyclophosphamide+other 145 5.9
  Cyclophosphamide+other 53 2.1
  Cyclophosphamide+total body irradiation 639 25.9
  Cyclophosphamide+total body irradiation+other 90 3.6
  
Cyclophosphamide+total body 
irradiation+busulphan 
251 10.2
  
Cyclophosphamide+total body irradiation+Ara-C 504 20.4
  
Cyclophosphamide+total body irradiation+VP16-
213 
220 8.9
  other 59 2.4
  Total body irradiation+other 267 10.8
Cyclophosphamide 
dose 
none 295 11.9
  <120 576 23.3
  120 (standard) 1262 51.1
  
>120 312 12.6
  unknown 24 1.0
Total Body Irradiation none 486 19.7
  <1200 336 13.6
  1200 1485 60.1
  >1200 149 6.0
  unknown 13 .5
No of nucleated cells <251 509 20.6
  
251-400 1437 58.2
  >400 503 20.4
  unknown 20 .8
GVHD prophylaxis No of different regimens 21  
  Cyclosporin A - based 1818 73.6
  Tacrolimus - based 641 26.0
  Other 10 .4
Antithymoglobulin unknown 4 .2
  no ATG 2279 92.3
  ATG 186 7.5
T-cell depletion unknown 4 .2
  no T-cell depletion 2448 99.1
  T-cell depletion 17 .7 
HLA matching 5-locus matched 925 37.5 
 mismatched 1544 62.5 
 
Table 1: Baseline characteristics of an unselected HSCT population 
(n=2469) from the JMDP registry 
 
 
 
 
 
 
 
 
 Category comparison p-value 
case 
all no 
control 
all no 
case 
pos 
case 
neg 
control 
pos 
control 
neg 
Odds 
Ratio 
Confidence 
interval 
confidence 
interval comment 
GVHD 
prophylaxis 
No TcD v TcD 
0.039 1444 968 13 1431 3 965 2.9222 0.83051 10.282 
No TcD higher risk 
GVHD 
prophylaxis 
No ATG v ATG 
0.002 1447 968 128 1316 54 914 1.64629 1.18468 2.28777 
ATG protective 
HLA matching mismatch v 5 
locus match <0.0001 968 1447 653 315 837 610 1.5108 1.27436 1.79111 
HLA mismatch higher risk 
Diagnosis high risk 
(ALL+CML) v low 
risk (other) <0.0001 968 1447 566 402 703 744 1.49007 1.2644 1.75603 
ALL, CML risk 
GVHD 
prophylaxis 
Cyclosporin v 
tacrolimus 
<0.0001 968 1447 751 214 1032 411 1.39762 1.15566 1.69023 
CyA higher risk 
Donor age >30y v <30y 
<0.0001 968 1447 652 316 863 584 1.39625 1.17735 1.65585 
higher age-higher risk 
Conditioning Other v CyTBI 
0.002 968 1447 218 750 408 1039 1.35098 1.11792 1.63263 
Non-CyTBI higher risk 
Conditioning Cy no/low dose v 
standard/high 
dose 0.001 956 1436 964 472 576 380 1.3474 1.13674 1.59709 
no/low have higher risk 
Conditioning TBI standard 
dose v 
lower/higher 
dose 0.023 964 1438 797 167 1135 303 1.27406 1.03325 1.57098 
standard dose protective 
Donor age >40y v <40y 
0.021 968 1447 265 703 335 1112 1.25127 1.03809 1.50822 
higher age-higher risk 
Recipient 
gender 
Male v Female 
0.062 968 1447 600 368 842 605 1.17151 0.99173 1.38388 
  
Donor gender Male v Female 
0.14 968 1447 605 363 856 590 1.14875 0.97195 1.35772 
  
ABO matching matched v 
mismatched 0.156 962 1434 474 488 749 685 0.88832 0.75437 1.04604 
  
No of nucleated 
cells 
high v low 
0.215 954 1441 85 869 108 1333 1.20727 0.89727 1.62438 
  
Donor-Recipient 
gender 
mismatch 
Female into Male 
v other 
0.495 968 1446 197 771 311 1135 0.9325 0.76304 1.13958 
  
Recipient age >40y v <40y 
1 968 1447 179 789 267 1180 1.00264 0.81297 1.23657 
  
Conditioning TBI v non-TBI 1 964 1438 774 190 1155 283 0.99814 0.81302 1.22542   
 
Table 2: Univariate analysis of clinical risk factors in an unselected cohort of Japanese HSCT from the JMDP register 
(1993-2000) 
 
  
B SE Wald df Sig. Exp(B) 
95.0% CI for 
Exp(B) 
  Lower Upper 
No ATG v ATG -.500 .147 11.604 1 .001 1.648 1.236 2.197
HLA mismatch v 5-
locus match 
-.413 .071 34.048 1 .000 1.511 1.315 1.736
Cyclosporin A v 
Tacrolimus 
.347 .080 18.812 1 .000 1.415 1.210 1.656
No CyTBI v CyTBI -.241 .084 8.244 1 .004 1.271 1.079 1.498
High risk diagnosis 
(ALL+CML) v other 
.236 .068 12.080 1 .001 1.266 1.108 1.447
Donor age >30y v 
<30y 
.009 .003 6.862 1 .009 1.009 1.002 1.016
Cyclophosphamide 
non/low v 
standard/high 
-.007 .003 4.992 1 .025 1.007 1.001 1.013
TBI v no TBI .152 .092 2.769 1 .096 1.164 .973 1.393
Donor age >40y v 
<40y 
.004 .003 1.870 1 .172 1.004 .998 1.009
TBI dose low/high 
v standard 
-.009 .008 1.546 1 .214 .991 .976 1.005
TcD v no TCD -.672 .581 1.339 1 .247 .511 .164 1.594
ABO matched v 
mismatched 
.072 .066 1.190 1 .275 1.075 .944 1.225
Nucleated cell 
count low v high 
.122 .117 1.086 1 .297 1.129 .898 1.419
Female into male 
gender mismatch 
-.110 .139 .625 1 .429 .896 .682 1.177
Recipient gender -.061 .088 .474 1 .491 .941 .792 1.119
Donor gender -.072 .107 .455 1 .500 .930 .754 1.147
Recipient age 
>40y v <40y 
-.001 .002 .135 1 .713 .999 .995 1.003
 
Table 3: Multivariate analysis (Cox regression) of clinical risk factors in 
an unselected Japanese HSCT cohort from the JMDP registry, 1993-2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2. Designing a study cohort accounting for clinical risk 
factors 
 
A large proportion of HSCT in Japan by JMDP between 1993 and 2000 
included one or more statistically significant risk factors for moderate-severe 
acute GVHD (grade 2-4), (see table 4). This outcome was chosen because 
GVHD was one of the most commonly reported HSCT outcomes in the 
literature. The challenge was to devise a model for cohort selection that 
eliminated the strongest effects of these clinical risk factors, while preserving 
a sample size that would provide adequate statistical power. Knowing that the 
effect of HLA mismatching has an OR of approximately 1.5, it was aimed for a 
sample size that would undercut this OR with regards to statistical power. It 
was estimated that for a single outcome a sample size of approximately 
n=500 in each of the two screening steps (or 1000 altogether) would be 
required to achieve an OR of 1.3 for an allele frequency of 0.2.  
I order to reduce the effect of HLA mismatching, a higher degree HLA-
matched subgroup was analysed as a comparison (mismatched only for either 
one HLA-DQB1 or HLA-DPB1 locus, largely representing an 8/8 match of HLA 
A, B, C, DR) and non- ATG group as a control to compare variability and 
significance of the clinical risk factors in the different models. 
GVHD prophylaxis with either cyclosporine A or tacrolimus was not applied for 
cohort selection as this would have introduced a strong time bias 
(cyclosporine A was largely replaced by tacrolimus in the late 1990’s when 
registry studies showed that this measure significantly reduced the incidence 
of acute GVHD). Donor age >30 years has a strong effect, but such limitation 
would have been practically unrealistic with regards to sample size and power. 
These data showed that a standard dose Cyclophosphamide/TBI regimen 
carried the lowest risk of acute GVHD, but this regimen was in practice not 
suitable for all patients, especially high-risk ones. TBI in itself was known to 
induce a higher risk for acute GVHD; however, in this analysis TBI showed 
only a trend in this direction. In summary, the data on the different 
conditioning regimen and their dosages indicate that a TBI versus non-TBI 
analysis carried a large number of confounders. 
Table 5 gives an overview of the models devised. Model 1 followed strictly the 
order of the effect size of the multivariate analysis. The second selection step 
(ATG given – HLA mismatched removed) already reduced the sample size 
below target (870 HSCT pairs). This is the model used as a control to study 
variability, significance and effect sizes of risk factors in the other models. 
In Model 2, the focus was on the conditioning regimen (ATG given – 
conditioning other than Cyclophosphamide/TBI), reaching a sample size of 
609 HSCT pairs, which would have been unfeasible. 
Model 3 concentrated on the underlying diagnosis (excluding ALL and CML – 
ATG given included), resulting in a sample size of 1054 HSCT pairs. A 
diagnosis-driven approach appeared the most feasible. However, concerns 
about this approach included the bundling of a multitude of diagnoses in the 
low-risk group (including malignancies and non-malignancies), versus two 
very different diagnoses in the high risk group (ALL, and CML – the latter one 
almost abandoned as a HSCT indication). Hence, a cohort selecting the two 
large, relevant acute leukaemia groups (ALL, ANLL) was included in the 
following comparison (Model 4). 
In model 1, donor age >30, cyclosporine-based GVHD prophylaxis, non-
Cy/TBI conditioning regimens and TBI remained the most important clinical 
confounders (table 6), despite high degree of HLA matching. Model 3 (table 7) 
favoured a multitude of low-risk diagnosis over full HLA matching, resulting in 
a wider variety of clinical confounders, which amongst donor age >30 years 
and cyclosporine-based GVHD prophylaxis also included non-
cyclophosphamide/TBI conditioning regimens, cyclophosphamide dose, TBI 
dose and HLA mismatching. 
In contrast, model 4 (table 8) displayed cyclosporine GVHD prophylaxis, 
donor age and HLA mismatching as the strongest confounders, while aspects 
of conditioning regimens and AB0 mismatch had a borderline significant role. 
As this model provided a sample size of adequate statistical power, it was 
chosen as the preferred model for cohort design. At this point, it was chosen 
to exclude HSCT pairs of a recipient age <4 years and >40 years. Leukaemia 
in infants and small children had very different causes and outcomes 
compared to the leukaemia of older children and adults. Also, an analysis of 
age groups (5 year intervals) showed a significant increase in risk of acute 
GVHD grade 2-4 with recipient age >40 (data not shown here). This reduced 
the number of eligible sample pairs to n=1000. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
risk factor 
frequency 
unselected 
No ATG 92.50%
HLA mismatch 62.50%
CyA GVHd 
prophylaxis 73.60%
Non-CyTBI regimen 74.10%
High risk diagnosis 54.40%
Donor age >30y 63%
Cy dose none/low 36.30%
TBI 80.30%
 
Table 4: Proportion of clinical risk factors in unselected HSCT 
population from the JMDP registry, 1993-2000 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Model  1 
ATG given 
removed 
HLA 
mismatched 
removed 
high risk 
diagnosis 
removed 
donor age 
>30y 
removed 
Cy dose 
none/low 
removed 
TBI 
removed
Remaining no 2469 2279 870 416 170 107 25
Model  2 
ATG given 
removed 
Non-CyTBI 
removed 
high risk 
diagnosis 
removed 
donor age 
>30y 
removed 
Cy dose 
none/low 
removed 
TBI 
removed
Remaining no 2469 2279 609 311 118 93 0
Model  3 
high risk 
diagnosis 
removed 
ATG given 
removed 
Non-CyTBI 
removed 
donor age 
>30y 
removed 
Cy dose 
none/low 
removed 
TBI 
removed
Remaining no 2469 1173 1054 311 118 93 0
Model 4 
ALL/ANLL 
selected 
ATG given 
removed 
Non-CyTBI 
removed 
donor age 
>30y 
removed 
Cy dose 
none/low 
removed 
TBI 
removed
  2469 1270 1209 273 99 82 0
 
Table 5: Modelling of hypothetic study cohorts. Model 1 represents a 5-locus HLA matched and ATG removed cohort, 
Model 2 is selected for homogeneity of conditioning regimens, while models 3 and 4 were selected by diagnosis (model 3: 
non-high risk diagnosis, model 4: ALL and ANLL selected). Model 4 was chosen for cohort design, as it provides the best 
statistical power. 
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Variables in the Equation  
log rank
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
univariate Lower Upper 
Cyclosporin v tacrolimus 0.003 .468 .148 10.047 1 .002 1.597 1.196 2.134 
Donor age <30 v >30 0.001 .016 .006 6.912 1 .009 1.016 1.004 1.029 
Cyclophosphamide+TBI v 
other 
0.021 -.387 .151 6.586 1 .010 .679 .505 .913 
TBI v noTBI 0.778 .319 .162 3.884 1 .049 1.375 1.002 1.889 
Cyclophosphamide no/low v 
standard/high dose 
0.104 -.008 .006 2.045 1 .153 .992 .981 1.003 
recipient age <40 v >40 0.368 .003 .003 .843 1 .359 1.003 .996 1.010 
donor age <40 v >40 0.06 .003 .004 .473 1 .492 1.003 .994 1.012 
abo matched v mismatched 0.62 .068 .119 .330 1 .566 1.071 .848 1.353 
Female donor into male recip 
v other 
0.977 -.082 .148 .309 1 .578 .921 .689 1.231 
high risk doagnosis v other 0.148 .040 .119 .113 1 .737 1.041 .824 1.315 
T-cell depletion v no T cell 
depletion 
0.94 -.178 1.012 .031 1 .860 .837 .115 6.083 
ATG given v no ATG NA     . 0a .       
5-locus HLA match v 
mismatch 
NA 
    
. 0a . 
      
 
Table 6: Multivariate analysis (binary logistic regression) of model 1 
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Variables in the Equation  
log rank
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
univariate Lower Upper 
Donor age <30 v >30 0.0001 .021 .006 14.678 1 .000 1.021 1.010 1.032 
Cyclosporin v tacrolimus 0.00001 .483 .126 14.631 1 .000 1.621 1.265 2.075 
Cyclophosphamide+TBI v 
other 
0.001 -.343 .135 6.467 1 .011 .710 .545 .924 
5-locus HLA match v 
mismatch 
0.013 -.254 .111 5.192 1 .023 .776 .624 .965 
Cyclophosphamide no/low v 
standard/high dose 
0.001 .248 .113 4.842 1 .028 1.282 1.027 1.599 
TBI dose standard v 
none/high 
0.009 -.024 .012 4.095 1 .043 .976 .954 .999 
TBI v noTBI 0.798 .218 .142 2.350 1 .125 1.244 .941 1.645 
Female donor into male recip 
v other 
0.376 .098 .137 .507 1 .476 1.103 .842 1.444 
recipient age <40 v >40 0.575 -.001 .003 .166 1 .684 .999 .993 1.005 
donor age <40 v >40 0.029 .001 .004 .084 1 .772 1.001 .993 1.009 
T-cell depletion v no T cell 
depletion 
0.846 -.147 1.011 .021 1 .885 .863 .119 6.265 
abo matched v mismatched 0.621 .009 .107 .008 1 .929 1.010 .819 1.245 
high risk doagnosis v other NA     . 0
a .       
ATG given v no ATG NA     . 0a .       
 
Table 7: multivariate analysis (binary logistic regression) of model 3 
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log rank
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
univariate Lower Upper 
5-locus HLA match v 
mismatch 
0.0001 -3.879 x10-1 .099 15.224 1 .000 .678 .558 .824 
Cyclosporin v tacrolimus 0.01 .308 .111 7.694 1 .006 1.361 1.095 1.691 
Donor age <30 v >30 0.0001 .013 .005 7.309 1 .007 1.013 1.004 1.023 
Cyclophosphamide no/low v 
standard/high dose 
0.009 -8.952 x10-3 .004 4.135 1 .042 .991 .983 1.000 
abo matched v mismatched 0.024 .192 .095 4.119 1 .042 1.212 1.007 1.460 
donor age <40 v >40 0.0001 .007 .004 3.944 1 .047 1.007 1.000 1.014 
high risk doagnosis v other 0.042 .167 .097 2.950 1 .086 1.181 .977 1.428 
Cyclophosphamide+TBI v 
other 
0.046 -2.150 x10-1 .126 2.906 1 .088 .807 .630 1.033 
Female donor into male recip 
v other 
0.6 -6.642 x10-2 .118 .320 1 .572 .936 .743 1.178 
recipient age <40 v >40 0.382 -1.168 x10-3 .003 .132 1 .717 .999 .993 1.005 
TBI v noTBI 0.785 -2.637 x10-2 .147 .032 1 .858 .974 .730 1.299 
T-cell depletion v no T cell 
depletion 
0.188 -1.009 x10-1 117.788 .007 1 .932 .000 2.269 x10-
105 
7.551 x10+95 
TBI dose standard v 
none/high 
0.976 .000 .011 .000 1 .986 1.000 .979 1.022 
ATG given v no ATG NA     . 0a .       
 
Table 8: multivariate analysis (binary logisitc regression) of model 4. This model was chosen as the preferred model for 
cohort design.
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Power calculation 
 
The power of association testing was calculated based on following 2x2 contingency tables. 
Given a microsatellite loci with k alleles, we created 2x2 contingency tables (table 3.1) for each indiv    
chi-squared test or Fisher’s exact test. 
Power for each pool was calculated, changing combinations of following parameters: 
• Odds ratio: 1.5, 2.0, and 2.5 
• Marker allele frequency: 0.03, 0.05, 0.10, and 0.30 
• Type I error rate: 0.05 
 
Power was calculated by using the software ‘PS: Power and Sample Size Calculation’.  
The statistical power was calculated in the total cells as the power to detect association in successiv       
association tests in pool 1 and pool 2 are significant (p<0.05). Therefore,  
Power (Total) = Power(Pool 1) * Power(Pool 2) 
The reason why we calculated the total power described above is that we select microsatellite mark    
successive pools 1 and 2 as candidates for next screening.  
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Supplementary file 2.3: 
 
Construction of final study cohorts and their 
characteristics 
 
 
1. Initial assessment of DNA sample number, quantity and 
concentration 
 
At this point it was decided to assess the actual availability of DNA samples 
for the chosen cohort model.  The first step was the identification of selected 
samples from the database and the sample collection, stored in different 
freezers at -70°C. 
The Japan marrow Donor Programme (JMDP) provided two large data files: 
One contained the clinical data, with a unique pair number (UPN) and a DNA 
sample number as identifiers. The second file contained the UPN, the DNA 
sample number, and a new DNA Bank number for each sample which was 
established recently when the JMDP DNA collections from different time 
periods were integrated into one system. Samples were in cardboard boxes in 
simple numerical order, representing the timely order of the transplantations. 
As an initial step, a data file of the intended cohort linking all sample 
information and clinical information together was created. From this data file 
lists were extracted to enable the identification of the targeted samples in the 
boxes. Original DNA samples of the intended cohorts were then obtained from 
the original collection and sorted into a separate set of boxes. Samples were 
separated into donors/recipients, ALL/ANLL, grades of GVHD 0-4, and finally 
in numerical order. 
At the same instance, the total volume of each sample was estimated by 
comparing its volume to standard test volumes pipetted in 50 μl intervals (50-
800 μl) into a set of identical test tubes. This later enabled an estimation of the 
total amount of DNA per original sample tube in ng/μg (see below). 
Missing and depleted samples were identified by simple visual inspection, and 
listed accordingly. Of the initial n=1000 pairs, n=112 were completely (both 
pair partners) or partially (one pair partner) depleted and therefore excluded. 
N=543 pairs had at least some DNA and were therefore extracted from the 
collection for further exploration. N=345 pairs had been transferred to Tokyo 
University (Research Group Professor Ogawa) to be included in a separate 
study. These samples were mostly fully HLA matched. Enquiries with 
Professor Ogawa’s team revealed that of the n=345 sample pairs, n=74 pairs 
were also depleted and excluded. 
This meaned that a maximum of only n=814 samples would be available for 
this study, with at that point an unknown amount of DNA, and at that point 
uncertainty when a larger proportion of fully HLA matched pairs would 
become available from Tokyo University. 
As time was constraint, a feasibility report explored the available options. 
 
 
1.1. Sample Availability and Study Scenario Feasibility 
 
Three different study scenarios, reflecting a spectrum between a genome 
wide scanning study and an individual genotyping study have been assessed 
for feasibility from a sample availability point of view (table 1). From the 
experience of previous microsatellite and SNP studies in the Tokai University 
laboratory, the required amount of DNA was estimated for these scenarios 
(table 2). 
 
 
 
 
 
 
 
 
 
 
 1 Genome wide scanning using approximately 30.000 MS markers 
2 Limited genome scanning of immune regulatory genes, approximately 
3000 MS markers  
3 Individual genotyping study using approximately 100 MS and SNP 
markers 
 
Table 1: Scenarios for feasibility assessment 
 
 
 
 
 
 
Study type Minimum DNA 
in microgr 
Genome wide, 30.000 MS 30 
Limited scanning, 3000 MS 5 
Individual genotyping, 100 MS/SNP 1 
 
Table 2: Estimates of DNA amount required 
 
 
 
 
 
 
 
 
 
 
 
 
1.2. Sample Concentration and volumes 
 
Samples available at Tokai University. All available samples of pairs from the 
initial ALL and ANLL cohorts (age stratified 4-40 years) were identified from 
different freezers at Tokai University. Available and unavailable samples were 
marked in a list, and the volume of the available samples was estimated using 
a simple model. 
The DNA concentration of 1086 (543 pairs) available samples was measured 
using the PICO Green method (described in the methods section). Total 
amount was calculated multiplying concentration with estimated volume.  
 
Tokyo University samples. Professor Ogawa kindly provided a table with 
concentration and quality data of all samples from this cohort he used in his 
study. These data did not contain any total volume estimations, therefore at 
this stage these have been estimated applying data available from the 
samples at Tokai University. We estimated samples with a concentration 
>5ng/µl to correspond with a total amount of >1µ, a concentration of >10ng/µg 
with a total amount of >5µg, and a concentration of >50ng/µl with a total 
amount of >30µ, accordingly. 
 
Summary of sample availability: Table 3 summarises the sample availability 
for the different study scenarios. The data for Tokai University samples are 
accurate, while the Tokyo University data are estimates for the reasons 
explained above. 
 
 
 
 
 
 
 
 
 
 
 
Scenario Samples 
available 
at Tokai 
HLA  
matched 
8/8 
Sample
s 
availabl
e at 
Tokyo 
HLA 
matche
d 8/8 
Total (HLA 
matched) 
Pairs 
require
d for 
scenari
o 
+ / - 
Genome wide 44 15 (34%) 41 27 
(66%) 
85  
(42, 49%) 
900+ -815 
Limited 
genome 
407 81 
(19.9%) 
271 195 
(72%) 
678  
(276, 40%) 
600+ / 
900+ 
+78/ 
-222 
Individual 
typing 
543 120 (22%) 271 195 
(72%) 
814  
(315, 38%) 
500+ +31
4 
 
Table 3: Summary of expected sample availability for different study 
approaches 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 1.3. Conclusions 
 
Genome wide scanning. This scenario was not feasible given the very limited 
number of pairs having a sufficient amount of DNA. Even extrapolated to the 
entire study population (2469 pairs), which would be completely unselected, 
no more than 330 pairs would have had a sufficient amount of DNA.  
 
Limited genome scanning. This approach was a feasible option if samples 
from Tokyo University were  included, and if the study would only implicate 
two screening steps. Application to JMDP for further sample access was 
required.  
 
Individual Genotyping. This was also a feasible option. The cohort size of over 
800 may even allow for some further selection. Although even with the 
samples available at Tokai University this could be feasible, the proportion of 
8/8 HLA matched pairs is low for a Japanese population (20%). A better 
approach would be to include the matched pairs from Tokyo University. 
 
The options were discussed between the team at Tokai University and JMDP 
in October 2007. All partners were keen on undertaking a genomic screening 
study, rather than a candidate gene association study. It was agreed to 
combine samples from Tokai and Tokyo Universities for a first screening step 
on pooled DNA, using microsatellite markers, on the selected cohort that was 
proposed. Access to further samples was approved, and samples and dataset 
prepared. The first screening would encompass HSCT between 1993 and 
2000, while the second cohort would include those between 2001 and 2005. 
 
 
 
 
 
 
2. Application of selection criteria for construction of a 
discovery and a confirmatory cohort 
 
HSCT pairs for the first cohort (time frame 1993-2000, n=460) were selected 
on the basis of criteria for model 4, and DNA availability. Criteria included: 
 
• Acute leukaemia (ALL or ANLL) 
• Myeloablative conditioning 
• T-cell replete 
• Full bone marrow HSCT 
• Recipient age 4-40 years 
• DNA availability for both donor and recipient sample of 5 µg. 
 
The second cohort (n=462) was selected by the same criteria. In order to 
reduce confounding by different grades of HLA mismatching, samples were 
paired for HLA matching between first and second cohort. In practice, for each 
of the 48 allele mismatch combinations, an equivalent was chosen from the 
2001-2005 stem population. 
All donor-recipient pairs were HLA-typed retrospectively to allele level at six 
loci (HLA-A, HLA-B, HLA-C, HLA-DRB1, HLA-DQB1, HLA-DPB1). The 
distribution of HLA matching of the confirmatory cohort was adjusted to that of 
the screening cohort by matching each sample of the screening cohort with a 
confirmatory cohort sample of the same HLA class or HLA class combination 
according to the previous literature (Sasazuki et al., 1998, Morishima et al., 
2002) and our own analyses of risk matches/mismatches within this study 
population (data not shown). 
Table 4 shows the demographic and clinical characteristics of the selected 
cohorts. There was no statistically significant difference between the cohorts 
in the baseline demographic criteria. Tables 5 and 6 specify the degree of 
HLA matching and mismatching. For reasons of comparison, we have used 
the NMDP/CIBMTR classification of HLA matching (Weisdorf et al., 2008). 
According to this classification, 357 HSCT pairs had an 8/8 (HLA A, B, C, 
DRB1) high-resolution allele match, 331 (35.9%) were partially matched (1 
mismatch within these HLA loci), and 234 (25.4%) were mismatched (two or 
more mismatches within these HLA loci). Considering the HLA DQ and DP 
loci also, only 78 HSCT pairs (8.5%) had a 12/12 allele match. In Japanese, 
HLA A, B, and C mismatches were associated with risk of acute GVHD. HLA 
C mismatches, however, had a protective effect on relapse (whilst HLA A, C 
and B mismatches associate with a risk of death) (Sasazuki et al., 1998, 
Morishima et al., 2002, Morishima et al., 2007b). More recent research had 
focused on specific allele mismatches, rather than mismatches in loci, aiming 
to identify non-permissive mismatches for acute GVHD (Kawase et al., 2007) 
or protective mismatches against relapse (Kawase et al., 2009), as well as 
risk HLA haplotypes for GVHD(Morishima et al., 2010). 
Multivariate analysis of the finally selected combined cohorts (n=922 HSCT 
pairs, table 7) showed that diagnosis, recipient age and HLA mismatch remain 
the most significant confounding variables. ALL had a higher risk for 
moderate-severe acute GVHD than ANLL. Recipient age below 10 years was 
carrying a higher GVHD risk. 8/8 loci HLA match is protective against GVHD. 
Relapse and major ABO mismatch still showed trends towards risk. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Screening Confirmation Difference p= 
Demographic        
Recipients 460 462   
Recipient gender Male 269 (58.48%) 289 (62.55%) n/s 
Recipient gender Female 191 (41.52%) 173 (37.45%) n/s 
Donor gender Male 267 (58.04%) 278 (60.17%) n/s 
Donor gender Female 193 (41.96%) 182 (39.39%) n/s 
Female donor to Male recipient transplant 102 (22.17%) 84 (18.18%) n/s 
Recipient age range 4-40 y 4-40 y n/s 
Recipient age mean 21.7 y 24.1 y n/s 
Donor age range 20-70y 19-51 y n/s 
Donor age mean 34 y 34.3 y n/s 
Clinical       
Diagnosis Acute lymphoblastic leukaemia 260 (56.52%) 254 (54.98%) n/s 
Diagnosis Acute non-ALL 200 (43.48%) 208 (45.02%) n/s 
High risk leukaemia 279 (60.65%) 246 (53.25%) <0.1 
HLA matching – 12/12 loci 41 (8.91%) 37 (8%) n/s 
HLA matching – 12/12 and 10/10 loci 160 (34.78%) 166 (35.93%) n/s 
HLA matching - GVHD risk mismatches 220 (47.83%) 229 (49.57%) n/s 
Conditioning – Cyclophosphamide + total 
body irradiation (TBI) 334 (72.61%) 322 (69.67%) n/s 
Conditioning – 
Busulphan/Cyclophosphamide or Busulphan 
based 53 (11.52%) 47 (10.17%) n/s 
Conditioning - TBI based 73 (15.87%) 83 (17.97%) n/s 
Conditioning - other 0 10 (2.16%) n/s 
GVHD prophylaxis – Cyclosporin A based 279 (60.65%) 154 (33.33%) <0.05 
GVHD prophylaxis - Tacrolimus based 177 (34.48%) 305 (66.02%) <0.05 
GVHD prophylaxis - other 4 (0.87%) 3 (0.65%) n/s 
Outcome      
Acute GVHD grade 0 124 (26.96%) 124 (26.84%) n/s 
Acute GVHD grade 1 153 (33.26%) 99 (21.42%) <0.05 
Acute GVHD grade 2 105 (22.83%) 143 (30.95%) <0.05 
Acute GVHD grade 3 50 (10.87%) 72 (15.58%) <0.05 
Acute GVHD grade 4 28 (6.09%) 24 (5.19%) n/s 
Chronic GVHD - none 244 (53.04%) 242 (52.38%) n/s 
Chronic GVHD - limited disease 71 (15.43%) 63 (13.64%) n/s 
Chronic GVHD - extensive disease 95 (20.65%) 106 (22.94%) n/s 
Chronic GVHD - unknown 50 (10.86%) 49 (10.6%) n/s 
Relapse 115 (25%) 110 (23.81%) n/s 
Survival – 100 days 395 (86.9%) 403 (87.23%) n/s 
Survival – 1 year 306 (66.52%) 312 (67.53%) n/s 
Survival – 3 years 245 (53.26%) 258 (55.84%) n/s 
 
Table 4: Population characteristics. p refers to statistically significant 
differences between the screening and confirmation cohorts. 
 
 
  alleles mismatched n= % 
Matched 8/8 HLA-DQ-DP 30 3.3 
n=357 (38.7%) HLA-DQ  6 0.7 
  HLA-DP 243 26.4 
  Fully matched 78 8.5 
Partially mismatched HLA-DR 1 0.1 
n=331 (35.9%) HLA-C-DQ  3 0.3 
  HLA-C-DP 92 10 
  HLA-A 11 1.2 
  HLA-C 25 2.7 
  HLA-DR-DQ-DP 104 11.3 
  HLA-DR-DQ  18 2 
  HLA-DR-DP 17 1.8 
  HLA-A-DQ 1 0.1 
  HLA-A-DP 41 4.4 
  HLA-B-DQ  1 0.1 
  HLA-B-DP 3 0.3 
  HLA-C-DQ-DP 11 1.2 
  HLA-B-DQ-DP 2 0.2 
  HLA-A-DQ-DP 1 0.1 
Mismatched HLA-C-DR 6 0.7 
n=234 (25.4%) HLA-A-DR 2 0.2 
  HLA-C-DR-DQ  11 1.2 
  HLA-C-DR-DP 14 1.5 
  HLA-B-DR-DQ 1 0.1 
  HLA-A-B-C-DR-DQ-DP 4 0.4 
  HLA-A-B-C-DQ-DP 2 0.2 
  HLA-A-B-C-DP 8 0.9 
  HLA-A-B-C 2 0.2 
  HLA-A-B-DR-DQ-DP 2 0.2 
  HLA-A-C-DR-DQ-DP 22 2.4 
  HLA-B-C-DR-DQ-DP 2 0.2 
  HLA-A-C-DR-DQ  3 0.3 
  HLA-A-C-DR-DP 5 0.5 
  HLA-A-C-DQ-DP 3 0.3 
  HLA-B-C-DR-DP 1 0.1 
  HLA-B-C-DQ-DP 1 0.1 
  HLA-A-B-DP 1 0.1 
  HLA-A-C-DQ  2 0.2 
  HLA-A-C-DP 22 2.4 
  HLA-B-C-DP 21 2.3 
  HLA-A-B 1 0.1 
  HLA-A-C 10 1.1 
  HLA-B-C 2 0.2 
  HLA-A-DR-DQ-DP 9 1 
  HLA-B-DR_DQ_DP 6 0.7 
  HLA-C-DR-DQ-DP 68 7.4 
  HLA-A-DR-DQ 2 0.2 
  HLA-A-DR-DP 1 0.1 
Total   922 100 
 
Table 5: Detailed HLA mismatch. All matches and mismatches are based 
on high-resolution allele typing of the HLA A, B, C, DRB1, DQB1 and 
DPB1 loci. The classification as outlined by NMDP/CIBMTR (Weisdorf et 
al., 2008), which focuses on the HLA A, B, C and DRB1 loci only, without 
consideration of HLA DQB1 or DPB1. Matched 8/8 refers to allele match 
at the loci HLA A, B, C and DRB1. Partially matched HSCT allows for one 
allele mismatch within this group, whereas mismatched HSCT has two 
or more allele mismatches within HLA A, B, C and DRB1. 340 HSCT pairs 
(36.9%) had an HLA C mismatch. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mismatch group group total n= % 
3 HLA I +3 HLA II 4 0.433839
3 HLA I +2 HLA II 2 0.21692
3 HLA I +1 HLA II 8 0.867679
3 HLA I + 0 HLA II 2 0.21692
2 HLA I +3 HLA II 26 2.819957
2 HLA I +2 HLA II 13 1.409978
2 HLA I +1 HLA II 46 4.989154
2 HLA I +0 HLA II 13 1.409978
1 HLA I +3 HLA II 83 9.002169
1 HLA I +2 HLA II 43 4.663774
1 HLA I +1 HLA II 149 16.16052
1 HLA I +0 HLA II 36 3.904555
3 HLA II 104 11.27983
2 HLA II 65 7.049892
1 HLA II 250 27.11497
fully matched 78 8.45987
Total 922 100
 
Table 6: Summary of HLA mismatch by HLA class I and II. 
 
 
 
 
 
 
 
 
 
 
 
 
 
   B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B) 
              Lower Upper 
ALL v ANLL 0.427 0.143 8.92683 1 0.0028101 1.533921 1.158557 2.0309
Recipient age group <10y -0.151 0.069 4.718277 1 0.0298436 0.859 0.748918 0.985262
8/8 HLA match -0.303 0.145 4.324559 1 0.0375661 0.738402 0.55483 0.982711
Relapse 0.307 0.163 3.553663 1 0.0594142 1.360325 0.987856 1.873232
ABO major mismatch 0.134 0.079 2.859926 1 0.0908117 1.143999 0.978841 1.337022
TBI given -0.346 0.215 2.595402 1 0.1071743 0.706824 0.463431 1.078048
Female to male transplant -0.458 0.288 2.531509 1 0.1115935 0.632177 0.359336 1.112182
Donor age >30 -0.229 0.159 2.060951 1 0.1511158 1.257433 0.919734 1.719125
Recipient sex 0.24 0.189 1.605145 1 0.2051755 1.271931 0.876715 1.845307
CyA GVHD prophylaxis 0.09855 0.138 0.505388 1 0.477142 1.103564 0.841017 1.448073
High risk leukaemia 0.797 1.166 0.467833 1 0.4939857 2.220418 0.225799 21.83475
Non-Cy-TBI conditioning 0.0796 0.156 0.259843 1 0.6102281 1.082876 0.797305 1.47073
Donor age >40y 0.024 1.442 0.000283 1 0.9865867 1.024548 0.060624 17.315
Donor sex -41.663 56841.8 5.37E-07 1 0.9994152 8.05E-19 0 . 
 
Table 7: Multivariate analysis of risk factors for grade 2-4 acute GVHD in the finally chosen combined study cohort. 
 
 
 
 
Gene Symbol status
3.8-1 included
3.8-1.2 included
3.8-1.3 included
3.8-1.4 included
3.8-1.5 included
A2M excluded - no marker
A2ML1 included
A4GALT included
AATK included
ABCA1 included
ABCB1 included
ABCC1 included
ABCC11 included
ABCC4 included
ABCF1 included
ABCG2 included
ABO included
ACACA included
ACE included
ACE2 included
ACHE included - new MS design
ACOT11 included
ACOT8 included
ACTA1 included
ACTB included
ACTC1 included
ACTG1 included
ACTL7B included
ACTN1 included
ACTN2 included
ACTN3 included
ADA included
ADAM10 included
ADAM12 included
ADAM17 included
ADAM8 included
ADAMTS13 included
ADAT2 included
ADD1 included
ADIPOQ excluded - no marker
ADK included
ADM included
ADORA1 included
ADORA2 included
ADORA3 included
AGER included
AGPAT1 included
AGPAT4 included
AGPS included
AGTR1 included
AGTR2 included
AGTRL1 included
AICDA included
AIF1 included
AIFM1 included
AIM2 included
AIP included
AIRE included
AKAP12 included
AKAP13 included
AKAP7 included
AKT1 included
AKT2 included
AKT3 included
AKTIP included - new MS design
ALAS2 included
ALCAM included
ALK included
ALKBH1 included
ALKBH2 included
ALKBH3 included
ALKBH4 included
ALKBH5 included
ALKBH6 included
ALKBH7 included
ALKBH8 included
ALOX12 included
ALOX12B included
ALOX15 included
ALOX15B included
ALOX5 included
ALOX5AP included
ANGPT1 included
ANGPT2 included
ANGPTL1 included
ANK1 included
ANK2 included
ANK3 included
ANKDD1A included
ANKRD6 included
ANP32B included
ANPEP included
ANXA1 included
ANXA2 included
ANXA5 included
APAF1 included
APBB1IP included
APC included
APEX1 included
API5 included
APLN included
APOL6 included
APOM included
APS included
AQP1 included
AR included
AREG included
ARG1 included
ARHGDIA included
ARHGDIB included
ARID1B included
ARL6IP5 included
ARRB1 included
ARRB2 included
ART1 included
ART4 included
ARTN included
ARTS1 included
ASB1 included
ASCL1 included
ASPM included
ATBF1 included
ATF1 included
ATF3 included
ATF4 included
ATF5 included
ATG5 included
ATM included
ATP10A included
ATP1B3 included
ATP6V1G2 included
ATXN1 included
AVEN included
AXIN1 included
AXIN2 included
AZGP1 included
AZU1 included
B2M included
B3GALNT1 included
B3GALT4 included
B3GAT1 included
B3GNT3 included
BAALC included
BAD included
BAG1 included
BAG2 included
BAG3 included
BAG4 included
BAG5 included
BAGE included
BAGE2 included
BAGE3 included
BAGE4 included
BAGE5 included
BAI3 included
BAIAP2L1 included
BAK1 included
BANK1 included
BAT1 included
BAT2 included
BAT2, BAT2 GT, BAT2included
BAT3 included
BAT4 included
BAT5 included
BAX included
BAZ1A included
BBC3 included
BCAM included
BCAP31 included
BCAS2 included
BCKDHB included
BCL10 included
BCL2 included
BCL2A1 included
BCL2L1 included
BCL2L10 included
BCL2L11 included
BCL2L12 included
BCL2L13 included
BCL2L14 included
BCL2L2 included
BCL3 included
BCR included
BDKRB1 included
BDKRB2 included
BDNF included
BFAR excluded - no marker
BGN included
BID included
BIK included
BIRC2 included
BIRC3 included
BIRC4 included
BIRC5 included
BIRC6 included
BIRC7 included
BIRC8 included
BLK included
BLM included
BLNK included
BLR1 included
BLVRB included
BMI-1 included
BMP2 included
BMP3 included
BMP4 included
BMP5 included
BMP6 included
BMP7 included
BMPR1A included
BMPR1B included
BMPR2 included
BMX included
BNIP1 included
BNIP2 included
BNIP3 included
BNIP3L included
BNIP3P excluded - no marker
BNIPL included
BOK included
BPI included
BRCA2 included
BRD2 included
BRD8 included
BRDG1 included
BRF1 included
BSG included
BST1 included
BST2 included
BTAF included
BTBD9 included
BTC included
BTG1 included
BTG3 included
BTK included
BTLA included
BTN3A1 included
BTNL2 included
BTRC included
BUB3 included
BXDC1 included
C10orf26 included
C19orf10 included
C1QA included
C1QB included
C1QBP included
C1QG included
C1QL1 included
C1QL2 included
C1QL3 included
C1QL4 included
C1QR included
C1QTNF2 included
C1QTNF3 included
C1QTNF4 included
C1QTNF5 included
C1QTNF6 included
C1QTNF7 included
C1R excluded - no marker
C1RL included
C1S excluded - no marker
C2 excluded - no marker
C2orf47 included
C3 included
C3AR1 included
C4A excluded - no marker
C4B excluded - no marker
C4BPA included
C4BPB included
C5 included
C5R1 included
C6 included
C6orf10 included
C6orf12 included
C6orf123 included
C6orf134 included
C6orf136 included
C6orf138 included
C6orf15 included
C6orf174,KIAA0408 included
C6orf18 included
C6orf204 included
C6orf205 included
C6orf21 included
C6orf25 included
C6orf27 included
C6orf47 included
C6orf48 included
C6orf65 included
C6orf91 included
C7 included
C8A included
C8B included
C8G included
C9 included
CABIN1 included
CADM1 included
CADM2 included
CADM3 included
CADM4 included
CALR included
CAMK2D included
CAMK4 included
CAMP excluded - no marker
CANX included
CARD10 included
CARD11 included
CARD14 included
CARD6 included
CARD8 included
CARD9 excluded - no marker
CARM1 included
CASP1 included
CASP10 included
CASP12 included
CASP14 included
CASP2 included
CASP3 excluded - no marker
CASP4 included
CASP5 included
CASP7 included
CASP8 included
CASP8AP2 included
CASP9 included
CAT included
CAV1 included
CBFA2T2 included
CBFB included
CBL excluded - no marker
CBLB included
CCBP2 included
CCL1 included
CCL11 included
CCL13 included
CCL14 included
CCL15 included
CCL16 included
CCL17 included
CCL18 included
CCL19 included
CCL2 included
CCL20 included
CCL21 included
CCL22 included
CCL23 included
CCL24 included
CCL25 included
CCL26 included
CCL27 included
CCL28 included
CCL3 included
CCL3L1 excluded - no marker
CCL3L3 excluded - no marker
CCL4 included
CCL4L1 excluded - no marker
CCL4L2 excluded - no marker
CCL5 included
CCL7 included
CCL8 included
CCNA1 included
CCNA2 included
CCNB1 included
CCNB1IP1 included
CCNB2 included
CCNB3 included
CCNC excluded - no marker
CCND1 included
CCND2 included
CCND3 included
CCNE1 included
CCNE2 included
CCNG1 included
CCNH included
CCR1 included
CCR10 included
CCR2 included
CCR3 included
CCR4 included
CCR5 included
CCR6 included
CCR7 included
CCR8 included
CCR9 included
CCRL1 included
CCRL2 included
CCRN4L included
CD109 included
CD139 excluded - unknown location
CD14 included
CD151 included
CD160 included
CD163 excluded - no marker
CD164 included
CD164L1 included
CD177 included
CD19 excluded - no marker
CD1A included
CD1B included
CD1C included
CD1D included
CD1E included
CD2 included
CD200 included
CD200R1 included
CD200R2 included
CD207 included
CD209 included
CD22 included
CD24 included
CD244 included
CD245 excluded - unknown location
CD274 included
CD276 included
CD28 included
CD2AP included
CD2BP2 included
CD300A included
CD300C included
CD300E included
CD300LB included
CD300LF included
CD302 included
CD320 excluded - no marker
CD33 included
CD33L3 included
CD34 included
CD36 included
CD37 included
CD38 included
CD3D included
CD3E included
CD3EAP included
CD3G included
CD3Z included
CD4 included
CD40LG included
CD44 included
CD47 included
CD48 included
CD5 included
CD53 included
CD55 included
CD58 included
CD59 included
CD5L included
CD6 excluded - no marker
CD63 included
CD65 excluded - unknown location
CD68 included
CD69 included
CD7 included
Cd72 included
CD74 included
CD79A included
CD79B included
CD80 included
CD81 included
CD82 included
CD83 included
CD84 included
CD86 included
CD8A included
CD8B1 included
CD8BP excluded - no marker
CD9 included
CD96 included
CD97 included
CD99 excluded - no marker
CD99L2 included
CDA included
CDC2 included
CDC20 included
CDC25A excluded - no marker
CDC25B included
CDC37 included
CDC42 excluded - no marker
CDC42EP5 included
CDCP1 included
CDH1 included
CDH2 included
CDH5 included
CDK10 excluded - no marker
CDK2 included
CDK3 excluded - no marker
CDK4 included
CDK5 included
CDK6 included
CDK7 included
CDK8 included
CDK9 included
CDKAL1 included
CDKN1A included
CDKN1B excluded - no marker
CDKN1C included
CDKN2A included
CDKN2B included
CDKN2C included
CDKN2D included
CDKN3 included
CDO1 included
CDSN included
CDw12 excluded - unknown location
CDW52 included
CDW93 included
CDX2 included
CEACAM1 included
CEACAM3 included
CEACAM5 included
CEACAM6 included
CEACAM8 included
CEBPA included
CEBPE included
CEBPG included
CENPF included
CENPM included
CERK included
CES1 included
CFB excluded - no marker
CFD included
CFDP1 included
CFH included
CFHR1 included
CFHR2 included
CFHR3 included
CFHR4 included
CFHR5 included
CFI included
CFL1 included
CFL2 included
CFLAR included
CFP included
CGA included
CGB included
CHAF1B included
CHERP included
CHES1 included
CHI3L2 included
CHLI included
CHMP1B included
CHMP2A included
CHMP2B included
CHMP4A included
CHMP4B included
CHMP4C included
CHMP5 included
CHMP6 included
CHMP7 included
CHRAC1 included
CHUK included
CIDEA excluded - no marker
CIITA included
CIR included
CISH excluded - no marker
CITED2 included
CKLF included
CKS1B included
CKS2 included
CLASP1 included
CLASP2 included
CLC included
CLCF1 included
CLDN23 included
CLDN3 included
CLEC12A included
CLEC1A included
CLEC1B included
CLEC2B included
CLEC3A included
CLEC4a included
CLEC4C included
CLEC4D included
CLEC4E included
CLEC4M included
CLEC5A included
CLEC6A excluded - no marker
CLEC7A included
CLECSF10A included
CLIC1 included
CLIP1 included
CLIP2 included
CLK1 included
CLU included
CMKLR1 included
CMTM1 included
CMTM2 included
CMTM3 included
CMTM4 included
CMTM5 included
CMTM6 included
CMTM7 included
CMTM8 included
CNTN2 included
COL11A2 included
COL14A1 included
COL1A1 included
COL1A2 included
COL21A1 included
COL3A1 included
COL4A1 included
COL4A2 included
COL4A3 included
COL4A3BP included
COL4A4 included
COL4A5 included
COL4A6 included
COL5A1 included
COL5A2 included
COL5A3 included
COL6A1 included
COL6A2 included
COL6A3 included
COLEC12 included
COP1 included
CORO1A excluded - no marker
COX2 included
CPE included
CPS1 included
CR1 included
CR1L included
CR2 included
CRADD included
CREB1 included
CREBBP included
CREBL1 excluded - no marker
CREM included
CRF1R included
CRF2R included
CRH included
CRHR2 included
CRKL included
CRLF1 included
CRLF2 excluded - no marker
CRLF3 included
CRP included
CSDA included
CSF1 included
CSF1R included
CSF2 included
CSF2RA excluded - no marker
CSF2RB included
CSF3 included
CSF3R included
CSH1 included
CSK included
CSNK1A1 included
CSNK2B included
CSPG2 included
CST1 included
CTDSP2 included
CTDSPL included
CTF1 included
CTGF included
CTLA4 included
CTNNB1 included
CTNS included
CTPS included
CTSA included
CTSB included
CTSD included
CTSF included
CTSG included
CTSH included
CTSK included
CTSL1 included
CTSS included
CTSZ included
CUGBP2 included
CUL4A included
CX3CL1 included
CX3CR1 included
CXCL1 included
CXCL10 included
CXCL11 included
CXCL12 included
CXCL13 included
CXCL14 included
CXCL16 included
CXCL2 included
CXCL3 included
CXCL5 included
CXCL6 included
CXCL9 included
CXCR3 included
CXCR4 included
CXCR6 included
CXCR7 included
CYBA included
CYBB included
CYCS included
CYP11A1 included
CYP11B1 included
CYP11B2 included
CYP17A1 included
CYP19A1 included
CYP1A1 included
CYP1A2 included
CYP1B1 included
CYP20A1 included
CYP21A2 excluded - no marker
CYP26A1 included
CYP26B1 included
CYP26C1 included
CYP27A1 included
CYP27B1 included
CYP2A13 included
CYP2A6 included
CYP2A7 included
CYP2B included
CYP2B6 included
CYP2C18 included
CYP2C19 included - new MS design
CYP2C8 included
CYP2C9 included - new MS design
CYP2D6 included
CYP2E1 included
CYP2F1 included
CYP2J2 included
CYP2R1 included
CYP2S1 included
CYP2U1 included
CYP2W1 included
CYP39A1 included
CYP3A11 included
CYP3A3 included
CYP3A43 included
CYP3A5 included
CYP3A7 included
CYP46A1 included
CYP4B1 included
CYP4F11 included
CYP4F12 included
CYP4F2 included
CYP4F3 included
CYP4F8 included
CYP4V2 included
CYP4X1 included
CYP4Z1 included
CYP51A1 included
CYP7A1 included
CYP7B1 included
CYP8B1 included
CYSLTR1 included
CYSLTR2 included
CYTL1 included
D6S2723E included
DAAM2 included
DAD1 included
DAG1 included
DAP included
DAPK1 included
DAPK2 included
DAPK3 excluded - no marker
DARC included
DAXX included
DCAL1 included
DCD included
DCLRE1C included
DCN included
DCTN2 included
DDAH1 included
DDAH2 included
DDR1 included
DDX1 included
DDX10 included
DDX11 included
DDX12 included
DDX17 included
DDX18 included
DDX19A included
DDX19B included
DDX20 included
DDX21 included
DDX23 included
DDX24 included
DDX25 included
DDX26B included
DDX27 excluded - no marker
DDX28 included
DDX31 included
DDX39 included
DDX3X included
DDX3Y included - new MS design
DDX4 included
DDX41 included
DDX42 included
DDX43 included
DDX46 included
DDX47 included
DDX49 included
DDX5 included
DDX50 included
DDX51 excluded - no marker
DDX52 included
DDX53 included
DDX54 included
DDX55 included
DDX56 included
DDX58 included
DDX59 included
DDX6 included
DEDD included
DEDD2 included
DEFA1 included
DEFA1A3 included
DEFA3 included
DEFA4 included
DEFA5 included
DEFA6 included
DEFB1 included
DEFB4 excluded - no marker
DFB103A excluded - no marker
DFB103B excluded - no marker
DFB104A excluded - no marker
DFB104B excluded - no marker
DFB105A excluded - no marker
DFB106A excluded - no marker
DFB106B excluded - no marker
DFB107A excluded - no marker
DFB107B included
DFB108B included
DFB110 included
DFB111 included
DFB112 included
DFB113 included
DFB114 included
DFB115 included
DFB116 included
DFB118 excluded - no marker
DFB119 excluded - no marker
DFB121 excluded - no marker
DFB122 included
DFB123 included
DFB124 included
DFB125 included
DFB126 included
DFB127 included
DFB128 included
DFB129 included
DFB130 included
DFB131 included
DFB133 excluded - unknown location
DFB134 included
DFB136 included
DFB137 included
DFFA included
DFFB included
DGCR2 included
DGK alpha included
DGKB included
DHFR included
DHH included
DHX15 included
DHX16 included
DHX29 included
DHX30 included
DHX32 included
DHX33 included
DHX34 included
DHX35 included
DHX36 included
DHX37 included
DHX38 included
DHX40 included
DHX57 included
DHX8 included
DHX9 included
DIABLO included
DIAPH2 included
DIDO1 included
DIP included
DKC1 included
DLG5 included
DLL1 included
DLL4 included
DLX3 included
DMBT1 included
DNAH8 included
DNAM1 included
DNASE1 included
DNM2 included
DNTT included
DOCK2 included
DOK1 included
DOK2 included
DOM3Z excluded - no marker
DPCR1 included
DPP4 included
DQX1 included
DRG1 included
DRG2 included
DSCAM included
DSP included
DSS1 included
DTX1 included
DUSP1 included
DUSP10 included
DUSP11 included
DUSP12 included
DUSP13 included
DUSP14 included
DUSP15 included
DUSP16 included
DUSP18 included
DUSP19 included
DUSP2 included
DUSP21 included
DUSP22 included
DUSP23 included
DUSP26 included
DUSP28 included
DUSP3 included
DUSP4 included
DUSP5 included
DUSP6 included
DUSP7 included
DUSP8 excluded - no marker
DUSP9 included
DVL1 included
DYRK1A included
DYRK1B included
DYRK2 included
DYRK3 included
DYRK4 included
E2F4 included
EBF included
EBF2 included
EBI2 included
EBI3 included
ECGF1 included
ECSIT included
EDA included
EDAR included
EDARADD included
EDG1 included
EDN1 included
EDN2 excluded - no marker
EDN3 included
EEA1 included
EEF1A1 included
EEF1A2 included
EEF2 included
EFHC1 included
EFNA1 included
EGF1 included
EGFL11 included
EGFL8 included
EGFR included
EGFTM7 included
EGR1 included
EGR2 included
EGR3 included
EHMT2 excluded - no marker
EIF4A3 included
EIF4G2 excluded - no marker
ELA1 included
ELA2 included
ELA2A included
ELA2B included
ELA3A excluded - no marker
ELA3B excluded - no marker
ELF3 included
ELK4 included
ELMO1 included
EMP3 included
EMR1 included
EMR2 included
EMR3 included
ENC1 included
ENG included
ENPEP included
ENPP3 included
ENSG00000179038 included
ENSG00000204345 included
ENTPD1 included
EOMES included
EP300 included
EPB41L2 included
EPHA1 included
EPHA7 included
EPHB1 included
EPHB2 included
EPHX1 included
EPO included
EPOR included
EPX included
ERBB2 included
ERC2 included
ERCC1 included
ERCC2 included
ERCC5 included
EREG included
ERG included
ERGIC2 included
ERMAP included
ESR1 included
ESR2 included
ESRRA included
ESRRB included
ESRRG included
ETF1P1 included
ETV1 included
ETV6 included
EVI1 included
EXO1 included
EZH2 included
F2 included
F2R included
F2RL1 included
F2RL2 included
F3 included
F5 included
F8 included
FABP3 included
FABP4 included
FABP5 included
FADD included
FAF1 included
FAIM3 included
FAM120B included
FAT10 included
FBXW7 included
FCAMR included
FCAR included
FCER1A included
FCER1G included
FCER2 included
FCGR1A included
FCGR1B included - new MS design
FCGR1C excluded - unknown location
FCGR2A included - new MS design
FCGR2B included
FCGR2C included
FCGR3A included
FCGR3B included
FCGRT included - new MS design
FCN1 included
FCN2 included
FCN3 excluded - no marker
FCRL1 included
FCRL2 included
FCRL3 included
FCRL4 included
FCRL5 included
FCRL6 included
FCRLA included
FCRLB included
FEEL-2 included
FEN1 included
FES included
FGA included
FGB included
FGC included
FGF1 included
FGF10 included
FGF11 included
FGF12 included
FGF13 included
FGF14 included
FGF16 included
FGF17 included
FGF18 excluded - no marker
FGF19 included
FGF2 included
FGF20 included
FGF21 included
FGF22 included
FGF23 included
FGF3 included
FGF4 included
FGF5 included
FGF6 included
FGF7 included
FGF8 included
FGF9 included
FGFR1 included
FGFR2 included
FGFR3 included
FGFR4 included
FGG included
FGL2 included
FGR included
FIGF included
FKBP10 included
FKBP11 included
FKBP14 excluded - no marker
FKBP15 included
FKBP1A included
FKBP1AC included
FKBP1B included
FKBP2 included
FKBP3 included
FKBP4 included
FKBP5 included
FKBP8 included
FKBP9 included
FKBP9L included
FKBPL included
FLJ20105 included
FLJ43763 included
FLJ45422 included
FLJ46831 included
FLOT1 included
FLT1 included
FLT3 included
FLT3LG included
FLT4 included
FMOD included
FN1 included
FOS included
FOSB included
FOSL1 included
FOXA1 included
FOXA2 included
FOXA3 included
FOXB1 included
FOXB2 included
FOXC1 included
FOXC2 included
FOXD1 included
FOXD2 included
FOXD3 included
FOXD4 excluded - no marker
FOXE1 included
FOXE3 included
FOXF1 included
FOXF2 included
FOXG1B included
FOXG1C included
FOXH1 excluded - no marker
FOXI2 included
FOXJ1 included
FOXJ2 included
FOXJ3 included
FOXK1 included
FOXK2 included
FOXL1 included
FOXL2 included
FOXN1 included
FOXN2 included
FOXN4 included
FOXO1A included
FOXO1B included
FOXO3A included
FOXO3B included
FOXP1 included
FOXP2 included
FOXP3 included
FOXP4 included
FOXQ1 included
FOXR1 included
FOXR2 excluded - no marker
FPR1 included
FPRL1 included
FRAP1 included
FRK included
FRZB included
FSHR included
FURIN included
FUT1 included
FUT3 included
FUT4 included
FYB included
FYN included
FZD10 included
FZD4 included
FZD9 included
G6PD included
GAB2 included
GADD45B included
GADD45G included
GALC included
GAPDH included
GAS1 included
GAS2 included
GATA1 included
GATA2 included
GATA3 included
GATA4 included
GATA5 included
GATA6 included
GBA excluded - no marker
GBP1 included
GBP2 included
GBP3 included
GBP5 included
GCA included
GCG included
GCK included
GCLC included
GCLM included
GCNT2 included
GDF15 included
GEM included
GFRAL included
GGT1 included
GGT2 included
GH1 included
GH2 included
GHR included
GINS2 included
GLI1 included
GLI2 included
GLI3 included
GMDS included
GNA13 included
GNAI1 included
GNAI2 included
GNAI3 included
GNAL included
GNB3 included
GNL1 included
GNL2 included
GNLY included
GNRH1 included
GNRHR included
GP1BA included
GP1BB included
GP5 included
GP9 included
GPATCH3 included
GPHA2 included
GPHB5 included
GPNMB included
GPR107 included
GPR109B included
GPR132 included
GPR4 included
GPR44 included
GPR56 included
GPR65 included
GPR68 included
GPS2 included
GPSM3 included
GPX1 included
GPX2 included
GPX3 included
GPX4 excluded - no marker
GRAIL included
GRAP2 included
GRB10 included
GRB2 included
GRIK1 included
GRIK2 included
GSK3A included
GSK3B included
GSR included
GSST1 included
GSTA1 included
GSTM1 included
GSTP1 included
GTF2A1 included
GTF2A2 included
GTF2B included
GTF2E1 included
GTF2E2 included
GTF2F1 included
GTF2F2 included
GTF2F2L included
GTF2H1 included
GTF2H2 excluded - no marker
GTF2H3 included
GTF2H4 included
GTF2H5 included
GTF2I included
GTF2IRD1 included
GTF2IRD2 excluded - no marker
GTF2IRD2B included
GTF3A included
GTF3C1 included
GTF3C2 included
GTF3C3 included
GTF3C4 included
GTF3C5 included
GTF3C6 included
GUSB included
GYPA included
GYPB included
GYPC included
GYPE excluded - no marker
GZMA included
GZMB included - new MS design
GZMH excluded - no marker
GZMK included
GZMM included
H2AFX included
H2AFZ included
HACE1 included
HAMP included
HAT1 included
HAVCR2 included
HBA1 included
HBA2 included
HBD included
HBEGF included
hcg-2038200 included
HCG2P1 excluded - unknown location
HCG2P2 excluded - unknown location
HCG2P4 included
HCG2P6 included
HCG2P7 included
HCG2P8 included
HCG4 included
HCG4P1 excluded - unknown location
HCG4P10 included
HCG4P11 excluded - unknown location
HCG4P2 excluded - unknown location
HCG4P3 included
HCG4P4 included
HCG4P5 included
HCG4P6 included
HCG4P7 included
HCG4P8 included
HCG4P9 excluded - unknown location
HCG5P8 included
HCG8 excluded - unknown location
HCG9 included
HCG9P1 excluded - unknown location
HCG9P2 excluded - unknown location
HCG9P3 excluded - unknown location
HCG9P5 included
HCGVIII-2 included
HCK included
HCP5 included
HCP5P10 included
HCP5P12 included
HCP5P13 included
HCP5P14 included
HCP5P15 included
HCP5P2 included
HCP5P3 included
HDAC1 included
HDAC10 excluded - no marker
HDAC2 included
HDAC3 included
HDAC4 included
HDAC5 included
HDAC6 included
HDAC7A included
HDAC8 included
HDAC9 included
HDC included
HDGFL1 included
HECA included
HERC5 included
HERC6 included
HESX1 included
HEXA included
HFE included
HGF included
HISPPD2A included
HIST2H2AA4 excluded - no marker
HIST2H4A excluded - no marker
HIST3H2A included
HIVEP2 included
HLA-16 included
HLA-21 included
HLA-75 included
HLA-80 included
HLA-90 included
HLA-A included
HLA-B excluded - no marker
HLABC-CA included
HLA-C excluded - no marker
HLA-DMA included
HLA-DMB included
HLA-DOA included
HLA-DOB included
HLA-DPA1 included
HLA-DPA3 excluded - unknown location
HLA-DPB1 included
HLA-DPB2 included
HLA-DQA1 included
HLA-DQA2 included
HLA-DQB1 included - new MS design
HLA-DQB2 included
HLA-DQB3 excluded - unknown location
HLA-DRA included
HLA-DRB1 included
HLA-DRB2 included
HLA-DRB3 included
HLA-DRB4 included
HLA-DRB5 included
HLA-DRB9 included
HLA-E included
HLA-F included
HLA-G included
HLA-H included
HLA-J included
HLA-K included
HLA-L included
HLA-N excluded - unknown location
HLA-S excluded - unknown location
HLA-X excluded - unknown location
HLA-Z excluded - unknown location
HLF included
HLTF included
HLX1 included
HM13 included
HMGB1 included
HMGCR included
HMGN3 included
HMHA1 included
HMHB1 included
HMMR included
HMOX1 included
HMOX2 included
HMSD included
HNF4A included
HNF4G included
HNMT included
HNRPF excluded - no marker
HOXA5 included
HOXB4 included
HOXC11 included
HOXD10 included
HPA included
HPGD included
HPS3 included
HRB included
HRH1 included
HRH2 included
HRH3 included
HRH4 included
HRK included
HS3ST1 included
HSCT included
HSD17B8 included
HSD3B1 included
HSH2D included
HSP B8 included
HSP90AA1 included
HSP90AB1 included
HSP90B1 included
HSPA1A included
HSPA1B included
HSPA1L included
HSPA4 included
HSPA5 included
HSPB1 included
HSPD1 included
HSPG2 included
HTATIP included
HTN3 included
HTR1B included
HTR2A included
HTR2B included
HTRA2 included
IBD2 included
IBD3 included
IBD5 included
ICAM1 included
ICAM2 included
ICAM3 included
ICAM4 included
ICAM5 included
ICEBERG included
ICOS included
ICOSLG included
IER3 included
IFI16 included
IFI27 included
IFI30 included
IFI35 included
IFI44 included
IFIH1 included
IFIT1 included
IFIT1L included
IFIT2 included
IFIT3 included
IFIT5 included
IFITM1 included
IFITM4P included
IFNA1 included
IFNA10 included
IFNA13 included
IFNA14 included
IFNA16 included
IFNA17 included
IFNA2 included
IFNA21 included
IFNA4 included
IFNA5 included
IFNA6 included
IFNA7 included
IFNA8 included
IFNAR1 included
IFNAR2 included
IFNB1 included
IFNB3 excluded - unknown location
IFNE1 included
IFNG included - new MS design
IFNGR1 included
IFNGR2 included
IFNK included
IFNR excluded - unknown location
IFNW1 included
IFRD1 included
IFRG28 included
IGF1 included
IGF1R included
IGF2 included
IGF2R included
IGFBP2 included
IGHD1-20 included
IGJ included
IGKV1-12 included
IGLL1 included
IGSF1 included
IGSF10 included
IGSF11 included
IGSF2 included
IGSF21 included
IGSF22 included
IGSF3 included
IGSF5 included
IGSF6 included
IGSF8 included
IGSF9 included
IGSF9B included
IHH included
IKBKAP included
IKBKB included
IKBKE included
IKBKG included
IKZF1 included
IL10 included - new MS design
IL10RA included
IL10RB included
IL11 included
IL11RA included
IL12A included
IL12B included
IL12RB1 included
IL12RB2 included
IL13 included
IL13RA1 included
IL13RA2 included
IL15 included
IL15RA included
IL15RB excluded - unknown location
IL16 included
IL17A included
IL17B included
IL17C included
IL17D included
IL17F included
IL17RA included
IL17RB included
IL17RC included
IL17RD included
IL17RE included
IL18 included
IL18BP included
IL18R1 included
IL18RAP included
IL19 included
IL1A included
IL1B included - new MS design
IL1F10 included
IL1F5 included
IL1F7 included - new MS design
IL1F8 included
IL1F9 included
IL1R1 included
IL1R2 included
IL1RAP included
IL1RAPL1 included
IL1RAPL2 included
IL1RL1 included - new MS design
IL1RL2 included
IL1RN included
IL2 included
IL20 included
IL20RA included
IL20RB included
IL21 included
IL21R included
IL22 included
IL22RA1 included
IL22RA2 included
IL23A included
IL23R included
IL24 included
IL25 included
IL26 included
IL27 included
IL27RA included
IL28A included
IL28B included
IL28RA included
IL29 included
IL2RA included
IL2RB included
IL2RG included
IL3 included
IL31 included
IL31RA included
IL32 included
IL33 included
IL3RA excluded - no marker
IL4 included
IL4I1 included
IL4R included
IL5 included
IL5RA included
IL6 included
IL6R included - new MS design
IL6RL1 included
IL6ST included
IL6STP included
IL7 included
IL7R included
IL8 included - new MS design
IL8RA included
IL8RB included
IL9 included
IL9R excluded - no marker
ILF2 included
ILF3 included
ILK included
INCA included
INDO included
INHA included
INHBA included
INHBB included
INHBC included
INHBE included
INPP5D included
INSR included
IRAK1 included
IRAK1BP1 included
IRAK2 included
IRAK3 included
IRAK4 included
IRF1 included
IRF2 included
IRF3 included
IRF4 included
IRF5 included
IRF6 included
IRF7 excluded - no marker
IRF8 included
IRGC included
IRGM included
ISG15 included
ISG20 included
ISGF3G included
ITCH included
ITFG1 included
ITGA1 included
ITGA10 included
ITGA11 included
ITGA2 included
ITGA2B included
ITGA3 included
ITGA4 included
ITGA5 included
ITGA6 included
ITGA7 included
ITGA8 included
ITGA9 included
ITGAD included
ITGAE included
ITGAL included
ITGAM included - new MS design
ITGAV included
ITGAW excluded - unknown location
ITGAX included
ITGB1 included
ITGB1BP1 included
ITGB2 included
ITGB3 included
ITGB4 included
ITGB5 included
ITGB6 included
ITGB7 included
ITGB8 included
ITGBL1 included
ITK included
ITPKB included
ITPR1 included
ITPR2 included
ITPR3 included
JAG1 included
JAG2 included
JAK1 included
JAK2 included
JAK3 included
JAM1 included
JAM2 included
JAM3 included
JARID1C included
JARID1D included
JMJD1A included
JUN included
JUNB included
JUND included
KCNQ5,LOC642681 included
KDR included
KEAP1 included
KEL included
KHDRBS1 included
KHDRBS2 included
KIAA0020 included
KIAA1949 included
KIFC1 included
KIR2DL1 included
KIR2DL2 included
KIR2DL3 included
KIR2DL4 excluded - unknown location
KIR2DL5A excluded - unknown location
KIR2DL5B excluded - unknown location
KIR2DP1 included
KIR2DS1 included
KIR2DS2 included
KIR2DS3 included
KIR2DS4 included
KIR2DS5 included
KIR3DL1 included
KIR3DL2 included
KIR3DL3 included
KIR3DP1 included
KIR3DS1 included
KIR3DX1 included
KIT included
KITLG included
KLF10 included
KLF11 included
KLF2 included
KLF7 included
KLHL32 included
KLRA1 included
KLRB1 included
KLRC1 included
KLRC2 included
KLRC3 included
KLRD1 included
KLRF1 included
KLRG1 included
KLRG2 included
KLRK1 included
KNG1 included
KPNA2 excluded - no marker
KRAS included
KRT15 included
KRT18 included
KRT34 included
KRT35 included
KRT5 included
KRT6A included
KRT8 included
L1CAM included
LAG3 included
LAIR1 included
LAIR2 included
LAMA1 included
LAMA2 included
LAMA3 included
LAMA4 included
LAMA5 included
LAMB1 included
LAMB2 excluded - no marker
LAMB2L excluded - unknown location
LAMB3 included
LAMB4 included
LAMC1 excluded - no marker
LAMC2 included
LAMC3 included
LAMP1 included
LAMP2 included
LAMP3 included
LAT excluded - no marker
LAT2 included
LATS2 included
LAX1 included
LBP included
LCK included
LCN2 included
LCP2 included
LCT included
LDLR included
LEAP2 included
LECT1 included
LECT2 included
LEDGF included
LENG8 included
LEP included
LEPR included
LGALS1 excluded - no marker
LGALS12 included
LGALS13 included
LGALS14 included
LGALS2 included
LGALS3 included
LGALS3BP included
LGALS4 included
LGALS5 excluded - unknown location
LGALS6 excluded - unknown location
LGALS7 included
LGALS8 included
LGALS9 included
LGMN included
LGP2 included
LHB included
LHCGR included
LHFPL2 included
LIF included
LIFR included
LIG1 included
LIG4 included
LILRA1 included
LILRA2 included
LILRA3 included
LILRA4 included
LILRA5 included
LILRA6 included
LILRB1 included
LILRB2 included
LILRB3 included
LILRB4 included
LILRB5 included
LILRP1 included
LILRP2 included
LIPA included
LITAF included
LMAN1 included
LOC401252 included
LOC441792 included
LOC643962 included
LOC645740 included
LOC646702 included
LOC728195 excluded - no marker
LPC2 included
LPO excluded - no marker
LRDD excluded - no marker
LRP1 excluded - no marker
LRP5 included
LRP6 included
LRRC16 included
LRRC23 included
LSM2 included
LSP1 included
LST1 included
LTA included
LTA4H included
LTB included
LTB4DH included
LTB4R2 included
LTBP1 included
LTBP3 included
LTBR included
LTC4S included
LTF included
LY64 included
LY6E included
LY6G5B included
LY6G5C included
LY6G6C included
LY6G6D included
LY6G6E included
LY75 included
LY86 included
LY9 included
LY96 included
LYG2 included
LYL1 included
LYN included
LYPLA2P1 included
LYST included
LYZ excluded - no marker
MAD2LI included
MADCAM1 included
MADD included
MAF included
MALT1 included
MAML2 included
MAN1A1 included
MAP2K1 included
MAP2K2 included
MAP2K3 included
MAP2K4 included
MAP2K5 included
MAP2K6 included
MAP2K7 included
MAP3K1 included
MAP3K10 included
MAP3K11 included
MAP3K12 excluded - no marker
MAP3K13 included
MAP3K14 included
MAP3K15 included
MAP3K2 included
MAP3K3 included
MAP3K4 included
MAP3K5 included
MAP3K6 excluded - no marker
MAP3K7 included
MAP3K7IP1 included
MAP3K7IP2 included
MAP3K8 included
MAP3K9 included
MAP4K1 included
MAP4K2 included
MAP4K3 included
MAP4K4 included
MAP4K5 included
MAP7 included
MAPK1 included
MAPK10 included
MAPK11 excluded - no marker
MAPK12 excluded - no marker
MAPK13 included
MAPK14 included
MAPK15 included
MAPK3 excluded - no marker
MAPK4 included
MAPK6 included
MAPK7 included
MAPK8 included
MAPK8IP1 included
MAPK8IP2 included
MAPK8IP3 included
MAPK9 included
MAPKAPK2 included
MAPKAPK3 excluded - no marker
MARCH7_ included
MARCO included
MASP1 included
MASP2 included
MBL2 included
MBP included
MC1R included
MC3R included
MC4R included
MC5R included
MCAM included
MCCD1 included
MCL1 included
MCM2 included
MCM6 included
MCP included
MCRS1 included
MDC1 included
MDFIC included
MDM2 included
MDM4 included
MEF2D included
MEFV included
MELK included
MERTK included
MET included
MFI2 included
MGA included
MGMT included
MICA included
MICB included
MICC included
MICD included
MICE included
MICF included
MICG included
MIF included
MINK included
MITF included
MKLN1 included
MLLT7 included
MME included
MMP1 included
MMP10 included
MMP11 included
MMP12 included
MMP13 included
MMP14 included
MMP15 included
MMP16 included
MMP17 excluded - no marker
MMP19 included
MMP2 included
MMP20 included
MMP21 included
MMP23A included
MMP23B included
MMP24 included
MMP25 included
MMP26 included
MMP27 included
MMP28 included
MMP3 included
MMP7 included
MMP8 included
MMP9 included
MN1 included
MOAP1 included
MOG included
MOXD1 included
MPG included
MPL included
MPO included - new MS design
MPS1 included
MPZL1 included
MR1 included
MRC1 included
MRC1L1 included
MRC2 included
MRE11A included
MRPL28 included
MRPS18B included
MS4A1 included
MS4A3 included
MS4A5 included
MSH5 included
MSR1 included
MST1 included
MST1R included
MT1A included
MT1F included
MT1G included
MT1X included
MT2A included
MT3 included
MTHFR included
MTMR11 included
MTRR included
MUC1 included
MVP included
MX1 included
MX2 included
MXD1 included
MYC included
MYCL1 included
MYCN included
MyD88 included - new MS design
MYH11 included
MYH2 included
MYH9 included
MYLK included
MYO1F included
MYO1G included
MZF1 included
NAB2 included
NACA included
NAIP excluded - no marker
NAT2 included
NBS1 included
NCAM1 included
NCAPH included
NCF1 included
NCF2 included
NCF3 included
NCKAP1L included
NCOA3 included
NCOA7 included
NCOR1 included
NCOR2 included
NCR1 included
NCR2 included
NCR3 included
NDUFA2 included
NDUFS3 included
NEDD9 included
NEU1 excluded - no marker
NFAM1 included
NFAT5 included
NFATC1 included
NFATC2 included
NFATC2IP excluded - no marker
NFATC3 included
NFATC4 included
NFE2 included
NFE2L1 included
NFIL3 included
NFKB1 included
NFKB2 included
NFKBIA included
NFKBIB included
NFKBIE included
NFKBIL1 included
NFKBIZ included
NFX1 included
NFYA included
NFYB included
NFYC included
NGFB included
NGFR included
NHLH1 included
NID1 included
NKAIN2 included
NKIRAS1 included
NKTR included
NLRC3 included
NLRC4 included
NLRC5 included
NLRP1 included
NLRP10 included
NLRP11 included
NLRP12 included
NLRP13 included
NLRP14 included
NLRP2 included
NLRP2P included
NLRP3 included
NLRP3P included
NLRP4 included
NLRP5 included
NLRP6 included
NLRP7 included
NLRP8 included
NLRP9 included
NLRP9P included
NLRX1 excluded - no marker
NME1 included
NMI included
NOD1 included
NOD2 included
NOL3 included
NOS1 included
NOS2A included
NOS3 included
NOSIP included
NOTCH1 included
NOTCH2 included
NOTCH3 included
NOTCH4 included - new MS design
NOV included
NOX1 included
NOX3 included
NOX4 included
NOXA1 included - new MS design
NOXO1 included
NPM1 excluded - no marker
NPPA included
NPPB included
NPTN included
NPY included
NPY2R included
NQO1 included
NR0B1 included
NR0B2 included
NR1D1 included
NR1D2 included
NR1H2 included
NR1H3 included
NR1H4 included
NR1I2 included
NR1I3 included
NR2C1 included
NR2C2 included
NR2D1 included
NR2E1 included
NR2E3 included
NR2F1 included
NR2F2 included
NR2F6 included
NR3C1 included
NR3C2 included
NR4A1 excluded - no marker
NR4A2 included
NR4A3 included
NR5A1 included
NR5A2 included
NR6A1 included
NRAS included
NRF1 included
NRG2 included
NRG3 included
NRG4 included
NRM included
NRP1 included
NSMAF included
NT5E included
NUMA1 included
NUSAP1 included
NXF1 included
OAS1 included
OAS2 excluded - no marker
OAS3 included
OASL included
OFCC1 included
OLIG2 included
OLR1 included
OPMR1 included
OPRK1 included
OPRL1 included
ORM1 included
ORM2 included
OSCAR included
OSM included
P2RX1 included
P2RX2 included
P2RX3 included
P2RX4 included
P2RX5 included
P2RX6 included
P2RX7 included
P2RY1 included
P2RY11 included
P2RY13 included
P2RY14 included
P2RY2 included
P2RY4 included
P2RY5 included
P2RY6 included
P5-04 included
P5-05 included
P5-07 included
P5-09 included
P5-11 included
PACRG included
PACSIN1 included
PADI4 included
PAFAH1B1 included
PAFAH1B2 excluded - no marker
PAFAH1B3 included
PAFAH2 included
PAG1 included
PAK1 included
PAK2 included
PAK3 included
PARK2 included
PARP1 included
PARVG included
PAWR included
PBEF1 included
PBX2 included
PCDHB16 included
PCDHB5 included
PCMT1 included
PCOLN3 excluded - no marker
PDCD1 included
PDCD10 included
PDCD1LG2 included
PDCD2 included
PDCD5 included
PDCD6 included
PDCD6IP included
PDCD7 included
PDE10A included
PDE4A included
PDE4B included
PDE4C included
PDE4D included
PDGFA excluded - no marker
PDGFB included
PDGFRA included
PDGFRB included
PDIA3 included - new MS design
PDK1 included
PDK2 included
PDRG1 included
PDXK included
PEA15 excluded - no marker
PECAM1 included
PELI1 included
PELI2 included
PELI3 included
PEX6 included
PF4 included
PF4V1 included
PFDN6 included
PFN1 included
PGDS included
PGLYRP1 included
PGLYRP2 included
PGLYRP3 included
PGLYRP4 included
PGR included
PHACTR1 included
PHACTR2 included
PHLDA2 excluded - no marker
PI3 included
PI4K2B included
PIAS4 included
PIGF included
PIK3C2A included
PIK3C2B included
PIK3C2G included
PIK3C3 included
PIK3CA included
PIK3CB included
PIK3CD included
PIK3CG included
PIK3R1 included
PIK3R2 included
PIK3R3 included
PIK3R4 included
PIK3R5 included
PIK4CA excluded - no marker
PIK4CB included
PILB included
PILRA included
PIM1 included
PIN1 included
PINX1 included
PKD1 included
PKD2 included
PKD3 included
PKHD1 included
PLA1A included
PLA2G10 excluded - no marker
PLA2G2D included
PLA2G6 included
PLA2G7 included
PLA2R1 included
PLAA included
PLAU included
PLAUR included
PLCB2 included
PLCB3 included
PLCG1 included
PLCL2 included
PLEC1 excluded - no marker
PLEKHB1 included
PLEKHH2 included
PLK1 included
PLK3 included
PLK4 included
PLXNA1 included
PLXNB1 included
PLXNC1 included
PLXND1 included
PMS2L3 included
POLA2 included
POLD3 included
POLDIP3 included
POLE3 included
POMC included
POP1 included
POT1 included
POU2AF1 included
POU2F3 included
POU4F1 included
POU5F1 included
PPAP2B included
PPARA included
PPARD included
PPARG included
PPBP included
PPIA included
PPIAL included
PPIAL4 included
PPIB included
PPIC included
PPID included
PPIE included
PPIF included
PPIG included
PPIH included
PPIL1 included
PPIL2 included
PPIL3 included
PPIL4 included
PPIL5 included
PPIL6 included
PPIP9 included
PPP1R10 included
PPP1R11 included
PPP1R16A included
PPP1R16B excluded - no marker
PPP1R2P1 included
PPP2R4 included
PPP3CA included
PPP3CB included
PPP3CC included
PPP3R1 included
PPP3R2 included
PPT2 included
PRAME included
PRDM1 included
PRDX4 included
PRDX6 included
PRF1 included
PRG1 included
PRG2 included
PRG4 included
PRKAA2 included
PRKACA included
PRKACB included
PRKACG included
PRKCA included
PRKCB1 included
PRKCD included
PRKCG included
PRKCH included
PRKCI included
PRKCQ included
PRKCZ included
PRKD1 included
PRKDC included
PRKRIR included
PRL included
PRLR included
PRM3 included
PRMT1 included
PRMT2 included
PRMT3 included
PRMT5 included
PRMT6 included
PRMT7 included
PRMT8 included
PRNP included
PROC included
PROCR included
PROM1 included
Protein S included
PRPF40A included
PRR3 included
PRRT1 included
PRSS16 included
PRTN3 included
PSCD1 included
PSCDBP included
PSG1 included
PSMB1 included
PSMB10 included
PSMB5 included
PSMB6 included
PSMB7 included
PSMB8 included
PSMB9 included
PSMC6 included
PSME1 included
PSME2 included
PSME3 included
PSMF1 included
PSORS1C1 included
PSORS1C2 included
PSTPIP1 included
PTAFR included
PTCH1 included
PTDSR included
PTDSS1 included
PTEN included
PTGDR included
PTGDS included
PTGER1 included
PTGER2 included
PTGER3 included
PTGER4 included
PTGES included
PTGES2 included
PTGFR included
PTGFRN included
PTGIR excluded - no marker
PTGIS included
PTGS1 included
PTGS2 included
PTH included
PTHLH included
PTHR1 included
PTK 2B included
PTK2 included
PTK7 included
PTP4A1 included
PTP4A2 included
PTP4A3 included
PTPMT1 included
PTPN1 included
PTPN11 included
PTPN12 included
PTPN13 included
PTPN14 included
PTPN18 included
PTPN2 included
PTPN20A excluded - no marker
PTPN20B excluded - no marker
PTPN20C included
PTPN21 included
PTPN22 included
PTPN23 included
PTPN3 included
PTPN4 included
PTPN5 included
PTPN6 included
PTPN7 included
PTPN9 included
PTPRA included
PTPRB included
PTPRC included
PTPRCAP included
PTPRD included
PTPRE included
PTPRF included
PTPRG included
PTPRH included
PTPRJ included
PTPRK included
PTPRM included
PTPRN included
PTPRN2 included
PTPRO included
PTPRQ included
PTPRR included
PTPRS included
PTPRT included
PTPRU included
PTPRV included
PTPRZ1 included
PTX3 included
PVR included
PVRL1 included
PVRL2 included
PVRL3 included
PXDN included
PXMP3 included
PYCARD excluded - no marker
PYDC1 excluded - no marker
QSCN6 included
RAB19 included
RAB3D included
RAC1 included
RAC2 included
RAC3 excluded - no marker
RAD23A included
RAD50 included
RAD51 included - new MS design
RAD9A included
RAD9B included
RAE1 included
RAET1E included
RAF1 excluded - no marker
RAG1 included
RAG2 included
RAGE included
RALBP1 included
RAN included
RANBP2 included
RANP1 included
RAP1A included
RAPGEF1 included
RARA included
RARB included
RARG included
RARRES2 included
RARRES3 included
RASA1 included
RASGRP1 included
RASGRP2 included
RASGRP3 included
RASSF5 included
RAX included
RBPSUH included
RDBP excluded - no marker
RDX included
REL included
RELA included
RELB included
RELN included
RFC1 included
RFX1 included
RFX2 included
RFX3 included
RFX4 included
RFX5 included
RFXANK included
RFXAP included
RFXDC1 included
RGL2 included
RGS13 included
RHAG included
RHBDL2 included
RHCE included
RHD included
RHOA included
RHOC included
RHOD included
RHOH included
RING1 included
RIPK1 included
RIPK2 included
RIPK3 included
RNASE6 included
RNASE7 included
RNASEH2A included
RND2 excluded - no marker
RNF39 included
RNF4 included
RNF5 included
RNF7 included
RNMT included
ROCK1 included
ROCK2 included
RORA included
RORB included
RORC included
RPA3 included
RPL23AP1 included
RPL32P1 included
RPL7AP7 included
RPLP1 included
RPP21 included
RPS18 included
RPS4X included
RPS4Y1 included - new MS design
RPS6KA2 included
RRM1 included
RSAD2 included
RUNX1 included
RUNX1T1 included
RUNX2 included
RUNX3 included
RXRA excluded - no marker
RXRB included
RXRG included
S100A11 included
S100A12 included
S100A4 included
S100A6 included
S100A8 included
S100A9 included
SAA1 included
SAA2 included
SAA3P included
SAMHD1 included
SAP18 included
SARM1 included
SATB1 excluded - no marker
SCAP1 included
SCARA3 included
SCARA5 included
SCARB1 included
SCARB2 included
SCARF1 included
SCARF2 included
SCGB3A1 included
SCL11A1 included
SCMH1 included
SCML2 included
SCYE1 included
SDC1 included
SDC2 included
SDC3 included
SDC4 included
SDCBP included
SDF2 excluded - no marker
SDF2L1 included
SEC61A1 included
SEC61A2 included
SEC61B included
SECTM1 included
SELE included
SELL included
SELP included
SELPLG included
SEMA3E included
SEMA4D included
SEMA7A included
SEMG1 included
SEPHS2 included
SEPT2 included
SERPINA2 included
SERPINB2 included
SERPINB8 included
SERPINB9 included
SERPINC1 included
SERPINE1 included
SERPING1 included
SET included
SFRS2IP included
SFTBA1B excluded - no marker
SFTPA1 included
SFTPB included
SFTPD included
SGK included
SH2D1A included
SH2D1B included
SH2D2A included
SH3KBP1 included
SHB included
SHH included
SHMT1 excluded - no marker
SHMT2 included - new MS design
SIGIRR included - new MS design
SIGLEC1 included
SIGLEC10 included
SIGLEC5 included
SIGLEC6 included
SIGLEC7 included
SIGLEC8 included
SIGLEC9 included
SILV included
SIM1 included
SIPA1 included
SIRPA included
SIRPB1 included
SIRPB2 included
SIT1 included
SIVA included
SKAP1 included
SKIV2L excluded - no marker
SKP2 included
SLAMF1 included
SLAMF6 included
SLAMF7 included
SLAMF8 included
SLAMF9 included
SLC14A1 included
SLC19A1 included - new MS design
SLC1A5 included
SLC22A1 included
SLC22A4 included
SLC22A5 included
SLC25A19 included
SLC39A7 included
SLC3A2 included
SLC40A1 included
SLC44A1 included
SLC44A4 excluded - no marker
SLC4A1 included
SLC6A4 included
SLC7A5 included
SLC9A1 included
SLC9A2 included
SLC9A3 included
SLC9A4 included
SLC9A5 included
SLC9A6 included
SLC9A7 included
SLC9A8 included
SLC9A9 included
SLPI included
SMAD1 included
SMAD3 included
SMAD7 included
SMARCA1 included
SMARCA2 included
SMARCA4 included
SMARCA5 included
SMARCAL1 included
SMC3 included
SMG6 included
SMO included
SNFT included
SNRP70 included
SNRPN included
SNX9 included
SOBP included
SOCS1 included
SOCS2 included
SOCS3 included
SOCS4 included
SOCS5 included
SOCS6 included
SOCS6/CBLN2 included
SOCS7 excluded - no marker
SOD1 included - new MS design
SOD2 included
SOD3 included
SORL1 included
SOS1 included
SOX13 included
SP1 included
SP110 included
SP3 included
SPEN included
SPHK1 included
SPHK2 included
SPI1 included
SPN included
SPP1 included
SQSTM1 included
SRC included
SREBF1 included
SRPK1 included
SRPK2 included
SRPK3 excluded - no marker
SST included
SSTR1 included
SSTR2 included
ST3GAL5 included
ST6GAL1 included
ST8SIA6 included
STAB1 included
STAT1 included
STAT2 included
STAT3 included
STAT4 included
STAT5A included
STAT5B included
STAT6 included
STIL included
STK17A included
STK17B included
STK19 excluded - no marker
STK3 included
STK38 included
STK4 included
STT3B included
STX11 included
STXBP5 included
STYX included
SULT1C2 included
SUMO1 excluded - no marker
SUV39H1 included
SVEP1/MUSK included
SYK included
SYN3/LARGE included
SYNE1 included
SYT7 included
SYTL1 excluded - no marker
Tac1 included
TACC1 included
TACSTD1 included
TAF13 included
TAF9 included
TAL1 included
TAL2 included
TA-NFKBH included
TANK included
TAP1 included
TAP2 included
TAPBP included
TBK1 excluded - no marker
TBL1X included
TBL1XR1 included
TBL1Y included
TBP included
TBX21 included
TBXAR2 included
TBXAS1 included
TCAM2 included
TCD@ included
TCF12 included
TCF19 included
TCF3 included
TCF4 included
TCF7 excluded - no marker
TCF8 included
TCIRG1 included
TCN2 included
TEC included
TEK included
TEP1 included
TERC included
TERT included
TFAP2C included
TFB1M included
TFDP2 included
TFF1 excluded - no marker
TFF2 excluded - no marker
TFF3 included
TFRC included
TGFA included
TGFB1 included - new MS design
TGFB2 included
TGFB3 included
TGFBR1 included
TGFBR2 included
TGFBR3 included
TGIF1 included
TGM3 included
THBD included
THBS1 included
THOC1 included
THPO included
THRA included
THRB included
THY1 included
TIAF1 included
TICAM1 included
TIMELESS included
TIMP1 included
TIMP2 included
TIMP3 included
TIMP4 included
TIRAP included
TIRG1 included
TLE3 included
TLN1 included
TLR1 included
TLR10 included - new MS design
TLR11 excluded - unknown location
TLR12 excluded - unknown location
TLR13 excluded - unknown location
TLR2 included
TLR3 included
TLR4 included
TLR5 included
TLR6 included
TLR7 included
TLR8 included
TLR9 included
TM7SF4 included
TMC8 included
TMEM142A excluded - no marker
TMEM158 included
TMEM37 included
TMPO included
TMPRSS11D included
TMSB4X included
TMSB4Y included
TNC included
TNF included
TNFa included
TNFAIP3 included
TNFb included
TNFd included
TNFRSF10A included - new MS design
TNFRSF10B included
TNFRSF10C included - new MS design
TNFRSF10D included - new MS design
TNFRSF11A included
TNFRSF11B included
TNFRSF12A included
TNFRSF13B included
TNFRSF13C included
TNFRSF14 included - new MS design
TNFRSF17 included - new MS design
TNFRSF18 included - new MS design
TNFRSF19 included
TNFRSF19L included
TNFRSF1A included
TNFRSF1B included
TNFRSF21 included
TNFRSF25 included
TNFRSF4 excluded - no marker
TNFRSF5 included
TNFRSF6 included
TNFRSF6B included
TNFRSF7 included
TNFRSF8 included
TNFRSF9 included
TNFSF10 included
TNFSF11 included
TNFSF12 included
TNFSF12-13 included
TNFSF13 included
TNFSF13B included
TNFSF14 included
TNFSF15 included
TNFSF18 included
TNFSF4 included
TNFSF6 included
TNFSF7 included
TNFSF8 included
TNFSF9 included
TNN included
TNR included
TNXB excluded - no marker
TOLLIP excluded - no marker
TOP2A included
TOR3A included
TP35 included
TP73L included
TPMT included
TPT1 included
TRA@ included
TRADD included
TRAF1 included
TRAF2 included
TRAF3 included
TRAF3IP1 included
TRAF4 excluded - no marker
TRAF5 included
TRAF6 included
TRAF7 included
TRAM1 included
TRAM2 included
TRAT1 included
TRB@ included
TREM1 included
TREM2 included
TREML1 included
TREML2 included
TREML3 included
TREML4 included
TRERF1 included
TRG@ included
TRH included
TRHR included
TRIM10 included
TRIM15 included
TRIM22 included
TRIM25 included
TRIM26 included
TRIM31 included
TRIM39 included
TRIM40 included
TRIM59 included
TRPM2 included
TRPV1 included
TRPV2 included
TSC22D3 included
TSHB included
TSHR included
TSLP included
TSPAN7 included
TSPYL2 included
TTRAP included
TTYH1 included
TUBA1 included
TUBA1A included
TUBB included
TWIST1 included
TXK included
TXN included
TXNDC included
TXNRD1 included
TYK2 included
TYMS included
TYR included
TYROBP included
UBB excluded - no marker
UBC included
UBD included
UBE2D1 included
UBE2L6 included
UBE2N included
UBE2V1 included
UCN included
UGCG included
UGT1A1 included
UGT1A9 included
UGT2B17 included
UGT2B28 included
UGT2B7 included
ULBP1 included
ULBP2 included
ULBP3 included
UNC5CL included
UNC84B included
UNC93B1 included
UNG included
Unknown included
USF1 included
USF2 included
USP18 excluded - no marker
USP9Y included
UTRN included
UTY included
UVRAG included
VARS included
VARSL included
VASP included
VAV1 included
VAV2 included
VAV3 included
VCAM1 included
VDR included
VEGFA included
VEGFB included
VEGFC included
VIM included
VIP included
VISA included
VNN1 included
VPREB1 included
VPS24 included
VPS52 included
VRK2 included
VTCN1 included
VTN included
VWF included
WAS included
WASF1 included
WASF3 included
WDR46 included
WFDC12 included
WIPF1 included
WNT1 included
WNT3 included
WNT4 included
WNT5A included
WRNIP1 included
WT1 excluded - no marker
WTAP included
XBP1 included
XCL1 included
XCL2 included
XCR1 included
XDH included
XG included
XK included
XPA included
XPC included
XRCC1 included
XRCC3 included
XRCC5 included
YES1 included
YWHA2 included
YWHAQ included
YY1 included
ZAP70 included
ZBTB12 excluded - no marker
ZBTB22 included
ZBTB32 included
ZBTB7 excluded - no marker
ZFAND3 included
ZFP36 included
ZNF192 included
ZNF193 included
ZNF3 included
ZNF451 included
ZNRD1 included
Gene Symbol Aliases Gene location (genecard) Chromosome
TNFRSF18 GITR Chromosome 1:1,128,751-1,131,952 1
DVL1 DSH Chromosome 1:1,260,521-1,274,623 1
MMP23B Chromosome 1:1,557,337-1,623,109 1
PRKCZ PKCξ Chromosome 1:1,971,769-2,106,694 1
DFFA Chromosome 1:10,439,166-10,455,200 1
VCAM1 CD106 Chromosome 1:100,957,885-100,977,189 1
EDG1 sphingosine-1-phosphate Chromosome 1:101,475,032-101,479,662 1
PRMT6 PRMT6 Chromosome 1:107,400,824-107,403,439 1
VAV3 Chromosome 1:107,915,305-108,309,108 1
VAV3 Chromosome 1:107,915,305-108,309,108 1
VAV3 Chromosome 1:107,915,305-108,309,108 1
VAV3 Chromosome 1:107,915,305-108,309,108 1
TAF13 POLII Chromosome 1:109,406,644-109,420,147 1
GNAI3 G protein alpha i3 Chromosome 1:109,892,824-109,938,498 1
GNAI3 G protein alpha i3 Chromosome 1:109,892,824-109,938,498 1
MASP2 MAp19 Chromosome 1:11,009,167-11,029,877 1
MASP2 MAp19 Chromosome 1:11,009,167-11,029,877 1
FRAP1 mTOR Chromosome 1:11,089,179-11,245,176 1
FRAP1 mTOR Chromosome 1:11,089,179-11,245,176 1
FRAP1 mTOR Chromosome 1:11,089,179-11,245,176 1
MTHFR Chromosome 1:11,768,367-11,788,702 1
NPPA ANP Chromosome 1:11,828,353-11,830,989 1
CSF1 M-CSF Chromosome 1:110,254,778-110,275,144 1
CD53 Chromosome 1:111,215,344-111,244,081 1
CD53 Chromosome 1:111,215,344-111,244,081 1
CHI3L2 Chi3I3 Chromosome 1:111,571,804-111,587,585 1
ADORA3 Adenosin receptor 3 Chromosome 1:111,827,493-111,908,107 1
ADORA3 Adenosin receptor 3 Chromosome 1:111,827,493-111,908,107 1
RAP1A Rap-1 Chromosome 1:111,886,363-112,060,836 1
RHOC RhoC Chromosome 1:113,045,251-113,051,579 1
PTPN22 Chromosome 1:114,092,981-114,215,904 1
PTPN22 Chromosome 1:114,092,981-114,215,904 1
BCAS2 Chromosome 1:114,911,701-114,925,788 1
NRAS Ras Chromosome 1:115,048,613-115,102,147 1
TSHB TSHB Chromosome 1:115,373,938-115,378,464 1
NGFB NGFB Chromosome 1:115,630,060-115,682,380 1
CD58 LFA-3 Chromosome 1:116,858,680-116,915,184 1
IGSF3 Chromosome 1:116,918,554-117,011,898 1
CD2 LFA-2 Chromosome 1:117,098,530-117,113,374 1
PTGFRN CD315, prostaglandin rec Chromosome 1:117,254,202-117,334,503 1
PTGFRN CD315, prostaglandin rec Chromosome 1:117,254,202-117,334,503 1
VTCN1 Chromosome 1:117,487,732-117,555,079 1
VTCN1 Chromosome 1:117,487,732-117,555,079 1
HSD3B1 3 beta hydroxysteroid dehChromosome 1:119,851,356-119,859,200) 1
TNFRSF8 CD30 Chromosome 1:12,046,021-12,126,851 1
TNFRSF1B CD120b Chromosome 1:12,149,647-12,191,872 1
NOTCH2 Chromosome 1:120,255,699-120,413,799 1
FCGR1B Chromosome 1:120,728,502-120,737,460 1
FCGR1B Chromosome 1:120,728,502-120,737,460 1
ITGA10 Chromosome 1:144,236,248-144,255,225 1
CD160 Chromosome 1:144,407,155-144,426,971 1
PPIAL4 Chromosome 1:146,418,535-146,422,374 1
FCGR1A CD64 Chromosome 1:146,567,361-146,577,147 1
MTMR11 CRA Chromosome 1:148,167,168-148,175,396 1
MCL1 Chromosome 1:148,813,658-148,818,760 1
CTSS Cathepsin S Chromosome 1:148,969,175-149,005,057 1
CTSK cathepsin K Chromosome 1:149,035,311-149,047,436 1
CTSK cathepsin K Chromosome 1:149,035,311-149,047,436 1
BNIPL Chromosome 1:149,275,670-149,286,700 1
PIK4CB Chromosome 1:149,531,037-149,566,815 1
ELA2A Chromosome 1:15,655,811-15,690,482 1
ELA2B Chromosome 1:15,655,811-15,690,482 1
RORC RORg, NR1F3 Chromosome 1:150,039,364-150,070,972 1
S100A11 S100a11 Chromosome 1:150,271,606-150,276,135 1
PGLYRP3 PGRP-Ia Chromosome 1:151,536,962-151,549,818 1
S100A12 S100A12 Chromosome 1:151,612,808-151,614,749 1
S100A6 S100a6 Chromosome 1:151,773,699-151,775,344 1
S100A4 S100a4 Chromosome 1:151,782,713-151,789,236 1
ILF2 Chromosome 1:151,900,905-151,910,148 1
ILF2 Chromosome 1:151,900,905-151,910,148 1
MPS1 Chromosome 1:152,229,853-152,231,250 1
MPS1 Chromosome 1:152,229,853-152,231,250 1
IL6R CD126 Chromosome 1:152,644,293-152,708,550 1
IL6R CD126 Chromosome 1:152,644,293-152,708,550 1
CKS1B Chromosome 1:153,213,753-153,218,348 1
EFNA1 Ephrin A1 Chromosome 1:153,366,560-153,374,010 1
MUC1 MUC1 Chromosome 1:153,424,924-153,429,330 1
MEF2D Chromosome 1:154,700,143-154,737,244 1
SH2D2A RIBP Chromosome 1:155,042,659-155,053,270 1
SH2D2A RIBP Chromosome 1:155,042,659-155,053,270 1
FCRL5 CD307 Chromosome 1:155,749,791-155,788,934 1
FCRL4 Chromosome 1:155,810,163-155,834,494 1
FCRL2 Chromosome 1:155,982,145-156,013,546 1
FCRL2 Chromosome 1:155,982,145-156,013,546 1
CD1D Chromosome 1:156,416,361-156,421,310 1
CD1C Chromosome 1:156,526,200-156,530,044 1
IFI16 Ifi204 Chromosome 1:157,236,382-157,291,569 1
IFI16 Ifi204 Chromosome 1:157,236,382-157,291,569 1
DARC CD234, Duffy blood group   Chromosome 1:157,408,023-157,442,914 1
FCER1A Chromosome 1:157,526,128-157,544,638 1
CRP Chromosome 1:157,948,703-157,951,003 1
DUSP23 Chromosome 1:158,017,346-158,018,957 1
IGSF9 Chromosome 1:158,163,453-158,182,010 1
IGSF8 CD316 Chromosome 1:158,327,754-158,335,103 1
NHLH1 HEN1 Chromosome 1:158,603,481-158,609,262 1
SLAMF6 NTBA Chromosome 1:158,721,444-158,759,676 1
CD48 Chromosome 1:158,915,160-158,948,265 1
LY9 CD229 Chromosome 1:159,032,552-159,064,669 1
JAM1 CD321, JAM-A, F11R Chromosome 1:159,231,625-159,275,404 1
JAM1 CD321, JAM-A, F11R Chromosome 1:159,231,625-159,275,404 1
FCER1G Chromosome 1:159,451,693-159,457,113 1
NR1I3 NR1I3 Chromosome 1:159,466,079-159,474,590 1
FCGR2A CD32 Chromosome 1:159,741,844-159,755,984 1
FCGR3B CD16b Chromosome 1:159,859,610-159,867,620 1
SPEN SHARP Chromosome 1:16,046,946-16,139,542 1
SH2D1B EAT2b Chromosome 1:160,631,680-160,648,552 1
RXRG NR2B3 Chromosome 1:163,636,778-163,681,057 1
CD3Z CD247, CD3 zeta chain Chromosome 1:165,666,501-165,754,471 1
CD3Z CD247, CD3 zeta chain Chromosome 1:165,666,501-165,754,471 1
MPZL1 concanavalin A receptor Chromosome 1:165,957,832-166,026,684 1
XCL2 Chromosome 1:166,776,626-166,779,859 1
XCL1 Chromosome 1:166,812,335-166,817,939 1
F5 Factor V Chromosome 1:167,750,028-167,822,450 1
SELP CD62P Chromosome 1:167,824,661-167,866,031 1
SELP CD62P Chromosome 1:167,824,661-167,866,031 1
SELL L-Selectin, CD62L Chromosome 1:167,926,432-167,947,463 1
PADI4 Chromosome 1:17,507,277-17,563,086 1
TNFSF6 CD178, FASL Chromosome 1:170,894,777-170,902,637 1
TNFSF6 CD178, FASL Chromosome 1:170,894,777-170,902,637 1
TNFSF18 GITRL Chromosome 1:171,275,723-171,286,679 1
TNFSF18 GITRL Chromosome 1:171,275,723-171,286,679 1
TNFSF4 CD252, OX40L Chromosome 1:171,419,493-171,443,094 1
TNFSF4 CD252, OX40L Chromosome 1:171,419,493-171,443,094 1
PRDX6 Chromosome 1:171,713,028-171,724,569 1
SERPINC1 Antithrombin Chromosome 1:172,139,562-172,153,139 1
TNN tenascin Chromosome 1:173,303,617-173,383,825 1
TNR tenascin Chromosome 1:173,558,558-173,979,529 1
TNR tenascin Chromosome 1:173,558,558-173,979,529 1
TNR tenascin Chromosome 1:173,558,558-173,979,529 1
TNR tenascin Chromosome 1:173,558,558-173,979,529 1
TNR tenascin Chromosome 1:173,558,558-173,979,529 1
TNR tenascin Chromosome 1:173,558,558-173,979,529 1
ANGPTL1 Angioarrestin Chromosome 1:177,085,293-177,106,838 1
TOR3A ADIR Chromosome 1:177,317,735-177,333,653 1
TOR3A ADIR Chromosome 1:177,317,735-177,333,653 1
QSCN6 Chromosome 1:178,390,591-178,439,788 1
QSCN6 Chromosome 1:178,390,591-178,439,788 1
MR1 MR1=HLALS Chromosome 1:179,269,762-179,292,312 1
IGSF21 Chromosome 1:18,306,827-18,577,563 1
IGSF21 Chromosome 1:18,306,827-18,577,563 1
IGSF21 Chromosome 1:18,306,827-18,577,563 1
IGSF21 Chromosome 1:18,306,827-18,577,563 1
DHX9 Chromosome 1:181,075,127-181,123,510 1
DHX9 Chromosome 1:181,075,127-181,123,510 1
LAMC2 Chromosome 1:181,422,022-181,480,662 1
LAMC2 Chromosome 1:181,422,022-181,480,662 1
NCF2 neutrophil cytosolic factor Chromosome 1:181,791,320-181,826,634 1
PRG4 MSF Chromosome 1:184,532,034-184,550,317 1
PTGES2 Chromosome 1:184,907,546-184,916,179 1
RGS13 Chromosome 1:190,871,905-190,896,059 1
RGS13 Chromosome 1:190,871,905-190,896,059 1
CFH Chromosome 1:194,887,631-194,983,257 1
CFH Chromosome 1:194,887,631-194,983,257 1
CFHR4 Chromosome 1:195,010,571-195,154,386 1
CFHR2 Chromosome 1:195,179,520-195,194,979 1
PTPRC CD45 Chromosome 1:196,874,424-196,993,035 1
NR5A2 LRH-1 Chromosome 1:198,263,353-198,413,175 1
DDX59 Chromosome 1:198,859,647-198,905,749 1
DDX59 Chromosome 1:198,859,647-198,905,749 1
TNFRSF14 CD270, LIGHTR, HVEM Chromosome 1:2,479,150-2,486,613 1
TNFRSF14 CD270, LIGHTR, HVEM Chromosome 1:2,479,150-2,486,613 1
PLA2G2D Phospholipase Chromosome 1:20,311,019-20,318,637 1
PLA2G2D Phospholipase Chromosome 1:20,311,019-20,318,637 1
PLA2G2D Phospholipase Chromosome 1:20,311,019-20,318,637 1
CDA CDD Chromosome 1:20,788,028-20,817,988 1
CDA Chromosome 1:20,788,028-20,817,988 1
ELF3 ERT Chromosome 1:200,243,696-200,252,939 1
PTPN7 Chromosome 1:200,382,764-200,397,332 1
PTPRV Chromosome 1:200,403,802-200,425,104 1
ADORA1 Adenosin receptor 1 Chromosome 1:201,326,405-201,403,156 1
ADORA1 Adenosin receptor 1 Chromosome 1:201,326,405-201,403,156 1
ADORA1 Adenosin receptor 1 Chromosome 1:201,326,405-201,403,156 1
FMOD Fibromodulin Chromosome 1:201,576,375-201,587,240 1
LAX1 Chromosome 1:202,000,957-202,012,123 1
SOX13 SOX13 (SRY box 13) Chromosome 1:202,308,866-202,363,494 1
SOX13 SOX13 (SRY box 13) Chromosome 1:202,308,866-202,363,494 1
PIK3C2B Chromosome 1:202,658,379-202,726,175 1
MDM4 Chromosome 1:202,752,134-202,793,871 1
CNTN2 Chromosome 1:203,278,963-203,313,761 1
CNTN2 Chromosome 1:203,278,963-203,313,761 1
ELK4 Chromosome 1:203,833,330-203,868,623 1
IKBKE IKKepsilon, IKKi Chromosome 1:204,710,414-204,736,846 1
DYRK3 Chromosome 1:204,875,504-204,924,381 1
MAPKAPK2 Chromosome 1:204,924,912-204,974,251 1
IL10 Interleukin 10 Chromosome 1:205,007,570-205,012,462 1
IL19 Chromosome 1:205,038,838-205,082,949 1
IL20 Chromosome 1:205,105,322-205,109,191 1
IL24 Chromosome 1:205,137,411-205,144,107 1
C4BPB Chromosome 1:205,328,810-205,339,961 1
C4BPA Chromosome 1:205,344,230-205,384,940 1
CD55 CD55, DAF Chromosome 1:205,561,476-205,600,934 1
CR2 CD21 Chromosome 1:205,694,198-205,729,863 1
CR1 Chromosome 1:205,736,096-205,881,733 1
CR1 Chromosome 1:205,736,096-205,881,733 1
CR1 Chromosome 1:205,736,096-205,881,733 1
MCP CD46 Chromosome 1:205,992,025-206,035,481 1
CD34 Chromosome 1:206,116,942-206,151,370 1
CD34 Chromosome 1:206,116,942-206,151,370 1
CD34 Chromosome 1:206,116,942-206,151,370 1
LAMB3 Chromosome 1:207,854,838-207,892,443 1
LAMB3 Chromosome 1:207,854,838-207,892,443 1
LAMB3 Chromosome 1:207,854,838-207,892,443 1
IRF6 Chromosome 1:208,025,659-208,046,102 1
TRAF5 Chromosome 1:209,566,580-209,614,911 1
TRAF5 Chromosome 1:209,566,580-209,614,911 1
ATF3 ATF3 Chromosome 1:210,805,374-210,860,742 1
ATF3 ATF3 Chromosome 1:210,805,374-210,860,742 1
PTPN14 Chromosome 1:212,597,474-212,791,265 1
PTPN14 Chromosome 1:212,597,474-212,791,265 1
CENPF Centromere protein F Chromosome 1:212,843,155-212,904,537 1
ESRRG NR3B3 Chromosome 1:214,743,211-215,377,720 1
ESRRG NR3B3 Chromosome 1:214,743,211-215,377,720 1
ESRRG NR3B3 Chromosome 1:214,743,211-215,377,720 1
ESRRG NR3B3 Chromosome 1:214,743,211-215,377,720 1
ESRRG NR3B3 Chromosome 1:214,743,211-215,377,720 1
ESRRG NR3B3 Chromosome 1:214,743,211-215,377,720 1
ESRRG NR3B3 Chromosome 1:214,743,211-215,377,720 1
TGFB2 Chromosome 1:216,586,200-216,684,584 1
HLX1 Hlx Chromosome 1:219,119,366-219,125,022 1
HLX1 Hlx Chromosome 1:219,119,366-219,125,022 1
DUSP10 MKP-5 Chromosome 1:219,941,389-219,982,141 1
DUSP10 MKP-5 Chromosome 1:219,941,389-219,982,141 1
DUSP10 MKP-5 Chromosome 1:219,941,389-219,982,141 1
HSPG2 Perlecan Chromosome 1:22,021,324-22,136,377 1
WNT4 Chromosome 1:22,318,177-22,342,197 1
C1QA Chromosome 1:22,835,705-22,838,762 1
C1QA Chromosome 1:22,835,705-22,838,762 1
C1QA Chromosome 1:22,835,705-22,838,762 1
EPHB2 Chromosome 1:22,910,045-23,114,405 1
TLR5 CD285 Chromosome 1:221,350,270-221,383,247 1
EPHX1 Chromosome 1:224,064,459-224,099,884 1
EPHX1 Chromosome 1:224,064,459-224,099,884 1
PARP1 Chromosome 1:224,615,015-224,662,414 1
PARP1 Chromosome 1:224,615,015-224,662,414 1
ITPKB Chromosome 1:224,886,014-224,993,647 1
ITPKB Chromosome 1:224,886,014-224,993,647 1
HIST3H2A Histone 3 Chromosome 1:226,711,303-226,712,197 1
ACTA1 F-actin Chromosome 1:227,633,615-227,636,468 1
ACTA1 F-actin Chromosome 1:227,633,615-227,636,468 1
LYST Chromosome 1:233,890,964-234,113,563 1
LYST Chromosome 1:233,890,964-234,113,563 1
LYST Chromosome 1:233,890,964-234,113,563 1
LYST Chromosome 1:233,890,964-234,113,563 1
NID1 entactin Chromosome 1:234,205,753-234,303,706 1
NID1 entactin Chromosome 1:234,205,753-234,303,706 1
EDARADD Chromosome 1:234,624,303-234,714,649 1
EDARADD Chromosome 1:234,624,303-234,714,649 1
EDARADD Chromosome 1:234,624,303-234,714,649 1
ACTN2 alpha actinin 2 Chromosome 1:234,916,422-234,994,554 1
IL22RA1 Chromosome 1:24,318,848-24,342,198 1
IL22RA1 Chromosome 1:24,318,848-24,342,198 1
IL22RA1 Chromosome 1:24,318,848-24,342,198 1
EXO1 Chromosome 1:240,078,105-240,119,864 1
AKT3 PKB Chromosome 1:241,718,158-242,080,053 1
AKT3 PKB Chromosome 1:241,718,158-242,080,053 1
AKT3 PKB Chromosome 1:241,718,158-242,080,053 1
AKT3 PKB Chromosome 1:241,718,158-242,080,053 1
AKT3 PKB Chromosome 1:241,718,158-242,080,053 1
NLRP3 NALP3, CIAS1, PYPAF1,    Chromosome 1:245,647,974-245,679,033 1
NLRP3 NALP3, CIAS1, PYPAF1,    Chromosome 1:245,647,974-245,679,033 1
RUNX3 Chromosome 1:25,098,596-25,164,062 1
RUNX3 Chromosome 1:25,098,596-25,164,062 1
RHD RhD antigen, CD240D Chromosome 1:25,471,568-25,529,523 1
RHCE CD240CE Chromosome 1:25,561,327-25,629,270 1
PAFAH2 PAF, platelet activating fa Chromosome 1:26,158,845-26,197,235 1
PAFAH2 PAF, platelet activating fa Chromosome 1:26,158,845-26,197,235 1
CDW52 CD52, CAMPATH Chromosome 1:26,516,998-26,519,601 1
GPATCH3 NR0B2 Chromosome 1:27,089,567-27,099,549 1
NR0B2 NR0B2 Chromosome 1:27,110,566-27,113,047 1
SLC9A1 NHE-1 Chromosome 1:27,297,893-27,366,059 1
SLC9A1 NHE-1 Chromosome 1:27,297,893-27,366,059 1
FGR Chromosome 1:27,811,162-27,834,375 1
FGR Chromosome 1:27,811,162-27,834,375 1
PTAFR Chromosome 1:28,346,264-28,392,971 1
PTAFR Chromosome 1:28,346,264-28,392,971 1
PTPRU Chromosome 1:29,435,611-29,525,899 1
PTPRU Chromosome 1:29,435,611-29,525,899 1
DFFB Chromosome 1:3,763,705-3,791,853 1
SDC3 Syndecan Chromosome 1:31,114,901-31,166,301 1
SDC3 Syndecan Chromosome 1:31,114,901-31,166,301 1
FABP3 FABP3 Chromosome 1:31,610,687-31,618,510 1
FABP3 FABP3 Chromosome 1:31,610,687-31,618,510 1
PTP4A2 Chromosome 1:32,144,609-32,176,578 1
PTP4A2 Chromosome 1:32,144,609-32,176,578 1
KHDRBS1 Chromosome 1:32,252,017-32,299,037 1
LCK Chromosome 1:32,489,480-32,524,353 1
LCK Chromosome 1:32,489,480-32,524,353 1
HDAC1 Chromosome 1:32,530,274-32,571,823 1
CSF3R CD114 Chromosome 1:36,704,231-36,721,466 1
CSF3R CD114 Chromosome 1:36,704,231-36,721,466 1
GNL2 Ngp Chromosome 1:37,805,004-37,834,109 1
PPIE Chromosome 1:39,977,117-40,002,173 1
PPIE Chromosome 1:39,977,117-40,002,173 1
MYCL1 l-myc Chromosome 1:40,133,685-40,140,274 1
NFYC Chromosome 1:40,929,829-41,009,864 1
NFYC Chromosome 1:40,929,829-41,009,864 1
CTPS CTP synthase Chromosome 1:41,217,951-41,250,815 1
SCMH1 Scmh1 Chromosome 1:41,265,461-41,480,375 1
SCMH1 Scmh1 Chromosome 1:41,265,461-41,480,375 1
FOXJ3 Chromosome 1:42,414,797-42,574,135 1
FOXJ3 Chromosome 1:42,414,797-42,574,135 1
PPIH Chromosome 1:42,896,635-42,915,016 1
ERMAP Chromosome 1:43,055,363-43,083,247 1
ERMAP Chromosome 1:43,055,363-43,083,247 1
MPL CD110, F36VMpl, thrombo  Chromosome 1:43,576,062-43,592,722 1
CDC20 Chromosome 1:43,597,213-43,601,461 1
PTPRF Chromosome 1:43,769,134-43,861,924 1
PTPRF Chromosome 1:43,769,134-43,861,924 1
ARTN ARTN Chromosome 1:44,171,579-44,175,499 1
PLK3 Chromosome 1:45,038,623-45,049,479 1
PIK3R3 Chromosome 1:46,278,399-46,371,054 1
CYP4B1 Chromosome 1:47,037,305-47,057,672 1
CYP4B1 Chromosome 1:47,037,305-47,057,672 1
CYP4X1 Chromosome 1:47,261,827-47,289,010 1
TAL1 SCL=TAL1 Chromosome 1:47,454,550-47,469,974 1
TAL1 SCL=TAL1 Chromosome 1:47,454,550-47,469,974 1
FOXE3 Chromosome 1:47,654,331-47,656,311 1
FOXD2 Chromosome 1:47,674,276-47,678,950 1
FAF1 Chromosome 1:50,677,738-51,198,524 1
FAF1 Chromosome 1:50,677,738-51,198,524 1
FAF1 Chromosome 1:50,677,738-51,198,524 1
FAF1 Chromosome 1:50,677,738-51,198,524 1
FAF1 Chromosome 1:50,677,738-51,198,524 1
FAF1 Chromosome 1:50,677,738-51,198,524 1
PPAP2B Chromosome 1:56,732,527-56,817,845 1
PPAP2B Chromosome 1:56,732,527-56,817,845 1
PPAP2B Chromosome 1:56,732,527-56,817,845 1
PRKAA2 AMPK Chromosome 1:56,883,583-56,953,596 1
C8A Chromosome 1:57,093,065-57,156,482 1
JUN AP-1 Chromosome 1:59,019,048-59,022,587 1
TNFRSF25 TRAMP Chromosome 1:6,443,798-6,502,708 1
TNFRSF25 TRAMP Chromosome 1:6,443,798-6,502,708 1
CYP2J2 Chromosome 1:60,131,568-60,165,050 1
FOXD3 Chromosome 1:63,561,300-63,563,385 1
JAK1 Chromosome 1:65,071,500-65,204,775 1
JAK1 Chromosome 1:65,071,500-65,204,775 1
JAK1 Chromosome 1:65,071,500-65,204,775 1
LEPR CD295, leptin receptor Chromosome 1:65,658,858-65,879,830 1
LEPR CD295, leptin receptor Chromosome 1:65,658,858-65,879,830 1
LEPR CD295, leptin receptor Chromosome 1:65,658,858-65,879,830 1
PDE4B Phosphodiesterases Chromosome 1:66,030,781-66,612,850 1
PDE4B Phosphodiesterases Chromosome 1:66,030,781-66,612,850 1
PDE4B Phosphodiesterases Chromosome 1:66,030,781-66,612,850 1
PDE4B Phosphodiesterases Chromosome 1:66,030,781-66,612,850 1
PDE4B Phosphodiesterases Chromosome 1:66,030,781-66,612,850 1
IL23R Chromosome 1:67,404,671-67,498,250 1
IL23R Chromosome 1:67,404,671-67,498,250 1
IL12RB2 Chromosome 1:67,545,635-67,635,171 1
TNFRSF9 CDw137, 4-1BB Chromosome 1:7,902,494-7,923,513 1
TNFRSF9 CDw137, 4-1BB Chromosome 1:7,902,494-7,923,513 1
PTGER3 EP3 Chromosome 1:71,090,624-71,286,079 1
PTGER3 EP3 Chromosome 1:71,090,624-71,286,079 1
PTGER3 EP3 Chromosome 1:71,090,624-71,286,079 1
PTGER3 EP3 Chromosome 1:71,090,624-71,286,079 1
PTGFR Chromosome 1:78,542,156-78,778,974 1
PTGFR Chromosome 1:78,542,156-78,778,974 1
PTGFR Chromosome 1:78,542,156-78,778,974 1
IFI44 Chromosome 1:78,888,104-78,902,351 1
IFI44 Chromosome 1:78,888,104-78,902,351 1
EGFTM7 Chromosome 1:79,128,037-79,279,105 1
EGFTM7 Chromosome 1:79,128,037-79,279,105 1
PRKACB Chromosome 1:84,316,329-84,476,769 1
PRKACB Chromosome 1:84,316,329-84,476,769 1
BCL10 Chromosome 1:85,504,519-85,516,359 1
BCL10 Chromosome 1:85,504,519-85,516,359 1
DDAH1 Chromosome 1:85,556,756-85,703,415 1
DDAH1 Chromosome 1:85,556,756-85,703,415 1
GTF2B TFIIB Chromosome 1:89,091,203-89,129,889 1
GBP3 Chromosome 1:89,244,948-89,261,132 1
GBP2 Chromosome 1:89,344,403-89,414,311 1
GBP5 Chromosome 1:89,498,853-89,511,119 1
PIK3CD Chromosome 1:9,634,390-9,711,564 1
TGFBR3 Betaglycan Chromosome 1:91,918,488-92,144,147 1
TGFBR3 Betaglycan Chromosome 1:91,918,488-92,144,147 1
TGFBR3 Betaglycan Chromosome 1:91,918,488-92,144,147 1
ISG15 G1P2, ISRE, UCRP Chromosome 1:938,666-939,783 1
GCLM Chromosome 1:94,123,349-94,147,600 1
F3 CD142, coag factor 3, tiss  Chromosome 1:94,767,369-94,779,944 1
CHUK IKK1 Chromosome 10:101,899,841-101,979,366 10
CHUK IKK1 Chromosome 10:101,899,841-101,979,366 10
BTRC Beta-TRCP Chromosome 10:103,103,810-103,307,068 10
BTRC Beta-TRCP Chromosome 10:103,103,810-103,307,068 10
BTRC Beta-TRCP Chromosome 10:103,103,810-103,307,068 10
FGF8 FGF8 Chromosome 10:103,519,877-103,525,817 10
NFKB2 p100, p52 Chromosome 10:104,144,320-104,152,271 10
C10orf26 OPAL1 Chromosome 10:104,525,996-104,566,011 10
CYP17A1 17 alpha hydroxylase Chromosome 10:104,580,278-104,587,280 10
CUGBP2 Chromosome 10:11,087,290-11,418,680 10
CUGBP2 Chromosome 10:11,087,290-11,418,680 10
CUGBP2 Chromosome 10:11,087,290-11,418,680 10
CUGBP2 Chromosome 10:11,087,290-11,418,680 10
CUGBP2 Chromosome 10:11,087,290-11,418,680 10
CUGBP2 Chromosome 10:11,087,290-11,418,680 10
DUSP5 VH3 Chromosome 10:112,247,586-112,261,292 10
SMC3 BAM11 Chromosome 10:112,317,439-112,354,384 10
SMC3 BAM11 Chromosome 10:112,317,439-112,354,384 10
CASP7 Chromosome 10:115,428,925-115,480,654 10
SEC61A2 Chromosome 10:12,211,642-12,251,966 10
SEC61A2 Chromosome 10:12,211,642-12,251,966 10
BAG3 Chromosome 10:121,400,872-121,427,321 10
BAG3 Chromosome 10:121,400,872-121,427,321 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
FGFR2 KGF/FGF receptor, CD33 Chromosome 10:122,473,377-123,347,962 10
DMBT1 gp340 Chromosome 10:124,310,171-124,393,242 10
DMBT1 gp340 Chromosome 10:124,310,171-124,393,242 10
BUB3 Chromosome 10:124,903,783-124,914,876 10
BUB3 Chromosome 10:124,903,783-124,914,876 10
MMP21 Chromosome 10:127,445,012-127,454,380 10
DHX32 Chromosome 10:127,514,896-127,575,017 10
ADAM12 metalloproteinase desineg  Chromosome 10:127,690,940-128,067,055 10
ADAM12 metalloproteinase desineg  Chromosome 10:127,690,940-128,067,055 10
ADAM12 metalloproteinase desineg  Chromosome 10:127,690,940-128,067,055 10
ADAM12 metalloproteinase desineg  Chromosome 10:127,690,940-128,067,055 10
FOXI2 Chromosome 10:129,425,504-129,429,440 10
PTPRE Chromosome 10:129,595,315-129,774,155 10
PTPRE Chromosome 10:129,595,315-129,774,155 10
MGMT Chromosome 10:131,155,456-131,455,358 10
MGMT Chromosome 10:131,155,456-131,455,358 10
MGMT Chromosome 10:131,155,456-131,455,358 10
BNIP3 Chromosome 10:133,631,181-133,645,450 10
ADAM8 CD156a Chromosome 10:134,925,898-134,940,362 10
CYP2E1 Chromosome 10:135,190,857-135,224,714 10
DCLRE1C Chromosome 10:14,979,364-15,036,437 10
DCLRE1C Chromosome 10:14,979,364-15,036,437 10
ITGA8 Chromosome 10:15,595,954-15,802,130 10
ITGA8 Chromosome 10:15,595,954-15,802,130 10
ITGA8 Chromosome 10:15,595,954-15,802,130 10
ITGA8 Chromosome 10:15,595,954-15,802,130 10
C1QL3 Chromosome 10:16,595,748-16,604,010 10
C1QL3 Chromosome 10:16,595,748-16,604,010 10
VIM Vimentin Chromosome 10:17,311,283-17,319,598 10
MRC1L1 Mannose receptor Chromosome 10:17,891,368-17,993,184 10
MRC1 CD206, Mannose recepto Chromosome 10:18,138,358-18,240,097 10
BMI-1 BMI-1 Chromosome 10:22,650,146-22,660,194 10
APBB1IP RIAM, PEL1 Chromosome 10:26,767,138-26,896,738 10
APBB1IP RIAM, PEL1 Chromosome 10:26,767,138-26,896,738 10
APBB1IP RIAM, PEL1 Chromosome 10:26,767,138-26,896,738 10
MAP3K8 TPL2 Chromosome 10:30,762,872-30,790,768 10
MAP3K8 TPL2 Chromosome 10:30,762,872-30,790,768 10
TCF8 Chromosome 10:31,647,430-31,858,748 10
TCF8 Chromosome 10:31,647,430-31,858,748 10
TCF8 Chromosome 10:31,647,430-31,858,748 10
TCF8 Chromosome 10:31,647,430-31,858,748 10
TCF8 Chromosome 10:31,647,430-31,858,748 10
TCF8 Chromosome 10:31,647,430-31,858,748 10
ITGB1 CD29 Chromosome 10:33,229,326-33,287,204 10
ITGB1 CD29 Chromosome 10:33,229,326-33,287,204 10
NRP1 CD304, BDCA4, NeuropiliChromosome 10:33,506,426-33,665,196 10
NRP1 CD304, BDCA4, NeuropiliChromosome 10:33,506,426-33,665,196 10
CREM ICER Chromosome 10:35,455,807-35,541,892 10
CREM ICER Chromosome 10:35,455,807-35,541,892 10
CREM ICER Chromosome 10:35,455,807-35,541,892 10
CXCL12 SDF1 Chromosome 10:44,185,611-44,200,548 10
ALOX5 5-LO Chromosome 10:45,189,635-45,261,571 10
ALOX5 5-LO Chromosome 10:45,189,635-45,261,571 10
PTPN20C Chromosome 10:48,926,216-49,033,022 10
MAPK8 JNK Chromosome 10:49,184,739-49,317,409 10
MAPK8 JNK Chromosome 10:49,184,739-49,317,409 10
MBL2 Chromosome 10:54,195,146-54,201,466 10
UBE2D1 UBCH5 Chromosome 10:59,764,745-59,800,515 10
UBE2D1 UBCH5 Chromosome 10:59,764,745-59,800,515 10
IL15RA Chromosome 10:6,034,340-6,060,156 10
IL2RA Chromosome 10:6,092,658-6,144,294 10
PRKCQ PKCλ Chromosome 10:6,509,111-6,662,269 10
PRKCQ PKCλ Chromosome 10:6,509,111-6,662,269 10
PRKCQ PKCλ Chromosome 10:6,509,111-6,662,269 10
ANK3 Chromosome 10:61,458,165-61,819,494 10
ANK3 Chromosome 10:61,458,165-61,819,494 10
ANK3 Chromosome 10:61,458,165-61,819,494 10
ANK3 Chromosome 10:61,458,165-61,819,494 10
ANK3 Chromosome 10:61,458,165-61,819,494 10
CDC2 CDK1 Chromosome 10:62,205,690-62,224,616 10
EGR2 Chromosome 10:64,241,762-64,246,133 10
EGR2 Chromosome 10:64,241,762-64,246,133 10
DDX50 Chromosome 10:70,331,040-70,376,609 10
PRG1 serglycin Chromosome 10:70,517,834-70,534,573 10
PRF1 Perforin Chromosome 10:72,027,110-72,032,521 10
PPP3CB calcineurin Chromosome 10:74,866,192-74,925,765 10
PPP3CB calcineurin Chromosome 10:74,866,192-74,925,765 10
PLAU Plasminogen activator  Chromosome 10:75,340,896-75,347,261 10
ADK adenosine kinase Chromosome 10:75,580,971-76,139,067 10
ADK adenosine kinase Chromosome 10:75,580,971-76,139,067 10
ADK adenosine kinase Chromosome 10:75,580,971-76,139,067 10
ADK adenosine kinase Chromosome 10:75,580,971-76,139,067 10
ADK adenosine kinase Chromosome 10:75,580,971-76,139,067 10
ADK adenosine kinase Chromosome 10:75,580,971-76,139,067 10
DUSP13 Chromosome 10:76,524,196-76,538,976 10
DLG5 Chromosome 10:79,220,557-79,356,384 10
DLG5 Chromosome 10:79,220,557-79,356,384 10
GATA3 Chromosome 10:8,136,662-8,157,170 10
GATA3 Chromosome 10:8,136,662-8,157,170 10
PPIF Chromosome 10:80,777,226-80,785,096 10
PPIF Chromosome 10:80,777,226-80,785,096 10
SFTPD SP-D Chromosome 10:81,687,476-81,698,841 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
NRG3 NRG3 Chromosome 10:83,624,786-84,736,913 10
BMPR1A CD292 Chromosome 10:88,506,376-88,674,925 10
PTEN Chromosome 10:89,612,850-89,721,667 10
PTEN Chromosome 10:89,612,850-89,721,667 10
TNFRSF6 FAS, CD95 Chromosome 10:90,739,206-90,765,522 10
LIPA Chromosome 10:90,963,306-91,164,294 10
LIPA Chromosome 10:90,963,306-91,164,294 10
LIPA Chromosome 10:90,963,306-91,164,294 10
CYP26C1 Chromosome 10:94,811,011-94,818,444 10
CYP2C18 Chromosome 10:96,433,368-96,485,937 10
CYP2C19 Chromosome 10:96,512,371-96,603,007 10
CYP2C19 Chromosome 10:96,512,371-96,603,007 10
CYP2C9 Chromosome 10:96,688,418-96,739,137 10
CYP2C8 Chromosome 10:96,786,519-96,819,244 10
ENTPD1 CD39 Chromosome 10:97,461,526-97,619,442 10
ENTPD1 CD39 Chromosome 10:97,461,526-97,619,442 10
ENTPD1 CD39 Chromosome 10:97,461,526-97,619,442 10
BLNK Chromosome 10:97,941,445-98,021,316 10
DNTT Chromosome 10:98,054,075-98,088,311 10
DNTT Chromosome 10:98,054,075-98,088,311 10
CTSD cathepsin D Chromosome 11:1,730,558-1,741,798 11
CTSD cathepsin D Chromosome 11:1,730,558-1,741,798 11
LSP1 Chromosome 11:1,830,776-1,870,069 11
ADM Chromosome 11:10,283,172-10,285,499 11
PGR NR3C3 Chromosome 11:100,414,313-100,506,465 11
PGR NR3C3 Chromosome 11:100,414,313-100,506,465 11
BIRC3 Chromosome 11:101,693,404-101,713,675 11
MMP7 Chromosome 11:101,896,449-101,906,688 11
MMP20 Chromosome 11:101,952,776-102,001,273 11
MMP27 Chromosome 11:102,067,625-102,081,678 11
MMP10 Chromosome 11:102,146,444-102,156,569 11
MMP3 Chromosome 11:102,211,738-102,219,552 11
MMP13 Chromosome 11:102,318,934-102,331,672 11
MMP13 Chromosome 11:102,318,934-102,331,672 11
CASP12 Caspase 12 Chromosome 11:104,261,876-104,274,607 11
CASP4 Chromosome 11:104,318,804-104,345,373 11
CASP5 Chromosome 11:104,370,180-104,384,909 11
ICEBERG Chromosome 11:104,513,879-104,515,663 11
ICEBERG Chromosome 11:104,513,879-104,515,663 11
ALKBH8 Chromosome 11:106,878,664-106,941,637 11
ALKBH8 Chromosome 11:106,878,664-106,941,637 11
ATM Ataxia teleangiectasia mu Chromosome 11:107,598,769-107,745,036 11
ATM Ataxia teleangiectasia mu Chromosome 11:107,598,769-107,745,036 11
ATM Ataxia teleangiectasia mu Chromosome 11:107,598,769-107,745,036 11
ATM Ataxia teleangiectasia mu Chromosome 11:107,598,769-107,745,036 11
DDX10 Chromosome 11:108,041,014-108,316,866 11
DDX10 Chromosome 11:108,041,014-108,316,866 11
DDX10 Chromosome 11:108,041,014-108,316,866 11
RDX Chromosome 11:109,605,376-109,672,647 11
RDX Chromosome 11:109,605,376-109,672,647 11
POU2AF1 Chromosome 11:110,728,190-110,755,627 11
POU2AF1 Chromosome 11:110,728,190-110,755,627 11
IL18 Chromosome 11:111,519,186-111,540,050 11
IL18 Chromosome 11:111,519,186-111,540,050 11
NCAM1 CD56 Chromosome 11:112,337,368-112,653,781 11
NCAM1 CD56 Chromosome 11:112,337,368-112,653,781 11
NCAM1 CD56 Chromosome 11:112,337,368-112,653,781 11
CADM1 Chromosome 11:114,550,227-114,880,325 11
CADM1 Chromosome 11:114,550,227-114,880,325 11
CADM1 Chromosome 11:114,550,227-114,880,325 11
CADM1 Chromosome 11:114,550,227-114,880,325 11
CADM1 Chromosome 11:114,550,227-114,880,325 11
CADM1 Chromosome 11:114,550,227-114,880,325 11
IL10RA CDw210a, IL10R1 Chromosome 11:117,362,319-117,377,404 11
IL10RA CDw210a, IL10R1 Chromosome 11:117,362,319-117,377,404 11
CD3E CD3 Chromosome 11:117,680,662-117,692,100 11
CD3D CD3 Chromosome 11:117,710,475-117,718,669 11
DDX6 Chromosome 11:118,125,623-118,167,082 11
DDX6 Chromosome 11:118,125,623-118,167,082 11
BLR1 CD185, CXCR5 Chromosome 11:118,259,777-118,272,181 11
BLR1 CD185, CXCR5 Chromosome 11:118,259,777-118,272,181 11
MCAM CD146 Chromosome 11:118,684,444-118,693,050 11
PVRL1 CD111 Chromosome 11:119,014,018-119,104,645 11
PVRL1 CD111 Chromosome 11:119,014,018-119,104,645 11
POU2F3 Chromosome 11:119,616,256-119,695,863 11
POU2F3 Chromosome 11:119,616,256-119,695,863 11
POU2F3 Chromosome 11:119,616,256-119,695,863 11
SORL1 Chromosome 11:120,828,130-121,005,621 11
SORL1 Chromosome 11:120,828,130-121,005,621 11
DDX25 Chromosome 11:125,279,550-125,298,215 11
DDX25 Chromosome 11:125,279,550-125,298,215 11
TIRAP Mal Chromosome 11:125,658,192-125,672,683 11
TIRAP Mal Chromosome 11:125,658,192-125,672,683 11
PTH Chromosome 11:13,470,177-13,474,143 11
IGSF9B Chromosome 11:133,290,395-133,327,321 11
IGSF9B Chromosome 11:133,290,395-133,327,321 11
IGSF9B Chromosome 11:133,290,395-133,327,321 11
JAM3 CD323 Chromosome 11:133,444,030-133,526,861 11
JAM3 CD323 Chromosome 11:133,444,030-133,526,861 11
B3GAT1 CD57 Chromosome 11:133,753,608-133,787,022 11
CYP2R1 Chromosome 11:14,856,131-14,870,327 11
PIK3C2A Chromosome 11:17,067,861-17,147,864 11
PIK3C2A Chromosome 11:17,067,861-17,147,864 11
SAA3P Saa3 Chromosome 11:18,090,596-18,094,695 11
SAA2 Chromosome 11:18,223,365-18,226,758 11
SAA2 Chromosome 11:18,223,365-18,226,758 11
GTF2H1 Chromosome 11:18,300,719-18,345,153 11
IGSF22 Chromosome 11:18,682,435-18,704,353 11
PTPN5 Chromosome 11:18,706,051-18,769,965 11
IGF2 IGF2 Chromosome 11:2,106,918-2,125,616 11
CD81 TAPA1 Chromosome 11:2,355,096-2,375,225 11
CD81 TAPA1 Chromosome 11:2,355,096-2,375,225 11
CDKN1C Chromosome 11:2,861,019-2,863,577 11
PRMT3 PRMT3 Chromosome 11:20,365,679-20,487,404 11
PRMT3 PRMT3 Chromosome 11:20,365,679-20,487,404 11
GAS2 GAS2 Chromosome 11:22,646,230-22,791,123 11
GAS2 GAS2 Chromosome 11:22,646,230-22,791,123 11
GAS2 GAS2 Chromosome 11:22,646,230-22,791,123 11
NLRP6 NALP6, PYPAF5, PAN3 Chromosome 11:268,570-275,304 11
NLRP6 NALP6, PYPAF5, PAN3 Chromosome 11:268,570-275,304 11
BDNF BDNF Chromosome 11:27,633,016-27,699,872 11
BDNF BDNF Chromosome 11:27,633,016-27,699,872 11
ART1 CHAT1, ADP ribosyl trans  Chromosome 11:3,622,937-3,642,222 11
CD59 protectin, MIRL Chromosome 11:33,681,132-33,714,600 11
CD59 protectin, MIRL Chromosome 11:33,681,132-33,714,600 11
CAT Catalase Chromosome 11:34,417,054-34,450,183 11
CD44 Chromosome 11:35,116,993-35,210,525 11
CD44 Chromosome 11:35,116,993-35,210,525 11
CD44 Chromosome 11:35,116,993-35,210,525 11
TRAF6 Chromosome 11:36,467,299-36,488,398 11
RAG1 Chromosome 11:36,546,139-36,557,877 11
SIGIRR Chromosome 11:395,716-407,397 11
SIGIRR Chromosome 11:395,716-407,397 11
MMP26 Chromosome 11:4,745,076-4,970,235 11
MMP26 Chromosome 11:4,745,076-4,970,235 11
MMP26 Chromosome 11:4,745,076-4,970,235 11
MMP26 Chromosome 11:4,745,076-4,970,235 11
API5 Chromosome 11:43,290,109-43,322,655 11
ALKBH3 Chromosome 11:43,858,971-43,898,392 11
CD82 CD82, KAI1 Chromosome 11:44,543,717-44,597,915 11
CD82 CD82, KAI1 Chromosome 11:44,543,717-44,597,915 11
MAPK8IP1 Chromosome 11:45,863,778-45,884,592 11
MAPK8IP1 Chromosome 11:45,863,778-45,884,592 11
F2 Alpha-Thrombin, prothromChromosome 11:46,697,331-46,717,631 11
F2 Alpha-Thrombin, prothromChromosome 11:46,697,331-46,717,631 11
NR1H3 NR1H3 Chromosome 11:47,227,083-47,246,972 11
NR1H3 NR1H3 Chromosome 11:47,227,083-47,246,972 11
NDUFS3 NADH dehydrogenase Chromosome 11:47,543,464-47,562,690 11
NDUFS3 NADH dehydrogenase Chromosome 11:47,543,464-47,562,690 11
C1QTNF4 Chromosome 11:47,567,792-47,580,516 11
PTPRJ CD148 Chromosome 11:47,958,689-48,146,246 11
PTPRJ CD148 Chromosome 11:47,958,689-48,146,246 11
HBD Hbb-b1 Chromosome 11:5,203,270-5,212,454 11
HBD Hbb-b1 Chromosome 11:5,203,270-5,212,454 11
TRIM22 Chromosome 11:5,667,495-5,688,669 11
TRIM22 Chromosome 11:5,667,495-5,688,669 11
TRIM22 Chromosome 11:5,667,495-5,688,669 11
AGTRL1 apelin receptor Chromosome 11:56,757,630-56,761,489 11
P2RX3 P2X3 Chromosome 11:56,862,525-56,894,125 11
PRG2 Chromosome 11:56,910,832-56,914,706 11
UBE2L6 Ubch8 Chromosome 11:57,075,705-57,092,333 11
SERPING1 Chromosome 11:57,121,603-57,138,902 11
SERPING1 Chromosome 11:57,121,603-57,138,902 11
MS4A3 Chromosome 11:59,580,677-59,595,164 11
MS4A5 Chromosome 11:59,953,638-59,971,841 11
ILK Integrin linked kinase Chromosome 11:6,581,540-6,588,677 11
ILK Integrin linked kinase Chromosome 11:6,581,540-6,588,677 11
ILK Integrin linked kinase Chromosome 11:6,581,540-6,588,677 11
GPR44 CRTH2 Chromosome 11:60,374,983-60,380,020 11
CD5 Leu1 Chromosome 11:60,626,543-60,651,900 11
SYT7 SytVII Chromosome 11:61,039,361-61,104,874 11
SYT7 SytVII Chromosome 11:61,039,361-61,104,874 11
FEN1 ok Chromosome 11:61,316,726-61,321,286 11
NXF1 TAP Chromosome 11:62,316,219-62,329,529 11
SLC3A2 CD98 Chromosome 11:62,380,094-62,412,929 11
LGALS12 galectin12 Chromosome 11:63,030,132-63,040,815 11
VEGFB Chromosome 11:63,758,646-63,762,835 11
FKBP2 Calcineurin Chromosome 11:63,764,989-63,768,262 11
ESRRA NR3B1 Chromosome 11:63,829,616-63,840,786 11
RASGRP2 CalDAG-GEFI Chromosome 11:64,250,959-64,269,504 11
GPHA2 GPHA2 Chromosome 11:64,458,519-64,459,936 11
GPHA2 GPHA2 Chromosome 11:64,458,519-64,459,936 11
POLA2 Chromosome 11:64,786,006-64,821,664 11
LTBP3 Chromosome 11:65,062,850-65,082,275 11
LTBP3 Chromosome 11:65,062,850-65,082,275 11
RELA p65 Chromosome 11:65,177,649-65,186,959 11
CFL1 cofilin Chromosome 11:65,378,858-65,383,462 11
CFL1 cofilin Chromosome 11:65,378,858-65,383,462 11
CD164L1 CD248, endosialin, TEM1 Chromosome 11:65,838,534-65,841,091 11
PELI3 Pellino3 Chromosome 11:65,990,974-66,001,382 11
ACTN3 alpha actinin 3 Chromosome 11:66,070,967-66,087,373 11
CTSF Cathepsin F Chromosome 11:66,087,511-66,092,623 11
RHOD RHOD Chromosome 11:66,580,897-66,596,060 11
RHOD RHOD Chromosome 11:66,580,897-66,596,060 11
CLCF1 cardiotrophin-like cytokine Chromosome 11:66,888,215-66,897,782 11
CLCF1 cardiotrophin-like cytokine Chromosome 11:66,888,215-66,897,782 11
AIP Chromosome 11:67,007,097-67,015,150 11
GSTP1 Chromosome 11:67,107,862-67,110,701 11
UNC93B1 Chromosome 11:67,515,151-67,528,169 11
TCIRG1 V-ATPase Chromosome 11:67,563,059-67,574,942 11
LRP5 Chromosome 11:67,836,674-67,973,317 11
LRP5 Chromosome 11:67,836,674-67,973,317 11
LRP5 Chromosome 11:67,836,674-67,973,317 11
LRP5 Chromosome 11:67,836,674-67,973,317 11
LRP5 Chromosome 11:67,836,674-67,973,317 11
CCND1 cyclinD1 Chromosome 11:69,165,054-69,178,423 11
FGF4 FGF4 Chromosome 11:69,296,978-69,299,352 11
FADD MC159 Chromosome 11:69,726,917-69,731,144 11
NLRP14 NALP14, LRR, NOD5, GCChromosome 11:7,016,373-7,049,333 11
NLRP14 NALP14, LRR, NOD5, GCChromosome 11:7,016,373-7,049,333 11
NLRP10 NALP10, PYNOD, PAN5, Chromosome 11:7,937,547-7,941,780 11
NLRP10 NALP10, PYNOD, PAN5, Chromosome 11:7,937,547-7,941,780 11
DFB108B Chromosome 11:71,221,894-71,226,256 11
IL18BP Chromosome 11:71,387,587-71,394,409 11
P2RY2 P2Y2 Chromosome 11:72,606,992-72,625,045 11
P2RY2 P2Y2 Chromosome 11:72,606,992-72,625,045 11
P2RY2 P2Y2 Chromosome 11:72,606,992-72,625,045 11
TNFRSF19L Chromosome 11:72,765,053-72,786,167 11
PLEKHB1 Chromosome 11:73,023,592-73,051,512 11
POLD3 Chromosome 11:73,981,277-74,031,413 11
ARRB1 Beta arrestin 1 Chromosome 11:74,654,130-74,740,521 11
ARRB1 Beta arrestin 1 Chromosome 11:74,654,130-74,740,521 11
UVRAG Chromosome 11:75,203,923-75,531,342 11
UVRAG Chromosome 11:75,203,923-75,531,342 11
UVRAG Chromosome 11:75,203,923-75,531,342 11
UVRAG Chromosome 11:75,203,923-75,531,342 11
PRKRIR PKR Chromosome 11:75,738,652-75,769,528 11
PRKRIR PKR Chromosome 11:75,738,652-75,769,528 11
PAK1 PAK Chromosome 11:76,710,708-76,862,581 11
PAK1 PAK Chromosome 11:76,710,708-76,862,581 11
GAB2 Chromosome 11:77,603,990-77,806,414 11
GAB2 Chromosome 11:77,603,990-77,806,414 11
GAB2 Chromosome 11:77,603,990-77,806,414 11
CD151 Chromosome 11:822,952-828,835 11
FZD4 CD344, FZ4 Chromosome 11:86,334,369-86,344,081 11
FZD4 CD344, FZ4 Chromosome 11:86,334,369-86,344,081 11
TYR Chromosome 11:88,550,268-88,668,474 11
TYR Chromosome 11:88,550,268-88,668,474 11
TYR Chromosome 11:88,550,268-88,668,474 11
NOX4 Chromosome 11:88,699,160-88,864,301 11
MRE11A Chromosome 11:93,790,114-93,866,688 11
MRE11A Chromosome 11:93,790,114-93,866,688 11
CLEC12A MICL Chromosome 12:10,015,281-10,029,461 12
CLEC12A MICL Chromosome 12:10,015,281-10,029,461 12
CLEC1A Chromosome 12:10,113,421-10,142,872 12
OLR1 SCARE1, LOX1, LDL receChromosome 12:10,202,167-10,216,004 12
OLR1 SCARE1, LOX1, LDL receChromosome 12:10,202,167-10,216,004 12
KLRD1 CD94/NKG2A Chromosome 12:10,351,684-10,359,983 12
KLRC3 Chromosome 12:10,456,181-10,464,461 12
KLRA1 Ly49 Chromosome 12:10,633,039-10,643,431 12
CSDA Chromosome 12:10,742,955-10,767,171 12
IGF1 IGF1 Chromosome 12:101,313,806-101,398,471 12
IGF1 IGF1 Chromosome 12:101,313,806-101,398,471 12
ASCL1 MASH1 Chromosome 12:101,875,594-101,878,421 12
ASCL1 MASH1 Chromosome 12:101,875,594-101,878,421 12
FEEL-2 FEEL-2 Chromosome 12:102,505,181-102,684,635 12
FEEL-2 FEEL-2 Chromosome 12:102,505,181-102,684,635 12
FEEL-2 FEEL-2 Chromosome 12:102,505,181-102,684,635 12
FEEL-2 FEEL-2 Chromosome 12:102,505,181-102,684,635 12
FEEL-2 FEEL-2 Chromosome 12:102,505,181-102,684,635 12
HSP90B1 gp96 phox Chromosome 12:102,848,290-102,865,833 12
NFYB Chromosome 12:103,034,988-103,056,170 12
NFYB Chromosome 12:103,034,988-103,056,170 12
TXNRD1 TrxR alpha Chromosome 12:103,204,857-103,268,192 12
RFX4 RFX4 Chromosome 12:105,501,163-105,680,711 12
RFX4 RFX4 Chromosome 12:105,501,163-105,680,711 12
RFX4 RFX4 Chromosome 12:105,501,163-105,680,711 12
CMKLR1 ChemR23 Chromosome 12:107,208,800-107,257,218 12
SELPLG CD162, PSGL1, CLA, 6-s   Chromosome 12:107,539,800-107,551,799 12
ALKBH2 Chromosome 12:108,010,379-108,015,660 12
ALKBH2 Chromosome 12:108,010,379-108,015,660 12
FOXN4 Chromosome 12:108,200,167-108,231,408 12
FOXN4 Chromosome 12:108,200,167-108,231,408 12
RAD9B Chromosome 12:109,424,388-109,454,274 12
RAD9B Chromosome 12:109,424,388-109,454,274 12
ETV6 Chromosome 12:11,694,055-11,939,603 12
ETV6 Chromosome 12:11,694,055-11,939,603 12
ETV6 Chromosome 12:11,694,055-11,939,603 12
ETV6 Chromosome 12:11,694,055-11,939,603 12
PTPN11 SHP2 Chromosome 12:111,340,919-111,432,100 12
PTPN11 SHP2 Chromosome 12:111,340,919-111,432,100 12
OAS1 Chromosome 12:111,829,122-111,854,374 12
DTX1 DELTEX Chromosome 12:111,980,045-112,020,216 12
DTX1 DELTEX Chromosome 12:111,980,045-112,020,216 12
HRK harakiri Chromosome 12:115,783,410-115,803,615 12
HRK harakiri Chromosome 12:115,783,410-115,803,615 12
NOS1 NO synthase Chromosome 12:116,135,362-116,283,965 12
NOS1 NO synthase Chromosome 12:116,135,362-116,283,965 12
NOS1 NO synthase Chromosome 12:116,135,362-116,283,965 12
HSP B8 Chromosome 12:118,100,978-118,116,934 12
HSP B8 Chromosome 12:118,100,978-118,116,934 12
OASL Chromosome 12:119,942,478-119,961,164 12
OASL Chromosome 12:119,942,478-119,961,164 12
BCL2L14 Chromosome 12:12,115,145-12,255,214 12
BCL2L14 Chromosome 12:12,115,145-12,255,214 12
LRP6 Chromosome 12:12,164,953-12,311,013 12
DUSP16 Chromosome 12:12,520,098-12,606,584 12
DUSP16 Chromosome 12:12,520,098-12,606,584 12
DUSP16 Chromosome 12:12,520,098-12,606,584 12
DDX47 Chromosome 12:12,770,130-12,874,182 12
P2RX7 P2X7, P2Z Chromosome 12:120,055,061-120,108,259 12
P2RX7 P2X7, P2Z Chromosome 12:120,055,061-120,108,259 12
IL31 Chromosome 12:121,222,530-121,224,699 12
CLIP1 RSN Chromosome 12:121,321,934-121,473,069 12
CLIP1 RSN Chromosome 12:121,321,934-121,473,069 12
GPR109B HM74 Chromosome 12:121,765,256-121,767,297 12
DDX55 Chromosome 12:122,652,625-122,671,435 12
GTF2H3 TFIIH, TFIIK Chromosome 12:122,684,333-122,711,573 12
NCOR2 SMRT Chromosome 12:123,374,914-123,568,793 12
NCOR2 SMRT Chromosome 12:123,374,914-123,568,793 12
NCOR2 SMRT Chromosome 12:123,374,914-123,568,793 12
NCOR2 SMRT Chromosome 12:123,374,914-123,568,793 12
NCOR2 SMRT Chromosome 12:123,374,914-123,568,793 12
SCARB1 SR-BI Chromosome 12:123,828,129-123,914,346 12
SCARB1 Chromosome 12:123,828,129-123,914,346 12
DHX37 Chromosome 12:123,997,325-124,039,620 12
NLRP9P NOD25 Chromosome 12:128,063,805-128,067,640 12
FZD10 CD350 Chromosome 12:129,212,957-129,216,238 12
FZD10 CD350 Chromosome 12:129,212,957-129,216,238 12
RAN Chromosome 12:129,922,521-129,927,316 12
P2RX2 P2X2 Chromosome 12:131,705,476-131,709,045 12
ART4 CD297 Chromosome 12:14,873,512-14,887,680 12
ART4 CD297 Chromosome 12:14,873,512-14,887,680 12
ARHGDIB Rho GD2 Chromosome 12:14,986,217-15,005,870 12
ARHGDIB Rho GD2 Chromosome 12:14,986,217-15,005,870 12
PTPRO PTPROt Chromosome 12:15,366,754-15,641,602 12
PTPRO PTPROt Chromosome 12:15,366,754-15,641,602 12
PTPRO PTPROt Chromosome 12:15,366,754-15,641,602 12
PTPRO PTPROt Chromosome 12:15,366,754-15,641,602 12
PIK3C2G Chromosome 12:18,305,741-18,692,617 12
PIK3C2G Chromosome 12:18,305,741-18,692,617 12
PIK3C2G Chromosome 12:18,305,741-18,692,617 12
PIK3C2G Chromosome 12:18,305,741-18,692,617 12
PIK3C2G Chromosome 12:18,305,741-18,692,617 12
FKBP4 Calcineurin Chromosome 12:2,774,414-2,783,385 12
FKBP4 Calcineurin Chromosome 12:2,774,414-2,783,385 12
KRAS Chromosome 12:25,249,447-25,295,121 12
KRAS Chromosome 12:25,249,447-25,295,121 12
ITPR2 Chromosome 12:26,377,193-26,877,398 12
ITPR2 Chromosome 12:26,377,193-26,877,398 12
ITPR2 Chromosome 12:26,377,193-26,877,398 12
ITPR2 Chromosome 12:26,377,193-26,877,398 12
ITPR2 Chromosome 12:26,377,193-26,877,398 12
ITPR2 Chromosome 12:26,377,193-26,877,398 12
ITPR2 Chromosome 12:26,377,193-26,877,398 12
ITPR2 Chromosome 12:26,377,193-26,877,398 12
PTHLH PTHrP Chromosome 12:28,002,284-28,016,183 12
PTHLH PTHrP Chromosome 12:28,002,284-28,016,183 12
PTHLH PTHrP Chromosome 12:28,002,284-28,016,183 12
ERGIC2 Chromosome 12:29,381,556-29,425,410 12
ERGIC2 Chromosome 12:29,381,556-29,425,410 12
PRMT8 PRMT8 Chromosome 12:3,470,686-3,573,400 12
PRMT8 PRMT8 Chromosome 12:3,470,686-3,573,400 12
PRMT8 PRMT8 Chromosome 12:3,470,686-3,573,400 12
DDX11 Chromosome 12:31,118,061-31,148,992 12
DDX11 Chromosome 12:31,118,061-31,148,992 12
CCND2 Chromosome 12:4,253,199-4,284,777 12
FGF6 FGF6 Chromosome 12:4,413,569-4,425,041 12
DYRK4 Chromosome 12:4,569,505-4,593,302 12
DYRK4 Chromosome 12:4,569,505-4,593,302 12
IRAK4 Chromosome 12:42,439,047-42,468,166 12
IRAK4 Chromosome 12:42,439,047-42,468,166 12
SFRS2IP Caspase 11 Chromosome 12:44,601,459-44,670,615 12
SFRS2IP Caspase 11 Chromosome 12:44,601,459-44,670,615 12
HDAC7A Chromosome 12:46,462,772-46,499,924 12
HDAC7A Chromosome 12:46,462,772-46,499,924 12
DDX23 Chromosome 12:47,509,806-47,532,224 12
DDX23 Chromosome 12:47,509,806-47,532,224 12
WNT1 Chromosome 12:47,658,503-47,662,746 12
DHH desert Hh Chromosome 12:47,769,471-47,774,869 12
TUBA1A Chromosome 12:47,864,847-47,869,153 12
C1QL4 Chromosome 12:48,012,467-48,017,238 12
MCRS1 Mcrs1 Chromosome 12:48,238,352-48,248,178 12
ATF1 Chromosome 12:49,444,128-49,500,328 12
ATF1 Chromosome 12:49,444,128-49,500,328 12
ATF1 Chromosome 12:49,444,128-49,500,328 12
VWF vWf Chromosome 12:5,928,301-6,104,097 12
VWF vWf Chromosome 12:5,928,301-6,104,097 12
VWF vWf Chromosome 12:5,928,301-6,104,097 12
VWF vWf Chromosome 12:5,928,301-6,104,097 12
VWF vWf Chromosome 12:5,928,301-6,104,097 12
ELA1 Chromosome 12:50,008,494-50,026,730 12
KRT6A Keratin 6 Chromosome 12:51,167,231-51,173,289 12
KRT8 CARD2 Chromosome 12:51,577,238-51,585,127 12
KRT8 CARD2 Chromosome 12:51,577,238-51,585,127 12
ITGB7 LPAM (integrin alpha4/bet     Chromosome 12:51,871,374-51,887,267 12
RARG RARgamma, NR1B3 Chromosome 12:51,890,621-51,912,253 12
SP1 Chromosome 12:52,060,246-52,096,497 12
SP1 Chromosome 12:52,060,246-52,096,497 12
HOXC11 HOX cluster Chromosome 12:52,653,177-52,656,470 12
NFE2 NF-E2 p45 Chromosome 12:52,972,162-52,981,058 12
NFE2 NF-E2 p45 Chromosome 12:52,972,162-52,981,058 12
ITGA5 CD49e Chromosome 12:53,075,312-53,099,317 12
DCD dermicidin Chromosome 12:53,324,642-53,328,416 12
DCD dermicidin Chromosome 12:53,324,642-53,328,416 12
ITGA7 Chromosome 12:54,364,619-54,387,949 12
ITGA7 Chromosome 12:54,364,619-54,387,949 12
DGK alpha Chromosome 12:54,611,213-54,634,074 12
SILV SIL Chromosome 12:54,634,156-54,646,765 12
IL23A Chromosome 12:55,018,926-55,020,461 12
NACA NAC Chromosome 12:55,392,484-55,407,248 12
NACA NAC Chromosome 12:55,392,484-55,407,248 12
NAB2 Chromosome 12:55,769,157-55,775,526 12
SHMT2 serine hydroxymethyltransChromosome 12:55,909,819-55,914,981 12
SHMT2 serine hydroxymethyltransChromosome 12:55,909,819-55,914,981 12
INHBC inhibin Chromosome 12:56,114,810-56,130,876 12
INHBE inhibin Chromosome 12:56,135,363-56,138,058 12
CDK4 Chromosome 12:56,428,270-56,432,431 12
CTDSP2 NIF2 Chromosome 12:56,499,977-56,527,014 12
CD9 MRP1 Chromosome 12:6,179,134-6,217,688 12
TNFRSF1A CD120a Chromosome 12:6,308,184-6,321,522 12
TNFRSF1A CD120a Chromosome 12:6,308,184-6,321,522 12
LTBR LTbetaR Chromosome 12:6,363,595-6,370,994 12
GAPDH GAPD Chromosome 12:6,513,872-6,517,797 12
GAPDH GAPD Chromosome 12:6,513,872-6,517,797 12
CD4 OKT4, Leu3a Chromosome 12:6,768,912-6,800,237 12
GNB3 G-protein beta Chromosome 12:6,819,636-6,826,819 12
IRAK3 IRAK M Chromosome 12:64,869,270-64,928,684 12
IRAK3 IRAK M Chromosome 12:64,869,270-64,928,684 12
DYRK2 Chromosome 12:66,329,021-66,340,410 12
DYRK2 Chromosome 12:66,329,021-66,340,410 12
IFNG Chromosome 12:66,834,816-66,839,790 12
IFNG Chromosome 12:66,834,816-66,839,790 12
IFNG Chromosome 12:66,834,816-66,839,790 12
IFNG Interferon gamma Chromosome 12:66,834,816-66,839,790 12
IL22 Chromosome 12:66,928,292-66,933,651 12
MDM2 Chromosome 12:67,488,247-67,520,481 12
MDM2 Chromosome 12:67,488,247-67,520,481 12
PTPRB Chromosome 12:69,201,231-69,317,469 12
PTPRB Chromosome 12:69,201,231-69,317,469 12
PTPRR Chromosome 12:69,318,129-69,600,853 12
PTPRR Chromosome 12:69,318,129-69,600,853 12
C1RL Chromosome 12:7,138,291-7,153,069 12
CLEC4C BDCA2 Chromosome 12:7,773,278-7,793,336 12
CLEC4C BDCA2 Chromosome 12:7,773,278-7,793,336 12
PAWR PRKC1 Chromosome 12:78,509,876-78,608,921 12
PTPRQ Chromosome 12:79,318,597-79,598,099 12
PTPRQ Chromosome 12:79,318,597-79,598,099 12
PTPRQ Chromosome 12:79,318,597-79,598,099 12
FOXJ2 Chromosome 12:8,076,626-8,099,385 12
FOXJ2 Chromosome 12:8,076,626-8,099,385 12
CLEC4a DCIR Chromosome 12:8,167,493-8,182,470 12
CLEC4D Chromosome 12:8,557,403-8,566,229 12
A2ML1 alpha 2 microglobulin-like Chromosome 12:8,866,484-8,920,646 12
KITLG Stem cell factor=SCF Chromosome 12:87,410,697-87,498,369 12
KITLG Stem cell factor=SCF Chromosome 12:87,410,697-87,498,369 12
DUSP6 Chromosome 12:88,265,968-88,270,427 12
DUSP6 Chromosome 12:88,265,968-88,270,427 12
KLRG1 Chromosome 12:9,033,484-9,054,610 12
DDX12 Chromosome 12:9,460,894-9,492,092 12
DDX12 Chromosome 12:9,460,894-9,492,092 12
DDX12 Chromosome 12:9,460,894-9,492,092 12
KLRB1 CD161 Chromosome 12:9,638,415-9,651,764 12
KLRF1 Chromosome 12:9,871,344-9,888,871 12
DCN Decorin Chromosome 12:90,063,166-90,100,937 12
DCN Decorin Chromosome 12:90,063,166-90,100,937 12
BTG1 Chromosome 12:91,061,030-91,063,751 12
EEA1 Chromosome 12:91,693,257-91,847,138 12
EEA1 Chromosome 12:91,693,257-91,847,138 12
UBE2N UBC13 Chromosome 12:92,326,219-92,360,157 12
SOCS2 Chromosome 12:92,487,729-92,494,109 12
SOCS2 Chromosome 12:92,487,729-92,494,109 12
CRADD CED-3, RAIDD Chromosome 12:92,595,282-92,768,663 12
CRADD CED-3, RAIDD Chromosome 12:92,595,282-92,768,663 12
CRADD CED-3, RAIDD Chromosome 12:92,595,282-92,768,663 12
CRADD CED-3, RAIDD Chromosome 12:92,595,282-92,768,663 12
PLXNC1 CD232, Plexin C1 Chromosome 12:93,066,630-93,223,356 12
PLXNC1 CD232, Plexin C1 Chromosome 12:93,066,630-93,223,356 12
PLXNC1 CD232, Plexin C1 Chromosome 12:93,066,630-93,223,356 12
NR2C1 NR2C1 Chromosome 12:93,939,802-93,991,487 12
LTA4H Chromosome 12:94,918,742-94,953,496 12
LTA4H Chromosome 12:94,918,742-94,953,496 12
TMPO thymopoietin Chromosome 12:97,433,527-97,468,250 12
TMPO thymopoietin Chromosome 12:97,433,527-97,468,250 12
APAF1 CED-4 Chromosome 12:97,563,209-97,653,342 12
APAF1 CED-4 Chromosome 12:97,563,209-97,653,342 12
APAF1 CED-4 Chromosome 12:97,563,209-97,653,342 12
NR1H4 NR1H4 Chromosome 12:99,391,810-99,481,774 12
NR1H4 NR1H4 Chromosome 12:99,391,810-99,481,774 12
NR1H4 NR1H4 Chromosome 12:99,391,810-99,481,774 12
NR1H4 NR1H4 Chromosome 12:99,391,810-99,481,774 12
ITGBL1 Chromosome 13:100,902,857-101,169,146 13
ITGBL1 Chromosome 13:100,902,857-101,169,146 13
ITGBL1 Chromosome 13:100,902,857-101,169,146 13
ITGBL1 Chromosome 13:100,902,857-101,169,146 13
FGF14 FGF14 Chromosome 13:101,169,308-101,852,156 13
FGF14 FGF14 Chromosome 13:101,169,308-101,852,156 13
FGF14 FGF14 Chromosome 13:101,169,308-101,852,156 13
FGF14 FGF14 Chromosome 13:101,169,308-101,852,156 13
FGF14 FGF14 Chromosome 13:101,169,308-101,852,156 13
FGF14 FGF14 Chromosome 13:101,169,308-101,852,156 13
FGF14 FGF14 Chromosome 13:101,169,308-101,852,156 13
ERCC5 Chromosome 13:102,295,195-102,326,346 13
LIG4 Chromosome 13:107,657,791-107,668,717 13
TNFSF13B CD257, BAFF, BLYS Chromosome 13:107,719,978-107,758,826 13
COL4A1 Chromosome 13:109,599,311-109,757,505 13
COL4A1 Chromosome 13:109,599,311-109,757,505 13
COL4A2 Chromosome 13:109,757,632-109,963,375 13
LAMP1 CD107a Chromosome 13:112,999,557-113,025,746 13
IL17D Chromosome 13:20,175,479-20,195,237 13
SAP18 Chromosome 13:20,612,650-20,621,221 13
SAP18 Chromosome 13:20,612,650-20,621,221 13
FGF9 FGF9 Chromosome 13:21,143,170-21,176,637 13
FGF9 FGF9 Chromosome 13:21,143,170-21,176,637 13
TNFRSF19 Chromosome 13:23,042,723-23,148,232 13
TNFRSF19 Chromosome 13:23,042,723-23,148,232 13
TNFRSF19 Chromosome 13:23,042,723-23,148,232 13
CDK8 Chromosome 13:25,726,276-25,877,375 13
CDK8 Chromosome 13:25,726,276-25,877,375 13
CDK8 Chromosome 13:25,726,276-25,877,375 13
WASF3 Wiskott Aldrich Chromosome 13:26,029,840-26,161,085 13
GTF3A Chromosome 13:26,896,681-26,907,823 13
GTF3A Chromosome 13:26,896,681-26,907,823 13
CDX2 Chromosome 13:27,434,273-27,441,317 13
FLT3 CD135 Chromosome 13:27,475,411-27,572,729 13
FLT3 CD135 Chromosome 13:27,475,411-27,572,729 13
FLT1 CD308, VEGFR1 Chromosome 13:27,773,790-27,967,232 13
FLT1 CD308, VEGFR1 Chromosome 13:27,773,790-27,967,232 13
FLT1 CD308, VEGFR1 Chromosome 13:27,773,790-27,967,232 13
HMGB1 Chromosome 13:29,930,884-30,089,729 13
HMGB1 Chromosome 13:29,930,884-30,089,729 13
HMGB1 Chromosome 13:29,930,884-30,089,729 13
HMGB1 Chromosome 13:29,930,884-30,089,729 13
ALOX5AP Chromosome 13:30,207,645-30,236,556 13
BRCA2 Chromosome 13:31,787,617-31,871,809 13
CCNA1 Chromosome 13:35,904,495-35,915,008 13
RFXAP Chromosome 13:36,291,339-36,301,740 13
FOXO1A Chromosome 13:40,027,801-40,138,734 13
FOXO1A Chromosome 13:40,027,801-40,138,734 13
TNFSF11 CD254, TRANCE, OPGL, Chromosome 13:42,034,872-42,080,148 13
TNFSF11 CD254, TRANCE, OPGL, Chromosome 13:42,034,872-42,080,148 13
GTF2F2 Chromosome 13:44,592,650-44,756,237 13
GTF2F2 Chromosome 13:44,592,650-44,756,237 13
GTF2F2 Chromosome 13:44,592,650-44,756,237 13
TPT1 Chromosome 13:44,809,008-44,813,505 13
HTR2A 5-HT2A Chromosome 13:46,305,514-46,368,179 13
HTR2A 5-HT2A Chromosome 13:46,305,514-46,368,179 13
P2RY5 Chromosome 13:47,883,170-47,887,947 13
P2RY5 Chromosome 13:47,883,170-47,887,947 13
CYSLTR2 Chromosome 13:48,178,692-48,181,499 13
LECT1 chondromodulin 1 Chromosome 13:52,175,400-52,211,948 13
ABCC4 ABCC4, MRP4 Chromosome 13:94,470,084-94,751,688 13
ABCC4 ABCC4, MRP4 Chromosome 13:94,470,084-94,751,688 13
ABCC4 ABCC4, MRP4 Chromosome 13:94,470,084-94,751,688 13
ABCC4 ABCC4, MRP4 Chromosome 13:94,470,084-94,751,688 13
EBI2 Chromosome 13:98,744,790-98,757,708 13
EBI2 Chromosome 13:98,744,790-98,757,708 13
HSP90AA1 HSP90 Chromosome 14:101,617,139-101,675,776 14
RAGE Chromosome 14:101,762,375-101,841,284 14
TRAF3 Chromosome 14:102,313,569-102,442,381 14
TRAF3 Chromosome 14:102,313,569-102,442,381 14
BAG5 Chromosome 14:103,092,642-103,098,907 14
XRCC3 Chromosome 14:103,233,707-103,251,549 14
SIVA Chromosome 14:104,290,529-104,297,036 14
GPR132 G2A Chromosome 14:104,586,782-104,602,799 14
IGHD1-20 Chromosome 14:105,428,094-105,428,110 14
IGHD1-20 Chromosome 14:105,428,094-105,428,110 14
CCNB1IP1 Chromosome 14:19,849,367-19,871,297 14
CCNB1IP1 Chromosome 14:19,849,367-19,871,297 14
RNASE6 Chromosome 14:20,319,050-20,320,464 14
RNASE7 ribonuclease Chromosome 14:20,580,251-20,582,226 14
TRA@ TCR Chromosome 14:21,159,897-22,090,915 14
TRA@ TCR Chromosome 14:21,159,897-22,090,915 14
TRA@ TCR Chromosome 14:21,159,897-22,090,915 14
TRA@ TCR Chromosome 14:21,159,897-22,090,915 14
TRA@ TCR Chromosome 14:21,159,897-22,090,915 14
TRA@ TCR Chromosome 14:21,159,897-22,090,915 14
TRA@ TCR Chromosome 14:21,159,897-22,090,915 14
TRA@ TCR Chromosome 14:21,159,897-22,090,915 14
TRA@ TCR Chromosome 14:21,159,897-22,090,915 14
MMP14 Chromosome 14:22,375,633-22,386,643 14
MMP14 Chromosome 14:22,375,633-22,386,643 14
PRMT5 PRMT5 Chromosome 14:22,459,573-22,468,501 14
CEBPE Chromosome 14:22,656,355-22,658,665 14
BCL2L2 Chromosome 14:22,845,866-22,850,798 14
IL25 IL17E Chromosome 14:22,911,858-22,915,452 14
PSME1 Chromosome 14:23,661,207-23,678,016 14
CHMP4A CHMP4A Chromosome 14:23,748,627-23,755,020 14
NFATC4 Chromosome 14:23,907,094-23,918,650 14
CTSG carthepsin G Chromosome 14:24,112,564-24,115,306 14
GZMB Granzyme B Chromosome 14:24,170,000-24,173,313 14
GZMB Granzyme B Chromosome 14:24,170,000-24,173,313 14
FOXG1C Chromosome 14:28,304,801-28,308,621 14
FOXG1C Chromosome 14:28,304,801-28,308,621 14
PRKD1 Chromosome 14:29,115,436-29,466,651 14
PRKD1 Chromosome 14:29,115,436-29,466,651 14
PRKD1 Chromosome 14:29,115,436-29,466,651 14
PRKD1 Chromosome 14:29,115,436-29,466,651 14
PRKD1 Chromosome 14:29,115,436-29,466,651 14
CFL2 Chromosome 14:34,249,398-34,253,649 14
CFL2 Chromosome 14:34,249,398-34,253,649 14
NFKBIA IkB alpha Chromosome 14:34,940,468-34,943,703 14
NFKBIA IkB alpha Chromosome 14:34,940,468-34,943,703 14
FOXA1 Chromosome 14:37,128,940-37,134,240 14
FOXA1 Chromosome 14:37,128,940-37,134,240 14
SSTR1 sst1 receptor Chromosome 14:37,746,955-37,752,019 14
SSTR1 sst1 receptor Chromosome 14:37,746,955-37,752,019 14
FKBP3 Calcineurin Chromosome 14:44,654,859-44,674,272 14
PPIL5 Chromosome 14:49,135,165-49,151,140 14
MAP4K5 Chromosome 14:49,954,993-50,069,126 14
MAP4K5 Chromosome 14:49,954,993-50,069,126 14
TXNDC Chromosome 14:50,776,686-50,792,512 14
PTGDR Chromosome 14:51,804,181-51,813,192 14
PTGER2 EP2 Chromosome 14:51,850,863-51,865,074 14
PSMC6 Chromosome 14:52,243,668-52,264,466 14
BMP4 BMP4 Chromosome 14:53,486,207-53,493,362 14
BMP4 BMP4 Chromosome 14:53,486,207-53,493,362 14
CDKN3 Chromosome 14:53,933,423-53,956,682 14
SOCS4 Chromosome 14:54,563,594-54,585,960 14
PELI2 Pellino2 Chromosome 14:55,654,846-55,837,784 14
PELI2 Pellino2 Chromosome 14:55,654,846-55,837,784 14
PELI2 Pellino2 Chromosome 14:55,654,846-55,837,784 14
PELI2 Pellino2 Chromosome 14:55,654,846-55,837,784 14
PRKCH PKCή Chromosome 14:60,858,186-61,087,451 14
PRKCH PKCή Chromosome 14:60,858,186-61,087,451 14
PRKCH PKCή Chromosome 14:60,858,186-61,087,451 14
PRKCH PKCή Chromosome 14:60,858,186-61,087,451 14
GPHB5 GPHB5 Chromosome 14:62,849,395-62,854,316 14
GPHB5 GPHB5 Chromosome 14:62,849,395-62,854,316 14
ESR2 Estrogen receptor beta, NChromosome 14:63,621,388-63,875,070 14
ESR2 Estrogen receptor beta, NChromosome 14:63,621,388-63,875,070 14
ESR2 Estrogen receptor beta, NChromosome 14:63,621,388-63,875,070 14
GPX2 Chromosome 14:64,475,625-64,479,284 14
ACTN1 alpha actinin 1 Chromosome 14:68,410,793-68,515,747 14
ACTN1 alpha actinin 1 Chromosome 14:68,410,793-68,515,747 14
MAP3K9 Chromosome 14:70,264,605-70,345,641 14
MAP3K9 Chromosome 14:70,264,605-70,345,641 14
FOS C-Fos Chromosome 14:74,815,284-74,818,685 14
BTAF Chromosome 14:75,058,537-75,083,086 14
BTAF Chromosome 14:75,058,537-75,083,086 14
TGFB3 Chromosome 14:75,494,195-75,517,242 14
TGFB3 Chromosome 14:75,494,195-75,517,242 14
ESRRB NR3B2 Chromosome 14:75,907,479-76,036,961 14
ESRRB NR3B2 Chromosome 14:75,907,479-76,036,961 14
ESRRB NR3B2 Chromosome 14:75,907,479-76,036,961 14
ALKBH1 Chromosome 14:77,208,502-77,244,109 14
ALKBH1 Chromosome 14:77,208,502-77,244,109 14
TSHR thyroid stimulating hormon  Chromosome 14:80,491,528-80,682,399 14
TSHR thyroid stimulating hormon  Chromosome 14:80,491,528-80,682,399 14
GTF2A1 TFIIA Chromosome 14:80,716,147-80,757,328 14
GALC Lactosylceramide Chromosome 14:87,469,111-87,529,660 14
GALC Lactosylceramide Chromosome 14:87,469,111-87,529,660 14
PTPN21 PTPD1 Chromosome 14:88,003,867-88,090,876 14
PTPN21 PTPD1 Chromosome 14:88,003,867-88,090,876 14
CHES1 FOXN3 Chromosome 14:88,692,274-88,953,127 14
CHES1 FOXN3 Chromosome 14:88,692,274-88,953,127 14
CHES1 FOXN3 Chromosome 14:88,692,274-88,953,127 14
CHES1 FOXN3 Chromosome 14:88,692,274-88,953,127 14
GPR68 OGR1, I-2 Chromosome 14:90,768,629-90,789,977 14
GPR68 OGR1, I-2 Chromosome 14:90,768,629-90,789,977 14
LGMN AEP Chromosome 14:92,239,907-92,284,765 14
LGMN AEP Chromosome 14:92,239,907-92,284,765 14
MOAP1 Chromosome 14:92,718,294-92,721,002 14
DDX24 Chromosome 14:93,587,019-93,617,311 14
DDX24 Chromosome 14:93,587,019-93,617,311 14
SERPINA2 Serpin a3g Chromosome 14:93,900,404-93,914,178 14
SERPINA2 Serpin a3g Chromosome 14:93,900,404-93,914,178 14
BDKRB2 Bradykinin receptor Chromosome 14:95,740,950-95,780,542 14
BDKRB2 Bradykinin receptor Chromosome 14:95,740,950-95,780,542 14
CYP46A1 Chromosome 14:99,220,407-99,263,391 14
CYP46A1 Chromosome 14:99,220,407-99,263,391 14
YY1 Chromosome 14:99,774,855-99,814,557 14
YY1 Chromosome 14:99,774,855-99,814,557 14
SNRPN Chromosome 15:22,619,887-23,215,702 15
SNRPN Chromosome 15:22,619,887-23,215,702 15
SNRPN Chromosome 15:22,619,887-23,215,702 15
SNRPN Chromosome 15:22,619,887-23,215,702 15
SNRPN Chromosome 15:22,619,887-23,215,702 15
AVEN Chromosome 15:31,945,720-32,118,595 15
AVEN Chromosome 15:31,945,720-32,118,595 15
AVEN Chromosome 15:31,945,720-32,118,595 15
ACTC1 F-actin Chromosome 15:32,869,723-32,875,181 15
ACTC1 F-actin Chromosome 15:32,869,723-32,875,181 15
RASGRP1 rasGRP Chromosome 15:36,567,590-36,644,224 15
THBS1 thrombospondin Chromosome 15:37,660,572-37,676,960 15
THBS1 thrombospondin Chromosome 15:37,660,572-37,676,960 15
PLCB2 phospholipase beta 2 Chromosome 15:38,366,448-38,387,330 15
RAD51 Chromosome 15:38,774,661-38,811,646 15
DLL4 Delta4 Chromosome 15:39,008,839-39,018,529 15
DLL4 Delta4 Chromosome 15:39,008,839-39,018,529 15
NUSAP1 Chromosome 15:39,412,361-39,460,538 15
MGA Chromosome 15:39,739,902-39,849,433 15
MGA Chromosome 15:39,739,902-39,849,433 15
HISPPD2A IPS1 Chromosome 15:41,612,949-41,769,525 15
HISPPD2A IPS1 Chromosome 15:41,612,949-41,769,525 15
PDIA3 ERp57 Chromosome 15:41,825,882-41,852,096 15
B2M Beta-2 microglobulin Chromosome 15:42,790,977-42,797,649 15
B2M Beta-2 microglobulin Chromosome 15:42,790,977-42,797,649 15
FGF7 KGF Chromosome 15:47,502,751-47,566,815 15
FGF7 KGF Chromosome 15:47,502,751-47,566,815 15
HDC Chromosome 15:48,321,436-48,345,218 15
CYP19A1 Chromosome 15:49,288,961-49,418,086 15
CYP19A1 Chromosome 15:49,288,961-49,418,086 15
MAPK6 Chromosome 15:50,098,739-50,145,754 15
BCL2L10 Chromosome 15:50,189,114-50,192,264 15
TCF12 HEB/SCBP Chromosome 15:54,998,125-55,368,008 15
TCF12 HEB/SCBP Chromosome 15:54,998,125-55,368,008 15
TCF12 HEB/SCBP Chromosome 15:54,998,125-55,368,008 15
TCF12 HEB/SCBP Chromosome 15:54,998,125-55,368,008 15
TCF12 HEB/SCBP Chromosome 15:54,998,125-55,368,008 15
ADAM10 CDw156c Chromosome 15:56,675,802-56,829,469 15
ADAM10 CDw156c Chromosome 15:56,675,802-56,829,469 15
CCNB2 cyclin B2 Chromosome 15:57,184,612-57,204,536 15
GTF2A2 Chromosome 15:57,718,358-57,736,991 15
FOXB1 Chromosome 15:58,084,427-58,085,434 15
FOXB1 Chromosome 15:58,084,427-58,085,434 15
ANXA2 Annexin-2 Chromosome 15:58,426,642-58,477,477 15
RORA RORa, NR1F1 Chromosome 15:58,576,755-59,308,794 15
RORA RORa, NR1F1 Chromosome 15:58,576,755-59,308,794 15
RORA RORa, NR1F1 Chromosome 15:58,576,755-59,308,794 15
RORA RORa, NR1F1 Chromosome 15:58,576,755-59,308,794 15
RORA RORa, NR1F1 Chromosome 15:58,576,755-59,308,794 15
RORA RORa, NR1F1 Chromosome 15:58,576,755-59,308,794 15
RORA RORa, NR1F1 Chromosome 15:58,576,755-59,308,794 15
DAPK2 Chromosome 15:61,986,288-62,125,574 15
DAPK2 Chromosome 15:61,986,288-62,125,574 15
DAPK2 Chromosome 15:61,986,288-62,125,574 15
PPIB Chromosome 15:62,235,067-62,242,407 15
ANKDD1A Chromosome 15:62,995,046-63,038,086 15
ANKDD1A Chromosome 15:62,995,046-63,038,086 15
PDCD7 Chromosome 15:63,196,770-63,213,227 15
MAP2K1 MEK1 Chromosome 15:64,466,674-64,570,936 15
MAP2K1 MEK1 Chromosome 15:64,466,674-64,570,936 15
MAP2K1 MEK1 Chromosome 15:64,466,674-64,570,936 15
SMAD3 Chromosome 15:65,145,249-65,274,587 15
SMAD3 Chromosome 15:65,145,249-65,274,587 15
MAP2K5 Chromosome 15:65,622,075-65,886,506 15
MAP2K5 Chromosome 15:65,622,075-65,886,506 15
MAP2K5 Chromosome 15:65,622,075-65,886,506 15
ITGA11 Chromosome 15:66,381,096-66,511,546 15
ITGA11 Chromosome 15:66,381,096-66,511,546 15
ITGA11 Chromosome 15:66,381,096-66,511,546 15
RPLP1 P1 Chromosome 15:67,532,177-67,534,939 15
TLE3 Chromosome 15:68,127,597-68,177,310 15
TLE3 Chromosome 15:68,127,597-68,177,310 15
NR2E3 NR2E3 Chromosome 15:69,889,948-69,897,654 15
NR2E3 NR2E3 Chromosome 15:69,889,948-69,897,654 15
HEXA Hexasaminidase Chromosome 15:70,364,122-70,455,868 15
NPTN SDFR1 Chromosome 15:71,639,410-71,712,806 15
CD276 B7-H3 Chromosome 15:71,763,675-71,793,912 15
CYP11A1 Chromosome 15:72,417,157-72,447,134 15
CYP11A1 Chromosome 15:72,417,157-72,447,134 15
CYP1A1 Chromosome 15:72,798,943-72,804,930 15
CYP1A1 Chromosome 15:72,798,943-72,804,930 15
PTPN9 Chromosome 15:73,546,515-73,658,680 15
NRG4 NRG4 Chromosome 15:74,020,333-74,091,842 15
NRG4 NRG4 Chromosome 15:74,020,333-74,091,842 15
PSTPIP1 Chromosome 15:75,074,609-75,116,727 15
PSTPIP1 Chromosome 15:75,074,609-75,116,727 15
CTSH Cathepsin H Chromosome 15:77,001,162-77,024,475 15
CTSH Cathepsin H Chromosome 15:77,001,162-77,024,475 15
BCL2A1 Bfl-1, BCL2-A1, BCL2a1b    Chromosome 15:78,040,290-78,050,698 15
IL16 Chromosome 15:79,262,148-79,392,157 15
IL16 Chromosome 15:79,262,148-79,392,157 15
IL16 Chromosome 15:79,262,148-79,392,157 15
AKAP13 HA-3 Chromosome 15:83,578,821-84,093,590 15
AKAP13 HA-3 Chromosome 15:83,578,821-84,093,590 15
AKAP13 HA-3 Chromosome 15:83,578,821-84,093,590 15
AKAP13 HA-3 Chromosome 15:83,578,821-84,093,590 15
AKAP13 HA-3 Chromosome 15:83,578,821-84,093,590 15
AKAP13 HA-3 Chromosome 15:83,578,821-84,093,590 15
ISG20 Chromosome 15:86,983,039-87,000,684 15
ISG20 Chromosome 15:86,983,039-87,000,684 15
ANPEP CD13 Chromosome 15:88,129,130-88,159,072 15
ANPEP CD13 Chromosome 15:88,129,130-88,159,072 15
BLM Bloom syndrome Chromosome 15:89,061,606-89,159,688 15
BLM Bloom syndrome Chromosome 15:89,061,606-89,159,688 15
BLM Bloom syndrome Chromosome 15:89,061,606-89,159,688 15
FURIN Chromosome 15:89,212,889-89,227,691 15
NR2F2 NR2F2 Chromosome 15:94,674,950-94,683,048 15
NR2F2 NR2F2 Chromosome 15:94,674,950-94,683,048 15
IGF1R CD221 Chromosome 15:97,010,288-97,319,034 15
IGF1R CD221 Chromosome 15:97,010,288-97,319,034 15
IGF1R CD221 Chromosome 15:97,010,288-97,319,034 15
IGF1R CD221 Chromosome 15:97,010,288-97,319,034 15
MAPK8IP3 Chromosome 16:1,696,222-1,760,319 16
NOXO1 Chromosome 16:1,968,919-1,971,441 16
CIITA MHC2TA=CIITA, C2ta Chromosome 16:10,867,648-10,926,341 16
CIITA MHC2TA=CIITA, C2ta Chromosome 16:10,867,648-10,926,341 16
SOCS1 Chromosome 16:11,255,775-11,257,540 16
SOCS1 Chromosome 16:11,255,775-11,257,540 16
LITAF lipopolysaccharide induce   Chromosome 16:11,549,357-11,588,823 16
LITAF lipopolysaccharide induce   Chromosome 16:11,549,357-11,588,823 16
TNFRSF17 CD269, BCMA Chromosome 16:11,966,465-11,969,426 16
TNFRSF17 CD269, BCMA Chromosome 16:11,966,465-11,969,426 16
MYH11 Chromosome 16:15,704,493-15,858,388 16
MYH11 Chromosome 16:15,704,493-15,858,388 16
MYH11 Chromosome 16:15,704,493-15,858,388 16
ABCC1 MRP Chromosome 16:15,950,935-16,143,774 16
HBA2 Chromosome 16:162,875-163,708 16
TRAF7 Chromosome 16:2,145,800-2,168,131 16
IGSF6 Chromosome 16:21,559,426-21,571,473 16
IGSF6 Chromosome 16:21,559,426-21,571,473 16
PLK1 Plk1 Chromosome 16:23,597,692-23,609,189 16
PLK1 Plk1 Chromosome 16:23,597,692-23,609,189 16
PRKCB1 PKC beta Chromosome 16:23,754,823-24,139,358 16
PRKCB1 PKC beta Chromosome 16:23,754,823-24,139,358 16
PRKCB1 PKC beta Chromosome 16:23,754,823-24,139,358 16
PRKCB1 PKC beta Chromosome 16:23,754,823-24,139,358 16
PRKCB1 PKC beta Chromosome 16:23,754,823-24,139,358 16
PRKCB1 PKC beta Chromosome 16:23,754,823-24,139,358 16
IL4R CD124 Chromosome 16:27,232,752-27,283,600 16
IL4R CD124 Chromosome 16:27,232,752-27,283,600 16
GTF3C1 Chromosome 16:27,379,436-27,468,775 16
AXIN1 Chromosome 16:277,441-342,465 16
IL27 Chromosome 16:28,418,184-28,425,656 16
IL27 Chromosome 16:28,418,184-28,425,656 16
SPN CD43 Chromosome 16:29,581,801-29,589,688 16
MVP lung resistance protein Chromosome 16:29,731,591-29,766,842 16
TNFRSF12A CD266, TWEAKR Chromosome 16:3,010,343-3,012,385 16
TNFRSF12A CD266, TWEAKR Chromosome 16:3,010,343-3,012,385 16
MEFV Pyrin Chromosome 16:3,232,029-3,246,628 16
MEFV Pyrin Chromosome 16:3,232,029-3,246,628 16
NLRC3 NOD3 Chromosome 16:3,531,826-3,567,290 16
NLRC3 NOD3 Chromosome 16:3,531,826-3,567,290 16
DNASE1 Chromosome 16:3,630,847-3,654,064 16
CREBBP CBP Chromosome 16:3,716,568-3,870,723 16
CREBBP CBP Chromosome 16:3,716,568-3,870,723 16
CREBBP CBP Chromosome 16:3,716,568-3,870,723 16
SEPHS2 SPS2 Chromosome 16:30,362,453-30,364,725 16
ITGAL LFA1, CD11a Chromosome 16:30,391,551-30,442,007 16
CTF1 CTF1 Chromosome 16:30,815,429-30,822,382 16
ITGAM Mac-1, CD11B Chromosome 16:31,178,789-31,251,714 16
ITGAM Mac-1, CD11B Chromosome 16:31,178,789-31,251,714 16
ITGAX CD11c, CR4 Chromosome 16:31,274,010-31,301,819 16
HMOX2 Chromosome 16:4,466,426-4,500,349 16
ITFG1 CDA08, TIP Chromosome 16:45,746,798-46,052,519 16
ITFG1 CDA08, TIP Chromosome 16:45,746,798-46,052,519 16
ITFG1 CDA08, TIP Chromosome 16:45,746,798-46,052,519 16
ABCC11 MRP8 Chromosome 16:46,758,323-46,838,806 16
ABCC11 MRP8 Chromosome 16:46,758,323-46,838,806 16
NOD2 BLAU, CARD15, CD, PSO  Chromosome 16:49,288,551-49,324,488 16
NOD2 BLAU, CARD15, CD, PSO  Chromosome 16:49,288,551-49,324,488 16
AKTIP FTS Chromosome 16:52,082,693-52,094,671 16
AKTIP FTS Chromosome 16:52,082,693-52,094,671 16
MMP2 Chromosome 16:54,070,589-54,098,104 16
MMP2 Chromosome 16:54,070,589-54,098,104 16
CES1 Carboxylesterase 3 Chromosome 16:54,394,264-54,424,576 16
MT3 Chromosome 16:55,180,768-55,182,501 16
MT3 Chromosome 16:55,180,768-55,182,501 16
NLRC5 NOD27 Chromosome 16:55,581,018-55,673,941 16
NLRC5 NOD27 Chromosome 16:55,581,018-55,673,941 16
NLRC5 NOD27 Chromosome 16:55,581,018-55,673,941 16
CCL22 Chromosome 16:55,950,219-55,957,602 16
CCL17 Chromosome 16:55,996,180-56,007,475 16
MMP15 Chromosome 16:56,616,783-56,638,306 16
MMP15 Chromosome 16:56,616,783-56,638,306 16
CDH5 CD144, VE-cadherin Chromosome 16:64,958,064-64,996,190 16
CDH5 CD144, VE-cadherin Chromosome 16:64,958,064-64,996,190 16
CKLF Chromosome 16:65,143,967-65,170,463 16
CBFB Chromosome 16:65,620,551-65,692,462 16
CBFB Chromosome 16:65,620,551-65,692,462 16
TRADD Chromosome 16:65,745,605-65,751,306 16
NOL3 MYC Chromosome 16:65,765,371-65,767,127 16
PSMB10 proteasome subunit Chromosome 16:66,525,908-66,528,254 16
PSMB10 proteasome subunit Chromosome 16:66,525,908-66,528,254 16
NFATC3 Chromosome 16:66,676,845-66,818,338 16
PRMT7 PRMT7 Chromosome 16:66,902,446-66,948,663 16
MPG Chromosome 16:67,018-75,845 16
CDH1 CD324, E-cadherin Chromosome 16:67,328,696-67,426,945 16
NFAT5 Chromosome 16:68,156,498-68,296,054 16
NFAT5 Chromosome 16:68,156,498-68,296,054 16
DDX19B Chromosome 16:68,890,573-68,925,232 16
DHX38 Chromosome 16:70,685,116-70,704,312 16
DHX38 Chromosome 16:70,685,116-70,704,312 16
ATBF1 Chromosome 16:71,378,456-71,639,775 16
ATBF1 Chromosome 16:71,378,456-71,639,775 16
ATBF1 Chromosome 16:71,378,456-71,639,775 16
ATBF1 Chromosome 16:71,378,456-71,639,775 16
ATBF1 Chromosome 16:71,378,456-71,639,775 16
ATBF1 Chromosome 16:71,378,456-71,639,775 16
CFDP1 Chromosome 16:73,885,109-74,024,888 16
CFDP1 Chromosome 16:73,885,109-74,024,888 16
CFDP1 Chromosome 16:73,885,109-74,024,888 16
CLEC3A Chromosome 16:76,613,992-76,623,499 16
MAF cMaf Chromosome 16:78,185,732-78,192,112 16
MAF cMaf Chromosome 16:78,185,732-78,192,112 16
GINS2 Chromosome 16:84,268,781-84,280,089 16
IRF8 ICSBP Chromosome 16:84,490,275-84,513,713 16
IRF8 ICSBP Chromosome 16:84,490,275-84,513,713 16
FOXF1 Chromosome 16:85,101,659-85,105,548 16
FOXF1 Chromosome 16:85,101,659-85,105,548 16
SLC7A5 Chromosome 16:86,421,130-86,460,615 16
SLC7A5 Chromosome 16:86,421,130-86,460,615 16
IL17C Chromosome 16:87,232,502-87,234,383 16
MC1R MC1 Chromosome 16:88,512,527-88,529,713 16
SCARF1 Chromosome 17:1,483,902-1,495,792 17
SCARF1 Chromosome 17:1,483,902-1,495,792 17
SMG6 Chromosome 17:1,909,888-2,220,160 17
SMG6 Chromosome 17:1,909,888-2,220,160 17
SMG6 Chromosome 17:1,909,888-2,220,160 17
SMG6 Chromosome 17:1,909,888-2,220,160 17
MYH2 myosin heavy chain 2a Chromosome 17:10,365,192-10,393,704 17
MYH2 myosin heavy chain 2a Chromosome 17:10,365,192-10,393,704 17
MAP2K4 MKK4 Chromosome 17:11,864,860-11,987,865 17
IL6STP Chromosome 17:15,616,046-15,629,130 17
IL6STP Chromosome 17:15,616,046-15,629,130 17
NCOR1 NCoR Chromosome 17:15,875,983-16,059,570 17
NCOR1 NCoR Chromosome 17:15,875,983-16,059,570 17
TRPV2 Chromosome 17:16,259,613-16,281,042 17
TNFRSF13B CD267, TAC1 Chromosome 17:16,783,123-16,816,127 17
SREBF1 SREBP1a,b,c Chromosome 17:17,655,794-17,681,050 17
DRG2 DRG2 Chromosome 17:17,932,008-17,952,017 17
DRG2 DRG2 Chromosome 17:17,932,008-17,952,017 17
ALKBH5 Chromosome 17:18,028,014-18,053,993 17
FOXO3B Chromosome 17:18,516,347-18,516,964 17
MAPK7 Chromosome 17:19,221,659-19,227,445 17
PAFAH1B1 PAF, platelet activating fa Chromosome 17:2,443,686-2,535,638 17
PAFAH1B1 PAF, platelet activating fa Chromosome 17:2,443,686-2,535,638 17
PAFAH1B1 PAF, platelet activating fa Chromosome 17:2,443,686-2,535,638 17
MAP2K3 Chromosome 17:21,128,581-21,159,118 17
LGALS9 Galectin 9 Chromosome 17:22,980,951-23,000,711 17
NOS2A NO synthase, iNOS Chromosome 17:23,107,919-23,151,682 17
NOS2A NO synthase, iNOS Chromosome 17:23,107,919-23,151,682 17
VTN Chromosome 17:23,718,425-23,721,844 17
FOXN1 Chromosome 17:23,875,086-23,889,302 17
TIAF1 TGF antiapoptotic factor Chromosome 17:24,424,663-24,531,556 17
TIAF1 TGF antiapoptotic factor Chromosome 17:24,424,663-24,531,556 17
TIAF1 TGF antiapoptotic factor Chromosome 17:24,424,663-24,531,556 17
TIAF1 TGF antiapoptotic factor Chromosome 17:24,424,663-24,531,556 17
SLC6A4 5-HTT Chromosome 17:25,549,032-25,586,831 17
SLC6A4 5-HTT Chromosome 17:25,549,032-25,586,831 17
CRLF3 Chromosome 17:26,133,828-26,175,826 17
CRLF3 Chromosome 17:26,133,828-26,175,826 17
CCL2 MCP1 Chromosome 17:29,606,409-29,608,335 17
CCL13 MCP4 Chromosome 17:29,707,584-29,709,742 17
CCL1 Chromosome 17:29,711,512-29,714,365 17
TRPV1 VR1 Chromosome 17:3,415,491-3,459,454 17
TRPV1 VR1 Chromosome 17:3,415,491-3,459,454 17
CTNS Chromosome 17:3,486,522-3,511,585 17
ITGAE HML-1, CD103 Chromosome 17:3,564,671-3,660,578 17
P2RX1 P2X1 Chromosome 17:3,746,634-3,766,709 17
MMP28 Chromosome 17:31,116,989-31,146,753 17
CCL5 RANTES Chromosome 17:31,222,611-31,231,490 17
LOC441792 NO synthase Chromosome 17:31,811,186-31,816,297 17
ACACA BCL2A1-ACC1 Chromosome 17:32,516,040-32,841,015 17
ACACA BCL2A1-ACC1 Chromosome 17:32,516,040-32,841,015 17
ACACA BCL2A1-ACC1 Chromosome 17:32,516,040-32,841,015 17
DUSP14 Chromosome 17:32,924,064-32,947,709 17
DDX52 Chromosome 17:33,046,526-33,077,600 17
ERBB2 CD340 Chromosome 17:35,097,919-35,138,441 17
ERBB2 CD340 Chromosome 17:35,097,919-35,138,441 17
CSF3 Chromosome 17:35,425,214-35,427,592 17
THRA NR1A1 Chromosome 17:35,472,589-35,503,646 17
NR1D1 NR1D1 Chromosome 17:35,502,567-35,510,499 17
NR1D1 NR1D1 Chromosome 17:35,502,567-35,510,499 17
RARA NR1B1 Chromosome 17:35,718,972-35,767,420 17
TOP2A Chromosome 17:35,798,321-35,827,695 17
CCR7 CD197 Chromosome 17:35,963,547-35,975,250 17
CCR7 CD197 Chromosome 17:35,963,547-35,975,250 17
KRT34 HA-4 Chromosome 17:36,787,447-36,792,181 17
KRT35 HA-5 Chromosome 17:36,886,467-36,891,194 17
KRT35 HA-5 Chromosome 17:36,886,467-36,891,194 17
FKBP10 Chromosome 17:37,222,727-37,232,995 17
FKBP10 Chromosome 17:37,222,727-37,232,995 17
LGP2 Chromosome 17:37,506,952-37,518,277 17
LGP2 Chromosome 17:37,506,952-37,518,277 17
STAT5B Chromosome 17:37,604,721-37,681,950 17
STAT5B Chromosome 17:37,604,721-37,681,950 17
STAT5B Chromosome 17:37,604,721-37,681,950 17
CCR10 Chromosome 17:38,084,961-38,087,371 17
PSME3 Chromosome 17:38,238,949-38,249,303 17
DHX8 Chromosome 17:38,916,860-38,957,206 17
DHX8 Chromosome 17:38,916,860-38,957,206 17
DHX8 Chromosome 17:38,916,860-38,957,206 17
DUSP3 Chromosome 17:39,199,015-39,211,872 17
DUSP3 Chromosome 17:39,199,015-39,211,872 17
DUSP3 Chromosome 17:39,199,015-39,211,872 17
HDAC5 Chromosome 17:39,509,647-39,556,540 17
HDAC5 Chromosome 17:39,509,647-39,556,540 17
SLC4A1 CD233 Chromosome 17:39,682,566-39,700,993 17
ITGA2B CD41, HPA1 Chromosome 17:39,805,076-39,822,399 17
ALOX15 Chromosome 17:4,480,963-4,491,709 17
ARRB2 Beta arrestin 2 Chromosome 17:4,560,533-4,571,544 17
PSMB6 Chromosome 17:4,646,397-4,648,756 17
MINK Chromosome 17:4,683,351-4,742,135 17
GP1BA HPA5a,b, CD42b Chromosome 17:4,776,372-4,779,067 17
PFN1 Profilin Chromosome 17:4,789,692-4,793,067 17
C1QL1 Chromosome 17:40,392,587-40,401,170 17
C1QL1 Chromosome 17:40,392,587-40,401,170 17
MAP3K14 NIK Chromosome 17:40,696,278-40,750,148 17
MAP3K14 NIK Chromosome 17:40,696,278-40,750,148 17
MAP3K14 NIK Chromosome 17:40,696,278-40,750,148 17
CRF1R CRHR1 Chromosome 17:41,217,449-41,268,973 17
CRF1R CRHR1 Chromosome 17:41,217,449-41,268,973 17
CRF1R CRHR1 Chromosome 17:41,217,449-41,268,973 17
WNT3 Chromosome 17:42,196,855-42,251,081 17
WNT3 Chromosome 17:42,196,855-42,251,081 17
WNT3 Chromosome 17:42,196,855-42,251,081 17
ITGB3 CD60, HPA2, Mac-2, GPI Chromosome 17:42,686,207-42,745,076 17
ITGB3 CD60, HPA2, Mac-2, GPI Chromosome 17:42,686,207-42,745,076 17
ITGB3 CD60, HPA2, Mac-2, GPI Chromosome 17:42,686,207-42,745,076 17
TBX21 T-bet Chromosome 17:43,165,609-43,178,484 17
TBX21 T-bet Chromosome 17:43,165,609-43,178,484 17
TBX21 T-bet Chromosome 17:43,165,609-43,178,484 17
NFE2L1 Chromosome 17:43,480,720-43,493,841 17
SKAP1 SKAP55 Chromosome 17:43,565,804-43,862,551 17
SKAP1 SKAP55 Chromosome 17:43,565,804-43,862,551 17
SKAP1 SKAP55 Chromosome 17:43,565,804-43,862,551 17
HOXB4 HOX cluster Chromosome 17:44,007,868-44,010,742 17
NGFR CD271 Chromosome 17:44,927,654-44,947,360 17
DLX3 Delta-like 2 Chromosome 17:45,422,368-45,427,587 17
COL1A1 collagen alpha 1 Chromosome 17:45,616,456-45,633,992 17
COL1A1 collagen alpha 1 Chromosome 17:45,616,456-45,633,992 17
NME1 NM23H1 Chromosome 17:46,585,919-46,604,103 17
C1QBP Chromosome 17:5,276,823-5,283,195 17
DHX33 Chromosome 17:5,284,956-5,312,905 17
NLRP1 NALP1, CARD7, DEFCAPChromosome 17:5,343,472-5,428,553 17
HLF Hlf Chromosome 17:50,697,370-50,755,886 17
HLF Hlf Chromosome 17:50,697,370-50,755,886 17
TRIM25 ZNF147 Chromosome 17:52,320,269-52,346,408 17
TRIM25 ZNF147 Chromosome 17:52,320,269-52,346,408 17
EPX eosinophil peroxidase Chromosome 17:53,625,088-53,636,783 17
MPO Chromosome 17:53,702,201-53,713,295 17
MPO Chromosome 17:53,702,201-53,713,295 17
DHX40 Chromosome 17:54,997,668-55,040,484 17
DHX40 Chromosome 17:54,997,668-55,040,484 17
MRC2 Endo180, CD280, mannos   Chromosome 17:58,058,494-58,124,629 17
MRC2 Endo180, CD280, mannos   Chromosome 17:58,058,494-58,124,629 17
MRC2 Endo180, CD280, mannos   Chromosome 17:58,058,494-58,124,629 17
ACE CD143 Chromosome 17:58,908,166-58,952,935 17
DDX42 Chromosome 17:59,205,299-59,250,409 17
GH1 GH1 Chromosome 17:59,348,294-59,349,930 17
PECAM1 CD31 Chromosome 17:59,754,142-59,817,723 17
DDX5 Chromosome 17:59,926,200-59,932,872 17
ALOX12 Chromosome 17:6,840,108-6,856,220 17
CLECSF10A CD301, MGL1, CLEC10A Chromosome 17:6,918,580-6,924,324 17
GNA13 Chromosome 17:60,437,295-60,483,216 17
GNA13 Chromosome 17:60,437,295-60,483,216 17
AXIN2 Chromosome 17:60,955,143-60,988,227 17
AXIN2 Chromosome 17:60,955,143-60,988,227 17
PRKCA PKC alpha Chromosome 17:61,729,388-62,237,324 17
PRKCA PKC alpha Chromosome 17:61,729,388-62,237,324 17
PRKCA PKC alpha Chromosome 17:61,729,388-62,237,324 17
PRKCA PKC alpha Chromosome 17:61,729,388-62,237,324 17
PRKCA PKC alpha Chromosome 17:61,729,388-62,237,324 17
PRKCA PKC alpha Chromosome 17:61,729,388-62,237,324 17
PRKCA PKC alpha Chromosome 17:61,729,388-62,237,324 17
MAP2K6 Chromosome 17:64,922,433-65,051,067 17
MAP2K6 Chromosome 17:64,922,433-65,051,067 17
SSTR2 sst2 receptor Chromosome 17:68,672,755-68,679,689 17
SSTR2 sst2 receptor Chromosome 17:68,672,755-68,679,689 17
SSTR2 sst2 receptor Chromosome 17:68,672,755-68,679,689 17
CD300A IGSF12, MAIR1, IRC1, IR Chromosome 17:69,974,117-69,992,528 17
CD300A IGSF12, MAIR1, IRC1, IR Chromosome 17:69,974,117-69,992,528 17
GPS2 Chromosome 17:7,156,702-7,173,362 17
FGF11 FGF11 Chromosome 17:7,283,413-7,288,980 17
TNFRSF13C CD268, BAFFR Chromosome 17:7,392,932-7,405,649 17
TNFSF12-13 Chromosome 17:7,393,099-7,405,649 17
ALOX15B Chromosome 17:7,883,083-7,893,177 17
CD300C CMRF35A1-6, -H, LIR Chromosome 17:70,048,842-70,053,877 17
ENSG00000204MAIR2, CD300d Chromosome 17:70,087,099-70,100,017 17
CD300LF IREM1 Chromosome 17:70,202,047-70,220,712 17
SLC25A19 Mup1 Chromosome 17:70,780,669-70,797,109 17
SLC25A19 Mup1 Chromosome 17:70,780,669-70,797,109 17
ITGB4 CD104 Chromosome 17:71,229,111-71,265,494 17
FOXJ1 Chromosome 17:71,644,009-71,648,966 17
FOXJ1 Chromosome 17:71,644,009-71,648,966 17
SPHK1 sphingosine kinase Chromosome 17:71,892,297-71,895,536 17
SPHK1 sphingosine kinase Chromosome 17:71,892,297-71,895,536 17
PTDSR Chromosome 17:72,220,514-72,234,158 17
BIRC5 SURVIVIN Chromosome 17:73,721,872-73,733,311 17
BIRC5 SURVIVIN Chromosome 17:73,721,872-73,733,311 17
SOCS3 Chromosome 17:73,864,454-73,867,753 17
SOCS3 Chromosome 17:73,864,454-73,867,753 17
PSCD1 Cytohesin-1 Chromosome 17:74,181,727-74,289,971 17
PSCD1 Cytohesin-1 Chromosome 17:74,181,727-74,289,971 17
TIMP2 Chromosome 17:74,360,654-74,433,067 17
EIF4A3 Chromosome 17:75,723,612-75,735,533 17
EIF4A3 Chromosome 17:75,723,612-75,735,533 17
CHMP6 CHMP6 Chromosome 17:76,580,274-76,588,528 17
AATK Chromosome 17:76,705,160-76,754,467 17
ACTG1 F-actin Chromosome 17:77,091,594-77,094,422 17
ARHGDIA Rho GD1 Chromosome 17:77,418,886-77,422,527 17
CD7 gp40, gp41 Chromosome 17:77,866,035-77,868,769 17
SECTM1 Chromosome 17:77,872,189-77,884,930 17
FOXK2 ILF1 Chromosome 17:78,070,883-78,153,743 17
FOXK2 ILF1 Chromosome 17:78,070,883-78,153,743 17
PIK3R5 Chromosome 17:8,722,953-8,756,559 17
PIK3R5 Chromosome 17:8,722,953-8,756,559 17
PIK3R5 Chromosome 17:8,722,953-8,756,559 17
GNAL G protein alpha Chromosome 18:11,679,263-11,871,922 18
GNAL G protein alpha Chromosome 18:11,679,263-11,871,922 18
GNAL G protein alpha Chromosome 18:11,679,263-11,871,922 18
GNAL G protein alpha Chromosome 18:11,679,263-11,871,922 18
GNAL G protein alpha Chromosome 18:11,679,263-11,871,922 18
PTPN2 Chromosome 18:12,775,480-12,874,334 18
PTPN2 Chromosome 18:12,775,480-12,874,334 18
RNMT Chromosome 18:13,716,680-13,754,554 18
RNMT Chromosome 18:13,716,680-13,754,554 18
MC5R melanocortin receptor 5 Chromosome 18:13,815,543-13,816,861 18
ROCK1 Chromosome 18:16,787,533-16,944,869 18
ROCK1 Chromosome 18:16,787,533-16,944,869 18
GATA6 Chromosome 18:18,003,414-18,036,225 18
LAMA3 Chromosome 18:19,523,560-19,789,028 18
LAMA3 Chromosome 18:19,523,560-19,789,028 18
LAMA3 Chromosome 18:19,523,560-19,789,028 18
HRH4 Chromosome 18:20,294,591-20,313,919 18
HRH4 Chromosome 18:20,294,591-20,313,919 18
THOC1 Chromosome 18:204,522-258,049 18
CDH2 CD325, N-cadherin Chromosome 18:23,784,933-24,011,189 18
CDH2 CD325, N-cadherin Chromosome 18:23,784,933-24,011,189 18
CDH2 CD325, N-cadherin Chromosome 18:23,784,933-24,011,189 18
CDH2 CD325, N-cadherin Chromosome 18:23,784,933-24,011,189 18
CDH2 CD325, N-cadherin Chromosome 18:23,784,933-24,011,189 18
TGIF1 Chromosome 18:3,402,072-3,448,409 18
TGIF1 Chromosome 18:3,402,072-3,448,409 18
TGIF1 Chromosome 18:3,402,072-3,448,409 18
COLEC12 SRCL-1, SCARA4 Chromosome 18:309,356-490,685 18
COLEC12 SRCL-1, SCARA4 Chromosome 18:309,356-490,685 18
PIK3C3 Chromosome 18:37,789,197-37,915,446 18
PIK3C3 Chromosome 18:37,789,197-37,915,446 18
PIK3C3 Chromosome 18:37,789,197-37,915,446 18
SLC14A1 Kidd antigen Chromosome 18:41,558,155-41,585,297 18
SLC14A1 Kidd antigen Chromosome 18:41,558,155-41,585,297 18
CD33L3 Chromosome 18:41,659,543-41,678,045 18
SMAD7 Chromosome 18:44,700,221-44,731,079 18
SMAD7 Chromosome 18:44,700,221-44,731,079 18
MAPK4 Chromosome 18:46,340,482-46,512,194 18
MAPK4 Chromosome 18:46,340,482-46,512,194 18
MAPK4 Chromosome 18:46,340,482-46,512,194 18
TCF4 ITF2 Chromosome 18:51,045,967-51,406,858 18
TCF4 ITF2 Chromosome 18:51,045,967-51,406,858 18
TCF4 ITF2 Chromosome 18:51,045,967-51,406,858 18
TCF4 ITF2 Chromosome 18:51,045,967-51,406,858 18
MALT1 Chromosome 18:54,489,598-54,568,350 18
MALT1 Chromosome 18:54,489,598-54,568,350 18
RAX Chromosome 18:55,085,251-55,091,605 18
RAX Chromosome 18:55,085,251-55,091,605 18
LMAN1 MBL1 Chromosome 18:55,148,088-55,177,463 18
MC4R melanocortin receptor 4 Chromosome 18:56,189,564-56,190,562 18
MC4R melanocortin receptor 4 Chromosome 18:56,189,564-56,190,562 18
TNFRSF11A CD265, OPG, RANK Chromosome 18:58,143,500-58,205,872 18
TNFRSF11A CD265, OPG, RANK Chromosome 18:58,143,500-58,205,872 18
BCL2 Chromosome 18:58,941,559-59,137,593 18
BCL2 Chromosome 18:58,941,559-59,137,593 18
BCL2 Chromosome 18:58,941,559-59,137,593 18
SERPINB2 Chromosome 18:59,705,922-59,722,100 18
HMSD Chromosome 18:59,767,574-59,779,093 18
LAMA1 laminin Chromosome 18:6,931,885-7,107,813 18
LAMA1 laminin Chromosome 18:6,931,885-7,107,813 18
LAMA1 laminin Chromosome 18:6,931,885-7,107,813 18
TYMS Thymidylate synthase, TSChromosome 18:647,619-663,492 18
DNAM1 CD226 Chromosome 18:65,681,172-65,775,140 18
DNAM1 CD226 Chromosome 18:65,681,172-65,775,140 18
DNAM1 CD226 Chromosome 18:65,681,172-65,775,140 18
SOCS6 Chromosome 18:66,107,243-66,145,329 18
SOCS6 Chromosome 18:66,107,243-66,145,329 18
PTPRM Chromosome 18:7,557,817-8,396,854 18
PTPRM Chromosome 18:7,557,817-8,396,854 18
PTPRM Chromosome 18:7,557,817-8,396,854 18
PTPRM Chromosome 18:7,557,817-8,396,854 18
PTPRM Chromosome 18:7,557,817-8,396,854 18
PTPRM Chromosome 18:7,557,817-8,396,854 18
PTPRM Chromosome 18:7,557,817-8,396,854 18
PTPRM Chromosome 18:7,557,817-8,396,854 18
PTPRM Chromosome 18:7,557,817-8,396,854 18
YES1 Chromosome 18:711,592-802,547 18
YES1 Chromosome 18:711,592-802,547 18
MBP Chromosome 18:72,819,777-72,973,762 18
MBP Chromosome 18:72,819,777-72,973,762 18
NFATC1 Chromosome 18:75,256,760-75,390,311 18
NFATC1 Chromosome 18:75,256,760-75,390,311 18
RALBP1 RIP1 Chromosome 18:9,465,007-9,528,106 18
HMHA1 HA-1 Chromosome 19:1,018,174-1,037,627 19
TCF3 E12 Chromosome 19:1,560,293-1,603,328 19
TCF3 E12 Chromosome 19:1,560,293-1,603,328 19
TCF3 E12 Chromosome 19:1,560,293-1,603,328 19
P2RY11 P2Y11 Chromosome 19:10,083,197-10,087,065 19
P2RY11 P2Y11 Chromosome 19:10,083,197-10,087,065 19
ICAM4 CD242 Chromosome 19:10,258,650-10,260,198 19
TYK2 Chromosome 19:10,322,205-10,352,211 19
KEAP1 Chromosome 19:10,457,796-10,475,243 19
DNM2 Dynamin2 Chromosome 19:10,673,106-10,803,579 19
CARM1 PRMT4 Chromosome 19:10,843,253-10,894,448 19
SMARCA4 SWI/SNF Chromosome 19:10,932,606-11,033,953 19
LDLR LDL receptor Chromosome 19:11,061,132-11,105,490 19
RAB3D Rab3d Chromosome 19:11,296,093-11,311,321 19
EPOR Chromosome 19:11,348,883-11,356,019 19
ECSIT Chromosome 19:11,477,744-11,500,972 19
JUNB Chromosome 19:12,763,286-12,765,129 19
CALR Calreticulin Chromosome 19:12,910,423-12,916,303 19
RAD23A CARD1 Chromosome 19:12,917,654-12,925,455 19
RFX1 RFX1 Chromosome 19:13,933,352-13,978,097 19
RFX1 RFX1 Chromosome 19:13,933,352-13,978,097 19
PRKACA PKA alpha Chromosome 19:14,063,500-14,089,559 19
CD97 Chromosome 19:14,353,213-14,380,535 19
PTGER1 EP1 Chromosome 19:14,444,278-14,447,174 19
EMR3 CD313 Chromosome 19:14,570,918-14,646,810 19
EMR2 CD312 Chromosome 19:14,704,205-14,750,353 19
CASP14 Chromosome 19:15,024,015-15,027,900 19
CASP14 Chromosome 19:15,024,015-15,027,900 19
NOTCH3 Chromosome 19:15,131,444-15,172,792 19
PGLYRP2 PGRP-L Chromosome 19:15,440,463-15,451,312 19
CYP4F8 Chromosome 19:15,587,421-15,601,445 19
CYP4F3 Chromosome 19:15,612,707-15,634,634 19
CYP4F2 Chromosome 19:15,849,834-15,869,885 19
CYP4F11 Chromosome 19:15,884,181-15,906,326 19
HSH2D Chromosome 19:16,105,838-16,130,381 19
HSH2D Chromosome 19:16,105,838-16,130,381 19
HSH2D Chromosome 19:16,105,838-16,130,381 19
KLF2 KLF2 Chromosome 19:16,296,648-16,299,345 19
CHERP calcium homooestasis reg  Chromosome 19:16,489,705-16,514,248 19
NR2F6 NR2F6 Chromosome 19:17,203,694-17,217,151 19
NR2F6 NR2F6 Chromosome 19:17,203,694-17,217,151 19
BST2 CD317 Chromosome 19:17,374,755-17,377,457 19
BST2 CD317 Chromosome 19:17,374,755-17,377,457 19
B3GNT3 Chromosome 19:17,766,658-17,785,385 19
B3GNT3 Chromosome 19:17,766,658-17,785,385 19
JAK3 Chromosome 19:17,788,322-17,819,800 19
IL12RB1 CD212 Chromosome 19:18,031,371-18,058,702 19
PIK3R2 Chromosome 19:18,125,016-18,142,343 19
GDF15 CA19-9, MIC1 Chromosome 19:18,357,968-18,360,987 19
GDF15 CA19-9, MIC1 Chromosome 19:18,357,968-18,360,987 19
FKBP8 Calcineurin Chromosome 19:18,503,568-18,515,383 19
DDX49 Chromosome 19:18,891,494-18,900,436 19
RFXANK Chromosome 19:19,164,008-19,173,678 19
GADD45B Chromosome 19:2,427,135-2,429,257 19
GADD45B Chromosome 19:2,427,135-2,429,257 19
TBXAR2 thromboxane A2 receptor Chromosome 19:3,545,504-3,557,658 19
EEF2 Chromosome 19:3,927,054-3,936,461 19
PIAS4 Chromosome 19:3,958,748-3,990,383 19
CCNE1 Chromosome 19:34,994,741-35,007,059 19
CCNE1 Chromosome 19:34,994,741-35,007,059 19
PDCD5 Chromosome 19:37,763,944-37,770,171 19
CEBPA Chromosome 19:38,482,776-38,485,160 19
CEBPA Chromosome 19:38,482,776-38,485,160 19
CEBPA Chromosome 19:38,482,776-38,485,160 19
MAP2K2 MEK3 Chromosome 19:4,041,319-4,075,126 19
EBI3 IL35 Chromosome 19:4,180,495-4,188,525 19
EBI3 IL35 Chromosome 19:4,180,495-4,188,525 19
C19orf10 Chromosome 19:4,608,557-4,621,415 19
C19orf10 Chromosome 19:4,608,557-4,621,415 19
TICAM1 TRIF Chromosome 19:4,766,944-4,782,716 19
TICAM1 TRIF Chromosome 19:4,766,944-4,782,716 19
USF2 USF2a,b Chromosome 19:40,451,721-40,462,558 19
USF2 USF2a,b Chromosome 19:40,451,721-40,462,558 19
ZBTB32 ROG Chromosome 19:40,895,670-40,899,780 19
TA-NFKBH Chromosome 19:41,070,983-41,085,025 19
TA-NFKBH Chromosome 19:41,070,983-41,085,025 19
TA-NFKBH Chromosome 19:41,070,983-41,085,025 19
ALKBH6 Chromosome 19:41,191,863-41,196,981 19
MAP4K1 Chromosome 19:43,770,121-43,800,471 19
MAP4K1 Chromosome 19:43,770,121-43,800,471 19
LGALS4 galectin 4 Chromosome 19:43,984,155-43,995,422 19
NFKBIB IkB beta Chromosome 19:44,082,455-44,091,374 19
NFKBIB IkB beta Chromosome 19:44,082,455-44,091,374 19
NFKBIB IkB beta Chromosome 19:44,082,455-44,091,374 19
IL28B Chromosome 19:44,426,033-44,427,609  19
IL28A Chromosome 19:44,450,997-44,452,572 19
ZFP36 TTP Chromosome 19:44,589,293-44,591,885 19
LGALS13 galectin13 Chromosome 19:44,785,004-44,789,954 19
LGALS14 Chromosome 19:44,886,786-44,891,928 19
CLC galectin 10 Chromosome 19:44,913,735-44,920,508 19
MADCAM1 Chromosome 19:447,490-456,342 19
MADCAM1 Chromosome 19:447,490-456,342 19
MAP3K10 Chromosome 19:45,389,491-45,413,314 19
MAP3K10 Chromosome 19:45,389,491-45,413,314 19
MAP3K10 Chromosome 19:45,389,491-45,413,314 19
BLVRB Chromosome 19:45,645,541-45,663,516 19
BLVRB Chromosome 19:45,645,541-45,663,516 19
CYP2A6 Chromosome 19:46,041,284-46,226,008 19
CYP2A7 Chromosome 19:46,041,286-46,226,008 19
CYP2A7 Chromosome 19:46,041,286-46,226,008 19
CYP2S1 Chromosome 19:46,390,955-46,405,284 19
TGFB1 Chromosome 19:46,528,254-46,551,656 19
TGFB1 Chromosome 19:46,528,254-46,551,656 19
CEACAM5 CD66e Chromosome 19:46,904,377-46,925,686 19
CEACAM5 CD66e Chromosome 19:46,904,377-46,925,686 19
CEACAM3 CD66d Chromosome 19:46,992,381-47,007,431 19
CEACAM3 CD66d Chromosome 19:46,992,381-47,007,431 19
DEDD2 Chromosome 19:47,394,592-47,416,115 19
DEDD2 Chromosome 19:47,394,592-47,416,115 19
KIR2DL5B Chromosome 19:47,577,500-47,579,250 19
CEACAM1 CD66a Chromosome 19:47,703,298-47,724,479 19
CEACAM8 CD66b Chromosome 19:47,776,235-47,790,890 19
CEACAM8 CD66b Chromosome 19:47,776,235-47,790,890 19
PSG1 CD66f Chromosome 19:48,063,198-48,075,711 19
PSG1 CD66f Chromosome 19:48,063,198-48,075,711 19
CD177 CD177, PRV1 Chromosome 19:48,549,651-48,559,368 19
CD177 CD177, PRV1 Chromosome 19:48,549,651-48,559,368 19
XRCC1 Chromosome 19:48,739,032-48,771,998 19
XRCC1 Chromosome 19:48,739,032-48,771,998 19
PLAUR CD87 Chromosome 19:48,842,088-48,866,539 19
IRGC IGTP, TGTP Chromosome 19:48,912,078-48,916,013 19
IRGC IGTP, TGTP Chromosome 19:48,912,078-48,916,013 19
PVR CD155 Chromosome 19:49,839,066-49,858,690 19
PVR CD155 Chromosome 19:49,839,066-49,858,690 19
BCL3 Chromosome 19:49,943,820-49,955,140 19
BCL3 Chromosome 19:49,943,820-49,955,140 19
PTPRS Chromosome 19:5,157,379-5,237,399 19
PTPRS Chromosome 19:5,157,379-5,237,399 19
FUT3 CD174 Chromosome 19:5,793,902-5,802,482 19
FUT3 CD174 Chromosome 19:5,793,902-5,802,482 19
RFX2 RFX2 Chromosome 19:5,944,175-6,061,554 19
RFX2 RFX2 Chromosome 19:5,944,175-6,061,554 19
RELB Chromosome 19:50,196,539-50,233,292 19
ERCC2 XPD Chromosome 19:50,546,686-50,565,669 19
ERCC2 XPD Chromosome 19:50,546,686-50,565,669 19
ERCC1 Chromosome 19:50,604,712-50,619,017 19
GPR4 Chromosome 19:50,784,865-50,797,294 19
FOXA3 Chromosome 19:51,059,358-51,068,895 19
FOXA3 Chromosome 19:51,059,358-51,068,895 19
FOXA3 Chromosome 19:51,059,358-51,068,895 19
PGLYRP1 PGRP-Ia Chromosome 19:51,214,255-51,218,163 19
PKD2 Chromosome 19:51,869,413-51,911,597 19
KIR2DL4 Chromosome 19:52,356,000-52.367.000 19
BBC3 PUMA Chromosome 19:52,415,921-52,427,863 19
C5R1 CD88 Chromosome 19:52,504,971-52,517,173 19
DHX34 Chromosome 19:52,544,386-52,577,795 19
LIG1 Chromosome 19:53,310,515-53,365,372 19
CARD8 TUCAN, CARDINAL Chromosome 19:53,403,325-53,450,955 19
EMP3 Emp3 Chromosome 19:53,520,441-53,525,623 19
SPHK2 sphingosine kinase Chromosome 19:53,814,360-53,825,474 19
FUT1 CD173 Chromosome 19:53,943,080-53,950,459 19
FGF21 FGF21 Chromosome 19:53,950,628-53,953,395 19
FGF21 FGF21 Chromosome 19:53,950,628-53,953,395 19
BAX Chromosome 19:54,149,929-54,156,867 19
LHB LHB Chromosome 19:54,211,049-54,212,159 19
CGB CGB Chromosome 19:54,217,939-54,244,212 19
SNRP70 Chromosome 19:54,280,277-54,303,682 19
CD37 Chromosome 19:54,530,240-54,535,675 19
CD37 Chromosome 19:54,530,240-54,535,675 19
CD37 Chromosome 19:54,530,240-54,535,675 19
FCGRT FCRn Chromosome 19:54,708,304-54,721,402 19
FCGRT FCRn Chromosome 19:54,708,304-54,721,402 19
NOSIP NO synthase Chromosome 19:54,750,780-54,775,626 19
IL4I1 Chromosome 19:55,084,723-55,124,598 19
NR1H2 LXRbeta Chromosome 19:55,571,515-55,578,051 19
NR1H2 LXRbeta Chromosome 19:55,571,515-55,578,051 19
SIGLEC9 CDw329 Chromosome 19:56,319,977-56,325,379 19
SIGLEC9 CDw329 Chromosome 19:56,319,977-56,325,379 19
SIGLEC10 CDw330 Chromosome 19:56,605,087-56,612,869 19
SIGLEC6 CDw327 Chromosome 19:56,714,795-56,726,922 19
SIGLEC5 CD170 Chromosome 19:56,806,996-56,831,696 19
FPR1 Chromosome 19:56,940,839-56,946,962 19
FPRL1 Annexin-1R, f-MLP Chromosome 19:56,955,995-56,965,591 19
BIRC8 Chromosome 19:58,484,666-58,486,687 19
BIRC8 Chromosome 19:58,484,666-58,486,687 19
NLRP12 NALP12, RNO2, PYPAF7  Chromosome 19:58,988,650-59,019,409 19
NLRP12 NALP12, RNO2, PYPAF7  Chromosome 19:58,988,650-59,019,409 19
PRKCG PKC gamma, Cgamma Chromosome 19:59,077,279-59,102,713 19
PRKCG PKC gamma, Cgamma Chromosome 19:59,077,279-59,102,713 19
OSCAR Chromosome 19:59,289,745-59,297,806 19
OSCAR Chromosome 19:59,289,745-59,297,806 19
LILRB3 CD85a, PIRB (mouse) Chromosome 19:59,412,549-59,418,709 19
LILRA3 Chromosome 19:59,491,666-59,496,077 19
LAIR1 CD305 Chromosome 19:59,557,047-59,568,533 19
TTYH1 Chromosome 19:59,618,417-59,639,882 19
KIR3DX1 KIR3DL0 Chromosome 19:59,738,595-59,748,862 19
LILRP2 ILT10 Chromosome 19:59,911,791-59,916,501 19
GTF2F1 TFIIF Chromosome 19:6,235,811-6,344,184 19
ALKBH7 Chromosome 19:6,323,444-6,326,040 19
TNFSF9 4-1BBL Chromosome 19:6,482,037-6,486,933 19
TNFSF7 CD70 Chromosome 19:6,536,850-6,542,163 19
C3 C3bBb, C3bBb3b Chromosome 19:6,628,878-6,671,660 19
C3 C3bBb, C3bBb3b Chromosome 19:6,628,878-6,671,660 19
VAV1 Chromosome 19:6,723,722-6,808,371 19
EMR1 CD311 Chromosome 19:6,838,577-6,891,464 19
EMR1 CD311 Chromosome 19:6,838,577-6,891,464 19
FCAR CD89 Chromosome 19:60,077,361-60,095,055 19
NLRP2 NALP2, LRR,PYPAF2, NBChromosome 19:60,168,465-60,204,318 19
PTPRH Chromosome 19:60,384,428-60,412,654 19
NLRP9 NALP9, NOD6 Chromosome 19:60,911,610-60,941,580 19
NLRP9 NALP9, NOD6 Chromosome 19:60,911,610-60,941,580 19
NLRP13 NALP13, NOD14 Chromosome 19:61,099,123-61,135,489 19
CHMP2A CHMP2A Chromosome 19:63,754,745-63,758,298 19
INSR CD220, Insulin receptor Chromosome 19:7,067,049-7,245,045 19
INSR CD220, Insulin receptor Chromosome 19:7,067,049-7,245,045 19
INSR CD220, Insulin receptor Chromosome 19:7,067,049-7,245,045 19
FCER2 CD23 Chromosome 19:7,659,662-7,673,032 19
FCER2 CD23 Chromosome 19:7,659,662-7,673,032 19
CLEC4M CD299, DC-SIGN-R, L-SIGChromosome 19:7,734,081-7,740,491 19
MAP2K7 Chromosome 19:7,874,728-7,885,363 19
AZU1 HBP, CAP37 Chromosome 19:776,097-783,017 19
CCL25 Chromosome 19:8,023,934-8,033,547 19
MYO1F IF Chromosome 19:8,491,689-8,548,330 19
CFD Chromosome 19:810,665-814,624 19
PIN1 Chromosome 19:9,806,999-9,821,358 19
COL5A3 Chromosome 19:9,931,237-9,982,147 19
PXDN Chromosome 2:1,614,666-1,727,298 2
KLF11 TIEG Chromosome 2:10,101,133-10,112,414 2
MAP4K4 Chromosome 2:101,680,920-101,877,584 2
IL1R2 CD121b Chromosome 2:101,974,738-102,011,317 2
IL1R1 CD121a Chromosome 2:102,125,678-102,162,766 2
IL1RL2 Chromosome 2:102,169,865-102,222,243 2
IL1RL1 ST2 Chromosome 2:102,294,394-102,334,929 2
IL18R1 CDw218a Chromosome 2:102,345,529-102,381,650 2
IL18RAP CDw218b Chromosome 2:102,401,686-102,435,457 2
SLC9A2 NHE-2 Chromosome 2:102,602,598-102,694,241 2
SULT1C2 Chromosome 2:108,360,853-108,370,702 2
SULT1C2 Chromosome 2:108,360,853-108,370,702 2
RANBP2 Chromosome 2:108,702,369-108,767,683 2
EDAR Chromosome 2:108,877,361-108,972,260 2
ROCK2 ROCKalpha Chromosome 2:11,239,229-11,402,162 2
ROCK2 ROCKalpha Chromosome 2:11,239,229-11,402,162 2
ROCK2 ROCKalpha Chromosome 2:11,239,229-11,402,162 2
BCL2L11 Bim, BIM Chromosome 2:111,597,781-111,641,058 2
BCL2L11 Bim, BIM Chromosome 2:111,597,781-111,641,058 2
MERTK Mer Receptor Tyrosine kinChromosome 2:112,372,662-112,503,416 2
MERTK Mer Receptor Tyrosine kinChromosome 2:112,372,662-112,503,416 2
IL1A Chromosome 2:113,247,963-113,259,442 2
IL1B Chromosome 2:113,303,808-113,310,827 2
IL1B Chromosome 2:113,303,808-113,310,827 2
IL1B Chromosome 2:113,303,808-113,310,827 2
IL1F7 Chromosome 2:113,387,017-113,392,930 2
IL1F7 Chromosome 2:113,387,017-113,392,930 2
IL1F7 Chromosome 2:113,387,017-113,392,930 2
IL1F9 Chromosome 2:113,452,077-113,459,698 2
IL1RN CD25, IL1RA Chromosome 2:113,591,941-113,608,064 2
IL1RN CD25, IL1RA Chromosome 2:113,591,941-113,608,064 2
DDX18 Chromosome 2:118,288,725-118,306,425 2
MARCO SCARA2 Chromosome 2:119,416,215-119,468,706 2
MARCO SCARA2 Chromosome 2:119,416,215-119,468,706 2
C1QL2 Chromosome 2:119,630,289-119,632,941 2
C1QL2 Chromosome 2:119,630,289-119,632,941 2
TMEM37 Chromosome 2:119,905,950-119,911,486 2
TMEM37 Chromosome 2:119,905,950-119,911,486 2
PTPN4 Chromosome 2:120,233,677-120,451,507 2
PTPN4 Chromosome 2:120,233,677-120,451,507 2
PTPN4 Chromosome 2:120,233,677-120,451,507 2
INHBB Inhibin B Chromosome 2:120,819,469-120,825,444 2
INHBB Inhibin B Chromosome 2:120,819,469-120,825,444 2
GLI2 Gli2 Chromosome 2:121,266,327-121,466,321 2
GLI2 Gli2 Chromosome 2:121,266,327-121,466,321 2
GLI2 Gli2 Chromosome 2:121,266,327-121,466,321 2
GLI2 Gli2 Chromosome 2:121,266,327-121,466,321 2
CLASP1 clAP1 Chromosome 2:121,811,825-122,123,522 2
CLASP1 clAP1 Chromosome 2:121,811,825-122,123,522 2
CLASP1 clAP1 Chromosome 2:121,811,825-122,123,522 2
CLASP1 clAP1 Chromosome 2:121,811,825-122,123,522 2
CLASP1 clAP1 Chromosome 2:121,811,825-122,123,522 2
GYPC CD236c, CD236d, CD236Chromosome 2:127,130,154-127,170,716 2
GYPC CD236c, CD236d, CD236Chromosome 2:127,130,154-127,170,716 2
GYPC CD236c, CD236d, CD236Chromosome 2:127,130,154-127,170,716 2
MAP3K2 Chromosome 2:127,778,609-127,817,240 2
MAP3K2 Chromosome 2:127,778,609-127,817,240 2
PROC activated protein C Chromosome 2:127,892,486-127,903,288 2
PROC activated protein C Chromosome 2:127,892,486-127,903,288 2
PTPN18 Chromosome 2:130,830,088-130,848,614 2
PTPN18 Chromosome 2:130,830,088-130,848,614 2
MCM6 Chromosome 2:136,313,666-136,350,481 2
MCM6 Chromosome 2:136,313,666-136,350,481 2
CXCR4 CD184 Chromosome 2:136,705,639-136,709,450 2
CXCR4 CD184 Chromosome 2:136,705,639-136,709,450 2
HNMT HMT Chromosome 2:138,438,278-138,490,404 2
HNMT HMT Chromosome 2:138,438,278-138,490,404 2
DDX1 Chromosome 2:15,648,753-15,688,676 2
DDX1 Chromosome 2:15,648,753-15,688,676 2
MYCN n-myc Chromosome 2:15,998,134-16,004,580 2
MYCN n-myc Chromosome 2:15,998,134-16,004,580 2
NMI Chromosome 2:151,835,231-151,854,620 2
NMI Chromosome 2:151,835,231-151,854,620 2
PRPF40A FNBP3 Chromosome 2:153,216,334-153,283,014 2
PRPF40A FNBP3 Chromosome 2:153,216,334-153,283,014 2
NR4A2 NR4A2, NURR1 Chromosome 2:156,889,194-156,897,474 2
PSCDBP CYTIP Chromosome 2:157,979,377-158,008,850 2
PSCDBP CYTIP Chromosome 2:157,979,377-158,008,850 2
MARCH7_ Axotrophin Chromosome 2:160,277,256-160,333,330 2
MARCH7_ Axotrophin Chromosome 2:160,277,256-160,333,330 2
MARCH7_ Axotrophin Chromosome 2:160,277,256-160,333,330 2
LY75 CD205, DEC-205 Chromosome 2:160,368,118-160,469,493 2
PLA2R1 phospholipase A3 Chromosome 2:160,505,506-160,627,367 2
ITGB6 Chromosome 2:160,664,438-160,765,009 2
TANK NFKB activator Chromosome 2:161,701,712-161,800,928 2
TANK NFKB activator Chromosome 2:161,701,712-161,800,928 2
DPP4 CD26 Chromosome 2:162,557,001-162,639,298 2
DPP4 CD26 Chromosome 2:162,557,001-162,639,298 2
IFIH1 MDA5, Ifit1 Chromosome 2:162,831,835-162,883,285 2
PPIG Chromosome 2:170,149,096-170,202,500 2
PPIG Chromosome 2:170,149,096-170,202,500 2
HAT1 Chromosome 2:172,487,204-172,556,846 2
HAT1 Chromosome 2:172,487,204-172,556,846 2
ITGA6 CD49f Chromosome 2:173,000,616-173,079,256 2
PDK1 Chromosome 2:173,129,025-173,172,108 2
SP3 chondromodulin transcript  Chromosome 2:174,481,504-174,538,676 2
SP3 chondromodulin transcript  Chromosome 2:174,481,504-174,538,676 2
CIR Chromosome 2:174,921,124-174,968,689 2
CIR Chromosome 2:174,921,124-174,968,689 2
WIPF1 WASPIP Chromosome 2:175,132,548-175,255,873 2
WIPF1 WASPIP Chromosome 2:175,132,548-175,255,873 2
HOXD10 HOX cluster Chromosome 2:176,689,738-176,692,916 2
HOXD10 HOX cluster Chromosome 2:176,689,738-176,692,916 2
AGPS ADAP, alkylglycerone pho  Chromosome 2:177,965,731-178,112,411 2
AGPS ADAP, alkylglycerone pho  Chromosome 2:177,965,731-178,112,411 2
AGPS ADAP, alkylglycerone pho  Chromosome 2:177,965,731-178,112,411 2
ITGA4 VLA4, CD49d Chromosome 2:182,029,864-182,110,719 2
ITGA4 VLA4, CD49d Chromosome 2:182,029,864-182,110,719 2
FRZB sFRP3 Chromosome 2:183,406,982-183,439,743 2
DUSP19 Chromosome 2:183,651,732-183,673,616 2
DUSP19 Chromosome 2:183,651,732-183,673,616 2
ITGAV CD51 Chromosome 2:187,163,045-187,253,873 2
ITGAV CD51 Chromosome 2:187,163,045-187,253,873 2
ITGAV CD51 Chromosome 2:187,163,045-187,253,873 2
COL3A1 Chromosome 2:189,547,344-189,585,717 2
COL3A1 Chromosome 2:189,547,344-189,585,717 2
COL3A1 Chromosome 2:189,547,344-189,585,717 2
SLC40A1 ferroportin Chromosome 2:190,133,561-190,153,858 2
SLC40A1 ferroportin Chromosome 2:190,133,561-190,153,858 2
STAT1 Chromosome 2:191,542,121-191,587,181 2
STAT1 Chromosome 2:191,542,121-191,587,181 2
STAT4 Chromosome 2:191,602,551-191,724,539 2
GTF3C3 Chromosome 2:197,336,917-197,372,670 2
GTF3C3 Chromosome 2:197,336,917-197,372,670 2
HSPD1 HSP65 Chromosome 2:198,059,553-198,073,243 2
SDC1 Syndecan, CD138 Chromosome 2:20,264,039-20,288,675 2
PPIL3 Chromosome 2:201,443,924-201,462,244 2
PPIL3 Chromosome 2:201,443,924-201,462,244 2
CASP10 Chromosome 2:201,756,100-201,802,372 2
CFLAR cFLIP, vFLIP Chromosome 2:201,806,396-201,854,521 2
BMPR2 Chromosome 2:202,949,916-203,140,719 2
BMPR2 Chromosome 2:202,949,916-203,140,719 2
CYP20A1 Chromosome 2:203,811,658-203,878,579 2
CYP20A1 Chromosome 2:203,811,658-203,878,579 2
CD28 Chromosome 2:204,279,443-204,310,801 2
CD28 Chromosome 2:204,279,443-204,310,801 2
CTLA4 CD152 Chromosome 2:204,440,754-204,446,928 2
CTLA4 CD152 Chromosome 2:204,440,754-204,446,928 2
CTLA4 CD152 Chromosome 2:204,440,754-204,446,928 2
KLF7 Chromosome 2:207,653,323-207,738,859 2
KLF7 Chromosome 2:207,653,323-207,738,859 2
KLF7 Chromosome 2:207,653,323-207,738,859 2
CREB1 Chromosome 2:208,102,931-208,171,818 2
CPS1 Chromosome 2:211,050,678-211,252,076 2
CPS1 Chromosome 2:211,050,678-211,252,076 2
CPS1 Chromosome 2:211,050,678-211,252,076 2
CPS1 Chromosome 2:211,050,678-211,252,076 2
FN1 fibronectin Chromosome 2:215,933,409-216,009,041 2
FN1 fibronectin Chromosome 2:215,933,409-216,009,041 2
XRCC5 Chromosome 2:216,680,435-216,779,248 2
XRCC5 Chromosome 2:216,680,435-216,779,248 2
XRCC5 Chromosome 2:216,680,435-216,779,248 2
SMARCAL1 Chromosome 2:216,985,441-217,056,021 2
SMARCAL1 Chromosome 2:216,985,441-217,056,021 2
SMARCAL1 Chromosome 2:216,985,441-217,056,021 2
IGFBP2 Chromosome 2:217,206,372-217,237,404 2
IGFBP2 Chromosome 2:217,206,372-217,237,404 2
IL8RB CD128b, CXCR2 Chromosome 2:218,698,991-218,710,220 2
SCL11A1 NRAMP1 Chromosome 2:218,955,161-218,968,994 2
SCL11A1 NRAMP1 Chromosome 2:218,955,161-218,968,994 2
CYP27A1 Chromosome 2:219,354,745-219,388,259 2
CYP27A1 Chromosome 2:219,354,745-219,388,259 2
CYP27A1 Chromosome 2:219,354,745-219,388,259 2
IHH indian Hh Chromosome 2:219,628,173-219,633,433 2
IHH indian Hh Chromosome 2:219,628,173-219,633,433 2
IHH indian Hh Chromosome 2:219,628,173-219,633,433 2
TUBA1 Chromosome 2:219,822,677-219,826,882 2
INHA Inhibin A Chromosome 2:220,145,161-220,148,679 2
COL4A4 Chromosome 2:227,578,168-227,737,519 2
COL4A4 Chromosome 2:227,578,168-227,737,519 2
COL4A3 Chromosome 2:227,737,525-227,887,751 2
HRB HIV binding protein Chromosome 2:228,045,286-228,130,548 2
CCL20 Chromosome 2:228,386,814-228,390,494 2
CCL20 Chromosome 2:228,386,814-228,390,494 2
SP110 Chromosome 2:230,741,896-230,792,932 2
SP110 Chromosome 2:230,741,896-230,792,932 2
SP110 Chromosome 2:230,741,896-230,792,932 2
HTR2B 5-HT2B Chromosome 2:231,681,199-231,698,068 2
HTR2B 5-HT2B Chromosome 2:231,681,199-231,698,068 2
INPP5D SHIP1 Chromosome 2:233,633,433-233,781,288 2
INPP5D SHIP1 Chromosome 2:233,633,433-233,781,288 2
UGT1A1 UGT1 Chromosome 2:234,191,030-234,346,695 2
UGT1A1 UGT1 Chromosome 2:234,191,030-234,346,695 2
UGT1A1 UGT1 Chromosome 2:234,191,030-234,346,695 2
UGT1A1 UGT1 Chromosome 2:234,191,030-234,346,695 2
CXCR7 CMKOR1 Chromosome 2:237,143,182-237,155,730 2
CXCR7 CMKOR1 Chromosome 2:237,143,182-237,155,730 2
COL6A3 Chromosome 2:237,897,401-237,987,559 2
COL6A3 Chromosome 2:237,897,401-237,987,559 2
TRAF3IP1 Chromosome 2:238,893,821-238,972,536 2
TRAF3IP1 Chromosome 2:238,893,821-238,972,536 2
TRAF3IP1 Chromosome 2:238,893,821-238,972,536 2
ASB1 Chromosome 2:239,000,365-239,025,630 2
ASB1 Chromosome 2:239,000,365-239,025,630 2
HDAC4 Chromosome 2:239,635,319-239,987,580 2
HDAC4 Chromosome 2:239,635,319-239,987,580 2
HDAC4 Chromosome 2:239,635,319-239,987,580 2
HDAC4 Chromosome 2:239,635,319-239,987,580 2
FKBP1B Calcineurin Chromosome 2:24,126,075-24,140,055 2
FKBP1B Calcineurin Chromosome 2:24,126,075-24,140,055 2
DUSP28 Chromosome 2:241,148,144-241,152,104 2
DUSP28 Chromosome 2:241,148,144-241,152,104 2
SEPT2 Chromosome 2:241,903,396-241,942,115 2
SEPT2 Chromosome 2:241,903,396-241,942,115 2
BOK Chromosome 2:242,146,865-242,162,226 2
PDCD1 CD279, PD1 Chromosome 2:242,440,711-242,449,731 2
POMC POMC Chromosome 2:25,237,226-25,245,063 2
POMC POMC Chromosome 2:25,237,226-25,245,063 2
UCN urocortin Chromosome 2:27,383,769-27,384,634 2
ALK CD246 Chromosome 2:29,269,144-29,997,936 2
ALK CD246 Chromosome 2:29,269,144-29,997,936 2
ALK CD246 Chromosome 2:29,269,144-29,997,936 2
ALK CD246 Chromosome 2:29,269,144-29,997,936 2
ALK CD246 Chromosome 2:29,269,144-29,997,936 2
ALK CD246 Chromosome 2:29,269,144-29,997,936 2
XDH Xanthine oxidoreductase Chromosome 2:31,410,691-31,491,117 2
XDH Xanthine oxidoreductase Chromosome 2:31,410,691-31,491,117 2
XDH Xanthine oxidoreductase Chromosome 2:31,410,691-31,491,117 2
XDH Xanthine oxidoreductase Chromosome 2:31,410,691-31,491,117 2
NLRC4 CARD12, IPAF, CLAN Chromosome 2:32,303,022-32,344,427 2
NLRC4 CARD12, IPAF, CLAN Chromosome 2:32,303,022-32,344,427 2
BIRC6 Chromosome 2:32,435,234-32,697,470 2
BIRC6 Chromosome 2:32,435,234-32,697,470 2
LTBP1 Chromosome 2:33,025,896-33,478,080 2
LTBP1 Chromosome 2:33,025,896-33,478,080 2
LTBP1 Chromosome 2:33,025,896-33,478,080 2
LTBP1 Chromosome 2:33,025,896-33,478,080 2
LTBP1 Chromosome 2:33,025,896-33,478,080 2
LTBP1 Chromosome 2:33,025,896-33,478,080 2
LTBP1 Chromosome 2:33,025,896-33,478,080 2
LTBP1 Chromosome 2:33,025,896-33,478,080 2
LTBP1 Chromosome 2:33,025,896-33,478,080 2
RASGRP3 Chromosome 2:33,514,920-33,643,162 2
PKD3 Chromosome 2:37,331,149-37,398,541 2
PKD3 Chromosome 2:37,331,149-37,398,541 2
PKD3 Chromosome 2:37,331,149-37,398,541 2
CYP1B1 Cytochromes Chromosome 2:38,148,154-38,156,796 2
CYP1B1 Cytochromes Chromosome 2:38,148,154-38,156,796 2
DHX57 Chromosome 2:38,878,375-38,956,525 2
DHX57 Chromosome 2:38,878,375-38,956,525 2
DHX57 Chromosome 2:38,878,375-38,956,525 2
SOS1 Chromosome 2:39,066,469-39,201,067 2
SOS1 Chromosome 2:39,066,469-39,201,067 2
MAP4K3 Chromosome 2:39,329,911-39,517,946 2
MAP4K3 Chromosome 2:39,329,911-39,517,946 2
MAP4K3 Chromosome 2:39,329,911-39,517,946 2
PLEKHH2 MAX1 Chromosome 2:43,717,916-43,848,630 2
PRKCD PKC epsilon Chromosome 2:45,732,547-46,268,633 2
PRKCD PKC epsilon Chromosome 2:45,732,547-46,268,633 2
PRKCD PKC epsilon Chromosome 2:45,732,547-46,268,633 2
PRKCD PKC epsilon Chromosome 2:45,732,547-46,268,633 2
PRKCD PKC epsilon Chromosome 2:45,732,547-46,268,633 2
PIGF Chromosome 2:46,661,580-46,697,708 2
PIGF Chromosome 2:46,661,580-46,697,708 2
SOCS5 Chromosome 2:46,779,595-46,843,431 2
FOXN2 Chromosome 2:48,395,374-48,459,938 2
FOXN2 Chromosome 2:48,395,374-48,459,938 2
LHCGR LH-R Chromosome 2:48,767,471-48,836,321 2
FSHR follitropin receptor Chromosome 2:49,043,156-49,235,134 2
FSHR follitropin receptor Chromosome 2:49,043,156-49,235,134 2
FSHR follitropin receptor Chromosome 2:49,043,156-49,235,134 2
FSHR follitropin receptor Chromosome 2:49,043,156-49,235,134 2
VRK2 Chromosome 2:58,127,224-58,240,510 2
VRK2 Chromosome 2:58,127,224-58,240,510 2
RSAD2 CIG5 Chromosome 2:6,935,247-6,955,821 2
RSAD2 CIG5 Chromosome 2:6,935,247-6,955,821 2
RSAD2 CIG5 Chromosome 2:6,935,247-6,955,821 2
REL cREL Chromosome 2:60,962,254-61,003,682 2
PELI1 Pellino1 Chromosome 2:64,173,499-64,225,062 2
PELI1 Pellino1 Chromosome 2:64,173,499-64,225,062 2
PPP3R1 Chromosome 2:68,203,572-68,341,866 2
PPP3R1 Chromosome 2:68,203,572-68,341,866 2
PPP3R1 Chromosome 2:68,203,572-68,341,866 2
MXD1 MAD Chromosome 2:69,995,707-70,023,581 2
MXD1 MAD Chromosome 2:69,995,707-70,023,581 2
MXD1 MAD Chromosome 2:69,995,707-70,023,581 2
TGFA TGF alpha Chromosome 2:70,527,924-70,634,438 2
TGFA TGF alpha Chromosome 2:70,527,924-70,634,438 2
TGFA TGF alpha Chromosome 2:70,527,924-70,634,438 2
CD207 CD207, langerin Chromosome 2:70,910,855-70,916,461 2
CYP26B1 Chromosome 2:72,209,875-72,228,471 2
DUSP11 Chromosome 2:73,842,837-73,860,756 2
DQX1 Chromosome 2:74,598,766-74,606,826 2
DQX1 Chromosome 2:74,598,766-74,606,826 2
DOK1 Chromosome 2:74,634,795-74,638,181 2
SFTPB SP-B Chromosome 2:85,737,951-85,748,823 2
SFTPB SP-B Chromosome 2:85,737,951-85,748,823 2
ST3GAL5 Lactosylceramide Chromosome 2:85,919,782-85,969,648 2
ST3GAL5 Lactosylceramide Chromosome 2:85,919,782-85,969,648 2
JMJD1A H3K9me Chromosome 2:86,521,954-86,573,350 2
JMJD1A H3K9me Chromosome 2:86,521,954-86,573,350 2
JMJD1A H3K9me Chromosome 2:86,521,954-86,573,350 2
CD8A Chromosome 2:86,865,239-86,871,638 2
CD8B1 CD8B1 Chromosome 2:86,895,971-86,942,549 2
IGKV1-12 Chromosome 2:89,120,836-89,121,310 2
IGKV1-12 Chromosome 2:89,120,836-89,121,310 2
ITGB1BP1 Chromosome 2:9,463,264-9,481,127 2
YWHAQ Chromosome 2:9,641,552-9,688,629 2
DUSP2 PAC-1 Chromosome 2:96,172,638-96,174,906 2
NCAPH BRRN1 Chromosome 2:96,365,211-96,405,001 2
ZAP70 Chromosome 2:97,696,461-97,722,755 2
ZAP70 Chromosome 2:97,696,461-97,722,755 2
LYG2 lysozyme like Chromosome 2:99,225,141-99,238,002 2
LYG2 lysozyme like Chromosome 2:99,225,141-99,238,002 2
PSMF1 Chromosome 20:1,041,939-1,097,022 20
PSMF1 Chromosome 20:1,041,939-1,097,022 20
FKBP1A Calcineurin Chromosome 20:1,297,622-1,321,806 20
SIRPB2 CD172g Chromosome 20:1,399,386-1,420,233 20
SIRPB1 CD172b Chromosome 20:1,491,568-1,548,655 20
SIRPB1 CD172b Chromosome 20:1,491,568-1,548,655 20
SIRPA SIRPalpha1 Chromosome 20:1,822,813-1,868,543 20
SIRPA SIRPalpha1 Chromosome 20:1,822,813-1,868,543 20
JAG1 CD339, Jagged-1 Chromosome 20:10,566,334-10,602,636 20
JAG1 CD339, Jagged-1 Chromosome 20:10,566,334-10,602,636 20
DFB128 Chromosome 20:116,527-118,264 20
DFB129 Chromosome 20:155,899-158,527 20
TGM3 Chromosome 20:2,224,647-2,269,725 20
TGM3 Chromosome 20:2,224,647-2,269,725 20
PTPRA Chromosome 20:2,769,366-2,967,320 20
PTPRA Chromosome 20:2,769,366-2,967,320 20
PTPRA Chromosome 20:2,769,366-2,967,320 20
FOXA2 Chromosome 20:22,509,643-22,514,102 20
THBD CD141, thrombomodulin Chromosome 20:22,974,270-22,978,301 20
THBD CD141, thrombomodulin Chromosome 20:22,974,270-22,978,301 20
C1QR CD93 Chromosome 20:23,007,995-23,014,977 20
CST1 SN Chromosome 20:23,676,190-23,679,574 20
CST1 SN Chromosome 20:23,676,190-23,679,574 20
DFB115 Chromosome 20:29,309,128-29,311,096 20
DFB122 Chromosome 20:29,466,712-29,480,644 20
HM13 H13 Chromosome 20:29,565,892-29,621,031 20
BCL2L1 BCL-XL, Bcl-x (L) Chromosome 20:29,715,916-29,774,366 20
DUSP15 Chromosome 20:29,899,102-29,922,211 20
PDRG1 p53 Chromosome 20:29,996,419-30,003,556 20
SIGLEC1 CD169 Chromosome 20:3,615,617-3,635,775 20
SIGLEC1 CD169 Chromosome 20:3,615,617-3,635,775 20
SIGLEC1 CD169 Chromosome 20:3,615,617-3,635,775 20
CDC25B Chromosome 20:3,724,386-3,734,762 20
HCK Chromosome 20:30,103,715-30,153,320 20
HCK Chromosome 20:30,103,715-30,153,320 20
CBFA2T2 Chromosome 20:31,541,589-31,701,503 20
CBFA2T2 Chromosome 20:31,541,589-31,701,503 20
CBFA2T2 Chromosome 20:31,541,589-31,701,503 20
CHMP4B CHMP4B Chromosome 20:31,862,780-31,905,831 20
ITCH Chromosome 20:32,414,702-32,562,859 20
ITCH Chromosome 20:32,414,702-32,562,859 20
PROCR EPCR, CD201 Chromosome 20:33,212,131-33,228,828 20
PROCR EPCR, CD201 Chromosome 20:33,212,131-33,228,828 20
PROCR EPCR, CD201 Chromosome 20:33,212,131-33,228,828 20
MMP24 Chromosome 20:33,278,095-33,328,218 20
SAMHD1 Mg11 Chromosome 20:34,953,761-35,013,590 20
SRC Chromosome 20:35,406,502-35,467,239 20
SRC Chromosome 20:35,406,502-35,467,239 20
BPI Chromosome 20:36,365,991-36,399,321 20
LBP Chromosome 20:36,408,299-36,439,067 20
PPP1R16B Chromosome 20:36,867,762-36,985,081 20
PPP1R16B Chromosome 20:36,867,762-36,985,081 20
DHX35 Chromosome 20:37,024,409-37,101,778 20
PLCG1 Chromosome 20:39,199,291-39,237,775 20
PRNP CD230 Chromosome 20:4,614,996-4,630,236 20
PRNP CD230 Chromosome 20:4,614,996-4,630,236 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PTPRT Chromosome 20:40,134,806-41,252,024 20
PPIAL Chromosome 20:41,292,801-41,293,515 20
HNF4A HNF4 alpha 1,2,3,4, NR2AChromosome 20:42,417,855-42,493,444 20
HNF4A HNF4 alpha 1,2,3,4, NR2AChromosome 20:42,417,855-42,493,444 20
ADA adenosine deaminase Chromosome 20:42,681,577-42,713,797 20
ADA adenosine deaminase Chromosome 20:42,681,577-42,713,797 20
STK4 MST1/STK4 Chromosome 20:43,028,529-43,142,014 20
STK4 MST1/STK4 Chromosome 20:43,028,529-43,142,014 20
STK4 MST1/STK4 Chromosome 20:43,028,529-43,142,014 20
WFDC12 Chromosome 20:43,185,480-43,186,520 20
SEMG1 Chromosome 20:43,269,052-43,271,827 20
SDC4 Syndecan Chromosome 20:43,387,342-43,410,478 20
SDC4 Syndecan Chromosome 20:43,387,342-43,410,478 20
ACOT8 Chromosome 20:43,903,768-43,919,442 20
CTSA Cathepsin A Chromosome 20:43,952,190-43,960,866 20
MMP9 Chromosome 20:44,070,954-44,078,607 20
MMP9 Chromosome 20:44,070,954-44,078,607 20
TNFRSF5 CD40, 41 Chromosome 20:44,180,313-44,366,257 20
TNFRSF5 CD40, 41 Chromosome 20:44,180,313-44,366,257 20
TNFRSF5 CD40, 41 Chromosome 20:44,180,313-44,366,257 20
PTGIS Chromosome 20:47,553,818-47,618,114 20
PTGIS Chromosome 20:47,553,818-47,618,114 20
PTGIS Chromosome 20:47,553,818-47,618,114 20
SLC9A8 NHE-8 Chromosome 20:47,862,657-47,942,179 20
SLC9A8 NHE-8 Chromosome 20:47,862,657-47,942,179 20
UBE2V1 UEV1A Chromosome 20:48,131,068-48,203,678 20
UBE2V1 UEV1A Chromosome 20:48,131,068-48,203,678 20
PTPN1 Chromosome 20:48,560,294-48,634,706 20
PTPN1 Chromosome 20:48,560,294-48,634,706 20
PTPN1 Chromosome 20:48,560,294-48,634,706 20
NFATC2 Chromosome 20:49,441,083-49,592,665 20
NFATC2 Chromosome 20:49,441,083-49,592,665 20
NFATC2 Chromosome 20:49,441,083-49,592,665 20
MC3R melanocortin receptor 3 Chromosome 20:54,257,195-54,258,278 20
MC3R melanocortin receptor 3 Chromosome 20:54,257,195-54,258,278 20
TFAP2C Chromosome 20:54,637,765-54,647,746 20
BMP7 BMP7 Chromosome 20:55,177,211-55,275,091 20
BMP7 BMP7 Chromosome 20:55,177,211-55,275,091 20
BMP7 BMP7 Chromosome 20:55,177,211-55,275,091 20
RAE1 Chromosome 20:55,359,535-55,387,618 20
CTSZ Cathepsin Z Chromosome 20:56,990,597-57,015,697 20
CTSZ Cathepsin Z Chromosome 20:56,990,597-57,015,697 20
EDN3 endothelin 3 Chromosome 20:57,308,877-57,334,442 20
EDN3 endothelin 3 Chromosome 20:57,308,877-57,334,442 20
BMP2 BMP2 Chromosome 20:6,696,311-6,708,927 20
BMP2 BMP2 Chromosome 20:6,696,311-6,708,927 20
HRH3 Chromosome 20:60,223,421-60,228,718 20
LAMA5 Chromosome 20:60,317,510-60,375,763 20
GATA5 Chromosome 20:60,471,948-60,484,421 20
DIDO1 DATF1, Dio1 Chromosome 20:60,979,535-61,039,743 20
BIRC7 LIVIN Chromosome 20:61,337,680-61,342,299 20
EEF1A2 EF-1 alpha Chromosome 20:61,589,810-61,600,949 20
TNFRSF6B DcR3 Chromosome 20:61,759,607-61,800,495 20
TNFRSF6B DcR3 Chromosome 20:61,759,607-61,800,495 20
OPRL1 ORL1 Chromosome 20:62,181,932-62,215,047 20
BAGE4 Chromosome 21:10,042,713-10,120,798 21
BAGE4 Chromosome 21:10,042,713-10,120,798 21
BTG3 Chromosome 21:17,887,842-17,907,136 21
BTG3 Chromosome 21:17,887,842-17,907,136 21
JAM2 CD322 Chromosome 21:25,933,460-26,009,106 21
JAM2 CD322 Chromosome 21:25,933,460-26,009,106 21
GRIK1 Chromosome 21:29,831,125-30,234,153 21
GRIK1 Chromosome 21:29,831,125-30,234,153 21
GRIK1 Chromosome 21:29,831,125-30,234,153 21
GRIK1 Chromosome 21:29,831,125-30,234,153 21
GRIK1 Chromosome 21:29,831,125-30,234,153 21
GRIK1 Chromosome 21:29,831,125-30,234,153 21
SOD1 Superoxide dismutase, IP Chromosome 21:31,953,806-31,963,115 21
SOD1 Superoxide dismutase, IP Chromosome 21:31,953,806-31,963,115 21
OLIG2 RACK17 Chromosome 21:33,320,023-33,323,374 21
IFNAR2 Chromosome 21:33,524,076-33,559,839 21
IFNAR2 Chromosome 21:33,524,076-33,559,839 21
IFNAR1 Chromosome 21:33,619,079-33,654,038 21
IFNGR2 Chromosome 21:33,697,072-33,731,698 21
RUNX1 RUNX Chromosome 21:35,081,968-35,343,511 21
RUNX1 RUNX Chromosome 21:35,081,968-35,343,511 21
RUNX1 RUNX Chromosome 21:35,081,968-35,343,511 21
RUNX1 RUNX Chromosome 21:35,081,968-35,343,511 21
RUNX1 RUNX Chromosome 21:35,081,968-35,343,511 21
RUNX1 RUNX Chromosome 21:35,081,968-35,343,511 21
CHAF1B Chromosome 21:36,679,559-36,710,995 21
CHAF1B Chromosome 21:36,679,559-36,710,995 21
DYRK1A Chromosome 21:37,661,729-37,809,347 21
DYRK1A Chromosome 21:37,661,729-37,809,347 21
DYRK1A Chromosome 21:37,661,729-37,809,347 21
ERG Chromosome 21:38,675,671-38,955,488 21
ERG Chromosome 21:38,675,671-38,955,488 21
ERG Chromosome 21:38,675,671-38,955,488 21
ERG Chromosome 21:38,675,671-38,955,488 21
IGSF5 Chromosome 21:40,039,204-40,095,893 21
IGSF5 Chromosome 21:40,039,204-40,095,893 21
DSCAM Chromosome 21:40,306,213-41,140,909 21
DSCAM Chromosome 21:40,306,213-41,140,909 21
DSCAM Chromosome 21:40,306,213-41,140,909 21
DSCAM Chromosome 21:40,306,213-41,140,909 21
DSCAM Chromosome 21:40,306,213-41,140,909 21
DSCAM Chromosome 21:40,306,213-41,140,909 21
DSCAM Chromosome 21:40,306,213-41,140,909 21
DSCAM Chromosome 21:40,306,213-41,140,909 21
DSCAM Chromosome 21:40,306,213-41,140,909 21
DSCAM Chromosome 21:40,306,213-41,140,909 21
MX2 Chromosome 21:41,655,820-41,702,739 21
MX2 Chromosome 21:41,655,820-41,702,739 21
MX1 Chromosome 21:41,720,024-41,753,008 21
TFF3 Tff3 Chromosome 21:42,599,751-42,608,775 21
PDXK Chromosome 21:43,963,406-44,006,608 21
PDXK Chromosome 21:43,963,406-44,006,608 21
PDXK Chromosome 21:43,963,406-44,006,608 21
ICOSLG CD275 Chromosome 21:44,467,313-44,485,262 21
AIRE Chromosome 21:44,530,191-44,542,530 21
ITGB2 CD18, Mac-1, CR3 Chromosome 21:45,130,296-45,173,181 21
SLC19A1 RFC Chromosome 21:45,737,914-45,786,779 21
COL6A1 Chromosome 21:46,226,091-46,249,391 21
COL6A1 Chromosome 21:46,226,091-46,249,391 21
COL6A2 Chromosome 21:46,342,470-46,377,190 21
PRMT2 PRMT2 Chromosome 21:46,879,507-46,909,291 21
IL17RA CDw217, IL17R Chromosome 22:15,945,849-15,971,405 22
BCL2L13 Chromosome 22:16,501,485-16,593,383 22
BID Chromosome 22:16,591,460-16,631,812 22
BID Chromosome 22:16,591,460-16,631,812 22
GGT2 Chromosome 22:17,141,172-17,159,474 22
DGCR2 Chromosome 22:17,403,798-17,489,962 22
DGCR2 Chromosome 22:17,403,798-17,489,962 22
GP1BB CD42c, HPA3 Chromosome 22:18,091,066-18,092,297 22
GP1BB CD42c, HPA3 Chromosome 22:18,091,066-18,092,297 22
SCARF2 Chromosome 22:19,108,875-19,122,146 22
CRKL crkl Chromosome 22:19,601,714-19,638,034 22
CRKL crkl Chromosome 22:19,601,714-19,638,034 22
P2RX6 P2X6 Chromosome 22:19,699,449-19,713,119 22
SDF2L1 stromal cell derived factor Chromosome 22:20,326,542-20,328,588 22
MAPK1 p42 MAPK, Erk Chromosome 22:20,443,946-20,551,970 22
VPREB1 CD179a Chromosome 22:20,929,200-20,929,926 22
PRAME Chromosome 22:21,220,123-21,231,768 22
BCR B cell receptor Chromosome 22:21,852,552-21,990,224 22
BCR B cell receptor Chromosome 22:21,852,552-21,990,224 22
IGLL1 Ig kappa light chain, CD17Chromosome 22:22,245,312-22,252,495 22
IGLL1 Ig kappa light chain, CD17Chromosome 22:22,245,312-22,252,495 22
MIF Chromosome 22:22,369,647-22,567,417 22
MIF Chromosome 22:22,369,647-22,567,417 22
GSST1 Chromosome 22:22,706,141-22,714,271 22
CABIN1 Chromosome 22:22,737,765-22,904,596 22
CABIN1 Chromosome 22:22,737,765-22,904,596 22
ADORA2 Adenosin receptor 2 Chromosome 22:23,153,537-23,168,325 22
GGT1 CD224 Chromosome 22:23,309,718-23,354,972 22
MN1 Chromosome 22:26,474,265-26,527,486 22
MN1 Chromosome 22:26,474,265-26,527,486 22
XBP1 XBP1 Chromosome 22:27,520,548-27,526,560 22
LIF Chromosome 22:28,966,441-28,972,748 22
LIF Chromosome 22:28,966,441-28,972,748 22
TCN2 transcobalamin 2 Chromosome 22:29,333,161-29,353,047 22
DUSP18 Chromosome 22:29,388,039-29,393,872 22
DRG1 DRG1 Chromosome 22:30,125,539-30,160,438 22
DRG1 DRG1 Chromosome 22:30,125,539-30,160,438 22
TIMP3 Chromosome 22:31,526,802-31,589,028 22
TIMP3 Chromosome 22:31,526,802-31,589,028 22
HMOX1 Heme oxygenease 1 Chromosome 22:34,107,057-34,120,194 22
APOL6 Chromosome 22:34,374,370-34,394,402 22
APOL6 Chromosome 22:34,374,370-34,394,402 22
MYH9 Chromosome 22:35,007,272-35,113,958 22
CACNG2 Chromosome 22:35,290,050-35,428,849 22
NCF3 neutrophil cytosolic factor Chromosome 22:35,586,976-35,604,005 22
NCF3 neutrophil cytosolic factor Chromosome 22:35,586,976-35,604,005 22
IL2RB CD122 Chromosome 22:35,851,824-35,875,908 22
C1QTNF6 Chromosome 22:35,906,152-35,914,276 22
C1QTNF6 Chromosome 22:35,906,152-35,914,276 22
RAC2 Rac2 Chromosome 22:35,951,238-35,970,251 22
CARD10 CARD10 Chromosome 22:36,216,346-36,245,193 22
CARD10 CARD10 Chromosome 22:36,216,346-36,245,193 22
PLA2G6 Phospholipase Chromosome 22:36,837,448-36,907,763 22
PLA2G6 Phospholipase Chromosome 22:36,837,448-36,907,763 22
DDX17 Chromosome 22:37,209,389-37,232,262 22
DDX17 Chromosome 22:37,209,389-37,232,262 22
UNC84B Chromosome 22:37,460,681-37,481,928 22
UNC84B Chromosome 22:37,460,681-37,481,928 22
PDGFB Chromosome 22:37,949,310-37,971,006 22
MAP3K7IP1 TAB1 Chromosome 22:38,125,692-38,163,078 22
ATF4 Chromosome 22:38,246,515-38,248,637 22
GRAP2 Gads Chromosome 22:38,627,032-38,698,204 22
GRAP2 Gads Chromosome 22:38,627,032-38,698,204 22
EP300 Chromosome 22:39,817,736-39,906,024 22
CENPM PANE1 Chromosome 22:40,664,687-40,673,094 22
CENPM PANE1 Chromosome 22:40,664,687-40,673,094 22
CYP2D6 Chromosome 22:40,852,445-40,856,827 22
TCF20 Chromosome 22:40,885,963-40,941,389 22
NFAM1 Chromosome 22:41,108,917-41,158,340 22
NFAM1 Chromosome 22:41,108,917-41,158,340 22
POLDIP3 S6K1 Chromosome 22:41,309,671-41,340,906 22
A4GALT CD77, Lactosylceramide Chromosome 22:41,418,071-41,446,820 22
BIK Chromosome 22:41,836,701-41,855,662 22
BIK Chromosome 22:41,836,701-41,855,662 22
PPARA PPARalpha, NR1C1 Chromosome 22:44,925,163-45,018,317 22
DIP DIP Chromosome 22:45,394,963-45,454,352 22
DIP DIP Chromosome 22:45,394,963-45,454,352 22
CERK ceramide kinase Chromosome 22:45,458,971-45,512,816 22
ECGF1 Chromosome 22:49,311,047-49,315,321 22
MAPK8IP2 Chromosome 22:49,385,997-49,396,843 22
SHANK3 Chromosome 22:49,459,936-49,518,507 22
IRAK2 Chromosome 3:10,181,563-10,260,427 3
NFKBIZ Chromosome 3:103,029,547-103,062,556 3
NFKBIZ Chromosome 3:103,029,547-103,062,556 3
ALCAM CD166 Chromosome 3:106,568,403-106,778,434 3
ALCAM CD166 Chromosome 3:106,568,403-106,778,434 3
ALCAM CD166 Chromosome 3:106,568,403-106,778,434 3
CBLB Chromosome 3:106,859,799-107,070,577 3
CBLB Chromosome 3:106,859,799-107,070,577 3
CBLB Chromosome 3:106,859,799-107,070,577 3
CD47 IAP Chromosome 3:109,244,631-109,292,625 3
CD47 IAP Chromosome 3:109,244,631-109,292,625 3
CD47 IAP Chromosome 3:109,244,631-109,292,625 3
HRH1 Chromosome 3:11,269,400-11,279,415 3
HRH1 Chromosome 3:11,269,400-11,279,415 3
TRAT1 TRIM Chromosome 3:110,024,321-110,056,542 3
PVRL3 CDw113 Chromosome 3:112,273,555-112,395,063 3
PVRL3 CDw113 Chromosome 3:112,273,555-112,395,063 3
CD96 Chromosome 3:112,743,546-112,853,906 3
CD96 Chromosome 3:112,743,546-112,853,906 3
CD96 Chromosome 3:112,743,546-112,853,906 3
CD200 Chromosome 3:113,522,943-113,564,349 3
CD200 Chromosome 3:113,522,943-113,564,349 3
BTLA CD272=BTLA Chromosome 3:113,667,463-113,701,066 3
CD200R2 Chromosome 3:114,017,246-114,047,487 3
CD200R2 Chromosome 3:114,017,246-114,047,487 3
CD200R1 Chromosome 3:114,122,746-114,176,650 3
TIMP4 Chromosome 3:12,169,568-12,175,851 3
TIMP4 Chromosome 3:12,169,568-12,175,851 3
TIMP4 Chromosome 3:12,169,568-12,175,851 3
PPARG PPARgamma, NR1C3 Chromosome 3:12,304,359-12,450,843 3
PPARG PPARgamma, NR1C3 Chromosome 3:12,304,359-12,450,843 3
PPARG PPARgamma, NR1C3 Chromosome 3:12,304,359-12,450,843 3
IGSF11 Chromosome 3:120,102,167-120,347,588 3
IGSF11 Chromosome 3:120,102,167-120,347,588 3
IGSF11 Chromosome 3:120,102,167-120,347,588 3
CD80 B7-1 Chromosome 3:120,725,832-120,761,139 3
CD80 B7-1 Chromosome 3:120,725,832-120,761,139 3
PLA1A Phospholipase Chromosome 3:120,792,984-120,831,342 3
NR1I2 NR1I2 Chromosome 3:120,982,021-121,020,022 3
GSK3B Chromosome 3:121,028,233-121,295,954 3
GTF2E1 TFIIE Chromosome 3:121,937,926-121,984,605 3
CD86 B7-2 Chromosome 3:123,256,911-123,322,673 3
CD86 B7-2 Chromosome 3:123,256,911-123,322,673 3
CD86 B7-2 Chromosome 3:123,256,911-123,322,673 3
MYLK myosin light chain kinase Chromosome 3:124,813,833-125,085,839 3
MYLK myosin light chain kinase Chromosome 3:124,813,833-125,085,839 3
ITGB5 Chromosome 3:125,964,485-126,088,842 3
ITGB5 Chromosome 3:125,964,485-126,088,842 3
ITGB5 Chromosome 3:125,964,485-126,088,842 3
PLXNA1 Plexin-A1 Chromosome 3:128,190,192-128,238,922 3
PLXNA1 Plexin-A1 Chromosome 3:128,190,192-128,238,922 3
MCM2 Chromosome 3:128,799,943-128,823,969 3
MCM2 Chromosome 3:128,799,943-128,823,969 3
SEC61A1 Chromosome 3:129,253,902-129,273,216 3
SEC61A1 Chromosome 3:129,253,902-129,273,216 3
GATA2 Chromosome 3:129,680,960-129,694,718 3
GP9 CD42a Chromosome 3:130,262,300-130,263,941 3
PLXND1 Plexin-D1 Chromosome 3:130,756,708-130,808,351 3
PLXND1 Plexin-D1 Chromosome 3:130,756,708-130,808,351 3
TRH TRH Chromosome 3:131,176,253-131,179,470 3
TRH TRH Chromosome 3:131,176,253-131,179,470 3
TRH TRH Chromosome 3:131,176,253-131,179,470 3
PIK3R4 Chromosome 3:131,880,468-131,948,340) 3
PIK3R4 Chromosome 3:131,880,468-131,948,340) 3
CCRL1 Chromosome 3:133,798,784-133,804,072 3
EPHB1 Chromosome 3:135,996,950-136,461,999 3
EPHB1 Chromosome 3:135,996,950-136,461,999 3
EPHB1 Chromosome 3:135,996,950-136,461,999 3
EPHB1 Chromosome 3:135,996,950-136,461,999 3
EPHB1 Chromosome 3:135,996,950-136,461,999 3
EPHB1 Chromosome 3:135,996,950-136,461,999 3
EPHB1 Chromosome 3:135,996,950-136,461,999 3
IL20RB Chromosome 3:138,159,397-138,212,610 3
IL20RB Chromosome 3:138,159,397-138,212,610 3
PIK3CB Chromosome 3:139,856,921-139,960,875 3
PIK3CB Chromosome 3:139,856,921-139,960,875 3
XPC Chromosome 3:14,161,648-14,195,143 3
NR2C2 NR2C2 Chromosome 3:14,964,240-15,065,784 3
NR2C2 NR2C2 Chromosome 3:14,964,240-15,065,784 3
FOXL2 Chromosome 3:140,145,756-140,148,491 3
FOXL2 Chromosome 3:140,145,756-140,148,491 3
RNF7 Chromosome 3:142,939,741-142,947,933 3
RNF7 Chromosome 3:142,939,741-142,947,933 3
ATP1B3 CD298 Chromosome 3:143,078,160-143,128,072 3
SLC9A9 NHE-9 Chromosome 3:144,466,754-145,049,979 3
SLC9A9 NHE-9 Chromosome 3:144,466,754-145,049,979 3
SLC9A9 NHE-9 Chromosome 3:144,466,754-145,049,979 3
SLC9A9 NHE-9 Chromosome 3:144,466,754-145,049,979 3
SLC9A9 NHE-9 Chromosome 3:144,466,754-145,049,979 3
SLC9A9 NHE-9 Chromosome 3:144,466,754-145,049,979 3
SLC9A9 NHE-9 Chromosome 3:144,466,754-145,049,979 3
SLC9A9 NHE-9 Chromosome 3:144,466,754-145,049,979 3
SLC9A9 NHE-9 Chromosome 3:144,466,754-145,049,979 3
AGTR1 Angiotensin receptor Chromosome 3:149,898,355-149,943,478 3
AGTR1 Angiotensin receptor Chromosome 3:149,898,355-149,943,478 3
AGTR1 Angiotensin receptor Chromosome 3:149,898,355-149,943,478 3
HLTF Chromosome 3:150,230,604-150,287,007 3
HLTF Chromosome 3:150,230,604-150,287,007 3
HPS3 Hermansky-Pudlak syndro  Chromosome 3:150,330,061-150,373,995 3
P2RY14 P2Y14 Chromosome 3:152,412,595-152,478,847 3
P2RY14 P2Y14 Chromosome 3:152,412,595-152,478,847 3
IGSF10 Chromosome 3:152,637,167-152,659,187 3
P2RY1 P2Y1 Chromosome 3:154,035,426-154,038,535 3
P2RY1 P2Y1 Chromosome 3:154,035,426-154,038,535 3
DHX36 Chromosome 3:155,476,152-155,524,971 3
DHX36 Chromosome 3:155,476,152-155,524,971 3
MME CD10 Chromosome 3:156,280,153-156,384,186 3
MME CD10 Chromosome 3:156,280,153-156,384,186 3
PTX3 Chromosome 3:158,637,301-158,644,071 3
PLCL2 Chromosome 3:16,949,586-17,107,089 3
PLCL2 Chromosome 3:16,949,586-17,107,089 3
IL12A Chromosome 3:161,189,323-161,196,500 3
IL12A Chromosome 3:161,189,323-161,196,500 3
IL12A Chromosome 3:161,189,323-161,196,500 3
TRIM59 MRF1 Chromosome 3:161,427,938-161,650,320 3
TRIM59 MRF1 Chromosome 3:161,427,938-161,650,320 3
TRIM59 MRF1 Chromosome 3:161,427,938-161,650,320 3
B3GALNT1 Chromosome 3:162,284,365-162,305,854 3
PDCD10 Chromosome 3:168,884,388-168,935,345 3
PDCD10 Chromosome 3:168,884,388-168,935,345 3
EVI1 Chromosome 3:170,285,244-170,347,054 3
EVI1 Chromosome 3:170,285,244-170,347,054 3
TERC Chromosome 3:170,965,092-170,965,542 3
TERC Chromosome 3:170,965,092-170,965,542 3
PRKCI PKCθ Chromosome 3:171,422,919-171,506,459 3
PRKCI PKCθ Chromosome 3:171,422,919-171,506,459 3
TNFSF10 CD253, TRAIL Chromosome 3:173,706,158-173,723,963 3
TNFSF10 CD253, TRAIL Chromosome 3:173,706,158-173,723,963 3
TBL1XR1 TBLR1 Chromosome 3:178,221,867-178,397,734 3
TBL1XR1 TBLR1 Chromosome 3:178,221,867-178,397,734 3
TBL1XR1 TBLR1 Chromosome 3:178,221,867-178,397,734 3
PIK3CA Chromosome 3:180,349,005-180,435,194 3
PIK3CA Chromosome 3:180,349,005-180,435,194 3
LAMP3 CD208, DC-LAMP Chromosome 3:184,322,697-184,363,317 3
LAMP3 CD208, DC-LAMP Chromosome 3:184,322,697-184,363,317 3
THPO Thrombopoietin Chromosome 3:185,572,467-185,578,626 3
THPO Thrombopoietin Chromosome 3:185,572,467-185,578,626 3
MAP3K13 Chromosome 3:186,563,664-186,683,322 3
KNG1 Bradykinin Chromosome 3:187,917,814-187,944,437 3
KNG1 Bradykinin Chromosome 3:187,917,814-187,944,437 3
ST6GAL1 CD75s Chromosome 3:188,131,210-188,279,035 3
ST6GAL1 CD75s Chromosome 3:188,131,210-188,279,035 3
ST6GAL1 CD75s Chromosome 3:188,131,210-188,279,035 3
ST6GAL1 CD75s Chromosome 3:188,131,210-188,279,035 3
MASP1 MASP3 Chromosome 3:188,418,632-188,492,446 3
IFRG28 Chromosome 3:188,568,862-188,572,066 3
IFRG28 Chromosome 3:188,568,862-188,572,066 3
SST SST Chromosome 3:188,869,388-188,870,895 3
SST SST Chromosome 3:188,869,388-188,870,895 3
SST SST Chromosome 3:188,869,388-188,870,895 3
TP73L p63 Chromosome 3:190,831,910-191,097,759 3
TP73L p63 Chromosome 3:190,831,910-191,097,759 3
TP73L p63 Chromosome 3:190,831,910-191,097,759 3
IL1RAP Chromosome 3:191,714,585-191,858,537 3
IL1RAP Chromosome 3:191,714,585-191,858,537 3
IL1RAP Chromosome 3:191,714,585-191,858,537 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
FGF12 FGF12 Chromosome 3:193,342,413-193,928,066 3
GP5 CD42d, HPA4 Chromosome 3:195,595,348-195,601,523 3
TFRC transferrin receptor Chromosome 3:197,260,553-197,293,343 3
PAK2 Chromosome 3:197,951,312-198,043,756 3
PAK2 Chromosome 3:197,951,312-198,043,756 3
MFI2 CD228 Chromosome 3:198,214,553-198,241,043 3
MFI2 CD228 Chromosome 3:198,214,553-198,241,043 3
CHLI Chromosome 3:213,650-426,098 3
CHLI Chromosome 3:213,650-426,098 3
CHLI Chromosome 3:213,650-426,098 3
NKIRAS1 Chromosome 3:23,908,576-23,933,541 3
NR1D2 Chromosome 3:23,961,810-23,996,241 3
THRB NR1A2 Chromosome 3:24,134,709-24,511,317 3
THRB NR1A2 Chromosome 3:24,134,709-24,511,317 3
THRB NR1A2 Chromosome 3:24,134,709-24,511,317 3
THRB NR1A2 Chromosome 3:24,134,709-24,511,317 3
THRB NR1A2 Chromosome 3:24,134,709-24,511,317 3
RARB NR1B2 Chromosome 3:25,190,893-25,614,424 3
RARB NR1B2 Chromosome 3:25,190,893-25,614,424 3
RARB NR1B2 Chromosome 3:25,190,893-25,614,424 3
RARB NR1B2 Chromosome 3:25,190,893-25,614,424 3
RARB NR1B2 Chromosome 3:25,190,893-25,614,424 3
EOMES eomesodermin Chromosome 3:27,732,872-27,738,807 3
IL5RA CD125 Chromosome 3:3,086,421-3,127,031 3
IL5RA CD125 Chromosome 3:3,086,421-3,127,031 3
TGFBR2 Chromosome 3:30,622,998-30,710,638 3
TGFBR2 Chromosome 3:30,622,998-30,710,638 3
STT3B Chromosome 3:31,549,495-31,652,560 3
CMTM8 Chromosome 3:32,255,175-32,386,817 3
CMTM8 Chromosome 3:32,255,175-32,386,817 3
CMTM8 Chromosome 3:32,255,175-32,386,817 3
CMTM7 Chromosome 3:32,408,167-32,471,337 3
CMTM7 Chromosome 3:32,408,167-32,471,337 3
CMTM6 Chromosome 3:32,497,808-32,519,869 3
CMTM6 Chromosome 3:32,497,808-32,519,869 3
CCR4 CD194 Chromosome 3:32,968,070-32,972,840 3
CLASP2 c1AP2 Chromosome 3:33,512,741-33,734,852 3
PDCD6IP Chromosome 3:33,814,561-33,886,198 3
PDCD6IP Chromosome 3:33,814,561-33,886,198 3
ITGA9 Chromosome 3:37,468,817-37,836,285 3
ITGA9 Chromosome 3:37,468,817-37,836,285 3
ITGA9 Chromosome 3:37,468,817-37,836,285 3
ITGA9 Chromosome 3:37,468,817-37,836,285 3
ITGA9 Chromosome 3:37,468,817-37,836,285 3
ITGA9 Chromosome 3:37,468,817-37,836,285 3
ITGA9 Chromosome 3:37,468,817-37,836,285 3
CTDSPL NIF1 Chromosome 3:37,878,129-38,000,964 3
CTDSPL NIF1 Chromosome 3:37,878,129-38,000,964 3
MyD88 Chromosome 3:38,155,009-38,159,517 3
MyD88 Chromosome 3:38,155,009-38,159,517 3
CX3CR1 Chromosome 3:39,279,989-39,298,190 3
CX3CR1 Chromosome 3:39,279,989-39,298,190 3
CX3CR1 Chromosome 3:39,279,989-39,298,190 3
CCR8 CD198 Chromosome 3:39,346,219-39,351,077 3
ITPR1 Chromosome 3:4,510,136-4,864,081 3
ITPR1 Chromosome 3:4,510,136-4,864,081 3
ITPR1 Chromosome 3:4,510,136-4,864,081 3
ITPR1 Chromosome 3:4,510,136-4,864,081 3
ITPR1 Chromosome 3:4,510,136-4,864,081 3
ITPR1 Chromosome 3:4,510,136-4,864,081 3
CTNNB1 beta-catenin Chromosome 3:41,216,004-41,256,938 3
CTNNB1 beta-catenin Chromosome 3:41,216,004-41,256,938 3
NKTR Chromosome 3:42,617,151-42,665,237 3
CCBP2 D6 Chromosome 3:42,825,980-42,883,779 3
CYP8B1 Chromosome 3:42,888,688-42,892,637 3
CDCP1 CD318 Chromosome 3:45,098,773-45,162,918 3
CDCP1 CD318 Chromosome 3:45,098,773-45,162,918 3
CDCP1 CD318 Chromosome 3:45,098,773-45,162,918 3
TMEM158 RIS1 Chromosome 3:45,240,962-45,242,758 3
CCR9 CD198, 199 Chromosome 3:45,903,023-45,919,671 3
XCR1 Chromosome 3:46,037,295-46,043,983 3
CCR1 CD191 Chromosome 3:46,218,204-46,224,836 3
CCR3 CD193 Chromosome 3:46,227,186-46,283,166 3
CCRL2 Chromosome 3:46,423,725-46,426,018 3
LTF Lactoferrin Chromosome 3:46,452,500-46,481,657 3
PTHR1 PTHR1 Chromosome 3:46,894,240-46,926,585 3
PTHR1 PTHR1 Chromosome 3:46,894,240-46,926,585 3
PTPN23 Chromosome 3:47,397,528-47,429,935 3
DHX30 Chromosome 3:47,819,625-47,866,687 3
PLXNB1 Plexin-B Chromosome 3:48,420,266-48,446,464 3
GPX1 GSH peroxidase, cGPx Chromosome 3:49,369,613-49,370,795 3
RHOA RHOA Chromosome 3:49,371,582-49,424,530 3
DAG1 DAG Chromosome 3:49,482,595-49,548,048 3
DAG1 DAG Chromosome 3:49,482,595-49,548,048 3
MST1 MST1/STK4 Chromosome 3:49,696,391-49,701,099 3
MST1R CDw136 Chromosome 3:49,899,439-49,916,074 3
MST1R CDw136 Chromosome 3:49,899,439-49,916,074 3
MST1R CDw136 Chromosome 3:49,899,439-49,916,074 3
DUSP7 Chromosome 3:52,059,799-52,065,329 3
DUSP7 Chromosome 3:52,059,799-52,065,329 3
TLR9 CD289 Chromosome 3:52,230,138-52,248,223 3
TLR9 CD289 Chromosome 3:52,230,138-52,248,223 3
STAB1 FEEL-1 Chromosome 3:52,504,396-52,533,551 3
STAB1 FEEL-1 Chromosome 3:52,504,396-52,533,551 3
PRKCD PKC delta Chromosome 3:53,170,263-53,201,773 3
IL17RB Chromosome 3:53,855,612-53,874,867 3
IL17RB Chromosome 3:53,855,612-53,874,867 3
WNT5A Chromosome 3:55,474,783-55,496,371 3
ERC2 Chromosome 3:55,517,376-56,477,431 3
ERC2 Chromosome 3:55,517,376-56,477,431 3
ERC2 Chromosome 3:55,517,376-56,477,431 3
ERC2 Chromosome 3:55,517,376-56,477,431 3
ERC2 Chromosome 3:55,517,376-56,477,431 3
ERC2 Chromosome 3:55,517,376-56,477,431 3
ERC2 Chromosome 3:55,517,376-56,477,431 3
ERC2 Chromosome 3:55,517,376-56,477,431 3
ERC2 Chromosome 3:55,517,376-56,477,431 3
ERC2 Chromosome 3:55,517,376-56,477,431 3
IL17RD Chromosome 3:57,103,316-57,179,374 3
IL17RD Chromosome 3:57,103,316-57,179,374 3
IL17RD Chromosome 3:57,103,316-57,179,374 3
PTPRG Chromosome 3:61,522,285-62,255,613 3
PTPRG Chromosome 3:61,522,285-62,255,613 3
PTPRG Chromosome 3:61,522,285-62,255,613 3
PTPRG Chromosome 3:61,522,285-62,255,613 3
PTPRG Chromosome 3:61,522,285-62,255,613 3
PTPRG Chromosome 3:61,522,285-62,255,613 3
PTPRG Chromosome 3:61,522,285-62,255,613 3
PTPRG Chromosome 3:61,522,285-62,255,613 3
ARL6IP5 JWA Chromosome 3:69,216,780-69,237,929 3
MITF Chromosome 3:69,871,323-70,100,177 3
MITF Chromosome 3:69,871,323-70,100,177 3
MITF Chromosome 3:69,871,323-70,100,177 3
MITF Chromosome 3:69,871,323-70,100,177 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
FOXP1 Chromosome 3:71,087,426-71,715,830 3
CADM2 Chromosome 3:85,858,322-86,200,641 3
CADM2 Chromosome 3:85,858,322-86,200,641 3
CADM2 Chromosome 3:85,858,322-86,200,641 3
CADM2 Chromosome 3:85,858,322-86,200,641 3
CADM2 Chromosome 3:85,858,322-86,200,641 3
CHMP2B CHMP2B Chromosome 3:87,359,140-87,387,339 3
CHMP2B CHMP2B Chromosome 3:87,359,140-87,387,339 3
CHMP2B CHMP2B Chromosome 3:87,359,140-87,387,339 3
IL17RE Chromosome 3:9,919,150-9,933,086 3
IL17RC Chromosome 3:9,933,782-9,950,314 3
Protein S Chromosome 3:95,074,647-95,175,412 3
FGFR3 CD333 Chromosome 4:1,764,832-1,780,396 4
H2AFZ Chromosome 4:101,088,265-101,090,535 4
PPP3CA Chromosome 4:102,163,610-102,487,376 4
PPP3CA Chromosome 4:102,163,610-102,487,376 4
PPP3CA Chromosome 4:102,163,610-102,487,376 4
PPP3CA Chromosome 4:102,163,610-102,487,376 4
PPP3CA Chromosome 4:102,163,610-102,487,376 4
PPP3CA Chromosome 4:102,163,610-102,487,376 4
BANK1 B cell scaffold protein Chromosome 4:102,930,919-103,214,918 4
BANK1 B cell scaffold protein Chromosome 4:102,930,919-103,214,918 4
BANK1 B cell scaffold protein Chromosome 4:102,930,919-103,214,918 4
NFKB1 p105, p50 Chromosome 4:103,641,518-103,757,507 4
NFKB1 p105, p50 Chromosome 4:103,641,518-103,757,507 4
SCYE1 SCYE1 Chromosome 4:107,456,302-107,489,097 4
SCYE1 SCYE1 Chromosome 4:107,456,302-107,489,097 4
CYP2U1 Chromosome 4:109,072,166-109,094,062 4
CYP2U1 Chromosome 4:109,072,166-109,094,062 4
HS3ST1 Chromosome 4:11,009,086-11,040,487 4
HS3ST1 Chromosome 4:11,009,086-11,040,487 4
CFI Chromosome 4:110,881,301-110,942,590 4
EGF1 Chromosome 4:111,053,499-111,152,868 4
EGF1 Chromosome 4:111,053,499-111,152,868 4
EGF1 Chromosome 4:111,053,499-111,152,868 4
EGF1 Chromosome 4:111,053,499-111,152,868 4
ENPEP CD249 Chromosome 4:111,616,697-111,702,872 4
ENPEP CD249 Chromosome 4:111,616,697-111,702,872 4
ANK2 Chromosome 4:114,190,319-114,524,337 4
ANK2 Chromosome 4:114,190,319-114,524,337 4
ANK2 Chromosome 4:114,190,319-114,524,337 4
ANK2 Chromosome 4:114,190,319-114,524,337 4
CAMK2D CaMKII Chromosome 4:114,593,021-114,902,177 4
CAMK2D CaMKII Chromosome 4:114,593,021-114,902,177 4
CAMK2D CaMKII Chromosome 4:114,593,021-114,902,177 4
CAMK2D CaMKII Chromosome 4:114,593,021-114,902,177 4
CAMK2D CaMKII Chromosome 4:114,593,021-114,902,177 4
MAD2LI Chromosome 4:121,200,029-121,207,411 4
MAD2LI Chromosome 4:121,200,029-121,207,411 4
ANXA5 Chromosome 4:122,808,598-122,837,626 4
CCNA2 Chromosome 4:122,957,975-122,964,505 4
IL2 Chromosome 4:123,592,075-123,597,339 4
IL21 Chromosome 4:123,753,221-123,761,662 4
FGF2 FGF2 Chromosome 4:123,967,313-124,038,840 4
FGF2 FGF2 Chromosome 4:123,967,313-124,038,840 4
PLK4 Sak Chromosome 4:129,021,551-129,039,377 4
C1QTNF7 Chromosome 4:14,950,658-15,056,887 4
C1QTNF7 Chromosome 4:14,950,658-15,056,887 4
CCRN4L Chromosome 4:140,156,393-140,186,543 4
IL15 Chromosome 4:142,777,204-142,874,062 4
IL15 Chromosome 4:142,777,204-142,874,062 4
SMARCA5 Chromosome 4:144,654,066-144,694,017 4
SMARCA5 Chromosome 4:144,654,066-144,694,017 4
GYPB MNSs antigen, CD235b Chromosome 4:145,136,707-145,159,946 4
GYPA MNSs antigen, CD235a Chromosome 4:145,249,906-145,281,294 4
SMAD1 Chromosome 4:146,622,401-146,699,778 4
GTF2F2L Chromosome 4:148,646,691-148,647,812 4
GTF2F2L Chromosome 4:148,646,691-148,647,812 4
GTF2F2L Chromosome 4:148,646,691-148,647,812 4
NR3C2 NR3C2 Chromosome 4:149,219,370-149,582,973 4
NR3C2 NR3C2 Chromosome 4:149,219,370-149,582,973 4
NR3C2 NR3C2 Chromosome 4:149,219,370-149,582,973 4
NR3C2 NR3C2 Chromosome 4:149,219,370-149,582,973 4
NR3C2 NR3C2 Chromosome 4:149,219,370-149,582,973 4
BST1 CD157 Chromosome 4:15,313,738-15,343,508 4
BST1 CD157 Chromosome 4:15,313,738-15,343,508 4
CD38 Chromosome 4:15,388,999-15,460,167 4
PROM1 CD133, SCA Chromosome 4:15,578,955-15,686,664 4
PROM1 CD133, SCA Chromosome 4:15,578,955-15,686,664 4
FBXW7 Chromosome 4:153,461,860-153,675,622 4
FBXW7 Chromosome 4:153,461,860-153,675,622 4
FBXW7 Chromosome 4:153,461,860-153,675,622 4
FBXW7 Chromosome 4:153,461,860-153,675,622 4
TLR2 CD282 Chromosome 4:154,824,891-154,846,693 4
TLR2 CD282 Chromosome 4:154,824,891-154,846,693 4
FGB fibrinogen Chromosome 4:155,703,596-155,711,688 4
NPY2R Chromosome 4:156,349,231-156,357,678 4
PPID Chromosome 4:159,849,729-159,864,002 4
PPID Chromosome 4:159,849,729-159,864,002 4
CPE Chromosome 4:166,519,538-166,638,926 4
CPE Chromosome 4:166,519,538-166,638,926 4
HPGD Chromosome 4:175,647,955-175,680,213 4
HPGD Chromosome 4:175,647,955-175,680,213 4
HPGD Chromosome 4:175,647,955-175,680,213 4
HPGD Chromosome 4:175,647,955-175,680,213 4
VEGFC Chromosome 4:177,841,685-177,950,889 4
IRF2 Chromosome 4:185,545,909-185,632,697 4
IRF2 Chromosome 4:185,545,909-185,632,697 4
IRF2 Chromosome 4:185,545,909-185,632,697 4
TLR3 CD283 Chromosome 4:187,227,303-187,243,246 4
CYP4V2 Chromosome 4:187,349,668-187,371,606 4
CYP4V2 Chromosome 4:187,349,668-187,371,606 4
RNF4 Chromosome 4:2,440,605-2,487,382 4
ADD1 alpha adducin Chromosome 4:2,815,382-2,901,587 4
DHX15 Chromosome 4:24,138,185-24,195,282 4
DHX15 Chromosome 4:24,138,185-24,195,282 4
SOD3 IP01 Chromosome 4:24,405,153-24,411,562 4
SOD3 IP01 Chromosome 4:24,405,153-24,411,562 4
PI4K2B PI4K2B Chromosome 4:24,844,751-24,889,811 4
RBPSUH RBP-Jk Chromosome 4:25,930,430-26,045,851 4
RBPSUH RBP-Jk Chromosome 4:25,930,430-26,045,851 4
RBPSUH RBP-Jk Chromosome 4:25,930,430-26,045,851 4
RBPSUH RBP-Jk Chromosome 4:25,930,430-26,045,851 4
TLR10 CD290 Chromosome 4:38,450,255-38,460,984 4
TLR10 CD290 Chromosome 4:38,450,255-38,460,984 4
TLR6 CD286 Chromosome 4:38,504,618-38,507,555 4
RFC1 RFC Chromosome 4:38,965,471-39,044,390 4
RFC1 RFC Chromosome 4:38,965,471-39,044,390 4
RFC1 RFC Chromosome 4:38,965,471-39,044,390 4
RHOH RhoH Chromosome 4:39,874,965-39,922,663 4
RHOH RhoH Chromosome 4:39,874,965-39,922,663 4
TXK Txk, Rlk, thioredoxin Chromosome 4:47,762,988-47,831,030 4
TXK Txk, Rlk, thioredoxin Chromosome 4:47,762,988-47,831,030 4
TXK Txk, Rlk, thioredoxin Chromosome 4:47,762,988-47,831,030 4
CYTL1 cytokine-like 1 Chromosome 4:5,067,214-5,072,100 4
CYTL1 cytokine-like 1 Chromosome 4:5,067,214-5,072,100 4
PDGFRA CD140a Chromosome 4:54,790,204-54,859,171 4
PDGFRA CD140a Chromosome 4:54,790,204-54,859,171 4
KIT FLT3-ITD, CD117, c-KIT Chromosome 4:55,218,842-55,301,638 4
KIT FLT3-ITD, CD117, c-KIT Chromosome 4:55,218,842-55,301,638 4
KIT FLT3-ITD, CD117, c-KIT Chromosome 4:55,218,842-55,301,638 4
KDR CD309, VEGFR2 Chromosome 4:55,639,401-55,686,519 4
BRDG1 Chromosome 4:68,107,041-68,155,206 4
BRDG1 Chromosome 4:68,107,041-68,155,206 4
GNRHR GNRH1-R Chromosome 4:68,285,688-68,304,399 4
TMPRSS11D HAT Chromosome 4:68,369,189-68,432,311 4
TMPRSS11D HAT Chromosome 4:68,369,189-68,432,311 4
UGT2B17 UGT2 Chromosome 4:69,085,497-69,116,840 4
UGT2B7 Chromosome 4:69,996,782-70,013,293 4
UGT2B28 Chromosome 4:70,180,783-70,323,496 4
UGT2B28 Chromosome 4:70,180,783-70,323,496 4
HTN3 histatin 3 Chromosome 4:70,928,761-70,936,836 4
HTN3 histatin 3 Chromosome 4:70,928,761-70,936,836 4
IGJ Chromosome 4:71,740,548-71,751,128 4
IL8 CXCL8 Chromosome 4:74,825,139-74,828,297 4
CXCL6 Chromosome 4:74,921,277-74,923,341 4
PF4 CXCL4 Chromosome 4:75,065,660-75,066,541 4
CXCL3 Chromosome 4:75,121,170-75,123,354 4
EREG EREG Chromosome 4:75,449,724-75,473,341 4
AREG AREG Chromosome 4:75,529,717-75,539,590 4
AREG AREG Chromosome 4:75,529,717-75,539,590 4
BTC BTC betacellulin Chromosome 4:75,889,001-75,938,853 4
BTC BTC betacellulin Chromosome 4:75,889,001-75,938,853 4
CXCL9 Mig Chromosome 4:77,141,523-77,147,665 4
SCARB2 Chromosome 4:77,298,918-77,354,059 4
SCARB2 Chromosome 4:77,298,918-77,354,059 4
CXCL13 Chromosome 4:78,651,931-78,752,010 4
CXCL13 Chromosome 4:78,651,931-78,752,010 4
CXCL13 Chromosome 4:78,651,931-78,752,010 4
FGF5 FGF5 Chromosome 4:81,406,766-81,431,195 4
FGF5 FGF5 Chromosome 4:81,406,766-81,431,195 4
BMP3 BMP3 Chromosome 4:82,171,143-82,193,749 4
BMP3 BMP3 Chromosome 4:82,171,143-82,193,749 4
HPA Chromosome 4:84,432,639-84,475,330 4
MAPK10 Chromosome 4:87,156,656-87,593,307 4
MAPK10 Chromosome 4:87,156,656-87,593,307 4
MAPK10 Chromosome 4:87,156,656-87,593,307 4
MAPK10 Chromosome 4:87,156,656-87,593,307 4
MAPK10 Chromosome 4:87,156,656-87,593,307 4
PTPN13 Chromosome 4:87,734,909-87,955,326 4
PTPN13 Chromosome 4:87,734,909-87,955,326 4
PTPN13 Chromosome 4:87,734,909-87,955,326 4
SPP1 Osteopontin, Eta1 Chromosome 4:89,115,826-89,123,592 4
SPP1 Osteopontin, Eta1 Chromosome 4:89,115,826-89,123,592 4
ABCG2 CD338, BCRP, MRX, MXRChromosome 4:89,230,440-89,299,035 4
HERC6 FLJ20637 Chromosome 4:89,518,915-89,583,272 4
HERC6 FLJ20637 Chromosome 4:89,518,915-89,583,272 4
HERC6 FLJ20637 Chromosome 4:89,518,915-89,583,272 4
DFB131 Chromosome 4:9,055,358-9,061,338 4
PGDS Chromosome 4:95,438,730-95,483,050 4
BMPR1B CD293 Chromosome 4:95,898,151-96,295,099 4
BMPR1B CD293 Chromosome 4:95,898,151-96,295,099 4
BMPR1B CD293 Chromosome 4:95,898,151-96,295,099 4
BMPR1B CD293 Chromosome 4:95,898,151-96,295,099 4
BMPR1B CD293 Chromosome 4:95,898,151-96,295,099 4
IBD5 Chromosome 5 5
IBD5 Chromosome 5 5
TERT Chromosome 5:1,306,282-1,348,162 5
TERT Chromosome 5:1,306,282-1,348,162 5
DAP Chromosome 5:10,732,343-10,814,344 5
DAP Chromosome 5:10,732,343-10,814,344 5
TSLP Thymic stromal lymphopo Chromosome 5:110,433,677-110,441,623 5
TSLP Thymic stromal lymphopo Chromosome 5:110,433,677-110,441,623 5
CAMK4 CaMKIV Chromosome 5:110,587,968-110,858,483 5
CAMK4 CaMKIV Chromosome 5:110,587,968-110,858,483 5
CAMK4 CaMKIV Chromosome 5:110,587,968-110,858,483 5
CAMK4 CaMKIV Chromosome 5:110,587,968-110,858,483 5
APC Chromosome 5:112,101,483-112,209,835 5
APC Chromosome 5:112,101,483-112,209,835 5
TCAM2 TIRP Chromosome 5:114,942,247-114,989,610 5
TCAM2 TIRP Chromosome 5:114,942,247-114,989,610 5
CDO1 Chromosome 5:115,168,329-115,180,304 5
PPIC Chromosome 5:122,386,977-122,400,324 5
PPIC Chromosome 5:122,386,977-122,400,324 5
IL3 Chromosome 5:131,424,121-131,426,796 5
SLC22A4 OCTN1 Chromosome 5:131,658,035-131,707,798 5
SLC22A4 OCTN1 Chromosome 5:131,658,035-131,707,798 5
SLC22A4 OCTN1 Chromosome 5:131,658,035-131,707,798 5
SLC22A5 OCTN2 Chromosome 5:131,733,343-131,759,205 5
IRF1 Chromosome 5:131,845,200-131,854,389 5
RAD50 rad50 Chromosome 5:131,920,529-132,007,651 5
LEAP2 liver expressed antimicrob  Chromosome 5:132,235,913-132,238,637 5
LEAP2 liver expressed antimicrob  Chromosome 5:132,235,913-132,238,637 5
HSPA4 Chromosome 5:132,415,561-132,468,608 5
DDX46 Chromosome 5:134,122,360-134,194,710 5
DDX46 Chromosome 5:134,122,360-134,194,710 5
CXCL14 Chromosome 5:134,934,274-134,942,868 5
IL9 Chromosome 5:135,255,834-135,259,415 5
IL9 Chromosome 5:135,255,834-135,259,415 5
IL9 Chromosome 5:135,255,834-135,259,415 5
BRD8 SMAP Chromosome 5:137,503,358-137,542,257 5
BRD8 SMAP Chromosome 5:137,503,358-137,542,257 5
BRD8 SMAP Chromosome 5:137,503,358-137,542,257 5
EGR1 Chromosome 5:137,829,080-137,832,903 5
EGR1 Chromosome 5:137,829,080-137,832,903 5
NRG2 NRG2 Chromosome 5:139,207,444-139,403,063 5
NRG2 NRG2 Chromosome 5:139,207,444-139,403,063 5
NRG2 NRG2 Chromosome 5:139,207,444-139,403,063 5
HBEGF HBEGF Chromosome 5:139,692,612-139,706,359 5
HBEGF HBEGF Chromosome 5:139,692,612-139,706,359 5
CD14 Chromosome 5:139,991,501-139,993,439 5
NDUFA2 B8/HY Chromosome 5:140,005,142-140,007,424 5
PCDHB5 Chromosome 5:140,494,984-140,497,888 5
PCDHB16 Chromosome 5:140,541,164-140,545,980 5
HDAC3 Chromosome 5:140,980,627-140,996,596 5
FGF1 Chromosome 5:141,951,927-142,046,134 5
FGF1 Chromosome 5:141,951,927-142,046,134 5
NR3C1 GR Chromosome 5:142,637,689-142,795,270 5
NR3C1 GR Chromosome 5:142,637,689-142,795,270 5
HMHB1 HB-1 Chromosome 5:143,171,919-143,180,477 5
HMHB1 HB-1 Chromosome 5:143,171,919-143,180,477 5
IL17B Chromosome 5:148,734,023-148,739,031 5
IL17B Chromosome 5:148,734,023-148,739,031 5
CSNK1A1 casein kinase 1 Chromosome 5:148,855,038-148,911,200 5
CSF1R CD115 Chromosome 5:149,413,051-149,473,128 5
CSF1R CD115 Chromosome 5:149,413,051-149,473,128 5
PDGFRB CD140b Chromosome 5:149,473,595-149,515,615 5
PDGFRB CD140b Chromosome 5:149,473,595-149,515,615 5
CD74 p41 Chromosome 5:149,761,393-149,772,685 5
IRGM LRG47 Chromosome 5:150,207,879-150,260,488 5
GPX3 Chromosome 5:150,380,112-150,388,747 5
HAVCR2 TIM-3 Chromosome 5:156,445,421-156,468,716 5
ITK Itk Chromosome 5:156,540,432-156,614,687 5
ITK Itk Chromosome 5:156,540,432-156,614,687 5
EBF Chromosome 5:158,058,006-158,459,347 5
EBF Chromosome 5:158,058,006-158,459,347 5
EBF Chromosome 5:158,058,006-158,459,347 5
EBF Chromosome 5:158,058,006-158,459,347 5
EBF Chromosome 5:158,058,006-158,459,347 5
EBF Chromosome 5:158,058,006-158,459,347 5
IL12B Chromosome 5:158,674,369-158,690,059 5
IL12B Chromosome 5:158,674,369-158,690,059 5
IL12B Chromosome 5:158,674,369-158,690,059 5
C1QTNF2 Chromosome 5:159,707,339-159,730,207 5
C1QTNF2 Chromosome 5:159,707,339-159,730,207 5
CCNG1 Chromosome 5:162,797,155-162,804,600 5
HMMR CD168 Chromosome 5:162,820,241-162,851,525 5
DOCK2 dedicator of cytokinesis 2 Chromosome 5:168,996,871-169,442,959 5
DOCK2 dedicator of cytokinesis 2 Chromosome 5:168,996,871-169,442,959 5
DOCK2 dedicator of cytokinesis 2 Chromosome 5:168,996,871-169,442,959 5
DOCK2 dedicator of cytokinesis 2 Chromosome 5:168,996,871-169,442,959 5
DOCK2 dedicator of cytokinesis 2 Chromosome 5:168,996,871-169,442,959 5
DOCK2 dedicator of cytokinesis 2 Chromosome 5:168,996,871-169,442,959 5
DOCK2 dedicator of cytokinesis 2 Chromosome 5:168,996,871-169,442,959 5
DOCK2 dedicator of cytokinesis 2 Chromosome 5:168,996,871-169,442,959 5
FLJ46831 FOXI1 Chromosome 5:169,465,495-169,469,305 5
LCP2 SLP76 Chromosome 5:169,607,666-169,657,400 5
LPC2 SLP-76 Chromosome 5:169,607,666-169,657,400 5
DUSP1 MKP1 Chromosome 5:172,127,707-172,130,809 5
BNIP1 Chromosome 5:172,504,130-172,523,989 5
BNIP1 Chromosome 5:172,504,130-172,523,989 5
BNIP1 Chromosome 5:172,504,130-172,523,989 5
HRH2 Chromosome 5:175,017,637-175,045,847 5
HRH2 Chromosome 5:175,017,637-175,045,847 5
FGFR4 CD334 Chromosome 5:176,446,493-176,457,733 5
DDX41 Chromosome 5:176,871,184-176,876,573 5
DDX41 Chromosome 5:176,871,184-176,876,573 5
CANX Chromosome 5:179,058,536-179,091,248 5
MAPK9 Chromosome 5:179,595,388-179,640,218 5
FLT4 CD310, VEGFR3 Chromosome 5:179,945,812-180,009,172 5
FLT4 CD310, VEGFR3 Chromosome 5:179,945,812-180,009,172 5
FLT4 CD310, VEGFR3 Chromosome 5:179,945,812-180,009,172 5
FOXO1B Chromosome 5:180,458,383-180,460,484 5
FOXO1B Chromosome 5:180,458,383-180,460,484 5
PDCD6 Chromosome 5:324,739-488,225 5
PDCD6 Chromosome 5:324,739-488,225 5
PDCD6 Chromosome 5:324,739-488,225 5
C1QTNF3 Chromosome 5:34,022,040-34,160,396 5
C1QTNF3 Chromosome 5:34,022,040-34,160,396 5
C1QTNF3 Chromosome 5:34,022,040-34,160,396 5
PRLR PRLR Chromosome 5:35,084,621-35,266,334 5
PRLR PRLR Chromosome 5:35,084,621-35,266,334 5
PRLR PRLR Chromosome 5:35,084,621-35,266,334 5
PRLR PRLR Chromosome 5:35,084,621-35,266,334 5
IL7R CD127 Chromosome 5:35,892,748-35,915,462 5
IL7R CD127 Chromosome 5:35,892,748-35,915,462 5
SKP2 Chromosome 5:36,187,946-36,219,904 5
SKP2 Chromosome 5:36,187,946-36,219,904 5
SKP2 Chromosome 5:36,187,946-36,219,904 5
LIFR CD118 Chromosome 5:38,510,822-38,631,253 5
LIFR CD118 Chromosome 5:38,510,822-38,631,253 5
LIFR CD118 Chromosome 5:38,510,822-38,631,253 5
FYB SLAP-130, ADAP Chromosome 5:39,141,114-39,255,432 5
FYB SLAP-130, ADAP Chromosome 5:39,141,114-39,255,432 5
FYB SLAP-130, ADAP Chromosome 5:39,141,114-39,255,432 5
C9 Chromosome 5:39,320,061-39,400,412 5
PTGER4 EP4 Chromosome 5:40,715,789-40,729,594 5
PTGER4 EP4 Chromosome 5:40,715,789-40,729,594 5
CARD6 Chromosome 5:40,877,043-40,896,025 5
C7 Chromosome 5:40,945,356-41,018,798 5
C6 Chromosome 5:41,178,093-41,297,297 5
C6 Chromosome 5:41,178,093-41,297,297 5
GHR growth hormone receptor Chromosome 5:42,459,783-42,757,736 5
GHR growth hormone receptor Chromosome 5:42,459,783-42,757,736 5
GHR growth hormone receptor Chromosome 5:42,459,783-42,757,736 5
GHR growth hormone receptor Chromosome 5:42,459,783-42,757,736 5
CCL28 Chromosome 5:43,229,915-43,448,250 5
CCL28 Chromosome 5:43,229,915-43,448,250 5
CCL28 Chromosome 5:43,229,915-43,448,250 5
FGF10 FGF10 Chromosome 5:44,340,854-44,424,541 5
FGF10 FGF10 Chromosome 5:44,340,854-44,424,541 5
ITGA1 VLA1-3, CD49a Chromosome 5:52,119,531-52,285,242 5
ITGA1 VLA1-3, CD49a Chromosome 5:52,119,531-52,285,242 5
ITGA1 VLA1-3, CD49a Chromosome 5:52,119,531-52,285,242 5
ITGA2 CD49b Chromosome 5:52,321,014-52,423,947 5
ITGA2 CD49b Chromosome 5:52,321,014-52,423,947 5
GZMK Chromosome 5:54,355,838-54,366,155 5
GZMA Granzyme A Chromosome 5:54,434,230-54,441,837 5
DHX29 Chromosome 5:54,587,830-54,639,278 5
DDX4 Chromosome 5:55,069,609-55,148,362 5
DDX4 Chromosome 5:55,069,609-55,148,362 5
DDX4 Chromosome 5:55,069,609-55,148,362 5
IL31RA Chromosome 5:55,183,091-55,248,922 5
IL6ST CD130, gp130 Chromosome 5:55,266,680-55,326,529 5
MAP3K1 MEKK1 Chromosome 5:56,146,022-56,227,736 5
MAP3K1 MEKK1 Chromosome 5:56,146,022-56,227,736 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
PDE4D Phosphodiesterases Chromosome 5:58,302,468-59,320,301 5
LY64 CD180 Chromosome 5:66,513,872-66,528,368 5
LY64 CD180 Chromosome 5:66,513,872-66,528,368 5
LY64 CD180 Chromosome 5:66,513,872-66,528,368 5
PIK3R1 Chromosome 5:67,547,360-67,633,405 5
PIK3R1 Chromosome 5:67,547,360-67,633,405 5
CCNB1 Chromosome 5:68,498,593-68,509,828 5
CCNB1 Chromosome 5:68,498,593-68,509,828 5
CCNB1 Chromosome 5:68,498,593-68,509,828 5
TAF9 TAFII32 Chromosome 5:68,682,567-68,701,596 5
TAF9 TAFII32 Chromosome 5:68,682,567-68,701,596 5
MTRR Chromosome 5:7,922,217-7,954,237 5
MTRR Chromosome 5:7,922,217-7,954,237 5
FOXD1 Chromosome 5:72,777,839-72,780,108 5
FOXD1 Chromosome 5:72,777,839-72,780,108 5
ENC1 Chromosome 5:73,958,990-73,973,005 5
ENC1 Chromosome 5:73,958,990-73,973,005 5
ENC1 Chromosome 5:73,958,990-73,973,005 5
HMGCR HMG-CoA reductase Chromosome 5:74,668,790-74,693,685 5
HMGCR HMG-CoA reductase Chromosome 5:74,668,790-74,693,685 5
COL4A3BP Chromosome 5:74,702,684-74,843,719 5
F2RL2 PAR3 Chromosome 5:75,947,063-75,954,996 5
F2RL2 PAR3 Chromosome 5:75,947,063-75,954,996 5
F2R PAR1 Chromosome 5:76,047,542-76,067,054 5
F2RL1 PAR2 Chromosome 5:76,150,610-76,166,896 5
LHFPL2 Chromosome 5:77,816,794-77,841,979 5
LHFPL2 Chromosome 5:77,816,794-77,841,979 5
DHFR ok Chromosome 5:79,957,801-79,986,556) 5
DHFR ok Chromosome 5:79,957,801-79,986,556) 5
CSPG2 versican Chromosome 5:82,803,339-82,912,737 5
CSPG2 versican Chromosome 5:82,803,339-82,912,737 5
CSPG2 versican Chromosome 5:82,803,339-82,912,737 5
RASA1 Chromosome 5:86,599,461-86,723,489 5
RASA1 Chromosome 5:86,599,461-86,723,489 5
RASA1 Chromosome 5:86,599,461-86,723,489 5
NR2F1 NR2F1 Chromosome 5:92,944,799-92,956,077 5
ARTS1 ERAP1 Chromosome 5:96,122,277-96,169,559 5
ARTS1 ERAP1 Chromosome 5:96,122,277-96,169,559 5
ARTS1 ERAP1 Chromosome 5:96,122,277-96,169,559 5
IBD3 Chromosome 6 6
IBD3 Chromosome 6 6
FOXQ1 Chromosome 6:1,257,675-1,259,983 6
FOXQ1 Chromosome 6:1,257,675-1,259,983 6
FOXF2 Chromosome 6:1,335,068-1,340,831 6
FOXC1 Chromosome 6:1,555,206-1,559,131 6
GMDS Chromosome 6:1,569,040-2,190,845 6
GMDS Chromosome 6:1,569,040-2,190,845 6
GMDS Chromosome 6:1,569,040-2,190,845 6
GMDS Chromosome 6:1,569,040-2,190,845 6
GCNT2 Chromosome 6:10,636,575-10,737,587 6
GCNT2 Chromosome 6:10,636,575-10,737,587 6
SIM1 Chromosome 6:100,939,606-101,019,494 6
SIM1 Chromosome 6:100,939,606-101,019,494 6
GRIK2 Chromosome 6:101,953,385-102,624,651 6
HACE1 Chromosome 6:105,282,661-105,414,867 6
HACE1 Chromosome 6:105,282,661-105,414,867 6
PRDM1 Blimp1 Chromosome 6:106,640,888-106,664,507 6
PRDM1 Blimp1 Chromosome 6:106,640,888-106,664,507 6
ATG5 Atg5 Chromosome 6:106,739,044-106,880,388 6
ATG5 Atg5 Chromosome 6:106,739,044-106,880,388 6
SOBP Chromosome 6:107,918,010-108,089,195 6
SOBP Chromosome 6:107,918,010-108,089,195 6
NR2D1 NR2D1 Chromosome 6:108,593,955-108,616,706 6
NR2D1 NR2D1 Chromosome 6:108,593,955-108,616,706 6
NR2D1 NR2D1 Chromosome 6:108,593,955-108,616,706 6
FOXO3A Chromosome 6:108,987,719-109,108,661 6
FOXO3A Chromosome 6:108,987,719-109,108,661 6
CD164 Chromosome 6:109,794,412-109,810,353 6
PPIL6 Chromosome 6:109,820,624-109,868,524 6
NEDD9 Cas-L, HEF1 Chromosome 6:11,291,517-11,490,535 6
NEDD9 Cas-L, HEF1 Chromosome 6:11,291,517-11,490,535 6
NEDD9 Cas-L, HEF1 Chromosome 6:11,291,517-11,490,535 6
NEDD9 Cas-L, HEF1 Chromosome 6:11,291,517-11,490,535 6
NEDD9 Cas-L, HEF1 Chromosome 6:11,291,517-11,490,535 6
WASF1 Wiskott Aldrich Chromosome 6:110,527,715-110,607,900 6
WASF1 Wiskott Aldrich Chromosome 6:110,527,715-110,607,900 6
BXDC1 Chromosome 6:111,409,984-111,453,487 6
FYN FynT Chromosome 6:112,088,228-112,301,348 6
FYN FynT Chromosome 6:112,088,228-112,301,348 6
FYN FynT Chromosome 6:112,088,228-112,301,348 6
FYN FynT Chromosome 6:112,088,228-112,301,348 6
LAMA4 Chromosome 6:112,536,654-112,682,605 6
LAMA4 Chromosome 6:112,536,654-112,682,605 6
LAMA4 Chromosome 6:112,536,654-112,682,605 6
HDAC2 Chromosome 6:114,368,571-114,399,029 6
HDAC2 Chromosome 6:114,368,571-114,399,029 6
FRK FynT Chromosome 6:116,369,386-116,488,614 6
FRK FynT Chromosome 6:116,369,386-116,488,614 6
RFXDC1 RFXDC1 Chromosome 6:117,305,068-117,360,008 6
C6orf204 Chromosome 6:118,892,932-119,137,924 6
C6orf204 Chromosome 6:118,892,932-119,137,924 6
C6orf204 Chromosome 6:118,892,932-119,137,924 6
C6orf204 Chromosome 6:118,892,932-119,137,924 6
MAN1A1 Chromosome 6:119,540,965-119,712,625 6
MAN1A1 Chromosome 6:119,540,965-119,712,625 6
EDN1 Chromosome 6:12,398,582-12,405,413 6
EDN1 Chromosome 6:12,398,582-12,405,413 6
PHACTR1 Chromosome 6:12,825,819-13,396,624 6
NKAIN2 Chromosome 6:124,166,768-125,188,502 6
NCOA7 Chromosome 6:126,144,000-126,293,950 6
C6orf174,KIAA0408 Chromosome 6:127,813,023-127,879,540 6
PTPRK Chromosome 6:128,331,625-128,883,453 6
PTPRK Chromosome 6:128,331,625-128,883,453 6
PTPRK Chromosome 6:128,331,625-128,883,453 6
PTPRK Chromosome 6:128,331,625-128,883,453 6
PTPRK Chromosome 6:128,331,625-128,883,453 6
PTPRK Chromosome 6:128,331,625-128,883,453 6
LAMA2 Chromosome 6:129,246,035-129,879,407 6
LAMA2 Chromosome 6:129,246,035-129,879,407 6
LAMA2 Chromosome 6:129,246,035-129,879,407 6
LAMA2 Chromosome 6:129,246,035-129,879,407 6
LAMA2 Chromosome 6:129,246,035-129,879,407 6
LAMA2 Chromosome 6:129,246,035-129,879,407 6
LAMA2 Chromosome 6:129,246,035-129,879,407 6
EPB41L2 Chromosome 6:131,202,180-131,426,017 6
EPB41L2 Chromosome 6:131,202,180-131,426,017 6
AKAP7 Chromosome 6:131,508,154-131,646,366 6
AKAP7 Chromosome 6:131,508,154-131,646,366 6
ARG1 Arginase 1 Chromosome 6:131,935,977-131,947,165 6
ARG1 Arginase 1 Chromosome 6:131,935,977-131,947,165 6
ARG1 Arginase 1 Chromosome 6:131,935,977-131,947,165 6
ENPP3 CD203c Chromosome 6:132,000,135-132,110,243 6
ENPP3 CD203c Chromosome 6:132,000,135-132,110,243 6
CTGF Chromosome 6:132,310,199-132,314,206 6
CTGF Chromosome 6:132,310,199-132,314,206 6
MOXD1 Chromosome 6:132,658,887-132,764,357 6
MOXD1 Chromosome 6:132,658,887-132,764,357 6
VNN1 Chromosome 6:133,044,422-133,076,881 6
VNN1 Chromosome 6:133,044,422-133,076,881 6
SGK Chromosome 6:134,532,081-134,680,889 6
SGK Chromosome 6:134,532,081-134,680,889 6
SGK Chromosome 6:134,532,081-134,680,889 6
MAP7 Chromosome 6:136,705,565-136,913,485 6
MAP3K5 Chromosome 6:136,919,878-137,155,349 6
MAP3K5 Chromosome 6:136,919,878-137,155,349 6
MAP3K5 Chromosome 6:136,919,878-137,155,349 6
MAP3K5 Chromosome 6:136,919,878-137,155,349 6
IL20RA Chromosome 6:137,362,801-137,407,991 6
IL20RA Chromosome 6:137,362,801-137,407,991 6
IL22RA2 Chromosome 6:137,506,650-137,536,478 6
TNFAIP3 Chromosome 6:138,230,274-138,246,142) 6
TNFAIP3 Chromosome 6:138,230,274-138,246,142) 6
C6orf91 Chromosome 6:139,158,950-139,266,900 6
C6orf91 Chromosome 6:139,158,950-139,266,900 6
HECA Chromosome 6:139,497,942-139,543,639 6
HECA Chromosome 6:139,497,942-139,543,639 6
CITED2 p300 Chromosome 6:139,735,089-139,737,478 6
CD83 Chromosome 6:14,225,715-14,245,128 6
CD83 Chromosome 6:14,225,715-14,245,128 6
HIVEP2 Schnurri 2 Chromosome 6:143,114,297-143,308,031 6
HIVEP2 Schnurri 2 Chromosome 6:143,114,297-143,308,031 6
HIVEP2 Schnurri 2 Chromosome 6:143,114,297-143,308,031 6
HIVEP2 Schnurri 2 Chromosome 6:143,114,297-143,308,031 6
ADAT2 Chromosome 6:143,788,765-143,813,517 6
ADAT2 Chromosome 6:143,788,765-143,813,517 6
PHACTR2 Chromosome 6:143,971,010-144,194,014 6
PHACTR2 Chromosome 6:143,971,010-144,194,014 6
PHACTR2 Chromosome 6:143,971,010-144,194,014 6
STX11 Syntaxin 11 Chromosome 6:144,513,356-144,551,200 6
STX11 Syntaxin 11 Chromosome 6:144,513,356-144,551,200 6
STX11 Syntaxin 11 Chromosome 6:144,513,356-144,551,200 6
UTRN Chromosome 6:144,654,566-145,215,863 6
STXBP5 Chromosome 6:147,566,565-147,748,588 6
STXBP5 Chromosome 6:147,566,565-147,748,588 6
STXBP5 Chromosome 6:147,566,565-147,748,588 6
FLJ43763 Chromosome 6:148,313-151,392 6
FLJ43763 Chromosome 6:148,313-151,392 6
MAP3K7IP2 TAB2 Chromosome 6:149,680,756-149,774,442 6
MAP3K7IP2 TAB2 Chromosome 6:149,680,756-149,774,442 6
MAP3K7IP2 TAB2 Chromosome 6:149,680,756-149,774,442 6
MAP3K7IP2 TAB2 Chromosome 6:149,680,756-149,774,442 6
MAP3K7IP2 TAB2 Chromosome 6:149,680,756-149,774,442 6
MAP3K7IP2 TAB2 Chromosome 6:149,680,756-149,774,442 6
PPIL4 Chromosome 6:149,867,324-149,908,864 6
PCMT1 Chromosome 6:150,112,273-150,174,249 6
RAET1E ULBP4 Chromosome 6:150,251,294-150,253,863 6
ULBP2 Chromosome 6:150,304,829-150,312,064 6
AKAP12 Chromosome 6:151,603,202-151,719,602 6
AKAP12 Chromosome 6:151,603,202-151,719,602 6
ESR1 Estrogen receptor alpha, NChromosome 6:152,170,379-152,466,099 6
ESR1 Estrogen receptor alpha, NChromosome 6:152,170,379-152,466,099 6
ESR1 Estrogen receptor alpha, NChromosome 6:152,170,379-152,466,099 6
ESR1 Estrogen receptor alpha, NChromosome 6:152,170,379-152,466,099 6
SYNE1 Chromosome 6:152,484,515-153,000,227 6
SYNE1 Chromosome 6:152,484,515-153,000,227 6
SYNE1 Chromosome 6:152,484,515-153,000,227 6
SYNE1 Chromosome 6:152,484,515-153,000,227 6
VIP Chromosome 6:153,113,626-153,122,593 6
OPMR1 MOR Chromosome 6:154,402,136-154,609,693 6
TFB1M Chromosome 6:155,620,488-155,686,932 6
TFB1M Chromosome 6:155,620,488-155,686,932 6
NOX3 Chromosome 6:155,758,194-155,818,729 6
NOX3 Chromosome 6:155,758,194-155,818,729 6
NOX3 Chromosome 6:155,758,194-155,818,729 6
ARID1B Chromosome 6:157,140,756-157,572,094 6
ARID1B Chromosome 6:157,140,756-157,572,094 6
SNX9 Chromosome 6:158,164,282-158,286,097 6
SNX9 Chromosome 6:158,164,282-158,286,097 6
GTF2H5 Chromosome 6:158,509,372-158,535,008 6
GTF2H5 Chromosome 6:158,509,372-158,535,008 6
GTF2H5 Chromosome 6:158,509,372-158,535,008 6
ATXN1 Chromosome 6:16,407,322-16,869,700 6
SOD2 IP01 Chromosome 6:160,020,138-160,034,343 6
WTAP Chromosome 6:160,066,607-160,097,341 6
IGF2R CD222 Chromosome 6:160,310,121-160,447,573 6
IGF2R CD222 Chromosome 6:160,310,121-160,447,573 6
IGF2R CD222 Chromosome 6:160,310,121-160,447,573 6
SLC22A1 Chromosome 6:160,462,853-160,499,740 6
SLC22A1 Chromosome 6:160,462,853-160,499,740 6
SLC22A1 Chromosome 6:160,462,853-160,499,740 6
AGPAT4 Chromosome 6:161,471,047-161,615,097 6
AGPAT4 Chromosome 6:161,471,047-161,615,097 6
AGPAT4 Chromosome 6:161,471,047-161,615,097 6
PARK2 Chromosome 6:161,688,442-163,068,793 6
PACRG Chromosome 6:163,068,154-163,656,514 6
PDE10A Chromosome 6:165,660,766-165,995,578 6
RPS6KA2 Chromosome 6:166,742,844-167,195,761 6
CCR6 CD196 Chromosome 6:167,332,660-167,473,174 6
CCR6 CD196 Chromosome 6:167,332,660-167,473,174 6
CCR6 CD196 Chromosome 6:167,332,660-167,473,174 6
C6orf123 Chromosome 6:167,928,066-167,940,388 6
C6orf123 Chromosome 6:167,928,066-167,940,388 6
FAM120B Chromosome 6:170,457,769-170,556,162 6
FAM120B Chromosome 6:170,457,769-170,556,162 6
FAM120B Chromosome 6:170,457,769-170,556,162 6
PSMB1 Chromosome 6:170,686,134-170,704,312 6
PSMB1 Chromosome 6:170,686,134-170,704,312 6
TPMT Chromosome 6:18,236,521-18,263,353 6
WRNIP1 Chromosome 6:2,710,665-2,731,926 6
SERPINB9 PI-9 Chromosome 6:2,832,499-2,848,513 6
CDKAL1 Chromosome 6:20,642,667-21,340,614 6
PRL Prolactin Chromosome 6:22,395,459-22,405,709 6
PRL Prolactin Chromosome 6:22,395,459-22,405,709 6
HDGFL1 Chromosome 6:22,677,657-22,679,871 6
HDGFL1 Chromosome 6:22,677,657-22,679,871 6
DUSP22 Chromosome 6:237,053-296,355 6
DUSP22 Chromosome 6:237,053-296,355 6
TTRAP Chromosome 6:24,758,184-24,775,240 6
TTRAP Chromosome 6:24,758,184-24,775,240 6
LRRC16A Chromosome 6:25,387,285-25,728,737 6
HFE Chromosome 6:26,195,427-26,205,038 6
BTN3A1 CD277 Chromosome 6:26,510,460-26,523,445 6
BTN3A1 CD277 Chromosome 6:26,510,460-26,523,445 6
PRSS16 thymus serine protease Chromosome 6:27,323,487-27,332,327 6
PRSS16 thymus serine protease Chromosome 6:27,323,487-27,332,327 6
ZNF192 Chromosome 6:28,217,695-28,233,215 6
ZNF192 Chromosome 6:28,217,695-28,233,215 6
ZNF193 Chromosome 6:28,301,046-28,309,239 6
FAT10 Chromosome 6:29,631,368-29,778,041 6
UBD Ubiquitin Chromosome 6:29,631,368-29,778,041 6
MOG Chromosome 6:29,732,755-29,748,128 6
HLA-F Chromosome 6:29,798,531-29,803,052 6
HLA-F Chromosome 6:29,799,096-29,803,052 6
HLA-F Chromosome 6:29,799,096-29,803,052 6
HLA-F Chromosome 6:29,799,096-29,803,052 6
HLA-F Chromosome 6:29,799,096-29,803,052 6
RPL23AP1 Chromosome 6:29,802,425-29,802,895 6
HLA-A Chromosome 6:29,902,723-30,021,633 6
RIPK1 Chromosome 6:3,009,212-3,060,420 6
HLA-A M6S204 Chromosome 6:30,018,310-30,021,633 6
HLA-A M6S213 Chromosome 6:30,018,310-30,021,633 6
HLA-A Chromosome 6:30,018,310-30,021,633 6
HLA-A Chromosome 6:30,018,310-30,021,633 6
HLA-A Chromosome 6:30,018,310-30,021,633 6
HLA-A Chromosome 6:30,018,310-30,021,633 6
HLA-A Chromosome 6:30,018,310-30,021,633 6
HCG4P4 Chromosome 6:30,030,962-30,031,390 6
ETF1P1 Chromosome 6:30,107,469-30,109,633 6
TRIM40 Chromosome 6:30,212,487-30,224,491 6
TRIM10 Chromosome 6:30,227,701-30,236,690 6
RPP21 Chromosome 6:30,420,877-30,422,649 6
RANP1 Chromosome 6:30,561,651-30,562,700 6
HLA-E Chromosome 6:30,565,250-30,569,077 6
HLA-E Chromosome 6:30,565,250-30,569,077 6
GNL1 Chromosome 6:30,621,633-30,632,987 6
MDC1 Chromosome 6:30,775,563-30,793,645 6
hcg-2038200 Chromosome 6:30,888,622-30,906,415 6
GTF2H4 Chromosome 6:30,983,956-30,989,859 6
C6orf205 Chromosome 6:31,059,474-31,065,654 6
HLABC-CA Chromosome 6:31,344,505-31,432,935 6
HLA-C MICB-CA Chromosome 6:31,344,505-31,432,935 6
HLA-C Chromosome 6:31,344,505-31,432,935 6
HLA-C Chromosome 6:31,344,505-31,432,935 6
HLA-C Chromosome 6:31,344,505-31,432,935 6
HLA-B Chromosome 6:31,429,628-31,432,914 6
HLA-B Chromosome 6:31,429,628-31,432,914 6
HLA-B Chromosome 6:31,429,628-31,432,914 6
MICA Chromosome 6:31,475,540-31,491,069 6
HCP5 Chromosome 6:31,538,938-31,541,565 6
MCCD1 LOC401250 Chromosome 6:31,604,718-31,605,987 6
LTA TNFb Chromosome 6:31,648,042-31,650,080 6
LTA TNFb Chromosome 6:31,648,042-31,650,080 6
LTA TNFb Chromosome 6:31,648,042-31,650,080 6
LTA TNFb Chromosome 6:31,648,042-31,650,080 6
LTA TNFb Chromosome 6:31,648,042-31,650,080 6
LTA Chromosome 6:31,648,072-31,650,077 6
TNF Chromosome 6:31,651,329-31,654,091 6
AIF1 Chromosome 6:31,690,984-31,692,781 6
BAT2, BAT2 GT, BAT2CA Chromosome 6:31,696,429-31,713,533 6
LY6G5C Chromosome 6:31,752,440-31,759,796 6
HCG22 Chromosome 6:31129963-31135632 6
C2 Chromosome 6:32,003,473-32,021,428 6
C2 Chromosome 6:32,003,473-32,021,428 6
TNXB Chromosome 6:32,084,175-32,185,131 6
FKBPL Chromosome 6:32,204,462-32,206,045 6
NOTCH4 Chromosome 6:32,266,521-32,299,822 6
GPSM3 Chromosome 6:32,266,521-32,299,822 6
NOTCH4 Chromosome 6:32,270,598-32,299,822 6
C6orf10  TNFa/b Chromosome 6:32,368,453-32,460,310 6
C6orf10 Chromosome 6:32,368,464-32,447,662 6
HLA-DRA Chromosome 6:32,515,597-32,520,943 6
HLA-DRA DRA_CA, HLA-DRB1 Chromosome 6:32,515,625-32,520,801 6
HLA-DRB1 Chromosome 6:32,654,524-32,665,603 6
HLA-DQA1 Chromosome 6:32,713,112-32,719,407 6
HLA-DPB1 Chromosome 6:32,735,222-32,754,296 6
HLA-DQB1 G5-11525, G51152, G511Chromosome 6:32,735,222-32,754,296 6
HLA-DQB1 Chromosome 6:32,735,225-32,742,572 6
HLA-DQB2 Chromosome 6:32,831,445-32,839,446 6
HLA-DOB Chromosome 6:32,888,518-32,892,803 6
TAP2 Chromosome 6:32,897,588-32,914,525 6
BRD2 Chromosome 6:33,044,415-33,057,075 6
HLA-DPB2 Chromosome 6:33,188,206-33,204,868 6
COL11A2 Chromosome 6:33,238,447-33,268,223 6
COL11A2  M2_4_25 Chromosome 6:33,238,447-33,268,223 6
COL11A2 Chromosome 6:33,238,447-33,268,223 6
SLC39A7 Chromosome 6:33,276,631-33,280,192 6
VPS52 Chromosome 6:33,326,027-33,347,640 6
TAPBP Tapasin Chromosome 6:33,375,449-33,390,142 6
BAK1 Chromosome 6:33,648,307-33,655,997 6
ITPR3 Chromosome 6:33,696,500-33,772,329 6
PACSIN1 Chromosome 6:34,541,883-34,610,984 6
PACSIN1 Chromosome 6:34,541,883-34,610,984 6
PPARD PPARbeta, NR1C2 Chromosome 6:35,418,313-35,503,933 6
FKBP5 Calcineurin, Lymphoid effeChromosome 6:35,649,345-35,804,338 6
FKBP5 Calcineurin, Lymphoid effeChromosome 6:35,649,345-35,804,338 6
SRPK1 SFRS Chromosome 6:35,908,789-35,996,942 6
SRPK1 SFRS Chromosome 6:35,908,789-35,996,942 6
MAPK14 p38MAPK Chromosome 6:36,103,551-36,186,513 6
MAPK13 Chromosome 6:36,129,769-36,215,820 6
MAPK13 Chromosome 6:36,129,769-36,215,820 6
STK38 Chromosome 6:36,569,647-36,623,234 6
STK38 Chromosome 6:36,569,647-36,623,234 6
CDKN1A Chromosome 6:36,754,413-36,763,094 6
CDKN1A Chromosome 6:36,754,413-36,763,094 6
PPIL1 Chromosome 6:36,930,581-36,950,778 6
PPIL1 Chromosome 6:36,930,581-36,950,778 6
PIM1 Pim-1 Chromosome 6:37,245,957-37,251,182 6
ZFAND3 Chromosome 6:37,895,285-38,230,375 6
ZFAND3 Chromosome 6:37,895,285-38,230,375 6
ZFAND3 Chromosome 6:37,895,285-38,230,375 6
BTBD9 Chromosome 6:38,250,711-38,673,848 6
BTBD9 Chromosome 6:38,250,711-38,673,848 6
DNAH8 Chromosome 6:38,792,313-39,106,545 6
DNAH8 Chromosome 6:38,792,313-39,106,545 6
DNAH8 Chromosome 6:38,792,313-39,106,545 6
DNAH8 Chromosome 6:38,792,313-39,106,545 6
DAAM2 Chromosome 6:39,868,120-39,980,622 6
DAAM2 Chromosome 6:39,868,120-39,980,622 6
UNC5CL Chromosome 6:41,102,749-41,114,906 6
UNC5CL Chromosome 6:41,102,749-41,114,906 6
TREML1 TLT1 Chromosome 6:41,224,979-41,230,048 6
TREML3 Chromosome 6:41,284,270-41,298,360 6
NCR2 CD336, NKp44 Chromosome 6:41,411,505-41,426,603 6
FOXP4 Chromosome 6:41,622,142-41,678,100 6
FOXP4 Chromosome 6:41,622,142-41,678,100 6
FOXP4 Chromosome 6:41,622,142-41,678,100 6
CCND3 Chromosome 6:42,010,649-42,124,404 6
CCND3 Chromosome 6:42,010,649-42,124,404 6
TRERF1 Chromosome 6:42,300,647-42,527,767 6
TRERF1 Chromosome 6:42,300,647-42,527,767 6
TRERF1 Chromosome 6:42,300,647-42,527,767 6
TRERF1 Chromosome 6:42,300,647-42,527,767 6
PEX6 Chromosome 6:43,039,586-43,054,936 6
PEX6 Chromosome 6:43,039,586-43,054,936 6
PTK7 Chromosome 6:43,152,007-43,237,435 6
VEGFA Chromosome 6:43,845,924-43,862,202 6
VEGFA Chromosome 6:43,845,924-43,862,202 6
HSP90AB1 HSP90 Chromosome 6:44,322,802-44,329,598 6
HSP90AB1 HSP90 Chromosome 6:44,322,802-44,329,598 6
NFKBIE Chromosome 6:44,333,881-44,341,503 6
RUNX2 Chromosome 6:45,404,032-45,626,797 6
CYP39A1 Chromosome 6:46,625,404-46,728,482 6
CYP39A1 Chromosome 6:46,625,404-46,728,482 6
CYP39A1 Chromosome 6:46,625,404-46,728,482 6
PLA2G7 phospholipase A2 Chromosome 6:46,779,897-46,811,389 6
TNFRSF21 Chromosome 6:47,307,227-47,385,639 6
TNFRSF21 Chromosome 6:47,307,227-47,385,639 6
TNFRSF21 Chromosome 6:47,307,227-47,385,639 6
CD2AP Chromosome 6:47,553,899-47,702,620 6
CD2AP Chromosome 6:47,553,899-47,702,620 6
C6orf138 Chromosome 6:47,953,998-48,144,384 6
C6orf138 Chromosome 6:47,953,998-48,144,384 6
C6orf138 Chromosome 6:47,953,998-48,144,384 6
RHAG CD241 Chromosome 6:49,680,830-49,712,511 6
RHAG CD241 Chromosome 6:49,680,830-49,712,511 6
DFB114 Chromosome 6:50,035,964-50,039,777 6
DFB110 Chromosome 6:50,084,810-50,097,607 6
PKHD1 Chromosome 6:51,588,104-52,060,382 6
PKHD1 Chromosome 6:51,588,104-52,060,382 6
PKHD1 Chromosome 6:51,588,104-52,060,382 6
PKHD1 Chromosome 6:51,588,104-52,060,382 6
IL17A Chromosome 6:52,159,144-52,163,395 6
IL17F Chromosome 6:52,209,438-52,217,257 6
IL17F Chromosome 6:52,209,438-52,217,257 6
EFHC1 Chromosome 6:52,392,953-52,468,540 6
TRAM2 Chromosome 6:52,470,159-52,549,821 6
GSTA1 Gluthation-S-transferase Chromosome 6:52,764,183-52,776,616 6
GCLC Chromosome 6:53,470,098-53,517,790 6
GCLC Chromosome 6:53,470,098-53,517,790 6
GFRAL Chromosome 6:55,300,226-55,375,250 6
GFRAL Chromosome 6:55,300,226-55,375,250 6
BMP5 BMP5 Chromosome 6:55,726,402-55,848,334 6
BMP5 BMP5 Chromosome 6:55,726,402-55,848,334 6
BMP5 BMP5 Chromosome 6:55,726,402-55,848,334 6
BMP5 BMP5 Chromosome 6:55,726,402-55,848,334 6
COL21A1 Chromosome 6:56,029,347-56,366,851 6
COL21A1 Chromosome 6:56,029,347-56,366,851 6
COL21A1 Chromosome 6:56,029,347-56,366,851 6
C6orf65 Chromosome 6:56,927,732-57,000,099 6
ZNF451 Chromosome 6:57,019,470-57,143,057 6
BAG2 Chromosome 6:57,145,083-57,157,694 6
LY86 MD1 Chromosome 6:6,533,340-6,600,215 6
LY86 MD1 Chromosome 6:6,533,340-6,600,215 6
LY86 MD1 Chromosome 6:6,533,340-6,600,215 6
KHDRBS2 Chromosome 6:62,447,824-63,054,091 6
FKBP1AC Chromosome 6:63,964,538-63,980,909 6
FKBP1AC Chromosome 6:63,964,538-63,980,909 6
PTP4A1 Chromosome 6:64,339,879-64,351,448 6
EYS Chromosome 6:66,095,895-66,473,839 6
BAI3 Chromosome 6:69,401,980-70,156,124 6
DSP Chromosome 6:7,486,869-7,531,945 6
DSP Chromosome 6:7,486,869-7,531,945 6
DSP Chromosome 6:7,486,869-7,531,945 6
BMP6 BMP6 Chromosome 6:7,672,009-7,826,752 6
BMP6 BMP6 Chromosome 6:7,672,009-7,826,752 6
KCNQ5 Chromosome 6:73,388,241-73,965,295 6
DDX43 Chromosome 6:74,161,192-74,184,013 6
DDX43 Chromosome 6:74,161,192-74,184,013 6
EEF1A1 EF-1 alpha Chromosome 6:74,282,194-74,288,344 6
EEF1A1 EF-1 alpha Chromosome 6:74,282,194-74,288,344 6
CD109 Chromosome 6:74,462,548-74,591,509 6
CD109 Chromosome 6:74,462,548-74,591,509 6
CD109 Chromosome 6:74,462,548-74,591,509 6
HTR1B 5-HTR1B Chromosome 6:78,228,641-78,229,900 6
HTR1B 5-HTR1B Chromosome 6:78,228,641-78,229,900 6
IRAK1BP1 Chromosome 6:79,633,908-79,665,039 6
IRAK1BP1 Chromosome 6:79,633,908-79,665,039 6
HMGN3 Chromosome 6:79,967,681-80,001,174 6
HMGN3 Chromosome 6:79,967,681-80,001,174 6
BCKDHB Chromosome 6:80,873,083-81,112,706 6
BCKDHB Chromosome 6:80,873,083-81,112,706 6
BCKDHB Chromosome 6:80,873,083-81,112,706 6
NT5E CD73 Chromosome 6:86,216,528-86,262,215 6
NT5E CD73 Chromosome 6:86,216,528-86,262,215 6
LOC643962 Chromosome 6:87,597,028-87,709,921 6
LOC643962 Chromosome 6:87,597,028-87,709,921 6
CGA CGA Chromosome 6:87,851,935-87,861,569 6
OFCC1 Chromosome 6:9,813,644-10,168,908 6
ANKRD6 Chromosome 6:90,199,616-90,400,123 6
ANKRD6 Chromosome 6:90,199,616-90,400,123 6
ANKRD6 Chromosome 6:90,199,616-90,400,123 6
CASP8AP2 FLASH Chromosome 6:90,596,349-90,640,876 6
MAP3K7 TAK1 Chromosome 6:91,280,013-91,353,628 6
MAP3K7 TAK1 Chromosome 6:91,280,013-91,353,628 6
EPHA7 Chromosome 6:94,007,860-94,185,993 6
EPHA7 Chromosome 6:94,007,860-94,185,993 6
KLHL32 Chromosome 6:97,479,217-97,695,351 6
KLHL32 Chromosome 6:97,479,217-97,695,351 6
KLHL32 Chromosome 6:97,479,217-97,695,351 6
EPO Chromosome 7:100,156,359-100,159,259 7
ACHE Chromosome 7:100,325,551-100,331,651 7
ACHE Chromosome 7:100,325,551-100,331,651 7
ACHE Chromosome 7:100,325,551-100,331,651 7
SERPINE1 Plasminogen activator inh    Chromosome 7:100,557,172-100,569,026 7
SERPINE1 Plasminogen activator inh    Chromosome 7:100,557,172-100,569,026 7
APS SH2 adaptor protein Chromosome 7:101,715,172-101,748,898 7
ALKBH4 Chromosome 7:101,883,690-101,892,293 7
ALKBH4 Chromosome 7:101,883,690-101,892,293 7
RELN Chromosome 7:102,899,473-103,417,199 7
RELN Chromosome 7:102,899,473-103,417,199 7
RELN Chromosome 7:102,899,473-103,417,199 7
RELN Chromosome 7:102,899,473-103,417,199 7
RELN Chromosome 7:102,899,473-103,417,199 7
RELN Chromosome 7:102,899,473-103,417,199 7
SRPK2 SFRS Chromosome 7:104,544,059-104,816,577 7
SRPK2 SFRS Chromosome 7:104,544,059-104,816,577 7
SRPK2 SFRS Chromosome 7:104,544,059-104,816,577 7
SRPK2 SFRS Chromosome 7:104,544,059-104,816,577 7
SRPK2 SFRS Chromosome 7:104,544,059-104,816,577 7
PBEF1 visfatin Chromosome 7:105,677,892-105,712,603 7
PBEF1 visfatin Chromosome 7:105,677,892-105,712,603 7
PBEF1 visfatin Chromosome 7:105,677,892-105,712,603 7
PIK3CG Chromosome 7:106,292,977-106,334,828 7
PIK3CG Chromosome 7:106,292,977-106,334,828 7
LAMB1 Chromosome 7:107,351,499-107,431,040 7
LAMB1 Chromosome 7:107,351,499-107,431,040 7
LAMB4 Chromosome 7:107,451,232-107,558,036 7
IFRD1 Chromosome 7:111,850,462-111,903,483 7
IFRD1 Chromosome 7:111,850,462-111,903,483 7
FOXP2 Chromosome 7:113,842,288-114,117,391 7
FOXP2 Chromosome 7:113,842,288-114,117,391 7
FOXP2 Chromosome 7:113,842,288-114,117,391 7
FOXP2 Chromosome 7:113,842,288-114,117,391 7
CAV1 Caveolin-1 Chromosome 7:115,952,075-115,988,466 7
CAV1 Caveolin-1 Chromosome 7:115,952,075-115,988,466 7
CAV1 Caveolin-1 Chromosome 7:115,952,075-115,988,466 7
MET Chromosome 7:116,099,695-116,225,676 7
MET Chromosome 7:116,099,695-116,225,676 7
MET Chromosome 7:116,099,695-116,225,676 7
PTPRZ1 Chromosome 7:121,300,395-121,489,326 7
PTPRZ1 Chromosome 7:121,300,395-121,489,326 7
PTPRZ1 Chromosome 7:121,300,395-121,489,326 7
PTPRZ1 Chromosome 7:121,300,395-121,489,326 7
POT1 Chromosome 7:124,250,549-124,357,110 7
POT1 Chromosome 7:124,250,549-124,357,110 7
POT1 Chromosome 7:124,250,549-124,357,110 7
LEP Chromosome 7:127,668,567-127,684,917 7
LEP Chromosome 7:127,668,567-127,684,917 7
IRF5 Chromosome 7:128,365,230-128,377,325 7
IRF5 Chromosome 7:128,365,230-128,377,325 7
SMO Chromosome 7:128,615,949-128,640,622 7
SMO Chromosome 7:128,615,949-128,640,622 7
NRF1 NRF1 Chromosome 7:129,038,791-129,184,158 7
NRF1 NRF1 Chromosome 7:129,038,791-129,184,158 7
NRF1 NRF1 Chromosome 7:129,038,791-129,184,158 7
ETV1 Chromosome 7:13,897,379-13,995,289 7
ETV1 Chromosome 7:13,897,379-13,995,289 7
ETV1 Chromosome 7:13,897,379-13,995,289 7
ETV1 Chromosome 7:13,897,379-13,995,289 7
MKLN1 Mkln1 Chromosome 7:130,663,175-130,831,931 7
MKLN1 Mkln1 Chromosome 7:130,663,175-130,831,931 7
MKLN1 Mkln1 Chromosome 7:130,663,175-130,831,931 7
MKLN1 Mkln1 Chromosome 7:130,663,175-130,831,931 7
KLRG2 Chromosome 7:138,786,805-138,818,998 7
TBXAS1 Chromosome 7:139,124,668-139,366,560 7
TBXAS1 Chromosome 7:139,124,668-139,366,560 7
TBXAS1 Chromosome 7:139,124,668-139,366,560 7
TBXAS1 Chromosome 7:139,124,668-139,366,560 7
TBXAS1 Chromosome 7:139,124,668-139,366,560 7
TBXAS1 Chromosome 7:139,124,668-139,366,560 7
RAB19 Rab19 Chromosome 7:139,753,916-139,772,419 7
CLEC5A MDL1 Chromosome 7:141,273,626-141,293,252 7
CLEC5A MDL1 Chromosome 7:141,273,626-141,293,252 7
TRB@ TCR Chromosome 7:141,645,314-142,221,097 7
TRB@ TCR Chromosome 7:141,645,314-142,221,097 7
TRB@ TCR Chromosome 7:141,645,314-142,221,097 7
TRB@ TCR Chromosome 7:141,645,314-142,221,097 7
TRB@ TCR Chromosome 7:141,645,314-142,221,097 7
TRB@ TCR Chromosome 7:141,645,314-142,221,097 7
TRB@ TCR Chromosome 7:141,645,314-142,221,097 7
KEL CD238 Chromosome 7:142,348,323-142,369,625 7
KEL CD238 Chromosome 7:142,348,323-142,369,625 7
CASP2 Chromosome 7:142,695,524-142,714,907 7
EPHA1 Ephrin R Chromosome 7:142,798,327-142,816,107 7
EZH2 Chromosome 7:148,135,408-148,212,347 7
EZH2 Chromosome 7:148,135,408-148,212,347 7
EZH2 Chromosome 7:148,135,408-148,212,347 7
RARRES2 chemerin Chromosome 7:149,666,351-149,669,696 7
RARRES2 chemerin Chromosome 7:149,666,351-149,669,696 7
NOS3 NO synthase Chromosome 7:150,319,080-150,342,609 7
NOS3 NO synthase Chromosome 7:150,319,080-150,342,609 7
CDK5 Chromosome 7:150,381,832-150,385,929 7
SHH sonic Hh Chromosome 7:155,288,319-155,297,728 7
SHH sonic Hh Chromosome 7:155,288,319-155,297,728 7
PTPRN2 PTPRP Chromosome 7:157,024,516-158,073,179 7
PTPRN2 PTPRP Chromosome 7:157,024,516-158,073,179 7
PTPRN2 PTPRP Chromosome 7:157,024,516-158,073,179 7
PTPRN2 PTPRP Chromosome 7:157,024,516-158,073,179 7
PTPRN2 PTPRP Chromosome 7:157,024,516-158,073,179 7
PTPRN2 PTPRP Chromosome 7:157,024,516-158,073,179 7
PTPRN2 PTPRP Chromosome 7:157,024,516-158,073,179 7
HDAC9 Chromosome 7:18,501,894-19,003,518 7
HDAC9 Chromosome 7:18,501,894-19,003,518 7
HDAC9 Chromosome 7:18,501,894-19,003,518 7
HDAC9 Chromosome 7:18,501,894-19,003,518 7
HDAC9 Chromosome 7:18,501,894-19,003,518 7
HDAC9 Chromosome 7:18,501,894-19,003,518 7
HDAC9 Chromosome 7:18,501,894-19,003,518 7
HDAC9 Chromosome 7:18,501,894-19,003,518 7
HDAC9 Chromosome 7:18,501,894-19,003,518 7
HDAC9 Chromosome 7:18,501,894-19,003,518 7
TWIST1 Twist1 Chromosome 7:19,121,616-19,123,820 7
TWIST1 Twist1 Chromosome 7:19,121,616-19,123,820 7
CARD11 CARMA1 Chromosome 7:2,912,308-3,050,025 7
CARD11 CARMA1 Chromosome 7:2,912,308-3,050,025 7
ITGB8 Chromosome 7:20,337,250-20,421,907 7
ITGB8 Chromosome 7:20,337,250-20,421,907 7
ITGB8 Chromosome 7:20,337,250-20,421,907 7
IL6 Chromosome 7:22,732,028-22,738,141 7
IL6 Chromosome 7:22,732,028-22,738,141 7
GPNMB Chromosome 7:23,252,841-23,281,254 7
NPY Chromosome 7:24,290,332-24,298,002 7
NPY Chromosome 7:24,290,332-24,298,002 7
CYCS Chromosome 7:25,124,800-25,131,480 7
HOXA5 HOX cluster Chromosome 7:27,147,521-27,149,812 7
HOXA5 HOX cluster Chromosome 7:27,147,521-27,149,812 7
NOD1 CARD4 Chromosome 7:30,430,672-30,484,833 7
CRHR2 Chromosome 7:30,658,725-30,706,244 7
CRF2R CRF2R Chromosome 7:30,658,725-30,706,244 7
AQP1 Aquaporin 1 Chromosome 7:30,917,993-30,931,656 7
AQP1 Aquaporin 1 Chromosome 7:30,917,993-30,931,656 7
FKBP9 Chromosome 7:32,963,577-33,013,067 7
FKBP9 Chromosome 7:32,963,577-33,013,067 7
TRG@ TCR Chromosome 7:38,246,150-38,374,181 7
TRG@ TCR Chromosome 7:38,246,150-38,374,181 7
TRG@ TCR Chromosome 7:38,246,150-38,374,181 7
TRG@ TCR Chromosome 7:38,246,150-38,374,181 7
FOXK1 Chromosome 7:4,688,456-4,777,600 7
FOXK1 Chromosome 7:4,688,456-4,777,600 7
INHBA Inhibin B, Activin A Chromosome 7:41,695,126-41,709,231 7
INHBA Inhibin B, Activin A Chromosome 7:41,695,126-41,709,231 7
GLI3 Gli3 Chromosome 7:41,970,196-42,241,712 7
GLI3 Gli3 Chromosome 7:41,970,196-42,241,712 7
GLI3 Gli3 Chromosome 7:41,970,196-42,241,712 7
GLI3 Gli3 Chromosome 7:41,970,196-42,241,712 7
STK17A Chromosome 7:43,589,251-43,632,247 7
STK17A Chromosome 7:43,589,251-43,632,247 7
STK17A Chromosome 7:43,589,251-43,632,247 7
GCK Chromosome 7:44,150,395-44,195,563 7
GCK Chromosome 7:44,150,395-44,195,563 7
DDX56 Chromosome 7:44,571,928-44,581,175 7
DDX56 Chromosome 7:44,571,928-44,581,175 7
PPIA Chromosome 7:44,802,777-44,809,240 7
PPIA Chromosome 7:44,802,777-44,809,240 7
MYO1G HA-2 Chromosome 7:44,968,786-44,985,203 7
ACTB F-actin Chromosome 7:5,533,312-5,536,747 7
IKZF1 Ikaros Chromosome 7:50,314,924-50,438,053 7
GRB10 Grb10/Grb1R Chromosome 7:50,625,259-50,828,652 7
GRB10 Grb10/Grb1R Chromosome 7:50,625,259-50,828,652 7
GRB10 Grb10/Grb1R Chromosome 7:50,625,259-50,828,652 7
EGFR Chromosome 7:55,054,219-55,242,525 7
FKBP9L Chromosome 7:55,716,261-55,748,439 7
RAC1 Rac1 Chromosome 7:6,380,651-6,410,123 7
RAC1 Rac1 Chromosome 7:6,380,651-6,410,123 7
GUSB glucuronidase beta - MPSChromosome 7:65,063,110-65,084,635 7
GUSB glucuronidase beta - MPSChromosome 7:65,063,110-65,084,635 7
RPA3 Chromosome 7:7,643,100-7,724,763 7
RPA3 Chromosome 7:7,643,100-7,724,763 7
FZD9 CD349 Chromosome 7:72,486,045-72,488,386 7
CLDN3 Chromosome 7:72,821,263-72,822,536 7
LAT2 NTA, LAB, TFII-1, WBSCRChromosome 7:73,262,023-73,282,100 7
LAT2 NTA, LAB, TFII-1, WBSCRChromosome 7:73,262,023-73,282,100 7
CLIP2 CYLN2 Chromosome 7:73,341,741-73,458,201 7
CLIP2 CYLN2 Chromosome 7:73,341,741-73,458,201 7
GTF2IRD1 TFII-1 Chromosome 7:73,506,056-73,654,853 7
GTF2IRD1 TFII-1 Chromosome 7:73,506,056-73,654,853 7
GTF2I Chromosome 7:73,709,966-73,812,958 7
NCF1 neutrophil cytosolic factor Chromosome 7:73,826,245-73,841,595 7
GTF2IRD2 Chromosome 7:73,848,420-73,905,777 7
PMS2L3 PMS2L9 Chromosome 7:74,975,005-74,995,389 7
PMS2L3 PMS2L9 Chromosome 7:74,975,005-74,995,389 7
CCL26 Chromosome 7:75,236,778-75,257,150 7
CCL26 Chromosome 7:75,236,778-75,257,150 7
HSPB1 HSP27/28 Chromosome 7:75,769,859-75,771,548 7
FGL2 Chromosome 7:76,662,535-76,667,080 7
FGL2 Chromosome 7:76,662,535-76,667,080 7
PTPN12 Chromosome 7:77,004,351-77,107,324 7
PTPN12 Chromosome 7:77,004,351-77,107,324 7
GNAI1 Gi Chromosome 7:79,602,076-79,686,661 7
GNAI1 Gi Chromosome 7:79,602,076-79,686,661 7
CD36 SCARB3 Chromosome 7:80,069,459-80,144,262 7
CD36 SCARB3 Chromosome 7:80,069,459-80,144,262 7
HGF hepatocyte growth factor Chromosome 7:81,166,258-81,237,388 7
HGF hepatocyte growth factor Chromosome 7:81,166,258-81,237,388 7
SEMA3E Chromosome 7:82,831,158-83,116,260 7
SEMA3E Chromosome 7:82,831,158-83,116,260 7
SEMA3E Chromosome 7:82,831,158-83,116,260 7
SEMA3E Chromosome 7:82,831,158-83,116,260 7
SEMA3E Chromosome 7:82,831,158-83,116,260 7
SEMA3E Chromosome 7:82,831,158-83,116,260 7
SEMA3E Chromosome 7:82,831,158-83,116,260 7
SEMA3E Chromosome 7:82,831,158-83,116,260 7
ABCB1 CD243, MDR1 Chromosome 7:86,970,884-87,180,500 7
ABCB1 CD243, MDR1 Chromosome 7:86,970,884-87,180,500 7
ABCB1 CD243, MDR1 Chromosome 7:86,970,884-87,180,500 7
ABCB1 CD243, MDR1 Chromosome 7:86,970,884-87,180,500 7
CYP51A1 Chromosome 7:91,579,402-91,601,946 7
CYP51A1 Chromosome 7:91,579,402-91,601,946 7
CYP51A1 Chromosome 7:91,579,402-91,601,946 7
CDK6 Chromosome 7:92,072,171-92,301,148 7
CDK6 Chromosome 7:92,072,171-92,301,148 7
CDK6 Chromosome 7:92,072,171-92,301,148 7
COL1A2 collagen alpha 2 Chromosome 7:93,861,809-93,898,480 7
COL1A2 collagen alpha 2 Chromosome 7:93,861,809-93,898,480 7
COL1A2 collagen alpha 2 Chromosome 7:93,861,809-93,898,480 7
DSS1 Chromosome 7:96,156,015-96,177,139 7
DSS1 Chromosome 7:96,156,015-96,177,139 7
Tac1 Substance P Chromosome 7:97,199,311-97,207,720 7
Tac1 Substance P Chromosome 7:97,199,311-97,207,720 7
BAIAP2L1 Chromosome 7:97,760,007-97,868,316 7
BAIAP2L1 Chromosome 7:97,760,007-97,868,316 7
CYP2W1 Chromosome 7:989,361-995,802 7
CYP2W1 Chromosome 7:989,361-995,802 7
CYP3A3 CYP3A4 Chromosome 7:99,083,437-99,219,744 7
CYP3A3 CYP3A4 Chromosome 7:99,083,437-99,219,744 7
CYP3A43 Chromosome 7:99,263,572-99,302,109 7
ZNF3 Chromosome 7:99,499,406-99,517,299 7
PILB PILRbeta Chromosome 7:99,771,673-99,803,388 7
PILB PILRbeta Chromosome 7:99,771,673-99,803,388 7
DEFA1A3 Chromosome 8 8
DEFA1A3 Chromosome 8 8
PINX1 Chromosome 8:10,659,883-10,734,796 8
PINX1 Chromosome 8:10,659,883-10,734,796 8
PINX1 Chromosome 8:10,659,883-10,734,796 8
YWHA2 Chromosome 8:102,000,090-102,034,745 8
YWHA2 Chromosome 8:102,000,090-102,034,745 8
KLF10 TIEG1 Chromosome 8:103,730,188-103,737,128 8
KLF10 TIEG1 Chromosome 8:103,730,188-103,737,128 8
BAALC Chromosome 8:104,222,097-104,311,709 8
BAALC Chromosome 8:104,222,097-104,311,709 8
TM7SF4 DC-HIL Chromosome 8:105,421,228-105,438,092 8
TM7SF4 DC-HIL Chromosome 8:105,421,228-105,438,092 8
ANGPT1 Angiopoietin 1 Chromosome 8:108,330,886-108,579,459 8
ANGPT1 Angiopoietin 1 Chromosome 8:108,330,886-108,579,459 8
ANGPT1 Angiopoietin 1 Chromosome 8:108,330,886-108,579,459 8
ANGPT1 Angiopoietin 1 Chromosome 8:108,330,886-108,579,459 8
ANGPT1 Angiopoietin 1 Chromosome 8:108,330,886-108,579,459 8
BLK Chromosome 8:11,388,919-11,459,522 8
BLK Chromosome 8:11,388,919-11,459,522 8
BLK Chromosome 8:11,388,919-11,459,522 8
GATA4 Chromosome 8:11,599,122-11,654,920 8
DFB137 Chromosome 8:11,868,871-11,869,517 8
TRHR TRH-R Chromosome 8:110,168,900-110,200,989 8
TRHR TRH-R Chromosome 8:110,168,900-110,200,989 8
DFB130 Chromosome 8:12,212,843-12,220,196 8
TNFRSF11B Chromosome 8:120,004,977-120,033,492 8
TNFRSF11B Chromosome 8:120,004,977-120,033,492 8
NOV CCN3 Chromosome 8:120,497,882-120,505,776 8
NOV CCN3 Chromosome 8:120,497,882-120,505,776 8
COL14A1 undulin Chromosome 8:121,206,533-121,453,454 8
COL14A1 undulin Chromosome 8:121,206,533-121,453,454 8
COL14A1 undulin Chromosome 8:121,206,533-121,453,454 8
MYC c-myc Chromosome 8:128,817,498-128,822,856 8
MYC c-myc Chromosome 8:128,817,498-128,822,856 8
CHRAC1 nucleosome remodelling aChromosome 8:141,590,586-141,596,434 8
CHRAC1 nucleosome remodelling aChromosome 8:141,590,586-141,596,434 8
CHRAC1 nucleosome remodelling aChromosome 8:141,590,586-141,596,434 8
PTK2 FAK Chromosome 8:141,737,683-142,080,514 8
PTK2 FAK Chromosome 8:141,737,683-142,080,514 8
PTK2 FAK Chromosome 8:141,737,683-142,080,514 8
PTP4A3 Chromosome 8:142,501,189-142,510,802 8
CYP11B1 11 beta hydroxylase Chromosome 8:143,950,775-143,958,238 8
LY6E Ly6E/A Chromosome 8:144,171,274-144,175,199 8
MAPK15 Chromosome 8:144,870,498-144,876,619 8
MSR1 CD204, SR-A, SCARA1 Chromosome 8:16,009,761-16,094,595 8
MSR1 CD204, SR-A, SCARA1 Chromosome 8:16,009,761-16,094,595 8
MSR1 CD204, SR-A, SCARA1 Chromosome 8:16,009,761-16,094,595 8
FGF20 FGF20 Chromosome 8:16,894,049-16,904,061 8
FGF20 FGF20 Chromosome 8:16,894,049-16,904,061 8
FGF20 FGF20 Chromosome 8:16,894,049-16,904,061 8
NAT2 Chromosome 8:18,293,035-18,303,003 8
NAT2 Chromosome 8:18,293,035-18,303,003 8
DOK2 Chromosome 8:21,822,330-21,827,151 8
DOK2 Chromosome 8:21,822,330-21,827,151 8
FGF17 FGF17 Chromosome 8:21,955,883-21,962,266 8
FGF17 FGF17 Chromosome 8:21,955,883-21,962,266 8
PPP3CC Chromosome 8:22,354,541-22,454,583 8
PPP3CC Chromosome 8:22,354,541-22,454,583 8
EGR3 Chromosome 8:22,601,117-22,606,760 8
EGR3 Chromosome 8:22,601,117-22,606,760 8
EGR3 Chromosome 8:22,601,117-22,606,760 8
TNFRSF10B CD262, TRAILR2 Chromosome 8:22,933,591-22,982,637 8
TNFRSF10B CD262, TRAILR2 Chromosome 8:22,933,591-22,982,637 8
TNFRSF10C CD263, TRAILR3 Chromosome 8:23,016,377-23,030,895 8
TNFRSF10D CD264, TRAILR4 Chromosome 8:23,049,046-23,077,488 8
TNFRSF10D CD264, TRAILR4 Chromosome 8:23,049,046-23,077,488 8
TNFRSF10A CD261, TRAILR1 Chromosome 8:23,104,009-23,138,584 8
TNFRSF10A CD261, TRAILR1 Chromosome 8:23,104,009-23,138,584 8
CHMP7 CHMP7 Chromosome 8:23,157,114-23,175,452 8
GNRH1 GNRH1 Chromosome 8:25,332,693-25,338,087 8
EBF2 Chromosome 8:25,757,490-25,958,292 8
EBF2 Chromosome 8:25,757,490-25,958,292 8
EBF2 Chromosome 8:25,757,490-25,958,292 8
EBF2 Chromosome 8:25,757,490-25,958,292 8
BNIP3L Chromosome 8:26,296,331-26,326,562 8
PTK 2B PYK2 Chromosome 8:27,224,916-27,372,824 8
PTK 2B PYK2 Chromosome 8:27,224,916-27,372,824 8
PTK 2B PYK2 Chromosome 8:27,224,916-27,372,824 8
CLU Chromosome 8:27,510,351-27,528,288 8
CLU Chromosome 8:27,510,351-27,528,288 8
SCARA3 SCARA3 Chromosome 8:27,547,304-27,590,211 8
SCARA5 Chromosome 8:27,783,655-27,906,117 8
DUSP4 Chromosome 8:29,249,530-29,264,104 8
DUSP4 Chromosome 8:29,249,530-29,264,104 8
GTF2E2 Chromosome 8:30,555,422-30,635,274 8
GTF2E2 Chromosome 8:30,555,422-30,635,274 8
GTF2E2 Chromosome 8:30,555,422-30,635,274 8
DUSP26 Chromosome 8:33,568,393-33,577,043 8
DUSP26 Chromosome 8:33,568,393-33,577,043 8
BAG4 Chromosome 8:38,153,263-38,189,966 8
BAG4 Chromosome 8:38,153,263-38,189,966 8
FGFR1 Chromosome 8:38,389,406-38,445,296 8
FGFR1 Chromosome 8:38,389,406-38,445,296 8
FGFR1 Chromosome 8:38,389,406-38,445,296 8
TACC1 Chromosome 8:38,734,008-38,829,703 8
TACC1 Chromosome 8:38,734,008-38,829,703 8
INDO IDO Chromosome 8:39,890,485-39,905,120 8
INDO IDO Chromosome 8:39,890,485-39,905,120 8
ANK1 Chromosome 8:41,629,901-41,873,437 8
ANK1 Chromosome 8:41,629,901-41,873,437 8
ANK1 Chromosome 8:41,629,901-41,873,437 8
ANK1 Chromosome 8:41,629,901-41,873,437 8
IKBKB IKK2 Chromosome 8:42,247,986-42,309,130 8
IKBKB IKK2 Chromosome 8:42,247,986-42,309,130 8
PRKDC DNA-PK Chromosome 8:48,848,222-49,035,296 8
OPRK1 KOR Chromosome 8:54,300,829-54,326,747 8
OPRK1 KOR Chromosome 8:54,300,829-54,326,747 8
LYN Lyn Chromosome 8:56,954,926-57,086,493 8
LYN Lyn Chromosome 8:56,954,926-57,086,493 8
LYN Lyn Chromosome 8:56,954,926-57,086,493 8
CYP7A1 Chromosome 8:59,565,292-59,575,275 8
CYP7A1 Chromosome 8:59,565,292-59,575,275 8
NSMAF Chromosome 8:59,658,617-59,734,940 8
ANGPT2 Angiopoietin-2 Chromosome 8:6,344,580-6,408,338 8
ANGPT2 Angiopoietin-2 Chromosome 8:6,344,580-6,408,338 8
CYP7B1 Chromosome 8:65,671,246-65,873,902 8
CYP7B1 Chromosome 8:65,671,246-65,873,902 8
CYP7B1 Chromosome 8:65,671,246-65,873,902 8
CRH Chromosome 8:67,251,166-67,253,380 8
TRAM1 Chromosome 8:71,648,227-71,683,158 8
LY96 MD2 Chromosome 8:75,066,141-75,103,859 8
LY96 MD2 Chromosome 8:75,066,141-75,103,859 8
HNF4G NR2A2 Chromosome 8:76,482,826-76,641,623 8
HNF4G NR2A2 Chromosome 8:76,482,826-76,641,623 8
HNF4G NR2A2 Chromosome 8:76,482,826-76,641,623 8
PXMP3 Chromosome 8:78,057,713-78,074,994 8
PXMP3 Chromosome 8:78,057,713-78,074,994 8
IL7 Chromosome 8:79,807,560-79,880,313 8
IL7 Chromosome 8:79,807,560-79,880,313 8
IL7 Chromosome 8:79,807,560-79,880,313 8
CLDN23 Chromosome 8:8,597,076-8,599,026 8
CLDN23 Chromosome 8:8,597,076-8,599,026 8
PAG1 PAG Chromosome 8:82,042,600-82,186,858 8
PAG1 PAG Chromosome 8:82,042,600-82,186,858 8
FABP5 FABP5 Chromosome 8:82,355,326-82,359,563 8
FABP5 FABP5 Chromosome 8:82,355,326-82,359,563 8
FABP4 FABP4 Chromosome 8:82,553,481-82,558,023 8
CHMP4C CHMP4C Chromosome 8:82,807,243-82,834,305 8
CHMP4C CHMP4C Chromosome 8:82,807,243-82,834,305 8
MMP16 Chromosome 8:89,118,576-89,408,892 8
MMP16 Chromosome 8:89,118,576-89,408,892 8
MMP16 Chromosome 8:89,118,576-89,408,892 8
MMP16 Chromosome 8:89,118,576-89,408,892 8
MMP16 Chromosome 8:89,118,576-89,408,892 8
RIPK2 CARD3, RIP2, RICK Chromosome 8:90,839,110-90,872,433 8
RIPK2 CARD3, RIP2, RICK Chromosome 8:90,839,110-90,872,433 8
NBS1 NBS1 Chromosome 8:91,014,740-91,066,075 8
RUNX1T1 Chromosome 8:93,040,328-93,176,619 8
RUNX1T1 Chromosome 8:93,040,328-93,176,619 8
RUNX1T1 Chromosome 8:93,040,328-93,176,619 8
GEM GEM Chromosome 8:95,330,657-95,343,733 8
GEM GEM Chromosome 8:95,330,657-95,343,733 8
CCNE2 Chromosome 8:95,961,628-95,976,660 8
CCNE2 Chromosome 8:95,961,628-95,976,660 8
PTDSS1 Chromosome 8:97,343,340-97,415,950 8
PTDSS1 Chromosome 8:97,343,340-97,415,950 8
PTDSS1 Chromosome 8:97,343,340-97,415,950 8
PTDSS1 Chromosome 8:97,343,340-97,415,950 8
SDC2 Syndecan Chromosome 8:97,575,058-97,693,213 8
SDC2 Syndecan Chromosome 8:97,575,058-97,693,213 8
SDC2 Syndecan Chromosome 8:97,575,058-97,693,213 8
POP1 Chromosome 8:99,199,244-99,239,816 8
POP1 Chromosome 8:99,199,244-99,239,816 8
POP1 Chromosome 8:99,199,244-99,239,816 8
STK3 Chromosome 8:99,536,041-99,907,085 8
STK3 Chromosome 8:99,536,041-99,907,085 8
STK3 Chromosome 8:99,536,041-99,907,085 8
STK3 Chromosome 8:99,536,041-99,907,085 8
STK3 Chromosome 8:99,536,041-99,907,085 8
IL6RL1 Chromosome 9 9
IL6RL1 Chromosome 9 9
TGFBR1 Chromosome 9:100,907,233-100,956,406 9
TGFBR1 Chromosome 9:100,907,233-100,956,406 9
SEC61B Chromosome 9:101,024,380-101,032,722 9
NR4A3 Chromosome 9:101,623,958-101,668,994 9
NR4A3 Chromosome 9:101,623,958-101,668,994 9
PPP3R2 Chromosome 9:103,393,718-103,397,104 9
PPP3R2 Chromosome 9:103,393,718-103,397,104 9
SLC44A1 CDW92 Chromosome 9:107,046,724-107,241,273 9
SLC44A1 CDW92 Chromosome 9:107,046,724-107,241,273 9
TAL2 Chromosome 9:107,464,599-107,465,214 9
ACTL7B Chromosome 9:110,656,692-110,659,068 9
ACTL7B Chromosome 9:110,656,692-110,659,068 9
PTPN3 Chromosome 9:111,177,800-111,300,407 9
PTPN3 Chromosome 9:111,177,800-111,300,407 9
TXN Txk, Rlk, thioredoxin Chromosome 9:112,045,912-112,058,741 9
TXN Txk, Rlk, thioredoxin Chromosome 9:112,045,912-112,058,741 9
SVEP1/MUSK Chromosome 9:112,431,057-112,431,557 9
LTB4DH Chromosome 9:113,364,678-113,401,917 9
LTB4DH Chromosome 9:113,364,678-113,401,917 9
UGCG Chromosome 9:113,698,867-113,737,470 9
UGCG Chromosome 9:113,698,867-113,737,470 9
UGCG Chromosome 9:113,698,867-113,737,470 9
FKBP15 Chromosome 9:114,967,620-115,024,010 9
FKBP15 Chromosome 9:114,967,620-115,024,010 9
POLE3 Chromosome 9:115,209,336-115,212,773 9
POLE3 Chromosome 9:115,209,336-115,212,773 9
ORM1 ORM3 Chromosome 9:116,125,157-116,128,578 9
ORM2 Chromosome 9:116,131,890-116,135,357 9
TNFSF15 Chromosome 9:116,591,421-116,608,229 9
TNFSF15 Chromosome 9:116,591,421-116,608,229 9
TNFSF8 CD153 Chromosome 9:116,704,945-116,732,591 9
TNC tenascin Chromosome 9:116,822,634-116,920,260 9
TNC tenascin Chromosome 9:116,822,634-116,920,260 9
TLR4 CD284 Chromosome 9:119,506,405-119,519,589 9
TLR4 CD284 Chromosome 9:119,506,405-119,519,589 9
TRAF1 Chromosome 9:122,704,492-122,730,868 9
TRAF1 Chromosome 9:122,704,492-122,730,868 9
C5 Chromosome 9:122,754,434-122,852,375 9
PTGS1 PG synthase Chromosome 9:124,173,050-124,197,802 9
PTGS1 PG synthase Chromosome 9:124,173,050-124,197,802 9
PSMB7 Chromosome 9:126,155,565-126,217,542 9
PSMB7 Chromosome 9:126,155,565-126,217,542 9
NR5A1 Chromosome 9:126,283,336-126,309,530 9
NR6A1 NR6A1 Chromosome 9:126,319,380-126,573,410 9
NR6A1 NR6A1 Chromosome 9:126,319,380-126,573,410 9
HSPA5 grp78 Chromosome 9:127,036,953-127,043,430 9
CDK9 pTEFb Chromosome 9:129,587,898-129,592,887 9
CDK9 pTEFb Chromosome 9:129,587,898-129,592,887 9
ENG CD105, TGF beta receptoChromosome 9:129,617,112-129,656,856 9
LCN2 LCN2 Chromosome 9:129,951,171-129,956,333 9
SET Chromosome 9:130,485,844-130,498,488 9
PPP2R4 PP2A Chromosome 9:130,913,050-130,951,046 9
PTGES Chromosome 9:131,540,433-131,555,165 9
PTGES Chromosome 9:131,540,433-131,555,165 9
GPR107 Chromosome 9:131,855,526-131,942,264 9
GPR107 Chromosome 9:131,855,526-131,942,264 9
GPR107 Chromosome 9:131,855,526-131,942,264 9
LAMC3 Chromosome 9:132,874,325-132,958,267 9
LAMC3 Chromosome 9:132,874,325-132,958,267 9
RAPGEF1 C3G Chromosome 9:133,441,978-133,605,282 9
RAPGEF1 C3G Chromosome 9:133,441,978-133,605,282 9
DDX31 Chromosome 9:134,458,205-134,535,609 9
DDX31 Chromosome 9:134,458,205-134,535,609 9
GTF3C5 Chromosome 9:134,895,897-134,923,709 9
GTF3C5 Chromosome 9:134,895,897-134,923,709 9
ABO Chromosome 9:135,120,384-135,140,451 9
ADAMTS13 Chromosome 9:135,276,941-135,314,329 9
ADAMTS13 Chromosome 9:135,276,941-135,314,329 9
VAV2 Chromosome 9:135,616,837-135,847,547 9
VAV2 Chromosome 9:135,616,837-135,847,547 9
VAV2 Chromosome 9:135,616,837-135,847,547 9
VAV2 Chromosome 9:135,616,837-135,847,547 9
VAV2 Chromosome 9:135,616,837-135,847,547 9
COL5A1 Chromosome 9:136,673,473-136,876,510 9
FCN1 ficolin Chromosome 9:136,940,837-136,949,630 9
NOTCH1 Notch 1 Chromosome 9:138,508,717-138,560,135 9
TRAF2 Chromosome 9:138,900,786-138,940,888 9
NOXA1 Chromosome 9:139,437,668-139,448,679 9
NOXA1 Chromosome 9:139,437,668-139,448,679 9
LEDGF p75 Chromosome 9:15,454,064-15,501,017 9
LEDGF p75 Chromosome 9:15,454,064-15,501,017 9
SMARCA2 SWI/SNF Chromosome 9:2,005,342-2,183,624 9
SMARCA2 SWI/SNF Chromosome 9:2,005,342-2,183,624 9
SMARCA2 SWI/SNF Chromosome 9:2,005,342-2,183,624 9
KIAA0020 HA-8, PEN, CD162R Chromosome 9:2,794,152-2,834,095 9
KIAA0020 HA-8, PEN, CD162R Chromosome 9:2,794,152-2,834,095 9
IFNB1 IRG47 Chromosome 9:21,067,104-21,067,962 9
IFNB1 IRG47 Chromosome 9:21,067,104-21,067,962 9
IFNW1 Chromosome 9:21,130,213-21,132,144 9
IFNA7 Chromosome 9:21,191,234-21,229,990 9
IFNA13 Chromosome 9:21,357,423-21,358,961 9
IFNE1 Chromosome 9:21,470,838-21,472,312 9
IFNE1 Chromosome 9:21,470,838-21,472,312 9
CDKN2A Chromosome 9:21,957,751-21,984,490 9
CDKN2A Chromosome 9:21,957,751-21,984,490 9
CDKN2B Chromosome 9:21,992,902-21,999,312 9
PLAA PLA activatinp protein Chromosome 9:26,894,081-26,937,461 9
TEK CD202b Chromosome 9:27,099,236-27,220,173 9
TEK CD202b Chromosome 9:27,099,236-27,220,173 9
TEK CD202b Chromosome 9:27,099,236-27,220,173 9
IFNK Chromosome 9:27,514,302-27,516,496 9
RFX3 RFX3 Chromosome 9:3,208,297-3,515,983 9
RFX3 RFX3 Chromosome 9:3,208,297-3,515,983 9
RFX3 RFX3 Chromosome 9:3,208,297-3,515,983 9
RFX3 RFX3 Chromosome 9:3,208,297-3,515,983 9
RFX3 RFX3 Chromosome 9:3,208,297-3,515,983 9
DDX58 Chromosome 9:32,445,300-32,516,322 9
DDX58 Chromosome 9:32,445,300-32,516,322 9
BAG1 Chromosome 9:33,242,469-33,254,744 9
CHMP5 CHMP5 Chromosome 9:33,254,167-33,271,525 9
IL11RA Chromosome 9:34,636,635-34,651,884 9
IL11RA Chromosome 9:34,636,635-34,651,884 9
Cd72 Chromosome 9:35,599,976-35,608,753 9
TLN1 Talin Chromosome 9:35,687,334-35,722,369 9
TLN1 Talin Chromosome 9:35,687,334-35,722,369 9
MELK Melk Chromosome 9:36,562,873-36,667,679 9
MELK Melk Chromosome 9:36,562,873-36,667,679 9
SHB Chromosome 9:37,909,131-38,059,249 9
SHB Chromosome 9:37,909,131-38,059,249 9
JAK2 Chromosome 9:4,975,245-5,118,183 9
JAK2 Chromosome 9:4,975,245-5,118,183 9
CD274 CD274, PD1 ligand 1, PD   Chromosome 9:5,440,525-5,460,547 9
CD274 CD274, PD1 ligand 1, PD   Chromosome 9:5,440,525-5,460,547 9
PDCD1LG2 CD273, PD1 ligand 2, PD  Chromosome 9:5,500,570-5,561,252 9
IL33 Chromosome 9:6,205,809-6,247,983 9
IL33 Chromosome 9:6,205,809-6,247,983 9
PRKACG Chromosome 9:70,817,241-70,818,849 9
ANXA1 Annexin-1 Chromosome 9:74,956,493-74,975,129 9
ANXA1 Annexin-1 Chromosome 9:74,956,493-74,975,129 9
RORB RORb, NR1F2 Chromosome 9:76,302,072-76,491,937 9
RORB RORb, NR1F2 Chromosome 9:76,302,072-76,491,937 9
RORB RORb, NR1F2 Chromosome 9:76,302,072-76,491,937 9
FOXB2 Chromosome 9:78,824,391-78,825,689 9
PTPRD Chromosome 9:8,304,246-9,008,735 9
PTPRD Chromosome 9:8,304,246-9,008,735 9
PTPRD Chromosome 9:8,304,246-9,008,735 9
PTPRD Chromosome 9:8,304,246-9,008,735 9
PTPRD Chromosome 9:8,304,246-9,008,735 9
PTPRD Chromosome 9:8,304,246-9,008,735 9
GAS1 Chromosome 9:88,749,098-88,751,924 9
DAPK1 Chromosome 9:89,301,963-89,513,369 9
DAPK1 Chromosome 9:89,301,963-89,513,369 9
DAPK1 Chromosome 9:89,301,963-89,513,369 9
DAPK1 Chromosome 9:89,301,963-89,513,369 9
CKS2 Chromosome 9:91,115,925-91,121,438 9
SEMA4D CD100 Chromosome 9:91,181,972-91,302,708 9
SYK Chromosome 9:92,603,890-92,700,652 9
SYK Chromosome 9:92,603,890-92,700,652 9
NFIL3 nuclear factor interleukin i Chromosome 9:93,211,148-93,225,965 9
NFIL3 nuclear factor interleukin i Chromosome 9:93,211,148-93,225,965 9
PTCH1 Ptc Chromosome 9:97,245,083-97,318,923 9
PTCH1 Ptc Chromosome 9:97,245,083-97,318,923 9
PTCH1 Ptc Chromosome 9:97,245,083-97,318,923 9
XPA Chromosome 9:99,477,012-99,499,460 9
FOXE1 Chromosome 9:99,655,357-99,658,818 9
ANP32B acidic nucelar phosphoproChromosome 9:99,785,462-99,818,046 9
BTK Chromosome X:100,491,091-100,527,839 X
BTK Chromosome X:100,491,091-100,527,839 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
IL1RAPL2 Chromosome X:103,697,652-104,898,478 X
GRAIL Chromosome X:105,823,724-105,926,902 X
GRAIL Chromosome X:105,823,724-105,926,902 X
GRAIL Chromosome X:105,823,724-105,926,902 X
TSC22D3 DIP Chromosome X:106,843,107-106,905,858 X
TSC22D3 DIP Chromosome X:106,843,107-106,905,858 X
NLRP3P NOD13 Chromosome X:107,103,687-107,105,431 X
COL4A6 Chromosome X:107,285,493-107,569,383 X
COL4A6 Chromosome X:107,285,493-107,569,383 X
COL4A6 Chromosome X:107,285,493-107,569,383 X
COL4A6 Chromosome X:107,285,493-107,569,383 X
COL4A5 Chromosome X:107,569,810-107,827,431 X
COL4A5 Chromosome X:107,569,810-107,827,431 X
PAK3 Chromosome X:110,226,244-110,350,816 X
IL13RA2 CD213a2 Chromosome X:114,144,794-114,159,792 X
AGTR2 Angiotensin receptor Chromosome X:115,216,003-115,220,253 X
IL13RA1 CD213a1 Chromosome X:117,745,563-117,812,530 X
IL13RA1 CD213a1 Chromosome X:117,745,563-117,812,530 X
LAMP2 CD107b Chromosome X:119,446,367-119,487,189 X
LAMP2 CD107b Chromosome X:119,446,367-119,487,189 X
TLR7 CD287 Chromosome X:12,795,123-12,818,420 X
TLR8 CD288 Chromosome X:12,834,679-12,851,209 X
TMSB4X thymosin beta 4 Chromosome X:12,903,148-12,905,267 X
BIRC4 XIAP Chromosome X:122,821,558-122,875,510 X
BIRC4 XIAP Chromosome X:122,821,558-122,875,510 X
SH2D1A EAT2a, SAP Chromosome X:123,307,875-123,334,686 X
SH2D1A EAT2a, SAP Chromosome X:123,307,875-123,334,686 X
SMARCA1 ISWI Chromosome X:128,408,159-128,485,158 X
SMARCA1 ISWI Chromosome X:128,408,159-128,485,158 X
SMARCA1 ISWI Chromosome X:128,408,159-128,485,158 X
APLN apelin Chromosome X:128,607,006-128,616,595 X
APLN apelin Chromosome X:128,607,006-128,616,595 X
AIFM1 PDCD8 Chromosome X:129,091,018-129,127,489 X
AIFM1 PDCD8 Chromosome X:129,091,018-129,127,489 X
IGSF1 Chromosome X:130,235,161-130,361,358 X
IGSF1 Chromosome X:130,235,161-130,361,358 X
DDX26B Chromosome X:134,482,215-134,544,100 X
SLC9A6 NHE-6 Chromosome X:134,895,264-134,957,089 X
SLC9A6 NHE-6 Chromosome X:134,895,264-134,957,089 X
CD40LG CD40L, CD154, TNFSF5 Chromosome X:135,558,002-135,570,215 X
CD40LG CD40L, CD154, TNFSF5 Chromosome X:135,558,002-135,570,215 X
FGF13 FGF13 Chromosome X:137,541,401-137,894,912 X
FGF13 FGF13 Chromosome X:137,541,401-137,894,912 X
FGF13 FGF13 Chromosome X:137,541,401-137,894,912 X
FGF13 FGF13 Chromosome X:137,541,401-137,894,912 X
FGF13 FGF13 Chromosome X:137,541,401-137,894,912 X
FGF13 FGF13 Chromosome X:137,541,401-137,894,912 X
CD99L2 Chromosome X:149,685,467-149,817,837 X
CD99L2 Chromosome X:149,685,467-149,817,837 X
FIGF VEGFD Chromosome X:15,273,639-15,312,498 X
FIGF VEGFD Chromosome X:15,273,639-15,312,498 X
FIGF VEGFD Chromosome X:15,273,639-15,312,498 X
BMX Chromosome X:15,392,290-15,484,573 X
ACE2 Chromosome X:15,489,077-15,530,199 X
BGN Chromosome X:152,413,591-152,428,206 X
BGN Chromosome X:152,413,591-152,428,206 X
DUSP9 Chromosome X:152,561,182-152,569,975 X
L1CAM CD171 Chromosome X:152,780,163-152,804,802 X
IRAK1 Pelle Chromosome X:152,929,145-152,938,625 X
G6PD G6PDH Chromosome X:153,412,800-153,428,981 X
DKC1 dyskeratosis congenita Chromosome X:153,644,229-153,659,158 X
SCML2 Chromosome X:18,167,355-18,282,768 X
SCML2 Chromosome X:18,167,355-18,282,768 X
MAP3K15 Chromosome X:19,288,095-19,443,363 X
MAP3K15 Chromosome X:19,288,095-19,443,363 X
MAP3K15 Chromosome X:19,288,095-19,443,363 X
SH3KBP1 Chromosome X:19,462,014-19,815,640 X
SH3KBP1 Chromosome X:19,462,014-19,815,640 X
SH3KBP1 Chromosome X:19,462,014-19,815,640 X
XG Chromosome X:2,680,115-2,743,968 X
DDX53 Chromosome X:22,927,999-22,931,627 X
DDX53 Chromosome X:22,927,999-22,931,627 X
DDX53 Chromosome X:22,927,999-22,931,627 X
PRDX4 Chromosome X:23,592,300-23,614,437 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
IL1RAPL1 Chromosome X:28,515,437-29,884,761 X
NR0B1 NR0B1 Chromosome X:30,232,244-30,237,636 X
NR0B1 NR0B1 Chromosome X:30,232,244-30,237,636 X
NR0B1 NR0B1 Chromosome X:30,232,244-30,237,636 X
XK Chromosome X:37,429,931-37,476,322 X
CYBB NOX2 Chromosome X:37,524,208-37,557,658 X
TSPAN7 CD231 Chromosome X:38,305,553-38,433,118 X
TSPAN7 CD231 Chromosome X:38,305,553-38,433,118 X
DDX3X Chromosome X:41,077,595-41,108,669 X
DDX3X Chromosome X:41,077,595-41,108,669 X
DUSP21 Chromosome X:44,588,193-44,589,078 X
DUSP21 Chromosome X:44,588,193-44,589,078 X
SLC9A7 NHE-7 Chromosome X:46,349,697-46,503,434 X
SLC9A7 NHE-7 Chromosome X:46,349,697-46,503,434 X
SLC9A7 NHE-7 Chromosome X:46,349,697-46,503,434 X
TIMP1 Chromosome X:47,326,634-47,331,134 X
CFP properdin, PFC Chromosome X:47,368,557-47,374,648 X
WAS Wiskott Aldrich, WASP Chromosome X:48,427,112-48,434,762 X
SUV39H1 Suv39h1 Chromosome X:48,439,930-48,452,347 X
GATA1 Chromosome X:48,529,906-48,537,662 X
HDAC6 Chromosome X:48,545,170-48,568,336 X
FOXP3 Chromosome X:48,993,841-49,008,232 X
CCNB3 Chromosome X:49,856,156-50,111,653 X
CCNB3 Chromosome X:49,856,156-50,111,653 X
TSPYL2 CDA1 Chromosome X:53,128,274-53,134,447 X
TSPYL2 CDA1 Chromosome X:53,128,274-53,134,447 X
JARID1C SMCY homolog Chromosome X:53,238,059-53,271,329 X
JARID1C SMCY homolog Chromosome X:53,238,059-53,271,329 X
ALAS2 Alas2 Chromosome X:55,052,213-55,074,136 X
ALAS2 Alas2 Chromosome X:55,052,213-55,074,136 X
NLRP2P NOD24 Chromosome X:57,719,936-57,723,438 X
AR Androgen receptor, NR3CChromosome X:66,680,599-66,867,186 X
AR Androgen receptor, NR3CChromosome X:66,680,599-66,867,186 X
EDA Chromosome X:68,752,636-69,176,047 X
EDA Chromosome X:68,752,636-69,176,047 X
EDA Chromosome X:68,752,636-69,176,047 X
P2RY4 P2Y4 Chromosome X:69,394,741-69,396,379 X
P2RY4 P2Y4 Chromosome X:69,394,741-69,396,379 X
MLLT7 FOXO4 Chromosome X:70,232,772-70,240,110 X
IL2RG CD132 Chromosome X:70,243,979-70,248,188 X
CXCR3 CD183 Chromosome X:70,752,491-70,755,092 X
CXCR3 CD183 Chromosome X:70,752,491-70,755,092 X
FLJ20105 Chromosome X:71,341,232-71,375,602 X
FLJ20105 Chromosome X:71,341,232-71,375,602 X
FLJ20105 Chromosome X:71,341,232-71,375,602 X
HDAC8 Chromosome X:71,466,091-71,709,623 X
HDAC8 Chromosome X:71,466,091-71,709,623 X
HDAC8 Chromosome X:71,466,091-71,709,623 X
FGF16 FGF16 Chromosome X:76,596,303-76,598,669 X
FGF16 FGF16 Chromosome X:76,596,303-76,598,669 X
CYSLTR1 Chromosome X:77,413,617-77,469,743 X
CYSLTR1 Chromosome X:77,413,617-77,469,743 X
TBL1X Chromosome X:9,391,369-9,647,778 X
TBL1X Chromosome X:9,391,369-9,647,778 X
TBL1X Chromosome X:9,391,369-9,647,778 X
TBL1X Chromosome X:9,391,369-9,647,778 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
DIAPH2 Chromosome X:95,826,365-96,746,652 X
NOX1 Chromosome X:99,984,969-100,015,990 X
NOX1 Chromosome X:99,984,969-100,015,990 X
USP9Y A1/HY, DFFRY Chromosome Y:13,322,554-13,482,162 Y
DDX3Y DRB1*1501/HY, DBY, DQChromosome Y:13,525,413-13,541,784 Y
DDX3Y DRB1*1501/HY, DBY, DQChromosome Y:13,525,413-13,541,784 Y
UTY B60/HY Chromosome Y:13,869,653-14,101,947 Y
UTY B60/HY Chromosome Y:13,869,653-14,101,947 Y
TMSB4Y A33/HY Chromosome Y:14,324,841-14,327,298 Y
CD24 Chromosome Y:19,611,898-19,614,093 Y
RPS4Y1 B52/HY Chromosome Y:2,769,527-2,794,997 Y
RPS4Y1 B52/HY Chromosome Y:2,769,527-2,794,997 Y
JARID1D A2/HY, B7/HY, HLA-DQ5/   Chromosome Y:20,326,689-20,366,212 Y
TBL1Y Chromosome Y:6,838,727-7,019,724 Y
TBL1Y Chromosome Y:6,838,727-7,019,724 Y
Gene Start Position Gene End Position Internal marker name Marker database name
1128751 1131952 TNFRSF18 new design
1,260,521 1,274,623 0119C03 D1S1394i
1,557,337 1,623,109 0109H08 D1S1252i
1,971,769 2,106,694 0114H07 D1S1708i
10,439,166 10,455,200 0113C07 D1S0305i
100,957,885 100,977,189 0113E08 D1S0467i
101,475,032 101,479,662 0108A11 D1S206
107,400,824 107,403,439 0119H04 D1S1192i
107,915,305 108,309,108 0111G07 D1S0718i
107,915,305 108,309,108 0108H03 D1S1026i
107,915,305 108,309,108 0117D07 D1S1469i
107,915,305 108,309,108 0104H04 D1S1607i
109,406,644 109,420,147 0101H03 G09558
109,892,824 109,938,498 0117B09 D1S0465i
109,892,824 109,938,498 0109E10 D1S1307i
11,009,167 11,029,877 0114H04 D1S0758i
11,009,167 11,029,877 0116B01 D1S1176i
11,089,179 11,245,176 0116C01 D1S0037i
11,089,179 11,245,176 0105B06 D1S0070i
11,089,179 11,245,176 0113B06 D1S0307i
11,768,367 11,788,702 0108B09 D1S0057i
11,828,353 11,830,989 0109E01 D1S2740
110,254,778 110,275,144 9902C03 D1S1016i
111,215,344 111,244,081 0117A09 D1S0464i
111,215,344 111,244,081 004C07 D1S2809
111,571,804 111,587,585 0114C11 D1S0836i
111,827,493 111,908,107 0117G08 D1S0458i
111,827,493 111,908,107 0102C07 D1S2789
111,886,363 112,060,836 0104A07 D1S2837
113,045,251 113,051,579 0108H10 D1S2756
114,092,981 114,215,904 0111B02 D1S0280i
114,092,981 114,215,904 0113E02 D1S0471i
114,911,701 114,925,788 0117C06 D1S1220i
115,048,613 115,102,147 0119C07 G12424
115,373,938 115,378,464 0102A02 D1S1693i
115,630,060 115,682,380 0110E08 D1S0034i
116,858,680 116,915,184 0112F09 D1S1147i
116,918,554 117,011,898 0113B12 D1S0455i
117,098,530 117,113,374 335G10 AL365325.4_109510
117,254,202 117,334,503 0106E06 D1S1532i
117,254,202 117,334,503 0109A03 D1S252
117,487,732 117,555,079 0111G04 D1S0475i
117,487,732 117,555,079 0115G02 D1S0644i
119,851,356 119,859,200 0112C03 D1S0895i
12,046,021 12,126,851 0116F09 D1S1559i
12,149,647 12,191,872 264A06 AL355998.4_40197
120,255,699 120,413,799 9902B01 D1S1785i
120728502 120737460 FCGR1B new design
120728502 120737460 FCGR1B2 new design
144,236,248 144,255,225 T002F11 D1S2344
144,407,155 144,426,971 0102G04 D1S442
146,418,535 146,422,374 0110H02 D1S1378i
146,567,361 146,577,147 159F12 AL022240.8_87561
148,167,168 148,175,396 0113B01 D1S1407i
148,813,658 148,818,760 0119C12 D1S1299i
148,969,175 149,005,057 0101B10 D1S1006i
149,035,311 149,047,436 0111A05 D1S0479i
149,035,311 149,047,436 0119D06 D1S0483i
149,275,670 149,286,700 0113G07 D1S0513i
149,531,037 149,566,815 0118F04 D1S0139i
15,655,811 15,690,482 0104E01 D1S0157i
15,655,811 15,690,482 0118A12 D1S436
150,039,364 150,070,972 0108F12 D1S0489i
150,271,606 150,276,135 0119G12 D1S1490i
151,536,962 151,549,818 270A11 AL161636.7_109719
151,612,808 151,614,749 0119F05 D1S1558i
151,773,699 151,775,344 0111H06 D1S0685i
151,782,713 151,789,236 270G12 AL157404.7_111158
151,900,905 151,910,148 0110D05 D1S1454i
151,900,905 151,910,148 0101C02 Z67234
152,229,853 152,231,250 0116F05 D1S0498i
152,229,853 152,231,250 0109B03 D1S2858
152644293 152708550 IL6R1 new design
152644293 152708550 IL6R2 new design
153,213,753 153,218,348 336C06 AC027440.2_106016
153,366,560 153,374,010 0101F08 D1S1677i
153,424,924 153,429,330 0105D10 D1S0493i
154,700,143 154,737,244 690D09 DISD22_0000791
155,042,659 155,053,270 478G05 chr1.fa.O7frz.178252111
155,042,659 155,053,270 099D11 HUMUT2150
155,749,791 155,788,934 478C06 chr1.fa.O7frz.178941521
155,810,163 155,834,494 0119H03 D1S1317i
155,982,145 156,013,546 0115G06 D1S0009i
155,982,145 156,013,546 0116G01 D1S0030i
156,416,361 156,421,310 0108D08 D1S0898i
156,526,200 156,530,044 0117F06 D1S1291i
157,236,382 157,291,569 0112G02 D1S0886i
157,236,382 157,291,569 0105C04 Z67479
157,408,023 157,442,914 0106F05 D1S2635
157,526,128 157,544,638 0103A11 D1S1544i
157,948,703 157,951,003 0101E01 HUMUT1234
158,017,346 158,018,957 0102D01 D1S1636i
158,163,453 158,182,010 0119F10 D1S1617i
158,327,754 158,335,103 0105B03 D1S2707
158,603,481 158,609,262 0112D03 D1S0899i
158,721,444 158,759,676 0117E09 D1S0505i
158,915,160 158,948,265 0110H08 D1S0053i
159,032,552 159,064,669 0108D02 D1S0163i
159,231,625 159,275,404 336E06 AL354714.7_79226
159,231,625 159,275,404 0110F03 D1S1414i
159,451,693 159,457,113 0119H10 D1S1455i
159,466,079 159,474,590 0110G05 D1S1463i
159741844 159755984 FCGR2A new design
159,859,610 159,867,620 0114F08 D1S0904i
16,046,946 16,139,542 0111C09 D1S0770i
160,631,680 160,648,552 0107H03 D1S0515i
163,636,778 163,681,057 0107C03 D1S2878
165,666,501 165,754,471 0109H06 D1S0005i
165,666,501 165,754,471 0115G11 D1S1554i
165,957,832 166,026,684 0109C03 D1S2750
166,776,626 166,779,859 0102H01 D1S0187i
166,812,335 166,817,939 0115C05 D1S0109i
167,750,028 167,822,450 0110A10 D1S0095i
167,824,661 167,866,031 0110D11 D1S0164i
167,824,661 167,866,031 0104F06 D1S0168i
167,926,432 167,947,463 0111B01 D1S0249i
17,507,277 17,563,086 0107H09 D1S1144i
170,894,777 170,902,637 0110G11 D1S0194i
170,894,777 170,902,637 0116D10 D1S0257i
171,275,723 171,286,679 0104C12 D1S0032i
171,275,723 171,286,679 0117C05 D1S0271i
171,419,493 171,443,094 0119F02 D1S0235i
171,419,493 171,443,094 0104G09 D1S1477i
171,713,028 171,724,569 0101F06 D1S1070i
172,139,562 172,153,139 479E02 chr1.fa.O7frz.196094961
173,303,617 173,383,825 0113E10 D1S0159i
173,558,558 173,979,529 160E02 AL021919.4_42117
173,558,558 173,979,529 0116G09 D1S0031i
173,558,558 173,979,529 0105F06 D1S0200i
173,558,558 173,979,529 0111G01 D1S0265i
173,558,558 173,979,529 0109H05 D1S1565
173,558,558 173,979,529 104D05 HUMUT417
177,085,293 177,106,838 0112G09 D1S1153i
177,317,735 177,333,653 0116G07 D1S0510i
177,317,735 177,333,653 0113F11 D1S0533i
178,390,591 178,439,788 0113F05 D1S0517i
178,390,591 178,439,788 0106C11 D1S2883
179,269,762 179,292,312 0115B10 D1S0542i
18,306,827 18,577,563 0116A06 D1S0315i
18,306,827 18,577,563 0112C12 D1S1227i
18,306,827 18,577,563 0102E10 D1S2826
18,306,827 18,577,563 0118E02 Z67335
181,075,127 181,123,510 0110H05 D1S1464i
181,075,127 181,123,510 0103B08 D1S2623
181,422,022 181,480,662 0113H02 D1S0682i
181,422,022 181,480,662 0112E12 D1S1236i
181,791,320 181,826,634 0110H06 D1S1488i
184,532,034 184,550,317 270C08 AC074116.5_2995
184,907,546 184,916,179 0113D07 D1S0134i
190,871,905 190,896,059 0101C07 D1S0261i
190,871,905 190,896,059 0112G08 D1S1098i
194,887,631 194,983,257 0116C10 D1S0102i
194,887,631 194,983,257 0118B06 D1S0250i
195,010,571 195,154,386 9902C05 D1S0537i
195,179,520 195,194,979 0104B03 D1S1417i
196,874,424 196,993,035 0101A08 Z67221
198,263,353 198,413,175 0107C11 D1S0540i
198,859,647 198,905,749 0115D11 D1S0687i
198,859,647 198,905,749 0110F07 D1S1514i
2479150 2486613 TNF142 new design
2479150 2486613 TNFRSF14 new design
20,311,019 20,318,637 0119B05 D1S1199i
20,311,019 20,318,637 0117C02 D1S1264i
20,311,019 20,318,637 0105A10 D1S2843
20,788,028 20,817,988 333C12 AL365439.2_120643
20,788,028 20,817,988 079D08 D1S1571
200,243,696 200,252,939 005G10 D1S2615
200,382,764 200,397,332 0109F03 D1S1727
200,403,802 200,425,104 0107D06 D1S0482i
201,326,405 201,403,156 0111F05 D1S0528i
201,326,405 201,403,156 0104D02 D1S0693i
201,326,405 201,403,156 0103D10 D1S2683
201,576,375 201,587,240 0108C09 D1S0543i
202,000,957 202,012,123 0113A12 HUMUT8081B
202,308,866 202,363,494 005D12 D1S2668
202,308,866 202,363,494 0118D09 D1S2717
202,658,379 202,726,175 9902D07 D1S1504i
202,752,134 202,793,871 0105G03 D1S0955i
203,278,963 203,313,761 337H04 AL359927.2_44777
203,278,963 203,313,761 0108D05 D1S1579i
203,833,330 203,868,623 0113F12 D1S0523i
204,710,414 204,736,846 0119B10 D1S1245i
204,875,504 204,924,381 0105F10 D1S1678i
204,924,912 204,974,251 0110H09 D1S0094i
205,007,570 205,012,462 IL10G new design
205,038,838 205,082,949 0107C07 D1S2772
205,105,322 205,109,191 0111G05 D1S0548i
205,137,411 205,144,107 0106C01 D1S2735
205,328,810 205,339,961 006H01 D1S2727
205,344,230 205,384,940 0114A09 D1S1043i
205,561,476 205,600,934 0117G09 D1S0534i
205,694,198 205,729,863 0115A01 D1S1205i
205,736,096 205,881,733 9902G06 D1S1218i
205,736,096 205,881,733 0117H06 D1S1351i
205,736,096 205,881,733 0109A04 D1S2796
205,992,025 206,035,481 0105E03 D1S2685
206,116,942 206,151,370 0102C01 D1S0571i
206,116,942 206,151,370 0103G08 D1S2692
206,116,942 206,151,370 702B02 DID22N_0002526
207,854,838 207,892,443 0115F02 D1S0017i
207,854,838 207,892,443 0110F10 D1S0116i
207,854,838 207,892,443 0102F11 D1S471
208,025,659 208,046,102 0110C10 D1S0097i
209,566,580 209,614,911 0111A06 D1S0578i
209,566,580 209,614,911 0103A08 D1S2810
210,805,374 210,860,742 0115H07 D1S0456i
210,805,374 210,860,742 0113E12 D1S0556i
212,597,474 212,791,265 0103G05 D1S237
212,597,474 212,791,265 0119F01 D1S419
212,843,155 212,904,537 0117D12 D1S1134i
214,743,211 215,377,720 0111H04 D1S0478i
214,743,211 215,377,720 0112G04 D1S0944i
214,743,211 215,377,720 0101C08 D1S0967i
214,743,211 215,377,720 0112H06 D1S1047i
214,743,211 215,377,720 0112B07 D1S1053i
214,743,211 215,377,720 0109D04 D1S227
214,743,211 215,377,720 0118E09 Z66862
216,586,200 216,684,584 0103C08 D1S1390i
219,119,366 219,125,022 0113A01 D1S1593i
219,119,366 219,125,022 0105D06 D1S2641
219,941,389 219,982,141 0113F03 D1S0557i
219,941,389 219,982,141 0102C04 D1S2894
219,941,389 219,982,141 0113H10 HUMUT7354
22,021,324 22,136,377 0110E04 D1S1431i
22,318,177 22,342,197 0113F09 D1S0170i
22,835,705 22,838,762 333G05 AC025929.3_119355
22,835,705 22,838,762 0106C12 D1S0006i
22,835,705 22,838,762 0108H06 D1S1655i
22,910,045 23,114,405 0101B02 D1S2698
221,350,270 221,383,247 0110G01 D1S1361i
224,064,459 224,099,884 0101H06 D1S0569i
224,064,459 224,099,884 T001F03 D1S1230i
224,615,015 224,662,414 0107G03 D1S1644
224,615,015 224,662,414 0109C06 Z66645
224,886,014 224,993,647 0114C01 D1S0570i
224,886,014 224,993,647 0115B12 D1S1143i
226,711,303 226,712,197 0106G10 D1S1344i
227,633,615 227,636,468 0114D06 D1S1211i
227,633,615 227,636,468 0119D12 D1S1334i
233,890,964 234,113,563 336E08 AL390765.5_154842
233,890,964 234,113,563 0107H05 D1S0103i
233,890,964 234,113,563 0115H09 D1S0509i
233,890,964 234,113,563 0119A03 D1S235
234,205,753 234,303,706 0114H05 D1S0980i
234,205,753 234,303,706 0114D11 D1S1209i
234,624,303 234,714,649 0111H05 D1S0566i
234,624,303 234,714,649 9902H04 D1S1680
234,624,303 234,714,649 0109E04 D1S2850
234,916,422 234,994,554 0115H01 D1S1049i
24,318,848 24,342,198 0119E08 D1S1285i
24,318,848 24,342,198 0115F11 D1S1707i
24,318,848 24,342,198 0103C07 D1S1709i
240,078,105 240,119,864 0102F02 D1S0204i
241,718,158 242,080,053 0115F07 D1S0973i
241,718,158 242,080,053 0112E11 D1S1215i
241,718,158 242,080,053 0109C12 D1S1335i
241,718,158 242,080,053 0104E04 D1S1609
241,718,158 242,080,053 T002B01 D1S2811
245,647,974 245,679,033 0104B09 D1S0507i
245,647,974 245,679,033 0112F05 D1S0976i
25,098,596 25,164,062 0115D07 D1S0052i
25,098,596 25,164,062 0114E04 D1S0760i
25,471,568 25,529,523 0110B04 D1S1424i
25,561,327 25,629,270 0110C04 D1S1428i
26,158,845 26,197,235 0115H10 D1S0613i
26,158,845 26,197,235 0110F04 D1S1432i
26,516,998 26,519,601 0110A05 D1S1438i
27,089,567 27,099,549 0110E03 D1S1403i
27,110,566 27,113,047 002C08 D1S455
27,297,893 27,366,059 0101D08 D1S0325i
27,297,893 27,366,059 689G11 DISD22_0011961
27,811,162 27,834,375 0118E04 D1S0278i
27,811,162 27,834,375 002F08 D1S2639
28,346,264 28,392,971 0106D12 D1S1260i
28,346,264 28,392,971 0108C11 D1S1443i
29,435,611 29,525,899 0101D01 D1S0753i
29,435,611 29,525,899 0108C06 D1S1237i
3,763,705 3,791,853 0116H01 D1S0321i
31,114,901 31,166,301 0101D10 D1S513
31,114,901 31,166,301 095G12 HUMUT2521
31,610,687 31,618,510 0111H08 D1S0754i
31,610,687 31,618,510 0102B09 D1S1575i
32,144,609 32,176,578 0101G03 D1S0339i
32,144,609 32,176,578 0113B11 D1S0608i
32,252,017 32,299,037 0114F03 D1S0768i
32,489,480 32,524,353 0101H07 D1S0612i
32,489,480 32,524,353 0105E06 HUMUT7543
32,530,274 32,571,823 0218A07 D2S1413i
36,704,231 36,721,466 0210C02 D2S0082i
36,704,231 36,721,466 0218F01 D2S0144i
37,805,004 37,834,109 T002C12 D2S177
39,977,117 40,002,173 0210F02 D2S0106i
39,977,117 40,002,173 0203E12 D2S2238
40,133,685 40,140,274 0216G09 D2S0011i
40,929,829 41,009,864 0219H10 D2S1747i
40,929,829 41,009,864 0220B07 D2S1830i
41,217,951 41,250,815 091G10 HUMUT862
41,265,461 41,480,375 0203F12 D2S1229i
41,265,461 41,480,375 0213G06 D2S1251i
42,414,797 42,574,135 0216C06 D2S0976i
42,414,797 42,574,135 0205H06 D2S2306
42,896,635 42,915,016 338B07 AC013396.4_29951
43,055,363 43,083,247 0209F05 D2S1577i
43,055,363 43,083,247 0207F07 D2S1580i
43,576,062 43,592,722 0212B08 D2S0968i
43,597,213 43,601,461 0104F08 D1S0068i
43,769,134 43,861,924 0215D02 D2S0447i
43,769,134 43,861,924 0202C02 D2S2294
44,171,579 44,175,499 555F11 chr2.fa.O7frz.45953438
45,038,623 45,049,479 0204G12 D2S2174
46,278,399 46,371,054 0213H06 D2S1252i
47,037,305 47,057,672 0210D11 D2S0428i
47,037,305 47,057,672 716E12 DIJ28_10008354
47,261,827 47,289,010 0207C11 D2S1748i
47,454,550 47,469,974 0212C08 D2S0969i
47,454,550 47,469,974 0205A07 D2S1669i
47,654,331 47,656,311 0209H05 D2S1591i
47,674,276 47,678,950 0212G08 D2S0975i
50,677,738 51,198,524 170A08 AC007560.3_79097
50,677,738 51,198,524 0202C12 D2S0009i
50,677,738 51,198,524 0221B12 D2S0056i
50,677,738 51,198,524 0217F12 D2S0100i
50,677,738 51,198,524 0205G02 D2S0978i
50,677,738 51,198,524 0208A02 D2S2316
56,732,527 56,817,845 0206H06 D2S0079i
56,732,527 56,817,845 0219B03 D2S1406i
56,732,527 56,817,845 0213E11 D2S1414i
56,883,583 56,953,596 0207G01 D2S0021i
57,093,065 57,156,482 0221A09 D2S378
59,019,048 59,022,587 0210B02 D2S0081i
6,443,798 6,502,708 0102E07 D1S1391i
6,443,798 6,502,708 0105A07 D1S1448i
60,131,568 60,165,050 0116F10 D1S0367i
63,561,300 63,563,385 0104B01 HUMUT6372
65,071,500 65,204,775 334G11 AC025866.2_14272
65,071,500 65,204,775 266E11 AL354878.8_58838
65,071,500 65,204,775 0101G02 D1S0640i
65,658,858 65,879,830 0114C05 D1S0737i
65,658,858 65,879,830 0104B05 D1S1384i
65,658,858 65,879,830 T002E10 D1S2866
66,030,781 66,612,850 0116H10 D1S0390i
66,030,781 66,612,850 0114C04 D1S0713i
66,030,781 66,612,850 0105E05 D1S0716i
66,030,781 66,612,850 0102B02 D1S0721i
66,030,781 66,612,850 0105H11 D1S1484i
67,404,671 67,498,250 0116E06 D1S0407i
67,404,671 67,498,250 0106E05 D1S1158i
67,545,635 67,635,171 0107D10 D1S2806
7,902,494 7,923,513 0105G07 D1S0016i
7,902,494 7,923,513 0107A08 D1S0027i
71,090,624 71,286,079 159F03 AL031429.11_5207
71,090,624 71,286,079 0118D07 D1S0071i
71,090,624 71,286,079 0118A05 D1S0119i
71,090,624 71,286,079 0117G05 D1S0801i
78,542,156 78,778,974 0111F10 D1S0802i
78,542,156 78,778,974 0107G09 D1S0812i
78,542,156 78,778,974 T002H10 D1S2876
78,888,104 78,902,351 0113H01 D1S0408i
78,888,104 78,902,351 0116G11 D1S0412i
79,128,037 79,279,105 0111F11 D1S0818i
79,128,037 79,279,105 0116F02 D1S1196i
84,316,329 84,476,769 0111H11 D1S0824i
84,316,329 84,476,769 0117E02 D1S1301i
85,504,519 85,516,359 0114A07 D1S0428i
85,504,519 85,516,359 0111G10 D1S0803i
85,556,756 85,703,415 0117H04 D1S0035i
85,556,756 85,703,415 0103D05 D1S1676i
89,091,203 89,129,889 0108D07 D1S1380i
89,244,948 89,261,132 0116B12 D1S0421i
89,344,403 89,414,311 0109B07 D1S0391i
89,498,853 89,511,119 9902D01 D1S2004i
9,634,390 9,711,564 0104B07 D1S1626i
91,918,488 92,144,147 0119H02 D1S0406i
91,918,488 92,144,147 0112E10 D1S1185i
91,918,488 92,144,147 0106C07 D1S1314i
938,666 939,783 0105A06 D1S1425i
94,123,349 94,147,600 0105A03 D1S0252i
94,767,369 94,779,944 268F03 AL390314.6_23296
101,899,841 101,979,366 486G01 chr10.fa.O7frz.109393646
101,899,841 101,979,366 1010A07 D10S0301i
103,103,810 103,307,068 1006F10 D10S0600i
103,103,810 103,307,068 T001B11 D10S0605i
103,103,810 103,307,068 1010E04 HUMUT7406
103,519,877 103,525,817 1004D10 D10S0764i
104,144,320 104,152,271 1008D06 D10S0888i
104,525,996 104,566,011 1003B12 D10S1692
104,580,278 104,587,280 1002B10 D10S0155i
11,087,290 11,418,680 353D02 AC026887.4_12044
11,087,290 11,418,680 1002C02 D10S0127i
11,087,290 11,418,680 1008H04 D10S0169i
11,087,290 11,418,680 1011A02 D10S0698i
11,087,290 11,418,680 1007A03 D10S0709i
11,087,290 11,418,680 1001H05 D10S0715i
112,247,586 112,261,292 1009H06 D10S0682i
112,317,439 112,354,384 1009D11 D10S0516i
112,317,439 112,354,384 1005B04 G08785
115,428,925 115,480,654 1011F10 D10S0796i
12,211,642 12,251,966 1004F04 D10S0375i
12,211,642 12,251,966 1001B11 Z67393
121,400,872 121,427,321 212G07 AF134471.1_33637
121,400,872 121,427,321 1002F08 D10S0120i
122,473,377 123,347,962 320B08 AC009989.8_114829
122,473,377 123,347,962 591G08 chr10.fa.O7frz.132530934
122,473,377 123,347,962 578H05 chr10.fa.O7frz.133333262
122,473,377 123,347,962 1008F09 D10S0252i
122,473,377 123,347,962 1008B05 D10S0255i
122,473,377 123,347,962 1010A12 D10S0307i
122,473,377 123,347,962 1003D07 D10S0503i
122,473,377 123,347,962 1006D08 D10S0539i
122,473,377 123,347,962 1006H10 D10S0613i
122,473,377 123,347,962 1010D12 D10S0650i
122,473,377 123,347,962 1007D06 D10S0756i
122,473,377 123,347,962 1004E10 D10S0881i
122,473,377 123,347,962 1011E05 D10S0910i
124,310,171 124,393,242 1009F08 D10S0089i
124,310,171 124,393,242 1003A09 D10S0523i
124,903,783 124,914,876 1009E10 D10S0580i
124,903,783 124,914,876 1007G01 D10S0858i
127,445,012 127,454,380 1006B10 D10S0584i
127,514,896 127,575,017 1003E10 D10S0860i
127,690,940 128,067,055 1003F02 D10S0696i
127,690,940 128,067,055 1011C09 D10S0854i
127,690,940 128,067,055 1007G08 D10S0856i
127,690,940 128,067,055 1007B08 D10S0861i
129,425,504 129,429,440 T002F01 D10S217
129,595,315 129,774,155 1001D09 D10S0236i
129,595,315 129,774,155 1001F08 D10S0593i
131,155,456 131,455,358 1006H07 D10S0530i
131,155,456 131,455,358 1006A08 D10S0532i
131,155,456 131,455,358 1007C09 D10S0766i
133,631,181 133,645,450 1003E12 D10S0871i
134,925,898 134,940,362 1003E03 D10S0907i
135,190,857 135,224,714 1007F12 D10S0157i
14,979,364 15,036,437 1006H01 D10S0376i
14,979,364 15,036,437 1002G08 D10S0893i
15,595,954 15,802,130 1010D05 D10S0667i
15,595,954 15,802,130 1010G12 D10S0672i
15,595,954 15,802,130 1003A05 D10S0959i
15,595,954 15,802,130 1003D06 D10S1653
16,595,748 16,604,010 1002C12 D10S1477
16,595,748 16,604,010 1003H05 D10S674
17,311,283 17,319,598 1007A12 HUMUT463
17,891,368 17,993,184 1009E12 D10S0346i
18,138,358 18,240,097 1002A09 D10S0961i
22,650,146 22,660,194 1003A03 D10S0938i
26,767,138 26,896,738 1008G11 D10S0179i
26,767,138 26,896,738 1009C01 D10S0280i
26,767,138 26,896,738 1005H03 G10204
30,762,872 30,790,768 1006F09 D10S0570i
30,762,872 30,790,768 1011G06 D10S1674
31,647,430 31,858,748 212G02 AC005877.3_160520
31,647,430 31,858,748 212D08 AF225898.1_164426
31,647,430 31,858,748 146F11 AF225898.1_167611
31,647,430 31,858,748 1004G06 D10S0182i
31,647,430 31,858,748 1011D07 D10S208
31,647,430 31,858,748 1011F03 D10S565
33,229,326 33,287,204 318C04 AL133333.9_189168
33,229,326 33,287,204 1009C11 D10S0668i
33,506,426 33,665,196 1011D05 D10S0035i
33,506,426 33,665,196 1005E06 D10S0071i
35,455,807 35,541,892 1008G09 D10S0201i
35,455,807 35,541,892 1008A12 D10S0420i
35,455,807 35,541,892 1001B08 HUMUT5962
44,185,611 44,200,548 1003D03 D10S0927i
45,189,635 45,261,571 483G05 chr10.fa.O7frz.44957867
45,189,635 45,261,571 1008B11 D10S0203i
48,926,216 49,033,022 1004C01 D10S0911i
49,184,739 49,317,409 419G02 chr10.fa.O7frz.48816071
49,184,739 49,317,409 1008D07 D10S0556i
54,195,146 54,201,466 1005A12 D10S0330i
59,764,745 59,800,515 1002E01 D10S0909i
59,764,745 59,800,515 1005F03 Z67552
6,034,340 6,060,156 1006C09 D10S0559i
6,092,658 6,144,294 1009A11 D10S0177i
6,509,111 6,662,269 1010B12 D10S0063i
6,509,111 6,662,269 1011E11 D10S0096i
6,509,111 6,662,269 1002C04 D10S0951i
61,458,165 61,819,494 1006F04 D10S0460i
61,458,165 61,819,494 1006E08 D10S0549i
61,458,165 61,819,494 1001E08 D10S0892i
61,458,165 61,819,494 1007F01 D10S0919i
61,458,165 61,819,494 1002E12 D10S0971i
62,205,690 62,224,616 1006D11 D10S0627i
64,241,762 64,246,133 1007B11 D10S0087i
64,241,762 64,246,133 1006D01 D10S0351i
70,331,040 70,376,609 1002E02 D10S1678
70,517,834 70,534,573 578A01 chr10.fa.O7frz.73903894
72,027,110 72,032,521 1003G12 D10S537
74,866,192 74,925,765 1010D11 D10S0186i
74,866,192 74,925,765 1007E01 D10S0781i
75,340,896 75,347,261 603A10 chr10.fa.O7frz.79381928
75,580,971 76,139,067 1005C12 D10S0335i
75,580,971 76,139,067 1005G12 D10S0345i
75,580,971 76,139,067 1009D08 D10S0356i
75,580,971 76,139,067 1006G03 D10S0445i
75,580,971 76,139,067 1010C09 D10S0637i
75,580,971 76,139,067 1006G12 D10S0660i
76,524,196 76,538,976 1005B12 D10S0332i
79,220,557 79,356,384 1001B04 D10S0603i
79,220,557 79,356,384 1009C06 D10S0648i
8,136,662 8,157,170 1009C03 D10S0158i
8,136,662 8,157,170 9905E11 D10S0380i
80,777,226 80,785,096 1001B03 D10S0304i
80,777,226 80,785,096 1002D08 D10S201
81,687,476 81,698,841 9905F11 D10S0459i
83,624,786 84,736,913 1003F08 D10S0039i
83,624,786 84,736,913 1001F05 D10S0072i
83,624,786 84,736,913 1005B07 D10S0097i
83,624,786 84,736,913 1007B10 D10S0109i
83,624,786 84,736,913 1005D09 D10S0218i
83,624,786 84,736,913 1007H11 D10S0239i
83,624,786 84,736,913 1008C01 D10S0467i
83,624,786 84,736,913 1006F05 D10S0475i
83,624,786 84,736,913 1003C09 D10S0487i
83,624,786 84,736,913 1006E11 D10S0629i
83,624,786 84,736,913 1007E06 D10S0731i
83,624,786 84,736,913 1004E01 D10S0750i
83,624,786 84,736,913 1001E11 D10S0960i
83,624,786 84,736,913 1001E09 D10S1786
88,506,376 88,674,925 1008C12 D10S0585i
89,612,850 89,721,667 1001C07 D10S1765
89,612,850 89,721,667 1005D03 Z67254
90,739,206 90,765,522 1001F09 D10S1739
90,963,306 91,164,294 1008E02 D10S0221i
90,963,306 91,164,294 1006D06 D10S0485i
90,963,306 91,164,294 9906A02 D10S0771i
94,811,011 94,818,444 1010H09 D10S0671i
96,433,368 96,485,937 1005E04 HUMUT925
96512371 96603007 CYP2C191 new design
96512371 96603007 CYP2C192 new design
96688418 96739137 CYP2C9 new design
96,786,519 96,819,244 1006B06 D10S0481i
97,461,526 97,619,442 1003D10 D10S0154i
97,461,526 97,619,442 1001D06 D10S0899i
97,461,526 97,619,442 1011A08 D10S0953i
97,941,445 98,021,316 1005C10 D10S0254i
98,054,075 98,088,311 1001D03 D10S0939i
98,054,075 98,088,311 1002H01 D10S0946i
1,730,558 1,741,798 1108B01 D11S0457i
1,730,558 1,741,798 1111E09 D11S0827i
1,830,776 1,870,069 1101A06 D11S0967i
10,283,172 10,285,499 399D09 AC018539.4_114043
100,414,313 100,506,465 1106G10 D11S0557i
100,414,313 100,506,465 1104H02 D11S0935i
101,693,404 101,713,675 1109G04 D11S0870i
101,896,449 101,906,688 1110G10 HUMUT1283
101,952,776 102,001,273 1110B12 D11S4108
102,067,625 102,081,678 1105B12 D11S0258i
102,146,444 102,156,569 1105E12 D11S0269i
102,211,738 102,219,552 1104G07 Z66956
102,318,934 102,331,672 1109H10 D11S0391i
102,318,934 102,331,672 1102G06 D11S0599i
104,261,876 104,274,607 1106H10 D11S0558i
104,318,804 104,345,373 1105D02 D11S1886
104,370,180 104,384,909 1107A05 D11S0774i
104,513,879 104,515,663 1107F02 D11S0764i
104,513,879 104,515,663 1109B11 HUMUT2064
106,878,664 106,941,637 1102C11 D11S0559i
106,878,664 106,941,637 1103C02 D11S0944i
107,598,769 107,745,036 1108F07 D11S0615i
107,598,769 107,745,036 1109G09 D11S0619i
107,598,769 107,745,036 1111E02 D11S0622i
107,598,769 107,745,036 9906E05 D11S0848i
108,041,014 108,316,866 1109C07 D11S0404i
108,041,014 108,316,866 1102A06 D11S0409i
108,041,014 108,316,866 1104A09 D11S0952i
109,605,376 109,672,647 1103G06 D11S0285i
109,605,376 109,672,647 037E05 D11S927
110,728,190 110,755,627 1108A07 D11S0278i
110,728,190 110,755,627 1106C02 D11S0312i
111,519,186 111,540,050 1107B01 D11S0018i
111,519,186 111,540,050 1101D05 D11S0894i
112,337,368 112,653,781 1106B10 D11S0541i
112,337,368 112,653,781 1105G02 D11S3179
112,337,368 112,653,781 1105B03 Z67379
114,550,227 114,880,325 1108E09 D11S0537i
114,550,227 114,880,325 1109H05 D11S0542i
114,550,227 114,880,325 T001D11 D11S0568i
114,550,227 114,880,325 1110C08 D11S1885
114,550,227 114,880,325 684E12 DISD22_0006557
114,550,227 114,880,325 1102D05 Z67490
117,362,319 117,377,404 1104H05 D11S1356
117,362,319 117,377,404 111D09 U73649.1_16072
117,680,662 117,692,100 403B09 AC068591.2_86017
117,710,475 117,718,669 403A09 AP001582.3_115137
118,125,623 118,167,082 1108G11 D11S0300i
118,125,623 118,167,082 1110B06 D11S4104
118,259,777 118,272,181 704C08 DID22N_0040945
118,259,777 118,272,181 745B10 DIJ28_10013816
118,684,444 118,693,050 1109C12 D11S0315i
119,014,018 119,104,645 1101D10 D11S0560i
119,014,018 119,104,645 1107B04 D11S0857i
119,616,256 119,695,863 1108B06 D11S0563i
119,616,256 119,695,863 1111B03 D11S0632i
119,616,256 119,695,863 1103H02 Z67522
120,828,130 121,005,621 1107A01 D11S0765i
120,828,130 121,005,621 1107F05 D11S0778i
125,279,550 125,298,215 1106E03 D11S0341i
125,279,550 125,298,215 1108F01 D11S0427i
125,658,192 125,672,683 1106D11 D11S0573i
125,658,192 125,672,683 037H11 D11S934
13,470,177 13,474,143 1102A12 D11S926
133,290,395 133,327,321 1109A10 D11S0418i
133,290,395 133,327,321 1103E01 D11S968
133,290,395 133,327,321 1101H11 Z67178
133,444,030 133,526,861 1107C03 D11S0779i
133,444,030 133,526,861 1104G11 D11S4125
133,753,608 133,787,022 1104B12 D11S0676i
14,856,131 14,870,327 1111E01 D11S0104i
17,067,861 17,147,864 1111C04 D11S0661i
17,067,861 17,147,864 1103F07 D11S4160
18,090,596 18,094,695 1109E03 D11S0687i
18,223,365 18,226,758 1109G08 D11S0663i
18,223,365 18,226,758 1111G09 D11S0834i
18,300,719 18,345,153 1107F07 D11S0840i
18,682,435 18,704,353 1106D07 D11S0451i
18,706,051 18,769,965 740D01 DIJ28_10032405
2,106,918 2,125,616 1102D03 D11S0973i
2,355,096 2,375,225 1106A07 D11S0445i
2,355,096 2,375,225 1105B01 D11S1318
2,861,019 2,863,577 085D12 HUMUT6724B
20,365,679 20,487,404 1105C06 D11S0094i
20,365,679 20,487,404 1110B10 D11S4190
22,646,230 22,791,123 1107C08 D11S0353i
22,646,230 22,791,123 1106C04 D11S0356i
22,646,230 22,791,123 1101E12 D11S0363i
268,570 275,304 1108H05 D11S0006i
268,570 275,304 1101A04 D11S0978i
27,633,016 27,699,872 1111D01 D11S0077i
27,633,016 27,699,872 1110C05 D11S0144i
3,622,937 3,642,222 1104D09 D11S0838i
33,681,132 33,714,600 1107C12 D11S0166i
33,681,132 33,714,600 1111A02 D11S0460i
34,417,054 34,450,183 1111C07 D11S0739i
35,116,993 35,210,525 1105A04 D11S0012i
35,116,993 35,210,525 1105C04 D11S0020i
35,116,993 35,210,525 1105H07 D11S0139i
36,467,299 36,488,398 T003H08 D11S4083
36,546,139 36,557,877 1101E02 G10015
395716 407397 SIGIRR1 new design
395716 407397 SIGIRR2 new design
4,745,076 4,970,235 1105E06 D11S0102i
4,745,076 4,970,235 1108E08 D11S0105i
4,745,076 4,970,235 1108H06 D11S0582i
4,745,076 4,970,235 1103D12 D11S4181
43,290,109 43,322,655 1110C11 D11S0722i
43,858,971 43,898,392 591F11 chr11.fa.O7frz.46072222
44,543,717 44,597,915 1109F02 D11S0504i
44,543,717 44,597,915 1109A08 D11S0639i
45,863,778 45,884,592 1107D05 D11S0728i
45,863,778 45,884,592 1102G01 D11S0737i
46,697,331 46,717,631 1110C07 D11S0817i
46,697,331 46,717,631 1102B06 D11S0970i
47,227,083 47,246,972 1106D04 D11S0359i
47,227,083 47,246,972 1102B01 D11S0692i
47,543,464 47,562,690 400B11 AC067943.4_5205
47,543,464 47,562,690 1108A08 D11S0366i
47,567,792 47,580,516 1108F02 D11S0492i
47,958,689 48,146,246 1103F12 D11S1350
47,958,689 48,146,246 1101A10 D11S1784
5,203,270 5,212,454 1105A05 D11S0069i
5,203,270 5,212,454 1111C09 D11S0819i
5,667,495 5,688,669 487E06 chr11.fa.O7frz.5327809
5,667,495 5,688,669 1108A02 D11S0447i
5,667,495 5,688,669 1110D01 D11S0453i
56,757,630 56,761,489 1105A09 D11S0182i
56,862,525 56,894,125 1102A01 D11S0694i
56,910,832 56,914,706 1101E03 Z67514
57,075,705 57,092,333 T002G05 D11S0635i
57,121,603 57,138,902 1101E05 D11S0598i
57,121,603 57,138,902 1101B09 D11S1777
59,580,677 59,595,164 1108C05 D11S0872i
59,953,638 59,971,841 1104D05 D11S0690i
6,581,540 6,588,677 399A08 AC009796.4_61451
6,581,540 6,588,677 420H03 chr11.fa.O7frz.6316475
6,581,540 6,588,677 1109A02 D11S0577i
60,374,983 60,380,020 1111C12 D11S0927i
60,626,543 60,651,900 1109F05 D11S0506i
61,039,361 61,104,874 1102A08 D11S0075i
61,039,361 61,104,874 1110F06 D11S4076
61,316,726 61,321,286 1109H08 D11S0685i
62,316,219 62,329,529 1102G04 D11S0785i
62,380,094 62,412,929 1107F03 D11S0703i
63,030,132 63,040,815 1101E08 D11S0702i
63,758,646 63,762,835 1109G02 D11S0640i
63,764,989 63,768,262 1111D08 D11S0787i
63,829,616 63,840,786 1109E08 D11S0644i
64,250,959 64,269,504 1106F05 D11S0405i
64,458,519 64,459,936 563E04 chr11.fa.O7frz.68864733
64,458,519 64,459,936 682B03 DISO7_10017975
64,786,006 64,821,664 1108G05 D11S0645i
65,062,850 65,082,275 1101H05 D11S0388i
65,062,850 65,082,275 1102B05 HUMUT2269
65,177,649 65,186,959 1105A10 D11S0200i
65,378,858 65,383,462 401H03 AP001191.2_77147
65,378,858 65,383,462 1105D10 D11S0204i
65,838,534 65,841,091 1108G01 D11S0393i
65,990,974 66,001,382 1102F04 D11S0887i
66,070,967 66,087,373 1108B05 D11S0406i
66,087,511 66,092,623 1110F05 D11S0818i
66,580,897 66,596,060 1109D02 D11S0389i
66,580,897 66,596,060 1101G01 Z67088
66,888,215 66,897,782 1109H09 D11S0190i
66,888,215 66,897,782 1103A04 D11S0920i
67,007,097 67,015,150 1102A02 D11S1889
67,107,862 67,110,701 1103D10 D11S4155
67,515,151 67,528,169 1101C11 D11S0681i
67,563,059 67,574,942 1108G07 D11S0871i
67,836,674 67,973,317 1111G01 D11S0205i
67,836,674 67,973,317 1107B11 D11S0212i
67,836,674 67,973,317 1104A01 D11S1337
67,836,674 67,973,317 1110F11 D11S4178
67,836,674 67,973,317 1104C06 HUMUT5620
69,165,054 69,178,423 1111D06 D11S0717i
69,296,978 69,299,352 036B08 D11S4136
69,726,917 69,731,144 1105H03 HUMUT6360
7,016,373 7,049,333 1111D09 D11S0823i
7,016,373 7,049,333 1111F09 D11S0828i
7,937,547 7,941,780 1108C06 D11S0883i
7,937,547 7,941,780 726C10 DIJ28_10040944
71,221,894 71,226,256 1106D12 D11S0610i
71,387,587 71,394,409 1102E10 D11S0651i
72,606,992 72,625,045 1108F06 D11S0491i
72,606,992 72,625,045 1107A03 D11S0720i
72,606,992 72,625,045 1107G02 D11S0725i
72,765,053 72,786,167 1101D03 D11S0691i
73,023,592 73,051,512 1104C05 D11S916
73,981,277 74,031,413 1103A08 D11S0588i
74,654,130 74,740,521 1111D04 D11S0667i
74,654,130 74,740,521 1102E06 D11S0964i
75,203,923 75,531,342 1108B09 D11S0641i
75,203,923 75,531,342 1102D06 D11S0893i
75,203,923 75,531,342 1108F12 D11S0929i
75,203,923 75,531,342 1104A11 D11S1321
75,738,652 75,769,528 1104E06 D11S0174i
75,738,652 75,769,528 1109A07 D11S0515i
76,710,708 76,862,581 401D09 AP000486.4_115712
76,710,708 76,862,581 1103A07 D11S4186
77,603,990 77,806,414 1109G10 D11S0522i
77,603,990 77,806,414 1102F03 D11S0961i
77,603,990 77,806,414 1103B10 D11S937
822952 828835 CD151 new design
86,334,369 86,344,081 1109A06 D11S0221i
86,334,369 86,344,081 1111C11 D11S0903i
88,550,268 88,668,474 1108H03 D11S0254i
88,550,268 88,668,474 1101G07 D11S0260i
88,550,268 88,668,474 1106G09 D11S0529i
88,699,160 88,864,301 1105E10 D11S0223i
93,790,114 93,866,688 1101A11 D11S0226i
93,790,114 93,866,688 1106H09 D11S0532i
10,015,281 10,029,461 1205C11 D12S0288i
10,015,281 10,029,461 1203D03 D12S1674
10,113,421 10,142,872 1203F09 D12S1690
10,202,167 10,216,004 1211E02 D12S1696
10,202,167 10,216,004 1203C08 D12S77
10,351,684 10,359,983 1204B09 D12S0390i
10,456,181 10,464,461 1209H09 D12S0218i
10,633,039 10,643,431 1203F08 D12S0095i
10,742,955 10,767,171 1209C08 D12S0140i
101,313,806 101,398,471 1205C05 D12S0036i
101,313,806 101,398,471 1205F05 D12S0043i
101,875,594 101,878,421 1204A12 D12S0533i
101,875,594 101,878,421 9907E01 D12S0929i
102,505,181 102,684,635 357C05 AC063946.10_124699
102,505,181 102,684,635 9906B10 D12S0841i
102,505,181 102,684,635 1207B03 D12S0848i
102,505,181 102,684,635 9906H05 D12S360
102,505,181 102,684,635 1211B02 D12S865
102,848,290 102,865,833 099H02 HUMUT835B
103,034,988 103,056,170 565G02 chr12.fa.O7frz.111997282
103,034,988 103,056,170 1210G04 D12S338
103,204,857 103,268,192 1209H03 D12S0467i
105,501,163 105,680,711 1209B08 D12S0093i
105,501,163 105,680,711 1201C12 D12S0574i
105,501,163 105,680,711 1202G05 D12S330
107,208,800 107,257,218 1202A05 D12S1605
107,539,800 107,551,799 1204B04 D12S84
108,010,379 108,015,660 223A08 AC007637.9_40136
108,010,379 108,015,660 668F08 chr12.fa.O7frz.117355013
108,200,167 108,231,408 1210H01 D12S0004i
108,200,167 108,231,408 1210C05 D12S0070i
109,424,388 109,454,274 1204A03 D12S0030i
109,424,388 109,454,274 1210H05 D12S0174i
11,694,055 11,939,603 1204B01 D12S0024i
11,694,055 11,939,603 1205C09 D12S0172i
11,694,055 11,939,603 T003B10 D12S89
11,694,055 11,939,603 1202E01 D12S98
111,340,919 111,432,100 1207F10 D12S0747i
111,340,919 111,432,100 1208A06 HUMUT5428
111,829,122 111,854,374 040C04 D12S1340
111,980,045 112,020,216 1205G11 D12S0309i
111,980,045 112,020,216 1201F08 D12S0483i
115,783,410 115,803,615 1207E05 D12S0781i
115,783,410 115,803,615 1207D06 D12S0882i
116,135,362 116,283,965 1208H09 D12S0177i
116,135,362 116,283,965 9906H11 D12S0749i
116,135,362 116,283,965 9906A12 D12S0761i
118,100,978 118,116,934 1202A06 D12S0756i
118,100,978 118,116,934 658E07 DISO7_10003646
119,942,478 119,961,164 1211G05 D12S0076i
119,942,478 119,961,164 1201B03 D12S0573i
12,115,145 12,255,214 1209E11 D12S0050i
12,115,145 12,255,214 1205C10 D12S0217i
12,164,953 12,311,013 1204H10 D12S391
12,520,098 12,606,584 1208E12 D12S0041i
12,520,098 12,606,584 1203A07 D12S0983i
12,520,098 12,606,584 T003F09 D12S358
12,770,130 12,874,182 1204A02 D12S0120i
120,055,061 120,108,259 357F09 AC069209.16_27083
120,055,061 120,108,259 1209D12 D12S0011i
121,222,530 121,224,699 1206G02 D12S0378i
121,321,934 121,473,069 9906H08 D12S0382i
121,321,934 121,473,069 9906B09 D12S0550i
121,765,256 121,767,297 9906G09 D12S0767i
122,652,625 122,671,435 1210A09 D12S0307i
122,684,333 122,711,573 1210F12 D12S0606i
123,374,914 123,568,793 357B10 AC027706.2_46645
123,374,914 123,568,793 1209H07 D12S0808i
123,374,914 123,568,793 T001A02 D12S0811i
123,374,914 123,568,793 1201A12 D12S1611
123,374,914 123,568,793 040A07 D12S1612
123,828,129 123,914,346 1207B12 D12S0751i
123,828,129 123,914,346 1207E08 D12S0884i
123,997,325 124,039,620 1210C12 D12S0768i
128,063,805 128,067,640 1210D07 D12S0785i
129,212,957 129,216,238 1206C10 D12S0576i
129,212,957 129,216,238 1201G12 D12S0921i
129,922,521 129,927,316 1204D08 D12S0818i
131,705,476 131,709,045 1204D01 D12S357
14,873,512 14,887,680 1205A07 D12S0089i
14,873,512 14,887,680 1209F12 D12S0130i
14,986,217 15,005,870 1204C01 D12S0105i
14,986,217 15,005,870 1206H03 D12S0399i
15,366,754 15,641,602 1206B04 D12S0404i
15,366,754 15,641,602 1201E10 D12S0948i
15,366,754 15,641,602 1201E07 D12S0974i
15,366,754 15,641,602 1205E03 G08975
18,305,741 18,692,617 1206D03 D12S0392i
18,305,741 18,692,617 1204H11 D12S0629i
18,305,741 18,692,617 1207H10 D12S0849i
18,305,741 18,692,617 1207B08 D12S0855i
18,305,741 18,692,617 1210G07 D12S0859i
2,774,414 2,783,385 1205C08 D12S0129i
2,774,414 2,783,385 1201E09 D12S0132i
25,249,447 25,295,121 1204C10 D12S0103i
25,249,447 25,295,121 1203H11 D12S0922i
26,377,193 26,877,398 1205E12 D12S0325i
26,377,193 26,877,398 1206E01 D12S0354i
26,377,193 26,877,398 1204A10 D12S0523i
26,377,193 26,877,398 1207D04 D12S0648i
26,377,193 26,877,398 9906C11 D12S0658i
26,377,193 26,877,398 1202C05 D12S0667i
26,377,193 26,877,398 1207B05 D12S0671i
26,377,193 26,877,398 1207C10 D12S0679i
28,002,284 28,016,183 221B11 AC008011.11_31766
28,002,284 28,016,183 1203D06 D12S0923i
28,002,284 28,016,183 1211D01 HUMUT7594
29,381,556 29,425,410 1205E06 D12S0069i
29,381,556 29,425,410 1208B03 D12S0215i
3,470,686 3,573,400 1205C07 D12S0096i
3,470,686 3,573,400 1201D03 D12S1050
3,470,686 3,573,400 1201G01 D12S1062
31,118,061 31,148,992 1201C09 D12S0047i
31,118,061 31,148,992 1204C07 D12S0417i
4,253,199 4,284,777 1203A10 D12S1725
4,413,569 4,425,041 1205G09 D12S0185i
4,569,505 4,593,302 1205H07 D12S0117i
4,569,505 4,593,302 1201F07 D12S0191i
42,439,047 42,468,166 1206E10 D12S0580i
42,439,047 42,468,166 1205H01 D12S1663
44,601,459 44,670,615 1209B03 D12S0225i
44,601,459 44,670,615 1209E05 D12S0296i
46,462,772 46,499,924 1205H06 D12S0086i
46,462,772 46,499,924 1207E06 D12S0661i
47,509,806 47,532,224 1202B05 D12S0593i
47,509,806 47,532,224 1209H01 D12S0596i
47,658,503 47,662,746 9906C09 D12S0577i
47,769,471 47,774,869 1208B05 D12S0578i
47,864,847 47,869,153 432G04 chr12.fa.O7frz.51899683
48,012,467 48,017,238 1203G08 D12S1627
48,238,352 48,248,178 1206A01 D12S0333i
49,444,128 49,500,328 9906E06 D12S1135i
49,444,128 49,500,328 9906F06 D12S1137i
49,444,128 49,500,328 9906G07 D12S1214i
5,928,301 6,104,097 1210A05 D12S0009i
5,928,301 6,104,097 1205A10 D12S0199i
5,928,301 6,104,097 1203E01 D12S0939i
5,928,301 6,104,097 1203A02 D12S0966i
5,928,301 6,104,097 1201H05 D12S374
50,008,494 50,026,730 1202H07 D12S0865i
51,167,231 51,173,289 1210D01 G08922
51,577,238 51,585,127 1211E09 D12S0653i
51,577,238 51,585,127 9906C10 D12S0877i
51,871,374 51,887,267 1208F05 D12S0430i
51,890,621 51,912,253 1201B11 D12S0890i
52,060,246 52,096,497 1201F06 D12S0662i
52,060,246 52,096,497 1202B09 D12S1604
52,653,177 52,656,470 9906D06 D12S1131i
52,972,162 52,981,058 1207H01 D12S0426i
52,972,162 52,981,058 1206F10 D12S0589i
53,075,312 53,099,317 1209A02 D12S0248i
53,324,642 53,328,416 1208E08 D12S0431i
53,324,642 53,328,416 1201A03 D12S0609i
54,364,619 54,387,949 1201G05 D12S0801i
54,364,619 54,387,949 1201G02 D12S0950i
54,611,213 54,634,074 1202E02 D12S0802i
54,634,156 54,646,765 1203B02 D12S0585i
55,018,926 55,020,461 9906H09 D12S0797i
55,392,484 55,407,248 1206B06 D12S0449i
55,392,484 55,407,248 1206E11 D12S0605i
55,769,157 55,775,526 221D12 AF067572.1_2832
55909819 55914981 SHMT21 new design
55909819 55914981 SHMT22 new design
56,114,810 56,130,876 1203D11 D12S0982i
56,135,363 56,138,058 1206F06 D12S0455i
56,428,270 56,432,431 1206C11 D12S0601i
56,499,977 56,527,014 685G06 DISD22_0008338
6,179,134 6,217,688 1201F02 D12S0385i
6,308,184 6,321,522 1206B03 D12S0389i
6,308,184 6,321,522 1206D12 D12S0635i
6,363,595 6,370,994 1208A07 D12S0917i
6,513,872 6,517,797 1208B01 D12S0831i
6,513,872 6,517,797 1204A11 D12S0969i
6,768,912 6,800,237 1211C05 D12S0170i
6,819,636 6,826,819 1210B12 D12S0824i
64,869,270 64,928,684 322G08 AC025603.1_117614
64,869,270 64,928,684 1208F08 D12S0456i
66,329,021 66,340,410 1207A03 D12S0187i
66,329,021 66,340,410 1204A04 D12S335
66,834,816 66,839,790 224F06 AC007458.13_25451
66,834,816 66,839,790 1205C04 D12S0002i
66,834,816 66,839,790 1205D08 D12S0133i
66,834,816 66,839,790 IFNG new design
66,928,292 66,933,651 1206D06 D12S0451i
67,488,247 67,520,481 1209F05 D12S0544i
67,488,247 67,520,481 1207G01 D12S0857i
69,201,231 69,317,469 1202G03 D12S1043
69,201,231 69,317,469 1203C06 D12S1722
69,318,129 69,600,853 1202B12 D12S0294i
69,318,129 69,600,853 1206H01 D12S0362i
7,138,291 7,153,069 1209G04 D12S0826i
7,773,278 7,793,336 1211E11 D12S0142i
7,773,278 7,793,336 1208A10 D12S0886i
78,509,876 78,608,921 1209H08 D12S0453i
79,318,597 79,598,099 1209C10 D12S0339i
79,318,597 79,598,099 1210F10 D12S0520i
79,318,597 79,598,099 1202D01 D12S0955i
8,076,626 8,099,385 1205E08 D12S0148i
8,076,626 8,099,385 069E07 D12S397
8,167,493 8,182,470 1207D08 D12S0842i
8,557,403 8,566,229 1206E12 D12S0636i
8,866,484 8,920,646 1210A07 D12S0638i
87,410,697 87,498,369 1210D08 D12S0267i
87,410,697 87,498,369 1209A03 D12S0907i
88,265,968 88,270,427 097F07 HUMUT2007B
88,265,968 88,270,427 1202F02 Z67021
9,033,484 9,054,610 T003E09 D12S1695
9,460,894 9,492,092 1211E10 D12S0023i
9,460,894 9,492,092 1210G05 D12S0158i
9,460,894 9,492,092 1210A06 D12S0195i
9,638,415 9,651,764 1204G07 HUMUT1833
9,871,344 9,888,871 1204E02 Z67367
90,063,166 90,100,937 1205F04 D12S0012i
90,063,166 90,100,937 1205F03 G09612
91,061,030 91,063,751 1201D11 D12S0261i
91,693,257 91,847,138 1211B11 D12S0820i
91,693,257 91,847,138 1207D10 D12S0847i
92,326,219 92,360,157 1209H05 D12S0484i
92,487,729 92,494,109 1211C10 D12S0116i
92,487,729 92,494,109 1209B11 D12S0810i
92,595,282 92,768,663 1204D10 D12S0064i
92,595,282 92,768,663 1209E12 D12S0127i
92,595,282 92,768,663 1206A09 D12S0529i
92,595,282 92,768,663 T003F10 D12S1346
93,066,630 93,223,356 453H02 chr12.fa.O7frz.100507297
93,066,630 93,223,356 1210G02 D12S0464i
93,066,630 93,223,356 1210C04 D12S327
93,939,802 93,991,487 565D01 chr12.fa.O7frz.101640988
94,918,742 94,953,496 1207F08 D12S0853i
94,918,742 94,953,496 1211F04 D12S309
97,433,527 97,468,250 1208G05 D12S0255i
97,433,527 97,468,250 1205B02 D12S1706
97,563,209 97,653,342 220B04 AC011248.8_84442
97,563,209 97,653,342 1203C05 D12S0074i
97,563,209 97,653,342 1208B09 D12S0258i
99,391,810 99,481,774 219F07 AC010200.7_102437
99,391,810 99,481,774 224A12 AC010200.7_92076
99,391,810 99,481,774 1205D06 D12S0063i
99,391,810 99,481,774 1208E02 D12S0068i
100,902,857 101,169,146 1304H06 D13S0112i
100,902,857 101,169,146 1303F09 D13S0608i
100,902,857 101,169,146 1305F12 D13S0611i
100,902,857 101,169,146 1303B08 D13S0614i
101,169,308 101,852,156 1302G09 D13S0657i
101,169,308 101,852,156 1301B09 D13S0665i
101,169,308 101,852,156 1301C04 D13S0672i
101,169,308 101,852,156 1308D04 D13S1266
101,169,308 101,852,156 1304G02 D13S1323
101,169,308 101,852,156 1302F04 D13S174
101,169,308 101,852,156 1301G02 G10095
102,295,195 102,326,346 1308A03 D13S0024i
107,657,791 107,668,717 1305B01 D13S0342i
107,719,978 107,758,826 1305H04 D13S0419i
109,599,311 109,757,505 1307E09 D13S0634i
109,599,311 109,757,505 1301B05 Z66602
109,757,632 109,963,375 1307E03 D13S0204i
112,999,557 113,025,746 1306A08 D13S0145i
20,175,479 20,195,237 1301B12 D13S0638i
20,612,650 20,621,221 1306B02 D13S0585i
20,612,650 20,621,221 1301F12 HUMUT6291
21,143,170 21,176,637 1304F05 D13S0077i
21,143,170 21,176,637 1307H07 D13S0129i
23,042,723 23,148,232 1303H10 D13S0522i
23,042,723 23,148,232 1302A04 D13S0692i
23,042,723 23,148,232 040E10 D13S292
25,726,276 25,877,375 1306F09 D13S0173i
25,726,276 25,877,375 1306G08 D13S0358i
25,726,276 25,877,375 1305F08 D13S0507i
26,029,840 26,161,085 1306B12 D13S0366i
26,896,681 26,907,823 1303D03 D13S0372i
26,896,681 26,907,823 1306B10 D13S0475i
27,434,273 27,441,317 1301B07 D13S0079i
27,475,411 27,572,729 1304C10 D13S0242i
27,475,411 27,572,729 1305F07 D13S0482i
27,773,790 27,967,232 1305A05 D13S0420i
27,773,790 27,967,232 1301G07 D13S0655i
27,773,790 27,967,232 1303H06 D13S1242
29,930,884 30,089,729 1306E09 D13S0095i
29,930,884 30,089,729 1306G03 D13S0126i
29,930,884 30,089,729 1303B09 D13S1246
29,930,884 30,089,729 1302A02 D13S289
30,207,645 30,236,556 1304C01 D13S1238
31,787,617 31,871,809 1306H07 D13S0458i
35,904,495 35,915,008 1305A09 D13S0518i
36,291,339 36,301,740 1302G03 D13S0368i
40,027,801 40,138,734 1304B06 D13S0090i
40,027,801 40,138,734 1301A08 D13S1233
42,034,872 42,080,148 1304E10 D13S0244i
42,034,872 42,080,148 041B03 D13S1297
44,592,650 44,756,237 565H08 chr13.fa.O7frz.44272759
44,592,650 44,756,237 1308B06 D13S0229i
44,592,650 44,756,237 1307B08 D13S0455i
44,809,008 44,813,505 1308H03 D13S1312
46,305,514 46,368,179 325E05 AL136958.7_37916
46,305,514 46,368,179 1307F09 D13S0134i
47,883,170 47,887,947 9907B02 D13S0042i
47,883,170 47,887,947 1304H10 D13S0260i
48,178,692 48,181,499 1304E01 D13S1307
52,175,400 52,211,948 1303A10 D13S0047i
94,470,084 94,751,688 1304A12 D13S0303i
94,470,084 94,751,688 1303H02 D13S0506i
94,470,084 94,751,688 1307D06 D13S0635i
94,470,084 94,751,688 1301F04 HUMUT7403
98,744,790 98,757,708 1301D09 D13S0582i
98,744,790 98,757,708 1308B03 D13S1271
101,617,139 101,675,776 1401H06 D14S0309i
101,762,375 101,841,284 1405H03 D14S0453i
102,313,569 102,442,381 1406B04 D14S0349i
102,313,569 102,442,381 1401F08 D14S272
103,092,642 103,098,907 1405C03 D14S0472i
103,233,707 103,251,549 1402C11 D14S0512i
104,290,529 104,297,036 1405F06 D14S0488i
104,586,782 104,602,799 1405H10 D14S0024i
105,428,094 105,428,110 147E07 AB019441.1_31065
105,428,094 105,428,110 1406F10 D14S0475i
19,849,367 19,871,297 1401G07 D14S0500i
19,849,367 19,871,297 732G03 DIJ28_10035246
20,319,050 20,320,464 1406B07 D14S0499i
20,580,251 20,582,226 1403F01 D14S1070
21,159,897 22,090,915 1404D01 D14S0121i
21,159,897 22,090,915 9907E08 D14S0463i
21,159,897 22,090,915 1405E05 D14S0467i
21,159,897 22,090,915 1405E03 D14S0514i
21,159,897 22,090,915 1402B07 D14S0532i
21,159,897 22,090,915 1402F02 D14S0552i
21,159,897 22,090,915 1401D04 D14S1003
21,159,897 22,090,915 1401F11 D14S283
21,159,897 22,090,915 1403B06 G10057
22,375,633 22,386,643 1405B01 D14S0528i
22,375,633 22,386,643 1407E05 HUMUT1079
22,459,573 22,468,501 1402H02 Z67550
22,656,355 22,658,665 1401G11 D14S990
22,845,866 22,850,798 1401B08 D14S0468i
22,911,858 22,915,452 9907F08 D14S0470i
23,661,207 23,678,016 1403B01 D14S64
23,748,627 23,755,020 1401H02 D14S0173i
23,907,094 23,918,650 1405G11 D14S0313i
24,112,564 24,115,306 1404D04 D14S0177i
24170000 24173313 GZMB1 new design
24170000 24173313 GZMB2 new design
28,304,801 28,308,621 1402A12 D14S1042
28,304,801 28,308,621 1401H05 Z66624
29,115,436 29,466,651 9907D08 D14S0440i
29,115,436 29,466,651 1401C02 D14S0448i
29,115,436 29,466,651 1401F12 D14S0451i
29,115,436 29,466,651 1401C08 D14S0516i
29,115,436 29,466,651 1407C01 D14S252
34,249,398 34,253,649 1406B06 D14S0213i
34,249,398 34,253,649 1402D02 HUMUT7222
34,940,468 34,943,703 1406G02 D14S0190i
34,940,468 34,943,703 1406D09 D14S0321i
37,128,940 37,134,240 1406D12 D14S0144i
37,128,940 37,134,240 1406B05 D14S0148i
37,746,955 37,752,019 1407A10 D14S0138i
37,746,955 37,752,019 1406C06 D14S0329i
44,654,859 44,674,272 1405B12 D14S0136i
49,135,165 49,151,140 1402F09 Z67256
49,954,993 50,069,126 1407B06 D14S0158i
49,954,993 50,069,126 1407C06 D14S0162i
50,776,686 50,792,512 9907G08 D14S0490i
51,804,181 51,813,192 1406E10 D14S0323i
51,850,863 51,865,074 1406F08 D14S0160i
52,243,668 52,264,466 1404A11 D14S0331i
53,486,207 53,493,362 1404A06 D14S0217i
53,486,207 53,493,362 1401G05 Z67708
53,933,423 53,956,682 1405G10 D14S0230i
54,563,594 54,585,960 1401C10 D14S0548i
55,654,846 55,837,784 1401C01 D14S0112i
55,654,846 55,837,784 1407E10 D14S0342i
55,654,846 55,837,784 1403A03 D14S1056
55,654,846 55,837,784 1403D02 D14S1064
60,858,186 61,087,451 1404C03 D14S0154i
60,858,186 61,087,451 1404E03 D14S0159i
60,858,186 61,087,451 1404E11 D14S0339i
60,858,186 61,087,451 1405E04 D14S0375i
62,849,395 62,854,316 1404G07 D14S0262i
62,849,395 62,854,316 T003B12 D14S1012
63,621,388 63,875,070 1406F12 D14S0503i
63,621,388 63,875,070 1406A03 D14S0506i
63,621,388 63,875,070 T003C12 D14S63
64,475,625 64,479,284 1407E07 D14S0257i
68,410,793 68,515,747 1406E09 D14S0360i
68,410,793 68,515,747 1403B05 Z66914
70,264,605 70,345,641 1407E09 D14S0263i
70,264,605 70,345,641 1407F02 D14S1002
74,815,284 74,818,685 043D07 D14S76
75,058,537 75,083,086 1402F08 D14S0014i
75,058,537 75,083,086 1405C11 D14S0082i
75,494,195 75,517,242 1403B09 D14S0033i
75,494,195 75,517,242 1407G05 D14S0050i
75,907,479 76,036,961 1406E06 D14S0356i
75,907,479 76,036,961 1407C11 D14S0376i
75,907,479 76,036,961 1401A09 D14S0515i
77,208,502 77,244,109 1405E06 D14S594
77,208,502 77,244,109 1403C07 HUMUT1235
80,491,528 80,682,399 1403F10 D14S0071i
80,491,528 80,682,399 1407G07 D14S0275i
80,716,147 80,757,328 1403A09 D14S0031i
87,469,111 87,529,660 1407D03 D14S0045i
87,469,111 87,529,660 1404H09 D14S0301i
88,003,867 88,090,876 1402H11 D14S0272i
88,003,867 88,090,876 1403C05 Z67182
88,692,274 88,953,127 1403D09 D14S0036i
88,692,274 88,953,127 1402C02 D14S0070i
88,692,274 88,953,127 1401A07 D14S0418i
88,692,274 88,953,127 1401D12 D14S0422i
90,768,629 90,789,977 1406B03 D14S0428i
90,768,629 90,789,977 1406F03 D14S0539i
92,239,907 92,284,765 1406D05 D14S0407i
92,239,907 92,284,765 1405D06 D14S0447i
92,718,294 92,721,002 1405F07 D14S0483i
93,587,019 93,617,311 1401D01 D14S0287i
93,587,019 93,617,311 1401E03 D14S0398i
93,900,404 93,914,178 1404B10 D14S0304i
93,900,404 93,914,178 1407B05 D14S0534i
95,740,950 95,780,542 1402G03 D14S0345i
95,740,950 95,780,542 1401F04 D14S0555i
99,220,407 99,263,391 1406C05 D14S0355i
99,220,407 99,263,391 9907H08 D14S0491i
99,774,855 99,814,557 1401B01 D14S0521i
99,774,855 99,814,557 1401B12 Z67128
22,619,887 23,215,702 1503D06 D15S0006i
22,619,887 23,215,702 1505B09 D15S0228i
22,619,887 23,215,702 1505C09 D15S0230i
22,619,887 23,215,702 1506E01 D15S122
22,619,887 23,215,702 1502G05 D15S128
31,945,720 32,118,595 1505D04 D15S0304i
31,945,720 32,118,595 1504E03 D15S0477i
31,945,720 32,118,595 1503A02 D15S1040
32,869,723 32,875,181 1504G07 D15S0246i
32,869,723 32,875,181 1504D04 D15S0470i
36,567,590 36,644,224 1501C10 D15S0487i
37,660,572 37,676,960 1504F10 D15S0084i
37,660,572 37,676,960 1501A07 D15S0247i
38,366,448 38,387,330 1501G07 D15S994
38774661 38811646 RAD51 new design
39,008,839 39,018,529 1503F08 D15S0093i
39,008,839 39,018,529 1505G10 D15S0265i
39,412,361 39,460,538 1505G11 D15S0289i
39,739,902 39,849,433 1505D09 D15S0231i
39,739,902 39,849,433 1506D12 D15S0236i
41,612,949 41,769,525 1504D10 D15S0232i
41,612,949 41,769,525 1505A07 D15S0354i
41825882 41852096 PDIA3 new design
42,790,977 42,797,649 1504A03 D15S0312i
42,790,977 42,797,649 1505E01 D15S0315i
47,502,751 47,566,815 1504C10 D15S0253i
47,502,751 47,566,815 1506D07 D15S0259i
48,321,436 48,345,218 1505A02 D15S0115i
49,288,961 49,418,086 1506H07 D15S0139i
49,288,961 49,418,086 1504E04 D15S0447i
50,098,739 50,145,754 1503H01 D15S982
50,189,114 50,192,264 1505E12 D15S0302i
54,998,125 55,368,008 463E02 chr15.fa.O7frz.53612467
54,998,125 55,368,008 1503C12 D15S0180i
54,998,125 55,368,008 1506H10 D15S0446i
54,998,125 55,368,008 1503B05 D15S648
54,998,125 55,368,008 9907G10 Z67030
56,675,802 56,829,469 1505C10 D15S0255i
56,675,802 56,829,469 1501F02 D15S148
57,184,612 57,204,536 1504C12 D15S0027i
57,718,358 57,736,991 1506D09 D15S0393i
58,084,427 58,085,434 1506G06 D15S0158i
58,084,427 58,085,434 1503F05 HUMUT1232
58,426,642 58,477,477 1506A11 D15S0479i
58,576,755 59,308,794 1502G07 D15S0042i
58,576,755 59,308,794 1502G11 D15S0154i
58,576,755 59,308,794 1503A12 D15S0176i
58,576,755 59,308,794 1505E09 D15S0234i
58,576,755 59,308,794 1506G12 D15S0240i
58,576,755 59,308,794 1506D03 D15S970
58,576,755 59,308,794 104G09 Z67427
61,986,288 62,125,574 1503A05 D15S644
61,986,288 62,125,574 1502H06 D15S993
61,986,288 62,125,574 738A07 DIJ28_10022026
62,235,067 62,242,407 1506B09 D15S0227i
62,995,046 63,038,086 1501D07 D15S0013i
62,995,046 63,038,086 1506D01 D15S1009
63,196,770 63,213,227 1501B07 D15S0182i
64,466,674 64,570,936 1505C01 D15S0168i
64,466,674 64,570,936 1505F02 D15S0177i
64,466,674 64,570,936 1506H08 HUMUT5980
65,145,249 65,274,587 1502G12 D15S0156i
65,145,249 65,274,587 1502B06 D15S988
65,622,075 65,886,506 1506H04 D15S0269i
65,622,075 65,886,506 1503A03 D15S1015
65,622,075 65,886,506 1503D04 Z66922
66,381,096 66,511,546 1504G09 D15S0187i
66,381,096 66,511,546 1504G02 D15S0386i
66,381,096 66,511,546 1502A11 D15S0455i
67,532,177 67,534,939 1502E12 D15S0371i
68,127,597 68,177,310 1502D03 D15S650
68,127,597 68,177,310 T003G12 D15S977
69,889,948 69,897,654 1506B05 D15S0033i
69,889,948 69,897,654 T001B03 D15S0327i
70,364,122 70,455,868 1505B08 D15S0282i
71,639,410 71,712,806 1506A07 D15S0423i
71,763,675 71,793,912 1504B10 HUMUT744
72,417,157 72,447,134 T001C05 D15S0332i
72,417,157 72,447,134 1506A10 Z67571
72,798,943 72,804,930 1505C11 D15S0280i
72,798,943 72,804,930 1504H04 D15S0392i
73,546,515 73,658,680 1502A01 D15S0481i
74,020,333 74,091,842 1506C10 D15S0104i
74,020,333 74,091,842 1504A07 D15S0352i
75,074,609 75,116,727 328H08 AC051643.2_53971
75,074,609 75,116,727 1502H10 D15S0350i
77,001,162 77,024,475 1505D11 D15S0281i
77,001,162 77,024,475 1506F04 D15S1023
78,040,290 78,050,698 1503B04 D15S1005
79,262,148 79,392,157 1503G12 D15S0200i
79,262,148 79,392,157 1504C11 D15S0207i
79,262,148 79,392,157 1502E08 D15S1041
83,578,821 84,093,590 464A06 chr15.fa.O7frz.83916193
83,578,821 84,093,590 1506A06 D15S0272i
83,578,821 84,093,590 045A06 D15S972
83,578,821 84,093,590 1501A02 D15S999
83,578,821 84,093,590 100B03 HUMUT1211
83,578,821 84,093,590 1502D07 Z66702
86,983,039 87,000,684 9907F09 D15S0049i
86,983,039 87,000,684 1501G08 D15S0506i
88,129,130 88,159,072 9907G11 D15S0329i
88,129,130 88,159,072 1506A04 HUMUT644B
89,061,606 89,159,688 1505F08 D15S0202i
89,061,606 89,159,688 9907G09 D15S0273i
89,061,606 89,159,688 1503H03 D15S127
89,212,889 89,227,691 9907F12 D15S0399i
94,674,950 94,683,048 1501H01 D15S0106i
94,674,950 94,683,048 9907A10 D15S0306i
97,010,288 97,319,034 1504D09 D15S0215i
97,010,288 97,319,034 1501H03 D15S0433i
97,010,288 97,319,034 1502D10 D15S120
97,010,288 97,319,034 1502C03 Z67468
1,696,222 1,760,319 1603B11 D16S0217i
1,968,919 1,971,441 1606F08 D16S0494i
10,867,648 10,926,341 046B02 D16S414
10,867,648 10,926,341 1606C03 D16S497
11,255,775 11,257,540 1603H09 D16S0155i
11,255,775 11,257,540 1606D07 HUMUT1334
11,549,357 11,588,823 1602G01 D16S0316i
11,549,357 11,588,823 1604C04 D16S0512i
11966465 11969426 TNFRSF171 new design
11966465 11969426 TNFRSF172 new design
15,704,493 15,858,388 1603D05 D16S0011i
15,704,493 15,858,388 9908F03 D16S0032i
15,704,493 15,858,388 1602G02 D16S3060
15,950,935 16,143,774 1604C07 D16S0180i
162,875 163,708 1601F11 D16S0102i
2,145,800 2,168,131 1601E07 D16S0452i
21,559,426 21,571,473 1604A11 D16S0160i
21,559,426 21,571,473 1603H10 D16S0179i
23,597,692 23,609,189 1606G10 D16S0444i
23,597,692 23,609,189 1603B03 D16S417
23,754,823 24,139,358 9908B02 D16S0020i
23,754,823 24,139,358 1603E10 D16S0169i
23,754,823 24,139,358 1604D11 D16S0178i
23,754,823 24,139,358 1601C11 D16S0558i
23,754,823 24,139,358 1605D03 D16S0560i
23,754,823 24,139,358 1602H04 D16S420
27,232,752 27,283,600 1605C07 D16S0091i
27,232,752 27,283,600 1601H07 D16S0519i
27,379,436 27,468,775 1601D08 D16S0048i
277,441 342,465 682C07 DISO7_12395103
28,418,184 28,425,656 663D02 chr16.fa.O7frz.38545966
28,418,184 28,425,656 1604C11 D16S0112i
29,581,801 29,589,688 1606F12 D16S0531i
29,731,591 29,766,842 1603B06 D16S0030i
3,010,343 3,012,385 1605B07 D16S0007i
3,010,343 3,012,385 1603F01 D16S3082
3,232,029 3,246,628 1603F06 D16S0040i
3,232,029 3,246,628 1604E08 D16S0211i
3,531,826 3,567,290 1605C12 D16S0002i
3,531,826 3,567,290 1602C08 D16S0103i
3,630,847 3,654,064 1606B08 D16S0120i
3,716,568 3,870,723 1605C11 D16S0023i
3,716,568 3,870,723 1603C08 D16S0101i
3,716,568 3,870,723 1601B06 D16S3065
30,362,453 30,364,725 1602E07 D16S0552i
30,391,551 30,442,007 1606G11 D16S0462i
30,815,429 30,822,382 1601F05 D16S0562i
31178789 31251714 ITGAM1 new design
31178789 31251714 ITGAM2 new design
31,274,010 31,301,819 1604F03 D16S0471i
4,466,426 4,500,349 1604E12 D16S0328i
45,746,798 46,052,519 1604B01 D16S0508i
45,746,798 46,052,519 1602G12 D16S0517i
45,746,798 46,052,519 1602G07 D16S3044
46,758,323 46,838,806 9908A08 D16S0425i
46,758,323 46,838,806 1601H10 D16S0427i
49,288,551 49,324,488 1604G06 D16S0350i
49,288,551 49,324,488 1601F09 D16S3035
52082693 52094671 AKTIP1 new design
52082693 52094671 AKTIP2 new design
54,070,589 54,098,104 493H04 chr16.fa.O7frz.65771871
54,070,589 54,098,104 9908A06 D16S0335i
54,394,264 54,424,576 1603A11 D16S0198i
55,180,768 55,182,501 9908H04 D16S0287i
55,180,768 55,182,501 1603D02 D16S3071
55,581,018 55,673,941 1606A04 D16S0356i
55,581,018 55,673,941 1605E10 D16S0377i
55,581,018 55,673,941 1601A06 D16S0380i
55,950,219 55,957,602 1605F06 D16S0364i
55,996,180 56,007,475 1601B10 D16S0158i
56,616,783 56,638,306 9908E04 D16S0281i
56,616,783 56,638,306 1601H11 HUMUT5103
64,958,064 64,996,190 1602C06 D16S0343i
64,958,064 64,996,190 1601G10 D16S0541i
65,143,967 65,170,463 1604E11 D16S0353i
65,620,551 65,692,462 1601B03 D16S0422i
65,620,551 65,692,462 1606E07 Z66903
65,745,605 65,751,306 1606H11 D16S0424i
65,765,371 65,767,127 1606D01 D16S421
66,525,908 66,528,254 1602F03 D16S0298i
66,525,908 66,528,254 1601D12 D16S0386i
66,676,845 66,818,338 1604A04 D16S0313i
66,902,446 66,948,663 T001E06 D16S0381i
67,018 75,845 1601C05 D16S521
67,328,696 67,426,945 1604C06 D16S0412i
68,156,498 68,296,054 1605A07 D16S0344i
68,156,498 68,296,054 1604E06 D16S0556i
68,890,573 68,925,232 1604C12 D16S0246i
70,685,116 70,704,312 1603D07 D16S0079i
70,685,116 70,704,312 047H01 D16S3106
71,378,456 71,639,775 1603C06 D16S0034i
71,378,456 71,639,775 1603E06 D16S0039i
71,378,456 71,639,775 1603D08 D16S0105i
71,378,456 71,639,775 1602H03 D16S0113i
71,378,456 71,639,775 1603A10 D16S0159i
71,378,456 71,639,775 9908B05 D16S0299i
73,885,109 74,024,888 9908D06 D16S0339i
73,885,109 74,024,888 1606E10 D16S0362i
73,885,109 74,024,888 1604H01 D16S0544i
76,613,992 76,623,499 1606E06 D16S518
78,185,732 78,192,112 9908G06 D16S0375i
78,185,732 78,192,112 1603B01 D16S3040
84,268,781 84,280,089 1601H09 D16S0565i
84,490,275 84,513,713 1601G09 D16S0414i
84,490,275 84,513,713 1601A01 D16S0487i
85,101,659 85,105,548 1601A02 D16S0526i
85,101,659 85,105,548 1606F05 D16S520
86,421,130 86,460,615 1602C05 D16S0554i
86,421,130 86,460,615 1602E01 D16S413
87,232,502 87,234,383 9908F02 D16S0251i
88,512,527 88,529,713 1604B08 D16S0252i
1,483,902 1,495,792 1706D12 D17S0145i
1,483,902 1,495,792 1702B07 D17S0440i
1,909,888 2,220,160 1701G08 D17S0205i
1,909,888 2,220,160 1704E11 D17S0208i
1,909,888 2,220,160 1703D10 D17S0211i
1,909,888 2,220,160 1702A12 D17S0496i
10,365,192 10,393,704 1705D12 D17S0038i
10,365,192 10,393,704 1706D04 D17S1852
11,864,860 11,987,865 1702E05 D17S0111i
15,616,046 15,629,130 1702E04 D17S0372i
15,616,046 15,629,130 1704F01 D17S0374i
15,875,983 16,059,570 1701G03 D17S0001i
15,875,983 16,059,570 1701F01 D17S1843
16,259,613 16,281,042 1701B01 D17S1857
16,783,123 16,816,127 1704E03 D17S0425i
17,655,794 17,681,050 1702D07 D17S0428i
17,932,008 17,952,017 1704F03 D17S0430i
17,932,008 17,952,017 1701B12 D17S0525i
18,028,014 18,053,993 1705G04 D17S0483i
18,516,347 18,516,964 9909F02 D17S0459i
19,221,659 19,227,445 1705F09 D17S0433i
2,443,686 2,535,638 1704A09 D17S0041i
2,443,686 2,535,638 1704E12 D17S0360i
2,443,686 2,535,638 1705E04 D17S0484i
21,128,581 21,159,118 1705F03 D17S0154i
22,980,951 23,000,711 1704C03 D17S0441i
23,107,919 23,151,682 1704E09 D17S0024i
23,107,919 23,151,682 1704C05 D17S0472i
23,718,425 23,721,844 9909C02 D17S0404i
23,875,086 23,889,302 1702H03 D17S0401i
24,424,663 24,531,556 1702D06 D17S0402i
24,424,663 24,531,556 9908E09 D17S0406i
24,424,663 24,531,556 1706B05 D17S0522i
24,424,663 24,531,556 1706H05 D17S841
25,549,032 25,586,831 1705B01 D17S0153i
25,549,032 25,586,831 1701E04 Z67368
26,133,828 26,175,826 1705G05 D17S0196i
26,133,828 26,175,826 1702A05 D17S0465i
29,606,409 29,608,335 1706H06 D17S1293
29,707,584 29,709,742 1706B04 D17S0493i
29,711,512 29,714,365 331G12 AC011193.2_31574
3,415,491 3,459,454 1701B06 D17S0309i
3,415,491 3,459,454 1701D09 D17S829
3,486,522 3,511,585 1701G07 D17S0090i
3,564,671 3,660,578 1701B04 D17S1298
3,746,634 3,766,709 1701E06 D17S1828
31,116,989 31,146,753 1701E01 D17S1833
31,222,611 31,231,490 1703A07 D17S0086i
31,811,186 31,816,297 1702F11 D17S0438i
32,516,040 32,841,015 1705A03 D17S0107i
32,516,040 32,841,015 1706D09 D17S0265i
32,516,040 32,841,015 1704D11 D17S0272i
32,924,064 32,947,709 1701B02 D17S0124i
33,046,526 33,077,600 1703E07 D17S0095i
35,097,919 35,138,441 1703B07 D17S0089i
35,097,919 35,138,441 1705D02 D17S0260i
35,425,214 35,427,592 303B05 AC007776.1_62510
35,472,589 35,503,646 303C05 AC007776.1_75537
35,502,567 35,510,499 9908H11 D17S0330i
35,502,567 35,510,499 1706D11 D17S0452i
35,718,972 35,767,420 1706E09 D17S0280i
35,798,321 35,827,695 1704G10 D17S0273i
35,963,547 35,975,250 1706D08 D17S0285i
35,963,547 35,975,250 1703E04 HUMUT186
36,787,447 36,792,181 1703A08 D17S0108i
36,886,467 36,891,194 1705D08 D17S0053i
36,886,467 36,891,194 1702F02 D17S0530i
37,222,727 37,232,995 1706B11 D17S0368i
37,222,727 37,232,995 1706B01 HUMUT8182
37,506,952 37,518,277 1703E12 D17S0266i
37,506,952 37,518,277 1702F01 HUMUT8184
37,604,721 37,681,950 1706C05 D17S0161i
37,604,721 37,681,950 048G02 D17S1801
37,604,721 37,681,950 1706G10 D17S1802
38,084,961 38,087,371 1701C11 D17S0521i
38,238,949 38,249,303 1702C05 G10143
38,916,860 38,957,206 1704H09 D17S0170i
38,916,860 38,957,206 1706G11 D17S0426i
38,916,860 38,957,206 092E08 HUMUT573
39,199,015 39,211,872 1705G11 D17S0007i
39,199,015 39,211,872 1706G03 D17S0173i
39,199,015 39,211,872 1702F06 D17S951
39,509,647 39,556,540 1703A09 D17S0134i
39,509,647 39,556,540 1706B10 D17S0320i
39,682,566 39,700,993 1702A11 D17S1860
39,805,076 39,822,399 1703D08 D17S0122i
4,480,963 4,491,709 1705A01 D17S0238i
4,560,533 4,571,544 1701A02 D17S0350i
4,646,397 4,648,756 607C09 chr17.fa.O7frz.5865115
4,683,351 4,742,135 331A03 AC015913.4_60812
4,776,372 4,779,067 571C11 chr17.fa.O7frz.5607732
4,789,692 4,793,067 1704H04 D17S0432i
40,392,587 40,401,170 1701G01 D17S0506i
40,392,587 40,401,170 738D08 DIJ28_10035753
40,696,278 40,750,148 1704C09 D17S0025i
40,696,278 40,750,148 1705C11 D17S0142i
40,696,278 40,750,148 1702D05 D17S950
41,217,449 41,268,973 9908C10 D17S0253i
41,217,449 41,268,973 1703F12 D17S0267i
41,217,449 41,268,973 1701E10 D17S0480i
42,196,855 42,251,081 9908C12 D17S0339i
42,196,855 42,251,081 1702C12 D17S791
42,196,855 42,251,081 1703D02 D17S920
42,686,207 42,745,076 332C05 AC064817.4_80427
42,686,207 42,745,076 1706A03 D17S0092i
42,686,207 42,745,076 9909B01 D17S0373i
43,165,609 43,178,484 1703E08 D17S0123i
43,165,609 43,178,484 1702D10 D17S0527i
43,165,609 43,178,484 1706F12 D17S806
43,480,720 43,493,841 1705D09 D17S0281i
43,565,804 43,862,551 9908F10 D17S0286i
43,565,804 43,862,551 1704G07 D17S0453i
43,565,804 43,862,551 1703B02 D17S958
44,007,868 44,010,742 1704D01 D17S1827
44,927,654 44,947,360 1702G03 D17S797
45,422,368 45,427,587 1705F05 D17S0188i
45,616,456 45,633,992 1703B09 D17S0135i
45,616,456 45,633,992 1704B09 D17S0358i
46,585,919 46,604,103 1705B02 D17S0004i
5,276,823 5,283,195 1704H11 D17S0113i
5,284,956 5,312,905 1701B10 D17S0224i
5,343,472 5,428,553 1702E08 D17S0517i
50,697,370 50,755,886 1706C06 D17S0021i
50,697,370 50,755,886 1704C06 D17S1799
52,320,269 52,346,408 1702E06 D17S0105i
52,320,269 52,346,408 1703A10 D17S0168i
53,625,088 53,636,783 1702F09 D17S0193i
53702201 53713295 MPO1 new design
53702201 53713295 MPO2 new design
54,997,668 55,040,484 9908B12 D17S0336i
54,997,668 55,040,484 9909G01 D17S0391i
58,058,494 58,124,629 1702C03 D17S1835
58,058,494 58,124,629 1701H10 D17S794
58,058,494 58,124,629 1701A07 D17S808
58,908,166 58,952,935 1705A06 D17S0349i
59,205,299 59,250,409 1704G02 D17S0271i
59,348,294 59,349,930 1705D06 D17S0278i
59,754,142 59,817,723 1704D06 D17S0439i
59,926,200 59,932,872 1706F11 D17S0390i
6,840,108 6,856,220 1705A02 D17S0158i
6,918,580 6,924,324 465E03 chr17.fa.O7frz.7725213
60,437,295 60,483,216 1702B05 D17S1792
60,437,295 60,483,216 1703A03 D17S1825
60,955,143 60,988,227 1701D12 D17S0486i
60,955,143 60,988,227 1702G04 D17S0519i
61,729,388 62,237,324 150E09 AC006263.1_34791
61,729,388 62,237,324 1704E08 D17S0011i
61,729,388 62,237,324 1703G06 D17S0075i
61,729,388 62,237,324 1704C07 D17S0454i
61,729,388 62,237,324 1703B04 D17S1291
61,729,388 62,237,324 048C10 D17S1816
61,729,388 62,237,324 1701E03 D17S942
64,922,433 65,051,067 1705G09 D17S0337i
64,922,433 65,051,067 1701A09 D17S1786
68,672,755 68,679,689 467B04 chr17.fa.O7frz.78835314
68,672,755 68,679,689 9908E12 D17S0343i
68,672,755 68,679,689 1706D05 D17S0399i
69,974,117 69,992,528 1704F10 D17S0297i
69,974,117 69,992,528 9908F12 D17S0345i
7,156,702 7,173,362 1701H07 D17S0478i
7,283,413 7,288,980 1704A01 D17S0479i
7,392,932 7,405,649 1701C05 Z67321
7,393,099 7,405,649 1704C12 D17S0018i
7,883,083 7,893,177 1706F05 D17S0446i
70,048,842 70,053,877 1706E01 HUMUT7429
70,087,099 70,100,017 1703B05 HUMUT1523
70,202,047 70,220,712 1702D04 D17S0394i
70,780,669 70,797,109 1702F07 D17S0356i
70,780,669 70,797,109 1705H03 D17S0383i
71,229,111 71,265,494 1706F07 D17S1839
71,644,009 71,648,966 303G08 AC015801.21_117665
71,644,009 71,648,966 303H08 AC015801.21_98885
71,892,297 71,895,536 049G01 D17S1817
71,892,297 71,895,536 1703G03 D17S785
72,220,514 72,234,158 9908A11 D17S0302i
73,721,872 73,733,311 1705E03 D17S0049i
73,721,872 73,733,311 1704B04 D17S0529i
73,864,454 73,867,753 T002C05 D17S0219i
73,864,454 73,867,753 1703G04 HUMUT952
74,181,727 74,289,971 1704E05 D17S0410i
74,181,727 74,289,971 1704G04 D17S0463i
74,360,654 74,433,067 1703A11 D17S0222i
75,723,612 75,735,533 1706H11 D17S0294i
75,723,612 75,735,533 1704B06 D17S0471i
76,580,274 76,588,528 1705B11 D17S0223i
76,705,160 76,754,467 1704A05 D17S0531i
77,091,594 77,094,422 1706B03 D17S0407i
77,418,886 77,422,527 9908H08 D17S0215i
77,866,035 77,868,769 1702E12 D17S928
77,872,189 77,884,930 1701E11 D17S0537i
78,070,883 78,153,743 1704A07 D17S0411i
78,070,883 78,153,743 1701D04 D17S0516i
8,722,953 8,756,559 1704D09 D17S0019i
8,722,953 8,756,559 1704B11 D17S0020i
8,722,953 8,756,559 1701A01 D17S786
11,679,263 11,871,922 1804E09 D18S0049i
11,679,263 11,871,922 1805C07 D18S0278i
11,679,263 11,871,922 1805C10 D18S0344i
11,679,263 11,871,922 9901C03 D18S0507i
11,679,263 11,871,922 1804D07 D18S482
12,775,480 12,874,334 573D07 chr18.fa.O7frz.16363530
12,775,480 12,874,334 1803F04 D18S0050i
13,716,680 13,754,554 1806G09 D18S0055i
13,716,680 13,754,554 1803A03 Z67649
13,815,543 13,816,861 1801D09 Z67345
16,787,533 16,944,869 1803D05 D18S0073i
16,787,533 16,944,869 1806D06 D18S0554i
18,003,414 18,036,225 1801B01 Z67399
19,523,560 19,789,028 1802H07 D18S0204i
19,523,560 19,789,028 1804H04 D18S0285i
19,523,560 19,789,028 1801C03 D18S0448i
20,294,591 20,313,919 1803E01 D18S1107
20,294,591 20,313,919 1802F09 D18S1108
204,522 258,049 1801D01 D18S0041i
23,784,933 24,011,189 1803A06 D18S0087i
23,784,933 24,011,189 1803B06 D18S0090i
23,784,933 24,011,189 1805H02 D18S0226i
23,784,933 24,011,189 1805A04 D18S0410i
23,784,933 24,011,189 1804H01 D18S0479i
3,402,072 3,448,409 123D10 AC006211.1_151493
3,402,072 3,448,409 113B09 AC006211.1_168801
3,402,072 3,448,409 1804B03 D18S0455i
309,356 490,685 1803B10 D18S0192i
309,356 490,685 1804H09 D18S0429i
37,789,197 37,915,446 1803D08 D18S0155i
37,789,197 37,915,446 1803H10 D18S0206i
37,789,197 37,915,446 1802E08 D18S0312i
41,558,155 41,585,297 1803E07 D18S0129i
41,558,155 41,585,297 1805H03 D18S0144i
41,659,543 41,678,045 1805F11 D18S0385i
44,700,221 44,731,079 1803D11 D18S0223i
44,700,221 44,731,079 1805F05 D18S0297i
46,340,482 46,512,194 1804G12 D18S0119i
46,340,482 46,512,194 1802D08 D18S0490i
46,340,482 46,512,194 1803D02 D18S479
51,045,967 51,406,858 418H01 AC018994.3_111068
51,045,967 51,406,858 1804B08 D18S0003i
51,045,967 51,406,858 1806D10 D18S0382i
51,045,967 51,406,858 1806G06 HUMUT7024B
54,489,598 54,568,350 1802D12 D18S0565i
54,489,598 54,568,350 1802C12 D18S0566i
55,085,251 55,091,605 1805D08 D18S0317i
55,085,251 55,091,605 1804E01 D18S0518i
55,148,088 55,177,463 1801A05 D18S1155
56,189,564 56,190,562 575A04 chr18.fa.O7frz.64410150
56,189,564 56,190,562 1802D01 D18S0244i
58,143,500 58,205,872 1803H08 D18S0168i
58,143,500 58,205,872 1802B02 D18S0441i
58,941,559 59,137,593 1803A12 D18S0241i
58,941,559 59,137,593 1804A02 D18S0321i
58,941,559 59,137,593 1803H03 HUMUT574
59,705,922 59,722,100 1806F01 D18S68
59,767,574 59,779,093 9901E05 HUMUT2039
6,931,885 7,107,813 1806E11 D18S0258i
6,931,885 7,107,813 1805D04 D18S0350i
6,931,885 7,107,813 1805B03 D18S0352i
647,619 663,492 573C03 chr18.fa.O7frz.941566
65,681,172 65,775,140 1805B09 D18S0327i
65,681,172 65,775,140 1803H02 Z67518
65,681,172 65,775,140 1801D07 Z67555
66,107,243 66,145,329 1804C08 D18S0407i
66,107,243 66,145,329 1806C07 D18S0510i
7,557,817 8,396,854 1805E01 D18S0045i
7,557,817 8,396,854 1803E04 D18S0047i
7,557,817 8,396,854 1804E06 D18S0193i
7,557,817 8,396,854 1803C10 D18S0194i
7,557,817 8,396,854 1806E02 D18S0196i
7,557,817 8,396,854 1803E10 D18S0199i
7,557,817 8,396,854 1801A08 D18S0202i
7,557,817 8,396,854 9901B06 D18S0478i
7,557,817 8,396,854 1801E06 D18S1163
711,592 802,547 1801H06 D18S0446i
711,592 802,547 9909H05 D18S0452i
72,819,777 72,973,762 9901H05 D18S0498i
72,819,777 72,973,762 1802H04 D18S1097
75,256,760 75,390,311 1805G11 D18S0394i
75,256,760 75,390,311 9909E05 D18S0439i
9,465,007 9,528,106 1806C11 D18S0075i
1,018,174 1,037,627 9909H06 D19S886
1,560,293 1,603,328 1903H09 D19S0054i
1,560,293 1,603,328 9901B09 D19S0081i
1,560,293 1,603,328 1904B07 D19S0190i
10,083,197 10,087,065 1901B03 D19S0008i
10,083,197 10,087,065 1901E07 D19S0395i
10,258,650 10,260,198 1904D05 D19S0206i
10,322,205 10,352,211 1903A01 D19S0093i
10,457,796 10,475,243 1903B01 HUMUT5187
10,673,106 10,803,579 T001E09 D19S0283i
10,843,253 10,894,448 1901H01 D19S0245i
10,932,606 11,033,953 9909C08 D19S0301i
11,061,132 11,105,490 1902C03 D19S0372i
11,296,093 11,311,321 305C09 AC020561.3_124319
11,348,883 11,356,019 9901E08 D19S0139i
11,477,744 11,500,972 1902A06 D19S0364i
12,763,286 12,765,129 1903A02 D19S914
12,910,423 12,916,303 9909E06 HUMUT8091
12,917,654 12,925,455 1903C05 D19S0195i
13,933,352 13,978,097 1901D09 D19S0311i
13,933,352 13,978,097 1902D12 D19S0390i
14,063,500 14,089,559 1904A11 D19S0196i
14,353,213 14,380,535 1902F02 D19S0198i
14,444,278 14,447,174 1901H10 D19S226
14,570,918 14,646,810 1903H02 D19S0352i
14,704,205 14,750,353 1904D10 D19S0086i
15,024,015 15,027,900 1903E12 D19S0009i
15,024,015 15,027,900 1901F09 D19S929
15,131,444 15,172,792 1901C08 D19S0048i
15,440,463 15,451,312 1901G10 G08034
15,587,421 15,601,445 1901E08 D19S588
15,612,707 15,634,634 1903H05 D19S0318i
15,849,834 15,869,885 1902E08 D19S0050i
15,884,181 15,906,326 9901C11 D19S0354i
16,105,838 16,130,381 467D12 chr19.fa.O7frz.17685171
16,105,838 16,130,381 1901D08 D19S0248i
16,105,838 16,130,381 1901D03 D19S885
16,296,648 16,299,345 9901D09 D19S917
16,489,705 16,514,248 1904A02 D19S0114i
17,203,694 17,217,151 1902E10 D19S410
17,203,694 17,217,151 1901H08 D19S593
17,374,755 17,377,457 1904F08 D19S0151i
17,374,755 17,377,457 1903A10 D19S0162i
17,766,658 17,785,385 1902C08 D19S0109i
17,766,658 17,785,385 1902D02 D19S0159i
17,788,322 17,819,800 1901F12 D19S0022i
18,031,371 18,058,702 1902H04 D19S0051i
18,125,016 18,142,343 1901C11 D19S212
18,357,968 18,360,987 1902F12 D19S0215i
18,357,968 18,360,987 1901G06 D19S898
18,503,568 18,515,383 1903G09 D19S0284i
18,891,494 18,900,436 1903H06 D19S0013i
19,164,008 19,173,678 9901A08 D19S0087i
2,427,135 2,429,257 1904A07 D19S0370i
2,427,135 2,429,257 1901H07 D19S565
3,545,504 3,557,658 9901D11 D19S0106i
3,927,054 3,936,461 1903B07 D19S0366i
3,958,748 3,990,383 1902F06 D19S0328i
34,994,741 35,007,059 1902B01 D19S0044i
34,994,741 35,007,059 1901D05 G08036
37,763,944 37,770,171 1903B05 D19S0035i
38,482,776 38,485,160 9909H08 D19S0332i
38,482,776 38,485,160 674H06 DISO7_10007438
38,482,776 38,485,160 093E04 HUMUT1974
4,041,319 4,075,126 1902A02 D19S0032i
4,180,495 4,188,525 1903D05 D19S0123i
4,180,495 4,188,525 1901D07 D19S0137i
4,608,557 4,621,415 9901F10 D19S0040i
4,608,557 4,621,415 1901B11 D19S0131i
4,766,944 4,782,716 9901G10 D19S0060i
4,766,944 4,782,716 9909D07 D19S0098i
40,451,721 40,462,558 1902A08 D19S0085i
40,451,721 40,462,558 1904F02 D19S0273i
40,895,670 40,899,780 1902F01 D19S0384i
41,070,983 41,085,025 1903C10 D19S0002i
41,070,983 41,085,025 1904F01 D19S0227i
41,070,983 41,085,025 1901B07 D19S876
41,191,863 41,196,981 1902B09 D19S224
43,770,121 43,800,471 T002D09 D19S0380i
43,770,121 43,800,471 1901E12 D19S422
43,984,155 43,995,422 1901F01 D19S0361i
44,082,455 44,091,374 9901E11 D19S0108i
44,082,455 44,091,374 1902C04 D19S417
44,082,455 44,091,374 1902H07 D19S881
44,426,033 44,427,609 1901F07 D19S0193i
44,450,997 44,452,572 9909G07 D19S0285i
44,589,293 44,591,885 1902B08 D19S0375i
44,785,004 44,789,954 1902A03 D19S0260i
44,886,786 44,891,928 1902B02 D19S0275i
44,913,735 44,920,508 1901G08 D19S0083i
447,490 456,342 1902G10 D19S0073i
447,490 456,342 1903A04 D19S0338i
45,389,491 45,413,314 1902H08 D19S0226i
45,389,491 45,413,314 1902E07 HUMUT5576
45,389,491 45,413,314 9901B10 HUMUT6385
45,645,541 45,663,516 1904H05 D19S0210i
45,645,541 45,663,516 1903F05 D19S0276i
46,041,284 46,226,008 9901F08 D19S223
46,041,286 46,226,008 1901B10 D19S0262i
46,041,286 46,226,008 1901G07 HUMUT5036
46,390,955 46,405,284 1904C05 D19S0214i
46528254 46551656 TGFB11 new design
46528254 46551656 TGFB12 new design
46,904,377 46,925,686 239F08 AC005794.1_22677
46,904,377 46,925,686 1904D09 D19S0223i
46,992,381 47,007,431 576F01 chr19.fa.O7frz.51175481
46,992,381 47,007,431 051H06 D19S423
47,394,592 47,416,115 1902A10 D19S0094i
47,394,592 47,416,115 9909A08 D19S0293i
47,577,500 47,579,250 1902C10 D19S872
47,703,298 47,724,479 1902G05 D19S0111i
47,776,235 47,790,890 1904E07 D19S0103i
47,776,235 47,790,890 1903F08 D19S0126i
48,063,198 48,075,711 239F05 AC005260.1_494
48,063,198 48,075,711 9901B07 D19S211
48,549,651 48,559,368 1904G12 D19S0280i
48,549,651 48,559,368 1903F02 D19S0350i
48,739,032 48,771,998 1901A08 D19S0295i
48,739,032 48,771,998 9909A07 D19S408
48,842,088 48,866,539 9901C08 D19S0107i
48,912,078 48,916,013 1903F09 D19S0029i
48,912,078 48,916,013 9909B07 D19S217
49,839,066 49,858,690 1904A03 D19S0229i
49,839,066 49,858,690 1903F04 D19S574
49,943,820 49,955,140 9901H08 D19S0164i
49,943,820 49,955,140 1901A03 HUMUT7544
5,157,379 5,237,399 1904E06 D19S0265i
5,157,379 5,237,399 1901F10 D19S0362i
5,793,902 5,802,482 1904F10 D19S0130i
5,793,902 5,802,482 9901B11 D19S0325i
5,944,175 6,061,554 1903D01 D19S0303i
5,944,175 6,061,554 1901B01 D19S0304i
50,196,539 50,233,292 468B12 chr19.fa.O7frz.55431947
50,546,686 50,565,669 1903E07 D19S0105i
50,546,686 50,565,669 9901D12 D19S0317i
50,604,712 50,619,017 9901D08 D19S0077i
50,784,865 50,797,294 1903G08 D19S0001i
51,059,358 51,068,895 1904D11 D19S0221i
51,059,358 51,068,895 1901A11 D19S0387i
51,059,358 51,068,895 1901E02 D19S0393i
51,214,255 51,218,163 1904E10 D19S0110i
51,869,413 51,911,597 1904B04 D19S0253i
52,356,000 52.367.000 9901A12 D19S0181i
52,415,921 52,427,863 1902F04 D19S0264i
52,504,971 52,517,173 1904H08 D19S0185i
52,544,386 52,577,795 1901A02 D19S606
53,310,515 53,365,372 1904C01 D19S0160i
53,403,325 53,450,955 1904D01 D19S0287i
53,520,441 53,525,623 1902H05 D19S0171i
53,814,360 53,825,474 1904D07 D19S0271i
53,943,080 53,950,459 9901A11 D19S0166i
53,950,628 53,953,395 1904G10 D19S0173i
53,950,628 53,953,395 1904H04 D19S0180i
54,149,929 54,156,867 1903F07 D19S0179i
54,211,049 54,212,159 1904A09 D19S0186i
54,217,939 54,244,212 1904G05 D19S0289i
54,280,277 54,303,682 1901C01 D19S0297i
54,530,240 54,535,675 1903C08 D19S0072i
54,530,240 54,535,675 1902D06 D19S604
54,530,240 54,535,675 1901D02 HUMUT2523
54708304 54721402 FCGRT1 new design
54708304 54721402 FCGRT2 new design
54,750,780 54,775,626 1903H03 D19S0300i
55,084,723 55,124,598 1902D07 D19S0337i
55,571,515 55,578,051 469B02 chr19.fa.O7frz.63753376
55,571,515 55,578,051 9901H06 D19S0165i
56,319,977 56,325,379 154C08 AF135024.2_4066
56,319,977 56,325,379 9901G12 D19S0353i
56,605,087 56,612,869 1901A06 D19S0254i
56,714,795 56,726,922 1902A09 D19S0324i
56,806,996 56,831,696 1903F12 D19S0068i
56,940,839 56,946,962 1903A07 D19S0027i
56,955,995 56,965,591 9901C10 D19S0014i
58,484,666 58,486,687 1903B11 D19S0291i
58,484,666 58,486,687 1902C05 D19S921
58,988,650 59,019,409 9909G06 D19S0058i
58,988,650 59,019,409 1904E05 D19S0288i
59,077,279 59,102,713 1904H09 D19S0244i
59,077,279 59,102,713 670G07 DISO7_10004464
59,289,745 59,297,806 1902G12 D19S0170i
59,289,745 59,297,806 1903D03 D19S0355i
59,412,549 59,418,709 1904G11 D19S0230i
59,491,666 59,496,077 1903H07 D19S0038i
59,557,047 59,568,533 1904G06 D19S0235i
59,618,417 59,639,882 1902F05 D19S0239i
59,738,595 59,748,862 1904F04 D19S0169i
59,911,791 59,916,501 664A03 DISO7_10004466
6,235,811 6,344,184 1902C06 D19S0334i
6,323,444 6,326,040 1901B12 D19S0274i
6,482,037 6,486,933 1904D06 D19S0391i
6,536,850 6,542,163 608H08 chr19.fa.O7frz.7699148
6,628,878 6,671,660 663A12 chr19.fa.O7frz.7846308
6,628,878 6,671,660 9901F09 D19S0146i
6,723,722 6,808,371 9901G11 D19S0132i
6,838,577 6,891,464 1901E09 D19S0144i
6,838,577 6,891,464 9909D08 D19S0313i
60,077,361 60,095,055 1903G03 D19S926
60,168,465 60,204,318 9909D06 D19S0453i
60,384,428 60,412,654 1903F01 D19S605
60,911,610 60,941,580 1904G09 D19S0241i
60,911,610 60,941,580 1901G05 Z66860
61,099,123 61,135,489 1902G03 D19S0389i
63,754,745 63,758,298 1903D11 D19S0290i
7,067,049 7,245,045 305B05 AC010606.5_70425
7,067,049 7,245,045 1903C01 D19S0340i
7,067,049 7,245,045 1903G04 D19S406
7,659,662 7,673,032 1904A01 D19S0117i
7,659,662 7,673,032 9901C07 D19S905
7,734,081 7,740,491 1901C06 D19S912
7,874,728 7,885,363 1903F03 D19S0351i
776,097 783,017 1902D05 D19S0342i
8,023,934 8,033,547 1902F07 D19S922
8,491,689 8,548,330 1902A11 D19S0343i
810,665 814,624 1903C09 D19S0011i
9,806,999 9,821,358 1902G06 D19S0279i
9,931,237 9,982,147 1902A05 D19S583
1,614,666 1,727,298 0201A07 D2S0869i
10,101,133 10,112,414 0205D06 D2S0137i
101,680,920 101,877,584 0207D10 D2S2264
101,974,738 102,011,317 0220C03 HUMUT1265
102,125,678 102,162,766 0217B09 D2S1275i
102,169,865 102,222,243 0217B11 D2S1036i
102294394 102334929 IL1RL11 new design
102,345,529 102,381,650 0211B05 D2S0556i
102,401,686 102,435,457 0208E03 D2S373
102,602,598 102,694,241 0208E11 D2S0123i
108,360,853 108,370,702 0216C04 D2S0211i
108,360,853 108,370,702 0205B09 D2S1889
108,702,369 108,767,683 0201A02 D2S0205i
108,877,361 108,972,260 0216C11 D2S1281i
11,239,229 11,402,162 0206B05 D2S1586i
11,239,229 11,402,162 0205G04 D2S168
11,239,229 11,402,162 0202G05 Z67467
111,597,781 111,641,058 0205G06 D2S0198i
111,597,781 111,641,058 0208A05 D2S1892
112,372,662 112,503,416 377B11 AC067761.2_149902
112,372,662 112,503,416 0221H11 D2S0532i
113,247,963 113,259,442 0212G11 D2S1051i
113303808 113310827 IL1B1 new design
113303808 113310827 IL1B2 new design
113303808 113310827 IL1B3 new design
113387017 113392930 IL1F71 new design
113387017 113392930 IL1F72 new design
113387017 113392930 IL1F73 new design
113,452,077 113,459,698 0202E11 D2S1276i
113,591,941 113,608,064 0201D01 D2S0193i
113,591,941 113,608,064 0210G06 D2S0321i
118,288,725 118,306,425 0217C04 D2S0886i
119,416,215 119,468,706 0215E06 D2S0233i
119,416,215 119,468,706 0202B11 D2S0627i
119,630,289 119,632,941 0211A06 D2S0582i
119,630,289 119,632,941 0205C04 D2S2254
119,905,950 119,911,486 0202A10 D2S0218i
119,905,950 119,911,486 0216B01 D2S0592i
120,233,677 120,451,507 0218G01 D2S0897i
120,233,677 120,451,507 0212H06 D2S0911i
120,233,677 120,451,507 0209A04 D2S1533i
120,819,469 120,825,444 0202F10 D2S2329
120,819,469 120,825,444 0204A07 D2S2341
121,266,327 121,466,321 0203G09 D2S2212
121,266,327 121,466,321 0206B07 D2S2258
121,266,327 121,466,321 0208B04 D2S283
121,266,327 121,466,321 0207C09 Z67547
121,811,825 122,123,522 278D01 AC013399.2_117318
121,811,825 122,123,522 378G07 AC018737.3_67168
121,811,825 122,123,522 502H02 chr2.fa.O7frz.125811119
121,811,825 122,123,522 0217D12 D2S1064i
121,811,825 122,123,522 0221E05 D2S343
127,130,154 127,170,716 0211E06 D2S0593i
127,130,154 127,170,716 0211C07 D2S0617i
127,130,154 127,170,716 0219H11 D2S1467i
127,778,609 127,817,240 0209E07 D2S1631i
127,778,609 127,817,240 0206B04 D2S2271
127,892,486 127,903,288 0218D08 D2S0214i
127,892,486 127,903,288 0216D05 D2S0596i
130,830,088 130,848,614 0209F03 D2S1522i
130,830,088 130,848,614 0209D04 D2S1536i
136,313,666 136,350,481 0201H08 D2S0632i
136,313,666 136,350,481 0201G05 Z67485
136,705,639 136,709,450 0203E04 D2S1714i
136,705,639 136,709,450 0221C09 D2S2196
138,438,278 138,490,404 0213D08 D2S1302i
138,438,278 138,490,404 0206F10 D2S1810i
15,648,753 15,688,676 0219E10 D2S1383i
15,648,753 15,688,676 0218C05 D2S1389i
15,998,134 16,004,580 0210A09 D2S0381i
15,998,134 16,004,580 0203C08 D2S1828i
151,835,231 151,854,620 0214E05 D2S0657i
151,835,231 151,854,620 0214D12 D2S1334i
153,216,334 153,283,014 0211F07 D2S0624i
153,216,334 153,283,014 0204D02 D2S2299
156,889,194 156,897,474 0202B07 D2S1807i
157,979,377 158,008,850 0216D06 D2S0717i
157,979,377 158,008,850 0211D12 D2S0724i
160,277,256 160,333,330 0221D09 D2S0708i
160,277,256 160,333,330 0206G12 D2S156
160,277,256 160,333,330 009G10 D2S306
160,368,118 160,469,493 0213E02 D2S1128i
160,505,506 160,627,367 0201H05 D2S1122i
160,664,438 160,765,009 0213C11 D2S1403i
161,701,712 161,800,928 0217B03 D2S0677i
161,701,712 161,800,928 0211E12 D2S0725i
162,557,001 162,639,298 0218F11 D2S0929i
162,557,001 162,639,298 0214G04 D2S0932i
162,831,835 162,883,285 0215E09 D2S0917i
170,149,096 170,202,500 0216G02 D2S0649i
170,149,096 170,202,500 0213E08 D2S1313i
172,487,204 172,556,846 9902F08 D2S0689i
172,487,204 172,556,846 0214H01 D2S1444i
173,000,616 173,079,256 0210A02 D2S0048i
173,129,025 173,172,108 0211H05 D2S0581i
174,481,504 174,538,676 381G03 AC055875.2_105198
174,481,504 174,538,676 504B05 chr2.fa.O7frz.181842884
174,921,124 174,968,689 0201D08 D2S0320i
174,921,124 174,968,689 0201E02 D2S1731i
175,132,548 175,255,873 0211G11 D2S0705i
175,132,548 175,255,873 0209H08 D2S1665i
176,689,738 176,692,916 0210G01 D2S0046i
176,689,738 176,692,916 0219H07 D2S0260i
177,965,731 178,112,411 0211F10 D2S0687i
177,965,731 178,112,411 0213B11 D2S1399i
177,965,731 178,112,411 0203E07 D2S2173
182,029,864 182,110,719 0210G05 D2S0253i
182,029,864 182,110,719 0215D10 D2S1147i
183,406,982 183,439,743 0216A09 D2S0735i
183,651,732 183,673,616 0215D06 D2S1380i
183,651,732 183,673,616 0220E12 D2S1462i
187,163,045 187,253,873 279F08 AC017026.5_11120
187,163,045 187,253,873 381G05 AC017026.6_146393
187,163,045 187,253,873 381A06 AC017101.8_55453
189,547,344 189,585,717 381G07 AC066694.2_218537
189,547,344 189,585,717 429C05 chr2.fa.O7frz.197184084
189,547,344 189,585,717 0219D03 D2S0774i
190,133,561 190,153,858 0215H10 D2S0739i
190,133,561 190,153,858 0219B09 D2S0746i
191,542,121 191,587,181 0212H02 D2S0775i
191,542,121 191,587,181 0215G02 D2S1178i
191,602,551 191,724,539 0214H03 D2S0745i
197,336,917 197,372,670 0209H06 D2S1614i
197,336,917 197,372,670 0207F02 D2S1621i
198,059,553 198,073,243 0214C08 D2S1664i
20,264,039 20,288,675 0210C08 D2S0359i
201,443,924 201,462,244 0204E09 D2S116
201,443,924 201,462,244 0207D04 D2S1707i
201,756,100 201,802,372 0209E04 D2S1539i
201,806,396 201,854,521 0212G01 D2S0749i
202,949,916 203,140,719 0217C11 D2S0201i
202,949,916 203,140,719 0218G11 D2S1768i
203,811,658 203,878,579 0217B01 D2S1174i
203,811,658 203,878,579 0213E04 D2S1183i
204,279,443 204,310,801 0219F06 G09915
204,279,443 204,310,801 0208F10 HUMUT426
204,440,754 204,446,928 169G12 AF225900.1_4678
204,440,754 204,446,928 0219C01 D2S1188i
204,440,754 204,446,928 0221H04 D2S307
207,653,323 207,738,859 0208A11 D2S0057i
207,653,323 207,738,859 0215A11 D2S0116i
207,653,323 207,738,859 0213H11 D2S1424i
208,102,931 208,171,818 0221A07 D2S1701i
211,050,678 211,252,076 340F03 AC021150.7_98846
211,050,678 211,252,076 0220A12 D2S0094i
211,050,678 211,252,076 0221D05 D2S0298i
211,050,678 211,252,076 0213A12 D2S1430i
215,933,409 216,009,041 0214G12 D2S0265i
215,933,409 216,009,041 0210H06 D2S0323i
216,680,435 216,779,248 0221F07 D2S0052i
216,680,435 216,779,248 0219G07 D2S0226i
216,680,435 216,779,248 0205G10 D2S0230i
216,985,441 217,056,021 0204D05 D2S0809i
216,985,441 217,056,021 0206B06 D2S1655i
216,985,441 217,056,021 0219C03 D2S1659i
217,206,372 217,237,404 0217D03 D2S0278i
217,206,372 217,237,404 0219F12 D2S1476i
218,698,991 218,710,220 0204C02 D2S1206i
218,955,161 218,968,994 0219D05 D2S0791i
218,955,161 218,968,994 0220A10 D2S1538i
219,354,745 219,388,259 0219F02 D2S0828i
219,354,745 219,388,259 011A01 D2S2250
219,354,745 219,388,259 0221D02 G08149
219,628,173 219,633,433 0210A07 D2S0336i
219,628,173 219,633,433 0210B07 D2S0340i
219,628,173 219,633,433 0205G11 D2S0790i
219,822,677 219,826,882 0220B12 D2S0090i
220,145,161 220,148,679 0204H01 D2S1338i
227,578,168 227,737,519 0214E03 D2S0276i
227,578,168 227,737,519 0221G02 D2S1349
227,737,525 227,887,751 0201C03 D2S1802i
228,045,286 228,130,548 0204E11 D2S1673i
228,386,814 228,390,494 280F06 AC068692.3_9554
228,386,814 228,390,494 0214F12 HUMUT8098
230,741,896 230,792,932 0220G02 D2S172
230,741,896 230,792,932 0220F06 D2S1735i
230,741,896 230,792,932 0206B11 D2S1813i
231,681,199 231,698,068 0215H09 D2S0292i
231,681,199 231,698,068 0215G01 D2S0794i
233,633,433 233,781,288 0221A06 D2S331
233,633,433 233,781,288 0220D03 HUMUT8067
234,191,030 234,346,695 0220E08 D2S0042i
234,191,030 234,346,695 0218C03 D2S0839i
234,191,030 234,346,695 0216F12 D2S1220i
234,191,030 234,346,695 082D06 Z67659
237,143,182 237,155,730 0203C10 D2S0288i
237,143,182 237,155,730 0214B03 D2S1219i
237,897,401 237,987,559 0206A04 D2S1796i
237,897,401 237,987,559 0207F06 D2S1806i
238,893,821 238,972,536 383C04 AC013400.4_10628
238,893,821 238,972,536 506H10 chr2.fa.O7frz.250246308
238,893,821 238,972,536 0207H02 D2S0335i
239,000,365 239,025,630 0220D04 D2S0841i
239,000,365 239,025,630 0204C09 D2S1221i
239,635,319 239,987,580 0213C05 D2S1202i
239,635,319 239,987,580 0205H02 D2S1205i
239,635,319 239,987,580 0213F05 D2S1214i
239,635,319 239,987,580 0202H10 D2S1704i
24,126,075 24,140,055 0219E03 D2S0149i
24,126,075 24,140,055 0207A05 D2S1779i
241,148,144 241,152,104 0219G05 D2S0338i
241,148,144 241,152,104 0209D07 D2S1629i
241,903,396 241,942,115 0210C01 D2S0033i
241,903,396 241,942,115 0203H09 D2S1565i
242,146,865 242,162,226 0220G05 D2S1540i
242,440,711 242,449,731 0209G07 D2S1637i
25,237,226 25,245,063 0210D09 D2S0397i
25,237,226 25,245,063 0204C04 D2S171
27,383,769 27,384,634 0219A11 D2S1352i
29,269,144 29,997,936 0214G01 D2S0965i
29,269,144 29,997,936 0216E02 D2S1255i
29,269,144 29,997,936 0202A04 D2S146
29,269,144 29,997,936 0218A05 D2S1687i
29,269,144 29,997,936 0209E10 D2S1765i
29,269,144 29,997,936 0204E02 D2S2383
31,410,691 31,491,117 0215F01 D2S0437i
31,410,691 31,491,117 0210H11 D2S0446i
31,410,691 31,491,117 0202H07 D2S2203
31,410,691 31,491,117 0203H01 D2S352
32,303,022 32,344,427 0218E10 D2S0143i
32,303,022 32,344,427 0217C12 D2S1405i
32,435,234 32,697,470 0220B04 D2S0152i
32,435,234 32,697,470 0215D07 D2S0311i
33,025,896 33,478,080 0210G03 D2S0151i
33,025,896 33,478,080 0210D08 D2S0363i
33,025,896 33,478,080 0210F08 D2S0371i
33,025,896 33,478,080 0210C09 D2S0391i
33,025,896 33,478,080 0205C12 D2S0453i
33,025,896 33,478,080 0212B09 D2S0985i
33,025,896 33,478,080 0212D09 D2S0992i
33,025,896 33,478,080 0206B03 D2S2325
33,025,896 33,478,080 0205E12 D2S2347
33,514,920 33,643,162 0215D08 D2S0384i
37,331,149 37,398,541 0215H01 D2S0873i
37,331,149 37,398,541 0214A09 D2S0877i
37,331,149 37,398,541 0209E02 D2S1501i
38,148,154 38,156,796 0215H06 D2S0459i
38,148,154 38,156,796 0201A08 D2S0967i
38,878,375 38,956,525 0210F10 D2S0416i
38,878,375 38,956,525 0214G11 D2S0980i
38,878,375 38,956,525 0208C01 D2S2331
39,066,469 39,201,067 0202D03 D2S0425i
39,066,469 39,201,067 0215C03 D2S0431i
39,329,911 39,517,946 0210D01 D2S0036i
39,329,911 39,517,946 0207E03 D2S0101i
39,329,911 39,517,946 0208D11 D2S0109i
43,717,916 43,848,630 0202F06 D2S119
45,732,547 46,268,633 0217F04 D2S0434i
45,732,547 46,268,633 0220B11 D2S1482i
45,732,547 46,268,633 0205E10 D2S2182
45,732,547 46,268,633 0203C09 D2S2240
45,732,547 46,268,633 T002B12 D2S2291
46,661,580 46,697,708 0210A11 D2S0423i
46,661,580 46,697,708 0220D06 D2S1719i
46,779,595 46,843,431 0220A09 D2S1717i
48,395,374 48,459,938 0215E08 D2S0988i
48,395,374 48,459,938 0209B06 D2S1595i
48,767,471 48,836,321 0218B03 D2S0420i
49,043,156 49,235,134 0209D02 D2S1500i
49,043,156 49,235,134 0209A03 D2S1509i
49,043,156 49,235,134 0205A01 D2S1510i
49,043,156 49,235,134 0209B03 D2S1513i
58,127,224 58,240,510 376B06 AC068193.5_165968
58,127,224 58,240,510 0220C10 D2S0443i
6,935,247 6,955,821 0210C07 D2S0343i
6,935,247 6,955,821 0215D11 D2S0351i
6,935,247 6,955,821 0212E07 D2S0936i
60,962,254 61,003,682 0211E03 D2S0524i
64,173,499 64,225,062 0212G09 D2S1003i
64,173,499 64,225,062 0212H09 D2S1008i
68,203,572 68,341,866 0214D03 D2S0182i
68,203,572 68,341,866 0217G12 D2S0305i
68,203,572 68,341,866 0202E04 D2S0484i
69,995,707 70,023,581 376H04 AC019206.3_137449
69,995,707 70,023,581 0221C01 D2S0183i
69,995,707 70,023,581 0216B12 D2S0313i
70,527,924 70,634,438 0214D07 D2S0039i
70,527,924 70,634,438 0206F08 D2S0076i
70,527,924 70,634,438 0206F02 D2S292
70,910,855 70,916,461 0202D01 D2S1464i
72,209,875 72,228,471 0208E02 D2S2112
73,842,837 73,860,756 0201A12 D2S1715i
74,598,766 74,606,826 0205B12 D2S0066i
74,598,766 74,606,826 0209A10 D2S1745i
74,634,795 74,638,181 0220E03 D2S0062i
85,737,951 85,748,823 0214B09 D2S0171i
85,737,951 85,748,823 0219B08 D2S0315i
85,919,782 85,969,648 0216E03 D2S0575i
85,919,782 85,969,648 0208C03 D2S388
86,521,954 86,573,350 377E03 AC068288.3_48784
86,521,954 86,573,350 0216F03 D2S1052i
86,521,954 86,573,350 0219C02 D2S1437i
86,865,239 86,871,638 0214B05 D2S0560i
86,895,971 86,942,549 0206C05 D2S1847i
89,120,836 89,121,310 0212D06 D2S0889i
89,120,836 89,121,310 629H11 DISO7_10000926
9,463,264 9,481,127 0203H08 D2S2207
9,641,552 9,688,629 0203H02 D2S2169
96,172,638 96,174,906 0220F10 D2S1576i
96,365,211 96,405,001 0215F12 D2S0498i
97,696,461 97,722,755 377F07 AC017099.9_66660
97,696,461 97,722,755 0221B09 D2S2222
99,225,141 99,238,002 0215D04 D2S1049i
99,225,141 99,238,002 0206E02 D2S1524i
1,041,939 1,097,022 2005E12 D20S0407i
1,041,939 1,097,022 2003F01 D20S199
1,297,622 1,321,806 2005H10 D20S0258i
1,399,386 1,420,233 2004B05 D20S0382i
1,491,568 1,548,655 2004E05 D20S0171i
1,491,568 1,548,655 2001E04 D20S906
1,822,813 1,868,543 2001B11 D20S0035i
1,822,813 1,868,543 2001B01 G09329
10,566,334 10,602,636 2005A09 D20S0238i
10,566,334 10,602,636 2002H06 D20S894
116,527 118,264 2004F08 D20S0255i
155,899 158,527 2002E01 D20S864
2,224,647 2,269,725 245B06 AL031678.2_90137
2,224,647 2,269,725 2001A09 D20S0434i
2,769,366 2,967,320 2004E04 D20S0250i
2,769,366 2,967,320 2005D03 D20S0271i
2,769,366 2,967,320 2002G03 D20S0337i
22,509,643 22,514,102 2001B05 D20S0179i
22,974,270 22,978,301 2002D06 D20S0180i
22,974,270 22,978,301 2003A10 D20S0197i
23,007,995 23,014,977 2002F06 D20S0077i
23,676,190 23,679,574 T002B04 D20S0150i
23,676,190 23,679,574 2002G05 D20S0428i
29,309,128 29,311,096 9909E09 D20S0028i
29,466,712 29,480,644 2002B03 D20S484
29,565,892 29,621,031 2004C01 D20S0416i
29,715,916 29,774,366 2003G08 D20S0174i
29,899,102 29,922,211 2003A07 D20S0138i
29,996,419 30,003,556 2001B09 D20S863
3,615,617 3,635,775 246A03 AL132773.14_62387
3,615,617 3,635,775 2002E04 D20S0237i
3,615,617 3,635,775 2002A11 D20S867
3,724,386 3,734,762 2001E02 D20S0131i
30,103,715 30,153,320 240A08 AL049539.21_50629
30,103,715 30,153,320 2002C09 D20S0157i
31,541,589 31,701,503 2005E06 D20S0007i
31,541,589 31,701,503 2005B03 D20S0239i
31,541,589 31,701,503 2004E02 D20S0399i
31,862,780 31,905,831 2002B04 D20S878
32,414,702 32,562,859 9909G10 D20S0177i
32,414,702 32,562,859 2004E03 D20S0360i
33,212,131 33,228,828 507G12 chr20.fa.O7frz.34778324
33,212,131 33,228,828 2001A02 D20S0376i
33,212,131 33,228,828 664H06 DISO7_00021484
33,278,095 33,328,218 9909A10 Z67143
34,953,761 35,013,590 2004B04 D20S0396i
35,406,502 35,467,239 2002B05 D20S0201i
35,406,502 35,467,239 2003A01 D20S834
36,365,991 36,399,321 2003C06 D20S0115i
36,408,299 36,439,067 2004B06 D20S0364i
36,867,762 36,985,081 2002E10 D20S0046i
36,867,762 36,985,081 9909D11 D20S0365i
37,024,409 37,101,778 2003F10 D20S0215i
39,199,291 39,237,775 2004B01 D20S0418i
4,614,996 4,630,236 2004F09 D20S0053i
4,614,996 4,630,236 2005E03 D20S0284i
40,134,806 41,252,024 243F09 AL117374.39_58894
40,134,806 41,252,024 114A08 AL117374.39_74311
40,134,806 41,252,024 2001H04 D20S0066i
40,134,806 41,252,024 2003C07 D20S0141i
40,134,806 41,252,024 2003E09 D20S0191i
40,134,806 41,252,024 2003H09 D20S0196i
40,134,806 41,252,024 2004H08 D20S0200i
40,134,806 41,252,024 2001D06 D20S0298i
40,134,806 41,252,024 9909F11 D20S0403i
40,134,806 41,252,024 2001D02 D20S108
40,134,806 41,252,024 2003G02 D20S110
40,134,806 41,252,024 2002E09 HUMUT1688
41,292,801 41,293,515 2004C10 D20S0327i
42,417,855 42,493,444 2004G10 D20S0331i
42,417,855 42,493,444 2001C08 D20S0357i
42,681,577 42,713,797 2003F04 D20S0030i
42,681,577 42,713,797 2003B07 D20S0139i
43,028,529 43,142,014 2005A10 D20S0353i
43,028,529 43,142,014 2004H03 D20S119
43,028,529 43,142,014 240D10 Z93016.2_66966
43,185,480 43,186,520 9909B10 D20S481
43,269,052 43,271,827 2005G06 D20S0335i
43,387,342 43,410,478 242D04 AL031663.2_3148
43,387,342 43,410,478 2005G04 D20S0300i
43,903,768 43,919,442 246E05 AL050348.21_45960
43,952,190 43,960,866 2003C05 D20S0068i
44,070,954 44,078,607 001C11 D20S838
44,070,954 44,078,607 001D11 D20S856
44,180,313 44,366,257 155F12 AL162458.10_114045
44,180,313 44,366,257 2002G09 D20S0390i
44,180,313 44,366,257 2004A01 D20S836
47,553,818 47,618,114 2003F11 D20S0241i
47,553,818 47,618,114 2005B10 D20S0247i
47,553,818 47,618,114 2004H11 D20S0349i
47,862,657 47,942,179 2005F11 D20S0299i
47,862,657 47,942,179 2001A06 D20S0328i
48,131,068 48,203,678 2005G11 D20S0304i
48,131,068 48,203,678 2001B02 D20S0308i
48,560,294 48,634,706 2004C06 D20S0024i
48,560,294 48,634,706 2005C11 D20S0121i
48,560,294 48,634,706 2001F09 D20S0426i
49,441,083 49,592,665 2004D07 D20S0056i
49,441,083 49,592,665 2005C10 D20S0363i
49,441,083 49,592,665 2003C02 D20S857
54,257,195 54,258,278 2002D04 D20S0333i
54,257,195 54,258,278 2004G02 D20S0358i
54,637,765 54,647,746 2005C12 D20S0301i
55,177,211 55,275,091 9909E10 D20S0094i
55,177,211 55,275,091 2003D06 D20S0118i
55,177,211 55,275,091 2001C04 D20S0122i
55,359,535 55,387,618 2002E05 D20S0417i
56,990,597 57,015,697 2005C06 D20S0082i
56,990,597 57,015,697 2005C04 D20S0342i
57,308,877 57,334,442 2002D08 D20S171
57,308,877 57,334,442 2002B10 Z67390
6,696,311 6,708,927 2003B10 D20S0199i
6,696,311 6,708,927 2001E05 D20S0204i
60,223,421 60,228,718 T002G06 D20S0372i
60,317,510 60,375,763 2002D09 D20S0370i
60,471,948 60,484,421 2002D05 D20S0397i
60,979,535 61,039,743 2005B02 D20S0106i
61,337,680 61,342,299 2005C05 D20S0067i
61,589,810 61,600,949 2004D04 D20S0387i
61,759,607 61,800,495 2003D09 D20S0188i
61,759,607 61,800,495 2002C10 D20S0315i
62,181,932 62,215,047 2002H03 D20S0432i
10,042,713 10,120,798 2004D08 D20S0005i
10,042,713 10,120,798 2001A10 D20S901
17,887,842 17,907,136 2005G08 D20S0013i
17,887,842 17,907,136 2005B08 D20S0280i
25,933,460 26,009,106 2003H06 D20S0130i
25,933,460 26,009,106 2004F01 HUMUT278
29,831,125 30,234,153 2102G11 D21S0019i
29,831,125 30,234,153 2103H05 D21S0076i
29,831,125 30,234,153 2102C10 D21S0153i
29,831,125 30,234,153 2101E06 D21S0185i
29,831,125 30,234,153 2101C01 D21S0212i
29,831,125 30,234,153 9909B12 D21S0324i
31953806 31963115 SOD11 new design
31953806 31963115 SOD12 new design
33,320,023 33,323,374 2102A09 D21S0003i
33,524,076 33,559,839 2102F10 D21S0024i
33,524,076 33,559,839 718G09 DIJ28_10003558
33,619,079 33,654,038 2103E03 D21S0017i
33,697,072 33,731,698 2101E07 D21S0227i
35,081,968 35,343,511 157E06 AP001721.1_224451
35,081,968 35,343,511 2102B06 D21S0021i
35,081,968 35,343,511 2101D07 D21S0029i
35,081,968 35,343,511 2101E05 D21S0086i
35,081,968 35,343,511 2101G07 D21S0091i
35,081,968 35,343,511 9909G12 D21S0237i
36,679,559 36,710,995 2102A01 D21S0090i
36,679,559 36,710,995 2101F11 D21S0095i
37,661,729 37,809,347 2101E12 D21S0183i
37,661,729 37,809,347 2103C12 D21S0221i
37,661,729 37,809,347 2103E01 D21S270
38,675,671 38,955,488 2103F03 D21S0025i
38,675,671 38,955,488 2102E10 D21S0200i
38,675,671 38,955,488 2103G12 D21S0233i
38,675,671 38,955,488 2101E04 G08076
40,039,204 40,095,893 2102F09 D21S0089i
40,039,204 40,095,893 059F07 Z67428
40,306,213 41,140,909 2101G09 D21S0084i
40,306,213 41,140,909 2103E06 D21S0102i
40,306,213 41,140,909 2103D08 D21S0136i
40,306,213 41,140,909 2101H06 D21S0143i
40,306,213 41,140,909 2103C09 D21S0164i
40,306,213 41,140,909 2103H09 D21S0184i
40,306,213 41,140,909 2101D12 D21S0209i
40,306,213 41,140,909 2103E11 D21S0213i
40,306,213 41,140,909 2101F07 D21S1887
40,306,213 41,140,909 2101F03 D21S1906
41,655,820 41,702,739 2102H05 D21S0088i
41,655,820 41,702,739 2103C01 D21S266
41,720,024 41,753,008 2102D06 D21S0228i
42,599,751 42,608,775 2102F03 D21S0151i
43,963,406 44,006,608 2101F02 D21S0020i
43,963,406 44,006,608 2103B11 D21S0205i
43,963,406 44,006,608 2102G08 D21S0229i
44,467,313 44,485,262 2101B07 D21S1912
44,530,191 44,542,530 2101D06 D21S0097i
45,130,296 45,173,181 2101C05 D21S0241i
45737914 45786779 SLC19A1 new design
46,226,091 46,249,391 2102E07 D21S0007i
46,226,091 46,249,391 9909D12 D21S0206i
46,342,470 46,377,190 2101C12 D21S0262i
46,879,507 46,909,291 2102B10 D21S0245i
15,945,849 15,971,405 2202F03 D22S0091i
16,501,485 16,593,383 9910C08 D22S0210i
16,591,460 16,631,812 2202F12 D22S0026i
16,591,460 16,631,812 2201C06 D22S0231i
17,141,172 17,159,474 9910D07 D22S0216i
17,403,798 17,489,962 2201A09 D22S0151i
17,403,798 17,489,962 2202E04 D22S0205i
18,091,066 18,092,297 9910E02 D22S0041i
18,091,066 18,092,297 2201F09 D22S0206i
19,108,875 19,122,146 2202B03 D22S0089i
19,601,714 19,638,034 9910H02 D22S0046i
19,601,714 19,638,034 2201C11 D22S0128i
19,699,449 19,713,119 2202E03 D22S0228i
20,326,542 20,328,588 2201G07 D22S446
20,443,946 20,551,970 2201E11 D22S0109i
20,929,200 20,929,926 2202A11 D22S0119i
21,220,123 21,231,768 2201B10 D22S0232i
21,852,552 21,990,224 9910C03 D22S0055i
21,852,552 21,990,224 103C02 HUMUT8144
22,245,312 22,252,495 9910F03 D22S0068i
22,245,312 22,252,495 9910C05 D22S0156i
22,369,647 22,567,417 2201B11 D22S0163i
22,369,647 22,567,417 9910F06 D22S0186i
22,706,141 22,714,271 2202F02 D22S0169i
22,737,765 22,904,596 9910E06 D22S0184i
22,737,765 22,904,596 2202F01 D22S1174
23,153,537 23,168,325 2201B06 D22S0176i
23,309,718 23,354,972 9910B05 D22S0153i
26,474,265 26,527,486 2202D06 D22S0063i
26,474,265 26,527,486 2202G03 HUMUT7995
27,520,548 27,526,560 9910E07 D22S0218i
28,966,441 28,972,748 2202E07 D22S0018i
28,966,441 28,972,748 2201G01 HUMUT5900
29,333,161 29,353,047 2201B02 D22S0221i
29,388,039 29,393,872 2202B02 D22S0127i
30,125,539 30,160,438 2202C09 D22S0010i
30,125,539 30,160,438 9910H06 D22S0193i
31,526,802 31,589,028 2201G03 D22S0025i
31,526,802 31,589,028 251H05 Z17028.1_102
34,107,057 34,120,194 719C01 DIJ28_10030051
34,374,370 34,394,402 2201H11 D22S0042i
34,374,370 34,394,402 2202D10 D22S0132i
35,007,272 35,113,958 2201A02 D22S283
35,290,050 35,428,849 252H05 -H4251-
35,586,976 35,604,005 2202C02 D22S0165i
35,586,976 35,604,005 2201H09 D22S1177
35,851,824 35,875,908 2202E08 D22S0052i
35,906,152 35,914,276 T002D04 D22S0122i
35,906,152 35,914,276 2202F05 D22S0148i
35,951,238 35,970,251 2202G08 D22S0171i
36,216,346 36,245,193 2201C10 D22S0135i
36,216,346 36,245,193 9910B06 D22S0177i
36,837,448 36,907,763 2202C11 D22S0099i
36,837,448 36,907,763 2201F10 D22S0106i
37,209,389 37,232,262 2202G12 D22S0092i
37,209,389 37,232,262 9910F05 D22S0166i
37,460,681 37,481,928 2101D09 D21S1919
37,460,681 37,481,928 053B05 D21S267
37,949,310 37,971,006 2202F09 D22S0037i
38,125,692 38,163,078 2202G10 D22S0002i
38,246,515 38,248,637 2201B01 D22S428
38,627,032 38,698,204 2201G09 D22S0108i
38,627,032 38,698,204 2202G04 D22S284
39,817,736 39,906,024 2202C06 D22S0021i
40,664,687 40,673,094 2202B11 D22S0007i
40,664,687 40,673,094 2202A10 D22S0064i
40,852,445 40,856,827 2201D03 D22S0227i
40,885,963 40,941,389 9910B07 D22S0199i
41,108,917 41,158,340 2202H04 D22S0200i
41,108,917 41,158,340 2202H03 D22S0201i
41,309,671 41,340,906 252A05 Z93241.11_118962
41,418,071 41,446,820 2201D06 HUMUT1091
41,836,701 41,855,662 2201F05 D22S1151
41,836,701 41,855,662 054F01 D22S1179
44,925,163 45,018,317 2202F04 D22S1149
45,394,963 45,454,352 2201H01 D22S0202i
45,394,963 45,454,352 9910E08 D22S0225i
45,458,971 45,512,816 2202F10 D22S0173i
49,311,047 49,315,321 2202F07 D22S0096i
49,385,997 49,396,843 9910D08 D22S0222i
49,459,936 49,518,507 728A10 -
10,181,563 10,260,427 0304D05 D3S1329i
103,029,547 103,062,556 0301F10 D3S1228i
103,029,547 103,062,556 632E08 DISO7_10001184
106,568,403 106,778,434 0313F05 D3S1080i
106,568,403 106,778,434 0310D06 D3S1083i
106,568,403 106,778,434 0315A01 D3S1591
106,859,799 107,070,577 0310G09 D3S0029i
106,859,799 107,070,577 0309D06 D3S0668i
106,859,799 107,070,577 0301G07 D3S1493i
109,244,631 109,292,625 0310A05 D3S0548i
109,244,631 109,292,625 0309C01 D3S0552i
109,244,631 109,292,625 0302C06 Z67497
11,269,400 11,279,415 0314A07 D3S0216i
11,269,400 11,279,415 0301D05 D3S0835i
110,024,321 110,056,542 0303H10 D3S1302
112,273,555 112,395,063 0307C11 D3S0116i
112,273,555 112,395,063 0313B10 G08281
112,743,546 112,853,906 0309F05 D3S0644i
112,743,546 112,853,906 0302E07 D3S1443i
112,743,546 112,853,906 0306H04 D3S1572
113,522,943 113,564,349 0307C06 D3S1359i
113,522,943 113,564,349 0315D12 Z66960
113,667,463 113,701,066 0301F03 Z67725
114,017,246 114,047,487 0312E12 D3S0657i
114,017,246 114,047,487 0304C11 D3S1410i
114,122,746 114,176,650 0308F03 D3S0290i
12,169,568 12,175,851 393G02 AC015546.16_112255
12,169,568 12,175,851 396A05 AC026166.2_143575
12,169,568 12,175,851 0317H08 D3S1127i
12,304,359 12,450,843 0304H07 D3S0036i
12,304,359 12,450,843 0311H05 D3S0208i
12,304,359 12,450,843 0317C09 D3S1133i
120,102,167 120,347,588 0303G01 D3S0934i
120,102,167 120,347,588 0315H02 D3S3515
120,102,167 120,347,588 729D03 DIJ28_10010297
120,725,832 120,761,139 285H01 AC069519.8_29705
120,725,832 120,761,139 013E09 D3S3513
120,792,984 120,831,342 398B01 AC073352.7_5796
120,982,021 121,020,022 0306B04 D3S3620
121,028,233 121,295,954 0314D03 D3S0118i
121,937,926 121,984,605 0315B05 D3S1059i
123,256,911 123,322,673 0310G01 D3S1225i
123,256,911 123,322,673 0317A01 D3S1779i
123,256,911 123,322,673 0303B04 D3S3720
124,813,833 125,085,839 0316C06 D3S1322i
124,813,833 125,085,839 0306E04 D3S3552
125,964,485 126,088,842 0308E05 D3S0359i
125,964,485 126,088,842 0308G08 D3S0446i
125,964,485 126,088,842 0315D07 D3S0698i
128,190,192 128,238,922 0307B03 D3S1258i
128,190,192 128,238,922 0304D07 D3S1459i
128,799,943 128,823,969 0310H09 D3S0356i
128,799,943 128,823,969 013F11 D3S3607
129,253,902 129,273,216 0313A04 D3S0790i
129,253,902 129,273,216 0304C01 Z67486
129,680,960 129,694,718 0315F04 D3S0688i
130,262,300 130,263,941 0313E12 D3S0360i
130,756,708 130,808,351 0311E07 D3S0958i
130,756,708 130,808,351 0307G02 D3S1250i
131,176,253 131,179,470 0314E02 D3S0200i
131,176,253 131,179,470 0312B11 D3S0348i
131,176,253 131,179,470 0302B07 D3S1176i
131,880,468 131,948,340 0309F10 D3S0809i
131,880,468 131,948,340 0305B06 D3S1053i
133,798,784 133,804,072 0302G03 D3S1306i
135,996,950 136,461,999 390E07 AC016951.9_56629
135,996,950 136,461,999 0308D08 D3S0442i
135,996,950 136,461,999 0311C06 D3S0959i
135,996,950 136,461,999 0316E05 D3S1590
135,996,950 136,461,999 0315E10 D3S3641
135,996,950 136,461,999 0316A04 D3S3696
135,996,950 136,461,999 0303A05 Z67391
138,159,397 138,212,610 0308D05 D3S0357i
138,159,397 138,212,610 0301A12 D3S3617
139,856,921 139,960,875 0315F01 D3S0555i
139,856,921 139,960,875 0307E07 D3S1383i
14,161,648 14,195,143 0312A05 D3S0854i
14,964,240 15,065,784 0312G02 D3S0836i
14,964,240 15,065,784 0301H08 D3S0841i
140,145,756 140,148,491 0309D02 D3S0565i
140,145,756 140,148,491 0304C04 G09845
142,939,741 142,947,933 0308A05 D3S0345i
142,939,741 142,947,933 0301F12 D3S1451i
143,078,160 143,128,072 0305F10 D3S1061i
144,466,754 145,049,979 386E07 AC026673.12_150939
144,466,754 145,049,979 386D07 AC026673.12_52550
144,466,754 145,049,979 398G05 AC073242.3_44298
144,466,754 145,049,979 515D08 chr3.fa.O7frz.163941355
144,466,754 145,049,979 0305H03 D3S1171i
144,466,754 145,049,979 0307B04 D3S1276i
144,466,754 145,049,979 0317A12 D3S1281i
144,466,754 145,049,979 0305D08 D3S1536i
144,466,754 145,049,979 014E03 D3S3599
149,898,355 149,943,478 390F08 AF245699.1_60143
149,898,355 149,943,478 0312D03 D3S0592i
149,898,355 149,943,478 0317A09 D3S1131i
150,230,604 150,287,007 0313D08 D3S0585i
150,230,604 150,287,007 0303G02 D3S1555
150,330,061 150,373,995 0317H01 D3S0362i
152,412,595 152,478,847 387F12 AC024886.10_174359
152,412,595 152,478,847 0310E04 D3S1000i
152,637,167 152,659,187 0301B10 D3S1499i
154,035,426 154,038,535 0302G04 D3S0145i
154,035,426 154,038,535 0301F01 D3S1193i
155,476,152 155,524,971 0301D08 D3S3677
155,476,152 155,524,971 0305H05 D3S3710
156,280,153 156,384,186 0312E11 D3S0134i
156,280,153 156,384,186 0312G05 D3S1004i
158,637,301 158,644,071 0307A05 D3S1311i
16,949,586 17,107,089 0303C06 D3S1429i
16,949,586 17,107,089 0304D08 D3S1452i
161,189,323 161,196,500 388C05 AC026118.8_8957
161,189,323 161,196,500 0311D01 D3S2442
161,189,323 161,196,500 0303B05 D3S3580
161,427,938 161,650,320 0306C10 D3S0398i
161,427,938 161,650,320 0315C07 D3S0693i
161,427,938 161,650,320 0301E11 D3S1482i
162,284,365 162,305,854 0307B06 D3S1354i
168,884,388 168,935,345 0311G10 D3S0989i
168,884,388 168,935,345 0303D02 D3S1494i
170,285,244 170,347,054 0308E07 D3S0395i
170,285,244 170,347,054 T003G02 D3S1282
170,965,092 170,965,542 0309H08 D3S0726i
170,965,092 170,965,542 0302H04 D3S3523
171,422,919 171,506,459 0305D04 D3S1013i
171,422,919 171,506,459 0315B06 D3S1289i
173,706,158 173,723,963 0306B09 D3S0009i
173,706,158 173,723,963 0315C10 D3S0162i
178,221,867 178,397,734 0312D09 D3S1017i
178,221,867 178,397,734 0305A12 D3S1092i
178,221,867 178,397,734 0311D03 D3S1522i
180,349,005 180,435,194 0317F06 D3S1052i
180,349,005 180,435,194 0315D01 Z66727
184,322,697 184,363,317 0303C09 D3S1295i
184,322,697 184,363,317 0317D12 D3S1301i
185,572,467 185,578,626 389H02 AC068634.11_165297
185,572,467 185,578,626 0303D05 D3S3578
186,563,664 186,683,322 0317B09 D3S1132i
187,917,814 187,944,437 0311B11 D3S1037i
187,917,814 187,944,437 0306B12 D3S1093i
188,131,210 188,279,035 128G07 AC007488.15_56318
188,131,210 188,279,035 287H05 AC034190.2_77059
188,131,210 188,279,035 0311C01 D3S1030i
188,131,210 188,279,035 0305D10 D3S1397i
188,418,632 188,492,446 0316D10 D3S3600
188,568,862 188,572,066 0306E10 D3S0421i
188,568,862 188,572,066 706B03 DID22N_0041504
188,869,388 188,870,895 0311B08 D3S1021i
188,869,388 188,870,895 0315H11 D3S1293i
188,869,388 188,870,895 634E03 DISO7_10001334
190,831,910 191,097,759 389G03 AC063939.9_142349
190,831,910 191,097,759 0314C07 D3S0402i
190,831,910 191,097,759 0310H11 D3S1101i
191,714,585 191,858,537 0314A03 D3S0024i
191,714,585 191,858,537 0303B11 D3S0027i
191,714,585 191,858,537 0302F01 D3S1404i
193,342,413 193,928,066 389H04 AC026671.12_22466
193,342,413 193,928,066 389F04 AC027042.2_47409
193,342,413 193,928,066 0314H08 D3S0146i
193,342,413 193,928,066 0305C09 D3S0409i
193,342,413 193,928,066 0309D03 D3S0601i
193,342,413 193,928,066 0309F04 D3S0626i
193,342,413 193,928,066 0311F11 D3S1036i
193,342,413 193,928,066 0311F12 D3S1038i
193,342,413 193,928,066 076H08 D3S2418
193,342,413 193,928,066 015B03 D3S3663
193,342,413 193,928,066 0316F03 D3S3669
195,595,348 195,601,523 0311G12 D3S1039i
197,260,553 197,293,343 0305G02 D3S0165i
197,951,312 198,043,756 0313E04 D3S0161i
197,951,312 198,043,756 0310C11 D3S0163i
198,214,553 198,241,043 0313F11 D3S0158i
198,214,553 198,241,043 0302H08 D3S1464i
213,650 426,098 0311E11 D3S0597i
213,650 426,098 0317C07 D3S1067i
213,650 426,098 0307C01 D3S1206i
23,908,576 23,933,541 0310F04 D3S0837i
23,961,810 23,996,241 0311F04 D3S0472i
24,134,709 24,511,317 357H09 AC069214.5_236353
24,134,709 24,511,317 0307D10 D3S0003i
24,134,709 24,511,317 0312E08 D3S0048i
24,134,709 24,511,317 0314E04 D3S0223i
24,134,709 24,511,317 0307C08 D3S1469i
25,190,893 25,614,424 0313B08 D3S0234i
25,190,893 25,614,424 0317G01 D3S0238i
25,190,893 25,614,424 0308A10 D3S0479i
25,190,893 25,614,424 0308D10 D3S0486i
25,190,893 25,614,424 0301C01 D3S1583
27,732,872 27,738,807 0315D06 D3S1439i
3,086,421 3,127,031 0307F12 D3S0205i
3,086,421 3,127,031 0310C06 D3S0213i
30,622,998 30,710,638 0314B04 D3S0204i
30,622,998 30,710,638 0314E07 D3S0228i
31,549,495 31,652,560 0308A12 D3S0518i
32,255,175 32,386,817 0314B07 D3S0752i
32,255,175 32,386,817 0305F08 D3S1150i
32,255,175 32,386,817 0301B04 D3S1531i
32,408,167 32,471,337 384E06 AC026763.10_85474
32,408,167 32,471,337 384A06 AC046140.9_14929
32,497,808 32,519,869 393A07 AC010742.3_125628
32,497,808 32,519,869 384C06 AC046140.9_123741
32,968,070 32,972,840 0315B10 D3S1457i
33,512,741 33,734,852 0313B04 D3S0254i
33,814,561 33,886,198 282A02 AC078780.1_24631
33,814,561 33,886,198 084G01 Z66622
37,468,817 37,836,285 0315F10 D3S0073i
37,468,817 37,836,285 0304A01 D3S0246i
37,468,817 37,836,285 T001F01 D3S0438i
37,468,817 37,836,285 0315C04 D3S0453i
37,468,817 37,836,285 0315H04 D3S0776i
37,468,817 37,836,285 0313D07 D3S1400i
37,468,817 37,836,285 0303H02 D3S3623
37,878,129 38,000,964 0317G08 D3S1123i
37,878,129 38,000,964 9902F12 D3S1349i
38155009 38159517 MyD881 new design
38155009 38159517 MyD882 new design
39,279,989 39,298,190 0303H03 D3S0070i
39,279,989 39,298,190 0306F01 D3S3527
39,279,989 39,298,190 0303F12 D3S3593
39,346,219 39,351,077 0303H11 D3S0063i
4,510,136 4,864,081 0306E09 D3S0180i
4,510,136 4,864,081 0311G03 D3S0214i
4,510,136 4,864,081 0309D11 D3S0846i
4,510,136 4,864,081 0303A02 D3S1122i
4,510,136 4,864,081 0304F04 D3S1470i
4,510,136 4,864,081 0304H11 Z67067
41,216,004 41,256,938 0301C04 D3S1526i
41,216,004 41,256,938 0303G05 HUMUT2543
42,617,151 42,665,237 0302C09 D3S3687
42,825,980 42,883,779 0312F12 D3S1081i
42,888,688 42,892,637 0314E08 D3S0061i
45,098,773 45,162,918 0307F10 D3S0012i
45,098,773 45,162,918 0312D07 D3S0065i
45,098,773 45,162,918 9903A01 D3S1392i
45,240,962 45,242,758 0310D07 D3S1151i
45,903,023 45,919,671 0313A06 D3S0445i
46,037,295 46,043,983 0312E10 D3S0869i
46,218,204 46,224,836 0303B09 Z67705
46,227,186 46,283,166 0313C02 D3S0004i
46,423,725 46,426,018 0307E10 D3S0010i
46,452,500 46,481,657 0309F03 D3S0605i
46,894,240 46,926,585 0313G02 D3S0884i
46,894,240 46,926,585 0306E07 G08276
47,397,528 47,429,935 0316D11 D3S0236i
47,819,625 47,866,687 0317F02 D3S0840i
48,420,266 48,446,464 0301A03 D3S1313i
49,369,613 49,370,795 0306C07 D3S2409
49,371,582 49,424,530 0301D04 D3S1507i
49,482,595 49,548,048 0315F03 D3S0075i
49,482,595 49,548,048 0316C09 D3S3629
49,696,391 49,701,099 0304A11 D3S1378i
49,899,439 49,916,074 0317E01 D3S0077i
49,899,439 49,916,074 0315C03 D3S2449
49,899,439 49,916,074 0304F07 D3S3667
52,059,799 52,065,329 581B10 chr3.fa.O7frz.59298456
52,059,799 52,065,329 611B01 chr3.fa.O7frz.59596281
52,230,138 52,248,223 0317G04 D3S0058i
52,230,138 52,248,223 0304C07 D3S3561
52,504,396 52,533,551 0305E10 D3S1159i
52,504,396 52,533,551 0317G12 D3S1341i
53,170,263 53,201,773 0305F02 D3S0882i
53,855,612 53,874,867 0315G12 D3S1117i
53,855,612 53,874,867 0305G12 D3S1449i
55,474,783 55,496,371 0301B09 D3S3719
55,517,376 56,477,431 341H03 AC021129.3_44166
55,517,376 56,477,431 0313C08 D3S0261i
55,517,376 56,477,431 0309H03 D3S0609i
55,517,376 56,477,431 0309B12 D3S0885i
55,517,376 56,477,431 0310D08 D3S1416i
55,517,376 56,477,431 0303E05 D3S3588
55,517,376 56,477,431 0316B06 D3S3721
55,517,376 56,477,431 0304G05 D3S3724
55,517,376 56,477,431 076B07 G08284
55,517,376 56,477,431 0315H10 Z67483
57,103,316 57,179,374 0308C11 D3S0511i
57,103,316 57,179,374 0312H08 D3S0866i
57,103,316 57,179,374 0315G09 D3S1173i
61,522,285 62,255,613 0306C09 D3S0016i
61,522,285 62,255,613 0308D02 D3S0251i
61,522,285 62,255,613 0308B03 D3S0264i
61,522,285 62,255,613 0310H05 D3S0637i
61,522,285 62,255,613 0311D09 D3S0760i
61,522,285 62,255,613 0313G01 D3S0763i
61,522,285 62,255,613 0317B06 D3S1044i
61,522,285 62,255,613 0301F11 D3S1045i
69,216,780 69,237,929 0315E12 D3S0263i
69,871,323 70,100,177 611H02 chr3.fa.O7frz.81730591
69,871,323 70,100,177 0306D04 D3S1296
69,871,323 70,100,177 0316G02 D3S1366i
69,871,323 70,100,177 0307B07 D3S1373i
71,087,426 71,715,830 283C05 AC069204.3_182407
71,087,426 71,715,830 0316G01 D3S0080i
71,087,426 71,715,830 0311H11 D3S0095i
71,087,426 71,715,830 0313A01 D3S0098i
71,087,426 71,715,830 0309G05 D3S0645i
71,087,426 71,715,830 0314G12 D3S0651i
71,087,426 71,715,830 0309D12 D3S0887i
71,087,426 71,715,830 0309G12 D3S0892i
71,087,426 71,715,830 T003A02 D3S1562
71,087,426 71,715,830 0302B09 D3S3516
71,087,426 71,715,830 0303E09 D3S3568
85,858,322 86,200,641 430G11 chr3.fa.O7frz.92701960
85,858,322 86,200,641 430H11 chr3.fa.O7frz.92800740
85,858,322 86,200,641 0312E03 D3S0089i
85,858,322 86,200,641 9903F01 D3S1472i
85,858,322 86,200,641 0313H07 D3S1595
87,359,140 87,387,339 0312C11 D3S0289i
87,359,140 87,387,339 0315E08 D3S0894i
87,359,140 87,387,339 0301C12 D3S1513i
9,919,150 9,933,086 0301E06 D3S0050i
9,933,782 9,950,314 0311A03 D3S0179i
95,074,647 95,175,412 0305G09 D3S1471i
1,764,832 1,780,396 0415D12 D4S1055i
101,088,265 101,090,535 0411D02 D4S1218i
102,163,610 102,487,376 343G09 AP001963.1_82726
102,163,610 102,487,376 0402G08 D4S0206i
102,163,610 102,487,376 0411B03 D4S0343i
102,163,610 102,487,376 0415F08 D4S0796i
102,163,610 102,487,376 0413D09 D4S0802i
102,163,610 102,487,376 0414H05 D4S0966i
102,930,919 103,214,918 0410C06 D4S0099i
102,930,919 103,214,918 0409E09 D4S0514i
102,930,919 103,214,918 0406D09 D4S2961
103,641,518 103,757,507 0404D06 D4S0013i
103,641,518 103,757,507 0403C10 D4S0107i
107,456,302 107,489,097 0415A12 D4S0535i
107,456,302 107,489,097 0416C09 D4S0886i
109,072,166 109,094,062 0404F07 D4S0088i
109,072,166 109,094,062 0410A11 D4S0516i
11,009,086 11,040,487 0415G12 D4S0064i
11,009,086 11,040,487 0405G12 D4S2949
110,881,301 110,942,590 0416E04 D4S0738i
111,053,499 111,152,868 0411B01 D4S0023i
111,053,499 111,152,868 0405E10 D4S0035i
111,053,499 111,152,868 0410F08 D4S0091i
111,053,499 111,152,868 0411F06 D4S1217i
111,616,697 111,702,872 0406F09 D4S0877i
111,616,697 111,702,872 0407B11 D4S0961i
114,190,319 114,524,337 0406H08 D4S0048i
114,190,319 114,524,337 0401E03 D4S0096i
114,190,319 114,524,337 0409A10 D4S0524i
114,190,319 114,524,337 0415H11 D4S1250i
114,593,021 114,902,177 172G04 AC004168.2_12092
114,593,021 114,902,177 0401H01 D4S0003i
114,593,021 114,902,177 0408F09 D4S0066i
114,593,021 114,902,177 9911E01 D4S0112i
114,593,021 114,902,177 0402B05 D4S1611
121,200,029 121,207,411 0406A02 D4S0548i
121,200,029 121,207,411 0409B11 D4S0559i
122,808,598 122,837,626 0405C05 D4S0358i
122,957,975 122,964,505 0403B08 D4S1246i
123,592,075 123,597,339 0405G03 D4S1051i
123,753,221 123,761,662 0410A05 D4S0753i
123,967,313 124,038,840 583E05 chr4.fa.O7frz.130586887
123,967,313 124,038,840 0406D05 D4S0540i
129,021,551 129,039,377 0416B06 D4S0804i
14,950,658 15,056,887 0408H03 D4S1104i
14,950,658 15,056,887 0402G05 D4S2362
140,156,393 140,186,543 0415A01 D4S0352i
142,777,204 142,874,062 0411A07 D4S0680i
142,777,204 142,874,062 0414D10 D4S0778i
144,654,066 144,694,017 0416D04 D4S0734i
144,654,066 144,694,017 0404B05 D4S1292i
145,136,707 145,159,946 0401G07 D4S1279i
145,249,906 145,281,294 0404G04 D4S1223i
146,622,401 146,699,778 0403F04 Z67626
148,646,691 148,647,812 0416A01 -
148,646,691 148,647,812 0403F02 D4S0821i
148,646,691 148,647,812 0415G09 D4S1131i
149,219,370 149,582,973 0412A09 D4S0381i
149,219,370 149,582,973 0409H03 D4S0386i
149,219,370 149,582,973 0412G03 D4S0658i
149,219,370 149,582,973 0411G08 D4S0681i
149,219,370 149,582,973 0413E04 D4S0687i
15,313,738 15,343,508 0414G06 D4S1084i
15,313,738 15,343,508 0406F04 Z67830
15,388,999 15,460,167 0407E01 D4S2960
15,578,955 15,686,664 129E03 AC005598.6_64773
15,578,955 15,686,664 0402D10 D4S0060i
153,461,860 153,675,622 0408B12 D4S0270i
153,461,860 153,675,622 0401E09 D4S0599i
153,461,860 153,675,622 0401B11 D4S0610i
153,461,860 153,675,622 0406H01 D4S1057i
154,824,891 154,846,693 0408C05 D4S1132i
154,824,891 154,846,693 0402D08 D4S1179i
155,703,596 155,711,688 0416C03 D4S0101i
156,349,231 156,357,678 0404D12 D4S0183i
159,849,729 159,864,002 0415A07 D4S2997
159,849,729 159,864,002 129F08 D63861.1_4468
166,519,538 166,638,926 0414F01 D4S1252i
166,519,538 166,638,926 0415G01 D4S2952
175,647,955 175,680,213 292F09 AC009887.5_114826
175,647,955 175,680,213 292A10 AC021528.3_90278
175,647,955 175,680,213 0411C03 D4S0773i
175,647,955 175,680,213 0414E03 HUMUT880B
177,841,685 177,950,889 0413D08 D4S0874i
185,545,909 185,632,697 0402F07 D4S1535
185,545,909 185,632,697 0415A04 D4S3047
185,545,909 185,632,697 695E08 DISD22_0004409
187,227,303 187,243,246 0416E08 D4S0875i
187,349,668 187,371,606 0411G02 D4S0225i
187,349,668 187,371,606 0411D01 D4S0824i
2,440,605 2,487,382 0416H09 D4S0908i
2,815,382 2,901,587 0402A11 D4S0001i
24,138,185 24,195,282 0401D06 D4S0045i
24,138,185 24,195,282 0409C06 D4S0460i
24,405,153 24,411,562 0415H01 D4S0009i
24,405,153 24,411,562 0414H03 D4S0039i
24,844,751 24,889,811 T003B03 D4S2970
25,930,430 26,045,851 343F03 AC044869.2_137286
25,930,430 26,045,851 0404G01 D4S0451i
25,930,430 26,045,851 0407F06 Z67448
25,930,430 26,045,851 0415F02 Z67691
38450255 38460984 TLR101 new design
38450255 38460984 TLR102 new design
38,504,618 38,507,555 0405F09 D4S1050i
38,965,471 39,044,390 0402H07 D4S0279i
38,965,471 39,044,390 0402H02 D4S0805i
38,965,471 39,044,390 0414B11 D4S1181i
39,874,965 39,922,663 0413G01 D4S0288i
39,874,965 39,922,663 0403H10 D4S0292i
47,762,988 47,831,030 0403B03 D4S0441i
47,762,988 47,831,030 0411H11 D4S0449i
47,762,988 47,831,030 0416B08 D4S0864i
5,067,214 5,072,100 518E04 chr4.fa.O7frz.5109115
5,067,214 5,072,100 0415C05 HUMUT5936
54,790,204 54,859,171 0411E10 D4S0176i
54,790,204 54,859,171 0402D06 D4S1630
55,218,842 55,301,638 0413A08 D4S0005i
55,218,842 55,301,638 0405G02 D4S428
55,218,842 55,301,638 0401C09 G08377
55,639,401 55,686,519 0406C03 D4S1274i
68,107,041 68,155,206 0404H09 D4S0180i
68,107,041 68,155,206 0412H01 D4S0481i
68,285,688 68,304,399 0414H02 D4S3018
68,369,189 68,432,311 0409E01 D4S0303i
68,369,189 68,432,311 0410F09 D4S0332i
69,085,497 69,116,840 0414C07 D4S1323i
69,996,782 70,013,293 0408C07 D4S1288i
70,180,783 70,323,496 0414E07 D4S0082i
70,180,783 70,323,496 0414B07 D4S1245i
70,928,761 70,936,836 0414G12 D4S0723i
70,928,761 70,936,836 694C08 DISD22_0003744
71,740,548 71,751,128 0406F06 D4S0330i
74825139 74828297 IL81 new design
74,921,277 74,923,341 0408E11 D4S0196i
75,065,660 75,066,541 0406F05 D4S0494i
75,121,170 75,123,354 9903B03 D4S1308i
75,449,724 75,473,341 0409A07 D4S0471i
75,529,717 75,539,590 0413D04 D4S0475i
75,529,717 75,539,590 0416E10 D4S0942i
75,889,001 75,938,853 0407F10 D4S0951i
75,889,001 75,938,853 0414G02 D4S1558
77,141,523 77,147,665 0407D02 D4S3042
77,298,918 77,354,059 0403E10 D4S1291i
77,298,918 77,354,059 0407H01 D4S2990
78,651,931 78,752,010 0407H10 D4S0955i
78,651,931 78,752,010 0407A11 D4S0959i
78,651,931 78,752,010 0402A08 D4S1165i
81,406,766 81,431,195 0413C05 D4S0175i
81,406,766 81,431,195 0415C11 D4S0937i
82,171,143 82,193,749 0410A06 D4S0187i
82,171,143 82,193,749 0409E07 D4S0484i
84,432,639 84,475,330 0407H02 D4S395
87,156,656 87,593,307 0401E04 D4S0197i
87,156,656 87,593,307 0409F09 D4S0517i
87,156,656 87,593,307 0416F12 D4S1110i
87,156,656 87,593,307 9903A03 D4S1255i
87,156,656 87,593,307 0415F10 Z67188
87,734,909 87,955,326 0408F10 D4S0152i
87,734,909 87,955,326 0406G11 D4S1542
87,734,909 87,955,326 0408A08 G08379
89,115,826 89,123,592 0412B08 D4S0314i
89,115,826 89,123,592 0403E03 D4S1158i
89,230,440 89,299,035 0415F07 D4S0898i
89,518,915 89,583,272 0415A09 D4S0900i
89,518,915 89,583,272 0414D05 D4S0901i
89,518,915 89,583,272 0413F07 D4S1171i
9,055,358 9,061,338 0411H02 D4S0709i
95,438,730 95,483,050 0407H11 D4S0976i
95,898,151 96,295,099 0407C07 D4S0054i
95,898,151 96,295,099 0413H02 D4S0198i
95,898,151 96,295,099 0409A09 D4S0506i
95,898,151 96,295,099 0405G06 D4S0960i
95,898,151 96,295,099 0406A08 D4S0982i
0514C01 D5S1480
0504A06 D5S647
1,306,282 1,348,162 0515A11 D5S2005
1,306,282 1,348,162 018D04 D5S678
10,732,343 10,814,344 0513D06 D5S0309i
10,732,343 10,814,344 0507B01 D5S432
110,433,677 110,441,623 0503D08 D5S0383i
110,433,677 110,441,623 0509F12 D5S0676i
110,587,968 110,858,483 0506H08 D5S0122i
110,587,968 110,858,483 0512F03 D5S0345i
110,587,968 110,858,483 0509C11 D5S0643i
110,587,968 110,858,483 0511B01 D5S0649i
112,101,483 112,209,835 0502C01 D5S0048i
112,101,483 112,209,835 0509G12 D5S0677i
114,942,247 114,989,610 0514F09 D5S0658i
114,942,247 114,989,610 0510F07 D5S0873i
115,168,329 115,180,304 0508B12 D5S0358i
122,386,977 122,400,324 9903E11 D5S1319i
122,386,977 122,400,324 0502E08 Z67521
131,424,121 131,426,796 0501A03 D5S1174i
131,658,035 131,707,798 0509C01 D5S0386i
131,658,035 131,707,798 0515E01 D5S1984
131,658,035 131,707,798 661B02 DISO7_10004993
131,733,343 131,759,205 0512B12 D5S0822i
131,845,200 131,854,389 0511E05 D5S0707i
131,920,529 132,007,651 0513B07 D5S0868i
132,235,913 132,238,637 0507F07 D5S0004i
132,235,913 132,238,637 0507C11 D5S1011i
132,415,561 132,468,608 0501B03 D5S1016i
134,122,360 134,194,710 0506H11 D5S0021i
134,122,360 134,194,710 0501G10 D5S458
134,934,274 134,942,868 0501H01 D5S0829i
135,255,834 135,259,415 0508F06 D5S0085i
135,255,834 135,259,415 0513B12 D5S0780i
135,255,834 135,259,415 0504A05 D5S816
137,503,358 137,542,257 0514E07 D5S0182i
137,503,358 137,542,257 0503B06 D5S0421i
137,503,358 137,542,257 0501F02 D5S414
137,829,080 137,832,903 0507A12 D5S1032i
137,829,080 137,832,903 0502C06 D5S500
139,207,444 139,403,063 0513D01 D5S0272i
139,207,444 139,403,063 0509B02 D5S0415i
139,207,444 139,403,063 0511H07 D5S0694i
139,692,612 139,706,359 0501A06 D5S0273i
139,692,612 139,706,359 0503C09 D5S1305i
139,991,501 139,993,439 0504G03 D5S0084i
140,005,142 140,007,424 0511D07 D5S0704i
140,494,984 140,497,888 0506C07 D5S658
140,541,164 140,545,980 0504F08 D5S0116i
140,980,627 140,996,596 0506D11 D5S1267i
141,951,927 142,046,134 368A06 AC016560.6_172920
141,951,927 142,046,134 0506E12 D5S0125i
142,637,689 142,795,270 0514B11 D5S0041i
142,637,689 142,795,270 0510C02 D5S0500i
143,171,919 143,180,477 0509E05 D5S0505i
143,171,919 143,180,477 0511C05 D5S0699i
148,734,023 148,739,031 347A08 AC012613.5_58125
148,734,023 148,739,031 0506C06 D5S1196i
148,855,038 148,911,200 0514C02 D5S0717i
149,413,051 149,473,128 0514B07 D5S0162i
149,413,051 149,473,128 0508F09 D5S0264i
149,473,595 149,515,615 0508E08 D5S0157i
149,473,595 149,515,615 0503D05 D5S2015
149,761,393 149,772,685 0514H09 D5S0879i
150,207,879 150,260,488 0502E10 D5S1023i
150,380,112 150,388,747 0503E02 D5S0266i
156,445,421 156,468,716 0506H05 D5S0445i
156,540,432 156,614,687 369H02 AC009185.4_71677
156,540,432 156,614,687 0514G07 D5S0196i
158,058,006 158,459,347 254D05 AC007200.1_36545
158,058,006 158,459,347 369D03 AC011376.2_79673
158,058,006 158,459,347 0505E11 D5S0002i
158,058,006 158,459,347 0508B07 D5S0097i
158,058,006 158,459,347 0515G06 D5S2038
158,058,006 158,459,347 0506F06 D5S412
158,674,369 158,690,059 295G10 AC011376.2_147332
158,674,369 158,690,059 0511A09 D5S0722i
158,674,369 158,690,059 058F03 Z67033
159,707,339 159,730,207 0508A03 D5S1138i
159,707,339 159,730,207 0501A01 D5S403
162,797,155 162,804,600 0507G05 D5S2093
162,820,241 162,851,525 0513A12 D5S0091i
168,996,871 169,442,959 0514A07 D5S0160i
168,996,871 169,442,959 0510D07 D5S0277i
168,996,871 169,442,959 0508F11 D5S0341i
168,996,871 169,442,959 0511C06 D5S0726i
168,996,871 169,442,959 0505C10 D5S1456
168,996,871 169,442,959 0504B01 D5S1961
168,996,871 169,442,959 0505H02 D5S1973
168,996,871 169,442,959 0506E04 D5S504
169,465,495 169,469,305 0506A03 D5S0063i
169,607,666 169,657,400 0513H10 D5S0169i
169,607,666 169,657,400 0506H01 HUMUT7277
172,127,707 172,130,809 0511E06 D5S0736i
172,504,130 172,523,989 0511G07 D5S0747i
172,504,130 172,523,989 0514C05 D5S1088i
172,504,130 172,523,989 0503D09 D5S394
175,017,637 175,045,847 0514D06 D5S0066i
175,017,637 175,045,847 0508C08 D5S0155i
176,446,493 176,457,733 0513H04 D5S0448i
176,871,184 176,876,573 0513F09 D5S0512i
176,871,184 176,876,573 0506D09 D5S1078i
179,058,536 179,091,248 021C07 D5S2073
179,595,388 179,640,218 0504E02 D5S0752i
179,945,812 180,009,172 348F06 AC022095.4_12069
179,945,812 180,009,172 0513A04 D5S0755i
179,945,812 180,009,172 021D07 D5S408
180,458,383 180,460,484 9903F04 D5S1069i
180,458,383 180,460,484 0501E06 Z66649
324,739 488,225 672C05 chr5.fa.O7frz.1514538
324,739 488,225 0514G10 D5S1178i
324,739 488,225 0514A01 D5S392
34,022,040 34,160,396 0510G04 D5S0562i
34,022,040 34,160,396 0511B11 D5S0798i
34,022,040 34,160,396 0508B01 D5S1079i
35,084,621 35,266,334 0504H10 D5S0580i
35,084,621 35,266,334 0508F01 D5S1093i
35,084,621 35,266,334 0506E10 D5S1213i
35,084,621 35,266,334 0503C11 D5S493
35,892,748 35,915,462 0508H03 D5S1173i
35,892,748 35,915,462 0515F05 D5S2025
36,187,946 36,219,904 0508H10 D5S0326i
36,187,946 36,219,904 0506H06 D5S1268i
36,187,946 36,219,904 0504F02 Z66972
38,510,822 38,631,253 0501A09 D5S1071i
38,510,822 38,631,253 0511E02 D5S1197i
38,510,822 38,631,253 0503C05 Z67436
39,141,114 39,255,432 0507H07 D5S0146i
39,141,114 39,255,432 0508G08 D5S0217i
39,141,114 39,255,432 0505D06 D5S0573i
39,320,061 39,400,412 0510C03 D5S1073i
40,715,789 40,729,594 0505A02 D5S0954i
40,715,789 40,729,594 0505C08 D5S1061i
40,877,043 40,896,025 0513C07 D5S0566i
40,945,356 41,018,798 0507E06 D5S1457
41,178,093 41,297,297 597A07 chr5.fa.O7frz.46786737
41,178,093 41,297,297 0515A07 D5S0081i
42,459,783 42,757,736 0509H07 D5S0583i
42,459,783 42,757,736 0507E08 D5S0927i
42,459,783 42,757,736 0505H03 D5S1264i
42,459,783 42,757,736 0506A10 D5S1297i
43,229,915 43,448,250 0514G11 D5S0180i
43,229,915 43,448,250 9903A09 D5S0986i
43,229,915 43,448,250 0514F05 D5S1251i
44,340,854 44,424,541 0513G03 D5S0483i
44,340,854 44,424,541 0502D10 D5S2063
52,119,531 52,285,242 0515H02 D5S1202i
52,119,531 52,285,242 0503F10 D5S623
52,119,531 52,285,242 667F02 DISO7_10995141
52,321,014 52,423,947 0501E09 D5S1184i
52,321,014 52,423,947 0505F03 D5S1239i
54,355,838 54,366,155 0501H05 D5S1191i
54,434,230 54,441,837 667B03 DISO7_11025103
54,587,830 54,639,278 0508A01 D5S1056i
55,069,609 55,148,362 0508H08 D5S0225i
55,069,609 55,148,362 0513H06 D5S0578i
55,069,609 55,148,362 0503F03 D5S664
55,183,091 55,248,922 0504A01 D5S645
55,266,680 55,326,529 0502A11 D5S1340i
56,146,022 56,227,736 0509D08 D5S0591i
56,146,022 56,227,736 0505A09 D5S1237i
58,302,468 59,320,301 293D08 AC026095.3_41930
58,302,468 59,320,301 526B08 chr5.fa.O7frz.64839304
58,302,468 59,320,301 0508B05 D5S0012i
58,302,468 59,320,301 0508E06 D5S0079i
58,302,468 59,320,301 0513E01 D5S0585i
58,302,468 59,320,301 0510F04 D5S0785i
58,302,468 59,320,301 0511F12 D5S0843i
58,302,468 59,320,301 019A06 D5S2000
58,302,468 59,320,301 0502E03 D5S2080
58,302,468 59,320,301 0515B04 D5S2091
58,302,468 59,320,301 0501F04 D5S431
58,302,468 59,320,301 0507B02 D5S468
58,302,468 59,320,301 0504E06 HUMUT2092
58,302,468 59,320,301 0504G04 HUMUT5438
66,513,872 66,528,368 0512C10 D5S0188i
66,513,872 66,528,368 0508D11 D5S0336i
66,513,872 66,528,368 0503F08 D5S1210i
67,547,360 67,633,405 0512B10 D5S0235i
67,547,360 67,633,405 0509E08 D5S0593i
68,498,593 68,509,828 367A02 AC010273.3_156905
68,498,593 68,509,828 294A03 AC022107.5_95947
68,498,593 68,509,828 0501E07 HUMUT1151
68,682,567 68,701,596 9903G08 D5S0934i
68,682,567 68,701,596 0514E05 D5S1177i
7,922,217 7,954,237 0507B09 D5S0943i
7,922,217 7,954,237 0514B05 D5S0949i
72,777,839 72,780,108 0509H04 D5S0493i
72,777,839 72,780,108 0504F06 D5S1140i
73,958,990 73,973,005 0514D09 D5S0610i
73,958,990 73,973,005 0509A10 D5S0618i
73,958,990 73,973,005 0505G07 D5S0623i
74,668,790 74,693,685 0513C04 D5S0144i
74,668,790 74,693,685 0510E04 D5S0148i
74,702,684 74,843,719 0501G04 D5S0840i
75,947,063 75,954,996 0508D08 D5S0156i
75,947,063 75,954,996 0512B06 D5S0338i
76,047,542 76,067,054 0503F05 D5S1284i
76,150,610 76,166,896 0507E03 D5S424
77,816,794 77,841,979 0508F07 D5S0124i
77,816,794 77,841,979 0509D10 D5S0629i
79,957,801 79,986,556 0510G12 D5S1057i
79,957,801 79,986,556 0502C07 D5S1120i
82,803,339 82,912,737 0513F03 D5S0194i
82,803,339 82,912,737 9903D06 D5S0778i
82,803,339 82,912,737 9903C05 Z67581
86,599,461 86,723,489 0511E11 D5S0615i
86,599,461 86,723,489 0513G02 D5S1205i
86,599,461 86,723,489 0515D09 D5S1248i
92,944,799 92,956,077 0508G11 D5S0342i
96,122,277 96,169,559 0514G12 D5S0053i
96,122,277 96,169,559 0511F01 D5S0633i
96,122,277 96,169,559 0509H10 D5S0638i
0606D01 D6S426
0606F12 D6S461
1,257,675 1,259,983 9904D01 D6S0367i
1,257,675 1,259,983 0609F06 D6S0630i
1,335,068 1,340,831 0605B06 Z67528
1,555,206 1,559,131 0603H06 D6S0303i
1,569,040 2,190,845 0614H01 D6S0280i
1,569,040 2,190,845 0611G01 D6S0641i
1,569,040 2,190,845 0609A07 D6S0645i
1,569,040 2,190,845 0613H03 D6S0649i
10,636,575 10,737,587 0605F02 D6S0656i
10,636,575 10,737,587 0605H07 D6S1025i
100,939,606 101,019,494 0602F10 D6S0792i
100,939,606 101,019,494 0612F12 D6S0996i
101,953,385 102,624,651 0602B03 D6S1642
105,282,661 105,414,867 0609F11 D6S0772i
105,282,661 105,414,867 0605D02 D6S1254i
106,640,888 106,664,507 0614C09 D6S1049i
106,640,888 106,664,507 0606G07 D6S1241i
106,739,044 106,880,388 0612B08 D6S0031i
106,739,044 106,880,388 0606G05 D6S0779i
107,918,010 108,089,195 0608B04 D6S0085i
107,918,010 108,089,195 0613B04 D6S0999i
108,593,955 108,616,706 0613D02 D6S0043i
108,593,955 108,616,706 023G09 D6S1594
108,593,955 108,616,706 0604A01 Z67377
108,987,719 109,108,661 0607F07 D6S0497i
108,987,719 109,108,661 0605D07 D6S1167i
109,794,412 109,810,353 0607H09 D6S1050i
109,820,624 109,868,524 0604H03 D6S0905i
11,291,517 11,490,535 531B10 chr6.fa.O7frz.12034704
11,291,517 11,490,535 0608C04 D6S0089i
11,291,517 11,490,535 0603E10 D6S0103i
11,291,517 11,490,535 0610F08 D6S0283i
11,291,517 11,490,535 0608F12 D6S0386i
110,527,715 110,607,900 0609G05 D6S0605i
110,527,715 110,607,900 0602E08 HUMUT893
111,409,984 111,453,487 0603A07 D6S1698
112,088,228 112,301,348 0612G11 D6S0766i
112,088,228 112,301,348 0601A09 D6S0768i
112,088,228 112,301,348 023D10 D6S302
112,088,228 112,301,348 175G07 Z97989.1_71410
112,536,654 112,682,605 0608B06 D6S0172i
112,536,654 112,682,605 0612E09 D6S0394i
112,536,654 112,682,605 0612E02 D6S0775i
114,368,571 114,399,029 0609G11 D6S0776i
114,368,571 114,399,029 0601B03 D6S401
116,369,386 116,488,614 0605E06 D6S0428i
116,369,386 116,488,614 0602F07 D6S0878i
117,305,068 117,360,008 0606A01 D6S1206i
118,892,932 119,137,924 0614G08 D6S0282i
118,892,932 119,137,924 0602D01 D6S0548i
118,892,932 119,137,924 0612B04 D6S0784i
118,892,932 119,137,924 0601H06 D6S0790i
119,540,965 119,712,625 0607G06 D6S0273i
119,540,965 119,712,625 0609G02 D6S0461i
12,398,582 12,405,413 0602E02 D6S0100i
12,398,582 12,405,413 0614F03 D6S0144i
12,825,819 13,396,624 0601D05 D6S0371i
124,166,768 125,188,502 0602D11 D6S0559i
126,144,000 126,293,950 0612D02 D6S0930i
127,813,023 127,879,540 0613G06 D6S0573i
128,331,625 128,883,453 0613F06 D6S0077i
128,331,625 128,883,453 0613E04 D6S0270i
128,331,625 128,883,453 0603D01 D6S0536i
128,331,625 128,883,453 0605F03 D6S0822i
128,331,625 128,883,453 0607A05 D6S1030
128,331,625 128,883,453 0604D06 D6S1033
129,246,035 129,879,407 0612B06 D6S0589i
129,246,035 129,879,407 0604B10 D6S0798i
129,246,035 129,879,407 0611A06 D6S0833i
129,246,035 129,879,407 0601H03 D6S1047i
129,246,035 129,879,407 0601E03 D6S1075i
129,246,035 129,879,407 0605C03 D6S1226i
129,246,035 129,879,407 0602G07 D6S1244i
131,202,180 131,426,017 0607B08 D6S0834i
131,202,180 131,426,017 0607A04 D6S1572
131,508,154 131,646,366 0612E11 D6S0068i
131,508,154 131,646,366 0609D12 D6S0799i
131,935,977 131,947,165 9903D12 D6S1622i
131,935,977 131,947,165 024D02 D6S457
131,935,977 131,947,165 0605F01 HUMUT5174B
132,000,135 132,110,243 207D10 AC005587.1_83579
132,000,135 132,110,243 183F08 AL135904.11_38895
132,310,199 132,314,206 0612F06 D6S0028i
132,310,199 132,314,206 0614D03 D6S0041i
132,658,887 132,764,357 0608A09 D6S0271i
132,658,887 132,764,357 0614H07 D6S0998i
133,044,422 133,076,881 0605C07 D6S0407i
133,044,422 133,076,881 0613C10 D6S1171i
134,532,081 134,680,889 0614C07 D6S0807i
134,532,081 134,680,889 0601G06 D6S270
134,532,081 134,680,889 0601H01 D6S976
136,705,565 136,913,485 0611B10 D6S0835i
136,919,878 137,155,349 0604A08 D6S0422i
136,919,878 137,155,349 T001A12 D6S0478i
136,919,878 137,155,349 0602E11 D6S0800i
136,919,878 137,155,349 0613B07 D6S1003i
137,362,801 137,407,991 0613F11 D6S0808i
137,362,801 137,407,991 0606A06 D6S1009
137,506,650 137,536,478 0611G10 D6S0813i
138,230,274 138,246,142 0610B03 D6S0907i
138,230,274 138,246,142 0611A05 D6S0915i
139,158,950 139,266,900 0609B05 D6S0590i
139,158,950 139,266,900 0605F05 D6S0801i
139,497,942 139,543,639 0601C06 D6S0561i
139,497,942 139,543,639 0604A12 D6S0564i
139,735,089 139,737,478 0604A05 D6S1109i
14,225,715 14,245,128 0602A09 D6S0879i
14,225,715 14,245,128 0614A02 D6S429
143,114,297 143,308,031 0608G07 D6S0229i
143,114,297 143,308,031 0603H11 D6S0337i
143,114,297 143,308,031 094F12 HUMUT525
143,114,297 143,308,031 087H02 HUMUT7700
143,788,765 143,813,517 0605H11 D6S0094i
143,788,765 143,813,517 0610G11 D6S0560i
143,971,010 144,194,014 0608F07 D6S0228i
143,971,010 144,194,014 0603B06 D6S0552i
143,971,010 144,194,014 0614A01 D6S1704
144,513,356 144,551,200 0613D08 D6S0830i
144,513,356 144,551,200 0614G07 D6S0987i
144,513,356 144,551,200 0601E10 D6S1003
144,654,566 145,215,863 0603G05 D6S0836i
147,566,565 147,748,588 0609D06 D6S0626i
147,566,565 147,748,588 0609E06 D6S0627i
147,566,565 147,748,588 0607G07 D6S0628i
148,313 151,392 0603H10 D6S1086i
148,313 151,392 0610A01 D6S1139i
149,680,756 149,774,442 9903A12 -
149,680,756 149,774,442 187B08 AL031056.1_26387
149,680,756 149,774,442 183B02 AL031056.1_52627
149,680,756 149,774,442 0611H09 D6S0203i
149,680,756 149,774,442 0606G03 D6S0241i
149,680,756 149,774,442 024D06 D6S1553
149,867,324 149,908,864 9904A01 D6S0831i
150,112,273 150,174,249 0610B02 D6S1117i
150,251,294 150,253,863 0607G05 HUMUT5779
150,304,829 150,312,064 0601A08 D6S0841i
151,603,202 151,719,602 0612E04 D6S0933i
151,603,202 151,719,602 0601H08 D6S476
152,170,379 152,466,099 0603C04 D6S0027i
152,170,379 152,466,099 0609G01 D6S0433i
152,170,379 152,466,099 0609A03 D6S0468i
152,170,379 152,466,099 0610C09 D6S0846i
152,484,515 153,000,227 0610C11 D6S0117i
152,484,515 153,000,227 0605G05 D6S0226i
152,484,515 153,000,227 0611E12 D6S0853i
152,484,515 153,000,227 0611A12 D6S0935i
153,113,626 153,122,593 0613B10 D6S0593i
154,402,136 154,609,693 0611H10 D6S0346i
155,620,488 155,686,932 0601B01 D6S0937i
155,620,488 155,686,932 0604A11 D6S1162i
155,758,194 155,818,729 183G06 AL133474.9_33793
155,758,194 155,818,729 176F12 AL133474.9_63821
155,758,194 155,818,729 0609D02 D6S0453i
157,140,756 157,572,094 0605A09 D6S0470i
157,140,756 157,572,094 0610A03 D6S0838i
158,164,282 158,286,097 0613F01 D6S0044i
158,164,282 158,286,097 0606C02 D6S0582i
158,509,372 158,535,008 586F01 chr6.fa.O7frz.168445622
158,509,372 158,535,008 537F05 chr6.fa.O7frz.168477401
158,509,372 158,535,008 0611C07 D6S0863i
16,407,322 16,869,700 0609D04 D6S0516i
160,020,138 160,034,343 0611E08 D6S0970i
160,066,607 160,097,341 0601G02 D6S1581
160,310,121 160,447,573 0606F04 D6S0005i
160,310,121 160,447,573 0601E08 D6S0260i
160,310,121 160,447,573 0605C10 D6S0279i
160,462,853 160,499,740 0604G11 D6S0445i
160,462,853 160,499,740 0602B01 D6S0553i
160,462,853 160,499,740 0614D07 D6S0854i
161,471,047 161,615,097 0608C10 D6S0324i
161,471,047 161,615,097 0606E02 D6S0330i
161,471,047 161,615,097 0602G08 D6S0351i
161,688,442 163,068,793 T001G10 D6S1011i
163,068,154 163,656,514 0611G12 D6S0934i
165,660,766 165,995,578 0602G06 D6S0459i
166,742,844 167,195,761 0601C05 D6S1585
167,332,660 167,473,174 0613F09 D6S0086i
167,332,660 167,473,174 0606B11 D6S0566i
167,332,660 167,473,174 0612F07 D6S0859i
167,928,066 167,940,388 0608H03 D6S0075i
167,928,066 167,940,388 0606E10 D6S0218i
170,457,769 170,556,162 0608G04 D6S0105i
170,457,769 170,556,162 0608G10 D6S0331i
170,457,769 170,556,162 0601E11 D6S1590
170,686,134 170,704,312 0606D10 D6S0204i
170,686,134 170,704,312 0612B01 D6S0249i
18,236,521 18,263,353 0613H08 D6S0037i
2,710,665 2,731,926 0607F09 D6S1039i
2,832,499 2,848,513 0612B11 D6S0116i
20,642,667 21,340,614 0603B10 D6S0153i
22,395,459 22,405,709 0602C09 D6S0373i
22,395,459 22,405,709 0607C05 Z67232
22,677,657 22,679,871 0605B12 D6S0136i
22,677,657 22,679,871 0611F05 D6S0958i
237,053 296,355 0611C05 D6S0887i
237,053 296,355 0601E05 D6S1090i
24,758,184 24,775,240 135B03 AL031230.1_102019
24,758,184 24,775,240 0601B07 D6S0676i
25,387,285 25,728,737 0606D09 G08569
26,195,427 26,205,038 T002G03 D6S0284i
26,510,460 26,523,445 0607H08 D6S1026i
26,510,460 26,523,445 0602G12 D6S1248i
27,323,487 27,332,327 0603C01 D6S0243i
27,323,487 27,332,327 0613A05 D6S1155i
28,217,695 28,233,215 0611G03 D6S0111i
28,217,695 28,233,215 0610F02 D6S0660i
28,301,046 28,309,239 0606C06 D6S0147i
29,631,368 29,778,041 181A05 AC006162.1_38368
29,631,368 29,778,041 186A07 AL050328.24_38345
29,732,755 29,748,128 174B01 AL050328.24_40038
29,798,531 29,803,052 180G06 AF055066.1_308034
29799096 29803052 D6S2770 D6S2770
29799096 29803052 D6S2872 D6S2872
29799096 29803052 D6S2910 D6S2910
29799096 29803052 D6S2911 D6S2911
29,802,425 29,802,895 613G10 chr6.fa.O7frz.33382117
29,902,723 30,021,633 0610D04 D6S0668i
3,009,212 3,060,420 0607A11 D6S1088i
30018310 30021633 D6S2704 D6S2704
30018310 30021633 D6S2707 D6S2707
30018310 30021633 D6S2838 D6S2838
30018310 30021633 D6S2847 D6S2847
30018310 30021633 697B02 DISD22_0011489
30018310 30021633 022G02 -
30018310 30021633 186B05 -
30,030,962 30,031,390 0607C02 D6S265
30,107,469 30,109,633 0603F12 D6S0509i
30,212,487 30,224,491 733H11 DIJ28_10010194
30,227,701 30,236,690 0610D05 D6S0014i
30,420,877 30,422,649 0609C04 D6S0505i
30,561,651 30,562,700 0612D01 D6S0493i
30565250 30569077 C3_2_11, D6S2840 C3_2_11, D6S2840
30565250 30569077 D6S2799 D6S2799
30,621,633 30,632,987 0609G04 D6S0525i
30,775,563 30,793,645 0605H05 D6S1124i
30888622 30906415 C4_2_12, D6S2827 C4_2_12, D6S2827
30,983,956 30,989,859 0607D12 D6S1128i
31,059,474 31,065,654 0606D05 D6S0076i
31344505 31432935 C1_2_5, D6S2811 C1_2_5, D6S2811
31344505 31432935 C1_2_A, D6S2793 C1_2_A, D6S2793
31344505 31432935 C1_4_3, D6S2930 C1_4_3, D6S2930
31344505 31432935 C1_4_4, D6S2931 C1_4_4, D6S2931
31344505 31432935 D6S2792 D6S2792
31429628 31432914 C1_3_2a, D6S2902 C1_3_2a, D6S2902
31429628 31432914 C2_4_3, D6S2938 C2_4_3, D6S2938
31429628 31432914 C4_2_7, D6S2825 C4_2_7, D6S2825
31,475,540 31,491,069 186H03 AB031008.1_2319
31,538,938 31,541,565 0602G01 D6S0517i
31,604,718 31,605,987 0612H04 D6S1220i
31,648,042 31,650,080 TNFa Udalova
31,648,042 31,650,080 TNFb Udalova
31,648,042 31,650,080 TNFc Udalova
31,648,042 31,650,080 TNFd Udalova
31,648,042 31,650,080 TNFe Udalova
31648072 31650077 S2780, D6S1615, D6S27D6S2780, D6S1615, D6S278
31651329 31654091 D6S2924 D6S2924
31,690,984 31,692,781 022F03 D6S273
31696429 31713533 BAT2CA,  D6S2787 BAT2CA,  D6S2787
31,752,440 31,759,796 186A04 AF134726.1_179024
31,129,963 31,135,632 134E07 -
32003473 32021428 D6S2740 D6S2740
32003473 32021428 D6S2913 D6S2913
32084175 32185131 3-3, D6S2920 3-3, D6S2920
32,204,462 32,206,045 0603B07 D6S1255i
32,266,521 32,299,822 0613G11 D6S0267i
32,266,521 32,299,822 079C09 D6S1014
32270598 32299822 D6S2894 new design
32368453 32460310 3-7, D6S2892 3-7, D6S2892
32,368,464 32,447,662 0609D03 D6S0483i
32,515,597 32,520,943 0610H04 D6S0518i
32515625 32520801 DRA_CA, D6S2883 DRA_CA, D6S2883
32,654,524 32,665,603 310G03 AC026010.3_134784
32,713,112 32,719,407 022B04 D6S1666
32735222 32754296 D6S2818 D6S2818
32735222 32754296 G511525 new design
32,735,225 32,742,572 9903E12 D6S0067i
32,831,445 32,839,446 697A03 DISD22_0000187
32,888,518 32,892,803 132A02 X87344.1_184861
32,897,588 32,914,525 0602A04 D6S1104i
33,044,415 33,057,075 0614C04 D6S0274i
33,188,206 33,204,868 0602F11 D6S0512i
33238447 33268223 M2_2_9, D6S2731 M2_2_9, D6S2731
33238447 33268223 M2_4_25, D6S2822 M2_4_25, D6S2822
33238447 33268223 186C02 -
33,276,631 33,280,192 0609A04 D6S0498i
33,326,027 33,347,640 186G05 Z97183.1_16345
33,375,449 33,390,142 0608H06 D6S0196i
33,648,307 33,655,997 133F12 Z93017.6_2832
33,696,500 33,772,329 0601H07 D6S1165i
34,541,883 34,610,984 0601A01 HUMUT2253
34,541,883 34,610,984 0607F05 HUMUT6615
35,418,313 35,503,933 0613A02 D6S0990i
35,649,345 35,804,338 0614D11 D6S1211i
35,649,345 35,804,338 0603G11 D6S1645
35,908,789 35,996,942 0608H02 D6S0036i
35,908,789 35,996,942 0601G04 D6S0664i
36,103,551 36,186,513 0602C10 G10173
36,129,769 36,215,820 0611B04 D6S0035i
36,129,769 36,215,820 T002C03 D6S0078i
36,569,647 36,623,234 0611H01 D6S0234i
36,569,647 36,623,234 0605A03 D6S0992i
36,754,413 36,763,094 0605C05 D6S0335i
36,754,413 36,763,094 0605B02 D6S1051
36,930,581 36,950,778 0603H03 D6S0508i
36,930,581 36,950,778 9904H01 D6S1010i
37,245,957 37,251,182 0609A08 D6S0682i
37,895,285 38,230,375 0601A12 D6S0233i
37,895,285 38,230,375 0603C11 D6S0312i
37,895,285 38,230,375 0612F05 D6S0670i
38,250,711 38,673,848 0613D06 D6S0347i
38,250,711 38,673,848 0609H07 D6S0679i
38,792,313 39,106,545 0611A09 D6S0017i
38,792,313 39,106,545 0608B12 D6S0370i
38,792,313 39,106,545 0610E02 D6S0524i
38,792,313 39,106,545 0614F07 D6S0895i
39,868,120 39,980,622 0605E03 D6S1168i
39,868,120 39,980,622 0604D12 D6S1641
41,102,749 41,114,906 0614E03 D6S0047i
41,102,749 41,114,906 0603A10 D6S0302i
41,224,979 41,230,048 0607D02 D6S1575
41,284,270 41,298,360 9904A02 D6S1012i
41,411,505 41,426,603 0608G08 D6S0263i
41,622,142 41,678,100 0602D03 D6S0379i
41,622,142 41,678,100 0609B08 D6S0683i
41,622,142 41,678,100 0608H01 D6S1672
42,010,649 42,124,404 0608C12 D6S0372i
42,010,649 42,124,404 0604H07 D6S1552
42,300,647 42,527,767 0608A10 D6S0320i
42,300,647 42,527,767 0612H08 D6S0671i
42,300,647 42,527,767 0603C02 D6S1237i
42,300,647 42,527,767 0602A07 HUMUT2081
43,039,586 43,054,936 0601G12 D6S0294i
43,039,586 43,054,936 0606H05 D6S1209i
43,152,007 43,237,435 0605D03 D6S1582
43,845,924 43,862,202 0609E07 D6S0662i
43,845,924 43,862,202 0610H01 D6S1031i
44,322,802 44,329,598 0607A09 D6S1027i
44,322,802 44,329,598 0607A02 D6S1650
44,333,881 44,341,503 0607G08 D6S1024i
45,404,032 45,626,797 0611D06 D6S0918i
46,625,404 46,728,482 0608C03 D6S0060i
46,625,404 46,728,482 0603D10 D6S1541
46,625,404 46,728,482 0610D01 D6S1638
46,779,897 46,811,389 0604B11 D6S0691i
47,307,227 47,385,639 0605G11 D6S0290i
47,307,227 47,385,639 0604G10 D6S0489i
47,307,227 47,385,639 0604H02 Z66926
47,553,899 47,702,620 0611G07 D6S0874i
47,553,899 47,702,620 0604E03 D6S0978i
47,953,998 48,144,384 0609C08 D6S0686i
47,953,998 48,144,384 0610E07 D6S0715i
47,953,998 48,144,384 0604B07 HUMUT596
49,680,830 49,712,511 0613H10 D6S0299i
49,680,830 49,712,511 0613F02 HUMUT6326
50,035,964 50,039,777 0606D11 D6S0598i
50,084,810 50,097,607 0605D01 D6S0602i
51,588,104 52,060,382 0608F10 D6S0327i
51,588,104 52,060,382 0603C07 D6S0487i
51,588,104 52,060,382 0611H05 D6S0919i
51,588,104 52,060,382 0605H09 HUMUT7510
52,159,144 52,163,395 0612D03 D6S0702i
52,209,438 52,217,257 0605H02 D6S0250i
52,209,438 52,217,257 0604F04 D6S1195i
52,392,953 52,468,540 0609F02 D6S0460i
52,470,159 52,549,821 0610H02 D6S0709i
52,764,183 52,776,616 0606B02 D6S0115i
53,470,098 53,517,790 0610D03 D6S0692i
53,470,098 53,517,790 0606C07 D6S1623
55,300,226 55,375,250 0606D06 D6S1636
55,300,226 55,375,250 0607H02 D6S294
55,726,402 55,848,334 134G03 AL137178.7_78870
55,726,402 55,848,334 0602A06 D6S1236i
55,726,402 55,848,334 T003B05 D6S1661
55,726,402 55,848,334 058C03 G10114
56,029,347 56,366,851 181F03 AL034452.8_92704
56,029,347 56,366,851 0614F04 D6S0369i
56,029,347 56,366,851 0605A10 D6S1189i
56,927,732 57,000,099 0602H10 D6S1115i
57,019,470 57,143,057 0613H01 D6S0309i
57,145,083 57,157,694 0603F10 D6S0710i
6,533,340 6,600,215 174G08 AL031123.14_110913
6,533,340 6,600,215 0602C02 D6S0311i
6,533,340 6,600,215 0613E01 D6S0579i
62,447,824 63,054,091 0614G09 D6S1212i
63,964,538 63,980,909 0607D11 D6S1093i
63,964,538 63,980,909 0601E02 D6S1120i
64,339,879 64,351,448 0607A03 D6S1658
66,095,895 66,473,839 0608A05 D6S0119i
69,401,980 70,156,124 0609B03 D6S0469i
7,486,869 7,531,945 133H08 AL390026.1_29062
7,486,869 7,531,945 598G03 chr6.fa.O7frz.8505863
7,486,869 7,531,945 0605E10 D6S0377i
7,672,009 7,826,752 0603G03 D6S0225i
7,672,009 7,826,752 0609B07 D6S0647i
73,388,241 73,965,295 0611F04 D6S0927i
74,161,192 74,184,013 0609H05 D6S0609i
74,161,192 74,184,013 0610E01 D6S1228i
74,282,194 74,288,344 0612G07 D6S0726i
74,282,194 74,288,344 0613B11 D6S0882i
74,462,548 74,591,509 0605D09 D6S0741i
74,462,548 74,591,509 0614G05 D6S1596
74,462,548 74,591,509 0603D04 D6S406
78,228,641 78,229,900 0601D09 D6S1066i
78,228,641 78,229,900 0602G10 Z66785
79,633,908 79,665,039 0606C04 D6S1192i
79,633,908 79,665,039 0603F05 D6S1243i
79,967,681 80,001,174 585F07 chr6.fa.O7frz.86184415
79,967,681 80,001,174 0607C08 D6S0920i
80,873,083 81,112,706 0610G04 D6S0574i
80,873,083 81,112,706 0609E09 D6S0728i
80,873,083 81,112,706 0602A08 D6S1181i
86,216,528 86,262,215 0601A04 D6S0734i
86,216,528 86,262,215 0612G08 D6S1141i
87,597,028 87,709,921 0608C09 D6S0297i
87,597,028 87,709,921 0608H11 D6S0357i
87,851,935 87,861,569 0608C01 D6S1182i
9,813,644 10,168,908 0607H07 D6S0639i
90,199,616 90,400,123 0603B12 D6S0248i
90,199,616 90,400,123 0605A04 D6S0254i
90,199,616 90,400,123 0611C12 D6S0883i
90,596,349 90,640,876 0607F03 D6S1613
91,280,013 91,353,628 0612E06 D6S0738i
91,280,013 91,353,628 0607H03 D6S1570
94,007,860 94,185,993 0612F03 D6S0584i
94,007,860 94,185,993 0614B03 D6S1056
97,479,217 97,695,351 0608B09 D6S0288i
97,479,217 97,695,351 0611E07 D6S0884i
97,479,217 97,695,351 0601B05 D6S1246i
100,156,359 100,159,259 0710D03 D7S0053i
100325551 100331651 ACHE1 new design
100325551 100331651 ACHE2 new design
100325551 100331651 ACHE3 new design
100,557,172 100,569,026 0714E11 D7S1170i
100,557,172 100,569,026 0704D01 D7S1273i
101,715,172 101,748,898 0710E04 D7S0272i
101,883,690 101,892,293 0712D11 D7S0888i
101,883,690 101,892,293 026D09 D7S2448
102,899,473 103,417,199 0711C12 D7S0034i
102,899,473 103,417,199 0707B11 D7S0064i
102,899,473 103,417,199 0710H02 D7S1125i
102,899,473 103,417,199 T003G05 D7S2504
102,899,473 103,417,199 0701G09 D7S818
102,899,473 103,417,199 0706D06 Z66799
104,544,059 104,816,577 0711F08 D7S0303i
104,544,059 104,816,577 0708D07 D7S0399i
104,544,059 104,816,577 0702A04 D7S0732i
104,544,059 104,816,577 0705B08 D7S1841
104,544,059 104,816,577 0706G04 D7S2545
105,677,892 105,712,603 0702A08 D7S0255i
105,677,892 105,712,603 0711H05 D7S0358i
105,677,892 105,712,603 0702F12 D7S1083i
106,292,977 106,334,828 0712A03 D7S0621i
106,292,977 106,334,828 0705H07 D7S0909i
107,351,499 107,431,040 206C07 AC005048.2_36985
107,351,499 107,431,040 0709H10 D7S0882i
107,451,232 107,558,036 0701B12 D7S0018i
111,850,462 111,903,483 0702H02 D7S0267i
111,850,462 111,903,483 0709B08 D7S0811i
113,842,288 114,117,391 0706F08 D7S0095i
113,842,288 114,117,391 0701F03 D7S0693i
113,842,288 114,117,391 0713F02 D7S0983i
113,842,288 114,117,391 0707C08 D7S1244i
115,952,075 115,988,466 137G11 AJ133269.1_180046
115,952,075 115,988,466 0708C09 D7S0455i
115,952,075 115,988,466 0709D01 D7S0554i
116,099,695 116,225,676 0701D08 D7S0551i
116,099,695 116,225,676 0709C06 D7S0741i
116,099,695 116,225,676 0703E09 D7S2460
121,300,395 121,489,326 139C09 AC006020.2_128904
121,300,395 121,489,326 0702E11 D7S0384i
121,300,395 121,489,326 0705G12 D7S0404i
121,300,395 121,489,326 0701D09 D7S0566i
124,250,549 124,357,110 0702H07 D7S0017i
124,250,549 124,357,110 0708B05 D7S0322i
124,250,549 124,357,110 0710H04 D7S0939i
127,668,567 127,684,917 0705B05 D7S1166i
127,668,567 127,684,917 0707G06 D7S1171i
128,365,230 128,377,325 0704B10 D7S1076i
128,365,230 128,377,325 0705G02 D7S1278i
128,615,949 128,640,622 0712D01 D7S0936i
128,615,949 128,640,622 0712B09 D7S1068i
129,038,791 129,184,158 541E08 chr7.fa.O7frz.134016965
129,038,791 129,184,158 0712C01 D7S0929i
129,038,791 129,184,158 0706A06 D7S530
13,897,379 13,995,289 0707D12 D7S0119i
13,897,379 13,995,289 0702D09 D7S0199i
13,897,379 13,995,289 0702H04 D7S0211i
13,897,379 13,995,289 0702B05 D7S0679i
130,663,175 130,831,931 0713E11 D7S0800i
130,663,175 130,831,931 0705E02 D7S0816i
130,663,175 130,831,931 0701B02 D7S1235i
130,663,175 130,831,931 0707F08 D7S1255i
138,786,805 138,818,998 0713H09 D7S0374i
139,124,668 139,366,560 0713F06 D7S0049i
139,124,668 139,366,560 0714G01 D7S0143i
139,124,668 139,366,560 0713D02 D7S0323i
139,124,668 139,366,560 0704A03 D7S0327i
139,124,668 139,366,560 0711B10 D7S0995i
139,124,668 139,366,560 0705F10 D7S1003i
139,753,916 139,772,419 0707C04 D7S1107i
141,273,626 141,293,252 0712C04 D7S0948i
141,273,626 141,293,252 0711B11 D7S0950i
141,645,314 142,221,097 0713E03 D7S0604i
141,645,314 142,221,097 0709G05 D7S0727i
141,645,314 142,221,097 0711E09 D7S0972i
141,645,314 142,221,097 0707F04 D7S1113i
141,645,314 142,221,097 0701C09 D7S1193i
141,645,314 142,221,097 0711C03 D7S1199i
141,645,314 142,221,097 0704G05 D7S2473
142,348,323 142,369,625 0711C10 D7S0957i
142,348,323 142,369,625 0704F09 D7S1104i
142,695,524 142,714,907 0714D07 D7S0996i
142,798,327 142,816,107 0711H10 D7S1004i
148,135,408 148,212,347 0712D02 D7S0960i
148,135,408 148,212,347 9904G04 D7S1052i
148,135,408 148,212,347 0712D07 D7S1056i
149,666,351 149,669,696 9904E04 D7S0793i
149,666,351 149,669,696 0712F08 D7S0812i
150,319,080 150,342,609 542A05 chr7.fa.O7frz.157560056
150,319,080 150,342,609 T003A06 D7S636
150,381,832 150,385,929 0705C05 D7S1277i
155,288,319 155,297,728 0701D07 D7S0446i
155,288,319 155,297,728 0706C06 D7S550
157,024,516 158,073,179 0710A07 D7S0968i
157,024,516 158,073,179 0711A05 D7S1039i
157,024,516 158,073,179 0707D06 D7S1159i
157,024,516 158,073,179 0707F06 D7S1167i
157,024,516 158,073,179 0704H03 D7S1196i
157,024,516 158,073,179 0704A05 D7S1232i
157,024,516 158,073,179 0701H08 D7S2423
18,501,894 19,003,518 204F10 AC002433.1_139651
18,501,894 19,003,518 0707E11 D7S0073i
18,501,894 19,003,518 0710G04 D7S0086i
18,501,894 19,003,518 0701D02 D7S0163i
18,501,894 19,003,518 0714H01 D7S0186i
18,501,894 19,003,518 0705C09 D7S0578i
18,501,894 19,003,518 0709D04 D7S0651i
18,501,894 19,003,518 0709E04 D7S0655i
18,501,894 19,003,518 0709A09 D7S0832i
18,501,894 19,003,518 0702B07 D7S638
19,121,616 19,123,820 0708F10 D7S0488i
19,121,616 19,123,820 025E01 D7S2495
2,912,308 3,050,025 0701D10 D7S2484
2,912,308 3,050,025 0701D04 D7S2521
20,337,250 20,421,907 0707G12 D7S0132i
20,337,250 20,421,907 0714D08 D7S0200i
20,337,250 20,421,907 0713A03 D7S0208i
22,732,028 22,738,141 0703F04 D7S0667i
22,732,028 22,738,141 0701C07 D7S629
23,252,841 23,281,254 0712H01 D7S0842i
24,290,332 24,298,002 0706E08 D7S0088i
24,290,332 24,298,002 0714C11 D7S0644i
25,124,800 25,131,480 0703E04 D7S1791
27,147,521 27,149,812 0708B10 D7S0477i
27,147,521 27,149,812 0708E10 D7S0486i
30,430,672 30,484,833 0708H08 D7S0440i
30,658,725 30,706,244 0713F04 D7S0077i
30,658,725 30,706,244 0714C03 G09471
30,917,993 30,931,656 0705H03 D7S0658i
30,917,993 30,931,656 0706G01 D7S526
32,963,577 33,013,067 0709E06 D7S0749i
32,963,577 33,013,067 0713D07 D7S0843i
38,246,150 38,374,181 0710E10 D7S0036i
38,246,150 38,374,181 0706G08 D7S0106i
38,246,150 38,374,181 0706H08 D7S0176i
38,246,150 38,374,181 0705D09 D7S2497
4,688,456 4,777,600 0712A06 D7S1022i
4,688,456 4,777,600 0705C08 D7S511
41,695,126 41,709,231 9904A03 -
41,695,126 41,709,231 0706H02 D7S2548
41,970,196 42,241,712 0705A12 D7S0643i
41,970,196 42,241,712 0709C04 D7S0647i
41,970,196 42,241,712 0705G05 D7S0797i
41,970,196 42,241,712 0702E08 D7S671
43,589,251 43,632,247 0708F05 D7S0336i
43,589,251 43,632,247 0708D10 D7S0484i
43,589,251 43,632,247 0709C10 D7S0866i
44,150,395 44,195,563 0701H07 D7S1249i
44,150,395 44,195,563 0701C05 G09840
44,571,928 44,581,175 0708H01 D7S0167i
44,571,928 44,581,175 0704G06 D7S2488
44,802,777 44,809,240 0704H05 D7S0180i
44,802,777 44,809,240 0706A03 D7S478
44,968,786 44,985,203 0703D03 D7S2427
5,533,312 5,536,747 0706E07 G08627
50,314,924 50,438,053 0701A11 D7S1189i
50,625,259 50,828,652 0704F10 D7S0624i
50,625,259 50,828,652 0709F07 D7S0785i
50,625,259 50,828,652 0707F01 D7S0786i
55,054,219 55,242,525 0714A08 D7S0988i
55,716,261 55,748,439 0710H01 D7S1153i
6,380,651 6,410,123 0710A02 D7S1024i
6,380,651 6,410,123 0701C01 D7S1186i
65,063,110 65,084,635 0707B07 D7S1181i
65,063,110 65,084,635 0706B03 D7S2549
7,643,100 7,724,763 0709H04 D7S0680i
7,643,100 7,724,763 0702F03 G10238
72,486,045 72,488,386 0705D10 Z67541
72,821,263 72,822,536 0710C03 D7S1124i
73,262,023 73,282,100 0712C10 D7S1213i
73,262,023 73,282,100 0706B08 HUMUT623
73,341,741 73,458,201 0712A12 D7S0104i
73,341,741 73,458,201 0711F03 D7S0116i
73,506,056 73,654,853 0713C03 D7S0360i
73,506,056 73,654,853 0706H04 D7S2472
73,709,966 73,812,958 0706E03 D7S1870
73,826,245 73,841,595 138B07 AC004883.2_46325
73,848,420 73,905,777 9904G03 D7S1175i
74,975,005 74,995,389 0712G09 D7S0670i
74,975,005 74,995,389 0713A02 D7S1122i
75,236,778 75,257,150 0708B11 D7S0501i
75,236,778 75,257,150 0713C08 HUMUT533B
75,769,859 75,771,548 0711G01 D7S1218i
76,662,535 76,667,080 0713E12 D7S0900i
76,662,535 76,667,080 0701C03 D7S1077i
77,004,351 77,107,324 0706C09 D7S0240i
77,004,351 77,107,324 0707E07 D7S1210i
79,602,076 79,686,661 0708H11 D7S0519i
79,602,076 79,686,661 0702D06 D7S2443
80,069,459 80,144,262 0711G12 D7S0999i
80,069,459 80,144,262 0711B09 D7S1007i
81,166,258 81,237,388 0705H02 D7S0495i
81,166,258 81,237,388 0709F04 D7S0674i
82,831,158 83,116,260 0714A12 D7S0227i
82,831,158 83,116,260 0714F08 D7S0232i
82,831,158 83,116,260 0704A08 D7S0249i
82,831,158 83,116,260 0704F12 D7S0415i
82,831,158 83,116,260 0714B02 D7S0597i
82,831,158 83,116,260 0714G05 D7S0894i
82,831,158 83,116,260 0705D06 D7S1015i
82,831,158 83,116,260 0705G10 D7S2540
86,970,884 87,180,500 0702H08 D7S0121i
86,970,884 87,180,500 0708B04 D7S0275i
86,970,884 87,180,500 0713G07 D7S1228i
86,970,884 87,180,500 713C11 DIJ28_10004693
91,579,402 91,601,946 0714C04 D7S0248i
91,579,402 91,601,946 0708F03 D7S0250i
91,579,402 91,601,946 0705B11 D7S0677i
92,072,171 92,301,148 0714D04 D7S0251i
92,072,171 92,301,148 0704B06 D7S0278i
92,072,171 92,301,148 0714H04 D7S0522i
93,861,809 93,898,480 0710G11 D7S0123i
93,861,809 93,898,480 0703H05 D7S0302i
93,861,809 93,898,480 0711E01 D7S0640i
96,156,015 96,177,139 586G07 chr7.fa.O7frz.98288632
96,156,015 96,177,139 0702B01 D7S1274i
97,199,311 97,207,720 0706G11 D7S0543i
97,199,311 97,207,720 0703A11 HUMUT901
97,760,007 97,868,316 0710C04 D7S0022i
97,760,007 97,868,316 0710G07 D7S0057i
989,361 995,802 0703C09 D7S1263i
989,361 995,802 0703D12 D7S2474
99,083,437 99,219,744 0712C12 D7S0916i
99,083,437 99,219,744 0705C10 D7S647
99,263,572 99,302,109 540B09 chr7.fa.O7frz.102029376
99,499,406 99,517,299 698C04 DISD22_0005257
99,771,673 99,803,388 0710A06 D7S0755i
99,771,673 99,803,388 0702B11 D7S2480
6,825,000 6,900,000 0804G07 D8S1706
6,825,000 6,900,000 0801D07 D8S1819
10,659,883 10,734,796 0805A11 D8S0730i
10,659,883 10,734,796 0811A07 D8S0894i
10,659,883 10,734,796 0802G05 D8S520
102,000,090 102,034,745 350B05 AC027373.2_36983
102,000,090 102,034,745 0808G03 D8S0336i
103,730,188 103,737,128 0807F02 D8S0305i
103,730,188 103,737,128 0803B02 D8S1834
104,222,097 104,311,709 0809A10 D8S0324i
104,222,097 104,311,709 0811D06 D8S0643i
105,421,228 105,438,092 0802B08 D8S1738
105,421,228 105,438,092 0808D03 HUMUT5342
108,330,886 108,579,459 0804E04 D8S0323i
108,330,886 108,579,459 0807E12 D8S0566i
108,330,886 108,579,459 0801H01 D8S0781i
108,330,886 108,579,459 9904E09 D8S0787i
108,330,886 108,579,459 0804A11 D8S0797i
11,388,919 11,459,522 0804A05 D8S1695
11,388,919 11,459,522 0805C01 D8S1759
11,388,919 11,459,522 0801D03 D8S265
11,599,122 11,654,920 0806E02 D8S0813i
11,868,871 11,869,517 0811G09 D8S1033i
110,168,900 110,200,989 0801F10 D8S0907i
110,168,900 110,200,989 0808C03 D8S0923i
12,212,843 12,220,196 0807C07 D8S0411i
120,004,977 120,033,492 0801C12 D8S0421i
120,004,977 120,033,492 9904F09 D8S0793i
120,497,882 120,505,776 0802B04 D8S0048i
120,497,882 120,505,776 0805F04 D8S1823
121,206,533 121,453,454 9904G09 D8S0809i
121,206,533 121,453,454 0808B03 D8S0937i
121,206,533 121,453,454 0806G06 D8S1000i
128,817,498 128,822,856 0810G01 D8S0020i
128,817,498 128,822,856 0811F10 D8S0988i
141,590,586 141,596,434 0808G02 D8S0596i
141,590,586 141,596,434 0808D05 D8S0705i
141,590,586 141,596,434 030H03 D8S1717
141,737,683 142,080,514 T002F06 D8S0710i
141,737,683 142,080,514 0803F07 D8S1035i
141,737,683 142,080,514 0803F06 D8S1704
142,501,189 142,510,802 0803F08 D8S0822i
143,950,775 143,958,238 0811D08 D8S0811i
144,171,274 144,175,199 0808C05 D8S1011i
144,870,498 144,876,619 0811D03 D8S0722i
16,009,761 16,094,595 0806C12 D8S0211i
16,009,761 16,094,595 0801C07 D8S0449i
16,009,761 16,094,595 733H01 DIJ28_10036995
16,894,049 16,904,061 256D03 AB020858.1_88789
16,894,049 16,904,061 405D08 AC072058.1_86060
16,894,049 16,904,061 645F10 DISO7_10002436
18,293,035 18,303,003 0810E12 D8S0455i
18,293,035 18,303,003 T002A03 D8S1145
21,822,330 21,827,151 0805H08 D8S0073i
21,822,330 21,827,151 0802D07 D8S1025i
21,955,883 21,962,266 0811F05 D8S0467i
21,955,883 21,962,266 0803E08 HUMUT5312
22,354,541 22,454,583 0806D11 D8S0186i
22,354,541 22,454,583 0806D03 D8S0839i
22,601,117 22,606,760 0805A09 D8S0190i
22,601,117 22,606,760 0803B12 D8S0654i
22,601,117 22,606,760 0803F05 D8S1733
22,933,591 22,982,637 0801A07 D8S0005i
22,933,591 22,982,637 0802C01 D8S1008i
23016377 23030895 TNFRSF10C new design
23049046 23077488 TNFRSF10D1 new design
23049046 23077488 TNFRSF10D2 new design
23104009 23138584 TNFRSF10A1 new design
23104009 23138584 TNFRSF10A2 new design
23,157,114 23,175,452 0808F06 D8S0452i
25,332,693 25,338,087 0806D12 D8S0213i
25,757,490 25,958,292 0806E11 D8S0187i
25,757,490 25,958,292 0802F05 D8S0929i
25,757,490 25,958,292 0804B09 D8S1031i
25,757,490 25,958,292 713C09 DIJ28_10000970
26,296,331 26,326,562 0806A04 D8S0850i
27,224,916 27,372,824 0806B11 D8S0182i
27,224,916 27,372,824 0803H08 D8S0438i
27,224,916 27,372,824 0809H04 D8S0457i
27,510,351 27,528,288 0807G08 D8S0461i
27,510,351 27,528,288 0802H02 D8S1839
27,547,304 27,590,211 9904A09 D8S0690i
27,783,655 27,906,117 0806E03 D8S0841i
29,249,530 29,264,104 0811C03 D8S0718i
29,249,530 29,264,104 0809A02 D8S0891i
30,555,422 30,635,274 9904A06 -
30,555,422 30,635,274 543G11 chr8.fa.O7frz.33849047
30,555,422 30,635,274 0810C11 D8S0636i
33,568,393 33,577,043 544G01 chr8.fa.O7frz.37049102
33,568,393 33,577,043 028F04 D8S1845
38,153,263 38,189,966 0811H03 D8S0008i
38,153,263 38,189,966 0811A02 D8S1791
38,389,406 38,445,296 406A04 AC011237.4_133993
38,389,406 38,445,296 0804H08 D8S1038i
38,389,406 38,445,296 0811B08 D8S1821
38,734,008 38,829,703 349E03 AC016813.3_111110
38,734,008 38,829,703 0811A11 G10158
39,890,485 39,905,120 0810F05 D8S0218i
39,890,485 39,905,120 0809B01 D8S0924i
41,629,901 41,873,437 614G08 chr8.fa.O7frz.46429060
41,629,901 41,873,437 0808G04 D8S0083i
41,629,901 41,873,437 0809H02 D8S0240i
41,629,901 41,873,437 0808C02 D8S0687i
42,247,986 42,309,130 0808H08 D8S0250i
42,247,986 42,309,130 0802A05 D8S0742i
48,848,222 49,035,296 0804A12 D8S0897i
54,300,829 54,326,747 0811B03 D8S0712i
54,300,829 54,326,747 0811F11 D8S0716i
56,954,926 57,086,493 587G05 chr8.fa.O7frz.62681686
56,954,926 57,086,493 0802D09 D8S0902i
56,954,926 57,086,493 028C09 D8S1828
59,565,292 59,575,275 9904F08 D8S0253i
59,565,292 59,575,275 0805F02 D8S1723
59,658,617 59,734,940 0808C08 D8S0948i
6,344,580 6,408,338 543B01 chr8.fa.O7frz.7433403
6,344,580 6,408,338 0809G08 D8S0184i
65,671,246 65,873,902 0810F07 D8S0493i
65,671,246 65,873,902 0801F03 D8S544
65,671,246 65,873,902 064D05 G08709
67,251,166 67,253,380 0806F10 D8S0174i
71,648,227 71,683,158 0811E09 D8S0714i
75,066,141 75,103,859 0802G10 D8S0070i
75,066,141 75,103,859 0803C06 D8S526
76,482,826 76,641,623 0811A05 D8S0294i
76,482,826 76,641,623 0801C09 D8S0746i
76,482,826 76,641,623 0805E12 D8S0765i
78,057,713 78,074,994 0806E05 D8S0898i
78,057,713 78,074,994 0802G06 D8S0899i
79,807,560 79,880,313 407D09 AC048363.3_2317
79,807,560 79,880,313 T001A11 D8S0679i
79,807,560 79,880,313 056A04 Z67101
8,597,076 8,599,026 0802G07 D8S0827i
8,597,076 8,599,026 0808C07 D8S0830i
82,042,600 82,186,858 0806H08 D8S0101i
82,042,600 82,186,858 0808C11 D8S0296i
82,355,326 82,359,563 0806C08 D8S0062i
82,355,326 82,359,563 0809E03 D8S0085i
82,553,481 82,558,023 0808E09 D8S0081i
82,807,243 82,834,305 0807H10 D8S0496i
82,807,243 82,834,305 029C03 D8S525
89,118,576 89,408,892 0806A09 D8S0107i
89,118,576 89,408,892 0810D07 D8S0298i
89,118,576 89,408,892 0807E02 D8S0304i
89,118,576 89,408,892 0809G02 D8S0413i
89,118,576 89,408,892 0810E02 D8S0913i
90,839,110 90,872,433 0806A01 D8S0779i
90,839,110 90,872,433 0806F01 D8S0791i
91,014,740 91,066,075 0811C11 D8S0997i
93,040,328 93,176,619 0801D02 D8S0780i
93,040,328 93,176,619 0806D01 D8S0785i
93,040,328 93,176,619 0806H01 D8S0795i
95,330,657 95,343,733 0803B05 D8S1083
95,330,657 95,343,733 0805D07 Z66605
95,961,628 95,976,660 0807G11 D8S0545i
95,961,628 95,976,660 0802H07 D8S1042i
97,343,340 97,415,950 314B04 AC068091.3_100690
97,343,340 97,415,950 0804A07 D8S0102i
97,343,340 97,415,950 0804E08 D8S0944i
97,343,340 97,415,950 029A05 D8S1772
97,575,058 97,693,213 0810E10 D8S0108i
97,575,058 97,693,213 0803A10 D8S0796i
97,575,058 97,693,213 698H11 DISD22_0005839
99,199,244 99,239,816 0810H02 D8S0560i
99,199,244 99,239,816 0804B04 D8S1778
99,199,244 99,239,816 0805B04 D8S506
99,536,041 99,907,085 0810A08 D8S0103i
99,536,041 99,907,085 9904D10 D8S0852i
99,536,041 99,907,085 0806B04 D8S0855i
99,536,041 99,907,085 0811B07 D8S0926i
99,536,041 99,907,085 0803G04 D8S1749
91,883,383 91,884,738 0901B04 D9S1797
91,883,383 91,884,738 0902F09 D9S1820
100,907,233 100,956,406 0904E12 D9S0215i
100,907,233 100,956,406 0905H11 D9S0532i
101,024,380 101,032,722 0909D02 D9S0086i
101,623,958 101,668,994 0905H03 D9S0313i
101,623,958 101,668,994 0906C02 D9S0726i
103,393,718 103,397,104 0905A11 D9S0506i
103,393,718 103,397,104 9905A09 D9S0724i
107,046,724 107,241,273 9905H09 D9S0793i
107,046,724 107,241,273 0903C07 D9S1784
107,464,599 107,465,214 0908H02 D9S0219i
110,656,692 110,659,068 0909G09 D9S0390i
110,656,692 110,659,068 0901A05 D9S0830i
111,177,800 111,300,407 0906A07 D9S0748i
111,177,800 111,300,407 0904C04 D9S1835
112,045,912 112,058,741 0907H11 D9S0629i
112,045,912 112,058,741 031D09 D9S1675
112,431,057 112,431,557 0902C11 D9S1828
113,364,678 113,401,917 0908E06 D9S0213i
113,364,678 113,401,917 9905D06 D9S0608i
113,698,867 113,737,470 0909D11 D9S0513i
113,698,867 113,737,470 9905F06 D9S0616i
113,698,867 113,737,470 0907C03 D9S0802i
114,967,620 115,024,010 9905B09 D9S0754i
114,967,620 115,024,010 0903G02 D9S262
115,209,336 115,212,773 0904G11 D9S0165i
115,209,336 115,212,773 0907E10 D9S0510i
116,125,157 116,128,578 081G08 D9S302
116,131,890 116,135,357 0903A01 D9S0172i
116,591,421 116,608,229 0901C10 D9S0116i
116,591,421 116,608,229 0908H11 D9S0840i
116,704,945 116,732,591 0904G07 D9S0015i
116,822,634 116,920,260 0904F02 D9S155
116,822,634 116,920,260 0904H04 D9S1776
119,506,405 119,519,589 9905G04 D9S0554i
119,506,405 119,519,589 0909G10 D9S1864
122,704,492 122,730,868 0906A10 D9S0050i
122,704,492 122,730,868 0904E04 D9S1823
122,754,434 122,852,375 0904C08 D9S0039i
124,173,050 124,197,802 0907D12 D9S0318i
124,173,050 124,197,802 9905C07 D9S0649i
126,155,565 126,217,542 0905D12 D9S0545i
126,155,565 126,217,542 0904H06 HUMUT7968
126,283,336 126,309,530 0904B05 D9S1840
126,319,380 126,573,410 0908E08 D9S0176i
126,319,380 126,573,410 0902G04 Z67401
127,036,953 127,043,430 0904E05 D9S1825
129,587,898 129,592,887 414B02 AL162586.7_116830
129,587,898 129,592,887 0901F06 D9S0133i
129,617,112 129,656,856 317C02 AL157935.6_74493
129,951,171 129,956,333 0908A09 D9S0735i
130,485,844 130,498,488 0902H06 D9S0546i
130,913,050 130,951,046 0907C01 D9S0200i
131,540,433 131,555,165 352H04 AC007936.2_31251
131,540,433 131,555,165 0909H05 D9S0091i
131,855,526 131,942,264 0909E12 D9S0020i
131,855,526 131,942,264 0906F04 D9S0720i
131,855,526 131,942,264 9905H08 D9S0723i
132,874,325 132,958,267 0906C05 D9S0761i
132,874,325 132,958,267 0906G05 D9S0767i
133,441,978 133,605,282 0901H04 D9S0547i
133,441,978 133,605,282 0907G03 D9S0550i
134,458,205 134,535,609 0906G08 D9S0198i
134,458,205 134,535,609 9905H03 HUMUT6781
134,895,897 134,923,709 0903H01 D9S0032i
134,895,897 134,923,709 0906C09 D9S0045i
135,120,384 135,140,451 0909E11 D9S0620i
135,276,941 135,314,329 0906E04 D9S0785i
135,276,941 135,314,329 T003D07 D9S164
135,616,837 135,847,547 0906G09 D9S0049i
135,616,837 135,847,547 9904F12 D9S0052i
135,616,837 135,847,547 9904G12 D9S0057i
135,616,837 135,847,547 9905A01 D9S0062i
135,616,837 135,847,547 0902H08 D9S0858i
136,673,473 136,876,510 0901D02 D9S0634i
136,940,837 136,949,630 9905C03 D9S0548i
138,508,717 138,560,135 0909A08 D9S0347i
138,900,786 138,940,888 0901D04 D9S0734i
139437668 139448679 NOXA11 new design
139437668 139448679 NOXA12 new design
15,454,064 15,501,017 0909D05 D9S0187i
15,454,064 15,501,017 0909C04 D9S0668i
2,005,342 2,183,624 9905G02 D9S0348i
2,005,342 2,183,624 0905A06 D9S0367i
2,005,342 2,183,624 0903F01 D9S0371i
2,794,152 2,834,095 0908E02 D9S0561i
2,794,152 2,834,095 0908B06 D9S0566i
21,067,104 21,067,962 0907F05 D9S0224i
21,067,104 21,067,962 0901B03 D9S0783i
21,130,213 21,132,144 0905H05 D9S0366i
21,191,234 21,229,990 9905G09 D9S0786i
21,357,423 21,358,961 0909B09 D9S0369i
21,470,838 21,472,312 0906G10 D9S0122i
21,470,838 21,472,312 0901H02 D9S0373i
21,957,751 21,984,490 0909G05 D9S0018i
21,957,751 21,984,490 0906A11 D9S0115i
21,992,902 21,999,312 0904D01 D9S1870
26,894,081 26,937,461 0907G06 D9S0788i
27,099,236 27,220,173 9905F02 D9S0285i
27,099,236 27,220,173 0909B05 D9S0749i
27,099,236 27,220,173 0909E10 D9S169
27,514,302 27,516,496 0906F06 D9S0708i
3,208,297 3,515,983 0906G11 D9S0191i
3,208,297 3,515,983 0908D07 D9S0406i
3,208,297 3,515,983 0903D08 D9S0424i
3,208,297 3,515,983 T001F11 D9S0571i
3,208,297 3,515,983 0904B07 HUMUT537
32,445,300 32,516,322 0907G02 D9S0582i
32,445,300 32,516,322 0903D09 D9S0842i
33,242,469 33,254,744 0908H09 D9S0673i
33,254,167 33,271,525 0904D12 D9S0188i
34,636,635 34,651,884 0906H03 D9S0812i
34,636,635 34,651,884 063E02 Z67043
35,599,976 35,608,753 0906H07 D9S0693i
35,687,334 35,722,369 411A07 AL133410.26_90374
35,687,334 35,722,369 0909E02 D9S0363i
36,562,873 36,667,679 470C11 chr9.fa.O7frz.39457705
36,562,873 36,667,679 0905C08 D9S0435i
37,909,131 38,059,249 0908D03 D9S0445i
37,909,131 38,059,249 0906H01 D9S0683i
4,975,245 5,118,183 0905H06 D9S0413i
4,975,245 5,118,183 0902B02 D9S0838i
5,440,525 5,460,547 0902A05 D9S0755i
5,440,525 5,460,547 0901G11 D9S0762i
5,500,570 5,561,252 0906H04 D9S0768i
6,205,809 6,247,983 0909B08 D9S0235i
6,205,809 6,247,983 0904A01 D9S1852
70,817,241 70,818,849 0902C05 D9S0147i
74,956,493 74,975,129 0905H01 D9S0260i
74,956,493 74,975,129 0907C07 D9S0584i
76,302,072 76,491,937 0905E09 D9S0465i
76,302,072 76,491,937 0905F09 D9S0469i
76,302,072 76,491,937 9905F07 D9S0656i
78,824,391 78,825,689 0901H06 D9S0489i
8,304,246 9,008,735 0907D07 D9S0242i
8,304,246 9,008,735 0908H01 D9S0247i
8,304,246 9,008,735 0909F08 D9S0408i
8,304,246 9,008,735 0903B11 D9S0417i
8,304,246 9,008,735 0905E07 D9S0420i
8,304,246 9,008,735 T003G06 D9S1676
88,749,098 88,751,924 0902A09 D9S1680
89,301,963 89,513,369 0908F04 D9S0487i
89,301,963 89,513,369 0907B08 D9S0493i
89,301,963 89,513,369 0907F12 D9S0501i
89,301,963 89,513,369 0906G01 D9S257
91,115,925 91,121,438 412F07 AL160054.5_63624
91,181,972 91,302,708 0901C01 D9S906
92,603,890 92,700,652 0905F03 D9S0311i
92,603,890 92,700,652 0902C09 D9S1836
93,211,148 93,225,965 352B02 AL353645.3_94104
93,211,148 93,225,965 0908F11 D9S0194i
97,245,083 97,318,923 472F02 chr9.fa.O7frz.96923615
97,245,083 97,318,923 9905G01 D9S0585i
97,245,083 97,318,923 0904D03 D9S1816
99,477,012 99,499,460 0907G08 D9S0800i
99,655,357 99,658,818 472C04 chr9.fa.O7frz.100149745
99,785,462 99,818,046 0906E03 D9S0832i
100,491,091 100,527,839 2304C07 DXS0684i
100,491,091 100,527,839 2308F02 DXS0923i
103,697,652 104,898,478 2306D03 DXS0001i
103,697,652 104,898,478 2310B01 DXS0151i
103,697,652 104,898,478 2306H08 DXS0208i
103,697,652 104,898,478 2304G05 DXS0433i
103,697,652 104,898,478 2307D04 DXS0438i
103,697,652 104,898,478 2307E04 DXS0442i
103,697,652 104,898,478 2307H04 DXS0450i
103,697,652 104,898,478 2309D05 DXS0629i
103,697,652 104,898,478 2311B07 DXS0741i
103,697,652 104,898,478 2303A01 DXS0964i
103,697,652 104,898,478 2304D04 DXS0979i
103,697,652 104,898,478 2308C05 DXS8112
103,697,652 104,898,478 2304E10 Z67212
105,823,724 105,926,902 2301B07 DXS8048
105,823,724 105,926,902 055B11 DXS8097
105,823,724 105,926,902 2301A10 HUMUT1690
106,843,107 106,905,858 2306G07 DXS0175i
106,843,107 106,905,858 2307F04 DXS0443i
107,103,687 107,105,431 2307G04 DXS0447i
107,285,493 107,569,383 2301H07 DXS0140i
107,285,493 107,569,383 2301D09 DXS0141i
107,285,493 107,569,383 2311D11 DXS0640i
107,285,493 107,569,383 2304B01 DXS6797
107,569,810 107,827,431 2311H11 DXS0641i
107,569,810 107,827,431 2303D11 DXS0716i
110,226,244 110,350,816 2301G11 DXS0968i
114,144,794 114,159,792 2308A06 DXS0727i
115,216,003 115,220,253 552C03 chrX.fa.O7frz.114508264
117,745,563 117,812,530 2311B02 DXS0287i
117,745,563 117,812,530 2306B11 DXS0308i
119,446,367 119,487,189 2304F06 DXS0156i
119,446,367 119,487,189 2307H10 DXS0622i
12,795,123 12,818,420 2307D09 DXS0567i
12,834,679 12,851,209 2309E08 DXS0246i
12,903,148 12,905,267 2306A10 DXS0244i
122,821,558 122,875,510 2311B11 DXS0634i
122,821,558 122,875,510 2305H07 DXS8098
123,307,875 123,334,686 2305F09 DXS0171i
123,307,875 123,334,686 2310D06 DXS0613i
128,408,159 128,485,158 2303D04 DXS0835i
128,408,159 128,485,158 2304C10 DXS0839i
128,408,159 128,485,158 2301B08 DXS0843i
128,607,006 128,616,595 2305C02 DXS0166i
128,607,006 128,616,595 2307D11 DXS0635i
129,091,018 129,127,489 2306G08 DXS0205i
129,091,018 129,127,489 2310F07 DXS0483i
130,235,161 130,361,358 2306A09 DXS0212i
130,235,161 130,361,358 2307A11 DXS0624i
134,482,215 134,544,100 2305F03 DXS0701i
134,895,264 134,957,089 9910E12 DXS0735i
134,895,264 134,957,089 2301E05 DXS0826i
135,558,002 135,570,215 2307H06 DXS0495i
135,558,002 135,570,215 2301G06 DXS0829i
137,541,401 137,894,912 2308H11 DXS0042i
137,541,401 137,894,912 2302H08 DXS0173i
137,541,401 137,894,912 2308H10 DXS0184i
137,541,401 137,894,912 2308G10 DXS0199i
137,541,401 137,894,912 2309C05 DXS0869i
137,541,401 137,894,912 2306G02 HUMUT1537
149,685,467 149,817,837 260E03 AF002223.1_128496
149,685,467 149,817,837 2306C08 DXS0189i
15,273,639 15,312,498 721B09 DIJ28_10038784
15,273,639 15,312,498 2307G09 DXS0575i
15,273,639 15,312,498 258F05 U75931.1_14164
15,392,290 15,484,573 2303G09 DXS1053
15,489,077 15,530,199 2310A08 DXS0008i
152,413,591 152,428,206 2307F07 DXS0516i
152,413,591 152,428,206 2307A08 DXS0524i
152,561,182 152,569,975 2303G03 DXS8087
152,780,163 152,804,802 2310E04 DXS0638i
152,929,145 152,938,625 2311H05 HUMUT2234
153,412,800 153,428,981 2302B07 DXS1073
153,644,229 153,659,158 2309H10 DXS0494i
18,167,355 18,282,768 2305G08 DXS0133i
18,167,355 18,282,768 2304H09 DXS0667i
19,288,095 19,443,363 2310G03 DXS0240i
19,288,095 19,443,363 9911B02 DXS0782i
19,288,095 19,443,363 2305B08 DXS7592
19,462,014 19,815,640 2305D08 DXS0248i
19,462,014 19,815,640 2308B03 DXS0789i
19,462,014 19,815,640 2308E03 DXS0885i
2,680,115 2,743,968 9911C02 DXS0787i
22,927,999 22,931,627 2308E02 DXS0064i
22,927,999 22,931,627 2308E07 DXS0746i
22,927,999 22,931,627 2301F09 DXS7110
23,592,300 23,614,437 2311F06 DXS0350i
28,515,437 29,884,761 2306E04 DXS0044i
28,515,437 29,884,761 2306F05 DXS0094i
28,515,437 29,884,761 2309B08 DXS0339i
28,515,437 29,884,761 2304B12 DXS0343i
28,515,437 29,884,761 2306G12 DXS0348i
28,515,437 29,884,761 2307A01 DXS0351i
28,515,437 29,884,761 2310H06 DXS0361i
28,515,437 29,884,761 2307H09 DXS0576i
28,515,437 29,884,761 2308G07 DXS0783i
28,515,437 29,884,761 9911B03 DXS0936i
28,515,437 29,884,761 2306H01 Z67237
30,232,244 30,237,636 125G12 AC005185.1_116697
30,232,244 30,237,636 2310E11 DXS0063i
30,232,244 30,237,636 257A12 U31929.1_4333
37,429,931 37,476,322 2305G07 DXS0078i
37,524,208 37,557,658 2302D10 DXS0873i
38,305,553 38,433,118 2307H01 DXS0369i
38,305,553 38,433,118 2301G10 DXS0539i
41,077,595 41,108,669 2311B05 DXS0705i
41,077,595 41,108,669 2302D05 DXS993
44,588,193 44,589,078 2309D03 DXS0585i
44,588,193 44,589,078 2302H02 DXS0943i
46,349,697 46,503,434 2308C01 DXS0019i
46,349,697 46,503,434 2301A05 DXS1003
46,349,697 46,503,434 2308H03 DXS1055
47,326,634 47,331,134 2311C01 DXS0084i
47,368,557 47,374,648 2310D01 DXS0396i
48,427,112 48,434,762 2306H03 DXS0016i
48,439,930 48,452,347 2306F04 DXS0059i
48,529,906 48,537,662 2303D07 DXS0753i
48,545,170 48,568,336 2310B07 DXS0020i
48,993,841 49,008,232 2306E01 DXS1208
49,856,156 50,111,653 2308F07 DXS0765i
49,856,156 50,111,653 2302E07 DXS0803i
53,128,274 53,134,447 2301A07 DXS8017
53,128,274 53,134,447 055E03 DXS8062
53,238,059 53,271,329 2308B07 DXS0780i
53,238,059 53,271,329 2305H10 DXS988
55,052,213 55,074,136 665B12 DISO7_10004639
55,052,213 55,074,136 2308C02 DXS0807i
57,719,936 57,723,438 2301D01 DXS0074i
66,680,599 66,867,186 2311A06 DXS0033i
66,680,599 66,867,186 2303G11 DXS0108i
68,752,636 69,176,047 2308C10 DXS0109i
68,752,636 69,176,047 2307B04 DXS0425i
68,752,636 69,176,047 2305G12 DXS0841i
69,394,741 69,396,379 2308A02 DXS0724i
69,394,741 69,396,379 2302D02 DXS983
70,232,772 70,240,110 2302B01 DXS0830i
70,243,979 70,248,188 2310D04 DXS0553i
70,752,491 70,755,092 2310B10 DXS0421i
70,752,491 70,755,092 2303G06 DXS8101
71,341,232 71,375,602 2310A06 DXS0409i
71,341,232 71,375,602 2303A09 DXS0978i
71,341,232 71,375,602 257H02 U07360.1_98
71,466,091 71,709,623 2302H01 DXS0114i
71,466,091 71,709,623 2302C06 DXS0118i
71,466,091 71,709,623 2307F09 DXS0574i
76,596,303 76,598,669 2309F09 DXS0281i
76,596,303 76,598,669 072E09 G10119
77,413,617 77,469,743 2309G08 DXS0252i
77,413,617 77,469,743 2303A12 Z67046
9,391,369 9,647,778 2309A09 DXS0017i
9,391,369 9,647,778 2306A06 DXS0105i
9,391,369 9,647,778 2309A04 DXS0324i
9,391,369 9,647,778 2305G03 DXS8051
95,826,365 96,746,652 2311A01 DXS0012i
95,826,365 96,746,652 2308C12 DXS0146i
95,826,365 96,746,652 2307A05 DXS0454i
95,826,365 96,746,652 2301B12 DXS0458i
95,826,365 96,746,652 T001C06 DXS0588i
95,826,365 96,746,652 2304G12 DXS0649i
95,826,365 96,746,652 2305D03 DXS0651i
95,826,365 96,746,652 2303B12 DXS0653i
95,826,365 96,746,652 2307A12 DXS0655i
95,826,365 96,746,652 2307B12 DXS0657i
95,826,365 96,746,652 2301C06 DXS0818i
99,984,969 100,015,990 2304C06 DXS0191i
99,984,969 100,015,990 2309H09 DXS0592i
13,322,554 13,482,162 9911D06 DYS0039i
13525413 13541784 DDX3Y1 new design
13525413 13541784 DDX3Y2 new design
13,869,653 14,101,947 9911A06 DYS0035i
13,869,653 14,101,947 9911F11 DYS0083i
14,324,841 14,327,298 9911C12 DYS0088i
19,611,898 19,614,093 9911D12 DYS0089i
2769527 2794997 RPS4Y11 new design
2769527 2794997 RPS4Y12 new design
20,326,689 20,366,212 9911H09 DYS0069i
6,838,727 7,019,724 9911B10 DYS0071i
6,838,727 7,019,724 9911F10 DYS0075i
Marker Start Position Marker End Position Marker start - gene start Marker end - gene end
1118517 1118699 10234 13253
1377882 1378152 117,361 103,529
1674131 1674253 116,794 51,144
1965222 1965610 -6,547 -141,084
10480824 10481227 41,658 26,027
100984474 100984814 26,589 7,625
101457925 101458128 -17,107 -21,534
107413661 107414087 12,837 10,648
107942872 107943023 27,567 -366,085
108359820 108360046 444,515 50,938
107995615 107995824 80,310 -313,284
108101217 108101367 185,912 -207,741
109482692 109482919 76,048 62,772
109925706 109926123 32,882 -12,375
109854474 109854584 -38,350 -83,914
11024850 11025217 15,683 -4,660
10916159 10916533 -93,008 -113,344
11206544 11206940 117,365 -38,236
11275250 11275466 186,071 30,290
11136881 11137209 47,702 -107,967
11813253 11813518 44,886 24,816
11843587 11843676 15,234 12,687
110244279 110244430 -10,499 -30,714
111259436 111259863 44,092 15,782
111215883 111216019 539 -28,062
111576226 111576568 4,422 -11,017
111951031 111951504 123,538 43,397
111801431 111801622 -26,062 -106,485
112076662 112076907 190,299 16,071
113057162 113057354 11,911 5,775
114042643 114042849 -50,338 -173,055
114203304 114203593 110,323 -12,311
114891669 114891958 -20,032 -33,830
115021860 115022030 -26,753 -80,117
115380627 115380776 6,689 2,312
115626587 115626756 -3,473 -55,624
116813768 116814047 -44,912 -101,137
117015268 117015647 96,714 3,749
117126586 117126967 28,056 13,593
117222284 117222492 -31,918 -112,011
117358295 117358401 104,093 23,898
117554280 117554477 66,548 -602
117477252 117477671 -10,480 -77,408
119888983 119889236 37,627 30,036
12107161 12107554 61,140 -19,297
12156704 12156927 7,057 -34,945
120395204 120395554 139,505 -18,245
120698748 120698903 29754 38557
120724753 120724985 -3749 -12475
144243331 144243536 7,083 -11,689
144341864 144342095 -65,291 -84,876
146398562 146398665 -19,973 -23,709
146482484 146482839 -84,877 -94,308
148224704 148224871 57,536 49,475
148862649 148862853 48,991 44,093
149005432 149005676 36,257 619
149074817 149074986 39,506 27,550
149126523 149126710 91,212 79,274
149243779 149244097 -31,891 -42,603
149568202 149568358 37,165 1,543
15592470 15592659 -63,341 -97,823
15743102 15743307 87,291 52,825
150124005 150124257 84,641 53,285
150321738 150321938 50,132 45,803
151509676 151510156 -27,286 -39,662
151679764 151680119 66,956 65,370
151741386 151741558 -32,313 -33,786
151815693 151816092 32,980 26,856
151903033 151903133 2,128 -7,015
151981475 151981706 80,570 71,558
152254939 152255252 25,086 24,002
152311055 152311181 81,202 79,931
152640133 152640283 4160 68267
152689113 152689266 -44820 19284
153167546 153167951 -46,207 -50,397
153368540 153368689 1,980 -5,321
153695008 153695274 270,084 265,944
154674287 154674388 -25,856 -62,856
155099951 155100256 57,292 46,986
155091484 155091672 48,825 38,402
155821590 155821916 71,799 32,982
155907593 155907785 97,430 73,291
155968421 155968850 -13,724 -44,696
156053140 156053528 70,995 39,982
156491097 156491389 74,736 70,079
156581636 156581790 55,436 51,746
157182878 157183052 -53,504 -108,517
157343650 157343800 107,268 52,231
157436866 157437022 28,843 -5,892
157529540 157529738 3,412 -14,900
157905533 157905683 -43,170 -45,320
158026403 158026552 9,057 7,595
158110214 158110363 -53,239 -71,647
158339075 158339223 11,321 4,120
158611823 158611977 8,342 2,715
158710267 158710590 -11,177 -49,086
158994467 158994763 79,307 46,498
159042070 159042242 9,518 -22,427
159241305 159241641 9,680 -33,763
159289844 159289978 58,219 14,574
159476005 159476157 24,312 19,044
159547782 159547902 81,703 73,312
159718090 159718302 23754 37682
159925743 159926078 66,133 58,458
16068553 16068848 21,607 -70,694
160680728 160680994 49,048 32,442
163670101 163670279 33,323 -10,778
165776202 165776309 109,701 21,838
165742032 165742474 75,531 -11,997
165996572 165996681 38,740 -30,003
166760192 166760479 -16,434 -19,380
166847127 166847541 34,792 29,602
167782019 167782189 31,991 -40,261
167839015 167839240 14,354 -26,791
167888112 167888292 63,451 22,261
167934170 167934404 7,738 -13,059
17538987 17539227 31,710 -23,859
170879507 170879676 -15,270 -22,961
170974676 170975097 79,899 72,460
171297482 171297762 21,759 11,083
171264445 171264712 -11,278 -21,967
171384999 171385262 -34,494 -57,832
171509854 171509987 90,361 66,893
171743126 171743355 30,098 18,786
172228252 172228588 88,690 75,449
173372906 173373307 69,289 -10,518
173789361 173789708 230,803 -189,821
173663383 173663770 104,825 -315,759
173551440 173551669 -7,118 -427,860
173979342 173979564 420,784 35
173943745 173943862 385,187 -35,667
173783268 173783512 224,710 -196,017
177098271 177098441 12,978 -8,397
177222734 177223120 -95,001 -110,533
177468156 177468492 150,421 134,839
178439502 178439869 48,911 81
178371799 178371991 -18,792 -67,797
179291903 179292263 22,141 -49
18558257 18558663 251,430 -18,900
18453893 18454062 147,066 -123,501
18306011 18306145 -816 -271,418
18640976 18641135 334,149 63,572
181023651 181023751 -51,476 -99,759
181140182 181140466 65,055 16,956
181453066 181453438 31,044 -27,224
181485371 181485534 63,349 4,872
181778627 181778785 -12,693 -47,849
184498645 184499049 -33,389 -51,268
184973466 184973772 65,920 57,593
190964044 190964300 92,139 68,241
190826568 190826757 -45,337 -69,302
194983594 194984042 95,963 785
194917054 194917353 29,423 -65,904
195153322 195153523 142,751 -863
195259589 195259868 80,069 64,889
196859008 196859237 -15,416 -133,798
198427146 198427367 163,793 14,192
198979477 198979894 119,830 74,145
198766750 198766850 -92,897 -138,899
2521865 2522093
2530030 2530401 -50880 -43788
20310948 20311409 -71 -7,228
20246759 20246900 -64,260 -71,737
20383149 20383327 72,130 64,690
20807260 20807633 19,232 -10,355
20755451 20755747 -32,577 -62,241
200184737 200184971 -58,959 -67,968
200450701 200450807 67,937 53,475
200498563 200498816 94,761 73,712
201426851 201427023 100,446 23,867
201387330 201387616 60,925 -15,540
201338325 201338509 11,920 -64,647
201635202 201635518 58,827 48,278
201989619 201989975 -11,338 -22,148
202348103 202348336 39,237 -15,158
202327292 202327557 18,426 -35,937
202692591 202692790 34,212 -33,385
202816750 202817052 64,616 23,181
203304684 203304960 25,721 -8,801
203220013 203220180 -58,950 -93,581
203891616 203892025 58,286 23,402
204741554 204741703 31,140 4,857
204833379 204833538 -42,125 -90,843
205013527 205013705 88,615 39,454
N/A N/A N/A N/A
205048253 205048519 9,415 -34,430
205078640 205078851 -26,682 -30,340
205158514 205158736 21,103 14,629
205303798 205304022 -25,012 -35,939
205441979 205442426 97,749 57,486
205647276 205647722 85,800 46,788
205687370 205687674 -6,828 -42,189
205947729 205947928 211,633 66,195
205883859 205883961 147,763 2,228
205826044 205826169 89,948 -55,564
206056498 206056664 64,473 21,183
206137789 206138080 20,847 -13,290
206105499 206105697 -11,443 -45,673
206221446 206221542 104,504 70,172
207864747 207865168 9,909 -27,275
207949877 207950139 95,039 57,696
207783865 207784057 -70,973 -108,386
208036528 208036697 10,869 -9,405
209669985 209670146 103,405 55,235
209471360 209471602 -95,220 -143,309
210736987 210737439 -68,387 -123,303
210927833 210928181 122,459 67,439
212795947 212796130 198,473 4,865
212604688 212604861 7,214 -186,404
212919548 212919946 76,393 15,409
215300678 215300839 557,467 -76,881
214943506 214943765 200,295 -433,955
214784611 214784751 41,400 -592,969
214880392 214880547 137,181 -497,173
215160267 215160455 417,056 -217,265
215361062 215361182 617,851 -16,538
215216213 215216336 473,002 -161,384
216654129 216654315 67,929 -30,269
219115070 219115257 -4,296 -9,765
219201032 219201262 81,666 76,240
219906078 219906406 -35,311 -75,735
219865643 219865801 -75,746 -116,340
220066424 220066770 125,035 84,629
22081456 22081556 60,132 -54,821
22393746 22394082 75,569 51,885
22808779 22809269 -26,926 -29,493
22822726 22822865 -12,979 -15,897
22897463 22897645 61,758 58,883
23141418 23141558 231,373 27,153
221394688 221394784 44,418 11,537
224053319 224053540 -11,140 -46,344
224133098 224133270 68,639 33,386
224579194 224579455 -35,821 -82,959
224715979 224716073 100,964 53,659
225001629 225002044 115,615 8,397
224922112 224922501 36,098 -71,146
226712934 226713078 1,631 881
227588826 227589226 -44,789 -47,242
227637808 227638013 4,193 1,545
233985087 233985489 94,123 -128,074
234092495 234092797 201,531 -20,766
233918710 233919094 27,746 -194,469
233960402 233960594 69,438 -152,969
234369444 234369756 163,691 66,050
234215458 234215755 9,705 -87,951
234756938 234757107 132,635 42,458
234635612 234635898 11,309 -78,751
234697293 234697439 72,990 -17,210
234988436 234988869 72,014 -5,685
24365214 24365363 46,366 23,165
24284111 24284522 -34,737 -57,676
24327532 24327681 8,684 -14,517
240059211 240059445 -18,894 -60,419
241879146 241879476 160,988 -200,577
241929347 241929516 211,189 -150,537
241980312 241980412 262,154 -99,641
242132500 242132680 414,342 52,627
241757649 241757909 39,491 -322,144
245668817 245669049 20,843 -9,984
245753885 245754055 105,911 75,022
25083878 25084302 -14,718 -79,760
25156255 25156713 57,659 -7,349
25489580 25489690 18,012 -39,833
25605276 25605382 43,949 -23,888
26125160 26125617 -33,685 -71,618
26208532 26208633 49,687 11,398
26523553 26523675 6,555 4,074
27063369 27063469 -26,198 -36,080
27161953 27162115 51,387 49,068
27284905 27285150 -12,988 -80,909
27406448 27406579 108,555 40,520
27826445 27826654 15,283 -7,721
27810008 27810268 -1,154 -24,107
28304800 28304978 -41,464 -87,993
28390511 28390738 44,247 -2,233
29515207 29515334 79,596 -10,565
29594202 29594459 158,591 68,560
3713783 3714235 -49,922 -77,618
31104317 31104509 -10,584 -61,792
31184208 31184506 69,307 18,205
31579705 31579970 -30,982 -38,540
31691178 31691327 80,491 72,817
32160735 32161040 16,126 -15,538
32217659 32218079 73,050 41,501
32319158 32319636 67,141 20,599
32431626 32431870 -57,854 -92,483
32598999 32599175 109,519 74,822
32582337 32582751 52,063 10,928
36750332 36750555 46,101 29,089
36661487 36661961 -42,744 -59,505
37880392 37880591 75,388 46,482
39946153 39946337 -30,964 -55,836
40031816 40032000 54,699 29,827
40155002 40155420 21,317 15,146
40932954 40933281 3,125 -76,583
41048818 41049032 118,989 39,168
41152667 41152942 -65,284 -97,873
41431703 41431992 166,242 -48,383
41273561 41273803 8,100 -206,572
42533358 42533792 118,561 -40,343
42458163 42458359 43,366 -115,776
42869889 42870274 -26,746 -44,742
43008557 43008657 -46,806 -74,590
43127420 43127586 72,057 44,339
43537628 43537883 -38,434 -54,839
43534013 43534296 -63,200 -67,165
43834710 43835035 65,576 -26,889
43729147 43729375 -39,987 -132,549
44199795 44200229 28,216 24,730
45032172 45032449 -6,451 -17,030
46345335 46345508 66,936 -25,546
46969602 46969764 -67,703 -87,908
47134127 47134555 96,822 76,883
47346835 47346984 85,008 57,974
47518034 47518204 63,484 48,230
47416796 47416956 -37,754 -53,018
47658013 47658114 3,682 1,803
47717197 47717366 42,921 38,416
50870539 50870957 192,801 -327,567
51227256 51227512 549,518 28,988
50840440 50840693 162,702 -357,831
50614475 50614898 -63,263 -583,626
51062311 51062566 384,573 -135,958
50946157 50946278 268,419 -252,246
56865797 56865983 133,270 48,138
56704450 56704849 -28,077 -112,996
56794815 56795091 62,288 -22,754
56982831 56982992 99,248 29,396
57157156 57157372 64,091 890
59040129 59040337 21,081 17,750
6451748 6451891 7,950 -50,817
6552569 6552780 108,771 50,072
60193176 60193646 61,608 28,596
63594563 63594850 33,263 31,465
65266692 65266955 195,192 62,180
65098573 65098960 27,073 -105,815
65047672 65047939 -23,828 -156,836
65749437 65749865 90,579 -129,965
65868877 65869147 210,019 -10,683
65610383 65610582 -48,475 -269,248
66629082 66629540 598,301 16,690
66123732 66124206 92,951 -488,644
66279960 66280185 249,179 -332,665
66399431 66399713 368,650 -213,137
66030154 66030296 -627 -582,554
67522012 67522314 117,341 24,064
67422737 67423039 18,066 -75,211
67640744 67640896 95,109 5,725
7889010 7889252 -13,484 -34,261
7978140 7978428 75,646 54,915
71167018 71167270 76,394 -118,809
71269404 71269634 178,780 -16,445
71173779 71174035 83,155 -112,044
70958653 70958962 -131,971 -327,117
78505947 78506207 -36,209 -272,767
78679341 78679503 137,185 -99,471
78756727 78756953 214,571 -22,021
78913609 78913851 25,505 11,500
78833428 78833809 -54,676 -68,542
79149764 79149943 21,727 -129,162
79296770 79297183 168,733 18,078
84503775 84503929 187,446 27,160
84308970 84309145 -7,359 -167,624
85473216 85473695 -31,303 -42,664
85541131 85541346 36,612 24,987
85574178 85574426 17,422 -128,989
85702827 85703016 146,071 -399
89086765 89086983 -4,438 -42,906
89278228 89278608 33,280 17,476
89426234 89426486 81,831 12,175
89570050 89570158 71,197 59,039
9693234 9693397 58,844 -18,167
91852607 91852865 -65,881 -291,282
91967265 91967485 48,777 -176,662
92219475 92219731 300,987 75,584
988762 988968 50,096 49,185
94083562 94083798 -39,787 -63,802
94827241 94827552 59,872 47,608
102047157 102047636 147,316 68,270
101876767 101877235 -23,074 -102,131
103081011 103081184 -22,799 -225,884
103282436 103282643 178,626 -24,425
103186239 103186527 82,429 -120,541
103458963 103459149 -60,914 -66,668
104183819 104184212 39,499 31,941
104578855 104579053 52,859 13,042
104622910 104623111 42,632 35,831
11415824 11416266 328,534 -2,414
11136346 11136564 49,056 -282,116
11044923 11045394 -42,367 -373,286
11405372 11405511 318,082 -13,169
11230768 11230868 143,478 -187,812
11308543 11308703 221,253 -109,977
112213182 112213522 -34,404 -47,770
112437722 112438107 120,283 83,723
112381801 112381926 64,362 27,542
115398137 115398286 -30,788 -82,368
12315190 12315371 103,548 63,405
12185420 12185587 -26,222 -66,379
121395997 121396203 -4,875 -31,118
121442456 121442757 41,584 15,436
123119005 123119448 645,628 -228,514
122456224 122456679 -17,153 -891,283
122788975 122789407 315,598 -558,555
123192898 123193262 719,521 -154,700
123260196 123260544 786,819 -87,418
123077619 123078057 604,242 -269,905
123340429 123340702 867,052 -7,260
122634709 122634881 161,332 -713,081
123044495 123044666 571,118 -303,296
122923502 122923945 450,125 -424,017
122493370 122493470 19,993 -854,492
122956331 122956574 482,954 -391,388
122772594 122772780 299,217 -575,182
124310913 124311313 742 -81,929
124402715 124402918 92,544 9,676
124863927 124864289 -39,856 -50,587
125000685 125000816 96,902 85,940
127371251 127371500 -73,761 -82,880
127590942 127591112 76,046 16,095
127882368 127882572 191,428 -184,483
127989618 127989813 298,678 -77,242
128093957 128094069 403,017 27,014
127669764 127669864 -21,176 -397,191
129430152 129430372 4,648 932
129643468 129643725 48,153 -130,430
129532723 129532934 -62,592 -241,221
131176113 131176333 20,657 -279,025
131345857 131346011 190,401 -109,347
131534323 131534438 378,867 79,080
133656190 133656439 25,009 10,989
134980088 134980242 54,190 39,880
135205989 135206368 15,132 -18,346
14950401 14950560 -28,963 -85,877
15100482 15100739 121,118 64,302
15516539 15516781 -79,415 -285,349
15642982 15643419 47,028 -158,711
15863327 15863513 267,373 61,383
15717867 15718069 121,913 -84,061
16622065 16622206 26,317 18,196
16559201 16559433 -36,547 -44,577
17365771 17366154 54,488 46,556
17935391 17935717 44,023 -57,467
18281120 18281283 142,762 41,186
22622833 22622987 -27,313 -37,207
26880805 26881255 113,667 -15,483
26737714 26738072 -29,424 -158,666
26801475 26801569 34,337 -95,169
30761817 30761974 -1,055 -28,794
30856805 30856995 93,933 66,227
31788555 31788912 141,125 -69,836
31856227 31856469 208,797 -2,279
31859304 31859717 211,874 969
31602801 31603020 -44,629 -255,728
31720106 31720285 72,676 -138,463
31787228 31787345 139,798 -71,403
33306963 33307354 77,637 20,150
33203437 33203802 -25,889 -83,402
33559442 33559664 53,016 -105,532
33484703 33484876 -21,723 -180,320
35519919 35520311 64,112 -21,581
35448262 35448663 -7,545 -93,229
35598142 35598320 142,335 56,428
44277379 44277528 91,768 76,980
45135539 45135859 -54,096 -125,712
45246939 45247383 57,304 -14,188
49078072 49078274 151,856 45,252
49291720 49292060 106,981 -25,349
49173610 49173915 -11,129 -143,494
54251939 54252109 56,793 50,643
59749701 59749853 -15,044 -50,662
59827471 59827581 62,726 27,066
6102858 6103019 68,518 42,863
6162899 6163377 70,241 19,083
6549064 6549479 39,953 -112,790
6486119 6486280 -22,992 -175,989
6668019 6668169 158,908 5,900
61519163 61519332 60,998 -300,162
61820415 61820639 362,250 1,145
61766240 61766389 308,075 -53,105
61406911 61407069 -51,254 -412,425
61701830 61701989 243,665 -117,505
62198756 62198925 -6,934 -25,691
64180823 64181149 -60,939 -64,984
64312963 64313152 71,201 67,019
70356451 70356625 25,411 -19,984
70589837 70590132 72,003 55,559
72065347 72065494 38,237 32,973
74921438 74921888 55,246 -3,877
74830893 74831188 -35,299 -94,577
75407328 75407563 66,432 60,302
75601437 75601688 20,466 -537,379
75918063 75918234 337,092 -220,833
76125105 76125467 544,134 -13,600
76006821 76006993 425,850 -132,074
75772150 75772617 191,179 -366,450
76170406 76170578 589,435 31,511
76451805 76451971 -72,391 -87,005
79286180 79286359 65,623 -70,025
79346447 79346849 125,890 -9,535
8065595 8066046 -71,067 -91,124
8180349 8180566 43,687 23,396
80850406 80850658 73,180 65,562
80698998 80699282 -78,228 -85,814
81638448 81638647 -49,028 -60,194
83847088 83847379 222,302 -889,534
83755509 83755790 130,723 -981,123
83719442 83719602 94,656 -1,017,311
83685373 83685725 60,587 -1,051,188
84031913 84032082 407,127 -704,831
84521953 84522351 897,167 -214,562
84386417 84386858 761,631 -350,055
84449524 84449693 824,738 -287,220
83577298 83577601 -47,488 -1,159,312
84267294 84267468 642,508 -469,445
84582515 84582611 957,729 -154,302
84704476 84704620 1,079,690 -32,293
84127094 84127246 502,308 -609,667
83923333 83923579 298,547 -813,334
88575128 88575545 68,752 -99,380
89591521 89591700 -21,329 -129,967
89669236 89669389 56,386 -52,278
90802096 90802332 62,890 36,810
91044574 91045038 81,268 -119,256
91165956 91166186 202,650 1,892
90922229 90922428 -41,077 -241,866
94854112 94854543 43,101 36,099
96414616 96414782 -18,752 -71,155
96600924 96601325 -88553 1682
96616024 96616357 -103653 -13350
96754217 96754382 -65799 -15245
96815763 96815961 29,244 -3,283
97404709 97405004 -56,817 -214,438
97518155 97518364 56,629 -101,078
97676529 97676681 215,003 57,239
97939396 97939567 -2,049 -81,749
98037615 98037775 -16,460 -50,536
98113222 98113486 59,147 25,175
1700761 1701110 -29,797 -40,688
1811459 1811748 80,901 69,950
1918252 1918425 87,476 48,356
10344350 10344812 61,178 59,313
100348362 100348532 -65,951 -157,933
100436054 100436203 21,741 -70,262
101668113 101668513 -25,291 -45,162
101888016 101888260 -8,433 -18,428
102021483 102021595 68,707 20,322
102097115 102097340 29,490 15,662
102147724 102147929 1,280 -8,640
102258351 102258583 46,613 39,031
102293049 102293484 -25,885 -38,188
102336786 102336969 17,852 5,297
104249491 104249665 -12,385 -24,942
104320257 104320527 1,453 -24,846
104381250 104381373 11,070 -3,536
104609328 104609428 95,449 93,765
104537770 104538130 23,891 22,467
106786937 106787219 -91,727 -154,418
106906426 106906608 27,762 -35,029
107538799 107539227 -59,970 -205,809
107669690 107670063 70,921 -74,973
107772476 107772881 173,707 27,845
107729808 107730105 131,039 -14,931
108050931 108051390 9,917 -265,476
108348281 108348535 307,267 31,669
108177867 108178016 136,853 -138,850
109577663 109577952 -27,713 -94,695
109643389 109643531 38,013 -29,116
110687039 110687495 -41,151 -68,132
110820084 110820297 91,894 64,670
111587200 111587444 68,014 47,394
111495994 111496143 -23,192 -43,907
112504798 112505030 167,430 -148,751
112620528 112620720 283,160 -33,061
112393437 112393626 56,069 -260,155
114764099 114764567 213,872 -115,758
114834170 114834546 283,943 -45,779
114659989 114660149 109,762 -220,176
114494222 114494480 -56,005 -385,845
114630455 114630551 80,228 -249,774
114868813 114868970 318,586 -11,355
117421158 117421352 58,839 43,948
117321983 117322360 -40,336 -55,044
117700389 117700722 19,727 8,622
117710065 117710464 -410 -8,205
118198233 118198689 72,610 31,607
118140629 118140811 15,006 -26,271
118302331 118302484 42,554 30,303
118294141 118294291 34,364 22,110
118770905 118771288 86,461 78,238
119059296 119059573 45,278 -45,072
119177944 119178053 163,926 73,408
119585098 119585541 -31,158 -110,322
119723000 119723254 106,744 27,391
119637040 119637172 20,784 -58,691
120769755 120769894 -58,375 -235,727
121040925 121041033 212,795 35,412
125333610 125333823 54,060 35,608
125216965 125217304 -62,585 -80,911
125734783 125734933 76,591 62,250
125585523 125585702 -72,669 -86,981
13409041 13409169 -61,136 -64,974
133254024 133254494 -36,371 -72,827
133323661 133323811 33,266 -3,510
133365279 133365517 74,884 38,196
133524030 133524139 80,000 -2,722
133559866 133560110 115,836 33,249
133778960 133779196 25,352 -7,826
14884514 14884663 28,383 14,336
17113699 17113909 45,838 -33,955
17002331 17002575 -65,530 -145,289
18093321 18093663 2,725 -1,032
18229909 18230280 6,544 3,522
18297333 18297482 73,968 70,724
18378499 18378623 77,780 33,470
18658608 18658789 -23,827 -45,564
18855689 18855901 149,638 85,936
2156353 2156501 49,435 30,885
2420074 2420260 64,978 45,035
2283799 2283921 -71,297 -91,304
2792169 2792522 -68,850 -71,055
20299960 20300129 -65,719 -187,275
20387735 20387936 22,056 -99,468
22598011 22598324 -48,219 -192,799
22741651 22741808 95,421 -49,315
22816598 22816863 170,368 25,740
255428 255888 -13,142 -19,416
287487 287636 18,917 12,332
27637704 27637859 4,688 -62,013
27695872 27696148 62,856 -3,724
3640770 3640991 17,833 -1,231
33715142 33715474 34,010 874
33649572 33649789 -31,560 -64,811
34338576 34338725 -78,478 -111,458
35262509 35262746 145,516 52,221
35189696 35189866 72,703 -20,659
35105921 35106120 -11,072 -104,405
36450016 36450216 -17,283 -38,182
36588787 36589004 42,648 31,127
405192 405367 -9476 2030
413520 413946 -17804 -6549
4812943 4813113 67,867 -157,122
4975673 4976118 230,597 5,883
4874800 4875272 129,724 -94,963
4724509 4724721 -20,567 -245,514
43243236 43243507 -46,873 -79,148
43927725 43928112 68,754 29,720
44591879 44592346 48,162 -5,569
44536919 44537277 -6,798 -60,638
45860353 45860453 -3,425 -24,139
45933382 45933561 69,604 48,969
46807925 46808037 110,594 90,406
46634982 46635131 -62,349 -82,500
47332639 47332808 105,556 85,836
47223856 47224048 -3,227 -22,924
47566731 47567132 23,267 4,442
47460024 47460448 -83,440 -102,242
47658692 47659143 90,900 78,627
48137208 48137396 178,519 -8,850
47979419 47979563 20,730 -166,683
5127935 5128105 -75,335 -84,349
5258197 5258397 54,927 45,943
5640602 5641025 -26,893 -47,644
5685349 5685820 17,854 -2,849
5776756 5777027 109,261 88,358
56766568 56766738 8,938 5,249
56813022 56813215 -49,503 -80,910
56922052 56922231 11,220 7,525
57005540 57005740 -70,165 -86,593
57117326 57117551 -4,277 -21,351
57222126 57222292 100,523 83,390
59601726 59602151 21,049 6,987
59945379 59945684 -8,259 -26,157
6556371 6556806 -25,169 -31,871
6582930 6583317 1,390 -5,360
6644378 6644852 62,838 56,175
60310130 60310329 -64,853 -69,691
60646267 60646684 19,724 -5,216
61062251 61062545 22,890 -42,329
61119711 61119869 80,350 14,995
61376985 61377415 60,259 56,129
62284965 62285163 -31,254 -44,366
62458815 62458918 78,721 45,989
62993108 62993250 -37,024 -47,565
63719113 63719554 -39,533 -43,281
63794870 63795098 29,881 26,836
63927537 63927929 97,921 87,143
64249526 64249691 -1,433 -19,813
64524878 64525231 66,359 65,295
64462810 64462937 4,291 3,001
64807919 64808269 21,913 -13,395
65016310 65016478 -46,540 -65,797
65066933 65067116 4,083 -15,159
65222246 65222415 44,597 35,456
65462513 65462963 83,655 79,501
65346967 65347136 -31,891 -36,326
65854507 65854868 15,973 13,777
65975563 65975718 -15,411 -25,664
66132595 66133021 61,628 45,648
66187699 66187856 100,188 95,233
66600844 66601220 19,947 5,160
66526118 66526306 -54,779 -69,754
66871457 66871897 -16,758 -25,885
66948890 66949039 60,675 51,257
67069719 67069901 62,622 54,751
67168673 67168902 60,811 58,201
67457480 67457688 -57,671 -70,481
67624326 67624698 61,267 49,756
67855692 67855935 19,018 -117,382
68013498 68013891 176,824 40,574
67888234 67888517 51,560 -84,800
67945684 67945935 109,010 -27,382
67819950 67820156 -16,724 -153,161
69149669 69149895 -15,385 -28,528
69324892 69325079 27,914 25,727
69751899 69752017 24,982 20,873
7017138 7017337 765 -31,996
7096246 7096473 79,873 47,140
7867613 7867973 -69,934 -73,807
8027665 8027909 90,118 86,129
71155608 71155807 -66,286 -70,449
71429082 71429258 41,495 34,849
72666465 72666905 59,473 41,860
72539761 72539886 -67,231 -85,159
72616021 72616121 9,029 -8,924
72815181 72815466 50,128 29,299
73007538 73007678 -16,054 -43,834
73967405 73967700 -13,872 -63,713
74565726 74566012 -88,404 -174,509
74649816 74649977 -4,314 -90,544
75441946 75442301 238,023 -89,041
75563087 75563342 359,164 32,000
75228186 75228613 24,263 -302,729
75339935 75340147 136,012 -191,195
75724913 75725164 -13,739 -44,364
75822080 75822524 83,428 52,996
76713339 76713605 2,631 -148,976
76646166 76646333 -64,542 -216,248
77819086 77819508 215,096 13,094
77653879 77654097 49,889 -152,317
77531968 77532211 -72,022 -274,203
781048 781296 41904 47539
86300226 86300600 -34,143 -43,481
86416124 86416387 81,755 72,306
88608867 88609333 58,599 -59,141
88666039 88666278 115,771 -2,196
88575395 88575564 25,127 -92,910
88828457 88828630 129,297 -35,671
93885648 93885921 95,534 19,233
93792191 93792340 2,077 -74,348
10042469 10042693 27,188 13,232
10087332 10087531 72,051 58,070
10171994 10172269 58,573 29,397
10203130 10203222 963 -12,782
10252834 10253012 50,667 37,008
10429073 10429350 77,389 69,367
10537837 10538291 81,656 73,830
10622662 10622872 -10,377 -20,559
10740104 10740529 -2,851 -26,642
101316913 101317109 3,107 -81,362
101399150 101399375 85,344 904
101913847 101914133 38,253 35,712
101880231 101880528 4,637 2,107
102562239 102562561 57,058 -122,074
102657408 102657508 152,227 -27,127
102758254 102758474 253,073 73,839
102603254 102603466 98,073 -81,169
102538509 102538726 33,328 -145,909
102934516 102934867 86,226 69,034
102963757 102964206 -71,231 -91,964
103065571 103065835 30,583 9,665
103360732 103361193 155,875 93,001
105442833 105443296 -58,330 -237,415
105605002 105605216 103,839 -75,495
105703670 105703837 202,507 23,126
107227972 107228172 19,172 -29,046
107546197 107546409 6,397 -5,390
108055338 108055655 44,959 39,995
108083845 108084082 73,466 68,422
108248621 108248864 48,454 17,456
108195877 108196139 -4,290 -35,269
109352563 109352725 -71,825 -101,549
109439729 109440012 15,341 -14,262
11685531 11685738 -8,524 -253,865
11718773 11718949 24,718 -220,654
11793396 11793617 99,341 -145,986
11990747 11990978 296,692 51,375
111309260 111309377 -31,659 -122,723
111459825 111460188 118,906 28,088
111799546 111799692 -29,576 -54,682
112103089 112103288 123,044 83,072
112051097 112051240 71,052 31,024
115731355 115731467 -52,055 -72,148
115839045 115839149 55,635 35,534
116283881 116284210 148,519 245
116073014 116073216 -62,348 -210,749
116360490 116360689 225,128 76,724
118111422 118111554 10,444 -5,380
118081112 118081313 -19,866 -35,621
120041329 120041603 98,851 80,439
119906036 119906229 -36,442 -54,935
12146717 12147053 31,572 -108,161
12293759 12293984 178,614 38,770
12341197 12341421 176,244 30,408
12569802 12570166 49,704 -36,418
12605068 12605244 84,970 -1,340
12530591 12530790 10,493 -75,794
12923727 12923938 153,597 49,756
120085304 120085687 30,243 -22,572
120098187 120098601 43,126 -9,658
121227911 121228040 5,381 3,341
121504494 121504896 182,560 31,827
121379039 121379484 57,105 -93,585
121704586 121704690 -60,670 -62,607
122610261 122610730 -42,364 -60,705
122785607 122785735 101,274 74,162
123487252 123487709 112,338 -81,084
123335726 123336092 -39,188 -232,701
123437554 123437795 62,640 -130,998
123551451 123551625 176,537 -17,168
123478494 123478745 103,580 -90,048
123785839 123785947 -42,290 -128,399
123912323 123912419 84,194 -1,927
124113254 124113485 115,929 73,865
128051485 128051693 -12,320 -15,947
129137593 129137752 -75,364 -78,486
129286415 129286564 73,458 70,326
129903550 129903765 -18,971 -23,551
131664912 131665106 -40,564 -43,939
14919482 14919661 45,970 31,981
14874634 14874948 1,122 -12,732
14992281 14992518 6,064 -13,352
15056240 15056476 70,023 50,606
15300249 15300411 -66,505 -341,191
15674320 15674532 307,566 32,930
15426311 15426470 59,557 -215,132
15524891 15525092 158,137 -116,510
18686865 18687129 381,124 -5,488
18740430 18740725 434,689 48,108
18263410 18263511 -42,331 -429,106
18360074 18360183 54,333 -332,434
18449572 18449809 143,831 -242,808
2828263 2828442 53,849 45,057
2873844 2874055 99,430 90,670
25168001 25168287 -81,446 -126,834
25269412 25269582 19,965 -25,539
26314493 26314662 -62,700 -562,736
26813119 26813273 435,926 -64,125
26939529 26939766 562,336 62,368
26609551 26609775 232,358 -267,623
26693892 26694063 316,699 -183,335
26557884 26558019 180,691 -319,379
26458220 26458369 81,027 -419,029
26495532 26495631 118,339 -381,767
28008328 28008607 6,044 -7,576
28091917 28092066 89,633 75,883
28006325 28006573 4,041 -9,610
29352779 29352968 -28,777 -72,442
29431238 29431647 49,682 6,237
3645701 3645871 175,015 72,471
3538279 3538526 67,593 -34,874
3457675 3457844 -13,011 -115,556
31111945 31112104 -6,116 -36,888
31203775 31204068 85,714 55,076
4315826 4315989 62,627 31,212
4508240 4508410 94,671 83,369
4605075 4605250 35,570 11,948
4566036 4566290 -3,469 -27,012
42438703 42438812 -344 -29,354
42557887 42558129 118,840 89,963
44546904 44547358 -54,555 -123,257
44703079 44703522 101,620 32,907
46490799 46490990 28,027 -8,934
46556248 46556348 93,476 56,424
47544321 47544518 34,515 12,294
47583832 47584131 74,026 51,907
47684743 47684960 26,240 22,214
47770522 47770962 1,051 -3,907
47893345 47893701 28,498 24,548
48065378 48065631 52,911 48,393
48262703 48262971 24,351 14,793
49402209 49402647 -41,919 -97,681
49489767 49490229 45,639 -10,099
49591028 49591174 146,900 90,846
5978723 5978991 50,422 -125,106
6035146 6035410 106,845 -68,687
6104685 6104834 176,384 737
5945674 5945835 17,373 -158,262
5837039 5837319 -91,262 -266,778
50000958 50001096 -7,536 -25,634
51157078 51157229 -10,153 -16,060
51654720 51654947 77,482 69,820
51557334 51557446 -19,904 -27,681
51830228 51830548 -41,146 -56,719
51902241 51902398 11,620 -9,855
52091633 52091783 31,387 -4,714
52014232 52014508 -46,014 -81,989
52659623 52659825 6,446 3,355
53019917 53020186 47,755 39,128
53066185 53066285 94,023 85,227
53175440 53175857 100,128 76,540
53390512 53390893 65,870 62,477
53329249 53329539 4,607 1,123
54398484 54398764 33,865 10,815
54337267 54337416 -27,352 -50,533
54612617 54612828 1,404 -21,246
54675920 54676089 41,764 29,324
55099487 55099575 80,561 79,114
55442274 55442554 49,790 35,306
55498736 55498853 106,252 91,605
55791940 55792334 22,783 16,808
55950121 55950516 -40302 -35535
55951465 55951629 -41646 -36648
56022483 56022632 -92,327 -108,244
56231892 56232105 96,529 94,047
56377877 56378037 -50,393 -54,394
56589563 56589732 89,586 62,718
6235483 6235761 56,349 18,073
6324780 6324991 16,596 3,469
6288126 6288299 -20,058 -33,223
6439131 6439549 75,536 68,555
6587061 6587187 73,189 69,390
6597357 6597553 83,485 79,756
6792176 6792404 23,264 -7,833
6904463 6904614 84,827 77,795
64942912 64943311 73,642 14,627
64866094 64866556 -3,176 -62,128
66365842 66366077 36,821 25,667
66415802 66416056 86,781 75,646
66766121 66766542 -68,695 -73,248
66904234 66904403 69,418 64,613
66838693 66838991 3,877 -799
N/A N/A N/A N/A
66944798 66944968 16,506 11,317
67433795 67434235 -54,452 -86,246
67603158 67603380 114,911 82,899
69244866 69245030 43,635 -72,439
69299051 69299293 97,820 -18,176
69481619 69481905 163,490 -118,948
69673344 69673504 355,215 72,651
7170247 7170547 31,956 17,478
7709589 7709738 -63,689 -83,598
7794552 7794931 21,274 1,595
78562872 78563350 52,996 -45,571
79310149 79310458 -8,448 -287,641
79475665 79476124 157,068 -121,975
79557911 79558131 239,314 -39,968
8126572 8126744 49,946 27,359
8048872 8049081 -27,754 -50,304
8252748 8252849 85,255 70,379
8654797 8654971 97,394 88,742
8933305 8933450 66,821 12,804
87529479 87529893 118,782 31,524
87486164 87486560 75,467 -11,809
88226691 88227034 -39,277 -43,393
88320166 88320357 54,198 49,930
9046735 9046934 13,251 -7,676
9553148 9553304 92,254 61,212
9376108 9376310 -84,786 -115,782
9497176 9497448 36,282 5,356
9739603 9739784 101,188 88,020
9876479 9876698 5,135 -12,173
90039212 90039461 -23,954 -61,476
90073419 90073672 10,253 -27,265
91115769 91115992 54,739 52,241
91679397 91679629 -13,860 -167,509
91915912 91916032 222,655 68,894
92373939 92374337 47,720 14,180
92496455 92496742 8,726 2,633
92465871 92466225 -21,858 -27,884
92619073 92619331 23,791 -149,332
92574243 92574702 -21,039 -193,961
92781427 92781596 186,145 12,933
92708679 92708878 113,397 -59,785
93115238 93115652 48,608 -107,704
93037033 93037253 -29,597 -186,103
93294493 93294682 227,863 71,326
93844675 93845073 -95,127 -146,414
94863903 94864025 -54,839 -89,471
94989229 94989364 70,487 35,868
97476068 97476460 42,541 8,210
97392901 97393045 -40,626 -75,205
97592308 97592639 29,099 -60,703
97633038 97633348 69,829 -19,994
97528647 97529019 -34,562 -124,323
99472130 99472380 80,320 -9,394
99461304 99461632 69,494 -20,142
99423743 99424039 31,933 -57,735
99390197 99390525 -1,613 -91,249
101143927 101144100 241,070 -25,046
100850872 100851013 -51,985 -318,133
100921833 100921949 18,976 -247,197
101019349 101019512 116,492 -149,634
101405021 101405170 235,713 -446,986
101656393 101656559 487,085 -195,597
101521244 101521393 351,936 -330,763
101907920 101908082 738,612 55,926
101318212 101318481 148,904 -533,675
101752077 101752253 582,769 -99,903
101828869 101829043 659,561 -23,113
102346100 102346292 50,905 19,946
107736868 107737038 79,077 68,321
107844860 107845093 124,882 86,267
109801351 109801759 202,040 44,254
109648396 109648570 49,085 -108,935
109978018 109978413 220,386 15,038
112983609 112983911 -15,948 -41,835
20257883 20258180 82,404 62,943
20643000 20643381 30,350 22,160
20557425 20557629 -55,225 -63,592
21173783 21173991 30,613 -2,646
21215397 21215842 72,227 39,205
23139163 23139311 96,440 -8,921
23243644 23243795 200,921 95,563
23083142 23083346 40,419 -64,886
25963459 25963901 237,183 86,526
25834146 25834547 107,870 -42,828
25729969 25730139 3,693 -147,236
26078404 26078846 48,564 -82,239
26805545 26805847 -91,136 -101,976
26957206 26957639 60,525 49,816
27358433 27358626 -75,840 -82,691
27478401 27478570 2,990 -94,159
27618297 27618554 142,886 45,825
27953530 27953699 179,740 -13,533
27869868 27870023 96,078 -97,209
28043073 28043316 269,283 76,084
29970494 29970820 39,610 -118,909
29906396 29906794 -24,488 -182,935
30003534 30003738 72,650 -85,991
30163702 30163949 232,818 74,220
30244427 30244579 36,782 8,023
31922785 31923197 135,168 51,388
35835464 35835578 -69,031 -79,430
36317134 36317436 25,795 15,696
40132897 40133162 105,096 -5,572
39975108 39975292 -52,693 -163,442
41970551 41970720 -64,321 -109,428
42092311 42092485 57,439 12,337
44821373 44821567 228,723 65,330
44496186 44496554 -96,464 -259,683
44713243 44713628 120,593 -42,609
44830757 44830862 21,749 17,357
46302100 46302455 -3,414 -65,724
46345241 46345710 39,727 -22,469
47788809 47789010 -94,361 -98,937
47997390 47997628 114,220 109,681
48196230 48196355 17,538 14,856
52255232 52255509 79,832 43,561
94559555 94559705 89,471 -191,983
94698049 94698332 227,965 -53,356
94480217 94480614 10,133 -271,074
94740327 94740523 270,243 -11,165
98749659 98749833 4,869 -7,875
98666284 98666427 -78,506 -91,281
101709325 101709631 92,186 33,855
101822811 101823084 60,436 -18,200
102307652 102308130 -5,917 -134,251
102347697 102347928 34,128 -94,453
103022865 103023071 -69,777 -75,836
103312211 103312378 78,504 60,829
104341507 104341623 50,978 44,587
104670447 104670755 83,665 67,956
105529292 105529704 101,198 101,594
105335154 105335468 -92,940 -92,642
19826086 19826246 -23,281 -45,051
19906719 19906868 57,352 35,571
20276160 20276537 -42,890 -43,927
20618135 20618406 37,884 36,180
22182690 22182915 1,022,793 92,000
21479279 21479478 319,382 -611,437
22028150 22028453 868,253 -62,462
21328896 21329186 168,999 -761,729
21875450 21875599 715,553 -215,316
21577795 21577963 417,898 -512,952
21186185 21186349 26,288 -904,566
21757385 21757515 597,488 -333,400
21270918 21271150 111,021 -819,765
22439738 22439902 64,105 53,259
22280814 22281202 -94,819 -105,441
22535821 22536096 76,248 67,595
22656227 22656373 -128 -2,292
22814584 22814823 -31,282 -35,975
22962373 22962572 50,515 47,120
23630109 23630242 -31,098 -47,774
23839637 23839920 91,010 84,900
23943961 23944294 36,867 25,644
24044148 24044344 -68,416 -70,962
24121670 24121860 48330 51453
24192338 24192541 -22338 -19228
28330240 28330505 25,439 21,884
28257603 28257879 -47,198 -50,742
29435297 29435499 319,861 -31,152
29262603 29262789 147,167 -203,862
29526109 29526368 410,673 59,717
29016263 29016467 -99,173 -450,184
29148348 29148593 32,912 -318,058
34335036 34335455 85,638 81,806
34231541 34231758 -17,857 -21,891
34918147 34918589 -22,321 -25,114
35033722 35034192 93,254 90,489
37116005 37116456 -12,935 -17,784
37232711 37233184 103,771 98,944
37744676 37745101 -2,279 -6,918
37824490 37824956 77,535 72,937
44710536 44710892 55,677 36,620
49191881 49192154 56,716 41,014
49928543 49928979 -26,450 -140,147
50152652 50153047 197,659 83,921
50733159 50733451 -43,527 -59,061
51759902 51760366 -44,279 -52,826
51890305 51890758 39,442 25,684
52220528 52220682 -23,140 -43,784
53436482 53436805 -49,725 -56,557
53593304 53593509 107,097 100,147
53938580 53938926 5,157 -17,756
54629121 54629387 65,527 43,427
55811442 55811671 156,596 -26,113
55882115 55882567 227,269 44,783
55718215 55718408 63,369 -119,376
55573325 55573454 -81,521 -264,330
60903758 60903929 45,572 -183,522
61143560 61143747 285,374 56,296
60800266 60800425 -57,920 -287,026
61065410 61065576 207,224 -21,875
62818684 62818896 -30,711 -35,420
62892243 62892460 42,848 38,144
63585561 63585992 -35,827 -289,078
63876107 63876504 254,719 1,434
63720780 63720959 99,392 -154,111
64441002 64441427 -34,623 -37,857
68362589 68363050 -48,204 -152,697
68543815 68544025 133,022 28,278
70246928 70247317 -17,677 -98,324
70370762 70370929 106,157 25,288
74852031 74852209 36,747 33,524
75038385 75038685 -20,152 -44,401
75091785 75092149 33,248 9,063
75464406 75464680 -29,789 -52,562
75527214 75527586 33,019 10,344
75942526 75942991 35,047 -93,970
76025446 76025619 117,967 -11,342
75863464 75863650 -44,015 -173,311
77174362 77174469 -34,140 -69,640
77293976 77294208 85,474 50,099
80747781 80748039 256,253 65,640
80471349 80471808 -20,179 -210,591
80827913 80828075 111,766 70,747
87457690 87457886 -11,421 -71,774
87574460 87574634 105,349 44,974
87965948 87966195 -37,919 -124,681
88059646 88059898 55,779 -30,978
88860480 88860637 168,206 -92,490
88951893 88952084 259,619 -1,043
88657250 88657403 -35,024 -295,724
88740800 88740999 48,526 -212,128
90780037 90780475 11,408 -9,502
90693068 90693495 -75,561 -96,482
92208560 92209028 -31,347 -75,737
92301822 92301976 61,915 17,211
92665583 92665684 -52,711 -55,318
93664936 93665155 77,917 47,844
93521287 93521445 -65,732 -95,866
94013907 94014188 113,503 100,010
93907101 93907324 6,697 -6,854
95781905 95782117 40,955 1,575
95664504 95664706 -76,446 -115,836
99197450 99197788 -22,957 -65,603
99275129 99275290 54,722 11,899
99909870 99910019 135,015 95,462
99765742 99765988 -9,113 -48,569
23078354 23078568 458,467 -137,134
23155553 23155754 535,666 -59,948
22855116 22855330 235,229 -360,372
23231137 23231291 611,250 15,589
22681893 22682091 62,006 -533,611
32137907 32138284 192,187 19,689
32012936 32013103 67,216 -105,492
31913669 31913869 -32,051 -204,726
32820177 32820560 -49,546 -54,621
32973028 32973177 103,305 97,996
36508001 36508150 -59,589 -136,074
37776157 37776513 115,585 99,553
37660967 37661197 395 -15,763
38369373 38369590 2,925 -17,740
38739331 38739549 35330 72097
39052668 39052839 43,829 34,310
38931987 38932186 -76,852 -86,343
39544355 39544546 131,994 84,008
39752196 39752437 12,294 -96,996
39865926 39866373 126,024 16,940
41622051 41622403 9,102 -147,122
41706981 41707307 94,032 -62,218
41806120 41806270 19762 45826
42718636 42718849 -72,341 -78,800
42800986 42801377 10,009 3,728
47550841 47551198 48,090 -15,617
47657612 47658032 154,861 91,217
48393580 48394030 72,144 48,812
49407764 49408106 118,803 -9,980
49303014 49303192 14,053 -114,894
50146217 50146340 47,478 586
50215465 50215681 26,351 23,417
55019891 55020323 21,766 -347,685
55244562 55244793 246,437 -123,215
55368974 55369156 370,849 1,148
55165601 55165839 167,476 -202,169
54898634 54898816 -99,491 -469,192
56666269 56666486 -9,533 -162,983
56830252 56830385 154,450 916
57249332 57249720 64,720 45,184
57689592 57689840 -28,766 -47,151
58001826 58002255 -82,601 -83,179
58139383 58139534 54,956 54,100
58478125 58478377 51,483 900
58604444 58604688 27,689 -704,106
59297551 59297816 720,796 -10,978
58782555 58782724 205,800 -526,070
58877671 58877885 300,916 -430,909
58977946 58978364 401,191 -330,430
59087521 59087774 510,766 -221,020
59076470 59076626 499,715 -232,168
62073587 62073798 87,299 -51,776
62004907 62005089 18,619 -120,485
61905971 61906120 -80,317 -219,454
62317691 62317867 82,624 75,460
63127006 63127286 131,960 89,200
62942725 62942862 -52,321 -95,224
63239929 63240121 43,159 26,894
64414983 64415400 -51,691 -155,536
64646079 64646530 179,405 75,594
64540767 64540965 74,093 -29,971
65320336 65320572 175,087 45,985
65113637 65113910 -31,612 -160,677
65835777 65836140 213,702 -50,366
65626435 65626525 4,360 -259,981
65669136 65669238 47,061 -217,268
66422171 66422538 41,075 -89,008
66518358 66518512 137,262 6,966
66297190 66297339 -83,906 -214,207
67488489 67488729 -43,688 -46,210
68044119 68044251 -83,478 -133,059
68241434 68241634 113,837 64,324
69940758 69941117 50,810 43,463
69841475 69841628 -48,473 -56,026
70313328 70313733 -50,794 -142,135
71725492 71725884 86,082 13,078
71857694 71858093 94,019 64,181
72387628 72387823 -29,529 -59,311
72477905 72478090 60,748 30,956
72794409 72794608 -4,534 -10,322
72841471 72841726 42,528 36,796
73573462 73573611 26,947 -85,069
73935516 73935815 -84,817 -156,027
74102486 74102604 82,153 10,762
75018571 75018934 -56,038 -97,793
75079805 75080007 5,196 -36,720
77055934 77056165 54,772 31,690
76928739 76929010 -72,423 -95,465
78111951 78112070 71,661 61,372
79182433 79182589 -79,715 -209,568
79231537 79231915 -30,611 -160,242
79452215 79452352 190,067 60,195
83706160 83706564 127,339 -387,026
84166314 84166691 587,493 73,101
83712649 83712876 133,828 -380,714
84046409 84046579 467,588 -47,011
83678213 83678322 99,392 -415,268
83787882 83788129 209,061 -305,461
86956758 86957203 -26,281 -43,481
87096274 87096437 113,235 95,753
88099167 88099366 -29,963 -59,706
88188346 88188631 59,216 29,559
89007946 89008196 -53,660 -151,492
89079156 89079608 17,550 -80,080
89198746 89198873 137,140 39,185
89313939 89314196 101,050 86,505
94659259 94659444 -15,691 -23,604
94715440 94715645 40,490 32,597
96961037 96961440 -49,251 -357,594
97077023 97077172 66,735 -241,862
97409689 97409850 399,401 90,816
97249155 97249292 238,867 -69,742
1715132 1715300 18,910 -45,019
1941711 1941861 -27,208 -29,580
10960331 10960485 92,683 34,144
10988018 10988179 120,370 61,838
11253513 11253680 -2,262 -3,860
11325274 11325545 69,499 68,005
11545405 11545633 -3,952 -43,190
11498224 11498376 -51,133 -90,447
11952949 11953116 13516 16310
11968282 11968434 -1817 992
15946157 15946367 241,664 87,979
15832715 15832958 128,222 -25,430
15767606 15767801 63,113 -90,587
16039379 16039743 88,444 -104,031
160809 161082 -2,066 -2,626
2153935 2154221 8,135 -13,910
21639956 21640295 80,530 68,822
21491146 21491448 -68,280 -80,025
23634635 23635014 36,943 25,825
23684673 23684800 86,981 75,611
23807914 23808291 53,091 -331,067
24101554 24101749 346,731 -37,609
23742470 23742824 -12,353 -396,534
23995989 23996138 241,166 -143,220
24048207 24048621 293,384 -90,737
24143725 24143913 388,902 4,555
27332776 27333207 100,024 49,607
27222751 27222900 -10,001 -60,700
27491142 27491338 111,706 22,563
298680 298785 21,239 -43,680
28489310 28489545 71,126 63,889
28446611 28447003 28,427 21,347
29585304 29585508 3,503 -4,180
29717086 29717245 -14,505 -49,597
2973215 2973608 -37,128 -38,777
3057182 3057379 46,839 44,994
3270186 3270361 38,157 23,733
3174454 3174788 -57,575 -71,840
3463581 3464011 -68,245 -103,279
3548459 3548687 16,633 -18,603
3627974 3628208 -2,873 -25,856
3917284 3917686 200,716 46,963
3813919 3814095 97,351 -56,628
3762270 3762427 45,702 -108,296
30376915 30377064 14,462 12,339
30489388 30489681 97,837 47,674
30890227 30890376 74,798 67,994
31181102 31181270 -2313 70444
31253195 31253600 -74406 -1886
31345326 31345504 71,316 43,685
4473129 4473511 6,703 -26,838
45855925 45856074 109,127 -196,445
45755306 45755468 8,508 -297,051
45995121 45995315 248,323 -57,204
46689476 46689676 -68,847 -149,130
46924887 46925148 166,564 86,342
49384477 49384823 95,926 60,335
49215118 49215388 -73,433 -109,100
52131630 52131781 -48937 -37110
52126699 52126852 -44006 -32181
54106207 54106515 35,618 8,411
54032176 54032462 -38,413 -65,642
54433324 54433573 39,060 8,997
55183484 55183683 2,716 1,182
55222408 55222493 41,640 39,992
55651348 55651538 70,330 -22,403
55584461 55584781 3,443 -89,160
55709932 55710210 128,914 36,269
55911803 55912204 -38,416 -45,398
56024812 56025048 28,632 17,573
56590591 56590793 -26,192 -47,513
56552978 56553146 -63,805 -85,160
64882417 64882654 -75,647 -113,536
65094021 65094170 135,957 97,980
65191351 65191682 47,384 21,219
65689391 65689580 68,840 -2,882
65589309 65589450 -31,242 -103,012
65767425 65767574 21,820 16,268
65853212 65853417 87,841 86,290
66578451 66578711 52,543 50,457
66506488 66506719 -19,420 -21,535
66801026 66801324 124,181 -17,014
66883087 66883253 -19,359 -65,410
34295 34446 -32,723 -41,399
67515184 67515304 186,488 88,359
68100934 68101404 -55,564 -194,650
68218683 68218832 62,185 -77,222
68942004 68942399 51,431 17,167
70593921 70594124 -91,195 -110,188
70745261 70745460 60,145 41,148
71474329 71474502 95,873 -165,273
71600267 71600426 221,811 -39,349
71522743 71522918 144,287 -116,857
71647224 71647436 268,768 7,661
71565950 71566111 187,494 -73,664
71388652 71388936 10,196 -250,839
73875778 73875977 -9,331 -148,911
74082377 74082765 197,268 57,877
73955171 73955392 70,062 -69,496
76695528 76695807 81,536 72,308
78139168 78139367 -46,564 -52,745
78209120 78209232 23,388 17,120
84191615 84191780 -77,166 -88,309
84557968 84558256 67,693 44,543
84425825 84425974 -64,450 -87,739
85168301 85168450 66,642 62,902
85073645 85073835 -28,014 -31,713
86537558 86537707 116,428 77,092
86451405 86451551 30,275 -9,064
87174014 87174176 -58,488 -60,207
88523669 88524048 11,142 -5,665
1416045 1416342 -67,857 -79,450
1487303 1487473 3,401 -8,319
1916267 1916502 6,379 -303,658
2033583 2034001 123,695 -186,159
2139892 2140157 230,004 -80,003
2234574 2234733 324,686 14,573
10385987 10386367 20,795 -7,337
10456232 10456433 91,040 62,729
11939704 11940004 74,844 -47,861
15598218 15598513 -17,828 -30,617
15690829 15691057 74,783 61,927
16108494 16108764 232,511 49,194
16005240 16005438 129,257 -54,132
16355951 16356133 96,338 75,091
16748940 16749186 -34,183 -66,941
17664978 17665246 9,184 -15,804
17974790 17974994 42,782 22,977
17910409 17910576 -21,599 -41,441
18014334 18014766 -13,680 -39,227
18561196 18561412 44,849 44,448
19250890 19251272 29,231 23,827
2601331 2601728 157,645 66,090
2391141 2391510 -52,545 -144,128
2529345 2529750 85,659 -5,888
21176961 21177417 48,380 18,299
23056581 23056867 75,630 56,156
23154137 23154468 46,218 2,786
23225251 23225444 117,332 73,762
23684176 23684376 -34,249 -37,468
23874781 23874996 -305 -14,306
24379049 24379308 -45,614 -152,248
24505188 24505310 80,525 -26,246
24434601 24434751 9,938 -96,805
24566594 24566862 141,931 35,306
25564795 25565234 15,763 -21,597
25678162 25678329 129,130 91,498
26105502 26105934 -28,326 -69,892
26037647 26037843 -96,181 -137,983
29584279 29584562 -22,130 -23,773
29764758 29764899 57,174 55,157
29792535 29792972 81,023 78,607
3373807 3373992 -41,684 -85,462
3492018 3492267 76,527 32,813
3548917 3549166 62,395 37,581
3613299 3613543 48,628 -47,035
3757216 3757422 10,582 -9,287
31148163 31148318 31,174 1,565
31282300 31282469 59,689 50,979
31895852 31896098 84,666 79,801
32534609 32535044 18,569 -305,971
32834762 32835086 318,722 -5,929
32711674 32712041 195,634 -128,974
32956258 32956455 32,194 8,746
33158937 33159143 112,411 81,543
35105436 35105592 7,517 -32,849
35228291 35228766 130,372 90,325
35417890 35418210 -7,324 -9,382
35430632 35431010 -41,957 -72,636
35603899 35604099 101,332 93,600
35550014 35550259 47,447 39,760
35724808 35725225 5,836 -42,195
35779043 35779443 -19,278 -48,252
35892219 35892436 -71,328 -82,814
35943289 35943434 -20,258 -31,816
36715377 36715553 -72,070 -76,628
36795531 36795960 -90,936 -95,234
36963799 36964015 77,332 72,821
37200413 37200655 -22,314 -32,340
37147056 37147228 -75,671 -85,767
37462949 37463196 -44,003 -55,081
37552518 37552777 45,566 34,500
37658510 37658750 53,789 -23,200
37669310 37669548 64,589 -12,402
37607045 37607194 2,324 -74,756
38033506 38033655 -51,455 -53,716
38322089 38322316 83,140 73,013
38951249 38951561 34,389 -5,645
38891056 38891233 -25,804 -65,973
39002730 39002865 85,870 45,659
39300407 39300768 101,392 88,896
39268247 39268501 69,232 56,629
39175619 39175792 -23,396 -36,080
39566265 39566482 56,618 9,942
39480891 39481330 -28,756 -75,210
39725896 39726104 43,330 25,111
39790593 39790867 -14,483 -31,532
4460580 4461030 -20,383 -30,679
4517980 4518234 -42,553 -53,310
4689816 4690139 43,419 41,383
4696976 4697334 13,625 -44,801
4836563 4836811 60,191 57,744
4891427 4891649 101,735 98,582
40292502 40292652 -100,085 -108,518
40429552 40429701 36,965 28,531
40832522 40832863 136,244 82,715
40650583 40650997 -45,695 -99,151
40615954 40616143 -80,324 -134,005
41355644 41355844 138,195 86,871
41163611 41163780 -53,838 -105,193
41224893 41225048 7,444 -43,925
42280260 42280459 83,405 29,378
42211549 42211725 14,694 -39,356
42170071 42170171 -26,784 -80,910
42666508 42666979 -19,699 -78,097
42640875 42641066 -45,332 -104,010
42822486 42822768 136,279 77,692
43217422 43217588 51,813 39,104
43133649 43133803 -31,960 -44,681
43166868 43167022 1,259 -11,462
43434380 43434831 -46,340 -59,010
43688485 43688684 122,681 -173,867
43908084 43908198 342,280 45,647
43604048 43604148 38,244 -258,403
43993483 43993614 -14,385 -17,128
44909381 44909580 -18,273 -37,780
45465137 45465591 42,769 38,004
45714467 45714640 98,011 80,648
45676226 45676554 59,770 42,562
46642809 46643228 56,890 39,125
5217527 5217929 -59,296 -65,266
5398877 5399128 113,921 86,223
5499787 5499937 156,315 71,384
50660637 50660937 -36,733 -94,949
50795628 50795719 98,258 39,833
52385101 52385333 64,832 38,925
52310353 52310633 -9,916 -35,775
53541902 53542131 -83,186 -94,652
53676373 53676538 25828 36757
53748178 53748434 -45977 -35139
55075140 55075342 77,472 34,858
54982977 54983164 -14,691 -57,320
58100137 58100399 41,643 -24,230
58170985 58171216 112,491 46,587
58025847 58026005 -32,647 -98,624
59049850 59050293 141,684 97,358
59224879 59225107 19,580 -25,302
59430647 59431054 82,353 81,124
59731034 59731158 -23,108 -86,565
59967269 59967418 41,069 34,546
6878488 6878922 38,380 22,702
6936589 6936982 18,009 12,658
60490000 60490278 52,705 7,062
60458409 60458625 21,114 -24,591
60990600 60990816 35,457 2,589
60881229 60881381 -73,914 -106,846
61877737 61878096 148,349 -359,228
62261110 62261431 531,722 24,107
62309476 62309723 580,088 72,399
61711640 61711743 -17,748 -525,581
62080968 62081112 351,580 -156,212
61851099 61851367 121,711 -385,957
61919796 61919965 190,408 -317,359
64855856 64856266 -66,577 -194,801
65006332 65006492 83,899 -44,575
68671760 68672214 -995 -7,475
68732511 68732808 59,756 53,119
68655234 68655507 -17,521 -24,182
69882746 69883135 -91,371 -109,393
70021387 70021603 47,270 29,075
7198529 7198678 41,827 25,316
7284908 7285058 1,495 -3,922
7372005 7372151 -20,927 -33,498
7489622 7489957 96,523 84,308
7931173 7931386 48,090 38,209
70073050 70073218 24,208 19,341
70105487 70105785 18,388 5,768
70222075 70222326 20,028 1,614
70702761 70703017 -77,908 -94,092
70786563 70786985 5,894 -10,124
71313458 71313703 84,347 48,209
71694392 71694802 50,383 45,836
71713182 71713612 69,173 64,646
71993688 71993888 101,391 98,352
71942968 71943164 50,671 47,628
72178971 72179170 -41,543 -54,988
73725524 73725934 3,652 -7,377
73676900 73677071 -44,972 -56,240
73941484 73941691 77,030 73,938
73819950 73820073 -44,504 -47,680
74344438 74344538 162,711 54,567
74225834 74225976 44,107 -63,995
74531344 74531515 170,690 98,448
75761616 75761765 38,004 26,232
75677867 75677982 -45,745 -57,551
76576971 76577374 -3,303 -11,154
76681319 76681547 -23,841 -72,920
77007114 77007246 -84,480 -87,176
77477110 77477286 58,224 54,759
77846169 77846317 -19,866 -22,452
77876155 77876304 3,966 -8,626
78124664 78124790 53,781 -28,953
78031404 78031553 -39,479 -122,190
8828321 8828649 105,368 72,090
8699019 8699354 -23,934 -57,205
8752505 8752653 29,552 -3,906
11711693 11712033 32,430 -159,889
11658519 11658718 -20,744 -213,204
11744816 11745091 65,553 -126,831
11958362 11958526 279,099 86,604
11836214 11836512 156,951 -35,410
12887634 12888027 112,154 13,693
12727818 12728101 -47,662 -146,233
13777416 13777790 60,736 23,236
13839885 13839973 123,205 85,419
13884019 13884238 68,476 67,377
16805085 16805339 17,552 -139,530
16977216 16977636 189,683 32,767
18058126 18058326 54,712 22,101
19723502 19723775 199,942 -65,253
19578820 19579205 55,260 -209,823
19877984 19878126 354,424 89,098
20381987 20382104 87,396 68,185
20351017 20351251 56,426 37,332
280401 280685 75,879 22,636
23965447 23965692 180,514 -45,497
24000036 24000201 215,103 -10,988
24107196 24107651 322,263 96,462
23872009 23872476 87,076 -138,713
23793800 23794039 8,867 -217,150
3497155 3497572 95,083 49,163
3479862 3480208 77,790 31,799
3364217 3364349 -37,855 -84,060
312106 312275 2,750 -178,410
487260 487643 177,904 -3,042
37770662 37770882 -18,535 -144,564
37988134 37988309 198,937 72,863
37866368 37866652 77,171 -48,794
41524565 41524743 -33,590 -60,554
41585396 41585871 27,241 574
41676289 41676494 16,746 -1,551
44716381 44716621 16,160 -14,458
44753251 44753718 53,030 22,639
46532715 46532914 192,233 20,720
46428295 46428518 87,813 -83,676
46315429 46315724 -25,053 -196,470
51332534 51332775 286,567 -74,083
51404172 51404547 358,205 -2,311
51024679 51025142 -21,288 -381,716
51180270 51180704 134,303 -226,154
54396910 54397059 -92,688 -171,291
54506404 54506563 16,806 -61,787
55129037 55129236 43,786 37,631
55037573 55037818 -47,678 -53,787
55214674 55214878 66,586 37,415
56155298 56155498 -34,266 -35,064
56230893 56231162 41,329 40,600
58047669 58047838 -95,831 -158,034
58202155 58202421 58,655 -3,451
58946489 58946749 4,930 -190,844
59205218 59205463 263,659 67,870
59099824 59100129 158,265 -37,464
59688675 59688958 -17,247 -33,142
59837986 59838224 70,412 59,131
7127958 7128430 196,073 20,617
6997737 6998212 65,852 -109,601
6899223 6899685 -32,662 -208,128
581817 582320 -65,802 -81,172
65690141 65690343 8,969 -84,797
65752472 65752567 71,300 -22,573
65859492 65859736 178,320 84,596
66132759 66133155 25,516 -12,174
66169136 66169490 61,893 24,161
7778992 7779434 221,175 -617,420
8464921 8465102 907,104 68,248
7984004 7984360 426,187 -412,494
8013729 8013894 455,912 -382,960
8334247 8334531 776,430 -62,323
7666605 7666793 108,788 -730,061
7865967 7866267 308,150 -530,587
8115829 8116086 558,012 -280,768
7462347 7462548 -95,470 -934,306
776450 776582 64,858 -25,965
835049 835319 123,457 32,772
72997931 72998145 178,154 24,383
72908932 72909136 89,155 -64,626
75237085 75237284 -19,675 -153,027
75349212 75349491 92,452 -40,820
9433959 9434326 -31,048 -93,780
949793 949945 -68,381 -87,682
1593054 1593369 32,761 -9,959
1644992 1645289 84,699 41,961
1499518 1499954 -60,775 -103,374
10152253 10152466 69,056 65,401
10059407 10059556 -23,790 -27,509
10350483 10350898 91,833 90,700
10423635 10423825 101,430 71,614
10556822 10557079 99,026 81,836
10765925 10766099 92,819 -37,480
10924971 10925124 81,718 30,676
11032661 11032951 100,055 -1,002
11063825 11063974 2,693 -41,516
11356276 11356548 60,183 45,227
11372470 11372718 23,587 16,699
11525302 11525497 47,558 24,525
12802814 12802908 39,528 37,779
12933953 12934229 23,530 17,926
12971199 12971526 53,545 46,071
14051727 14052020 118,375 73,923
13906216 13906471 -27,136 -71,626
14154954 14155153 91,454 65,594
14353051 14353242 -162 -27,293
14494401 14494643 50,123 47,469
14563688 14563793 -7,230 -83,017
14748665 14748915 44,460 -1,438
14968243 14968433 -55,772 -59,467
15021462 15021719 -2,553 -6,181
15194816 15195102 63,372 22,310
15543228 15543409 102,765 92,097
15589231 15589400 1,810 -12,045
15714939 15715309 102,232 80,675
15891264 15891465 41,430 21,580
15953695 15953983 69,514 47,657
16193930 16194348 88,092 63,967
16037651 16037932 -68,187 -92,449
16070758 16070934 -35,080 -59,447
16222045 16222265 -74,603 -77,080
16531141 16531564 41,436 17,316
17258423 17258592 54,729 41,441
17169106 17169361 -34,588 -47,790
17326770 17327165 -47,985 -50,292
17390091 17390415 15,336 12,958
17864321 17864558 97,663 79,173
17673806 17674044 -92,852 -111,341
17899279 17899516 110,957 79,716
18057973 18058108 26,602 -594
18204062 18204270 79,046 61,927
18434072 18434264 76,104 73,277
18334781 18334960 -23,187 -26,027
18596135 18596500 92,567 81,117
18907905 18908245 16,411 7,809
19244455 19244606 80,447 70,928
2359629 2360065 -67,506 -69,192
2518233 2518400 91,098 89,143
3520176 3520412 -25,328 -37,246
3815090 3815483 -111,964 -120,978
4056047 4056223 97,299 65,840
34949852 34949994 -44,889 -57,065
35108867 35109072 114,126 102,013
37753523 37753848 -10,421 -16,323
38551264 38551463 68,488 66,303
38463100 38463321 -19,676 -21,839
38490143 38490435 7,367 5,275
4114285 4114447 72,966 39,321
4203947 4204292 23,452 15,767
4147222 4147508 -33,273 -41,017
4670127 4670407 61,570 48,992
4566051 4566324 -42,506 -55,091
4787727 4787891 20,783 5,175
4715221 4715370 -51,723 -67,346
40370496 40370686 -81,225 -91,872
40524699 40525124 72,978 62,566
40849125 40849278 -46,545 -50,502
41093259 41093629 22,276 8,604
41002573 41003041 -68,410 -81,984
41130266 41130440 59,283 45,415
41219912 41220169 28,049 23,188
43685112 43685348 -85,009 -115,123
43861960 43862144 91,839 61,673
43961164 43961313 -22,991 -34,109
44116079 44116286 33,624 24,912
44164440 44164669 81,985 73,295
44039969 44040105 -42,486 -51,269
44409308 44409582 -16,725 -18,027
44501732 44501959 50,735 49,387
44640675 44640827 51,382 48,942
44744928 44745192 -40,076 -44,762
44908211 44908484 21,425 16,556
45006026 45006179 92,291 85,671
563308 563498 115,818 107,156
415846 415954 -31,644 -40,388
45455194 45455466 65,703 42,152
45343168 45343343 -46,323 -69,971
45301489 45301656 -88,002 -111,658
45696050 45696398 50,509 32,882
45561131 45561521 -84,410 -101,995
46086668 46086902 45,384 -139,106
46181119 46181300 139,833 -44,708
46219373 46219573 178,087 -6,435
46432760 46433198 41,805 27,914
46490291 46490444 37963 61212
46577218 46577493 -48964 -25837
46844822 46845254 -59,555 -80,432
46931256 46931720 26,879 6,034
47031766 47032110 39,385 24,679
47035576 47035771 43,195 28,340
47498973 47499133 104,381 83,018
47378082 47378339 -16,510 -37,776
47672188 47672399 94,688 93,149
47723378 47723598 20,080 -881
47794025 47794473 17,790 3,583
47863332 47863642 87,097 72,752
48090542 48090821 27,344 15,110
48075856 48076050 12,658 339
48499452 48499725 -50,199 -59,643
48651654 48651757 102,003 92,389
48821392 48821629 82,360 49,631
48739218 48739421 186 -32,577
48883503 48883665 41,415 17,126
49007465 49007833 95,387 91,820
48973247 48973399 61,169 57,386
49891222 49891642 52,156 32,952
49815438 49815621 -23,628 -43,069
49939391 49939670 -4,429 -15,470
50022063 50022248 78,243 67,108
5235146 5235587 77,767 -1,812
5197861 5198012 40,482 -39,387
5716327 5716529 -77,575 -85,953
5753600 5753858 -40,302 -48,624
6057222 6057322 113,047 -4,232
5941449 5941609 -2,726 -119,945
50218332 50218758 21,793 -14,534
50566976 50567313 20,290 1,644
50627258 50627479 80,572 61,810
50685568 50685742 80,856 66,725
50867727 50868112 82,862 70,818
51149907 51150106 90,549 81,211
51069281 51069430 9,923 535
50965168 50965388 -94,190 -103,507
51258375 51258667 44,120 40,504
51999582 52000024 130,169 88,427
52287843 52288143 -68,157 #VALUE!
52479511 52479768 63,590 51,905
52560246 52560693 55,275 43,520
52665381 52665558 120,995 87,763
53289794 53290263 -20,721 -75,109
53497326 53497728 94,001 46,773
53597078 53597359 76,637 71,736
53728230 53728669 -86,130 -96,805
53977814 53978114 34,734 27,655
54048046 54048308 97,418 94,913
54011735 54012153 61,107 58,758
54093000 54093362 -56,929 -63,505
54148683 54149065 -62,366 -63,094
54306142 54306604 88,203 62,392
54349676 54349830 69,399 46,148
54481253 54481652 -48,987 -54,023
54588676 54588811 58,436 53,136
54550003 54550147 19,763 14,472
54706541 54706771 1763 14631
54681901 54682127 26403 39275
54855017 54855117 104,237 79,491
55136560 55136746 51,837 12,148
55639157 55639562 67,642 61,511
55635317 55635535 63,802 57,484
56256138 56256518 -63,839 -68,861
56373460 56373643 53,483 48,264
56557148 56557371 -47,939 -55,498
56747455 56747590 32,660 20,668
56824270 56824469 17,274 -7,227
56882106 56882414 -58,733 -64,548
56936254 56936533 -19,741 -29,058
58539617 58539988 54,951 53,301
58463052 58463285 -21,614 -23,402
58940168 58940511 -48,482 -78,898
59039205 59039528 50,555 20,119
59183053 59183531 105,774 80,818
59071302 59071402 -5,977 -31,311
59296330 59296582 6,585 -1,224
59337936 59338050 48,191 40,244
59421613 59421831 9,064 3,122
59507806 59508124 16,140 12,047
59609115 59609561 52,068 41,028
59639965 59640165 21,548 283
59816713 59817046 78,118 68,184
60001566 60001704 89,775 85,203
6280318 6280497 44,507 -63,687
6390343 6390493 66,899 64,453
6483239 6483667 1,202 -3,266
6581806 6582257 44,956 40,094
6727274 6727663 98,396 56,003
6728177 6728469 99,299 56,809
6806715 6806976 82,993 -1,395
6847573 6847856 8,996 -43,608
6958947 6959166 120,370 67,702
60180648 60180748 103,287 85,693
60227973 60228198 59,508 23,880
60443648 60443764 59,220 31,110
61001732 61002193 90,122 60,613
60832939 60833146 -78,671 -108,434
61134017 61134166 34,894 -1,323
63727333 63727711 -27,412 -30,587
7051801 7052153 -15,248 -192,892
7175922 7176033 108,873 -69,012
7325847 7326057 258,798 81,012
7703903 7704314 44,241 31,282
7575875 7576090 -83,787 -96,942
7777648 7777826 43,567 37,335
7862364 7862479 -12,364 -22,884
814977 815110 38,880 32,093
8043740 8043981 19,806 10,434
8579977 8580270 88,288 31,940
857763 858141 47,098 43,517
9823019 9823311 16,020 1,953
9919343 9919575 -11,894 -62,572
1635560 1635766 20,894 -91,532
10064907 10065113 -36,226 -47,301
101786053 101786292 105,133 -91,292
101938370 101938662 -36,368 -72,655
102106374 102106794 -19,304 -55,972
102261150 102261615 91,285 39,372
102290053 102290318 4341 44611
102455018 102455189 109,489 73,539
102507425 102507646 105,739 72,189
102647230 102647441 44,632 -46,800
108380997 108381406 20,144 10,704
108316120 108316326 -44,733 -54,376
108745666 108745881 43,297 -21,802
108808005 108808467 -69,356 -163,793
11238625 11238811 -604 -163,351
11362926 11363134 123,697 -39,028
11456297 11456511 217,068 54,349
111563281 111563537 -34,500 -77,521
111621235 111621463 23,454 -19,595
112450263 112450715 77,601 -52,701
112425429 112425722 52,767 -77,694
113252155 113252325 4,192 -7,117
113291647 113291849 12161 18978
113301990 113302140 1818 8687
113327324 113327515 -23516 -16688
113337859 113338068 49158 54862
113368629 113368782 18388 24148
113403842 113403998 -16825 -11068
113506055 113506308 53,978 46,610
113669561 113669798 77,620 61,734
113700657 113700828 108,716 92,764
118247280 118247750 -41,445 -58,675
119386668 119387021 -29,547 -81,685
119488782 119489080 72,567 20,374
119641557 119641741 11,268 8,800
119705324 119705531 75,035 72,590
119934392 119934620 28,442 23,134
119890835 119891310 -15,115 -20,176
120182572 120182998 -51,105 -268,509
120516976 120517154 283,299 65,647
120377555 120377657 143,878 -73,850
120889330 120889537 69,861 64,093
120831066 120831306 11,597 5,862
121242770 121242947 -23,557 -223,374
121509839 121509990 243,512 43,669
121360052 121360349 93,725 -105,972
121315817 121316005 49,490 -150,316
121766288 121766698 -45,537 -356,824
122104297 122104550 292,472 -18,972
121812877 121813253 1,052 -310,269
121974242 121974651 162,417 -148,871
122129611 122129803 317,786 6,281
127140694 127140865 10,540 -29,851
127049581 127049730 -80,573 -120,986
127209107 127209306 78,953 38,590
127700563 127700679 -78,046 -116,561
127816372 127816521 37,763 -719
127934462 127934872 41,976 31,584
127970447 127970908 77,961 67,620
130827865 130827965 -2,223 -20,649
130784258 130784358 -45,830 -64,256
136303743 136304012 -9,923 -46,469
136269039 136269185 -44,627 -81,296
136727093 136727249 21,454 17,799
136605162 136605427 -100,477 -104,023
138527183 138527354 88,905 36,950
138395897 138396179 -42,381 -94,225
15592895 15593325 -55,858 -95,351
15673405 15673832 24,652 -14,844
16063652 16063939 65,518 59,359
15947097 15947246 -51,037 -57,334
151759723 151760099 -75,508 -94,521
151856530 151856910 21,299 2,290
153172131 153172300 -44,203 -110,714
153344888 153345167 128,554 62,153
156968251 156968423 79,057 70,949
157919350 157919813 -60,027 -89,037
158010157 158010330 30,780 1,480
160241610 160241825 -35,646 -91,505
160357089 160357274 79,833 23,944
160270686 160270904 -6,570 -62,426
160545880 160546047 177,762 76,554
160617589 160617846 112,083 -9,521
160815133 160815302 150,695 50,293
161782178 161782614 80,466 -18,314
161691559 161691728 -10,153 -109,200
162552353 162552712 -4,648 -86,586
162681201 162681552 124,200 42,254
162909802 162910001 77,967 26,716
170257037 170257509 107,941 55,009
170146879 170147168 -2,217 -55,332
172601665 172601826 114,461 44,980
172455198 172455581 -32,006 -101,265
173007927 173008086 7,311 -71,170
173130555 173130772 1,530 -41,336
174397915 174398228 -83,589 -140,448
174636743 174637092 155,239 98,416
175027967 175028235 106,843 59,546
174925155 174925305 4,031 -43,384
175164442 175164721 31,894 -91,152
175332882 175332982 200,334 77,109
176667247 176667426 -22,491 -25,490
176603951 176604329 -85,787 -88,587
177939681 177939858 -26,050 -172,553
178011904 178012073 46,173 -100,338
178153782 178154014 188,051 41,603
181932598 181932857 -97,266 -177,862
182033480 182033762 3,616 -76,957
183366520 183366958 -40,462 -72,785
183634300 183634631 -17,432 -38,985
183725031 183725180 73,299 51,564
187125499 187125824 -37,546 -128,049
187265949 187266402 102,904 12,529
187262847 187263243 99,802 9,370
189497366 189497830 -49,978 -87,887
189506228 189506476 -41,116 -79,241
189579884 189580217 32,540 -5,500
190156650 190156854 23,089 2,996
190108896 190109299 -24,665 -44,559
191526857 191527026 -15,264 -60,155
191590367 191590753 48,246 3,572
191754776 191755181 152,225 30,642
197321773 197321897 -15,144 -50,773
197401116 197401357 64,199 28,687
198082891 198083253 23,338 10,010
20230058 20230279 -33,981 -58,396
201376547 201376682 -67,377 -85,562
201527804 201527957 83,880 65,713
201705357 201705459 -50,743 -96,913
201918390 201918559 111,994 64,038
203107022 203107471 157,106 -33,248
202949173 202949555 -743 -191,164
203824418 203824855 12,760 -53,724
203968240 203968485 156,582 89,906
204319505 204319838 40,062 9,037
204268566 204268692 -10,877 -42,109
204376043 204376456 -64,711 -70,472
204502851 204503305 62,097 56,377
204362811 204363029 -77,943 -83,899
207823747 207823907 170,424 85,048
207724573 207724826 71,250 -14,033
207653915 207654087 592 -84,772
208206806 208206955 103,875 35,137
211059790 211060170 9,112 -191,906
211303886 211304081 253,208 52,005
211032500 211032794 -18,178 -219,282
211152695 211152854 102,017 -99,222
216011459 216011836 78,050 2,795
216073556 216073815 140,147 64,774
216831445 216831638 151,010 52,390
216768241 216768666 87,806 -10,582
216707891 216708151 27,456 -71,097
217033833 217034140 48,392 -21,881
216946408 216946560 -39,033 -109,461
217091792 217092238 106,351 36,217
217187326 217187731 -19,046 -49,673
217336071 217336270 129,699 98,866
218770982 218771163 71,991 60,943
219036006 219036454 80,845 67,460
218989100 218989249 33,939 20,255
219353225 219353528 -1,520 -34,731
219465235 219465419 110,490 77,160
219474098 219474291 119,353 86,032
219688036 219688304 59,863 54,871
219612951 219613155 -15,222 -20,278
219573217 219573489 -54,956 -59,944
219868903 219869114 46,226 42,232
220107678 220107849 -37,483 -40,830
227601520 227601854 23,352 -135,665
227518054 227518321 -60,114 -219,198
227913019 227913180 175,494 25,429
228215209 228215360 169,923 84,812
228489886 228490260 103,072 99,766
228326339 228326699 -60,475 -63,795
230880789 230881058 138,893 88,126
230683311 230683483 -58,585 -109,449
230779461 230779629 37,565 -13,303
231755697 231755981 74,498 57,913
231619056 231619433 -62,143 -78,635
233552171 233552434 -81,262 -228,854
233659011 233659174 25,578 -122,114
234373969 234374118 182,939 27,423
234103483 234103910 -87,547 -242,785
234200801 234201279 9,771 -145,416
234264123 234264352 73,093 -82,343
237237672 237237861 94,490 82,131
237130467 237130772 -12,715 -24,958
237833843 237833992 -63,558 -153,567
237970209 237970467 72,808 -17,092
238925101 238925372 31,280 -47,164
238914010 238914471 20,189 -58,065
238882796 238883068 -11,025 -89,468
239090060 239090330 89,695 64,700
238976211 238976375 -24,154 -49,255
239635109 239635283 -210 -352,297
239758861 239759001 123,542 -228,579
240006107 240006256 370,788 18,676
239792233 239792387 156,914 -195,193
24184569 24184994 58,494 44,939
24088439 24088593 -37,636 -51,462
241248039 241248393 99,895 96,289
241121772 241121874 -26,372 -30,230
242004021 242004266 100,625 62,151
241784903 241785040 -118,493 -157,075
242146093 242146193 -772 -16,033
242515176 242515277 74,465 65,546
25229075 25229259 -8,151 -15,804
25271916 25272190 34,690 27,127
27359989 27360211 -23,780 -24,423
29283052 29283387 13,908 -714,549
29769672 29770144 500,528 -227,792
29445625 29445814 176,481 -552,122
29674360 29674791 405,216 -323,145
29971108 29971271 701,964 -26,665
30023269 30023475 754,125 25,539
31540002 31540341 129,311 49,224
31503570 31503810 92,879 12,693
31460330 31460583 49,639 -30,534
31354662 31354853 -56,029 -136,264
32296968 32297365 -6,054 -47,062
32411629 32412052 108,607 67,625
32707262 32707535 272,028 10,065
32673028 32673350 237,794 -24,120
33546531 33546691 520,635 68,611
33072497 33072647 46,601 -405,433
33182059 33182228 156,163 -295,852
33444125 33444284 418,229 -33,796
33280505 33280757 254,609 -197,323
33139067 33139288 113,171 -338,792
33360568 33360737 334,672 -117,343
33008934 33009129 -16,962 -468,951
33230300 33230581 204,404 -247,499
33643406 33643706 128,486 544
37275397 37275725 -55,752 -122,816
37379955 37380285 48,806 -18,256
37476967 37477095 145,818 78,554
38122920 38123241 -25,234 -33,555
38200775 38201036 52,621 44,240
39025472 39025631 147,097 69,106
38949294 38949683 70,919 -6,842
38797912 38798042 -80,463 -158,483
39265227 39265473 198,758 64,406
39186598 39186955 120,129 -14,112
39414513 39414683 84,602 -103,263
39475878 39476172 145,967 -41,774
39539072 39539253 209,161 21,307
43927500 43927723 209,584 79,093
46015353 46015816 282,806 -252,817
46231850 46231999 499,303 -36,634
46119173 46119410 386,626 -149,223
45897619 45897801 165,072 -370,832
45677512 45677730 -55,035 -590,903
46599373 46599542 -62,207 -98,166
46757023 46757216 95,443 59,508
46852045 46852194 72,450 8,763
48306665 48307044 -88,709 -152,894
48434165 48434286 38,791 -25,652
48747046 48747468 -20,425 -88,853
49110881 49110981 67,725 -124,153
48962781 48962881 -80,375 -272,253
49144683 49144836 101,527 -90,298
49234049 49234150 190,893 -984
58071245 58071703 -55,979 -168,807
58162400 58162586 35,176 -77,924
6994376 6994656 59,129 38,835
6963679 6963891 28,432 8,070
6894594 6894784 -40,653 -61,037
61024210 61024456 61,956 20,774
64100707 64100861 -72,792 -124,201
64179780 64180013 6,281 -45,049
68419257 68419661 215,685 77,795
68188178 68188626 -15,394 -153,240
68334128 68334399 130,556 -7,467
70005546 70006003 9,839 -17,578
70029761 70029990 34,054 6,409
69973877 69974356 -21,830 -49,225
70592440 70592767 64,516 -41,671
70649299 70649563 121,375 15,125
70555511 70555694 27,587 -78,744
70946526 70946787 35,671 30,326
72233266 72233397 23,391 4,926
73832042 73832250 -10,795 -28,506
74650343 74650585 51,577 43,759
74556566 74556774 -42,200 -50,052
74734382 74734584 99,587 96,403
85695372 85695693 -42,579 -53,130
85766676 85767120 28,725 18,297
86014326 86014777 94,544 45,129
85930443 85930702 10,661 -38,946
86481806 86482255 -40,148 -91,095
86607160 86607620 85,206 34,270
86662286 86662672 140,332 89,322
86841440 86841786 -23,799 -29,852
86908869 86909126 12,898 -33,423
89172886 89173170 52,050 51,860
89092632 89092736 -28,204 -28,574
9545244 9545477 81,980 64,350
9770787 9771039 129,235 82,410
96131524 96131764 -41,114 -43,142
96391129 96391330 25,918 -13,671
97648370 97648747 -48,091 -74,008
97665848 97666066 -30,613 -56,689
99248226 99248576 23,085 10,574
99198421 99198671 -26,720 -39,331
1075701 1075850 33,762 -21,172
1042062 1042169 123 -54,853
1278444 1278902 -19,178 -42,904
1414174 1414553 14,788 -5,680
1627603 1628002 136,035 79,347
1453576 1453824 -37,992 -94,831
1852526 1852809 29,713 -15,734
1915834 1915981 93,021 47,438
10468619 10469073 -97,715 -133,563
10647962 10648232 81,628 45,596
86338 86655 -30,189 -31,609
146257 146482 -9,642 -12,045
2243002 2243484 18,355 -26,241
2246502 2246660 21,855 -23,065
2885175 2885486 115,809 -81,834
2975709 2976093 206,343 8,773
2739652 2739854 -29,714 -227,466
22500092 22500389 -9,551 -13,713
22926217 22926435 -48,053 -51,866
23011100 23011259 36,830 32,958
23072431 23072641 64,436 57,664
23632827 23633072 -43,363 -46,502
23710443 23710602 34,253 31,028
29276254 29276633 -32,874 -34,463
29531589 29531787 64,877 51,143
29675979 29676128 110,087 55,097
29817890 29818039 101,974 43,673
29963244 29963452 64,142 41,241
30041477 30041705 45,058 38,149
3538319 3538503 -77,298 -97,272
3665638 3665883 50,021 30,108
3624718 3624988 9,101 -10,787
3807269 3807548 82,883 72,786
30177456 30177729 73,741 24,409
30144920 30145081 41,205 -8,239
31765768 31766217 224,179 64,714
31516174 31516542 -25,415 -184,961
31580139 31580333 38,550 -121,170
31929789 31929994 67,009 24,163
32523119 32523324 108,417 -39,535
32619207 32619328 204,505 56,469
33236471 33236781 24,340 7,953
33292497 33292779 80,366 63,951
33238509 33238874 26,378 10,046
33372401 33372550 94,306 44,332
34915492 34915592 -38,269 -97,998
35492476 35492649 85,974 25,410
35427085 35427236 20,583 -40,003
36321601 36321804 -44,390 -77,517
36454505 36454815 46,206 15,748
36969201 36969461 101,439 -15,620
36782486 36782761 -85,276 -202,320
37158641 37158802 134,232 57,024
39219224 39219373 19,933 -18,402
4597602 4597960 -17,394 -32,276
4706071 4706483 91,075 76,247
41150140 41150578 1,015,334 -101,446
41165683 41165948 1,030,877 -86,076
40231755 40231923 96,949 -1,020,101
40388945 40389228 254,139 -862,796
40508545 40508736 373,739 -743,288
40639843 40640123 505,037 -611,901
40768118 40768461 633,312 -483,563
41295115 41295398 1,160,309 43,374
40079904 40080130 -54,902 -1,171,894
40263871 40264054 129,065 -987,970
40903636 40903786 768,830 -348,238
40582810 40583087 448,004 -668,937
41384612 41384811 91,811 91,296
42343696 42343949 -74,159 -149,495
42469679 42469878 51,824 -23,566
42714600 42714852 33,023 1,055
42610838 42610995 -70,739 -102,802
42973139 42973586 -55,390 -168,428
43082466 43082583 53,937 -59,431
43128045 43128526 99,516 -13,488
43201734 43201901 16,254 15,381
43287293 43287673 18,241 15,846
43501370 43501723 114,028 91,245
43413351 43413737 26,009 3,259
43838223 43838449 -65,545 -80,993
43946095 43946254 -6,095 -14,612
44070803 44070923 -151 -7,684
44086162 44086318 15,208 7,711
44089440 44089828 -90,873 -276,429
44260258 44260495 79,945 -105,762
44373780 44373923 193,467 7,666
47462308 47462501 -91,510 -155,613
47597297 47597699 43,479 -20,415
47642731 47642937 88,913 24,823
47912603 47913082 49,946 -29,097
47824925 47825188 -37,732 -116,991
48163425 48163888 32,357 -39,790
48255969 48256203 124,901 52,525
48556244 48556641 -4,050 -78,065
48511333 48511761 -48,961 -122,945
48680433 48680690 120,139 45,984
49658775 49659075 217,692 66,410
49426684 49427092 -14,399 -165,573
49541678 49541893 100,595 -50,772
54255131 54255383 -2,064 -2,895
54317486 54317726 60,291 59,448
54701984 54702428 64,219 54,682
55241252 55241401 64,041 -33,690
55185102 55185276 7,891 -89,815
55141904 55142124 -35,307 -132,967
55406692 55406914 47,157 19,296
56963064 56963445 -27,533 -52,252
57058409 57058747 67,812 43,050
57241425 57241563 -67,452 -92,879
57408573 57408815 99,696 74,373
6625316 6625613 -70,995 -83,314
6739349 6739609 43,038 30,682
60168671 60168920 -54,750 -59,798
60337796 60337928 20,286 -37,835
60558269 60558438 86,321 74,017
60892936 60893230 -86,599 -146,513
61313485 61313944 -24,195 -28,355
61564795 61564907 -25,015 -36,042
61832661 61832866 73,054 32,371
61716515 61716673 -43,092 -83,822
62262741 62262890 80,809 47,843
10043338 10043640 625 -77,158
9989532 9989791 -53,181 -131,007
17849118 17849521 -38,724 -57,615
17983081 17983527 95,239 76,391
25851098 25851338 -82,362 -157,768
26038537 26038759 105,077 29,653
29900811 29901057 69,686 -333,096
30005976 30006392 174,851 -227,761
30182244 30182610 351,119 -51,543
30061909 30062119 230,784 -172,034
30272600 30272811 441,475 38,658
29948759 29948908 117,634 -285,245
31916276 31916427 37530 46688
32011915 32012170 -58109 -49055
33376373 33376722 56,350 53,348
33613191 33613533 89,115 53,694
33545939 33546338 21,863 -13,501
33661983 33662397 42,904 8,359
33741795 33742055 44,723 10,357
35265334 35265781 183,366 -77,730
35146018 35146410 64,050 -197,101
35005633 35005935 -76,335 -337,576
35189018 35189185 107,050 -154,326
35370855 35371031 288,887 27,520
35068535 35068771 -13,433 -274,740
36748728 36748907 69,169 37,912
36580779 36580938 -98,780 -130,057
37789223 37789394 127,494 -19,953
37615962 37616430 -45,767 -192,917
37752385 37752576 90,656 -56,771
39018313 39018754 342,642 63,266
38931371 38931761 255,700 -23,727
38648399 38648600 -27,272 -306,888
38811931 38812147 136,260 -143,341
40027996 40028375 -11,208 -67,518
40143204 40143396 104,000 47,503
40450061 40450313 143,848 -690,596
40555208 40555687 248,995 -585,222
40663023 40663237 356,810 -477,672
40267494 40267744 -38,719 -873,165
40746724 40746965 440,511 -393,944
40826561 40826826 520,348 -314,083
40378111 40378422 71,898 -762,487
40941939 40942140 635,726 -198,769
41137140 41137282 830,927 -3,627
41050684 41050855 744,471 -90,054
41649699 41650054 -6,121 -52,685
41606447 41606596 -49,373 -96,143
41812064 41812435 92,040 59,427
42536581 42536760 -63,170 -72,015
43880390 43880659 -83,016 -125,949
43996255 43996486 32,849 -10,122
44086865 44087171 123,459 80,563
44402316 44402488 -64,997 -82,774
44543483 44543743 13,292 1,213
45169636 45169867 39,340 -3,314
45691473 45691724 46441 95055
46224207 46224587 -1,884 -24,804
46145961 46146257 -80,130 -103,134
46361189 46361360 18,719 -15,830
46862014 46862352 -17,493 -46,939
15927772 15928021 -18,077 -43,384
16492436 16492647 -9,049 -100,736
16729284 16729487 137,824 97,675
16662641 16662798 71,181 30,986
17257781 17257992 116,609 98,518
17470252 17470477 66,454 -19,485
17430236 17430344 26,438 -59,618
18028865 18029187 -62,201 -63,110
18112524 18112689 21,458 20,392
19103184 19103404 -5,691 -18,742
19670598 19670976 68,884 32,942
19572504 19572679 -29,210 -65,355
19740853 19741038 41,404 27,919
20349158 20349359 22,616 20,771
20499076 20499254 55,130 -52,716
20890510 20890709 -38,690 -39,217
21261707 21261856 41,584 30,088
21878997 21879366 26,445 -110,858
21802539 21802905 -50,013 -187,319
22264873 22265321 19,561 12,826
22190160 22190641 -55,152 -61,854
22562953 22563211 193,306 -4,206
22377136 22377493 7,489 -189,924
22686745 22686893 -19,396 -27,378
22930381 22930811 192,616 26,215
22818525 22818750 80,760 -85,846
23222216 23222470 68,679 54,145
23337671 23338080 27,953 -16,892
26381581 26381950 -92,684 -145,536
26498810 26498919 24,545 -28,567
27519538 27519979 -1,010 -6,581
28956158 28956473 -10,283 -16,275
29029236 29029413 62,795 56,665
29341951 29342126 8,790 -10,921
29456612 29456883 68,573 63,011
30031450 30031827 -94,089 -128,611
30176682 30177150 51,143 16,712
31450148 31450450 -76,654 -138,578
31539392 31539625 12,590 -49,403
34058547 34058702 -48,510 -61,492
34415920 34416143 41,550 21,741
34302410 34302609 -71,960 -91,793
35080895 35081028 73,623 -32,930
35424938 35425370 134,888 -3,479
35557645 35557887 -29,331 -46,118
35593050 35593232 6,074 -10,773
35820296 35820671 -31,528 -55,237
35851391 35851592 -54,761 -62,684
35895899 35896251 -10,253 -18,025
36007306 36007695 56,068 37,444
36238295 36238522 21,949 -6,671
36120693 36121162 -95,653 -124,031
36906045 36906244 68,597 -1,519
36871605 36871832 34,157 -35,931
37247357 37247577 37,968 15,315
37183761 37184191 -25,628 -48,071
37486599 37486745 25,918 4,817
37389271 37389447 -71,410 -92,481
37919400 37919746 -29,910 -51,260
38219510 38219805 93,818 56,727
38284898 38285044 38,383 36,407
38712192 38712382 85,160 14,178
38646869 38646966 19,837 -51,238
39919883 39920230 102,147 14,206
40704695 40704916 40,008 31,822
40619325 40619533 -45,362 -53,561
40815249 40815400 -37,196 -41,427
40981112 40981560 95,149 40,171
41105397 41105499 -3,520 -52,841
41177565 41177665 68,648 19,325
41383433 41383663 73,762 42,757
41434402 41434575 16,331 -12,245
41870833 41870965 34,132 15,303
41922461 41922636 85,760 66,974
45051566 45051682 126,403 33,365
45299040 45299191 -95,923 -155,161
45413605 45413804 18,642 -40,548
45509532 45509786 50,561 -3,030
49234813 49235130 -76,234 -80,191
49460533 49460726 74,536 63,883
49460474 49460728 538 -57,779
10208686 10208853 27,123 -51,574
102968116 102968245 -61,431 -94,311
103063330 103063443 33,783 887
106551569 106552022 -16,834 -226,412
106647987 106648346 79,584 -130,088
106807881 106808123 239,478 29,689
106851878 106852192 -7,921 -218,385
107048902 107049121 189,103 -21,456
106952798 106952981 92,999 -117,596
109209127 109209520 -35,504 -83,105
109250569 109250846 5,938 -41,779
109333834 109334104 89,203 41,479
11197378 11197837 -72,022 -81,578
11254679 11254947 -14,721 -24,468
110035267 110035399 10,946 -21,143
112338828 112339040 65,273 -56,023
112445269 112445591 171,714 50,528
112868680 112868834 125,134 14,928
112655521 112655677 -88,025 -198,229
112748266 112748509 4,720 -105,397
113554037 113554143 31,094 -10,206
113449323 113449472 -73,620 -114,877
113692065 113692250 24,602 -8,816
114081491 114081928 64,245 34,441
114005884 114006128 -11,362 -41,359
114223163 114223318 100,417 46,668
12123407 12123628 -46,161 -52,223
12101709 12102085 -67,859 -73,766
12204119 12204322 34,551 28,471
12378958 12379239 74,599 -71,604
12498126 12498519 193,767 47,676
12279897 12280164 -24,462 -170,679
120284930 120285218 182,763 -62,370
120015537 120015806 -86,630 -331,782
120134965 120135262 32,798 -212,326
120796510 120796967 70,678 35,828
120677301 120677559 -48,531 -83,580
120823420 120823858 30,436 -7,484
120998689 120998791 16,668 -21,231
121155634 121156063 127,401 -139,891
121870902 121871125 -67,024 -113,480
123303006 123303106 46,095 -19,567
123396463 123396648 139,552 73,975
123210703 123210923 -46,208 -111,750
124772394 124772566 -41,439 -313,273
124855458 124855626 41,625 -230,213
126053110 126053281 88,625 -35,561
125948267 125948488 -16,218 -140,354
126085702 126086143 121,217 -2,699
128158099 128158222 -32,093 -80,700
128303650 128303799 113,458 64,877
128834841 128835209 34,898 11,240
128755657 128755810 -44,286 -68,159
129206800 129207266 -47,102 -65,950
129327711 129327945 73,809 54,729
129676452 129676740 -4,508 -17,978
130255163 130255513 -7,137 -8,428
130696065 130696265 -60,643 -112,086
130797403 130797545 40,695 -10,806
131154887 131155349 -21,366 -24,121
131118245 131118683 -58,008 -60,787
131274401 131274623 98,148 95,153
131843700 131843869 -36,768 -104,471
131959370 131959656 78,902 11,316
133789603 133789873 -9,181 -14,199
136196410 136196750 199,460 -265,249
136143198 136143369 146,248 -318,630
136054090 136054290 57,140 -407,709
136438745 136438953 441,795 -23,046
136252285 136252508 255,335 -209,491
136188036 136188314 191,086 -273,685
135992348 135992576 -4,602 -469,423
138243465 138243644 84,068 31,034
138083953 138084144 -75,444 -128,466
139948493 139948794 91,572 -12,081
139895432 139895573 38,511 -65,302
14249625 14250066 87,977 54,923
14999681 15000102 35,441 -65,682
15053659 15053955 89,419 -11,829
140135455 140135609 -10,301 -12,882
140178488 140178621 32,732 30,130
142922442 142922615 -17,299 -25,318
143028493 143028642 88,752 80,709
143136660 143136941 58,500 8,869
144615085 144615510 148,331 -434,469
144648165 144648641 181,411 -401,338
144668952 144669389 202,198 -380,590
144639705 144640061 172,951 -409,918
144973524 144973682 506,770 -76,297
144448464 144448568 -18,290 -601,411
144488538 144488737 21,784 -561,242
145073738 145073951 606,984 23,972
144857188 144857315 390,434 -192,664
149952513 149952999 54,158 9,521
149976962 149977436 78,607 33,958
149868165 149868384 -30,190 -75,094
150213359 150213677 -17,245 -73,330
150289891 150290111 59,287 3,104
150414025 150414174 83,964 40,179
152509339 152509795 96,744 30,948
152339241 152339542 -73,354 -139,305
152716121 152716270 78,954 57,083
154031072 154031358 -4,354 -7,177
154120967 154121177 85,541 82,642
155427064 155427303 -49,088 -97,668
155589179 155589445 113,027 64,474
156407786 156408228 127,633 24,042
156249833 156250291 -30,320 -133,895
158638468 158638646 1,167 -5,425
16961643 16961799 12,057 -145,290
17038051 17038200 88,465 -68,889
161194913 161195256 5,590 -1,244
161245854 161246231 56,531 49,731
161100987 161101226 -88,336 -95,274
161690165 161690454 262,227 40,134
161436231 161436642 8,293 -213,678
161625424 161625573 197,486 -24,747
162251830 162251933 -32,535 -53,921
168949108 168949307 64,720 13,962
168833517 168833666 -50,871 -101,679
170219421 170219646 -65,823 -127,408
170372859 170373131 87,615 26,077
170895747 170895916 -69,345 -69,626
171020671 171020869 55,579 55,327
171363766 171364063 -59,153 -142,396
171515475 171515767 92,556 9,308
173724754 173724981 18,596 1,018
173812150 173812389 105,992 88,426
178446469 178446914 224,602 49,180
178174819 178175056 -47,048 -222,678
178254443 178254788 32,576 -142,946
180516380 180516580 167,375 81,386
180323340 180323565 -25,665 -111,629
184376402 184376542 53,705 13,225
184326816 184327087 4,119 -36,230
185526515 185526993 -45,952 -51,633
185567433 185567672 -5,034 -10,954
186703004 186703195 139,340 19,873
187875736 187875938 -42,078 -68,499
187996326 187996626 78,512 52,189
188317899 188318222 186,689 39,187
188312881 188313124 181,671 34,089
188224772 188225106 93,562 -53,929
188194004 188194153 62,794 -84,882
188507872 188508028 89,240 15,582
188634626 188634924 65,764 62,858
188579376 188579540 10,514 7,474
188798106 188798308 -71,282 -72,587
188937753 188937918 68,365 67,023
188900192 188900343 30,804 29,448
191144735 191145104 312,825 47,345
191048532 191048849 216,622 -48,910
190872935 190873279 41,025 -224,480
191722646 191723031 8,061 -135,506
191756252 191756520 41,667 -102,017
191898171 191898346 183,586 39,809
193781715 193782162 439,302 -145,904
193828174 193828524 485,761 -99,542
193924266 193924734 581,853 -3,332
193664886 193665176 322,473 -262,890
193536541 193536779 194,128 -391,287
193312726 193312978 -29,687 -615,088
193608045 193608247 265,632 -319,819
193713280 193713480 370,867 -214,586
193799704 193799798 457,291 -128,268
193364280 193364490 21,867 -563,576
193984752 193984947 642,339 56,881
195612863 195613062 17,515 11,539
197281986 197282263 21,433 -11,080
197875295 197875768 -76,017 -167,988
198052565 198052956 101,253 9,200
198252634 198252993 38,081 11,950
198168374 198168523 -46,179 -72,520
465678 465899 252,028 39,801
361084 361288 147,434 -64,810
231615 231715 17,965 -194,383
23944667 23945055 36,091 11,514
24018594 24018974 56,784 22,733
24545094 24545334 410,385 34,017
24577657 24577856 442,948 66,539
24288568 24288991 153,859 -222,326
24064710 24065181 -69,999 -446,136
24175310 24175459 40,601 -335,858
25136830 25137297 -54,063 -477,127
25203109 25203551 12,216 -410,873
25359477 25359658 168,584 -254,766
25473129 25473325 282,236 -141,099
25530112 25530260 339,219 -84,164
27723823 27723978 -9,049 -14,829
3086273 3086423 -148 -40,608
3200420 3200759 113,999 73,728
30590202 30590620 -32,796 -120,018
30720274 30720742 97,276 10,104
31740012 31740181 190,517 87,621
32402636 32403110 147,461 16,293
32348393 32348673 93,218 -38,144
32198506 32198655 -56,669 -188,162
32456272 32456710 48,105 -14,627
32447050 32447482 38,883 -23,855
32524818 32525172 27,010 5,303
32543007 32543393 45,199 23,524
32936903 32937052 -31,167 -35,788
33536989 33537441 24,248 -197,411
33909013 33909443 94,452 23,245
33925095 33925275 110,534 39,077
37461970 37462196 -6,847 -374,089
37775429 37775715 306,612 -60,570
37809795 37809977 340,978 -26,308
37670513 37670816 201,696 -165,469
37713670 37713912 244,853 -122,373
37850622 37851043 381,805 14,758
37418535 37418751 -50,282 -417,534
37937943 37938198 59,814 -62,766
38023873 38024064 145,744 23,100
38127210 38127534 27799 31983
38161282 38161636 -6273 -2119
39257447 39257690 -22,542 -40,500
39320377 39320479 40,388 22,289
39199400 39199618 -80,589 -98,572
39446257 39446520 100,038 95,443
4876254 4876519 366,118 12,438
4832494 4832872 322,358 -31,209
4781593 4781804 271,457 -82,277
4698222 4698487 188,086 -165,594
4583243 4583393 73,107 -280,688
4485046 4485212 -25,090 -378,869
41172200 41172349 -43,804 -84,589
41306264 41306412 90,260 49,474
42594931 42595094 -22,220 -70,143
42841832 42842244 15,852 -41,535
42900696 42901020 12,008 8,383
45199774 45199980 101,001 37,062
45011167 45011590 -87,606 -151,328
45142568 45142795 43,795 -20,123
45263523 45263921 22,561 21,163
45903618 45904033 595 -15,638
46074095 46074529 36,800 30,546
46144797 46145013 -73,407 -79,823
46336205 46336648 109,019 53,482
46401276 46401512 -22,449 -24,506
46491942 46492111 39,442 10,454
46860093 46860540 -34,147 -66,045
46931413 46931658 37,173 5,073
47451821 47452115 54,293 22,180
47765967 47766335 -53,658 -100,352
48415084 48415298 -5,182 -31,166
49393088 49393211 23,475 22,416
49427208 49427357 55,626 2,827
49511017 49511233 28,422 -36,815
49558179 49558426 75,584 10,378
49625686 49625812 -70,705 -75,287
49859515 49859943 -39,924 -56,131
49923515 49923708 24,076 7,634
50007020 50007186 107,581 91,112
52036909 52037364 -22,890 -27,965
52054689 52055066 -5,110 -10,263
52286085 52286236 55,947 38,013
52316909 52317131 86,771 68,908
52613885 52614138 109,489 80,587
52434354 52434553 -70,042 -98,998
53246513 53246700 76,250 44,927
53791209 53791406 -64,403 -83,461
53904935 53905084 49,323 30,217
55425928 55426196 -48,855 -70,175
55836133 55836594 318,757 -640,837
55619313 55619790 101,937 -857,641
56213888 56214062 696,512 -263,369
56414576 56414806 897,200 -62,625
56004075 56004456 486,699 -472,975
56060867 56061016 543,491 -416,415
55859873 55860077 342,497 -617,354
56349535 56349754 832,159 -127,677
56112600 56112949 595,224 -364,482
55722077 55722348 204,701 -755,083
57078366 57078527 -24,950 -100,847
57046568 57047046 -56,748 -132,328
57181340 57181675 78,024 2,301
61956352 61956609 434,067 -299,004
62226514 62226673 704,229 -28,940
61626104 61626266 103,819 -629,347
61682765 61683068 160,480 -572,545
61772859 61773059 250,574 -482,554
61867383 61867832 345,098 -387,781
61497237 61497440 -25,048 -758,173
62296778 62297057 774,493 41,444
69259615 69259764 42,835 21,835
70114551 70115020 243,228 14,843
69846156 69846339 -25,167 -253,838
70069183 70069284 197,860 -30,893
69960754 69960855 89,431 -139,322
71335460 71335925 248,034 -379,905
71351850 71352127 264,424 -363,703
71457450 71457742 370,024 -258,088
71420710 71421171 333,284 -294,659
71087575 71087734 149 -628,096
71222608 71223046 135,182 -492,784
70983838 70984011 -103,588 -731,819
71171878 71172047 84,452 -543,783
71306578 71306754 219,152 -409,076
71781906 71782154 694,480 66,324
71628689 71628882 541,263 -86,948
85935192 85935630 76,870 -265,011
85929648 85930029 71,326 -270,612
86192598 86193017 334,276 -7,624
85833674 85833914 -24,648 -366,727
86253467 86253771 395,145 53,130
87453954 87454428 94,814 67,089
87392611 87393047 33,471 5,708
87293190 87293339 -65,950 -94,000
9891003 9891262 -28,147 -41,824
9955770 9956127 21,988 5,813
95182209 95182404 107,562 6,992
1844042 1844191 79,210 63,795
100987954 100988334 -100,311 -102,201
102399439 102399803 235,829 -87,573
102460576 102460872 296,966 -26,504
102173312 102173642 9,702 -313,734
102090753 102090902 -72,857 -396,474
102302495 102302806 138,885 -184,570
102544483 102544608 380,873 57,232
103316992 103317306 386,073 102,388
102899998 102900157 -30,921 -314,761
103090116 103090278 159,197 -124,640
103629738 103629995 -11,780 -127,512
103771250 103771515 129,732 14,008
107473178 107473346 16,876 -15,751
107549273 107549473 92,971 60,376
109183586 109183767 111,420 89,705
109095707 109096066 23,541 2,004
10987732 10987897 -21,354 -52,590
11132788 11132942 123,702 92,455
110947867 110948099 66,566 5,509
111108984 111109377 55,485 -43,491
111059774 111060015 6,275 -92,853
111144623 111144956 91,124 -7,912
111209425 111209797 155,926 56,929
111750660 111750873 133,963 48,001
111660189 111660304 43,492 -42,568
114299703 114299984 109,384 -224,353
114441829 114442039 251,510 -82,298
114505760 114505920 315,441 -18,417
114189341 114189592 -978 -334,745
114751373 114751803 158,352 -150,374
114804123 114804276 211,102 -97,901
114895679 114895902 302,658 -6,275
114735895 114736320 142,874 -165,857
114666872 114667148 73,851 -235,029
121101041 121101289 -98,988 -106,122
121289276 121289447 89,247 82,036
122796943 122797242 -11,655 -40,384
122998899 122999071 40,924 34,566
123623389 123623622 31,314 26,283
123808107 123808474 54,886 46,812
123999861 124000330 32,548 -38,510
124091902 124092114 124,589 53,274
129081051 129081251 59,500 41,874
14949957 14950055 -701 -106,832
15067035 15067178 116,377 10,291
140139173 140139435 -17,220 -47,108
142918195 142918396 140,991 44,334
142747350 142747806 -29,854 -126,256
144784738 144784938 130,672 90,921
144643663 144643873 -10,403 -50,144
145251285 145251463 114,578 91,517
145343248 145343397 93,342 62,103
146628973 146629132 6,572 -70,646
148694873 148695044 48,182 47,232
148728876 148729091 82,185 81,279
148630720 148630879 -15,971 -16,933
149464740 149465171 245,370 -117,802
149553364 149553513 333,994 -29,460
149626153 149626618 406,783 43,645
149176605 149176874 -42,765 -406,099
149264531 149264995 45,161 -317,978
15309403 15309506 -4,335 -34,002
15391181 15391316 77,443 47,808
15437088 15437326 48,089 -22,841
15574959 15575288 -3,996 -111,376
15495669 15495898 -83,286 -190,766
153719243 153719437 257,383 43,815
153558686 153558858 96,826 -116,764
153367165 153367353 -94,695 -308,269
153668416 153668561 206,556 -7,061
154843330 154843447 18,439 -3,246
154800523 154800675 -24,368 -46,018
155740786 155741000 37,190 29,312
156346337 156346595 -2,894 -11,083
159864775 159865028 15,046 1,026
159861066 159861428 11,337 -2,574
166576680 166576837 57,142 -62,089
166675084 166675272 155,546 36,346
175662258 175662651 14,303 -17,562
175646323 175646739 -1,632 -33,474
175605567 175605949 -42,388 -74,264
175701893 175702162 53,938 21,949
177770309 177770758 -71,376 -180,131
185472902 185473092 -73,007 -159,605
185647226 185647461 101,317 14,764
185672043 185672143 126,134 39,446
187170909 187171199 -56,394 -72,047
187457800 187458115 108,132 86,509
187334886 187335268 -14,782 -36,338
2386839 2387061 -53,766 -100,321
2721824 2722014 -93,558 -179,573
24298720 24298989 160,535 103,707
24080923 24081095 -57,262 -114,187
24396581 24396824 -8,572 -14,738
24360077 24360358 -45,076 -51,204
24918155 24918378 73,404 28,567
25913803 25914246 -16,627 -131,605
26008676 26008965 78,246 -36,886
26134170 26134276 203,740 88,425
25905930 25906161 -24,500 -139,690
38449059 38449209 1196 11775
38484472 38484698 -34217 -23714
38593669 38593836 89,051 86,281
39030814 39031106 65,343 -13,284
39119699 39119840 154,228 75,450
38970596 38971007 5,125 -73,383
39814214 39814640 -60,751 -108,023
39887974 39888210 13,009 -34,453
47681346 47681562 -81,642 -149,468
47777288 47777502 14,300 -53,528
47881493 47881692 118,505 50,662
5126764 5126914 59,550 54,814
5154914 5155199 87,700 83,099
54930185 54930462 139,981 71,291
54874295 54874440 84,091 15,269
55208701 55209058 -10,141 -92,580
55329233 55329427 110,391 27,789
55131776 55132001 -87,066 -169,637
55681727 55681904 42,326 -4,615
68186150 68186408 79,109 31,202
68108812 68109272 1,771 -45,934
68314886 68315084 29,198 10,685
68481367 68481536 112,178 49,225
68405345 68405758 36,156 -26,553
69163482 69163676 77,985 46,836
69964294 69964495 -32,488 -48,798
70324438 70324832 143,655 1,336
70218641 70218794 37,858 -104,702
70876983 70877195 -51,778 -59,641
70865559 70865801 -63,202 -71,035
71805399 71805595 64,851 54,467
74813468 74813625 11671 14672
74931168 74931437 9,891 8,096
75109594 75109837 43,934 43,296
75184280 75184429 63,110 61,075
75375163 75375322 -74,561 -98,019
75473514 75473835 -56,203 -65,755
75572861 75573015 43,144 33,425
75936170 75936270 47,169 -2,583
76010639 76010916 121,638 72,063
77124888 77125098 -16,635 -22,567
77388926 77389112 90,008 35,053
77309459 77309619 10,541 -44,440
78790555 78790655 138,624 38,645
78824160 78824260 172,229 72,250
78753926 78754076 101,995 2,066
81440222 81440617 33,456 9,422
81336012 81336161 -70,754 -95,034
82154182 82154482 -16,961 -39,267
82071273 82071442 -99,870 -122,307
84465266 84465396 32,627 -9,934
87122526 87122759 -34,130 -470,548
87451125 87451294 294,469 -142,013
87163936 87164088 7,280 -429,219
87243136 87243335 86,480 -349,972
87496152 87496301 339,496 -97,006
88030621 88030782 295,712 75,456
87892055 87892269 157,146 -63,057
87820478 87820651 85,569 -134,675
89068189 89068667 -47,637 -54,925
89200552 89200710 84,726 77,118
89342337 89342585 111,897 43,550
89433693 89433842 -85,222 -149,430
89465513 89465701 -53,402 -117,571
89534671 89535042 15,756 -48,230
9112896 9113268 57,538 51,930
95515379 95515479 76,649 32,429
96009126 96009407 110,975 -285,692
96260569 96261012 362,418 -34,087
96125625 96125794 227,474 -169,305
95901519 95901686 3,368 -393,413
95847326 95847547 -50,825 -447,552
144123911 144124141 N/A N/A
66283133 66283274 N/A N/A
1395107 1395278 88,825 47,116
1418748 1418999 112,466 70,837
10786178 10786565 53,835 -27,779
10746187 10746304 13,844 -68,040
110508891 110509177 75,214 67,554
110380391 110380561 -53,286 -61,062
110850030 110850218 262,062 -8,265
110771375 110771838 183,407 -86,645
110629720 110629906 41,752 -228,577
110716110 110716457 128,142 -142,026
112183702 112183861 82,219 -25,974
112056138 112056374 -45,345 -153,461
114990414 114990773 48,167 1,163
114846596 114846964 -95,651 -142,646
115156987 115157287 -11,342 -23,017
122431585 122431784 44,608 31,460
122319834 122320020 -67,143 -80,304
131338683 131338839 -85,438 -87,957
131703037 131703208 45,002 -4,590
131622621 131622837 -35,414 -84,961
131642903 131643015 -15,132 -64,783
131779645 131780068 46,302 20,863
131862517 131862730 17,317 8,341
132039199 132039604 118,670 31,953
132206059 132206177 -29,854 -32,460
132276372 132276496 40,459 37,859
132568945 132569078 153,384 100,470
134220212 134220476 97,852 25,766
134044966 134045251 -77,394 -149,459
134896997 134897277 -37,277 -45,591
135256253 135256409 419 -3,006
135181575 135181956 -74,259 -77,459
135329409 135329651 73,575 70,236
137446099 137446559 -57,259 -95,698
137537642 137537892 34,284 -4,365
137606326 137606517 102,968 64,260
137753326 137753424 -75,754 -79,479
137874849 137875060 45,769 42,157
139126532 139126966 -80,912 -276,097
139403699 139403933 196,255 870
139224463 139224732 17,019 -178,331
139611679 139611963 -80,933 -94,396
139764668 139764823 72,056 58,464
139949412 139949666 -42,089 -43,773
140007688 140007888 2,546 464
140353100 140353373 -141,884 -144,515
140597349 140597601 56,185 51,621
141014799 141015032 34,172 18,436
141984877 141985233 32,950 -60,901
142026007 142026204 74,080 -19,930
142616498 142616665 -21,191 -178,605
142728153 142728455 90,464 -66,815
143103771 143103930 -68,148 -76,547
143191724 143191923 19,805 11,446
148635071 148635474 -98,952 -103,557
148766227 148766376 32,204 27,345
148918316 148918621 63,278 7,421
149351180 149351524 -61,871 -121,604
149436051 149436308 23,000 -36,820
149591133 149591407 117,538 75,792
149558530 149558702 84,935 43,087
149781333 149781782 19,940 9,097
150164772 150164958 -43,107 -95,530
150332712 150332911 -47,400 -55,836
156456397 156456677 10,976 -12,039
156615269 156615669 74,837 982
156652504 156652969 112,072 38,282
158477374 158477733 419,368 18,386
158338144 158338484 280,138 -120,863
158511682 158511889 453,676 52,542
158229060 158229320 171,054 -230,027
158315566 158315783 257,560 -143,564
158135261 158135438 77,255 -323,909
158600565 158600870 -73,804 -89,189
158683574 158683778 9,205 -6,281
158599281 158599499 -75,088 -90,560
159663198 159663369 -44,141 -66,838
159818253 159818409 110,914 88,202
162766478 162766599 -30,677 -38,001
162917627 162918055 97,386 66,530
169018539 169018879 21,668 -424,080
169475668 169476065 478,797 33,106
168932719 168933005 -64,152 -509,954
169282985 169283149 286,114 -159,810
168965098 168965291 -31,773 -477,668
169170475 169170654 173,604 -272,305
169421627 169421885 424,756 -21,074
169139843 169140023 142,972 -302,936
169540021 169540310 74,526 71,005
169581504 169581924 -26,162 -75,476
169726873 169727127 119,207 69,727
172124463 172124666 -3,244 -6,143
172599952 172600152 95,822 76,163
172491159 172491458 -12,971 -32,531
172525566 172525712 21,436 1,723
175084968 175085300 67,331 39,453
174951020 174951287 -66,617 -94,560
176398313 176398781 -48,180 -58,952
176945493 176945863 74,309 69,290
176850177 176850409 -21,007 -26,164
179112656 179112905 54,120 21,657
179718756 179718997 123,368 78,779
179933101 179933472 -12,711 -75,700
180029755 180030095 83,943 20,923
179920845 179921099 -24,967 -88,073
180485942 180486278 27,559 25,794
180522400 180522620 64,017 62,136
479256 479633 154,517 -8,592
570961 571185 246,222 82,960
355164 355260 30,425 -132,965
34111560 34111932 89,520 -48,464
34003498 34003758 -18,542 -156,638
34200645 34200758 178,605 40,362
35117563 35117808 32,942 -148,526
35189548 35189656 104,927 -76,678
35286579 35286824 201,958 20,490
34987917 34988196 -96,704 -278,138
35954991 35955133 62,243 39,671
36008337 36008544 115,589 93,082
36103624 36103791 -84,322 -116,113
36189035 36189184 1,089 -30,720
36319363 36319496 131,417 99,592
38729405 38729644 218,583 98,391
38603334 38603723 92,512 -27,530
38477427 38477589 -33,395 -153,664
39331462 39331679 190,348 76,247
39283567 39283799 142,453 28,367
39160686 39160938 19,572 -94,494
39472776 39473114 152,715 72,702
40635439 40635613 -80,350 -93,981
40821647 40821800 105,858 92,206
40957586 40958030 80,543 62,005
41069616 41069726 124,260 50,928
41166889 41167162 -11,204 -130,135
41381487 41381646 203,394 84,349
42817338 42817533 357,555 59,797
42459948 42460130 165 -297,606
42686198 42686487 226,415 -71,249
42603582 42603731 143,799 -154,005
43270004 43270157 40,089 -178,093
43313584 43313733 83,669 -134,517
43404843 43405143 174,928 -43,107
44476023 44476493 135,169 51,952
44294841 44295066 -46,013 -129,475
52286904 52287082 167,373 1,840
52321314 52321460 201,783 36,218
52071399 52071556 -48,132 -213,686
52367539 52367688 46,525 -56,259
52452062 52452213 131,048 28,266
54399325 54399474 43,487 33,319
54521287 54521362 87,057 79,525
54711128 54711244 123,298 71,966
55081967 55082127 12,358 -66,235
55233101 55233548 163,492 85,186
55009464 55009584 -60,145 -138,778
55341573 55341756 158,482 92,834
55401779 55401928 135,099 75,399
56232907 56233089 86,885 5,353
56130442 56130591 -15,580 -97,145
58411116 58411568 108,648 -908,733
58396439 58396906 93,971 -923,395
58718072 58718365 415,604 -601,936
58758848 58759110 456,380 -561,191
59394412 59394857 1,091,944 74,556
58940879 58941237 638,411 -379,064
59144945 59145157 842,477 -175,144
58650709 58650934 348,241 -669,367
59063947 59064205 761,479 -256,096
58658547 58658779 356,079 -661,522
58836457 58836637 533,989 -483,664
58547117 58547216 244,649 -773,085
58351415 58351623 48,947 -968,678
58218602 58218898 -83,866 -1,101,403
66447680 66448151 -66,192 -80,217
66516806 66516975 2,934 -11,393
66577175 66577328 63,303 48,960
67566652 67567078 19,292 -66,327
67692297 67692467 144,937 59,062
68423173 68423476 -75,420 -86,352
68432709 68432907 -65,884 -76,921
68549960 68550208 51,367 40,380
68780870 68781111 98,303 79,515
68742475 68742616 59,908 41,020
8011177 8011277 88,960 57,040
7940759 7941050 18,542 -13,187
72810180 72810334 32,341 30,226
72766794 72767076 -11,045 -13,032
73899600 73899983 -59,390 -73,022
73993056 73993295 34,066 20,290
74064408 74064581 105,418 91,576
74683673 74683972 14,883 -9,713
74736577 74736926 67,787 43,241
74859004 74859218 156,320 15,499
75914313 75914489 -32,750 -40,507
75979075 75979548 32,012 24,552
76087034 76087184 39,492 20,130
76193683 76193804 43,073 26,908
77839474 77839676 22,680 -2,303
77740930 77741105 -75,864 -100,874
79893408 79893741 -64,393 -92,815
79966232 79966428 8,431 -20,128
82904325 82904714 100,986 -8,023
82796665 82796820 -6,674 -115,917
82987070 82987224 183,731 74,487
86527996 86528232 -71,465 -195,257
86616588 86616991 17,127 -106,498
86741172 86741321 141,711 17,832
92967674 92967861 22,875 11,784
96145216 96145401 22,939 -24,158
96235335 96235731 113,058 66,172
96027674 96027845 -94,603 -141,714
40750185 40750393 N/A N/A
23689621 23689880 N/A N/A
1159779 1159928 -97,896 -100,055
1291534 1291703 33,859 31,720
1362983 1363179 27,915 22,348
1537496 1537776 -17,710 -21,355
1764964 1765120 195,924 -425,725
1959022 1959399 389,982 -231,446
2107768 2107968 538,728 -82,877
2213166 2213628 644,126 22,783
10746001 10746196 109,426 8,609
10693184 10693317 56,609 -44,270
100900687 100900946 -38,919 -118,548
101005179 101005379 65,573 -14,115
102376731 102376937 423,346 -247,714
105202933 105203167 -79,728 -211,700
105406658 105406836 123,997 -8,031
106666400 106666549 25,512 2,042
106541440 106541589 -99,448 -122,918
106976798 106977217 237,754 96,829
106852107 106852401 113,063 -27,987
108084109 108084360 166,099 -4,835
107949600 107949976 31,590 -139,219
108583332 108583656 -10,623 -33,050
108616334 108616467 22,379 -239
108515507 108515709 -78,448 -100,997
109146251 109146511 158,532 37,850
109014806 109015042 27,087 -93,619
109762832 109762933 -31,580 -47,420
109927815 109928055 107,191 59,531
11587673 11588033 296,156 97,498
11385084 11385253 93,567 -105,282
11441121 11441357 149,604 -49,178
11198485 11198798 -93,032 -291,737
11318907 11319078 27,390 -171,457
110508452 110508654 -19,263 -99,246
110672829 110672972 145,114 65,072
111422552 111422710 12,568 -30,777
112217930 112218213 129,702 -83,135
112303581 112303837 215,353 2,489
112105969 112106159 17,741 -195,189
112082075 112082266 -6,153 -219,082
112578044 112578213 41,390 -104,392
112630046 112630462 93,392 -52,143
112761184 112761648 224,530 79,043
114299456 114299626 -69,115 -99,403
114473807 114474016 105,236 74,987
116329269 116329511 -40,117 -159,103
116489219 116489425 119,833 811
117303398 117303578 -1,670 -56,430
118995007 118995176 102,075 -142,748
118918991 118919212 26,059 -218,712
118873276 118873676 -19,656 -264,248
119212984 119213280 320,052 75,356
119694333 119694588 153,368 -18,037
119509232 119509504 -31,733 -203,121
12383068 12383292 -15,514 -22,121
12430249 12430479 31,667 25,066
13287520 13287714 461,701 -108,910
124649327 124649565 482,559 -538,937
126327274 126327689 183,274 33,739
127955309 127955758 142,286 76,218
128797557 128798028 465,932 -85,425
128589350 128589677 257,725 -293,776
128866494 128866763 534,869 -16,690
128278260 128278482 -53,365 -604,971
128737875 128737978 406,250 -145,475
128392399 128392583 60,774 -490,870
129600106 129600534 354,071 -278,873
129887281 129887463 641,246 8,056
129705017 129705231 458,982 -174,176
129537242 129537375 291,207 -342,032
129177819 129178041 -68,216 -701,366
129445892 129446143 199,857 -433,264
129368447 129368616 122,412 -510,791
131230749 131231043 28,569 -194,974
131379267 131379380 177,087 -46,637
131746406 131746622 238,252 100,256
131487729 131488019 -20,425 -158,347
132016887 132017110 80,910 69,945
131896863 131897055 -39,114 -50,110
131844837 131845193 -91,140 -101,972
132082141 132082454 82,006 -27,789
132079887 132080322 79,752 -29,921
132275863 132276322 -34,336 -37,884
132244830 132245088 -65,369 -69,118
132663965 132664181 5,078 -100,176
132760308 132760778 101,421 -3,579
133147851 133148105 103,429 71,224
133010150 133010599 -34,272 -66,282
134512181 134512637 -19,900 -168,252
134696525 134696667 164,444 15,778
134444968 134445102 -87,113 -235,787
136744598 136744797 39,033 -168,688
137032600 137032874 112,722 -122,475
136868054 136868248 -51,824 -287,101
136945044 136945201 25,166 -210,148
137122101 137122569 202,223 -32,780
137470063 137470478 107,262 62,487
137343885 137344123 -18,916 -63,868
137565287 137565499 58,637 29,021
138231993 138232340 1,719 -13,802
138281966 138282176 51,692 36,034
139325903 139326076 166,953 59,176
139167175 139167474 8,225 -99,426
139515228 139515402 17,286 -28,237
139476054 139476284 -21,888 -67,355
139771105 139771310 36,016 33,832
14255105 14255391 29,390 10,263
14182432 14182667 -43,283 -62,461
143188002 143188185 73,705 -119,846
143239562 143239830 125,265 -68,201
143113267 143113467 -1,030 -194,564
143119565 143119738 5,268 -188,293
143875476 143875698 86,711 62,181
143788365 143788756 -400 -24,761
144114581 144114758 143,571 -79,256
144066879 144067132 95,869 -126,882
143923674 143923951 -47,336 -270,063
144555294 144555698 41,938 4,498
144502984 144503437 -10,372 -47,763
144635990 144636295 122,634 85,095
145032603 145032881 378,037 -182,982
147568161 147568310 1,596 -180,278
147683319 147683487 116,754 -65,101
147790657 147790963 224,092 42,375
138278 138481 -10,035 -12,911
175129 175297 26,816 23,905
149696454 149696628 15,698 -77,814
149647323 149647646 -33,433 -126,796
149621150 149621373 -59,606 -153,069
149582008 149582220 -98,748 -192,222
149731357 149731567 50,601 -42,875
149812637 149812866 131,881 38,424
149932908 149933057 65,584 24,193
150123828 150123960 11,555 -50,289
150264691 150264844 13,397 10,981
150370947 150371181 66,118 59,117
151757233 151757652 154,031 38,050
151635296 151635475 32,094 -84,127
152397002 152397299 226,623 -68,800
152364952 152365121 194,573 -100,978
152169260 152169426 -1,119 -296,673
152244388 152244779 74,009 -221,320
152780109 152780421 295,594 -219,806
152517174 152517336 32,659 -482,891
152604307 152604506 119,792 -395,721
152949445 152949667 464,930 -50,560
153150729 153151153 37,103 28,560
154472504 154472763 70,368 -136,930
155692088 155692331 71,600 5,399
155548292 155548441 -72,196 -138,491
155893582 155893858 135,388 75,129
155863580 155864011 105,386 45,282
155789784 155789943 31,590 -28,786
157524121 157524387 383,365 -47,707
157267984 157268385 127,228 -303,709
158254185 158254646 89,903 -31,451
158121699 158121941 -42,583 -164,156
158584828 158585237 75,456 50,229
158555320 158555779 45,948 20,771
158484231 158484466 -25,141 -50,542
16593127 16593309 185,805 -276,391
159987175 159987391 -32,963 -46,952
160196855 160197081 130,248 99,740
160239411 160239629 -70,710 -207,944
160362967 160363122 52,846 -84,451
160290616 160290792 -19,505 -156,781
160409020 160409197 -53,833 -90,543
160446790 160447044 -16,063 -52,696
160519187 160519548 56,334 19,808
161574009 161574229 102,962 -40,868
161511402 161511576 40,355 -103,521
161622111 161622284 151,064 7,187
162643942 162644142 955,500 -424,651
163377802 163378085 309,648 -278,429
165782129 165782332 121,363 -213,246
167030450 167030633 287,606 -165,128
167409422 167409870 76,762 -63,304
167355649 167355816 22,989 -117,358
167506629 167507105 173,969 33,931
167926871 167927049 -1,195 -13,339
167965406 167965699 37,340 25,311
170432845 170433032 -24,924 -123,130
170485524 170485694 27,755 -70,468
170601790 170602006 144,021 45,844
170677634 170677846 -8,500 -26,466
170761646 170762073 75,512 57,761
18259657 18260013 23,136 -3,340
2667715 2667828 -42,950 -64,098
2779403 2779870 -53,096 -68,643
20862105 20862340 219,438 -478,274
22419518 22419782 24,059 14,073
22472950 22473076 77,491 67,367
22713240 22713472 35,583 33,601
22637790 22637989 -39,867 -41,882
254547 254760 17,494 -41,595
345685 345874 108,632 49,519
24666439 24666704 -91,745 -108,536
24854231 24854406 96,047 79,166
25405006 25405194 17,721 -323,543
26245803 26246097 50,376 41,059
26411190 26411300 -99,270 -112,145
26518884 26519041 8,424 -4,404
27301166 27301398 -22,321 -30,929
27342916 27343329 19,429 11,002
28276700 28277070 59,005 43,855
28200881 28201258 -16,814 -31,957
28388134 28388412 87,088 79,173
29736234 29736446 104,866 -41,595
29751702 29751902 120,334 -26,139
29753266 29753582 20,511 5,454
29802123 29802482 3,592 -570
29550333 29550545 -248,763 -252,507
29476083 29476238 -323,013 -326,814
29670244 29670434 -128,852 -132,618
29644100 29644264 -154,996 -158,788
29831719 29832103 29,294 29,208
30027185 30027486 124,462 5,853
3103508 3103611 94,296 43,191
30284629 30284792 266,319 263,159
29822664 29822810 -195,646 -198,823
29930636 29930880 -87,674 -90,753
30396299 30396607 377,989 374,974
30238657 30238758 220,347 217,125
30127492 30127613 109,182 105,980
30170485 30170689 152,175 149,056
30127492 30127613 96,530 96,223
30170485 30170689 63,016 61,056
30213749 30213943 1,262 -10,548
30321166 30321536 93,465 84,846
30456329 30456500 35,452 33,851
30519687 30520097 -41,964 -42,603
30515634 30515830 -49,616 -53,247
30583169 30583395 17,919 14,318
30716816 30716971 95,183 83,984
30889107 30889213 113,544 95,568
30889030 30889254 408 -17,161
30967250 30967351 -16,706 -22,508
31145725 31146018 86,251 80,364
31367081 31367280 22,576 -65,655
31579685 31579894 235,180 146,959
31317048 31317463 -27,457 -115,472
31312116 31312543 -32,389 -120,392
31643332 31643497 298,827 210,562
31203290 31203573 -226,338 -229,341
31169575 31169993 -260,053 -262,921
30967161 30967384 -462,467 -465,530
31565689 31566052 90,149 74,983
31579571 31579777 40,633 38,212
31648097 31648514 43,379 42,527
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
N/A N/A N/A N/A
31817063 31817216 168,991 167,139
31944497 31944649 293,168 290,558
31791664 31791799 100,680 99,018
31685318 31685519 -11,111 -28,014
31814672 31814942 62,232 55,146
31145725 31146018 15,762 10,386
32327802 32328124 324,329 306,696
32434558 32434788 431,085 413,360
32153714 32153926 69,539 -31,205
32256603 32256752 52,141 50,707
32351960 32352307 85,439 52,485
32299615 32299751 33,094 -71
32299495 32299838 28,897 16
32377666 32377882 9,213 -82,428
32442933 32443084 74,469 -4,578
32505292 32505607 -10,305 -15,336
32511329 32511466 -4,296 -9,335
32707394 32707854 52,870 42,251
32721587 32721719 8,475 2,312
32845242 32845375 110,020 91,079
32778014 32778233 42,792 23,937
32785483 32785908 50,258 43,336
32825072 32825180 -6,373 -14,266
32845249 32845491 -43,269 -47,312
32961904 32962066 64,316 47,541
33074668 33074896 30,253 17,821
33232052 33232277 43,846 27,409
33281628 33281840 43,181 13,617
32961890 32962094 -276,557 -306,129
33232052 33232277 -6,395 -35,946
33281662 33281841 5,031 1,649
33410105 33410512 84,078 62,872
33485439 33485663 109,990 95,521
33571139 33571410 -77,168 -84,587
33790555 33790704 94,055 18,375
34598233 34598378 56,350 -12,606
34539204 34539322 -2,679 -71,662
35347923 35348320 -70,390 -155,613
35802250 35802399 152,905 -1,939
35690784 35691025 41,439 -113,313
35902460 35902742 -6,329 -94,200
35991821 35992093 83,032 -4,849
36098858 36099012 -4,693 -87,501
36178949 36179320 49,180 -36,500
36249771 36250032 120,002 34,212
36631575 36631969 61,928 8,735
36474795 36474972 -94,852 -148,262
36777970 36778156 23,557 15,062
36740976 36741204 -13,437 -21,890
36935456 36935633 4,875 -15,145
37035946 37036145 105,365 85,367
37239036 37239280 -6,921 -11,902
37940375 37940615 45,090 -289,760
38247153 38247408 351,868 17,033
38090015 38090486 194,730 -139,889
38493309 38493755 242,598 -180,093
38661618 38661787 410,907 -12,061
39001022 39001277 208,709 -105,268
39139577 39139747 347,264 33,202
38942886 38943198 150,573 -163,347
38780924 38781334 -11,389 -325,211
39725403 39725562 -142,717 -255,060
39886845 39886992 18,725 -93,630
41082755 41083006 -19,994 -31,900
41134037 41134248 31,288 19,342
41255583 41255684 30,604 25,636
41318854 41319059 34,584 20,699
41446952 41447121 35,447 20,518
41731825 41732017 109,683 53,917
41595883 41596064 -26,259 -82,036
41645731 41645924 23,589 -32,176
42214527 42214696 203,878 90,292
42063121 42063306 52,472 -61,098
42338104 42338355 37,457 -189,412
42560864 42561334 260,217 33,567
42468577 42468726 167,930 -59,041
42264562 42264712 -36,085 -263,055
42985652 42985811 -53,934 -69,125
43126184 43126373 86,598 71,437
43206691 43206837 54,684 -30,598
43874446 43874606 28,522 12,404
43778399 43778514 -67,525 -83,688
44355441 44355541 32,639 25,943
44238027 44238145 -84,775 -91,453
44420063 44420165 86,182 78,662
45550048 45550262 146,016 -76,535
46660973 46661151 35,569 -67,331
46759985 46760114 134,581 31,632
46578524 46578719 -46,880 -149,763
46873386 46873573 93,489 62,184
47278333 47278554 -28,894 -107,085
47413291 47413588 106,064 27,949
47321028 47321230 13,801 -64,409
47641939 47642107 88,040 -60,513
47533166 47533390 -20,733 -169,230
48083547 48083706 129,549 -60,678
48000731 48001102 46,733 -143,282
48167659 48167944 213,661 23,560
49759145 49759464 78,315 46,953
49648096 49648436 -32,734 -64,075
49956576 49956833 -79,388 -82,944
50121866 50122132 37,056 24,525
51889875 51890101 301,771 -170,281
51940304 51940523 352,200 -119,859
51774300 51774499 186,196 -285,883
52031461 52031628 443,357 -28,754
52103872 52104329 -55,272 -59,066
52312123 52312346 102,685 95,089
52194684 52194833 -14,754 -22,424
52386698 52386917 -6,255 -81,623
52498562 52498997 28,403 -50,824
52730587 52730812 -33,596 -45,804
53396387 53396728 -73,711 -121,062
53513334 53513603 43,236 -4,187
55363604 55363871 63,378 -11,379
55252250 55252341 -47,976 -122,909
55793444 55793854 67,042 -54,480
55916401 55916573 189,999 68,239
55746215 55746424 19,813 -101,910
55823016 55823210 96,614 -25,124
56026393 56026795 -2,954 -340,056
56363233 56363421 333,886 -3,430
56256568 56256729 227,221 -110,122
56907259 56907424 -20,473 -92,675
57111380 57111746 91,910 -31,311
57229312 57229578 84,229 71,884
6593132 6593306 59,792 -6,909
6695688 6695945 162,348 95,730
6515650 6516052 -17,690 -84,163
62715703 62715852 267,879 -338,239
64025660 64025763 61,122 44,854
63943648 63943828 -20,890 -37,081
64409345 64409563 69,466 58,115
66242287 66242460 146,392 -231,379
69583839 69584018 181,859 -572,106
7572898 7573321 86,029 41,376
7588877 7589345 102,008 57,400
7527288 7527559 40,419 -4,386
7870600 7870798 198,591 44,046
7768079 7768240 96,070 -58,512
73622850 73623097 234,609 -342,198
74179707 74179889 18,515 -4,124
74098291 74098441 -62,901 -85,572
74215696 74216093 -66,498 -72,251
74307562 74308009 25,368 19,665
74600600 74600791 138,052 9,282
74447747 74447957 -14,801 -143,552
74527430 74527633 64,882 -63,876
78324298 78324448 95,657 94,548
78161782 78162024 -66,859 -67,876
79706873 79707064 72,965 42,025
79596279 79596441 -37,629 -68,598
79895682 79896029 -71,999 -105,145
80004636 80004806 36,955 3,632
81110285 81110678 237,202 -2,028
80845205 80845354 -27,878 -267,352
81015266 81015415 142,183 -97,291
86217486 86217749 958 -44,466
86306353 86306776 89,825 44,561
87541626 87541795 -55,402 -168,126
87683307 87683476 86,279 -26,445
87893303 87893521 41,368 31,952
10027074 10027329 213,430 -141,579
90500971 90501238 301,355 101,115
90194376 90194670 -5,240 -205,453
90300037 90300236 100,421 -99,887
90652391 90652509 56,042 11,633
91342569 91342989 62,556 -10,639
91250703 91250837 -29,310 -102,791
94015023 94015428 7,163 -170,565
94154229 94154474 146,369 -31,519
97699568 97699739 220,351 4,388
97607534 97607736 128,317 -87,615
97475110 97475259 -4,107 -220,092
100065689 100066059 -90,670 -93,200
100284416 100284618 41135 47033
100371833 100372040 -46282 -40389
100350198 100350399 -24647 -18748
100599084 100599367 41,912 30,341
100520648 100520797 -36,524 -48,229
101727115 101727453 11,943 -21,445
101847243 101847689 -36,447 -44,604
101894447 101894688 10,757 2,395
103461676 103461883 562,203 44,684
103199971 103200196 300,498 -217,003
102867184 102867549 -32,289 -549,650
103252229 103252441 352,756 -164,758
103290070 103290220 390,597 -126,979
102979553 102979661 80,080 -437,538
104675130 104675331 131,071 -141,246
104633136 104633297 89,077 -183,280
104751564 104751762 207,505 -64,815
104851797 104851997 307,738 35,420
104504496 104504626 -39,563 -311,951
105597520 105597727 -80,372 -114,876
105726552 105726909 48,660 14,306
105778845 105779011 100,953 66,408
106243511 106243926 -49,466 -90,902
106396984 106397237 104,007 62,409
107470518 107470694 119,019 39,654
107378539 107378707 27,040 -52,333
107592145 107592427 140,913 34,391
111824685 111824903 -25,777 -78,580
111900209 111900439 49,747 -3,044
113908935 113909171 66,647 -208,220
114008219 114008422 165,931 -108,969
114127081 114127410 284,793 10,019
113776818 113777080 -65,470 -340,311
115950216 115950625 -1,859 -37,841
115893593 115893788 -58,482 -94,678
116023121 116023293 71,046 34,827
116059115 116059287 -40,580 -166,389
116097894 116098063 -1,801 -127,613
116195224 116195416 95,529 -30,260
121567185 121567481 266,790 78,155
121319883 121320093 19,488 -169,233
121255206 121255512 -45,189 -233,814
121485106 121485313 184,711 -4,013
124262464 124262696 11,915 -94,414
124156271 124156444 -94,278 -200,666
124399535 124399874 148,986 42,764
127688775 127688924 20,208 4,007
127775947 127776057 107,380 91,140
128353257 128353540 -11,973 -23,785
128285748 128285919 -79,482 -91,406
128557089 128557523 -58,860 -83,099
128623235 128623641 7,286 -16,981
129246648 129247097 207,857 62,939
129158656 129159071 119,865 -25,087
128989684 128989791 -49,107 -194,367
13987603 13987762 90,224 -7,527
13885483 13885755 -11,896 -109,534
13926485 13926682 29,106 -68,607
13956965 13957128 59,586 -38,161
130901037 130901516 237,862 69,585
130626751 130626968 -36,424 -204,963
130704200 130704377 41,025 -127,554
130802097 130802266 138,922 -29,665
138849100 138849459 62,295 30,461
139194175 139194611 69,507 -171,949
139097659 139097964 -27,009 -268,596
139225945 139226387 101,277 -140,173
139135339 139135585 10,671 -230,975
139305170 139305370 180,502 -61,190
139405578 139405792 280,910 39,232
139789996 139790107 36,080 17,688
141221537 141221992 -52,089 -71,260
141335286 141335486 61,660 42,234
141688394 141688757 43,080 -532,340
141721025 141721174 75,711 -499,923
141998654 141998853 353,340 -222,244
142251063 142251161 605,749 30,064
142106879 142107035 461,565 -114,062
141610267 141610638 -35,047 -610,459
141653645 141653800 8,331 -567,297
142320091 142320290 -28,232 -49,335
142405627 142405843 57,304 36,218
142689296 142689668 -6,228 -25,239
142867776 142868015 69,449 51,908
148276290 148276712 140,882 64,365
148097300 148097502 -38,108 -114,845
148187213 148187634 51,805 -24,713
149580075 149580254 -86,276 -89,442
149753800 149754258 87,449 84,562
150238918 150239214 -80,162 -103,395
150330368 150330582 11,288 -12,027
150440354 150440514 58,522 54,585
155325692 155325944 37,373 28,216
155210379 155210571 -77,940 -87,157
157042797 157043142 18,281 -1,030,037
158157657 158158010 1,133,141 84,831
157699810 157699923 675,294 -373,256
157995826 157995950 971,310 -77,229
157748493 157748669 723,977 -324,510
157192583 157192811 168,067 -880,368
157290561 157290805 266,045 -782,374
18597557 18597727 95,663 -405,791
18690418 18690684 188,524 -312,834
18553785 18554173 51,891 -449,345
18496813 18497048 -5,081 -506,470
18805042 18805336 303,148 -198,182
19033712 19033951 531,818 30,433
18654457 18654629 152,563 -348,889
18863320 18863549 361,426 -139,969
18938784 18939049 436,890 -64,469
18734483 18734687 232,589 -268,831
19114839 19115008 -6,777 -8,812
19168633 19168849 47,017 45,029
2951804 2951964 39,496 -98,061
3064503 3064632 152,195 14,607
20314699 20314890 -22,551 -107,017
20430187 20430336 92,937 8,429
20472026 20472374 134,776 50,467
22686506 22686666 -45,522 -51,475
22780505 22780763 48,477 42,622
23289662 23290111 36,821 8,857
24250716 24250982 -39,616 -47,020
24337173 24337322 46,841 39,320
25109167 25109342 -15,633 -22,138
27214588 27214796 67,067 64,984
27117510 27117680 -30,011 -32,132
30526941 30527100 96,269 42,267
30725605 30726020 66,880 19,776
30677886 30678096 19,161 -28,148
30991310 30991535 73,317 59,879
30915257 30915388 -2,736 -16,268
33054279 33054543 90,702 41,476
32983800 32984208 20,223 -28,859
38340284 38340671 94,134 -33,510
38428541 38428821 182,391 54,640
38305055 38305266 58,905 -68,915
38228183 38228384 -17,967 -145,797
4783375 4783779 94,919 6,179
4667320 4667540 -21,136 -110,060
41643773 41643924 -51,353 -65,307
41710718 41710920 15,592 1,689
42011383 42011643 41,187 -230,069
42068679 42068915 98,483 -172,797
42273776 42274081 303,580 32,369
41929666 41929811 -40,530 -311,901
43631796 43631966 42,545 -281
43706557 43706793 117,306 74,546
43536588 43536856 -52,663 -95,391
44142667 44142830 -7,728 -52,733
44241919 44242154 91,524 46,591
44632387 44632558 60,459 51,383
44516225 44516452 -55,703 -64,723
44852100 44852281 49,323 43,041
44898728 44898851 95,951 89,611
44931275 44931510 -37,511 -53,693
5597181 5597288 63,869 60,541
50488473 50488623 173,549 50,570
50630675 50630926 5,416 -197,726
50763329 50763515 138,070 -65,137
50912977 50913250 287,718 84,598
55252760 55252931 198,541 10,406
55712576 55712864 -3,685 -35,575
6499210 6499465 118,559 89,342
6356712 6356865 -23,939 -53,258
65153022 65153136 89,912 68,501
65032022 65032259 -31,088 -52,376
7753015 7753187 109,915 28,424
7699383 7699518 56,283 -25,245
72416806 72417046 -69,239 -71,340
72778377 72778776 -42,886 -43,760
73316412 73316839 54,389 34,739
73210018 73210124 -52,005 -71,976
73442297 73442641 100,556 -15,560
73472849 73473242 131,108 15,041
73702238 73702551 196,182 47,698
73520909 73521007 14,853 -133,846
73764718 73764835 54,752 -48,123
73779045 73779342 -47,200 -62,253
73997109 73997229 148,689 91,452
75050782 75051117 75,777 55,728
74924184 74924558 -50,821 -70,831
75293282 75293451 56,504 36,301
75257210 75257573 20,432 423
75693799 75694184 -76,060 -77,364
76697690 76698131 35,155 31,051
76601014 76601169 -61,521 -65,911
77176283 77176536 171,932 69,212
77004432 77004581 81 -102,743
79592066 79592297 -10,010 -94,364
79725585 79725727 123,509 39,066
80052425 80052625 -17,034 -91,637
80114473 80114720 45,014 -29,542
81227817 81228070 61,559 -9,318
81157943 81158229 -8,315 -79,159
83060391 83060632 229,233 -55,628
82749886 82750035 -81,272 -366,225
83007031 83007204 175,873 -109,056
83104217 83104369 273,059 -11,891
83150878 83151184 319,720 34,924
82884169 82884441 53,011 -231,819
82835248 82835533 4,090 -280,727
82954921 82955123 123,763 -161,137
87209744 87209965 238,860 29,465
86930460 86930671 -40,424 -249,829
87095596 87095934 124,712 -84,566
86997875 86998319 26,991 -182,181
91485569 91485814 -93,833 -116,132
91700349 91700641 120,947 98,695
91595624 91595882 16,222 -6,064
92092362 92092622 20,191 -208,526
92059629 92059887 -12,542 -241,261
92374977 92375168 302,806 74,020
93959064 93959397 97,255 60,917
93808120 93808314 -53,689 -90,166
93848657 93849063 -13,152 -49,417
96214944 96215331 58,929 38,192
96124060 96124209 -31,955 -52,930
97215408 97215667 16,097 7,947
97156808 97156953 -42,503 -50,767
97820947 97821303 60,940 -47,013
97871759 97872068 111,752 3,752
1070211 1070400 80,850 74,598
946405 946553 -42,956 -49,249
99001411 99001719 -82,026 -218,025
99106619 99106785 23,182 -112,959
99372196 99372582 108,624 70,473
99567451 99567565 68,045 50,266
99699860 99700229 -71,813 -103,159
99893639 99893859 121,966 90,471
6928203 6928471 103,203 28,471
6737377 6737597 -87,623 -162,403
10775389 10775489 115,506 40,693
10647006 10647407 -12,877 -87,389
10593772 10593964 -66,111 -140,832
101916022 101916387 -84,068 -118,358
102077256 102077611 77,166 42,866
103687505 103687722 -42,683 -49,406
103782232 103782461 52,044 45,333
104199534 104199829 -22,563 -111,880
104330863 104331321 108,766 19,612
105463228 105463438 42,000 25,346
105418932 105419286 -2,296 -18,806
108530678 108530942 199,792 -48,517
108639973 108640146 309,087 60,687
108295178 108295324 -35,708 -284,135
108415285 108415494 84,399 -163,965
108447214 108447385 116,328 -132,074
11387131 11387403 -1,788 -72,119
11515272 11515400 126,353 55,878
11317148 11317364 -71,771 -142,158
11657410 11657521 58,288 2,601
11896720 11896963 27,849 27,446
110146515 110146664 -22,385 -54,325
110238742 110239130 69,842 38,141
12277692 12277903 64,849 57,707
120032851 120033006 27,874 -486
119960673 119960872 -44,304 -72,620
120496958 120497185 -924 -8,591
120571321 120571545 73,439 65,769
121379855 121380093 173,322 -73,361
121487832 121488185 281,299 34,731
121169546 121169693 -36,987 -283,761
128831342 128831784 13,844 8,928
128738756 128738905 -78,742 -83,951
141580849 141581181 -9,737 -15,253
141502803 141503133 -87,783 -93,301
141631901 141632083 41,315 35,649
142079255 142079454 341,572 -1,060
142021823 142021972 284,140 -58,542
141720546 141720714 -17,137 -359,800
142536386 142536574 35,197 25,772
143921569 143921744 -29,206 -36,494
144169637 144170010 -1,637 -5,189
144799831 144799961 -70,667 -76,658
16052635 16052794 42,874 -41,801
15969566 15969745 -40,195 -124,850
16149300 16149451 139,539 54,856
16976421 16976768 82,372 72,707
16959613 16959877 65,564 55,816
16808197 16808365 -85,852 -95,696
18348129 18348454 55,094 45,451
18396794 18397013 103,759 94,010
21786803 21787029 -35,527 -40,122
21883796 21883949 61,466 56,798
21992576 21992958 36,693 30,692
22024661 22024894 68,778 62,628
22457030 22457199 102,489 2,616
22271221 22271353 -83,320 -183,230
22664958 22665199 63,841 58,439
22621327 22621551 20,210 14,791
22576582 22576836 -24,535 -29,924
22877189 22877449 -56,402 -105,188
22988344 22988515 54,753 5,878
22988349 22988557 28028 42338
23006985 23007135 42061 70353
23091332 23091506 -42286 -14018
23053800 23053961 50209 84623
23164037 23164144 -60028 -25560
23231860 23232223 74,746 56,771
25324253 25324459 -8,440 -13,628
25903546 25903705 146,056 -54,587
25786048 25786197 28,558 -172,095
25677104 25677260 -80,386 -281,032
26008411 26008844 250,921 50,552
26341334 26341468 45,003 14,906
27404034 27404230 179,118 31,406
27175459 27175647 -49,457 -197,177
27325382 27325791 100,466 -47,033
27566834 27567081 56,483 38,793
27438478 27438658 -71,873 -89,630
27651900 27652181 104,596 61,970
27905106 27905372 121,451 -745
29333818 29334040 84,288 69,936
29275807 29276226 26,277 12,122
30638173 30638286 82,751 3,012
30494188 30494669 -61,234 -140,605
30597094 30597515 41,672 -37,759
33574897 33575183 6,504 -1,860
33597800 33597900 29,407 20,857
38135122 38135485 -18,141 -54,481
38273218 38273456 119,955 83,490
38428745 38429115 39,339 -16,181
38423741 38423890 34,335 -21,406
38470657 38470800 81,251 25,504
38664547 38664985 -69,461 -164,718
38759699 38759848 25,691 -69,855
39963127 39963528 72,642 58,408
39912039 39912459 21,554 7,339
41679897 41680317 49,996 -193,120
41580307 41580646 -49,594 -292,791
41891541 41892002 261,640 18,565
41781623 41782012 151,722 -91,425
42180570 42180936 -67,416 -128,194
42279680 42279890 31,694 -29,240
48902172 48902351 53,950 -132,945
54273953 54274171 -26,876 -52,576
54236344 54236519 -64,485 -90,228
56878048 56878318 -76,878 -208,175
57014504 57014694 59,578 -71,799
56962552 56962755 7,626 -123,738
59498129 59498379 -67,163 -76,896
59579881 59580119 14,589 4,844
59779361 59779703 120,744 44,763
6331020 6331443 -13,560 -76,895
6462561 6463031 117,981 54,693
65668245 65668691 -3,001 -205,211
65753949 65754082 82,703 -119,820
65892255 65892470 221,009 18,568
67239580 67239810 -11,586 -13,570
71677981 71678184 29,754 -4,974
75026266 75026563 -39,875 -77,296
75089449 75089681 23,308 -14,178
76578720 76579194 95,894 -62,429
76482989 76483122 163 -158,501
76651602 76651729 168,776 10,106
78101362 78101487 43,649 26,493
78159151 78159299 101,438 84,305
79915926 79916400 108,366 36,087
79797810 79798011 -9,750 -82,302
79890586 79890857 83,026 10,544
8543660 8543916 -53,416 -55,110
8628444 8628823 31,368 29,797
81952954 81953128 -89,646 -233,730
82096153 82096502 53,553 -90,356
82356935 82357085 1,609 -2,478
82431027 82431467 75,701 71,904
82516244 82516636 -37,237 -41,387
82897681 82897943 90,438 63,638
82722795 82722947 -84,448 -111,358
89110896 89111061 -7,680 -297,831
89247886 89248270 129,310 -160,622
89337958 89338137 219,382 -70,755
89212552 89212980 93,976 -195,912
89463510 89463913 344,934 55,021
90917942 90918042 78,832 45,609
90858901 90859006 19,791 -13,427
91152169 91152323 137,429 86,248
93141896 93142035 101,568 -34,584
93200803 93200970 160,475 24,351
93040796 93040973 468 -135,646
95266645 95266936 -64,012 -76,797
95319278 95319375 -11,379 -24,358
96012888 96013065 51,260 36,405
95915699 95915848 -45,929 -60,812
97383890 97384321 40,550 -31,629
97420239 97420486 76,899 4,536
97267772 97267921 -75,568 -148,029
97358290 97358436 14,950 -57,514
97716363 97716772 141,305 23,559
97497725 97497852 -77,333 -195,361
97637410 97637623 62,352 -55,590
99173118 99173499 -26,126 -66,317
99237264 99237469 38,020 -2,347
99314722 99314844 115,478 75,028
99877084 99877508 341,043 -29,577
99489084 99489283 -46,957 -417,802
99572518 99572728 36,477 -334,357
99674116 99674491 138,075 -232,594
99995842 99995977 459,801 88,892
91916978 91917217 33,595 32,479
91786989 91787168 -96,394 -97,570
100993879 100994048 86,646 37,642
100874975 100875255 -32,258 -81,151
101098178 101098397 73,798 65,675
101718461 101718612 94,503 49,618
101629262 101629510 5,304 -39,484
103485871 103486076 92,153 88,972
103424966 103425174 31,248 28,070
107241482 107241633 194,758 360
107078566 107078751 31,842 -162,522
107422684 107423090 -41,915 -42,124
110630541 110630850 -26,151 -28,218
110705868 110706031 49,176 46,963
111282970 111283094 105,170 -17,313
111092789 111092904 -85,011 -207,503
111959406 111959869 -86,506 -98,872
112128955 112129173 83,043 70,432
112372536 112372710 -58,521 -58,847
113366245 113366636 1,567 -35,281
113272714 113272919 -91,964 -128,998
113683712 113683930 -15,155 -53,540
113830419 113830619 131,552 93,149
113622923 113623296 -75,944 -114,174
114982313 114982586 14,693 -41,424
115062577 115062731 94,957 38,721
115227413 115227573 18,077 14,800
115154388 115154722 -54,948 -58,051
116120936 116121193 -4,221 -7,385
116227615 116227889 95,725 92,532
116668752 116668979 77,331 60,750
116563365 116563680 -28,056 -44,549
116738516 116738733 33,571 6,142
116938283 116938406 115,649 18,146
116999255 116999373 176,621 79,113
119488179 119488441 -18,226 -31,148
119526784 119527053 20,379 7,464
122689596 122689918 -14,896 -40,950
122740185 122740291 35,693 9,423
122827363 122827582 72,929 -24,793
124198661 124198964 25,611 1,162
124127623 124127822 -45,427 -69,980
126152527 126152697 -3,038 -64,845
126236287 126236485 80,722 18,943
126327340 126327451 44,004 17,921
126589533 126589982 270,153 16,572
126482075 126482261 162,695 -91,149
126927953 126928083 -109,000 -115,347
129681037 129681437 93,139 88,550
129495867 129496149 -92,031 -96,738
129704568 129704898 87,456 48,042
129906842 129907203 -44,329 -49,130
130452455 130452746 -33,389 -45,742
131034543 131034982 121,493 83,936
131568037 131568281 27,604 13,116
131540451 131540610 18 -14,555
131981878 131982283 126,352 40,019
131868460 131868560 12,934 -73,704
131813132 131813407 -42,394 -128,857
132809082 132809187 -65,243 -149,080
132877228 132877328 2,903 -80,939
133469875 133470149 27,897 -135,133
133666409 133666820 224,431 61,538
134580977 134581315 122,772 45,706
134449296 134449448 -8,909 -86,161
134863769 134863988 -32,128 -59,721
134820916 134821281 -74,981 -102,428
135136149 135136394 15,765 -4,057
135355839 135355943 78,898 41,614
135245604 135245870 -31,337 -68,459
135840148 135840462 223,311 -7,085
135577518 135577837 -39,319 -269,710
135657141 135657317 40,304 -190,230
135621569 135621804 4,732 -225,743
135783008 135783198 166,171 -64,349
136964438 136964659 290,965 88,149
137036356 137036780 95,519 87,150
138653439 138653835 144,722 93,700
138995119 138995332 94,333 54,444
139457459 139457662 -19791 -8983
139420470 139420671 17198 28008
15506863 15507114 52,799 6,097
15360887 15361174 -93,177 -139,843
2024944 2025402 19,602 -158,222
2232821 2233002 227,479 49,378
2105279 2105468 99,937 -78,156
2752251 2752615 -41,901 -81,480
2912066 2912378 117,914 78,283
20935741 20936171 -131,363 -131,791
21039365 21039522 -27,739 -28,440
21114205 21114540 -16,008 -17,604
21243692 21243894 52,458 13,904
21356211 21356638 -1,212 -2,323
21565208 21565532 94,370 93,220
21473210 21473413 2,372 1,101
21906019 21906249 -51,732 -78,241
21980434 21980763 22,683 -3,727
22093010 22093220 100,108 93,908
26949029 26949436 54,948 11,975
27164842 27165270 65,606 -54,903
27046819 27046987 -52,417 -173,186
27228648 27228922 129,412 8,749
27468780 27468881 -45,522 -47,615
3281142 3281541 72,845 -234,442
3544644 3544980 336,347 28,997
3498882 3499045 290,585 -16,938
3400069 3400257 191,772 -115,726
3186982 3187226 -21,315 -328,757
32600144 32600521 154,844 84,199
32359022 32359212 -86,278 -157,110
33216433 33216792 -26,036 -37,952
33363102 33363251 108,935 91,726
34561479 34561628 -75,156 -90,256
34680403 34680591 43,768 28,707
35637621 35637723 37,645 28,970
35760341 35760701 73,007 38,332
35789354 35789592 102,020 67,223
36601472 36601839 38,599 -65,840
36484101 36484319 -78,772 -183,360
38111829 38112209 202,698 52,960
37910069 37910382 938 -148,867
4958776 4959028 -16,469 -159,155
5118035 5118336 142,790 153
5380164 5380319 -60,361 -80,228
5457161 5457445 16,636 -3,102
5565247 5565348 64,677 4,096
6257328 6257643 51,519 9,660
6225983 6226204 20,174 -21,779
70858087 70858318 40,846 39,469
74973531 74973701 17,038 -1,428
74937484 74937956 -19,009 -37,173
76459038 76459207 156,966 -32,730
76521849 76522049 219,777 30,112
76285354 76285597 -16,718 -206,340
78795407 78795606 -28,984 -30,083
8735688 8736162 431,442 -272,573
9009034 9009506 704,788 771
8848518 8848945 544,272 -159,790
8444760 8445059 140,514 -563,676
8556011 8556175 251,765 -452,560
8360163 8360362 55,917 -648,373
88811412 88811618 62,314 59,694
89237568 89238025 -64,395 -275,344
89352169 89352615 50,206 -160,754
89531653 89532080 229,690 18,711
89480562 89480826 178,599 -32,543
91063786 91064143 -52,139 -57,295
91324552 91324696 142,580 21,988
92619901 92620084 16,011 -80,568
92726100 92726294 122,210 25,642
93238292 93238774 27,144 12,809
93229630 93230091 18,482 4,126
97220242 97220584 -24,841 -98,339
97382350 97382577 137,267 63,654
97316684 97316834 71,601 -2,089
99544028 99544387 67,016 44,927
99580034 99580220 -75,323 -78,598
99763255 99763404 -22,207 -54,642
100501448 100501707 10,357 -26,132
100407272 100407429 -83,819 -120,410
104752869 104753042 1,055,217 -145,436
103689786 103690263 -7,866 -1,208,215
104974501 104974747 1,276,849 76,269
104456682 104456960 759,030 -441,518
104581497 104581666 883,845 -316,812
104658056 104658228 960,404 -240,250
103883505 103883704 185,853 -1,014,774
103769044 103769435 71,392 -1,129,043
103979556 103979822 281,904 -918,656
104275410 104275559 577,758 -622,919
104143910 104144105 446,258 -754,373
104795967 104796055 1,098,315 -102,423
104087653 104087862 390,001 -810,616
105823227 105823410 -497 -103,492
105909211 105909333 85,487 -17,569
105972467 105972746 148,743 45,844
106975337 106975491 132,230 69,633
106872121 106872323 29,014 -33,535
107105415 107105574 1,728 143
107278299 107278503 -7,194 -290,880
107439543 107439823 154,050 -129,560
107632123 107632510 346,630 63,127
107367721 107367989 82,228 -201,394
107730307 107730623 160,497 -96,808
107828967 107829118 259,157 1,687
110248276 110248425 22,032 -102,391
114207848 114207961 63,054 48,169
115212733 115213144 -3,270 -7,109
117879004 117879437 133,441 66,907
117739651 117739764 -5,912 -72,766
119453980 119454186 7,613 -33,003
119561339 119561516 114,972 74,327
12736292 12736478 -58,831 -81,942
12867195 12867544 32,516 16,335
12954091 12954250 50,943 48,983
122900720 122901135 79,162 25,625
122741956 122742205 -79,602 -133,305
123328200 123328482 20,325 -6,204
123238456 123238924 -69,419 -95,762
128330566 128330715 -77,593 -154,443
128491461 128491649 83,302 6,491
128543441 128543590 135,282 58,432
128592496 128592759 -14,510 -23,836
128696418 128696596 89,412 80,001
129065849 129066022 -25,169 -61,467
129183759 129184182 92,741 56,693
130150441 130150625 -84,720 -210,733
130362360 130362565 127,199 1,207
134537294 134537474 55,079 -6,626
134878912 134879135 -16,352 -77,954
134804730 134804881 -90,534 -152,208
135578308 135578507 20,306 8,292
135646407 135646556 88,405 76,341
137964497 137964874 423,096 69,962
137891004 137891269 349,603 -3,643
137728137 137728516 186,736 -166,396
137604666 137605004 63,265 -289,908
137564241 137564631 22,840 -330,281
137823373 137823635 281,972 -71,277
149632934 149633307 -52,533 -184,530
149876389 149876567 190,922 58,730
15326688 15326837 53,049 14,339
15198039 15198215 -75,600 -114,283
15355548 15355957 81,909 43,459
15478660 15478863 86,370 -5,710
15588538 15588942 99,461 58,743
152489599 152489748 76,008 61,542
152373131 152373302 -40,460 -54,904
152547564 152547852 -13,618 -22,123
152891940 152892419 111,777 87,617
153019904 153020179 90,759 81,554
153482102 153482322 69,302 53,341
153731409 153731887 87,180 72,729
18122986 18123230 -44,369 -159,538
18240921 18241213 73,566 -41,555
19224446 19224800 -63,649 -218,563
19357725 19357924 69,630 -85,439
19393734 19393958 105,639 -49,405
19754666 19754953 292,652 -60,687
19562040 19562267 100,026 -253,373
19910542 19910801 448,528 95,161
2808176 2808375 128,061 64,407
22857504 22857710 -70,495 -73,917
22895583 22895669 -32,416 -35,958
23021461 23021609 93,462 89,982
23538321 23538572 -53,979 -75,865
28588079 28588250 72,642 -1,296,511
29289511 29289680 774,074 -595,081
28794377 28794842 278,940 -1,089,919
28899808 28900047 384,371 -984,714
28961875 28962037 446,438 -922,724
29149530 29149756 634,093 -735,005
29490005 29490392 974,568 -394,369
29377719 29377891 862,282 -506,870
29757165 29757273 1,241,728 -127,488
28472648 28472797 -42,789 -1,411,964
29864516 29864640 1,349,079 -20,121
30226367 30226663 -5,877 -10,973
30328327 30328645 96,083 91,009
30234459 30234841 2,215 -2,795
37431232 37431480 1,301 -44,842
37639576 37639775 115,368 82,117
38424695 38424853 119,142 -8,265
38277921 38278106 -27,632 -155,012
41208756 41209117 131,161 100,448
41032627 41032932 -44,968 -75,737
44668655 44668973 80,462 79,895
44590422 44590571 2,229 1,493
46552780 46553089 203,083 49,655
46419355 46419539 69,658 -83,895
46311318 46311404 -38,379 -192,030
47353138 47353526 26,504 22,392
47454008 47454427 85,451 79,779
48374977 48375152 -52,135 -59,610
48462114 48462312 22,184 9,965
48578101 48578249 48,195 40,587
48674053 48674492 128,883 106,156
48979085 48979333 -14,756 -28,899
50182301 50182401 326,145 70,748
49842981 49843116 -13,175 -268,537
53048169 53048317 -80,105 -86,130
53095822 53095913 -32,452 -38,534
53254276 53254406 16,217 -16,923
53369759 53369896 131,700 98,567
54953808 54954092 -98,405 -120,044
55133388 55133663 81,175 59,527
57620180 57620347 -99,756 -103,091
66656193 66656458 -24,406 -210,728
66698869 66699073 18,270 -168,113
69046787 69047173 294,151 -128,874
68739704 68739875 -12,932 -436,172
68792255 68792404 39,619 -383,643
69331909 69332152 -62,832 -64,227
69364800 69364978 -29,941 -31,401
70209546 70209695 -23,226 -30,415
70309061 70309439 65,082 61,251
70784226 70784649 31,735 29,557
70680132 70680406 -72,359 -74,686
71446806 71447248 105,574 71,646
71391726 71391911 50,494 16,309
71285268 71285510 -55,964 -90,092
71603641 71603839 137,550 -105,784
71525068 71525326 58,977 -184,297
71687566 71687728 221,475 -21,895
76680233 76680680 83,930 82,011
76602179 76602564 5,876 3,895
77337821 77338182 -75,796 -131,561
77463255 77463486 49,638 -6,257
9564271 9564682 172,902 -83,096
9420805 9420968 29,436 -226,810
9722847 9723231 331,478 75,453
9459372 9459530 68,003 -188,248
96011001 96011437 184,636 -735,215
96142112 96142440 315,747 -604,212
96278822 96278995 452,457 -467,657
95916941 95917169 90,576 -829,483
96471479 96471643 645,114 -275,009
96776973 96777104 950,608 30,452
96381455 96381605 555,090 -365,047
96413437 96413629 587,072 -333,023
96543841 96543954 717,476 -202,698
96642364 96642533 815,999 -104,119
95815805 95815960 -10,560 -930,692
100049656 100049911 64,687 33,921
99895129 99895569 -89,840 -120,421
13419282 13419497 96,728 -62,665
13491144 13491474 34269 50310
13495975 13496187 29438 45597
13814930 13815340 -54,723 -286,607
14058204 14058304 188,551 -43,643
14261984 14262176 -62,857 -65,122
19577511 19577613 -34,387 -36,480
2748518 2748678 21009 46319
2768356 2768506 1171 26491
20388814 20389033 62,125 22,821
6921204 6921332 82,477 -98,392
7001434 7001541 162,707 -18,183
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all_169_indall_169_10 all_169_20 all_169_40 all_173_indall_173_10 all_173_20 all_173_40 all_177_ind
7 16.84735 13.25337 15.84178 27 37.90654 38.65567 37.39232 241
10 40.50675 31.4152 30.2175 13 25.72534 24.55138 24.5295 269
13 37.54609 8.151417 16.54119 24 31.58542 35.42731 32.88308 261
5 19.73258 17.15352 24.05867 33 40.55213 42.07973 39.17811 261
all_169_indall_169_10 all_169_20 all_169_40 all_173_indall_173_10 all_173_20 all_173_40 all_177_ind
7 20.81844 43.84921 22.22143 27 39.45429 37.7834 39.34286 241
10 27.31143 19.92455 25.64863 13 22.42095 23.70511 21.98454 269
13 37.21922 33.43653 26.8886 24 23.89866 31.46285 32.26633 261
5 42.80465 32.28724 41.59516 33 35.62134 39.09479 37.89782 261
all_169_indall_169_10 all_169_20 all_169_40 all_173_indall_173_10 all_173_20 all_173_40 all_177_ind
7 30.13636 24.48507 20.83099 27 31.00988 31.20896 33.76056 241
10 27.72346 16.51871 31.69862 13 25.73305 24.51724 27.89478 269
13 22.4442 14.33121 16.37622 24 31.49628 37.83439 31.13788 261
5 16.28648 25.77068 18.2372 33 49.28246 40.81193 44.67279 261
73_20 all_177_indi all_177_20 all_181_indi all_181_20 all_185_indi all_185_20 all_189_indi all_
066B03_H 
066B03_M 
73_20 all_177_indi all_177_20 all_181_indi all_181_20 all_185_indi all_185_20 all_189_indi all
all_173_40 all_177_20 all_181_10 all_185_indi all_185_40 all
Alleles 
066B03_L 
all_177_10 all_177_20 all_177_40 all_181_indall_181_10 all_181_20 all_181_40 all_185_indall_185_10
230.8411 231.934 229.9199 150 143.2025 145.1244 145.8586 13 13.20249
248.0861 253.8296 256.671 152 134.3829 139.9165 137.1045 29 25.29895
245.1249 263.9805 261.4703 130 119.7665 125.5109 122.5642 19 15.97706
254.0988 255.8287 246.7669 151 138.2953 138.4343 141.1516 23 21.32122
all_177_10 all_177_20 all_177_40 all_181_indall_181_10 all_181_20 all_181_40 all_185_indall_185_10
232.4166 223.704 229.3786 150 136.551 123.4355 138.9143 13 12.75969
262.2048 266.7847 264.8138 152 137.6857 138.961 137.903 29 24.37714
244.7066 245.6656 247.3752 130 125.37 121.5557 126.9526 19 18.8055
250.235 250.4206 241.9914 151 126.2491 132.65 133.2894 23 19.08989
all_177_10 all_177_20 all_177_40 all_181_indall_181_10 all_181_20 all_181_40 all_185_indall_185_10
230.8271 237.4925 237.5211 150 136.0504 137.2687 137.1972 13 13.97628
256.7618 265.3426 252.7436 152 137.9064 142.4087 137.9947 29 25.87522
250.9782 266.2739 255.5613 130 130.4492 114.0764 132.163 19 14.63213
242.1821 247.4787 241.6011 151 142.9826 138.2792 145.2284 23 23.2664
l_189_
D01
D24
P01
P24
D01
D24
P01
P24
l_189_
l_189_
D01
D24
P01
P24
all_185_20 all_185_40 all_189_indall_189_ all_189_ all_189_
13.03248 12.98741 2 0 0 0
24.28739 25.4775 0 0 0 0
16.92987 16.54119 3 0 0 0
20.50382 22.8447 0 0 0 0
all_185_20 all_185_40 all_189_indall_189_ all_189_ all_189_
13.22784 12.14286 2 0 0 0
24.6247 23.65004 0 0 0 0
17.87926 16.51729 3 0 0 0
19.54739 19.22621 0 0 0 0
all_185_20 all_185_40 all_189_indall_189_ all_189_ all_189_
11.54478 12.69014 2 0 0 0
25.21277 23.6683 0 0 0 0
17.48408 14.76166 3 0 0 0
21.6594 24.2605 0 0 0 0
